<SEC-DOCUMENT>0000896262-22-000055.txt : 20220728
<SEC-HEADER>0000896262-22-000055.hdr.sgml : 20220728
<ACCEPTANCE-DATETIME>20220728080303
ACCESSION NUMBER:		0000896262-22-000055
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220728
DATE AS OF CHANGE:		20220728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		221112874

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06,d:3ab6a0ff70694f7e9af47b41f794c5b6--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20220630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY180LTEtMS0xLTM1NzQ3_c188aa8e-3291-4f85-9294-0529c63e4638">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY182LTEtMS0xLTM1NzQ3_8bbb8022-3a9c-440d-8037-79dccef21ae8">2022</ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY183LTEtMS0xLTM1NzQ3_84f4ac99-0023-4f9f-b368-c870b5a55344">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY185LTEtMS0xLTM1NzQ3_d08381d7-2660-48a0-9ef5-03e1388711d8">AMEDISYS INC</ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY18xMC0xLTEtMS0zNTc0Nw_9f7a05b7-8420-4dfe-8435-6bd810dbeda8">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY18xMS0xLTEtMS0zNTc0Nw_9636a18e-5805-45e8-9335-c623044cbf40">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630" name="amed:AcutePhaseForHighAcuityCareServices" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa">P5D</ix:nonNumeric><ix:nonNumeric contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630" name="amed:AcutePhaseForHighAcuityCareServices" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f">P7D</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMS0xLTEtMS0zNTc0Nw_b14f540b-061a-42ab-b186-b8d38fd74bf0">9.7</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMS0yLTEtMS0zODgzMQ_6f1c4e78-56e2-4b4e-83b0-49fb33499aff">17.3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMi0xLTEtMS00Mjk2Nw_92db16db-464f-4eb5-8665-71a4d312fac1">1.8</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMi0yLTEtMS00Mjk2Nw_a5bf5e3a-7eae-491c-ad2d-e4254e5b0df7">1.8</ix:nonFraction><ix:nonNumeric contextRef="i64b5c595294245a18e553707a117c3d6_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82MS9mcmFnOjE1NWUxNmI2NGFiZjQ4OTk4MjM3YjI3MzAwMTBiM2I3L3RleHRyZWdpb246MTU1ZTE2YjY0YWJmNDg5OTgyMzdiMjczMDAxMGIzYjdfODA5_e99ac26b-23f1-49fd-b5c5-57f40a59fba3">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="i647490c601a147899ef03e7f74558833_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82MS9mcmFnOjE1NWUxNmI2NGFiZjQ4OTk4MjM3YjI3MzAwMTBiM2I3L3RleHRyZWdpb246MTU1ZTE2YjY0YWJmNDg5OTgyMzdiMjczMDAxMGIzYjdfODEw_823b03b5-9a76-4afc-b50b-4057a1696ff5">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83My9mcmFnOmMxZDZkOTQ5ODVlYjRkMWM4YzVhYzA5MzIzNzIyNDMzL3RhYmxlOjdlMDY5MGEwMmRjYjRjNjRiYjZhMjhiZTRmM2E0NGFkL3RhYmxlcmFuZ2U6N2UwNjkwYTAyZGNiNGM2NGJiNmEyOGJlNGYzYTQ0YWRfNS0xLTEtMS00MjA5Ng_721e0f53-2b28-45db-b636-c8e627a86189">510,249</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83My9mcmFnOmMxZDZkOTQ5ODVlYjRkMWM4YzVhYzA5MzIzNzIyNDMzL3RhYmxlOjdlMDY5MGEwMmRjYjRjNjRiYjZhMjhiZTRmM2E0NGFkL3RhYmxlcmFuZ2U6N2UwNjkwYTAyZGNiNGM2NGJiNmEyOGJlNGYzYTQ0YWRfNC0yLTEtMS00MTA3NQ_b805dbf5-9036-4235-b098-660ec9bb6623">490,634</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a29abe30dd410abda89d13c08ad47a_I20220722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if19ffbe3490c49479b91f735381591d3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1ddf9fbb9d354501832c0641468f679d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884839468e984a559b74bef4467c132b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f5d916ca034210bdab3c3695b2b7d5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51eae5477dbe4bb3813cfeef5b1df172_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2230db8bb5304021a778e00e8cbc9e95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32561722ebd4483cb2b211fd8482b221_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab48083f8c03445890bc710f5ef75ea7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9747ba22c25643a981e544cb176796d5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4391a27b2ec040e3b60979194de2e669_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4aeb15060148eba081e4dfc943a331_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ba1440544d42adba0dee3d24db10cd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc52bda628494beea698958f49b62ec5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9621fe17f1f49e2abf92921c9bbd090_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db8313abf4642c7a45dab30e9b2b38e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0b9d2e84db40329330261a2e77cf52_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae38203cf58b41608713238c84238a48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c45951e3954adf99132111ec0188e3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9333e57ab0fb4dc2aed54d98767627d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d48e25a4ab747bea24391142246d356_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e12a01376444b3e9c94160b47756002_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7645017f9994d879ea8bd6a157e52a6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe75fdc74ac74e3095b40024bdf5e396_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf858571fd5b4c4796c9d0b50d88e266_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e9c6f9bcae458e87824df14a960f90_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97712cb7eec54f298eacfb74dd9aa06e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7e2f3718a14010b98f596f57fe8413_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1ebf15a9194fddad714c86f2a2011f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9951a73c939a4d0aaf3f9c73a0930342_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac753950cce74a30b0bff2362d5e2d03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f83eb525d94a3eb4a2470165f6dff2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37433eb056c4c17b9f3d15134197084_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d5a9872b4a463fa7cbc23245d2f3f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc77839e04f4069814115134fefaae4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b210127b1934564bef8ed600a885868_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ec7ab4116e4010b85638d99e1435a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa2140950ab4b4ca199f88ab42de2aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be67241b82145fa8bc84a4faa53dbcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f13336bd8884514937d120c30ec2a30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9218609305b4e9cbeae0653ba8615ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7704d89a5ea49bda984ff3bb25a28ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f18cac2d0249a097657acce73eae01_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6eae4c7f67f4524a74a58848d23caef_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i12d3114d05584bdc834ec068c834314b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952b1caa605842b8b2c6cc1f6ed49167_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i6f689c40db574abeba5ad517246536ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idacfe2999ae746bea86d800a07b26023_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0fc66197bf4246a3cb7df9b28e8f04_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofjointventures"><xbrli:measure>amed:numberOfJointVentures</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="id11e4c1c56094d87b2ab9c56771f2868_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia755b346de2741dfa14730fe4f9e2fb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361addb20cb8421d8de1392e96b0844f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0b040e8e1d408f99b5efc4817437de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4fd711d218438abe660d1442afcde4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec1a19c1ba94e878ec8fda9cd5339f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da76d47f10d4c0c8c8c8b0fd249aa26_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd2cc70011c4d8ca45f2cd8312980c3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa76b1acfeaf486da02b9af11cc816a6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i751a2debd3674a8cb7cef6a38ae12130_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c50b0e545d4a1785eeb7d1a9c185cc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b3730a17e64e0f992cd153fd840cf2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6061248324244eebe4d0db40312edac_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib24ed3919fc848288bb8ac2ced90d84b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a28a2b65f4472ab0c894d89400b474_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cca52064ef477ab34029b221d6d69d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6190b80120f43e2a1575644159feb4e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63963cb819344481af520c8bff0b5d1d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fbb473e60d4729802929c3f20aeafe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89df7c974a654e3a941400b05e8929a4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5749f12c34ef4e4a81639e239b7a472e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica66251978d1405bb862d424880702f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb4c6bf9b7f441aba17bfa2e6583e74_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356d5eeddab246eca55259b8d751e968_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88871dd43ddc4081830db6b06e82af59_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e997d4464b4ea4bfa067035b64249a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35822c2e8f8846808fd72e3482edc1a8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dddcac370504787ba0022ab6dfadefd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id920f2f6a7f04db3b0281051fbbc33cf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1e1d42e8bb4d88b2aed4812e852cbb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926108a7b35d4c89a57993c4c6997466_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b91dd04f2634b899d9d8c66e3339361_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="visit"><xbrli:measure>amed:visit</xbrli:measure></xbrli:unit><xbrli:context id="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac48d82a63114da69e22201712a8c0c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a945b2920249189593bc4dfb36414a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21dc870eef3444a90c0b71790318d59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc3a77e521b04aeebf04452b84789764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6279924dc89846fe9e81f87aed338b84_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcff0785ecd9434fb01d7a18ff154dc6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cd0bb8003d49c6a5231bf472e9ed5b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec5f07fc2aa4973b444a7171d9a0911_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559e5275bf6a413d992d5f29b2508130_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09472bba331640d7b8fce12ca5f6d194_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ddd6046a8c4277a4a08449e4ec5af5_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf597362dfa64e339e5ded664c4686cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fa6d510c13404db32529ba1a32617b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d84b1e5c3f433e9b75ae592fa0fd06_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id339d8bb1ad54c308f39f7c547fbc108_D20220323-20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78865dd720d74892af146d51ab673d72_I20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedAndLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f617d6993d44d1bad636bee8dc70e0_I20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b948e672fa043169982437976dfddd2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86fb111888b450497127e23c0316217_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amed:BusinessCombinationAdjustmentsAxis">amed:PotentialClosingPaymentAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3846fa0b86854a5bb6a4eea857e8c9c5_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4fb833a0ee942bf86af673e369faa07_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b561742ec7246caa23ec4b10eecde20_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9100b6fd13145b3a354118b53a94340_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1b8914368b467da2e1219eea19c95b_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd47e369277544c6aac2253ba6754c51_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic36a53a0d50446a995344011bef59e29_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b7e4cb24c04e1eae0d3bc51631a3c0_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd89d4de539544fdb048cd299395703f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e82315a0db4ef2930ad63880f79a3f_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa48e07aa67b4e89a0601d5f3eee5d03_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac7ec89f6e9427cb5d656763a3bddc5_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb3273c875947fb92f75066e32951a9_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39d0ab5b15a45f6b8ac1c1e71d6931a_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac3f76ab9614d4688b0b8101d455be8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e721858874346608ff8de6222b8c390_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i043295b1e6fd4805ad86f88638f693aa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd5c5b90ca64ac5b24203d891eb6fa6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0111dd48d164a73bdbda6add2995d5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35487ebf2851440e915cf218928141e1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic12425e6cf2b4507ae0eb717031bd48e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib714a01635724ae086d93a794a849aa8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e1f02a946da41c68f1054d698474350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fdd1926c3d342b398329f841ae4f949_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68e48e4accd47829e3f2c108a5e0128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395b376b36064fa0b151bf87dcfde162_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e933e2b55f0441d8ade42bb9a6422c9_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368407cb268545c8a429573f1fdb24fd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98096f04576b4100a1338db93629914d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7d430c8d0f426aacb10538dea5c466_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfdd0581d7248b8b729caa375e55f7d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914232c463aa4978b4a531ac7e62be33_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d1ddcfb1a14175839570fdd3546981_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef3b974ffc54477b347ad7aba261ff0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3471a8de624944a9847b252690bec01b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61200e8a017c49809e956ccc90265bd5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea37ed79d51491fa4d4fe86aabbcd2b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651fdb8c74b14b81967263e6ff2e0db9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289a8de993e54ffabcd97d4bed94c9ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c330947191b484cabb14457b2008fec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6b509d3e8d4a32b2dc334213e3e90e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de7001e37e54eaea710b0dd411e567a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8f5ae337584aee9a115925a8e2d3ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c044924a75b44968b0831ab81455994_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342d3f4c7f564db587a6511cf32380e8_D20210730-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7465164416942ac8228a0f9daf738ff_D20210730-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a72248de9c483b86fc97e68ef07f13_D20231001-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325318cf209c4cb4a2a43b717a15c820_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d87584c975497d9c6f614b6f3f8e5e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff1249baba74d4bb0802f6d4bcf1199_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd2a0aeede64a10a02cea3509dc8376_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdfe5f5157c462fa0c08492c5359787_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ef4862c0c741ad8c38872eb9eb8d3c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908c39c20d774cf49e9e8591ddd0e31a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ac967f423744c484ee9385ced160bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b5c595294245a18e553707a117c3d6_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647490c601a147899ef03e7f74558833_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea90e266fd540c1b73334141496eeda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02b1044c0fa4fadb08f8e9354318b47_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a818c66a5b04529bf0bde65307825f1_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="i093a633cdc1f40ff80f2e4fe49d565e7_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33cb6496cb44a3fa5ff85100d4ce238_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73580cf813f4bacb80a34a16b93b064_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="i694cb74b423248c896a972c561852442_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b0119f2b2547fa916994d37a51982e_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i361b5e96bbca4bd8a455e792020b20e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57695b07d1464993ae80368c4d54fbe4_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f2e16b6e58440aa8210596de7977c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b93980fcec94641a3ac5597a6cf39a7_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07ad9b0c2284a67950bf5935cd96810_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a5f95eb6a3431691a8916273d87b3a_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7510142fa85d4f9d92232c8c96e894e5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509592a5ae784f308e714e6df14f611e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aaeb76718a141288630010cd2fca7f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i832d375adc9a4e25b37e1d449314a0b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a583ddc36234cbbac97618ef468484a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98dab006fb24cf1a5c08315e4408d0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>amed:Segments</xbrli:measure></xbrli:unit><xbrli:context id="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia015b8b24487424e96577269736c5919_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fa5b9a73964a099d44236118212346_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d43362c8b95458aac1aefacb3f78f19_I20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915c545146e94aa887017c72ca239d02_D20201223-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2ca64538594598a876edcc7a6780f5_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec884be61eb14776a28fa489974af68b_D20210802-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c6ff4104d347999b50900a9055f693_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41519bdb02894e4c88aa2695cb5691b9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6cf5eaf69a43afa1bd9eefc44f8038_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db1257495a248b09b389531c6e0153f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM4_2d9ae044-6227-446a-ab36-b42aa2a7413c">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6YzUxZmJlMDk2Yjg4NGU2OGExMzEzYmU2MmJlODY2MzAvdGFibGVyYW5nZTpjNTFmYmUwOTZiODg0ZTY4YTEzMTNiZTYyYmU4NjYzMF8wLTAtMS0xLTM1NzQ3_4549e0c1-44be-478b-bbef-7622a6e7d9ca">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8xMzg_030db3c3-facc-446e-becd-6153bf986996">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6Njg1ZjgwYzI3MWEyNGMyNGFjZDZjNzk2NWM2YzhkY2IvdGFibGVyYW5nZTo2ODVmODBjMjcxYTI0YzI0YWNkNmM3OTY1YzZjOGRjYl8wLTAtMS0xLTM1NzQ3_6e7644be-1ef2-4b75-a165-6a4d14f7ea7e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQy_f8174a68-f199-4060-a807-827b92fa938d">0-24260</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><img src="amed-20220630_g1.jpg" alt="amed-20220630_g1.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">AMEDISYS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6ZDZhZTBmMGI1OWQzNDc4ZTliOTczZWNhOWMzNWZiYTQvdGFibGVyYW5nZTpkNmFlMGYwYjU5ZDM0NzhlOWI5NzNlY2E5YzM1ZmJhNF8xLTAtMS0xLTM1NzQ3_babb8ce9-7521-4b2b-8485-d471dc189414">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6ZDZhZTBmMGI1OWQzNDc4ZTliOTczZWNhOWMzNWZiYTQvdGFibGVyYW5nZTpkNmFlMGYwYjU5ZDM0NzhlOWI5NzNlY2E5YzM1ZmJhNF8xLTItMS0xLTM1NzQ3_765fc8ff-3aee-4283-854d-3e2eccc3f74e">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM5_890f908e-d521-4621-94cb-55d879920f41">3854 American Way</ix:nonNumeric>, <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQz_1fcaa8a8-dae1-43bd-bb70-ce1712240785">Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjMy_5edbedbd-cfce-428e-92c3-55a4d2480490">Baton Rouge</ix:nonNumeric>, <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjMz_ece58989-ba45-47f2-8873-e5b6638c096e">LA</ix:nonNumeric> <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM0_1f5a5763-3ec9-4f68-812d-4ff24a9bc2c0">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQw_3c9ce76f-f75e-4454-8eea-b781da20815e">225</ix:nonNumeric>) <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM1_2c43934a-7b1e-4570-af10-5a29655c32c5">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTAtMS0xLTM1NzQ3_18e9a63a-bf8b-4b06-8a45-eb2a8a544c05">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTItMS0xLTM1NzQ3_7959c87c-2f6e-4a38-9e95-095e6852c183">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTQtMS0xLTM1NzQ3_e451f382-e90c-454d-bee5-45ea90fab3c9">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM2_1aff40c3-6712-4ff3-9c08-56b88ce72f56">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM3_47e52576-9d67-433d-94cd-6d1403ae98a6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF8xLTAtMS0xLTM1NzQ3_7d9198b8-75f1-4f6d-aea9-7ebf17192268">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF8zLTYtMS0xLTM1NzQ3_c9cf0ce2-e459-4e27-ad0e-fed21a1ebcf6">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF81LTItMS0xLTM1NzQ3_dd7c18ab-ebfe-4ca3-bce4-9cedddabba79">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQx_105a0d34-afcc-41a8-9393-3057f3728bfa">&#9744;</ix:nonNumeric>&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, <ix:nonFraction unitRef="shares" contextRef="ib7a29abe30dd410abda89d13c08ad47a_I20220722" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMTk5_660dc719-92f4-4db4-8f0f-c149930a67c2">32,443,341</ix:nonFraction> shares outstanding as of July&#160;22, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.854%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">;;;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_16">FINANCIAL STATEMENTS:</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2022 (UNAUDITED) AND DECEMBER&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_25">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_91">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_91">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_94">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_94">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_97">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_97">48</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_100">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_103">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_103">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_106">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_109">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_112">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_112">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_115">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_115">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_118">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_118">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_121">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_121">50</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ab6a0ff70694f7e9af47b41f794c5b6_124">51</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022, particularly, Part I, Item&#160;1A - Risk Factors therein, which are incorporated herein by reference, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:73.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMy0xLTEtMS0zNTc0Nw_9653ab6b-112e-446a-bf2c-bcfc769ff868">26,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMy0zLTEtMS0zNTc0Nw_2a75a866-dac0-4719-86d2-9df275e3dae4">42,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNC0xLTEtMS0zNTc0Nw_b2b50f87-bf9e-47ce-9e8e-c6f6f05ee95a">22,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNC0zLTEtMS0zNTc0Nw_697c3790-d8e4-4f58-8050-e3310dff25d6">3,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNS0xLTEtMS0zNTc0Nw_def2d44a-4b52-4041-befa-f9199fc71421">305,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNS0zLTEtMS0zNTc0Nw_970bac61-d8e0-43ee-9bc2-a4d4afa0acfd">274,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNi0xLTEtMS0zNTc0Nw_8e816394-026e-43f9-b0d4-3527c03b9aad">15,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNi0zLTEtMS0zNTc0Nw_161f8a00-8d1b-484e-98e7-cb83961f6ffa">10,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNy0xLTEtMS0zNTc0Nw_4391beaf-931e-479f-8af4-110f1e6c7a5f">25,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNy0zLTEtMS0zNTc0Nw_f2927236-023c-4742-8eb9-22012f88f132">25,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOC0xLTEtMS0zNTc0Nw_6c27fff5-7175-4761-9791-63b0db1d0cfb">394,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOC0zLTEtMS0zNTc0Nw_d169b3b4-4da1-46da-9a72-aa7932f84656">356,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjE2MDkwYWIyYzNlODRhYjViYzBjMzdkNjIxMDc4ZDU1XzYz_3629e6ef-4a41-4cf3-ab63-3fd7f8a4135e">100,265</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjE2MDkwYWIyYzNlODRhYjViYzBjMzdkNjIxMDc4ZDU1Xzcw_33bf26fa-eacc-4d40-9932-240daa2e7cda">96,937</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0xLTEtMS0zNTc0Nw_d5dbd9cc-5787-4370-aaca-639369557ab0">17,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0zLTEtMS0zNTc0Nw_9021878f-9902-41a8-b2ba-b7cacc24f1cf">18,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTAtMS0xLTEtMzU3NDc_978f4696-61d3-4bc7-873a-5c117fb077b9">107,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTAtMy0xLTEtMzU3NDc_82553caf-2933-4f09-8088-2de5da8f8b97">101,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTEtMS0xLTEtMzU3NDc_2f048f88-02b5-4823-8566-e1c7087e8ab1">1,289,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTEtMy0xLTEtMzU3NDc_04515a5c-f42e-49ec-ba91-01645131d77e">1,196,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpmN2FjNzkzMWQyZTE0M2FhOGJlNTYzNDAyOGQwMGRhOF81OA_520210d9-137c-4c8c-85fe-d6a66d9e9bef">9,109</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpmN2FjNzkzMWQyZTE0M2FhOGJlNTYzNDAyOGQwMGRhOF82NQ_258123da-8f15-4926-badd-b2517ff4a1d8">19,900</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMS0xLTEtMzU3NDc_56d721e8-0bd1-4c2f-9bf4-2aa4ec263b02">106,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMy0xLTEtMzU3NDc_abffa7bc-002c-46a7-8e66-740162a4dd00">111,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTMtMS0xLTEtMzU3NDc_d411550b-db21-4f3a-b995-23af16d08a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTMtMy0xLTEtMzU3NDc_0f61db1b-0105-4c99-a3f2-aaca4fa54a5e">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTQtMS0xLTEtMzU3NDc_3df489e4-6f88-4ba0-b4b1-d88a9857300f">84,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTQtMy0xLTEtMzU3NDc_8fa33ebf-2f3a-4e04-b4de-4d1de54b8462">73,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTUtMS0xLTEtMzU3NDc_1e715a86-7cdc-49d3-ae5d-ee91ea2d90a0">2,000,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTUtMy0xLTEtMzU3NDc_3e42870f-2217-40fb-979c-0002d5d676e6">1,856,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTgtMS0xLTEtMzU3NDc_d5f87da0-1189-4222-85c7-565a6993b254">43,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTgtMy0xLTEtMzU3NDc_90d22c14-d1f5-4872-9f39-4e72fde2cc16">38,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTktMS0xLTEtMzU3NDc_6a47560f-f899-47fb-a4cc-6b3965dcf8cc">161,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTktMy0xLTEtMzU3NDc_95eef06e-5661-4746-b4e7-787f313f042a">141,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjAtMS0xLTEtMzU3NDc_3ac89db5-ff5c-4746-9bbb-8ba19ce863ee">176,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjAtMy0xLTEtMzU3NDc_5f2bcf3a-889d-479b-9712-2d3a98760096">150,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjEtMS0xLTEtMzU3NDc_a4197291-aa0f-4f12-9e89-690b296c23d3">12,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjEtMy0xLTEtMzU3NDc_9b7af371-db11-4e57-81db-fdd5ab12b465">12,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjItMS0xLTEtMzU3NDc_706bde4d-ae85-4d8d-b516-a73545f04304">34,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjItMy0xLTEtMzU3NDc_c8feea01-ae18-4dd4-809f-d6975e6346a9">31,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjMtMS0xLTEtMzU3NDc_a211b362-0bb0-4889-b3d5-029f5b19d614">427,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjMtMy0xLTEtMzU3NDc_5c22d425-e4d7-4d14-ac2e-1706c9ca396d">374,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjQtMS0xLTEtMzU3NDc_6c8a64f0-fa59-4124-b2fc-dc4d9a85000d">442,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjQtMy0xLTEtMzU3NDc_8bb59ea6-ebb1-40fb-a4fc-0e217d6479f1">432,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjUtMS0xLTEtMzU3NDc_d1970fad-befe-4b53-9fc9-5b61fcdafc01">72,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjUtMy0xLTEtMzU3NDc_1cee193d-bb10-4f01-ae89-75ddec0b1940">69,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjYtMS0xLTEtMzU3NDc_5405ccad-5790-42c3-9fb2-4347dd1d1831">6,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjYtMy0xLTEtMzU3NDc_983e93ca-0137-4245-adc1-66fc79c3d31b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjctMS0xLTEtMzU3NDc_229d5886-dee7-4e27-956f-bb98eceba7b7">13,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjctMy0xLTEtMzU3NDc_c84d41f9-21ae-4823-9185-000a74ffb750">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjgtMS0xLTEtMzU3NDc_f089c6f3-7e95-46eb-a353-2070413c3728">961,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjgtMy0xLTEtMzU3NDc_67ace592-cc42-4634-b719-5212822bee2a">880,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies&#8212;Note 6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjktMS0xLTEtMzU3NDc_9ebbf8d7-a81c-4dcc-bc5a-ed4bd0db5827"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8yMQ_155018ef-27ba-41bc-93b2-d779358753df"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8yMQ_3b6b63de-27cb-427a-950e-9b6a54723821">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8zNQ_1084daff-aee0-402e-a9a7-99aaab60acac"><ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8zNQ_6561b659-b195-4a1d-b56b-134a9c4e68e8">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_07e97639-1a14-4987-ad35-61419eff52f1"><ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_5ea9a778-b01c-4091-b839-36391c2bf5da"><ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_9d5bd820-3f7d-43f9-9adb-0687b6883a66"><ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_aedc33f9-ce97-45d4-80d2-7db560253126">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMS0xLTEtMzU3NDc_573ab912-8c3f-4a5d-bbac-021a1006b193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMy0xLTEtMzU3NDc_28ce2e12-89de-4d79-96d2-c5c06a4dcae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8xOA_a84b11e2-623e-47ec-aa7d-11fd1cafcda2"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8xOA_f6b46d95-2d6c-4530-be6a-231d4f2023d2">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8zMg_72c6ac0d-4c58-40de-82c4-94f21730655f"><ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8zMg_965ec9ce-227a-4e7d-8191-cf78c242be21">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl81NA_8bb15419-3389-49bf-83d7-93cdb67c2f61">37,780,242</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl82MQ_0df9233d-495c-4ff1-bb3a-b26de8c9c4d9">37,674,868</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl84Mw_655f33a9-8674-49bf-bb00-6c06ddc65459">32,432,527</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl85MA_baec4329-5dbc-4b6b-8e59-dc0cc8f72b07">32,509,969</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMS0xLTEtMzU3NDc_e541e48f-1f3f-4e24-a226-d73a5ccdf5c9">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMy0xLTEtMzU3NDc_f978fb98-60a2-46c2-b490-e5623d9d17c5">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzMtMS0xLTEtMzU3NDc_c293f7de-975f-4861-bde8-76ddd13681ed">743,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzMtMy0xLTEtMzU3NDc_bbbf5adf-c14e-476c-82ac-6f426652c0d8">728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost <ix:nonFraction unitRef="shares" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplNzhjYTAwZTU3ZTg0YzJhOGYzNjM2OTUyOTRkZDQyNV8yOA_dcf89d31-20e7-456c-8e91-d63e51ff86ae">5,347,715</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplNzhjYTAwZTU3ZTg0YzJhOGYzNjM2OTUyOTRkZDQyNV8zNQ_1811b1bb-3f4e-4d5b-8d56-36479feaa29a">5,164,899</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMS0xLTEtMzU3NDc_73faf4d8-8269-4c58-8cf6-021fa9addd90">457,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMy0xLTEtMzU3NDc_89d16991-9030-4c2f-8e2c-104968988779">435,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzYtMS0xLTEtMzU3NDc_e78565a2-70f2-414e-bd23-ac82fab9f898">700,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzYtMy0xLTEtMzU3NDc_a8bb99df-d7d8-4492-9e1b-78c7e342f657">639,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzctMS0xLTEtMzU3NDc_e25d26f1-a5ea-4299-b526-be96c0dd24d1">985,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzctMy0xLTEtMzU3NDc_0793e8c8-6ade-42a9-b664-e0c5ca40c51c">931,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzgtMS0xLTEtMzU3NDc_611f506c-3381-4d33-a076-6ff9d1cad345">53,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzgtMy0xLTEtMzU3NDc_b482383d-f8a5-48e4-99da-754a045c3b81">44,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzktMS0xLTEtMzU3NDc_47e2b318-cb9b-4ad7-aaba-255407ec1eef">1,038,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzktMy0xLTEtMzU3NDc_c1c41e8c-f993-41d2-b8ea-309f52549e0c">976,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNDAtMS0xLTEtMzU3NDc_dbfa2ed8-ebfa-42fa-8b80-c181262e4fc6">2,000,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNDAtMy0xLTEtMzU3NDc_9bf5c9ac-88ad-411d-8513-ea0b70669b7b">1,856,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Six-Month&#160;<br/>Periods&#160;Ended&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi0xLTEtMS0zNTc0Nw_da58fbb7-0fb7-4d27-b7d7-659b300fc147">557,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi0zLTEtMS0zNTc0Nw_5a1e9b08-4cb3-4c23-baff-dc4ea3e87c9d">564,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi01LTEtMS0zNTg3NA_e7048ecd-ee39-4107-add6-4dcadcd46bd2">1,103,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi03LTEtMS0zNTg3NA_72811195-21a4-4431-b19c-d54f79135ad2">1,101,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy0xLTEtMS0zNTc0Nw_d7939c85-13e8-4e89-aeae-290ab8110630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy0zLTEtMS0zNTc0Nw_799d746a-d4ca-42d2-99c2-37a89b60e2aa">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy01LTEtMS0zNTg3NA_315da929-8cf2-426a-bdf4-d1398a68d1ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy03LTEtMS0zNTg3NA_d7b11aae-e024-4034-8ffb-73cd45caa2b3">13,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC0xLTEtMS0zNTc0Nw_40623407-7425-4afd-9b91-d95629142d33">316,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC0zLTEtMS0zNTc0Nw_6fad0a6e-e670-45c8-8f35-f71542a08340">308,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC01LTEtMS0zNTg3NA_709924b0-5ce7-49b6-a8e3-8048d3127bc4">621,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC03LTEtMS0zNTg3NA_e12c6b8d-c0b2-42cb-8815-d4a3858c073c">605,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi0xLTEtMS0zNTc0Nw_e17f95e9-d41a-42c8-99ed-445d86e0c4ed">127,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi0zLTEtMS0zNTc0Nw_d0630321-e9f0-48a2-828d-364f9e09b94e">114,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi01LTEtMS0zNTg3NA_29b88be8-6999-4303-8735-d49751cc9ef9">251,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi03LTEtMS0zNTg3NA_d9168c1d-dbfb-4db1-b023-1c8d19caab8e">230,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy0xLTEtMS0zNTc0Nw_418566da-8412-427b-8b4f-443161a6f85e">5,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy0zLTEtMS0zNTc0Nw_9d24da02-2810-499d-b1c3-168d0bcf3cca">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy01LTEtMS0zNTg3NA_6296f59b-f249-4180-b056-3441195e2d7b">12,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy03LTEtMS0zNTg3NA_1a4c401d-cdfd-43a7-a224-8391ec0622b0">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC0xLTEtMS0zNTc0Nw_2743e81b-46a0-4762-b334-f8ad64ebecb0">54,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC0zLTEtMS0zNTc0Nw_e142b514-8ddc-401a-9bcb-d52f0a7fd230">54,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC01LTEtMS0zNTg3NA_e09d567b-a5d9-4387-b4f0-97ac5c1728bf">108,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC03LTEtMS0zNTg3NA_0e5c001b-c9c4-4ae6-a132-9863dec3d70f">103,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS0xLTEtMS0zNTc0Nw_a2765de2-ccba-4832-b691-2cd2ea322909">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS0zLTEtMS0zNTc0Nw_5d3d2e61-c223-4283-9a99-a50490ea5fff">6,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS01LTEtMS0zNTg3NA_dbc20050-90fd-4465-b7b1-41ef5aa322ec">14,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS03LTEtMS0zNTg3NA_52d7598a-57a8-4d55-8aa8-cb8e95c2263e">14,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtMS0xLTEtMzU3NDc_6a79a4ba-95ed-4d70-98d3-bac6212b64d7">510,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtMy0xLTEtMzU3NDc_edc9a59b-06fe-4500-b328-cb86c222f9a2">490,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtNS0xLTEtMzU4NzQ_2581b4b7-a055-4a92-81d0-0db13e25146d">1,007,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtNy0xLTEtMzU4NzQ_91783ce7-9c14-4de2-9f3c-6cb062b8d568">967,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtMS0xLTEtMzU3NDc_325058c3-5760-4fc0-8b68-1cd35fc939be">47,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtMy0xLTEtMzU3NDc_dd6d942c-aeaa-44b1-90e4-351f77dae909">78,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtNS0xLTEtMzU4NzQ_fd0fd453-fad0-44eb-ba41-735205caa498">95,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtNy0xLTEtMzU4NzQ_2da13426-72b2-47c8-acac-02501a08d6bd">146,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtMS0xLTEtMzU3NDc_7b37da7a-6034-4991-8dd6-b5e47d458822">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtMy0xLTEtMzU3NDc_b4f80158-6895-44b1-b10b-8ab1bd69ee60">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtNS0xLTEtMzU4NzQ_9d7107c3-ecef-42fa-9747-3a788da7cada">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtNy0xLTEtMzU4NzQ_f13b51d5-4299-4e1e-8bc2-ec8fe5be6fb0">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtMS0xLTEtMzU3NDc_1ab5223d-0a73-4f73-ab9c-7d6b4bc5b8f4">8,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtMy0xLTEtMzU3NDc_b9bc6fc8-b6dc-4764-acba-7eb2969e448c">1,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtNS0xLTEtMzU4NzQ_407cce90-1412-4c6e-81c7-d93d80d7c592">11,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtNy0xLTEtMzU4NzQ_8f012391-0ed7-4290-8af4-dcc390a1327d">4,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtMS0xLTEtMzU3NDc_c1cfaa6c-cdec-46cb-a94f-34d0aed641d0">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtMy0xLTEtMzU3NDc_1b824a55-c762-4e70-a30d-4b22b591e4c1">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtNS0xLTEtMzU4NzQ_f3c01cbc-a020-45a9-a291-6048681935ad">744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtNy0xLTEtMzU4NzQ_5d536b40-0a3e-4f3e-abd0-9d8baf4b2c8e">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMS0xLTEtMzU4OTI_e37166d8-c064-40ef-b7b0-37d8168dbbf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMy0xLTEtMzU4OTI_f18077cf-ded9-49ee-8a82-6de0f83884db">31,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNS0xLTEtMzU4ODc_052246d4-5401-48c3-88f6-dd9302509138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNy0xLTEtMzU4ODc_e3241bce-3d2c-462c-a023-5be97d0c7d13">31,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMS0xLTEtMzU3NDc_22adee1a-a160-4cc0-8e14-51ec64d1ab3a">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMy0xLTEtMzU3NDc_0484e0c9-388c-434c-ba55-4bb20f67109e">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNS0xLTEtMzU4NzQ_3dc5cf99-03ef-412a-ac76-401b38821d89">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNy0xLTEtMzU4NzQ_a255a46f-86bc-4801-9fcf-da48acb5d819">763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctMS0xLTEtMzU3NDc_b05109e7-ee14-4276-b64f-0815583c0204">7,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctMy0xLTEtMzU3NDc_836a72df-d2a3-49bf-a145-23fab82da285">31,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctNS0xLTEtMzU4NzQ_1ae0e058-cca9-4b8a-9205-3eca50f8cd1f">11,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctNy0xLTEtMzU4NzQ_0aaebcb7-b064-4880-884c-c8bb670d0096">30,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtMS0xLTEtMzU3NDc_108ed650-1fe0-4359-a5e8-999de6f65c92">40,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtMy0xLTEtMzU3NDc_7a33a751-34a9-4117-9ce3-a1f4a44d7fe2">109,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtNS0xLTEtMzU4NzQ_7fc97e76-45e4-45ae-8d7a-7afe59185a4b">84,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtNy0xLTEtMzU4NzQ_df78fdbe-dee7-4311-be6b-c1e447122536">177,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktMS0xLTEtMzU3NDc_d9576197-c313-49f1-afef-da5efa1c83b4">11,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktMy0xLTEtMzU3NDc_7c841f6a-0134-4c78-aa58-4f3d895985b2">28,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktNS0xLTEtMzU4NzQ_deb3e8ac-4cf0-4f62-ad15-48fcd3046fbb">23,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktNy0xLTEtMzU4NzQ_f994af65-a4b6-488f-be91-aaa145f76a0b">46,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtMS0xLTEtMzU3NDc_3b904a2c-c233-4fac-b19c-74e6bde62cfc">29,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtMy0xLTEtMzU3NDc_880281e1-9e04-42ac-98dd-eb64c33b592a">80,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtNS0xLTEtMzU4NzQ_3e5822ab-3b45-4f57-b47e-f3b337810993">60,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtNy0xLTEtMzU4NzQ_df465871-5e33-4d59-b5e1-9a27d6ee455b">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtMS0xLTEtMzU3NDc_bb9093e3-f676-41f7-88dd-18b3bdf8e158">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtMy0xLTEtMzU3NDc_f6a7b550-11f2-4efa-ae41-9eadb3566374">470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtNS0xLTEtMzU4NzQ_3fb425b3-1530-4f56-a905-9860159b5285">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtNy0xLTEtMzU4NzQ_239a30b8-8262-47b0-bc8f-12bba7baeaae">892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItMS0xLTEtMzU3NDc_975104c0-9f70-42bf-a41c-739447988d8f">29,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItMy0xLTEtMzU3NDc_90eedf2a-a297-4395-9f9d-950700e3a824">80,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItNS0xLTEtMzU4NzQ_77ffc5b2-8117-4766-b70b-9a4decb06b67">61,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItNy0xLTEtMzU4NzQ_ff9836f3-7ae1-4272-bb16-99755e00e0c0">130,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjQtMS0xLTEtMzU3NDc_3aec8512-d584-43b7-9502-59f70681c02a">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjQtMy0xLTEtMzU3NDc_d60cb35f-a465-4691-ad49-9701191f331c">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNS0xLTEtMzU4ODc_150552d8-6446-485f-a1f3-7d4f23f33eb5">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNy0xLTEtMzU4ODc_f703bfc7-49d9-464d-84ca-18a3dcbb3fab">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtMS0xLTEtMzU3NDc_3d26fd30-f575-41db-be39-95f8df12a4c8">32,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtMy0xLTEtMzU3NDc_5063da07-4530-4cb7-b045-95918f35eba9">32,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNS0xLTEtMzU4NzQ_7c95f3ef-3b68-4ca0-bd0b-edc59ce4d798">32,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNy0xLTEtMzU4NzQ_041b94d3-fe44-4e00-8fe1-09eab9bd7132">32,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjctMS0xLTEtMzU3NDc_7752012c-0aba-4b5a-8fab-17f48faa1903">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjctMy0xLTEtMzU3NDc_37cf39f4-f344-4118-bd20-1f45ab73582b">2.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNS0xLTEtMzU4ODc_df1ca802-43b9-4d6c-bad2-8b0d8b5e6cd0">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNy0xLTEtMzU4ODc_883c2c4d-422f-45fb-9094-c7b94ce34255">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtMS0xLTEtMzU3NDc_e3207499-b61f-47c3-900c-5d9d5da0d7ca">32,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtMy0xLTEtMzU3NDc_53a0925b-5d2b-4ce7-9935-19061e44a65e">32,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNS0xLTEtMzU4NzQ_a9f91595-2dd8-4d55-a948-74f9952f4165">32,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNy0xLTEtMzU4NzQ_3c048e98-cc96-4396-a007-63920c18d177">33,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_28"></div><hr style="page-break-after:always"/><div style="min-height:4.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.694%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended June 30, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884839468e984a559b74bef4467c132b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xLTEtMS0zNTc0Nw_87eaa2e5-848d-4777-8d1b-5404bcae5e57">1,020,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71f5d916ca034210bdab3c3695b2b7d5_I20220331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0zLTEtMS0zNTc0Nw_1862fd7e-f6df-4107-b195-8d166badefcf">37,763,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f5d916ca034210bdab3c3695b2b7d5_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy01LTEtMS0zNTc0Nw_d140bfe4-d666-4754-903d-a9c763e40b08">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51eae5477dbe4bb3813cfeef5b1df172_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy03LTEtMS0zNTc0Nw_bf30a1c1-7af2-4a33-a3fc-7ba53697fbe3">736,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2230db8bb5304021a778e00e8cbc9e95_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy05LTEtMS0zNTc0Nw_b5becda2-8399-4517-b2e7-fc9021b24b84">440,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32561722ebd4483cb2b211fd8482b221_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xMS0xLTEtMzU3NDc_e8c7519a-b634-4bb9-b8cd-a433eedef9b4">670,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab48083f8c03445890bc710f5ef75ea7_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xMy0xLTEtMzU3NDc_e980fa6a-22c0-453d-a516-e30e850dd4d5">53,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC0xLTEtMS0zNTc0Nw_678c08b3-0bfc-4a8c-95a4-94857b639833">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC0zLTEtMS0zNTc0Nw_951907ab-64cf-4810-8a76-034b04bbc8a4">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC03LTEtMS0zNTc0Nw_ebde7948-6e4c-43b6-be0e-f219104f15ef">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS0xLTEtMS0zNTc0Nw_10375f7b-e9e7-492f-89fa-d734c46c954d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS0zLTEtMS0zNTc0Nw_be04eae2-9bd6-4614-9cda-0102db89b11b">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS01LTEtMS0zNTc0Nw_ec8e994a-85e5-4840-8231-f2ddfd96cb6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS03LTEtMS0zNTc0Nw_6ec629ef-fae2-4342-bd77-c502efe3e50a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi0xLTEtMS0zNTc0Nw_c8ee1787-48b3-4ba9-b75a-c8962803b9bf">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi0zLTEtMS0zNTc0Nw_ab0b4c9e-039e-4d19-b472-b51de100c9f5">6,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi03LTEtMS0zNTc0Nw_8911a46e-ac6f-4629-a429-c3c5fcf5f638">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNy0xLTEtMS0zNTc0Nw_c2b00f08-d5f4-4fb8-952c-866970189609">5,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNy03LTEtMS0zNTc0Nw_ab456a92-5b87-444a-86cc-b0de1d9b35bd">5,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOC0xLTEtMS0zNTc0Nw_ab8a6a87-ebaf-4dfb-b6ea-fd4545ebd61e">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOC05LTEtMS0zNTc0Nw_ca5976d3-2ce3-4bd9-8cbe-c811a3fb500c">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xLTEtMS0zODUzNQ_624998eb-79df-4244-a6da-a73fa02b74c6">17,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS05LTEtMS0zODUzNQ_16d2b9d6-d1c3-48ec-bc52-5458fa79b17e">17,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xLTEtMS0zNTc0Nw_47b24c5d-1a3d-432d-a9a1-39aaf304ac68">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xMy0xLTEtMzU3NDc_48b4b3bf-e4b8-4fc1-b52f-b670b2a7c582">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTAtMS0xLTEtMzU3NDc_631ff6f3-9a5a-444a-930f-81784ccd18fe">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTAtMTMtMS0xLTM1NzQ3_2e86e3c3-2360-4a3a-86a7-79636f9df26b">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMS0xLTEtMzU3NDc_8df57704-2ec7-4787-b6bb-495b30d206bd">29,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4391a27b2ec040e3b60979194de2e669_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMTEtMS0xLTM1NzQ3_4656a466-93d8-490d-870e-bcc20f1d5b20">29,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMTMtMS0xLTM1NzQ3_f712b06e-12c5-4a8e-9ef6-c45f39e08f47">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMS0xLTEtMzU3NDc_c9c041b2-0fab-4153-a767-c3006a8063ef">1,038,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMy0xLTEtMzU3NDc_5a9c65f9-06fe-4bdd-9524-50e8b77402a5">37,780,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItNS0xLTEtMzU3NDc_e4370d3b-052a-4699-b4fc-6a44d74b829e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba1440544d42adba0dee3d24db10cd_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItNy0xLTEtMzU3NDc_a47a0ac0-33d7-41d7-aa12-9fa97beea0e1">743,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc52bda628494beea698958f49b62ec5_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItOS0xLTEtMzU3NDc_815d46d2-c24d-42ac-a8b3-8e01f2d53294">457,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9621fe17f1f49e2abf92921c9bbd090_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMTEtMS0xLTM1NzQ3_3cede677-8c62-416a-8335-8747e2802d14">700,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMTMtMS0xLTM1NzQ3_506440ee-10a2-4417-a29c-67b00ee72605">53,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended June 30, 2021</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db8313abf4642c7a45dab30e9b2b38e_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMS0xLTEtMzU3NDc_60c68ba0-8d84-4000-bd7c-ab06814d5ceb">789,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMy0xLTEtMzU3NDc_c963a8d9-1612-42d5-b78f-ef12e43ac2e2">37,538,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctNS0xLTEtMzU3NDc_c61df3a3-c04a-4c95-af16-3c479c32968d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0b9d2e84db40329330261a2e77cf52_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctNy0xLTEtMzU3NDc_d912c650-e03f-47ff-9cd7-8b2a9dcd2a26">707,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae38203cf58b41608713238c84238a48_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctOS0xLTEtMzU3NDc_6121b704-95be-48de-b512-3040da236858">398,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c45951e3954adf99132111ec0188e3_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMTEtMS0xLTM1NzQ3_99007f67-9006-43ad-9e9b-5ea02587fdaf">479,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9333e57ab0fb4dc2aed54d98767627d6_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMTMtMS0xLTM1NzQ3_d9646f83-4dc1-48b4-bbb4-44d12b5cc4bf">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtMS0xLTEtMzU3NDc_f3798d00-24cc-4909-9656-43309b1e5c8f">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtMy0xLTEtMzU3NDc_e072bad0-b3e7-4315-8bdd-da5728def4c6">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtNy0xLTEtMzU3NDc_dab6c3b6-368f-4c86-ae7c-2979ef6d1f3d">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktMS0xLTEtMzU3NDc_1d879c12-9b69-4422-a462-34844ba7b213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktMy0xLTEtMzU3NDc_542a6082-d339-43bb-983d-4f8219b57fcb">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktNS0xLTEtMzU3NDc_737a00e6-2edd-4aa4-beb6-1b687cbd35f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktNy0xLTEtMzU3NDc_3cbdb883-dfb3-41a3-8eac-cdc6f86e3ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtMS0xLTEtMzU3NDc_3e383fbc-e4d0-4391-ba1b-8b1f31d63232">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtMy0xLTEtMzU3NDc_c76a6787-0e07-4bdd-a725-4db260c1dbc5">6,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtNy0xLTEtMzU3NDc_c604b08e-b3ab-444f-a100-f8a02020df96">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjEtMS0xLTEtMzU3NDc_363b7ca3-33ea-46a0-87db-8bc1051644ee">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjEtNy0xLTEtMzU3NDc_3e8e2f75-5089-4245-8e3a-50e796552aa0">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjItMS0xLTEtMzU3NDc_165dbdfa-7d20-4134-84aa-395a10d4221d">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjItOS0xLTEtMzU3NDc_f24b5d68-4fe0-43de-910d-a5747cbcf528">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjMtMS0xLTEtMzU3NDc_4b5ff3d9-263c-4969-b007-cf37131a4586">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjMtOS0xLTEtMzU3NDc_be44f33f-bbe8-4942-9abd-50e4c61f1d3d">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjQtMS0xLTEtMzU3NDc_788295c6-a08c-4e47-81e0-0a44b6ef646d">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e12a01376444b3e9c94160b47756002_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjQtMTMtMS0xLTM1NzQ3_5fa0f2f4-80d9-4799-a54c-d8c31bb26903">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMS0xLTEtMzU3NDc_79d6faee-81dc-452c-af8e-524e87bd4e93">80,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7645017f9994d879ea8bd6a157e52a6_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMTEtMS0xLTM1NzQ3_7605bc3e-79ee-49b9-bede-16b195503890">80,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e12a01376444b3e9c94160b47756002_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMTMtMS0xLTM1NzQ3_4520ee48-61cf-4fe7-9313-e4c2b91d188e">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMS0xLTEtMzU3NDc_6fc005cf-d7ba-417b-a3fd-f06bc729c539">875,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMy0xLTEtMzU3NDc_308431b1-4c7a-45b8-9fb4-070e6cb50ee2">37,553,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtNS0xLTEtMzU3NDc_aa31f256-96a4-4778-a360-37f063670b8f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e9c6f9bcae458e87824df14a960f90_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtNy0xLTEtMzU3NDc_381094a8-cbc1-4cb9-9df1-211cb2eb7616">714,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97712cb7eec54f298eacfb74dd9aa06e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtOS0xLTEtMzU3NDc_197d55f0-b2dc-4007-be30-ec40b74313f0">400,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7e2f3718a14010b98f596f57fe8413_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMTEtMS0xLTM1NzQ3_61b9202b-e418-4cc4-b40f-67e0f08c5878">560,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1ebf15a9194fddad714c86f2a2011f_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMTMtMS0xLTM1NzQ3_ee0177b2-df39-4435-8210-ac43f52f9843">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Months Ended June 30, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMS0xLTEtMzYxMTE_2d7ffb68-ced9-4fa5-9779-834b1b04d26d">976,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9951a73c939a4d0aaf3f9c73a0930342_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMy0xLTEtMzYxMTE_ddf475dd-160a-45f3-87da-594e621e25e6">37,674,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9951a73c939a4d0aaf3f9c73a0930342_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtNS0xLTEtMzYxMTE_52cf6ddf-c0fa-4043-901b-67e1e04b5546">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac753950cce74a30b0bff2362d5e2d03_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtNy0xLTEtMzYxMTE_ccbbb17e-ece8-406e-988e-6cdd200905b5">728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0f83eb525d94a3eb4a2470165f6dff2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtOS0xLTEtMzYxMTE_55847c5f-33c2-44bf-a477-7d01c74874f2">435,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37433eb056c4c17b9f3d15134197084_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMTEtMS0xLTM2MTMy_f1c72806-7c6e-4376-8be6-938dbf8a7959">639,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d5a9872b4a463fa7cbc23245d2f3f1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMTMtMS0xLTM2MTMy_4efdf866-5792-44bf-a981-b8e1a4cc0cc0">44,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItMS0xLTEtMzYxMTE_3aebaa07-7ddf-4c33-b830-f4bc2fa9eb10">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItMy0xLTEtMzYxMTE_4d6fd480-5b13-42d6-812c-724dd6cc3946">13,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItNy0xLTEtMzYxMTE_95a684e2-3853-4339-b61c-56e6000dc13a">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtMS0xLTEtMzYxMTE_3b08a3e2-5424-4c93-aeae-19f807c4973a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtMy0xLTEtMzYxMTE_b869cf1a-732c-44fd-8a22-eb08fcc474fe">84,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtNS0xLTEtMzYxMTE_cdae35ce-9e70-4451-9d6f-b987f2f84f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtNy0xLTEtMzYxMTE_7578cbaa-a778-4ce2-83d9-35bc902daf3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtMS0xLTEtMzYxMTE_63740a1f-b851-4527-b216-5569520efbda">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtMy0xLTEtMzYxMTE_7a7256fb-00cb-4c02-97d9-064210a2a442">7,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtNy0xLTEtMzYxMTE_50a7d43e-3c92-43da-b88c-8fca5e19022c">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzUtMS0xLTEtMzYxMTE_a8856928-6344-45e7-8fc2-ce31cf8c014d">12,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzUtNy0xLTEtMzYxMTE_58233c1f-a360-41ae-b032-64bf4e6f458e">12,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzYtMS0xLTEtMzYxMTE_b631af8b-6dcc-49b5-b31a-b4a6fa5e6a19">4,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzYtOS0xLTEtMzYxMTE_acf401fe-15d0-4cee-826b-451313848bac">4,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMS0xLTEtMzYxNDU_3e73db0f-db0a-4e87-accd-fb917aedb956">17,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctOS0xLTEtMzYxNDU_2f35f8e9-464a-4421-9b78-3837f92b310e">17,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMS0xLTEtMzYxMTE_eabfc283-74ff-46e0-8e6b-afaa07d1bc2d">9,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMTMtMS0xLTM2MTMy_67944bc5-0224-40f8-a5d1-8425adf40f3b">9,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzgtMS0xLTEtMzYxMTE_96da3402-b6cb-44cd-9a6c-6f5b8827edb0">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzgtMTMtMS0xLTM2MTMy_e75c5142-3863-402b-8838-725f8fada1d8">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMS0xLTEtMzYxMTE_0aa8d2a7-cbb1-4238-ab48-86ca93c0b043">60,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b210127b1934564bef8ed600a885868_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMTEtMS0xLTM2MTMy_a6704051-643c-4821-bb92-8f72c4c241ea">61,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMTMtMS0xLTM2MTMy_6736e143-f578-4783-a153-95ad65108952">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMS0xLTEtMzYxMTE_124cd356-06c5-4b54-8ecf-23a09a506c3c">1,038,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMy0xLTEtMzYxMTE_ad675a32-c20c-422c-be5e-2d099900b22b">37,780,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtNS0xLTEtMzYxMTE_1ce512f1-2fe7-4255-a911-f866273ab152">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba1440544d42adba0dee3d24db10cd_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtNy0xLTEtMzYxMTE_22fda383-3cd7-4667-92cc-2f1096bcb491">743,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc52bda628494beea698958f49b62ec5_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtOS0xLTEtMzYxMTE_6a7e593d-55f5-4088-aba8-8ed969270dcb">457,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9621fe17f1f49e2abf92921c9bbd090_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMTEtMS0xLTM2MTMy_27475af6-ca27-46cb-b957-b5512cd4529a">700,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMTMtMS0xLTM2MTMy_f71ac87c-765c-4c3e-a1c4-a58b2fdff8fd">53,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Months Ended June 30, 2021</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ec7ab4116e4010b85638d99e1435a4_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMS0xLTEtMzYwODY_050e8e2f-7814-4350-9e89-ce08f8858ce0">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafa2140950ab4b4ca199f88ab42de2aa_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMy0xLTEtMzYwODY_0946dc7a-e848-47b8-9b8c-d7c7ba5237b8">37,470,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa2140950ab4b4ca199f88ab42de2aa_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtNS0xLTEtMzYwODY_68af1289-79e9-422a-9267-a984fede5b4b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be67241b82145fa8bc84a4faa53dbcf_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtNy0xLTEtMzYwODY_8828b8d2-3776-4bee-9936-1a5145032444">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f13336bd8884514937d120c30ec2a30_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtOS0xLTEtMzYwODY_aa71648a-6568-413b-9b3e-f093c76492bd">319,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9218609305b4e9cbeae0653ba8615ae_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMTEtMS0xLTM2MDg2_afb69fa3-b3a4-4947-a7d7-12ec9d55526e">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7704d89a5ea49bda984ff3bb25a28ff_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMTMtMS0xLTM2MDg2_999cb2f6-ba83-4565-a05c-f8e7d88f38ba">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtMS0xLTEtMzYwODY_3629293c-b258-475d-a3eb-13073cf3d9dd">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtMy0xLTEtMzYwODY_24576aa7-f982-403a-a509-24a6c0533f35">8,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtNy0xLTEtMzYwODY_52253ecb-d96f-482f-b2f1-a81635ef35e8">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctMS0xLTEtMzYwODY_a3c364e4-defd-428a-a88c-119066845917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctMy0xLTEtMzYwODY_30e066de-1d45-4eb4-86e0-a7e8a4e6bccd">61,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctNS0xLTEtMzYwODY_8903a3ae-fc9f-4883-ad1f-ae8d45b0cf14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctNy0xLTEtMzYwODY_1d9b88c9-641d-423b-baf6-b9caeb16234d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtMS0xLTEtMzYwODY_4cd757f4-fb37-4548-b523-b27dfeada94c">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtMy0xLTEtMzYwODY_15b9cc6f-3d39-459c-9225-4dadc5033ebc">13,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtNy0xLTEtMzYwODY_d18e6790-d8bf-46ec-806e-d5b646e4ae10">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDktMS0xLTEtMzYwODY_3530c730-045d-40f9-aab2-8c76bcd1838e">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDktNy0xLTEtMzYwODY_96dbdacc-0499-48f4-aa39-d1e07a61442e">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTAtMS0xLTEtMzYwODY_fe90d4e1-768d-4b5c-a152-d76bec97da6f">6,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64f18cac2d0249a097657acce73eae01_D20210101-20210630" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTAtOS0xLTEtMzYwODY_40121735-7010-4892-9491-8bbc36020c39">6,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTEtMS0xLTEtMzYwODY_3b13fcd1-97af-470a-af83-f5401f830ee0">74,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64f18cac2d0249a097657acce73eae01_D20210101-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTEtOS0xLTEtMzYwODY_d564fb18-74c2-401f-ae9b-c4208a0b75e5">74,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTItMS0xLTEtMzYwODY_fb8d676c-cfcb-43a5-99f2-3044d4045f90">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTItMTMtMS0xLTM2MDg2_a7413441-7ce7-4cfb-8522-e265aef95837">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMS0xLTEtMzYwODY_aa8cd8d0-2e9f-44d1-9ac0-bade06b76c12">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6eae4c7f67f4524a74a58848d23caef_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMTEtMS0xLTM2MDg2_1e63f801-fcbc-4e0c-a815-7b9a57bcab14">130,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMTMtMS0xLTM2MDg2_8c43633b-bd4c-48ff-8b50-d67ac0cf0c1b">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMS0xLTEtMzYwODY_766f7898-0bc9-4cab-a653-2db314958bae">875,887</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMy0xLTEtMzYwODY_576d1772-a5fc-4a54-8db9-d77b2507543f">37,553,355</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtNS0xLTEtMzYwODY_68b81735-0079-40fa-a211-b15cfc4629ea">38</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e9c6f9bcae458e87824df14a960f90_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtNy0xLTEtMzYwODY_f87e69fd-5791-48a0-8f11-54c8f2d81ded">714,334</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97712cb7eec54f298eacfb74dd9aa06e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtOS0xLTEtMzYwODY_5e38ce66-6e24-431f-b08d-f568fcf73d89">400,110</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7e2f3718a14010b98f596f57fe8413_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMTEtMS0xLTM2MDg2_8763ab42-1f15-4e36-8083-c420e585cbb5">560,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1ebf15a9194fddad714c86f2a2011f_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMTMtMS0xLTM2MDg2_e2ab0635-1b27-44a1-9d16-e9aa03227bd1">1,615</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:4.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Six-Month&#160;<br/>Periods&#160;Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMy0xLTEtMS0zNTc0Nw_8919c176-9fbc-4f41-a273-184a10a18e8d">60,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMy0zLTEtMS0zNTc0Nw_4297a351-dd22-4755-a938-67263df90567">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNS0xLTEtMS0zNTc0Nw_4e752b23-3f1e-48d1-b486-419af23beffe">14,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNS0zLTEtMS0zNTc0Nw_1dd21d50-3ca2-4f74-9d7f-5dd353ff8153">14,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNi0xLTEtMS0zNTc0Nw_1864f1e8-9b37-4be4-b137-64db42e72149">12,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNi0zLTEtMS0zNTc0Nw_5dd053c4-762e-4315-bd07-74f16304250b">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNy0xLTEtMS0zNTc0Nw_837774ca-6df5-4efc-bed8-f6b69d999f6e">22,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNy0zLTEtMS0zNTc0Nw_c0876304-6bf6-486b-b25f-21e7e2172dbd">19,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOC0xLTEtMS0zNTc0Nw_cfd86b3d-e276-4471-bcd0-7315b41b9d4d">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOC0zLTEtMS0zNTc0Nw_e0473c08-1a60-491e-987c-064cde8b8861">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0xLTEtMS0zNjM1NQ_d8d3d43d-8065-4e42-8cff-1bceb5a7d327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0zLTEtMS0zNjM1NQ_300edbb5-0808-40f6-ba7f-13fc867d8a61">31,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0xLTEtMS0zNTc0Nw_b1a59435-c457-4c6a-9ad3-f0b75fbce138">6,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0zLTEtMS0zNTc0Nw_a3710e95-f3d8-4ce9-bf9d-e4d7113db152">22,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in loss (earnings) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTAtMS0xLTEtMzU3NDc_3c3a0502-6ba4-4af1-9400-278bbb2bbf2e">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTAtMy0xLTEtMzU3NDc_cc6746fb-66cd-4477-b21f-0e4ee0f3701c">2,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTEtMS0xLTEtMzU3NDc_6ad35214-8d86-4256-b466-63b01c0c67cb">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTEtMy0xLTEtMzU3NDc_07ed9f3c-d18f-465a-84a1-314966147363">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTItMS0xLTEtMzU3NDc_0d84f8b5-a26c-4b08-a23b-fe1d15d123da">2,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTItMy0xLTEtMzU3NDc_461edb8a-0be2-48b1-a6f1-1d83672045dd">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTQtMS0xLTEtMzU3NDc_b720cdaa-fc85-45d2-a9cc-aafbb6b1afc9">21,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTQtMy0xLTEtMzU3NDc_4bf003bd-dc2c-4a2d-81e4-94df27412880">22,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTUtMS0xLTEtMzU3NDc_a31acdc6-a90b-4357-96cc-144d8c6a2493">4,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTUtMy0xLTEtMzU3NDc_cc8d76e5-617d-4a17-ba63-9c18c9c59271">3,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTYtMS0xLTEtMzU3NDc_ba2779c1-fce6-4768-bcd9-9a2a56369d8e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTYtMy0xLTEtMzU3NDc_5b2b601a-3d1c-46fa-b0cc-a6beba6c6449">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTctMS0xLTEtMzU3NDc_e8e53106-8f23-4ed9-a0e4-1f04ca861122">4,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTctMy0xLTEtMzU3NDc_7fde7649-8a47-4368-9f96-7506534ecfb1">6,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTgtMS0xLTEtMzU3NDc_81bb68ca-3b79-4c65-a151-3b654b980b00">29,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTgtMy0xLTEtMzU3NDc_2424ec6f-f001-4304-8770-80d87a3c9cad">1,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTktMS0xLTEtMzU3NDc_24d18948-bc21-4823-8134-7206f73ed3c2">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTktMy0xLTEtMzU3NDc_df24fbd2-0c1c-4fca-8605-298f47ca97f2">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjAtMS0xLTEtMzU3NDc_7123c4bb-32e8-4d08-9130-eb1971ec7e9c">20,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjAtMy0xLTEtMzU3NDc_9f84cec3-ef8b-4ecd-832d-a99710cefa1d">17,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjEtMS0xLTEtMzU3NDc_8a223cc7-e356-48c2-a50d-777adccf4801">1,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjEtMy0xLTEtMzU3NDc_27ae7f07-c173-4633-948f-02f6270d0f98">1,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjItMS0xLTEtMzU3NDc_242b930b-9e73-4db6-8f92-40c9f49e4941">106,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjItMy0xLTEtMzU3NDc_6224ea17-4442-445c-8f6e-d2d23cddad29">121,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjQtMS0xLTEtMzU3NDc_fc60a92f-0aa3-47ae-b583-df5a36f501ca">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjQtMy0xLTEtMzU3NDc_030d2d0c-3b2e-4ea3-949e-79d6e99edc8e">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjUtMS0xLTEtMzU3NDc_a2cbc18c-e657-4bca-886c-6eb3d8d78ad9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjUtMy0xLTEtMzU3NDc_f03d1d03-bd83-44e9-9f7f-a3fd47b0ce7b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjYtMS0xLTEtMzU3NDc_1a91aabf-835b-4243-8dbd-789b0428a62f">2,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjYtMy0xLTEtMzU3NDc_a905caec-41e4-4e4c-8374-cad1bb658cea">2,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in technology assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjctMS0xLTEtMzU3NDc_e6382fd5-b19a-4b50-a40c-be6ec6fcbabc">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjctMy0xLTEtMzU3NDc_ece005a3-6da4-47dc-a440-68973beefe37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjgtMS0xLTEtMzU3NDc_87a42831-5d3d-4427-8897-f88be8b3037c">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjgtMy0xLTEtMzU3NDc_3a3ef4e7-4c35-48ed-8bdd-93b5ab66c9d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjktMS0xLTEtMzU3NDc_e547cb48-dd35-463b-8238-bff201f5ed8f">73,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjktMy0xLTEtMzU3NDc_a4978aae-fa94-4c85-a4b7-d3eb169e1a1c">2,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzAtMS0xLTEtMzU3NDc_28dee853-65b5-4035-a794-01279384d957">91,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzAtMy0xLTEtMzU3NDc_16b1dacf-0f90-4c1b-94c7-b3c6a7fa3844">5,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzItMS0xLTEtMzU3NDc_b5b519df-aa74-4753-afb6-7a7740d68920">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzItMy0xLTEtMzU3NDc_65ecf07e-9c59-477f-99a2-749268540b1c">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzMtMS0xLTEtMzU3NDc_e2641664-54f9-4bd2-9eaa-c48fe5ec35aa">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzMtMy0xLTEtMzU3NDc_ab9c3069-6b82-45db-ae71-818d5f9f7765">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzQtMS0xLTEtMzU3NDc_ea37a411-37bb-46ce-a248-57dd78844e1e">4,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzQtMy0xLTEtMzU3NDc_932cd504-ee8e-4585-b272-5a666e9d22f4">6,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzUtMS0xLTEtMzU3NDc_6ec9f869-3b95-47e3-85a2-1b95ca038f61">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzUtMy0xLTEtMzU3NDc_6dd25c24-b187-439f-a640-0165148a32b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzYtMS0xLTEtMzU3NDc_87283b9a-8131-40da-980a-6f5772373a2a">975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzYtMy0xLTEtMzU3NDc_82cd77d4-8e93-43e3-9e96-9f61e4ae908f">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzctMS0xLTEtMzU3NDc_d7fc5aec-1df0-4b37-88be-d582ce2cc5f9">298,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzctMy0xLTEtMzU3NDc_1684d4d0-427d-44db-9656-91d7bdf0dd6e">389,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzgtMS0xLTEtMzU3NDc_744ec7f5-a232-40d2-88a6-3cdfbcc40118">283,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzgtMy0xLTEtMzU3NDc_b60b0118-2156-48d6-92e1-3eca42b910ad">410,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzktMS0xLTEtMzU3NDc_111e6f70-2dc8-4923-89be-a1b7918d196e">6,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzktMy0xLTEtMzU3NDc_a225e629-5bc4-4a1d-ae63-14b1d1ccf5a6">5,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDAtMS0xLTEtMzU3NDc_a4067d10-0be7-4c31-ab24-df48f1e25917">17,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDAtMy0xLTEtMzU3NDc_0dc169f2-043f-4344-bc03-a6dd6bed7f0f">74,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:FundsReceivedFromProviderReliefFundAdvance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDEtMS0xLTEtMzU3NDc_90468678-f2bd-47fe-ac7f-f994fa9c209c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="amed:FundsReceivedFromProviderReliefFundAdvance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDEtMy0xLTEtMzU3NDc_d01d0af8-74ac-4d32-a178-c357f3693759">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDItMS0xLTEtMzU3NDc_8d2b335a-62f7-430f-854d-f45256f78456">11,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDItMy0xLTEtMzU3NDc_1adc16df-c7e0-4f9c-aa08-1407b8b226a2">107,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDMtMS0xLTEtMzU3NDc_fe5f55ae-a236-4fd2-83e4-18c02cedc93b">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDMtMy0xLTEtMzU3NDc_acdd876c-dd0d-42d1-aecf-08cb7936a06c">9,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDQtMS0xLTEtMzU3NDc_ba622055-0716-4acc-ae9e-6de500cfe71d">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ec7ab4116e4010b85638d99e1435a4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDQtMy0xLTEtMzU3NDc_bfc8d4e2-d14c-4510-bca9-f6a74cabfb05">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDUtMS0xLTEtMzU3NDc_dd3c8ed5-e38a-47cf-a2c6-d7e257762e5d">48,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDUtMy0xLTEtMzU3NDc_4c461e5f-4f4d-43f1-94c6-b519cee7bad3">92,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTMtMS0xLTEtMzU3NDc_97ba49ca-d7f7-4868-96f9-35a9d4904b62">4,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTMtMy0xLTEtMzU3NDc_a30d1901-f97c-4286-b441-157e01a51704">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTQtMS0xLTEtMzU3NDc_48f86985-5e07-4436-97e0-bd855eab1df7">22,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTQtMy0xLTEtMzU3NDc_6ecfcfb1-aaf1-49f3-8e23-f24c8f6157dc">8,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:CashPaidForOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTUtMS0xLTEtMzU3NDc_c00b895a-ff3d-40b5-bab6-a12670a2e561">22,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:CashPaidForOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTUtMy0xLTEtMzU3NDc_67349c5a-1449-45bd-92bf-073ff91e1ace">19,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTYtMS0xLTEtMzU3NDc_763bf131-e5f5-487b-b725-f18b0c1b3260">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTYtMy0xLTEtMzU3NDc_841bda49-bde1-438d-a28a-b2a78d05fdac">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTgtMS0xLTEtMzU3NDc_41a2b62c-5ecf-490d-88aa-30ce80cc238d">26,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTgtMy0xLTEtMzU3NDc_6e75aa30-c245-4924-aa6e-8ecd7143c569">20,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTktMS0xLTEtMzU3NDc_3219ea18-80d4-4cd2-a247-44ade552588e">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTktMy0xLTEtMzU3NDc_267ca97d-7605-4558-88f5-cbcff1d93a4f">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to right of use assets resulting from reductions to operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMS0xLTEtMzU3NDc_2295cfe9-e80c-4af0-b597-7d9b16788552">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMy0xLTEtMzU3NDc_c8361e88-c0e1-44c6-97df-63c58625e79b">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMS0xLTEtNDI4MDA_b7071ebe-2eec-4642-a4e4-b0e8fdfae972">19,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:NonCashAccruedContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMy0xLTEtNDI4NDE_06dcb23d-88b1-4d24-914e-36404a56e88a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest contribution</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjEtMS0xLTEtMzU3NDc_d7ca1fd8-7670-4a97-bdc2-3bd7e4df46af">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjEtMy0xLTEtMzU3NDc_544c62bd-e475-4cae-af11-1d6832097a2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Mw_7b872b71-7efd-49ce-9737-c53034f5e1d7" continuedAt="ie33b48c2307542dab6b0ead8a7d5db56" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="ie33b48c2307542dab6b0ead8a7d5db56" continuedAt="i9a0828e16a6b4dbfabedeccb9d046ae8"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately <ix:nonFraction unitRef="number" contextRef="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzQx_43389de9-dc1f-430a-962a-e21f76afc337"><ix:nonFraction unitRef="number" contextRef="i12d3114d05584bdc834ec068c834314b_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzQx_4bcc37b8-769b-406a-8880-ccd543730d34">74</ix:nonFraction></ix:nonFraction>% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately <ix:nonFraction unitRef="number" contextRef="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDM4NQ_2e2553cb-a0e7-4a8b-bb4e-4b07b34845d7"><ix:nonFraction unitRef="number" contextRef="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDM4NQ_a9ca6c13-31a2-4dff-98b6-8c0863f8d928">75</ix:nonFraction></ix:nonFraction>% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021. As of June&#160;30, 2022, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i952b1caa605842b8b2c6cc1f6ed49167_I20220630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDg0_c9d50f7b-ddde-439f-9210-cdf7eea89be4">353</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="i6f689c40db574abeba5ad517246536ed_I20220630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNTMy_413f654f-6b2c-4605-afe6-0b59e7b86a81">174</ix:nonFraction> Medicare-certified hospice care centers, <ix:nonFraction unitRef="care_center" contextRef="idacfe2999ae746bea86d800a07b26023_I20220630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNTc2_736a9e9e-e2ed-49ce-b452-8b768656f4c1">14</ix:nonFraction> personal-care care centers and <ix:nonFraction unitRef="numberofjointventures" contextRef="ica0fc66197bf4246a3cb7df9b28e8f04_I20220630" decimals="INF" name="amed:NumberOfJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjEw_550154a7-4356-4c22-8e4a-17d80532d510">9</ix:nonFraction> admitting high acuity care joint ventures in <ix:nonFraction unitRef="state" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjQ4_84d58fe7-3aa7-42c7-8996-c24196a5012c">38</ix:nonFraction> states within the United States and the District of Columbia. </span></div><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2NA_5362b1a1-1ec8-42b1-8d17-d112a6bf05c5" continuedAt="i2c6fbd8a2b3b4c6f922227c23eae93f1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2c6fbd8a2b3b4c6f922227c23eae93f1">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 24, 2022 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Ng_6df0a7f9-5f9d-44a2-822b-7a2993d47f02" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Nw_1e39a1bc-10c7-48e5-b823-8c5dc159332f" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM1Nw_109d4007-6091-42c8-9fd7-e5627e2636cb" continuedAt="i3db0b06479ec4d5ea1b491d64e78f45b" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzA4NA_1e09ad75-f3ac-4cfe-a180-0a514bd3418a">50</ix:nonFraction>%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzM4NA_cf5fe446-945a-47c1-8241-75fe9fd18087">50</ix:nonFraction>% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzU3Ng_0c56c056-4786-40d5-8e7b-b487bf4f5e32">45.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzU4Mw_aa6d238f-e202-457e-ba7a-96b49848ec97">48.1</ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $<ix:nonFraction unitRef="usd" contextRef="id11e4c1c56094d87b2ab9c56771f2868_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDcxMQ_a33fc84f-2ee0-4cc8-ab78-0364f896360b">31.1</ix:nonFraction>&#160;million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9a0828e16a6b4dbfabedeccb9d046ae8"><ix:continuation id="i3db0b06479ec4d5ea1b491d64e78f45b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="3" name="amed:MaximumPercentOwnershipForCostMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDIyMw_b02dcd50-e821-49a9-991c-663694bf1df8">20</ix:nonFraction>% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $<ix:nonFraction unitRef="usd" contextRef="ia755b346de2741dfa14730fe4f9e2fb7_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDQyNg_521eea87-49ac-4715-9dc5-c7335fb20ab1">15.0</ix:nonFraction>&#160;million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDU4MA_adcafc95-a9b2-4ec8-b6b7-ca88152b0586">20.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDU4Nw_cf7a5622-0050-4c06-b457-4a6637c3f654">5.0</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2OQ_b0021b94-fd82-4fdc-b814-396cc2ae6130" continuedAt="i38d51ea53877472eb918ee56bb7507db" escape="true">The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i38d51ea53877472eb918ee56bb7507db"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:61.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMy0xLTEtMS0zNTc0Nw_1d593092-db0c-40ca-8c63-fc78fa50c469">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMy0zLTEtMS0zNTc0Nw_eea23de3-4849-4b59-be03-3c216c61f38b">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNC0xLTEtMS0zNTc0Nw_8093620c-3bfe-410b-b6e3-be4270449876">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNC0zLTEtMS0zNTc0Nw_ae4d18ea-60ac-4bbb-9191-00fa4d3c2bf0">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNS0xLTEtMS0zNTc0Nw_7a3caac5-fcf0-434d-a118-0fb9b2612185">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNS0zLTEtMS0zNTc0Nw_1415baf0-6757-4003-8520-107a6d1a0e7d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNi0xLTEtMS0zNTc0Nw_34a27fa5-c2a5-458c-bab9-fab62c68073e">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNi0zLTEtMS0zNTc0Nw_4d62ac9a-bcb9-49ad-a381-810b9216a789">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNy0xLTEtMS0zNTc0Nw_f8d18914-78a3-4e25-8b18-a0963f908789">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNy0zLTEtMS0zNTc0Nw_9372fb8f-6c47-4287-9dbd-e947398e9d04">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOC0xLTEtMS0zNTc0Nw_4377c7c1-581a-4432-a6e4-b0bdfcb3c4ba">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOC0zLTEtMS0zNTc0Nw_879652b8-be0d-4e96-ae2e-b5c17fd3f21e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOS0xLTEtMS0zNTc0Nw_c81e27d2-83ce-4332-b10f-01052d8c5c62">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOS0zLTEtMS0zNTc0Nw_aa647b97-4cdd-4c51-ad43-fd0fa071a6bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTAtMS0xLTEtMzU3NDc_dabb0d05-cca8-47b6-bc5d-2237b9946859">24.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTAtMy0xLTEtMzU3NDc_56419427-357e-4e34-8c92-fcca173d56ff">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTMtMS0xLTEtMzU3NDc_c5922ac7-81a7-4615-8759-7c5ac9d903a7">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTMtMy0xLTEtMzU3NDc_ec499166-0c1c-49cc-bac6-88f1b0bc4c8d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTQtMS0xLTEtMzU3NDc_7b6f35d5-fadc-487e-b786-24f493035969">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTQtMy0xLTEtMzU3NDc_ce29157f-c412-44c5-bef5-9a1a6d00eebe">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTUtMS0xLTEtMzU3NDc_831da9e8-fd25-4aea-9c4e-9fd29dcfcde0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTUtMy0xLTEtMzU3NDc_8f319189-710a-4c68-937b-8b9333df5b83">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTYtMS0xLTEtMzU3NDc_a3a58391-1781-4fab-9a70-4403d82c7b88">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTYtMy0xLTEtMzU3NDc_40da0b40-806e-47e9-9f14-5514d2acc0d0">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTctMS0xLTEtMzU3NDc_c52e6455-334f-4ad5-99fe-70c1f71ad689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTctMy0xLTEtMzU3NDc_2ae470cf-a110-428f-bb84-a1b5d6946589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTgtMS0xLTEtMzU3NDc_349c9b49-fa07-4e67-838e-863ccb630549">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTgtMy0xLTEtMzU3NDc_f7656798-6697-494f-a437-bee040aa5b64">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_43"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTE_eea1145a-84dd-4331-bebe-abae406ca85c" continuedAt="id2d9bd4996794844959003da5c1d9257" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="id2d9bd4996794844959003da5c1d9257" continuedAt="i5785a2dc246343a8a2f1e7de23aa88cd"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTQ_8db2824e-2464-4a52-96b9-6eacdea2892a" continuedAt="i11688e0fbfa749c08243ee02ea807750" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately <ix:nonFraction unitRef="number" contextRef="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjMyMw_43389de9-dc1f-430a-962a-e21f76afc337"><ix:nonFraction unitRef="number" contextRef="i12d3114d05584bdc834ec068c834314b_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjMyMw_4bcc37b8-769b-406a-8880-ccd543730d34">74</ix:nonFraction></ix:nonFraction>% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately <ix:nonFraction unitRef="number" contextRef="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjcwMQ_4a864edd-74e7-4179-bf83-f66d17a1c798"><ix:nonFraction unitRef="number" contextRef="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjcwMQ_d727dcb2-42e6-4add-8c0a-207c0f9c39cb">75</ix:nonFraction></ix:nonFraction>% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMzg2Mw_972f2e82-44e1-4a8d-8df2-7d34e4bfedb1">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5785a2dc246343a8a2f1e7de23aa88cd" continuedAt="i6d159b6b281842979d964f6bc705582e"><ix:continuation id="i11688e0fbfa749c08243ee02ea807750" continuedAt="icb8fad4eff1d4afb8693220f675091bf"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDY_6f6a46b9-a30e-44fe-912d-45168a13467c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied4fd711d218438abe660d1442afcde4_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy0xLTEtMS0zNTc0Nw_95689e72-ec96-4697-893d-87dfef87eeae">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ec1a19c1ba94e878ec8fda9cd5339f1_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy0zLTEtMS0zNTc0Nw_2258c018-a946-4142-841a-9d1f758b1d37">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8da76d47f10d4c0c8c8c8b0fd249aa26_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy01LTEtMS0zNjQ0OQ_59e7e3fd-2413-4115-a061-dd74580f7014">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfd2cc70011c4d8ca45f2cd8312980c3_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy03LTEtMS0zNjQ0OQ_2b1b2ae5-3eb6-4946-b5a8-033b3bf72f0b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa76b1acfeaf486da02b9af11cc816a6_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC0xLTEtMS0zNTc0Nw_d941cbb1-928c-402b-87fc-596418c0600e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i751a2debd3674a8cb7cef6a38ae12130_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC0zLTEtMS0zNTc0Nw_e5ff7eda-7738-4694-bfee-51a1546e092a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82c50b0e545d4a1785eeb7d1a9c185cc_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC01LTEtMS0zNjQ0OQ_2403145c-cd60-43e9-bcc5-ae24df31d605">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1b3730a17e64e0f992cd153fd840cf2_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC03LTEtMS0zNjQ0OQ_839ab64e-eb3b-4aea-8326-a40a5c9b1830">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6061248324244eebe4d0db40312edac_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS0xLTEtMS0zNTc0Nw_87579fe2-b960-404e-af7f-eb8684c069f7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib24ed3919fc848288bb8ac2ced90d84b_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS0zLTEtMS0zNTc0Nw_a15bb436-fe3e-40e3-8b44-ead2fc375dc4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07a28a2b65f4472ab0c894d89400b474_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS01LTEtMS0zNjQ0OQ_17b62680-beb2-49bd-a6b8-cd8fe463e936">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53cca52064ef477ab34029b221d6d69d_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS03LTEtMS0zNjQ0OQ_c58aef29-e98d-40c4-bca3-4e059ebfd217">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6190b80120f43e2a1575644159feb4e_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy0xLTEtMS0zNTc0Nw_04f69329-8de4-4ecc-a4d7-b192754bad31">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63963cb819344481af520c8bff0b5d1d_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy0zLTEtMS0zNTc0Nw_8a05e671-1035-4f7a-a0e8-6043a3c4dcbb">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64fbb473e60d4729802929c3f20aeafe_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy01LTEtMS0zNjQ0OQ_25e9bdb0-e5cb-4396-8d74-a464c78b3dcb">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89df7c974a654e3a941400b05e8929a4_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy03LTEtMS0zNjQ0OQ_a3d665d9-5be0-4a9d-8387-adfc6aeef9bc">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5749f12c34ef4e4a81639e239b7a472e_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC0xLTEtMS0zNTc0Nw_f1deeebc-df27-4e73-b368-e97dfa089aee">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica66251978d1405bb862d424880702f5_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC0zLTEtMS0zNTc0Nw_29b049d1-dc48-4b8c-8acc-4442ffaa08d2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1eb4c6bf9b7f441aba17bfa2e6583e74_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC01LTEtMS0zNjQ0OQ_5ae88ac0-dc57-4775-93b3-f711b91137c4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i356d5eeddab246eca55259b8d751e968_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC03LTEtMS0zNjQ0OQ_0fba5a68-2280-4172-a3f8-4729b8186fba">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88871dd43ddc4081830db6b06e82af59_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS0xLTEtMS0zNTc0Nw_d533eabb-0e95-4c32-912b-d0eec2e75710">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5e997d4464b4ea4bfa067035b64249a_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS0zLTEtMS0zNTc0Nw_74f03d0d-3594-4e78-953f-2073b20accdc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35822c2e8f8846808fd72e3482edc1a8_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS01LTEtMS0zNjQ0OQ_018a0809-2ea3-4aac-a098-32dda34ac537">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dddcac370504787ba0022ab6dfadefd_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS03LTEtMS0zNjQ0OQ_4d6f1959-ba13-4747-bc00-98f75f05bc59">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id920f2f6a7f04db3b0281051fbbc33cf_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtMS0xLTEtNDA3NTY_e55d59bb-628e-4773-88c2-8b78de3d4cba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f1e1d42e8bb4d88b2aed4812e852cbb_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtMy0xLTEtMzU3NDc_16ae3d34-ae2f-4bb5-b364-1445588f09a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i926108a7b35d4c89a57993c4c6997466_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtNS0xLTEtMzY0NDk_bb609b69-bcf6-4bf6-8952-b077e494d70a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b91dd04f2634b899d9d8c66e3339361_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtNy0xLTEtMzY0NDk_e74f6986-edaf-4275-9301-96ba7bbe0f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtMS0xLTEtMzU3NDc_3d216b0d-c533-4618-ac65-7950318d1f83">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtMy0xLTEtMzU3NDc_c6b4d485-26b0-418e-9975-7ad8d41e5817">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtNS0xLTEtMzY0NjM_a92b5f17-ec57-463e-9c28-da0190a82a6f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtNy0xLTEtMzY0NjM_3ea261ca-6145-4ade-84fa-c975b82984e1">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNDQ5MQ_6a27d38b-0595-4a69-ab8e-9254cd54488d">30</ix:nonNumeric>-day periods of care rather than <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNDUyNg_1d04be51-73a0-4ce5-9f6c-8ea8d4ca5e29">60</ix:nonNumeric>-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTM4Nw_1d04be51-73a0-4ce5-9f6c-8ea8d4ca5e29">60</ix:nonNumeric>-day episode includes two <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTQxNQ_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day periods of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTU0NA_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjAwMQ_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care. We utilize our historical average length of stay for each <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjA4Mg_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjM1Mw_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjU0Nw_904fd5e5-7ecc-4a38-9f70-2e953c053f72">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="visit" contextRef="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjczNw_96fcd39d-5bbd-4d8a-a6ee-aa8fbc9c1072">two</ix:nonFraction> to <ix:nonFraction unitRef="visit" contextRef="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjc0Mw_b7ca17ed-97ff-46da-83a6-ae20a30b3965">six</ix:nonFraction> visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjkwNw_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNzA0Mg_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNzM2MA_29522484-c571-4fd0-b71e-1b6a87b6c205">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6d159b6b281842979d964f6bc705582e" continuedAt="i6a0ad7893ccf49adaa3d43af9ae74cba"><ix:continuation id="icb8fad4eff1d4afb8693220f675091bf" continuedAt="i931ca63a37a04ce7bd5edec6028420b4"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from <ix:nonFraction unitRef="number" contextRef="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfOTE3Mw_347cf8ad-a6d3-47a5-977c-6dc7385b07bb">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfOTE3OQ_06fc1d13-edbb-4dc0-bc6a-d2518c6d285a">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_4853c769-3e90-4b1c-8c8e-bf9766b74abd"><ix:nonFraction unitRef="number" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_6abe8cdd-8cb8-4bfd-849a-83cfef992c0e"><ix:nonFraction unitRef="number" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_b86821b3-6885-47bb-ac43-3350993c6455"><ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_ed0f8263-9030-440f-b19e-8e34db82869c">97</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTEzNjY_519d0fb6-a806-4cf3-bca8-ecc0481aef2d">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June&#160;30, 2022, we have recorded $<ix:nonFraction unitRef="usd" contextRef="iac48d82a63114da69e22201712a8c0c4_I20220630" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTIxMTM_d840192f-a181-4b3a-a179-8e4475d01dea">4.2</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022. As of December&#160;31, 2021, we had recorded $<ix:nonFraction unitRef="usd" contextRef="ie3a945b2920249189593bc4dfb36414a_I20211231" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTIyODI_8141cb9b-c414-4f47-b0fe-f083b3a78609">4.5</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6a0ad7893ccf49adaa3d43af9ae74cba" continuedAt="i7874fe9d90d64b9bae77abde0b5d00fe"><ix:continuation id="i931ca63a37a04ce7bd5edec6028420b4" continuedAt="i7a174b7524f0492cb7c9953cbf3a66cb"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a <ix:nonNumeric contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTQ4ODc_facf2de3-ec62-416d-b063-0cd1010267e6">30</ix:nonNumeric>-day (H@H) or <ix:nonNumeric contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTQ5MDM_d9a01fa1-e5b8-49f9-b978-541d4659f138">60</ix:nonNumeric>-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the <ix:nonNumeric contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUwODE_facf2de3-ec62-416d-b063-0cd1010267e6">30</ix:nonNumeric>-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the <ix:nonNumeric contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUxNjk_d9a01fa1-e5b8-49f9-b978-541d4659f138">60</ix:nonNumeric>-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a <ix:nonNumeric contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUzMzU_facf2de3-ec62-416d-b063-0cd1010267e6">30</ix:nonNumeric>-day or <ix:nonNumeric contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUzNDU_d9a01fa1-e5b8-49f9-b978-541d4659f138">60</ix:nonNumeric>-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7874fe9d90d64b9bae77abde0b5d00fe" continuedAt="i4a408a29ca3540319eff70f5089aa72f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a174b7524f0492cb7c9953cbf3a66cb">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</ix:continuation></span></div><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:GovernmentGrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTk_559acf22-cb51-4220-a320-5a35d6de1270" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDM_86a4344b-8a12-4370-bcd6-129a517e17b0" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ic21dc870eef3444a90c0b71790318d59_I20220630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MzU5Mg_74b568e1-13a0-4b73-b404-a5c615bfdac1">22.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc3a77e521b04aeebf04452b84789764_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTgzNjI_e30b6c56-626a-456a-99ec-798a880ad417">3.1</ix:nonFraction>&#160;million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzODk_4c501004-18c7-46ea-baed-1082ee9ac5e4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMS0xLTEtMS0zNTc0Nw_a78386a4-f282-4c89-b620-e4c04b91930b">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMS0zLTEtMS0zNTc0Nw_e8098997-df44-408b-a2ff-15bcb900a29a">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMi0xLTEtMS0zNTc0Nw_9784e1fb-aacd-4d57-94bc-6dbcaf36a5f4">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMi0zLTEtMS0zNTc0Nw_444eed69-ce0b-412b-91a7-15929fc0d53f">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMy0xLTEtMS0zNTc0Nw_2125a20d-fa16-4898-a1eb-052577d03d78">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMy0zLTEtMS0zNTc0Nw_573c198d-a893-4170-8ce3-b8fdff9c66fa">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzODU_f969a1b2-4a6b-447d-bf1f-b25da88e3655" continuedAt="i6bab1cc418604e9f87de0f1847ca607c" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2022, there is no single payor, other than Medicare, that accounts for more than <ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTkyNzY_977d75ed-2d6e-4b9d-a825-06ea67a95f22">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk3MzU_2c5a56d2-4df4-4ac3-ae52-e318bc563327"><ix:nonFraction unitRef="number" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk3MzU_64b1f648-bedd-42d8-a100-5703ef95198d">68</ix:nonFraction></ix:nonFraction>% of our patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk4NTg_faf59125-3564-43d8-93cf-2a4c69d53bcc">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i4a408a29ca3540319eff70f5089aa72f" continuedAt="i04c2e5b068864b0b9a7dcf04a37a30c9"><ix:continuation id="i6bab1cc418604e9f87de0f1847ca607c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MzYxMA_038d3628-be99-44fa-882a-e7db0f0bfa4a">30</ix:nonNumeric>-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:continuation><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDE_e144f12f-511a-4fe1-bc35-516920d3f476" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i04c2e5b068864b0b9a7dcf04a37a30c9"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTM_accd323b-fb24-4376-b414-f07c5597d3b7" continuedAt="i4e4d8180da1b450aa7c2fb0d933df5b8" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTU_64fe5ab8-f1cb-4cf4-ba4a-9b0d3a5a000f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi0xLTEtMS0zNTc0Nw_898bca59-e6b8-4523-a45b-41ee5a5cc337">456.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6279924dc89846fe9e81f87aed338b84_I20220630" decimals="1" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi0zLTEtMS0zNTc0Nw_40dc2241-2850-453c-91d1-e9c815637db7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcff0785ecd9434fb01d7a18ff154dc6_I20220630" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi01LTEtMS0zNTc0Nw_eee6f716-4cba-463c-9933-dd6e463bf316">476.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cd0bb8003d49c6a5231bf472e9ed5b_I20220630" decimals="1" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi03LTEtMS0zNTc0Nw_4406bfc0-8220-434a-b04e-2bd8da68b2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e4d8180da1b450aa7c2fb0d933df5b8">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTI_3a61968a-52d3-4f26-8be2-811877b60031" continuedAt="ib4f5050b0f4c46f0bd08fcd3b80101df" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib4f5050b0f4c46f0bd08fcd3b80101df">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTU_37c61de2-438a-4b33-82ad-05838b168f02" continuedAt="i1b57cef2e28d4eb3bf7839edc648020d" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i1b57cef2e28d4eb3bf7839edc648020d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi0xLTEtMS0zNTc0Nw_9c71983c-207c-4541-b5dc-03a4f7ef7a5d">32,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi0zLTEtMS0zNTc0Nw_d3a1ee6f-d767-49ef-b628-818a49b61cd4">32,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi01LTEtMS0zNjUzNA_bff20cc0-2718-4e8e-842a-9022006f388c">32,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi03LTEtMS0zNjUzNA_ce7560ab-c14c-4b07-b28f-1226c8ce3cbf">32,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC0xLTEtMS0zNTc0Nw_28668252-b840-4c1a-994d-92134fe284f0">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC0zLTEtMS0zNTc0Nw_d28e78fd-6966-4460-b99a-4a3bb713faa4">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC01LTEtMS0zNjUzNA_f070cc12-2c2a-4566-afad-9f513d1c05b1">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC03LTEtMS0zNjUzNA_b90fd759-a692-49a7-b4d6-6844b2ca58e6">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS0xLTEtMS0zNTc0Nw_6b75cbbc-aeee-46e5-8ac2-aff901f790b4">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS0zLTEtMS0zNTc0Nw_277e68b6-d63f-437a-b134-b68591340200">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS01LTEtMS0zNjUzNA_d2d94783-63d0-4f01-9548-c18081380f02">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS03LTEtMS0zNjUzNA_91f78155-4ca5-49a0-8500-cb8792daa17a">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi0xLTEtMS0zNTc0Nw_80075471-0034-4f0c-b4b9-7680082c8353">32,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi0zLTEtMS0zNTc0Nw_2c75c986-cc82-4eab-8f2a-a6a7e698ecb6">32,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi01LTEtMS0zNjUzNA_633a71e0-2537-4a6e-be9d-51468c9c91dd">32,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi03LTEtMS0zNjUzNA_676b7caf-afdb-43ad-90a0-4256bb36c347">33,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy0xLTEtMS0zNTc0Nw_c71fe7c7-1e94-4069-93b8-45186243a320">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy0zLTEtMS0zNTc0Nw_5231586c-ff11-4a6f-bbe3-2166500a0b92">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy01LTEtMS0zNjUzNA_632b6b91-7c85-4fea-8ab3-ef234dc87576">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy03LTEtMS0zNjUzNA_f8b08c1e-142c-419b-893c-c0a41b64976d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_49"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:COVID19TextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNDA0Mg_5850ce9b-e57e-4bad-941c-f50c1566ad4e" continuedAt="ie3fa5e0c0fbd49218b9dc1318fe31753" escape="true">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ix:nonNumeric></span></div><ix:continuation id="ie3fa5e0c0fbd49218b9dc1318fe31753"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $<ix:nonFraction unitRef="usd" contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327" decimals="-9" name="amed:FundingForHealthcareProvidersIncludingHospitals" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNzI5_55dd53fe-1c52-4e33-80d8-8e7580345ffd">175</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327" decimals="-9" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfODU0_665cd09f-c0bb-44e4-b5cf-a0cf2c81243a">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $<ix:nonFraction unitRef="usd" contextRef="i559e5275bf6a413d992d5f29b2508130_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTIxNA_a021af0b-7218-485f-bcb1-ebd44443ff2f">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327" decimals="-9" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTIzMg_51bf78d2-47a5-4bc4-82d8-76ed0c575bb4">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $<ix:nonFraction unitRef="usd" contextRef="i09472bba331640d7b8fce12ca5f6d194_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTMxNw_c03e0c40-cecd-4c4e-ba60-b328e3a68eee">2</ix:nonFraction>&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $<ix:nonFraction unitRef="usd" contextRef="i39ddd6046a8c4277a4a08449e4ec5af5_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTQyMg_d905ba9d-2213-4196-9d68-74105fcb9b8d">6</ix:nonFraction>&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the PRF funds received; all unutilized funds were repaid in October 2021. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNDA0MA_fca9aab6-ca7f-43df-ae0c-9603a16a4987" continuedAt="ibd1ff53198524003b9561f4826abcf94" escape="true">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="ibd1ff53198524003b9561f4826abcf94"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:76.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMS0xLTEtMS0zNTc0Nw_55affef6-d72a-4d36-9eb6-f87208da74da">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="amed:CARESActInterestRepaidToGovernment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjMzMmRkZmExNTVjMzRlNjM5ODkyOTY0MmZjYmQzOWQ4Xzcw_b17b2ed2-8689-40fa-837b-5edc5d432b15">0.2</ix:nonFraction>&#160;million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMi0xLTEtMS0zNTc0Nw_9d9d6e4d-2ebb-4690-8235-3d827541bf3e">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMy0xLTEtMS0zNTc0Nw_6a02594c-5ca9-4716-88c9-5f2fbc45b55e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfNC0xLTEtMS0zNTc0Nw_d697a39a-271b-4668-9126-b46100a8d195">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="amed:TotalCARESActProviderReliefFundsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfNS0xLTEtMS0zNTc0Nw_ca78e1d0-2d77-4d62-9271-d8df372fea5c">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and has been reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The suspension of sequestration increased net service revenue by $<ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzUwMw_85516709-5d4a-4936-b6c4-015e9befc7e7">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTA5OTUxMTYzMjIwNw_7ca0c453-70d3-4490-b8d8-a06475c57b90">13</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTA5OTUxMTYzMjAwNg_e06bdd30-7f57-44e0-921d-65e48e07aed7">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzUxMA_e7f53ac3-f9ae-4e98-b373-b887521719d6">18</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $<ix:nonFraction unitRef="usd" contextRef="icf597362dfa64e339e5ded664c4686cb_I20201231" decimals="-5" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzgxNA_05b81eb7-3423-414c-9de1-99af1e98ec69">55</ix:nonFraction>&#160;million of social security taxes. Approximately $<ix:nonFraction unitRef="usd" contextRef="i61fa6d510c13404db32529ba1a32617b_D20210101-20211231" decimals="-5" name="amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzg1Nw_c2a8cfad-fbbf-4d47-9b9d-35c988d53d3b"><ix:nonFraction unitRef="usd" contextRef="id1d84b1e5c3f433e9b75ae592fa0fd06_I20220630" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzg1Nw_efc04b74-1c7e-4fd6-8128-ed46cbd06855">27</ix:nonFraction></ix:nonFraction>&#160;million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0Ng_0bbcd6f2-dbba-4615-9e20-30521d95833d" continuedAt="id062ec16f4af4c22b9a37de9ee4202a0" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="id062ec16f4af4c22b9a37de9ee4202a0" continuedAt="i9f9dda30507e432ab59f32700c6479c2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="id339d8bb1ad54c308f39f7c547fbc108_D20220323-20220323" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTU3MQ_76b02b6c-5dee-4819-b040-141dda341203">8.5</ix:nonFraction>&#160;million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i78865dd720d74892af146d51ab673d72_I20220323" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTU5Ng_1cd5f8b8-ace7-47ce-956c-468151c1bfe7">0.4</ix:nonFraction>&#160;million (certificate of need and licenses) and noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="ib7f617d6993d44d1bad636bee8dc70e0_I20220323" decimals="-5" name="amed:BusinessCombinationAcquiredNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY2NQ_9e036146-aa0d-41fa-8842-eebf1be7947d">8.9</ix:nonFraction>&#160;million within our condensed consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjU4NQ_99f01391-2bc5-40b1-84b6-2812cd921251">15</ix:nonFraction> home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjU4OQ_52bd2f85-303c-4128-9db7-a32b4e59cd55">67.8</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401" decimals="-5" name="amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY0OTI2NzQ1NTY4MQ_4d559175-c88b-4a89-856f-32f27cbac09a">51.1</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA3OTM2MA_f2c940d8-00eb-4edc-83f2-5bd7204f84d9">16.7</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY0OTI2NzQ1NTY2Ng_db43943d-c51d-42ef-8c6d-efece35d459f">16.7</ix:nonFraction>&#160;million placed into escrow, $<ix:nonFraction unitRef="usd" contextRef="id86fb111888b450497127e23c0316217_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgzNw_38712355-d37e-4385-b266-24f575612ce2">1.0</ix:nonFraction>&#160;million has been set aside for any potential closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price is subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. We expect to finalize any changes to the purchase price resulting from the closing payment adjustment during the three-month period ending September 30, 2022. The remaining $<ix:nonFraction unitRef="usd" contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTg1MQ_0a0d0770-095e-4b21-819f-9c7a78a5bbb4">15.7</ix:nonFraction>&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $<ix:nonFraction unitRef="usd" contextRef="i3846fa0b86854a5bb6a4eea857e8c9c5_I20220401" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDM2Nw_6a9d6648-06bb-4ae1-a222-77f30f3c4261">15</ix:nonFraction>&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDQ3Mw_ee0eb62b-86be-4553-88aa-d54f848c6f61">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolution contributed $<ix:nonFraction unitRef="usd" contextRef="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDUwMA_89b6eaa9-3d99-4829-b4ef-f0adbd5c346d"><ix:nonFraction unitRef="usd" contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDUwMA_ac0732de-f093-4b43-8423-61afdade436d">11.3</ix:nonFraction></ix:nonFraction>&#160;million in net service revenue and an operating loss of $1.8 million during the three and six-month periods ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNjMzOA_89e86df5-3467-4c63-b2a9-c948ab0f7024" continuedAt="i70f94361828f4f3f9921c0c0e256e201" escape="true">Based on the Company's preliminary valuation, the total estimated consideration of $<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTUyNg_f7283e39-6e2b-407e-bf02-c83b3a81ea8d">67.8</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9f9dda30507e432ab59f32700c6479c2" continuedAt="ia4d9bfd2eb1d4570b7b4cec3476a3f3d"><div style="margin-top:6pt;text-align:center"><ix:continuation id="i70f94361828f4f3f9921c0c0e256e201"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMi0xLTEtMS00MDk5Nw_de75dfb6-4ea4-49c6-b7c9-afd0a306a519">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMy0xLTEtMS00MDk5Nw_fc98027b-ed94-4511-8bad-da3bd1f29721">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNC0xLTEtMS00MDk5Nw_bb846b9e-e793-40be-81cf-cb2479e7942b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNS0xLTEtMS00MDk5Nw_0d2aa237-c77b-4f78-9919-d47eda211f5a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNi0xLTEtMS00MDk5Nw_082921e7-3eea-402f-8e78-de2a3dc3c6e0">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4fb833a0ee942bf86af673e369faa07_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNy0xLTEtMS00MDk5Nw_af7e0ec6-6e11-43f6-8940-207127df8477">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfOC0xLTEtMS00MDk5Nw_b8c46430-6da4-427a-ae55-7f32f76c4642">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfOS0xLTEtMS00MDk5Nw_62bc8188-82e1-457c-8426-bae2c64bfb25">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTEtMS0xLTEtNDEwMDA_b04a9c4b-1a8a-4bc0-ace3-e9f1d7a035af">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTItMS0xLTEtNDEwMDA_fc08a3ab-1399-4b8c-bd3a-75eb3c77f835">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTMtMS0xLTEtNDEwMDA_99ecd5b9-40e9-4647-bda0-a38fc084b5b7">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTQtMS0xLTEtNDEwMDA_9316bc60-d52d-47c6-accf-2e483d923a7d">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTUtMS0xLTEtNDEwMDA_d3f638ba-e7ad-418d-a809-babb846c04de">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTYtMS0xLTEtNDEwMDA_f960fc74-f3dc-4ce4-ac0d-713b3bb70bbe">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTctMS0xLTEtNDEwMDQ_997fe9cb-4d0d-47f4-adf0-ee45a4be3414">9.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTgtMS0xLTEtNDEwMDI_4b227fd8-334f-43c9-8250-601c756b8687">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTktMS0xLTEtNDEwMDI_c42dc15c-28ff-4383-af8d-776f750447f5">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948e672fa043169982437976dfddd2_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMjAtMS0xLTEtNDEwMDI_481f5ad7-25b2-4da8-937f-7794d88b4ffd">67.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYyMA_7a6a7277-d25f-4127-a353-84ef5f9f197d">two</ix:nonFraction> home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYwNA_4fdecdbd-d8f9-4462-98d8-4227177ee1e9">24.7</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" decimals="-5" name="amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgyMg_e3b2ef9f-8c64-4101-b4d3-1ffa56311f02">22.2</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="i3b561742ec7246caa23ec4b10eecde20_I20220630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4MDAxMw_62061785-1ce9-4de2-b83f-aa09467e211f">2.5</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $<ix:nonFraction unitRef="usd" contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgwOA_c963930f-4af0-4b67-a127-c0e05f444ef6">2.5</ix:nonFraction>&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU1NQ_80d7dab1-6cc6-4ab1-a921-9827092a31ba"><ix:nonFraction unitRef="usd" contextRef="id9100b6fd13145b3a354118b53a94340_I20220401" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU1NQ_fc148cf2-7baa-4c93-9318-5d85b086f5d2">24.0</ix:nonFraction></ix:nonFraction>&#160;million and other intangibles of $<ix:nonFraction unitRef="usd" contextRef="id9100b6fd13145b3a354118b53a94340_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNzMxNg_4e699044-0dd0-4d24-95fb-140528c0995e">0.7</ix:nonFraction>&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="idc1b8914368b467da2e1219eea19c95b_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU3MA_dfe3dc46-c20e-402b-9698-4c272df94ce8">0.5</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="icd47e369277544c6aac2253ba6754c51_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU4NA_559f0d98-b391-4376-bca8-83c9346411fa">0.2</ix:nonFraction>&#160;million) and acquired names ($<ix:nonFraction unitRef="usd" contextRef="ic36a53a0d50446a995344011bef59e29_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU5OA_24af93fc-60fe-4965-b559-2e0e06854d99">0.1</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted average period of <ix:nonNumeric contextRef="i13b7e4cb24c04e1eae0d3bc51631a3c0_D20220401-20220401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTYxOA_1ce8cce9-dcee-4426-a073-9bb9c6e59a5b">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNjM4NA_67f86a80-da03-4a94-b96d-983d28511644">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AssistedCare contributed $<ix:nonFraction unitRef="usd" contextRef="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjM5MA_3923ca7b-689e-40ac-a02c-869c487e7f12"><ix:nonFraction unitRef="usd" contextRef="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjM5MA_bbc49720-c876-4c05-97bd-a4ac66ef2a55">2.6</ix:nonFraction></ix:nonFraction>&#160;million in net service revenue and operating income of $<ix:nonFraction unitRef="usd" contextRef="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjQwNA_2b2191d2-e4a1-4926-9e3a-3863cb93093c"><ix:nonFraction unitRef="usd" contextRef="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjQwNA_a043fc91-0f99-4eb2-ae05-f422ac204195">0.7</ix:nonFraction></ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTk5MQ_e7336e9b-25b5-4c3b-a344-1fd8ce7c6dfa">240.7</ix:nonFraction>&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $<ix:nonFraction unitRef="usd" contextRef="ifd89d4de539544fdb048cd299395703f_D20211001-20211231" decimals="-5" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ0Ng_823fc43b-567d-41ad-b83b-2368b76cd69b">0.6</ix:nonFraction>&#160;million from $<ix:nonFraction unitRef="usd" contextRef="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ1NA_7ed7f028-3790-480c-b1e8-d5b272813713">240.7</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ2MA_e511200c-27bf-465a-ad92-260bb2446d8e">241.3</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia4d9bfd2eb1d4570b7b4cec3476a3f3d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired, liabilities assumed and noncontrolling interests. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0OQ_b3dad2fe-2355-4075-bb3e-41dc19b2564e" continuedAt="i81c914f7e0fc4e43abbaee71cbf6fb88" escape="true">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc3Ng_a294a910-55e3-4e89-8f0a-0d4dadbe72fa">241.3</ix:nonFraction>&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i81c914f7e0fc4e43abbaee71cbf6fb88"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMi0xLTEtMS0zNTc0Nw_9eb07a11-de8b-4eca-add6-74e471d766ff">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMy0xLTEtMS0zNTc0Nw_a8c59744-7dcd-4819-b28b-dd5e800539ce">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNC0xLTEtMS0zNTc0Nw_cc3e6581-2bb6-419c-a273-ebf31d3f990c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNS0xLTEtMS0zNTc0Nw_974c32e5-0e92-4121-9456-5120a8010458">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNi0xLTEtMS0zNTc0Nw_a2c0262e-7f13-4c22-98f4-658a47f4a8ee">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNy0xLTEtMS0zNTc0Nw_99ef5fc3-ad8c-4ed2-815d-e27b05376df7">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfOC0xLTEtMS0zNTc0Nw_1287870a-3651-4d16-9503-43295cd86450">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfOS0xLTEtMS0zNTc0Nw_7aef234c-d601-4308-9ed2-3fc55d321e24">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTEtMS0xLTEtMzU3NDc_953c612b-64f4-45de-97ff-9df4bf5b8e3b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTItMS0xLTEtMzU3NDc_03e0aa7b-180d-4364-8646-54cb8355a6f5">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTMtMS0xLTEtMzU3NDc_6f38f2b1-4966-4489-82ee-b940b13b8796">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTQtMS0xLTEtMzU3NDc_35bb11bd-c2dd-4e60-9eb9-c2036e8a14db">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTUtMS0xLTEtMzU3NDc_19f31ddc-159a-4487-8196-03ca0122dc3b">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTYtMS0xLTEtMzU3NDc_41198824-7245-4f00-8284-ff2f10fe8b11">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTctMS0xLTEtMzU3NDc_35f0370c-7c12-4279-80c9-0494bf620bdf">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTgtMS0xLTEtMzU3NDc_58f857b4-4d3a-473b-b8b3-aaa63be3182d">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTktMS0xLTEtMzU3NDc_2f1da03e-eb5d-41c5-ad02-df8f26bac17f">43.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" sign="-" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjAtMS0xLTEtMzU3NDc_3ed616af-53bc-472a-b794-86254c060e28">43.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" sign="-" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjEtMS0xLTEtMzU3NDc_5cf7c9e1-4b01-494a-a51c-90a9bbe35943">53.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjItMS0xLTEtMzU3NDc_68dab358-4407-4f50-b3f2-c8f69e0bc97c">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjMtMS0xLTEtMzU3NDc_9a33a00d-a337-4dea-999b-44f822764e9d">233.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjQtMS0xLTEtMzU3NDc_1eef9b70-d61f-468c-b6f2-117e539d3458">241.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($<ix:nonFraction unitRef="usd" contextRef="ic2e82315a0db4ef2930ad63880f79a3f_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjk4MQ_2166f6e8-4456-4c09-a116-3340451d01a3">28.3</ix:nonFraction>&#160;million), technology ($<ix:nonFraction unitRef="usd" contextRef="iaa48e07aa67b4e89a0601d5f3eee5d03_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjk5OA_438ef73c-09ce-49b1-9098-f57fea319d35">19.8</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i1ac7ec89f6e9427cb5d656763a3bddc5_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzAzMA_2636ab8d-a29b-4184-9d4e-4bc66f310117">6.2</ix:nonFraction>&#160;million). The non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i4eb3273c875947fb92f75066e32951a9_D20210801-20210801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzExNA_716748bc-12bd-43dc-ae41-0210d4e442f6">2.0</ix:nonNumeric> years, and the technology will be amortized over a weighted-average period of <ix:nonNumeric contextRef="id39d0ab5b15a45f6b8ac1c1e71d6931a_D20210801-20210801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzE4OQ_3dbc69fa-495b-4311-b160-8ca8ce20b989">7.0</ix:nonNumeric> years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $<ix:nonFraction unitRef="usd" contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzQxMQ_204f3636-cdc2-42ef-829c-e978ac86586f">4.4</ix:nonFraction>&#160;million in net service revenue and an operating loss of $9.7&#160;million (inclusive of technology intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i9ac3f76ab9614d4688b0b8101d455be8_D20220401-20220630" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0NA_4921a180-d725-450f-a1a8-995b30b3b768">0.7</ix:nonFraction>&#160;million) during the three-month period ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYzMQ_28b7aa2a-0196-4bc1-b2a6-d79df8619475">7.2</ix:nonFraction>&#160;million in net service revenue and an operating loss of $17.3&#160;million (inclusive of technology intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i3e721858874346608ff8de6222b8c390_D20220101-20220630" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjY1OQ_c2e3856f-b533-4226-9e70-585250b61331">1.5</ix:nonFraction>&#160;million) during the six-month period ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details regarding the Company's 2021 acquisitions, see Note 4 to the audited consolidated financial statements in our 2021 Annual Report on Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_58"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2Ng_2d93126d-0dbe-4d0a-98b0-85cb8fe13646" continuedAt="ie85add1844ff45fa9c076953d6c8d289" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="ie85add1844ff45fa9c076953d6c8d289" continuedAt="if6449d11be8c4482a064e59810f66a90"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2Nw_5a9b1dcd-62aa-4387-b11b-24a404b86591" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:66.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i043295b1e6fd4805ad86f88638f693aa_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzQ_1348e0db-17da-4322-bb9d-69e600b3983a">450.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i7bd5c5b90ca64ac5b24203d891eb6fa6_I20220630" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzEwNw_be90d15b-b8a6-4d7d-9683-f5d4cd183e97">3.2</ix:nonFraction>% at June 30, 2022); due <ix:nonNumeric contextRef="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzEzNA_d69a42da-6c3e-41b5-aff5-1745340db782">July&#160;30, 2026</ix:nonNumeric></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i043295b1e6fd4805ad86f88638f693aa_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0xLTEtMS0zNTc0Nw_ce47fab0-0e78-441c-84e9-907f86bbee05">441.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0111dd48d164a73bdbda6add2995d5b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0zLTEtMS0zNTc0Nw_87cbc60c-faad-4232-a050-6bff8d192a46">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzQ_09399347-acb0-4e40-8fe6-7e94684f5c2b">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i35487ebf2851440e915cf218928141e1_I20220630" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzEwOTk1MTE2Mjc5NTg_c5f014ce-ce2c-455a-86a3-232ebfe4289d">2.7</ix:nonFraction>% at June 30, 2022); due <ix:nonNumeric contextRef="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzE1MQ_4b04893e-d462-4ff1-999a-ebbb99453792">July&#160;30, 2026</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0xLTEtMS0zNTc0Nw_09396a21-2c54-40b9-91f4-a8c06d16d283">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12425e6cf2b4507ae0eb717031bd48e_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0zLTEtMS0zNTc0Nw_33eaf906-5a5e-4a82-ad21-6568bb7334a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib714a01635724ae086d93a794a849aa8_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMy0xLTEtMS0zNTc0Nw_bcad530a-be20-41d8-bac2-4d168568ae3d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1f02a946da41c68f1054d698474350_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMy0zLTEtMS0zNTc0Nw_4a089904-504c-45b8-904e-117f453f5786">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdd1926c3d342b398329f841ae4f949_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNC0xLTEtMS0zNTc0Nw_0e3e4a08-ba14-4e33-8254-a16f45160c0c">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68e48e4accd47829e3f2c108a5e0128_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNC0zLTEtMS0zNTc0Nw_31efe446-3950-4790-ae7e-03ed9223f132">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNS0xLTEtMS0zNTc0Nw_1aa91f5c-a13c-4b82-ba8f-8e3094eca14f">459.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNS0zLTEtMS0zNTc0Nw_58dcfaaa-c8dd-4757-8832-ce7f17029240">449.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNi0xLTEtMS0zNTc0Nw_5a1e0c2e-8ef3-4dbf-8496-d3438e5a8d61">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNi0zLTEtMS0zNTc0Nw_66a0ddb3-db8d-4e63-aa34-c8c0325c7383">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNy0xLTEtMS0zNTc0Nw_f3583c98-3f0b-441b-9e9e-04feab7f49b1">454.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNy0zLTEtMS0zNTc0Nw_fb872b90-6e7c-4087-a606-0c55a6d6674e">445.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOC0xLTEtMS0zNTc0Nw_609162aa-6955-45e4-a473-a5292721eabb">12.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOC0zLTEtMS0zNTc0Nw_97bd43a8-9b29-4084-82d3-4f68cdbd49b2">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOS0xLTEtMS0zNTc0Nw_b836efb7-2850-4664-9061-f20c00cf1917">442.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOS0zLTEtMS0zNTc0Nw_14b9a0d6-25a9-4113-a722-8739fe0d74dd">432.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i395b376b36064fa0b151bf87dcfde162_I20210730" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDUx_67ad79c5-2e9d-4e21-85ef-02fd08df2159">1.0</ix:nonFraction>&#160;billion, which includes a $<ix:nonFraction unitRef="usd" contextRef="i5e933e2b55f0441d8ade42bb9a6422c9_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDcy_540ec138-94da-491b-bf91-3c978886b6c4">550.0</ix:nonFraction>&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTU5_908f2000-433b-4211-915a-a70bac691680">450.0</ix:nonFraction>&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $<ix:nonFraction unitRef="usd" contextRef="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzAz_68318572-68a7-4db8-b389-79ee21ebc66e">450.0</ix:nonFraction>&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5Nw_b2a5fb5c-9bda-4c90-8444-130bd2377569">0.50</ix:nonFraction>% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTIxNg_862f73b2-aa0c-4e77-b170-762d6a950a38">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2022, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="i368407cb268545c8a429573f1fdb24fd_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTYxMw_324d2796-d482-4c20-b7fd-4014af603510">0.50</ix:nonFraction>% per annum for Base Rate loans and <ix:nonFraction unitRef="number" contextRef="i98096f04576b4100a1338db93629914d_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTY1MA_c14fbbbc-7fbe-4cc9-b986-ee846d913d55">1.50</ix:nonFraction>% per annum for Eurodollar Rate loans. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2NQ_80c9ec5e-f5c1-49dd-ae26-e0dbf1a937d7" continuedAt="i8b78f6e1ed4d43aea26748a5bfdeaed1" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i8b78f6e1ed4d43aea26748a5bfdeaed1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:9.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; <ix:nonFraction unitRef="number" contextRef="i0f7d430c8d0f426aacb10538dea5c466_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmI0MmI2NzgwYWI0YjQzM2VhYzgyNjgyNDA5YmMzZDgwXzY_6f093086-c1f5-4ef7-b048-2ef62d7effa2">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dfdd0581d7248b8b729caa375e55f7d_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0yLTEtMS0zNTc0Nw_900e1332-3312-4132-a349-dbe6ce70f147">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i914232c463aa4978b4a531ac7e62be33_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0zLTEtMS0zNTc0Nw_5cde740e-14e6-4e1f-8a4c-9ae130803c1c">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS00LTEtMS0zNTc0Nw_923660db-dd72-45a8-80c1-c7e7e7ce0587">0.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS01LTEtMS0zNTc0Nw_b6b92155-9032-48a0-b80e-67beebcfc7f7">1.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonFraction unitRef="number" contextRef="i26d1ddcfb1a14175839570fdd3546981_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjBhYzNiNWVlYzJmZjQ2YzFiOTc0ODE3MGExOTllMzMyXzc_3befe24d-fadb-4e3b-b8b8-b1e8a70351a5">3.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i5ef3b974ffc54477b347ad7aba261ff0_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjBhYzNiNWVlYzJmZjQ2YzFiOTc0ODE3MGExOTllMzMyXzIz_5a27fa69-e7f4-49e5-aa47-cea2c2942f23">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3471a8de624944a9847b252690bec01b_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0yLTEtMS0zNTc0Nw_4372fae5-4441-4cd8-8ef5-d66c6f58ae00">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61200e8a017c49809e956ccc90265bd5_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0zLTEtMS0zNTc0Nw_8339b509-837b-479b-8cea-74d4f8daed3a">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi00LTEtMS0zNTc0Nw_df858993-d942-40ad-bbf4-21ac5469a3cc">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi01LTEtMS0zNTc0Nw_85849ff5-8b11-47ee-8f46-d573a9208958">1.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i6ea37ed79d51491fa4d4fe86aabbcd2b_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmZjZGZhNGE3YTgwODQ3NGNiM2NiNGVkNzM0MzIzYjVjXzY_5ee40b16-c035-4e31-9b13-3e1eda05a1b1">2.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i651fdb8c74b14b81967263e6ff2e0db9_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmZjZGZhNGE3YTgwODQ3NGNiM2NiNGVkNzM0MzIzYjVjXzIy_7b602401-6a7e-4896-8e78-11de8e4415d5">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i289a8de993e54ffabcd97d4bed94c9ec_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0yLTEtMS0zNTc0Nw_8b244faf-5abd-4d9b-adde-22e394cb18b4">0.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c330947191b484cabb14457b2008fec_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0zLTEtMS0zNTc0Nw_ae1b60d5-8791-492c-90ce-52df5fb4021d">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy00LTEtMS0zNTc0Nw_6bd102ca-eb59-4e54-a330-51d08ee08b5b">0.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy01LTEtMS0zNTc0Nw_7e67013d-e503-452f-a42f-151e3c9973bc">1.25</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i3d6b509d3e8d4a32b2dc334213e3e90e_D20220101-20220630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmU2NWZiZGI5MmNkODRhZDk5NmJiODkwZGQ0NmJhM2JlXzY_b087651e-8b4d-4a3a-a6fb-3dc82254d122">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de7001e37e54eaea710b0dd411e567a_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0yLTEtMS0zNTc0Nw_81045cb7-4ecf-448d-8e1d-b3161d7aba96">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f8f5ae337584aee9a115925a8e2d3ce_D20220101-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0zLTEtMS0zNTc0Nw_bd49e054-56cb-4c4a-8ef8-758b8a946185">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c044924a75b44968b0831ab81455994_D20220101-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC00LTEtMS0zNTc0Nw_f4a92a51-8703-402c-96a3-0df69d0129a6">0.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c044924a75b44968b0831ab81455994_D20220101-20220630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC01LTEtMS0zNTc0Nw_ee7ba182-6545-4462-95f9-7c5a9c5a1170">1.00</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is <ix:nonNumeric contextRef="i342d3f4c7f564db587a6511cf32380e8_D20210730-20260730" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTkwNQ_9601aa35-9f6d-4c65-a9ab-f769757d3d96">July 30, 2026</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="ia7465164416942ac8228a0f9daf738ff_D20210730-20230930" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjEyMA_0b3e7d13-3831-4ae5-bf00-77026c7b2000">0.625</ix:nonFraction>% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) <ix:nonFraction unitRef="number" contextRef="i17a72248de9c483b86fc97e68ef07f13_D20231001-20260730" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjIwOQ_84d59e5d-4d85-4c0a-af68-764bc8292004">1.250</ix:nonFraction>% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if6449d11be8c4482a064e59810f66a90" continuedAt="ia03e247e67b4443b8bde313802e8fd35"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i325318cf209c4cb4a2a43b717a15c820_D20210730-20210730" decimals="-5" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjgzMA_724391db-052b-4b7e-aa87-944bf7d78b9a">5</ix:nonFraction>&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730" decimals="INF" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDEyNA_1ffb12f6-5aa4-4558-b85b-9bc7930e6604">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730" decimals="INF" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDMwNw_e5748ee5-3dca-4624-9e86-abdd587143d2">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDU3Mg_417771d5-fac9-4e86-bb2f-bd4ddde01d23">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i03d87584c975497d9c6f614b6f3f8e5e_D20220401-20220630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDYwNQ_50c82b4f-a41f-463c-9636-1d8eaa3741da"><ix:nonFraction unitRef="number" contextRef="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDYwNQ_da2724f6-06ca-46d6-83fc-25935a15e3be">2.9</ix:nonFraction></ix:nonFraction>% for the three and six-month periods ended June 30, 2022, and <ix:nonFraction unitRef="number" contextRef="icff1249baba74d4bb0802f6d4bcf1199_D20210401-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjEyOQ_916ce642-f617-4724-976c-997b35025f0b">1.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2dd2a0aeede64a10a02cea3509dc8376_D20210101-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjEzNQ_17e8742c-0e63-4fc4-964c-75f5af22790e">1.8</ix:nonFraction>% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="i5fdfe5f5157c462fa0c08492c5359787_D20220401-20220630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDc0OA_f40edf77-0368-4362-b4fe-7206ba8bf059">2.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDc1NQ_9dde5797-cefb-4f7e-8eaa-eade7e531ca5">2.0</ix:nonFraction>% for the three and six-month periods ended June 30, 2022, respectively, and <ix:nonFraction unitRef="number" contextRef="i27ef4862c0c741ad8c38872eb9eb8d3c_D20210401-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjE0MQ_a2def64c-ab7c-46f3-a9b0-a8d876c19151">1.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i908c39c20d774cf49e9e8591ddd0e31a_D20210101-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjE0Nw_1d02fb30-212f-483e-a8be-0add6e2ae4ee">1.5</ix:nonFraction>% for the three and six-month periods ended June 30, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDg3Nw_7a74808f-2ca6-43bc-bad2-e1b1fa7dfaac">1.7</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="if19ffbe3490c49479b91f735381591d3_I20220630" decimals="INF" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDkyNg_0493790e-b5b1-4179-af89-374bb9425eb9">15.4</ix:nonFraction> and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our availability under our $<ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTMxMQ_37a04269-4e67-4d4b-abf8-f506dfb5e3ce">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM0NA_cd8c4f8c-ec8b-4358-b075-2262016f7f8f">507.3</ix:nonFraction> million as we have $<ix:nonFraction unitRef="usd" contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM1OA_09396a21-2c54-40b9-91f4-a8c06d16d283">15.0</ix:nonFraction>&#160;million outstanding in borrowings and $<ix:nonFraction unitRef="usd" contextRef="ie6ac967f423744c484ee9385ced160bb_I20220630" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM4OA_84e72066-cb4c-480b-98dc-3874cc292b19">27.7</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia03e247e67b4443b8bde313802e8fd35">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</ix:continuation></span></div><div><span><br/></span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_64"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAyNDE_89acf6cb-df30-44c0-9d84-c43b78e1026b" continuedAt="idb49d3b1ab4a4752a7f19a782f7aaef5" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="idb49d3b1ab4a4752a7f19a782f7aaef5" continuedAt="i5018d5c007404391ba0b74705572cd48"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $<ix:nonFraction unitRef="usd" contextRef="i0ea90e266fd540c1b73334141496eeda_I20210331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODk3_8bcd4f1f-3cb2-4d4a-83da-ed4e5ef3419b"><ix:nonFraction unitRef="usd" contextRef="ie02b1044c0fa4fadb08f8e9354318b47_I20210630" decimals="-5" name="amed:ReversalOfLossContingencyAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODk3_8d247b22-fdc4-4379-8d35-c2a11c749c76">6.5</ix:nonFraction></ix:nonFraction> million recorded to accrued expenses in our condensed consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="i5a818c66a5b04529bf0bde65307825f1_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTIxOQ_ffce2d09-133f-4452-bb97-828b6eff9c50">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i093a633cdc1f40ff80f2e4fe49d565e7_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTk2Mg_5ac26a20-8bf3-4357-8091-6a7400436d6a">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="ic33cb6496cb44a3fa5ff85100d4ce238_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMjU5Mg_fd93329e-389a-4335-8a48-b8d089db038a">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5018d5c007404391ba0b74705572cd48" continuedAt="i5778b601c9e2425c93c2044a445e17a8"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="ie73580cf813f4bacb80a34a16b93b064_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMzY2OA_8cda4e3b-b1a2-402c-ac8c-b931d3cf378e">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="i694cb74b423248c896a972c561852442_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDExMg_155a1e08-fc2d-4210-80d1-f19d4f8c7681">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="ie5b0119f2b2547fa916994d37a51982e_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDkxNQ_c3e7ee94-1f6d-4f57-852f-a6adef80fbac">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="ie5b0119f2b2547fa916994d37a51982e_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDk0MQ_9f2a93b5-81a5-42d7-bc32-3dd573860ec6">5.6</ix:nonFraction> million, including interest, based on <ix:nonFraction unitRef="claim" contextRef="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDk3NA_98ca610d-2b8e-452a-8d7f-46794b96f7fc">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="i694cb74b423248c896a972c561852442_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTAwNQ_aa214ae9-75de-4fbe-b3b0-5d29a1233856">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTA3OA_76e6df1f-bb84-4783-8cbc-273bf6bebfd3">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2022, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="i361b5e96bbca4bd8a455e792020b20e7_I20220630" decimals="-5" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTMyMw_e158d13d-dc5c-4a4d-997c-1c8860b8178a">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="i57695b07d1464993ae80368c4d54fbe4_I20190110" decimals="-5" name="amed:IndemnificationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTgyOA_9f8c173d-2a3d-4df6-8992-42a36bc7d6f8"><ix:nonFraction unitRef="usd" contextRef="i71f2e16b6e58440aa8210596de7977c5_I20220630" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTgyOA_e832aa7c-6ea3-438f-aecf-c464d9c49339">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an extrapolated overpayment of $<ix:nonFraction unitRef="usd" contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjY3Mw_4c5b8487-aa79-45bd-ac74-5035a5a1ed06">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="ib07ad9b0c2284a67950bf5935cd96810_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjcyMw_97925fcd-6060-4fa9-af66-d9d78f6e6609">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjc1MQ_d8b24e71-66b2-42ff-b12e-14a1c933713b">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjc4OA_a68819a6-fce4-4d69-b11f-cbba79ce81ee">100</ix:nonFraction>% error rate and an extrapolated overpayment of $<ix:nonFraction unitRef="usd" contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjgyNA_cb01ab9a-5a88-4392-81f1-293afe4b354d">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="if7a5f95eb6a3431691a8916273d87b3a_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjg3NQ_a1313ad2-6383-4c1d-9f42-2a48e0ff89f6">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjkwMw_a6e66330-6589-49b7-9aaf-cbee0eaac431">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjk0MA_f4862944-a595-4d3f-8bdd-d5988d32e3c7">100</ix:nonFraction>% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $<ix:nonFraction unitRef="usd" contextRef="i7510142fa85d4f9d92232c8c96e894e5_I20220630" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNzMwNA_cfd42072-330a-4f37-a482-1ebf87426037">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center was reduced to $<ix:nonFraction unitRef="usd" contextRef="i509592a5ae784f308e714e6df14f611e_I20220630" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNzM4Ng_eb284e9c-4f59-4312-b901-e29f13bef88f">3.3</ix:nonFraction> million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearing for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As of the date of this filing, we do not have a demand for repayment from Palmetto for the Clearwater Care Center or the Lakeland Care Centers. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing of the demand for repayment; however, the Company has updated its estimates of potential loss based on the ALJ's decisions. We have increased our total accrual related to these matters from $<ix:nonFraction unitRef="usd" contextRef="i3aaeb76718a141288630010cd2fca7f8_I20220331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODgwNQ_60190571-457e-48d1-a8ef-581a934f04e9">17.4</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i832d375adc9a4e25b37e1d449314a0b7_I20220630" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTA5OTUxMTY0MTIxMw_e8a78ff1-6a06-4f59-90d4-b66ac73dc105">25.8</ix:nonFraction>&#160;million. The net of these two amounts, $<ix:nonFraction unitRef="usd" contextRef="i5a583ddc36234cbbac97618ef468484a_D20220101-20220630" decimals="-5" name="amed:ReductionToNetServiceRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTA5OTUxMTY0MTIyOA_bc310bb1-00e1-455a-9040-6d505da9aca6">8.4</ix:nonFraction>&#160;million, was recorded as a reduction to net service revenue in our condensed consolidated statements of operations during the three-month period ended June 30, 2022. We expect to be indemnified by the prior owners for approximately $<ix:nonFraction unitRef="usd" contextRef="i832d375adc9a4e25b37e1d449314a0b7_I20220630" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODg5OA_0b8f88ff-252b-4c19-a540-d1019836f029">10.9</ix:nonFraction> million and have recorded this amount within other assets in our condensed consolidated balance sheets. As of June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic98dab006fb24cf1a5c08315e4408d0f_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfOTIyNQ_3d9e215b-2a35-4594-a710-3962bce9ddc9">1.5</ix:nonFraction> million of receivables have been impacted by these matters.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5778b601c9e2425c93c2044a445e17a8"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="amed:HealthInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAwNDc_20418646-f2e1-4993-8ee5-de11f02808b4">1.3</ix:nonFraction> million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="amed:WorkersCompensationInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAxNDQ_06613b99-9f3c-410c-9fa7-8046adfeaa8d">2.0</ix:nonFraction> million per incident and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAyMjY_4dff07b6-2987-498d-9931-0e31b0ed7d53">0.3</ix:nonFraction> million per incident.</span></div></ix:continuation><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_70"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfMTU5Mw_300c40a3-e7e7-41a3-a9e0-17f2b0fd4276" continuedAt="i9c33a47b392a4111b2893f671dc06205" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c33a47b392a4111b2893f671dc06205" continuedAt="iefdf413faeda4e3c996885e2d63f9eb4">Our operations involve servicing patients through our <ix:nonFraction unitRef="segments" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfODI_4329c70e-6529-4fd7-ac85-b30dd69c8f31">four</ix:nonFraction> reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iefdf413faeda4e3c996885e2d63f9eb4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfMTU4OA_057103b8-38f2-4e99-8f53-e7575b57d16c" continuedAt="i077cbc3dacbe439bbab7e6c680f27d08" escape="true">Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><ix:continuation id="i077cbc3dacbe439bbab7e6c680f27d08"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:45.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0xLTEtMS0zNTc0Nw_7e03ff0a-b692-4a70-87c2-c167476d8e44">340.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0zLTEtMS0zNTc0Nw_89c4aa2f-dfdf-4943-9236-24cb88ea4112">198.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi01LTEtMS0zNTc0Nw_c88718a2-8321-44be-9205-6355a5cd4551">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi03LTEtMS0zNTc0Nw_02e3c6a4-30b4-4e1c-9aff-24d4e3573d89">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi05LTEtMS0zNTc0Nw_ae78381a-f76f-45a5-bbbf-72f71e7ddaa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0xMS0xLTEtMzU3NDc_9c9c5b21-0d09-451a-a493-08788f1a80a0">557.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0xLTEtMS0zNTc0Nw_cf8d9889-578c-4556-a987-ce068f93741f">193.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0zLTEtMS0zNTc0Nw_aadd6b70-fcf3-4fe6-89ff-1beff749ac39">107.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy01LTEtMS0zNTc0Nw_2becf7e4-6694-4492-a2d1-99b8ef890444">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy03LTEtMS0zNTc0Nw_1c3b0fc5-b161-4fc1-840c-9b520222ce37">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy05LTEtMS0zNTc0Nw_fd068273-7e23-43bf-aa5e-bb731cc32b56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0xMS0xLTEtMzU3NDc_81607c31-94d2-4c8a-a0fa-0f63401e21e8">316.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0xLTEtMS0zNTc0Nw_afa7c7f4-723b-499c-a874-0a40e0ded1c9">87.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0zLTEtMS0zNTc0Nw_0a5ff394-3afa-4054-882d-6ad56d9a4c91">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC01LTEtMS0zNTc0Nw_d4637064-0f02-4e58-8a6c-99e8d5a6b9dd">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC03LTEtMS0zNTc0Nw_a59a9383-bd58-4c00-8ef9-94c69ac133a4">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC05LTEtMS0zNTc0Nw_5036f463-2d3f-46e6-9dc4-a0730a5b9529">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0xMS0xLTEtMzU3NDc_fba22b29-bd97-4be8-b1f4-7ef4d7b901fd">187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0xLTEtMS0zNTc0Nw_fa09ae80-13c4-4cca-8158-c3a724efc77b">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0zLTEtMS0zNTc0Nw_488e8f74-2a56-4f25-a6f4-402d04e6266b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS01LTEtMS0zNTc0Nw_a1cc49b5-5d45-4e0f-939a-84c569df4442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS03LTEtMS0zNTc0Nw_36cd66e6-b92d-4cba-a0c9-f39ba978eecd">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS05LTEtMS0zNTc0Nw_448f11c6-6fde-472c-b646-5aca4ebcc291">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0xMS0xLTEtMzU3NDc_d2c15a5d-1c29-48a5-850b-05d1083cc904">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi0xLTEtMS0zNTc0Nw_7ba0d3b5-7d3d-4e99-868b-8ea21ef92fc3">282.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi0zLTEtMS0zNTc0Nw_0d8a51fb-06be-40f5-a47c-7d6ddb71ec88">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi01LTEtMS0zNTc0Nw_c7db19c3-b809-44f0-888f-ae19462109ba">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi03LTEtMS0zNTc0Nw_70bcc25d-c665-4088-b6de-1cfe0e115ed7">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi05LTEtMS0zNTc0Nw_afeb8f81-1ccd-4f0f-924e-dbccf2f6574a">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0xLTEtMS0zNTc0Nw_729d38b6-f02a-457d-8c2e-888773a4c40c">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0zLTEtMS0zNTc0Nw_22dd5fe2-db46-44fd-8349-1d8a740e7ab5">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy01LTEtMS0zNTc0Nw_b461feba-0994-4731-874e-a047ceb50021">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy03LTEtMS0zNTc0Nw_3102372c-fd88-4ddd-966f-33774fe86a7f">9.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy05LTEtMS0zNTc0Nw_df09cb23-e7bc-4d28-87eb-c115d82aa7ac">40.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0xMS0xLTEtMzU3NDc_e99a6272-d787-4a8a-b762-44547b023c0b">47.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMS0xLTEtMzU3NDc_87d6eaa4-2a6d-44fa-a1e3-28f6952629d3">349.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMy0xLTEtMzU3NDc_386c1a97-6417-4fbb-8d2b-a84f6ee1edf2">197.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtNS0xLTEtMzU3NDc_f956b474-9a53-43af-aee9-ed123f35b7c0">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtNy0xLTEtMzU3NDc_83d9245b-9619-4e00-8d70-66f0b93b49ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtOS0xLTEtMzU3NDc_9b1adae8-3368-4d79-9477-c002ce8c940a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMTEtMS0xLTM1NzQ3_307736b9-6ea6-42ec-8d86-c4d3aeade6b7">564.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMS0xLTEtMzU3NDc_e8a9264e-8985-4154-909f-d6051382b2c3">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMy0xLTEtMzU3NDc_968575e2-8aed-4330-be46-f8e42f98deef">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItNS0xLTEtMzU3NDc_bee28046-8814-4424-8186-f10c2d900d3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItNy0xLTEtMzU3NDc_b70dad2d-1d1e-4429-8bea-318881d723a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItOS0xLTEtMzU3NDc_11784033-2a24-4643-93a0-6779a8cefd29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMTEtMS0xLTM1NzQ3_54a9e6e9-04ba-4d05-8229-8d755f9d3b95">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMS0xLTEtMzU3NDc_ec6a05d6-19e3-4f6b-a787-c85752942cf3">190.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMy0xLTEtMzU3NDc_476e2acc-d39d-40c2-8cdd-24e25b7532fa">105.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtNS0xLTEtMzU3NDc_478d4dc2-1797-4b13-960c-cb7816e4b773">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtNy0xLTEtMzU3NDc_f3625954-c065-4381-868e-3ccd893be716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtOS0xLTEtMzU3NDc_c6fbbd86-a6c0-47cd-b85c-3962c87ec3df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMTEtMS0xLTM1NzQ3_78936338-09f3-4ac9-9075-189a340a22d1">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMS0xLTEtMzU3NDc_07af11ac-d410-4d84-a64e-840bec446198">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMy0xLTEtMzU3NDc_01aad823-40a7-47c4-9458-b1ffd3f4f14a">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtNS0xLTEtMzU3NDc_13002a2a-0c1a-4bc0-9f77-76981469bb01">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtNy0xLTEtMzU3NDc_b4099be0-ebaa-48fe-be2d-31219f5fbead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtOS0xLTEtMzU3NDc_eded922b-18cc-490b-b48e-8367e85751f5">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMTEtMS0xLTM1NzQ3_cc7a2f94-2ff7-46e5-9599-7156979ed05a">175.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMS0xLTEtMzU3NDc_6e87c3b6-2727-400c-96f4-34c2ca9f5e1f">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMy0xLTEtMzU3NDc_7d8f83ee-826c-4c87-8854-ede72c59013f">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtNS0xLTEtMzU3NDc_ee45c6f9-9028-42a0-8e15-45c676b00e81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtNy0xLTEtMzU3NDc_bbd452ed-5a67-4032-9e6e-828c197178d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtOS0xLTEtMzU3NDc_4952fdf8-4ede-4295-97a6-a9f397156af7">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMTEtMS0xLTM1NzQ3_a9825107-ea94-4b43-89e5-fa1abedf6f1b">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtMS0xLTEtMzU3NDc_371038dd-2885-401d-9854-d0867425c8ec">272.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtMy0xLTEtMzU3NDc_1e160dd9-7579-42fe-a203-122cfbfd02aa">154.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtNS0xLTEtMzU3NDc_1f432a4d-0512-4cb2-8a63-748e07f8060b">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtNy0xLTEtMzU3NDc_b868015a-4a68-416a-8c5b-73c55b9e51b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtOS0xLTEtMzU3NDc_d9d0efda-aaaf-4a79-8841-81acab24dee5">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMS0xLTEtMzU3NDc_3c693861-2fd4-4423-b856-d29712d9b563">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMy0xLTEtMzU3NDc_b3075e0e-435f-4f80-9909-c83bda810005">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctNS0xLTEtMzU3NDc_252f7b3c-54cb-4a30-8618-0f4a3c973ca3">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctNy0xLTEtMzU3NDc_741cf825-b1a7-42f7-8af1-7628da5d3905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctOS0xLTEtMzU3NDc_ba0d40c4-aefa-45ab-a22a-75ce7cd8967c">47.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMTEtMS0xLTM1NzQ3_9a617909-2f63-43e8-9986-bf43a3fd689f">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMS0xLTEtMzY3NDQ_bd6472d1-7c54-47f3-9354-3398421a662a">675.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMy0xLTEtMzY3NDQ_cf2ff98c-21de-4621-86e5-a93e50be21d1">391.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtNS0xLTEtMzY3NDQ_be9f84bf-4957-49ce-9ebf-cf123770844f">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtNy0xLTEtMzY3NDQ_43022bc1-d124-4e40-94d6-7453ce95f895">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtOS0xLTEtMzY3NDQ_2d7ad864-b3b0-47a5-aff0-ed1eb9a5f15c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMTEtMS0xLTM2NzQ0_2e9fe6a2-0355-4f6a-a7ae-8914f9d224d7">1,103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMS0xLTEtMzY3NDQ_1488516f-1f1c-4e97-8507-54fcd030ab22">378.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMy0xLTEtMzY3NDQ_4518f1f6-dc54-4d79-93a8-c3cf82292c77">213.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItNS0xLTEtMzY3NDQ_12567481-1cd6-4043-91cb-efeff5c7240c">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItNy0xLTEtMzY3NDQ_08d49ce8-5c09-44b6-8588-3312fd0b689d">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItOS0xLTEtMzY3NDQ_a098c280-b382-43f6-8f52-7ac4e3fcfe2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMTEtMS0xLTM2NzQ0_81257ea6-6b1e-4cf5-bf04-e20c95467bc7">621.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMS0xLTEtMzY3NDQ_edee54a8-6b21-4dea-b4de-9928bb325789">171.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMy0xLTEtMzY3NDQ_3ac995ec-5bc2-48c9-b924-d84229dcd859">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtNS0xLTEtMzY3NDQ_28902541-3495-4b19-b983-f0d98d43fd28">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtNy0xLTEtMzY3NDQ_7e95b3fc-b4ab-4339-8b25-4e92c3a35bbf">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtOS0xLTEtMzY3NDQ_a6e82684-0e58-41ac-8cee-085c161285a0">77.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMTEtMS0xLTM2NzQ0_2649dba7-98a2-4244-b966-0f743b9be215">372.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMS0xLTEtMzY3NDQ_5035ee75-1412-4ef0-8b02-562ec80e6678">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMy0xLTEtMzY3NDQ_c26ad4c4-5cf6-4fe5-869c-47955a52b414">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtNS0xLTEtMzY3NDQ_c9f22da0-f267-4d72-b321-6a1ae91e68b7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtNy0xLTEtMzY3NDQ_2d0b3561-b289-48c0-98e8-c6a029a4cdcb">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtOS0xLTEtMzY3NDQ_56983de5-d9ac-478c-bc69-917b6d31d306">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMTEtMS0xLTM2NzQ0_da738f64-1a31-4f52-bf73-a17f34646b02">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMS0xLTEtMzY3NDQ_08f88899-b7b1-4e9f-b125-0f4be982c74c">551.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMy0xLTEtMzY3NDQ_cc3500e2-211d-491f-baed-c9e42b1e5b8c">318.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtNS0xLTEtMzY3NDQ_edbf116f-f370-49dc-9012-3b2fbc30feaa">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtNy0xLTEtMzY3NDQ_75b0d8ea-2bc1-4ad2-bb49-85d8028b664e">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtOS0xLTEtMzY3NDQ_dd43a571-992b-460c-b20f-6e20df95edc2">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMTEtMS0xLTM2NzQ0_8564cca7-470c-47af-b7e4-a4a95b731ccf">1,007.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMS0xLTEtMzY3NDQ_f754d515-72d2-4f88-b982-dd66ed30b7a4">124.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMy0xLTEtMzY3NDQ_970d5888-69ef-476d-911b-a381632a1fad">73.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtNS0xLTEtMzY3NDQ_ce629814-c834-4bf1-b32c-a62dcaa6b5cc">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtNy0xLTEtMzY3NDQ_9e7f8624-490e-408c-90c2-48c4c716a300">17.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtOS0xLTEtMzY3NDQ_323398df-059c-4d1e-a087-f117effc2fd7">86.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMTEtMS0xLTM2NzQ0_f8a6ba29-2b29-4351-a300-68384fb70dd3">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMS0xLTEtMzY3NjA_54390473-cd3b-4f68-b6be-8362e91fda6d">677.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMy0xLTEtMzY3NjA_7f4e7e07-5ddc-4f0a-a52c-b50bcb05c528">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtNS0xLTEtMzY3NjA_86526c7c-18ad-4401-b931-39865f9611ff">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtNy0xLTEtMzY3NjA_905e05b1-e8eb-4cc9-9682-00486cab83cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtOS0xLTEtMzY3NjA_0517d2ec-f61f-47fe-81a6-1247263876f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMTEtMS0xLTM2NzYw_616fab8c-8342-42ea-b2ca-58bc3702b9f6">1,101.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMS0xLTEtMzY3NjA_051aaf35-85de-4cfd-8080-bdfc9a3a1eb6">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMy0xLTEtMzY3NjA_0aa952ec-c38b-40c8-a270-fae5170b2c08">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtNS0xLTEtMzY3NjA_c10d59ef-ba93-44db-993d-3c6300593c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtNy0xLTEtMzY3NjA_6ab98f6d-ea33-4a97-9f59-95f75a63a599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtOS0xLTEtMzY3NjA_33e11ab7-a336-42d3-b8f2-5e7ebc2b5de9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMTEtMS0xLTM2NzYw_74a3e2fa-0f37-4aed-ab47-5c8c768c236f">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMS0xLTEtMzY3NjA_d465630b-e90c-431e-8d3c-8c0c5a5bbfcc">373.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMy0xLTEtMzY3NjA_6b0c1556-aca1-4ccb-828e-c30807c27954">206.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItNS0xLTEtMzY3NjA_653a7be7-960e-4e8f-b7a0-98f4a1e92766">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItNy0xLTEtMzY3NjA_5ff2099a-2c64-4af6-af60-bee655374bb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItOS0xLTEtMzY3NjA_5a71d9e3-2a0f-4573-ad77-533f83a03c94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMTEtMS0xLTM2NzYw_59729320-a6e4-497f-bf3b-05c453f2c0cd">605.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMS0xLTEtMzY3NjA_00a2ffa8-f98e-43b5-936e-0834b01cbd0d">161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMy0xLTEtMzY3NjA_ee6d83f8-9efa-4b5d-b89a-bac62ddb9b14">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtNS0xLTEtMzY3NjA_ea3040a4-3a1d-49cb-b330-66e17ba46d18">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtNy0xLTEtMzY3NjA_5b2a17e8-c48b-4fc9-b864-0d61ece05b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtOS0xLTEtMzY3NjA_f6603d40-99e8-4d51-ad18-718060578d78">84.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMTEtMS0xLTM2NzYw_9b57d007-9040-4104-9afc-fde118d471a5">347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMS0xLTEtMzY3NjA_eeeeef77-52a6-4715-ad65-c99228ee9a62">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMy0xLTEtMzY3NjA_4830990e-fe31-4444-b874-39fc5670a2ae">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtNS0xLTEtMzY3NjA_081f1bdc-5323-4d15-9651-f59418793e0f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtNy0xLTEtMzY3NjA_4f39e56c-3827-44be-b247-3c75f3fe3388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtOS0xLTEtMzY3NjA_c780e109-2fb8-4773-9f7e-ca01b77603a3">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMTEtMS0xLTM2NzYw_abac6d44-8e28-4b0d-88ca-47b9a46e25ff">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMS0xLTEtMzY3NjA_be733967-ebb8-4f0f-8529-7cf736c5510d">537.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMy0xLTEtMzY3NjA_3358c24a-7126-4f78-9ea0-17962b181019">303.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtNS0xLTEtMzY3NjA_8f65d0fd-6dcf-467c-bd9c-e44d1bf1d7a2">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtNy0xLTEtMzY3NjA_d824deae-8e61-4237-bb3e-8dfac38f8f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtOS0xLTEtMzY3NjA_02c1d668-9156-4294-9f64-a0b8a4899572">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMTEtMS0xLTM2NzYw_fd0e18b2-d97e-4556-befa-42d5b0800baf">967.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMS0xLTEtMzY3NjA_bd4efc8e-21f1-4e8c-b58f-37f968e9585f">148.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMy0xLTEtMzY3NjA_0e541e77-cd8c-4655-9d7d-cdb0cabf478a">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtNS0xLTEtMzY3NjA_bfea90f8-d656-429c-bdb3-e511d6f042d2">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtNy0xLTEtMzY3NjA_0e63b5ac-949d-4260-b9cf-d6039f434dfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtOS0xLTEtMzY3NjA_e3b699b8-33de-43b4-af20-5014e231a652">95.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMTEtMS0xLTM2NzYw_61168e94-25f2-42ea-97e0-c547f9638deb">147.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_79"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMjE0Mg_c90d1c16-3120-4e78-9faa-7411dbce09a9" continuedAt="i990203a4b4844efcaa542910eb9db556" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><ix:continuation id="i990203a4b4844efcaa542910eb9db556"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i3d43362c8b95458aac1aefacb3f78f19_I20201223" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTY3_0947e4b5-cbf4-4ebb-bb1e-c3c0d7c8ba90">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i915c545146e94aa887017c72ca239d02_D20201223-20211231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMjEw_d5f2466f-a2b7-470d-b569-7a6f2ffe1736">December 31, 2021</ix:nonNumeric> (the "2021 Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE3Mg_d481cf72-eca5-41f5-9342-6531b647a21e">4,757</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE2Mw_e1607321-e517-4452-90e8-410c21c7a902">249.72</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE3OQ_ea678b15-3805-440f-bbf7-35a26ae5c989">1</ix:nonFraction>&#160;million during the three-month period ended June 30, 2021 and <ix:nonFraction unitRef="shares" contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfODg2_8c1f6e3f-2945-47de-94c9-0afa883aa5f3">297,105</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfOTQ3_0c477c48-a1e5-46f5-a4ac-a45412741d73">249.29</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfOTk0_c9a247c8-b69f-4d1c-85b6-9d270b1a8881">74</ix:nonFraction>&#160;million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i8e2ca64538594598a876edcc7a6780f5_I20210802" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTI4OQ_a5978489-2066-4256-820f-501bd993f767">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="iec884be61eb14776a28fa489974af68b_D20210802-20221231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTMzMg_a5d3831e-4f46-4abd-a89e-a1d0b32605ae">December 31, 2022</ix:nonNumeric>. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTEzMg_ce9d60a0-ccae-4279-ae71-60f44aabcb4f"><ix:nonFraction unitRef="shares" contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTEzMg_ed6f4a40-bc5c-4543-aee6-94fae0df0d9e">150,000</ix:nonFraction></ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE1NA_aa0ddfd8-21f7-4f4e-8fe6-7c6e15dee2f7"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE1NA_c74b1674-cd04-4c53-8fbd-47c092878454">115.64</ix:nonFraction></ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE0MQ_0b0c10e5-d825-4428-ad55-10dcc58a83b2"><ix:nonFraction unitRef="usd" contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE0MQ_b0bc47f4-49e3-4d37-b72e-5dd103eb7b90">17</ix:nonFraction></ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.</span></div></ix:continuation><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_82"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfNDQ2_284c541f-7a13-4d56-b56d-fe5cf370cda1" continuedAt="i5d44fba58d2a4481a2b5e51bad2c2588" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d44fba58d2a4481a2b5e51bad2c2588">We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs totaling $<ix:nonFraction unitRef="usd" contextRef="ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMjU2_a3acfb26-6164-4789-9d88-8412b731c198">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41519bdb02894e4c88aa2695cb5691b9_D20220101-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMjYz_d5c3ba15-7131-470e-a11c-b0557133cdd9">4.7</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ice6cf5eaf69a43afa1bd9eefc44f8038_D20210401-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMTA5OTUxMTYyODUzMA_312bef3b-e738-40ac-acd9-7c0688b67a98">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8db1257495a248b09b389531c6e0153f_D20210101-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMTA5OTUxMTYyODU0NA_c29c900b-91cd-4244-8105-231e21f12f8c">2.6</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2021, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and six-month periods ended June&#160;30, 2022. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 24, 2022 (the &#8220;Form 10-K&#8221;), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;the Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 74% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa Health ("Contessa") on August 1, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. As of June&#160;30, 2022, we owned and operated 353 Medicare-certified home health care centers, 174 Medicare-certified hospice care centers, 14 personal-care care centers and 9 admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Startups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired fifteen home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City and Care Connection of Cincinnati ("Evolution"), for a purchase price of $68&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $25&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for a discussion of and updates regarding legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Centers for Medicare and Medicaid Services ("CMS") Payment Updates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 29, 2021, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2022, effective for services provided beginning October 1, 2021. CMS estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hospices serving Medicare beneficiaries would see a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.0% increase in payments. This increase was the result of a 2.7% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA") less a 0.7% productivity adjustment. Additionally, CMS increased the aggregate cap amount by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.0% to $31,298. The final rule also rebased the labor shares for all four levels of care, included updates to the hospice conditions of participation ("COPs"), which made permanent certain flexibilities allowed during the novel coronavirus pandemic ("COVID-19") public health emergency, and finalized changes to the Hospice Quality Reporting Program. Based on our analysis of the final rule, we estimated that our impact would be in line with the 2.0% increase. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2022, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2023, effective for services provided beginning October 1, 2022. CMS estimates hospices serving Medicare beneficiaries will see a 3.8% increase in payments. This increase is the result of a 4.1% market basket adjustment as required under PPACA less a 0.3% productivity adjustment. Additionally, CMS proposed to increase the aggregate cap amount by 3.8% to $32,487. Based on our analysis of the proposed rule, we expect our impact to be in line with the 3.8% increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 2, 2021, CMS issued the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home Health Final Rule for Medicare home health providers for calendar year 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. CMS estimated that the final rule would result in a 3.2% increase in payments to home health providers. This increase was the result of a 2.6% payment update (3.1% market basket adjustment less a 0.5% productivity adjustment) plus a 0.7% fixed-dollar loss ratio adjustment, reduced by 0.1% for the rural add-on. Based on our analysis of the final rule, we estimated that our impact would be in line with the 3.2% increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The final rule also provided for the expansion of the Home Health Value-Based Purchasing ("HHVBP") model to all 50 states beginning January 1, 2023 with calendar year 2023 being the first performance year and calendar year 2025 being the first payment year with a proposed maximum payment adjustment, up or down, of 5%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 17, 2022, CMS issued a proposed payment change for Medicare home health providers for calendar year 2023. CMS estimates that the proposed rule will result in a 4.2% decrease in payments to home health providers. This decrease is the result of a 2.9% payment update (3.3% market basket adjustment less a 0.4% productivity adjustment) less a permanent adjustment of 6.9% (derived from a 7.69% behavioral assumption adjustment), reduced by 0.2% for the update to the fixed-dollar loss ratio ("FDL") used in determining outlier payments. This rule also proposes a permanent 5% cap on negative wage index changes for home health agencies. Based on our preliminary analysis of the proposed rule, we expect our impact to be in line with the 4.2% rate cut.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the 6.9% permanent adjustment, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS is not proposing to apply the temporary adjustment to calendar year 2023; however, CMS is soliciting comments on how to best apply the adjustment in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A group of bipartisan lawmakers has introduced a bill, The Preserving Access to Home Health Act of 2022, which upon enactment, would pause the implementation of any temporary or permanent adjustments to the Medicare home health base payment rate until 2026. This would delay the cuts currently proposed by CMS and would allow time for the industry and CMS to work on a more reasonable methodology that adequately measures the impact of the transition to PDGM and fully accounts for the impacts that COVID-19 has had on utilization, patient mix and the level of care provided by home health agencies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sequestration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Congress passed the bipartisan Coronavirus Aid, Relief and Economic Security Act ("CARES Act") which provided for the suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements for the period April 1, 2022 through June 30, 2022 and has been fully reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The reinstatement of sequestration will result in a reduction of our net service revenue for the remainder of the year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance continue to be impacted by COVID-19. The financial impacts of COVID-19 are discussed in further detail under "Results of Operations" below. While we currently believe that we have a reasonable view of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations, the uncertainty created by COVID-19 could alter our outlook of the pandemic's impact on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact our performance: the increase or decrease in the number of COVID-19 cases nationwide; the severity and impacts of new variants of the virus; uncertainty regarding vaccine utilization rates and efficacy; staffing shortages due to clinician quarantines, the competitive labor market and federal, state and local vaccine mandates; the return of patient confidence to enter a hospital or a doctor's office; the utilization of elective procedures; the ability to have access to our patients in their homes and in facilities; supply chain disruption and our ability to find suitable alternative products at reasonable prices; cost normalization around personal protective equipment ("PPE"); and any future or prolonged shelter-in-place orders and other federal, state and local requirements. Potential impacts of COVID-19 on our results include lower revenue; higher salary and wage expense related to quarantine pay, contract clinicians, wage inflation, increased costs to hire and retain employees and training; and increased supply costs related to supply chain constraints, PPE and COVID-19 testing. The impacts to net service revenue may consist of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower reimbursement due to missed visits resulting in an increase in low utilization payment adjustments ("LUPAs") and lost billing periods; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower hospice average daily census due to a decline in our average length of stay.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$175 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we only utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred is reflected in other operating income within our condensed consolidated statements of operations.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of sequestration for the period May 1, 2020 through December 31, 2020. See The Centers for Medicare and Medicaid Services ("CMS") Payment Updates above for details on extensions beyond December 31, 2020.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55 million of social security tax. Approximately $27 million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of providing home health and hospice care to patients via telehealth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The well-being of our employees has been one of our top priorities during the pandemic. We have taken the following steps to support our employees: implemented paid leave during any required quarantine periods; awarded bonuses to our clinicians and caregivers who saw patients during the pandemic; completed an early cash pay-out of employee paid-time-off; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; expanded access to telehealth services to all employees; provided access to COVID-19 self-test kits to all employees and created a COVID-19 Resource Center, available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: developed clinical protocols for COVID-19 testing, proper usage of PPE, caring for COVID-positive patients and maintaining safety measures in our care centers; researched each state's vaccination plan to develop a state by state protocol to work with local health departments and other health systems to obtain vaccine appointments for our clinical staff; implemented software enabling us to track staff that have been vaccinated; procured PPE; and created a centralized distribution center for all critical PPE, allowing us to flex our supplies on a care center by care center basis, based on need and demand.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three-Month Period Ended June&#160;30, 2022 Compared to the Three-Month Period Ended June&#160;30, 2021 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On a consolidated basis, our operating income decreased $31 million on a $6 million decrease in net service revenue. The year-over-year decrease in operating income is primarily due to the acquisitions of Contessa on August 1, 2021 and Evolution and AssistedCare on April 1, 2022 (which combined contributed $18 million in revenue and an operating loss of $11 million), an $8 million accrual related to our Infinity Home Care, L.L.C. Zone Program Integrity Contractor ("Infinity ZPIC") audits and a $7 million favorable adjustment recorded in the prior year related to our U.S. Department of Justice ("DOJ") matters (see Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding both the Infinity ZPIC and DOJ matters). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our acquisitions and the Infinity ZPIC and DOJ matters, our operating income decreased $5 million on a $9 million decrease in net service revenue primarily due to a year over year decline in our home health volumes, the reinstatement of sequestration at 1%, a shift in our home health patient mix from episodic payors to lower margin per visit payors, a decrease in our other operating income due to the expiration of the CARES Act PRF funds and an increase in our cost of service resulting from labor cost increases. We were able to partially overcome these items through improvements in home health clinician utilization and reductions in our hospice staffing levels. Additionally, our year over year results were positively impacted by rate increases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we received CARES Act PRF funds in 2020 which were used to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. We recorded income related to these funds totaling $5 million in other operating income within our condensed consolidated statements of operations during the three-month period ended June 30, 2021. This income fully offset the COVID-19 costs incurred during this period, which totaled $5 million. Due to the expiration of the CARES Act PRF funds on June 30, 2021, we were not able to recognize any operating income during the three-month period ended June 30, 2022 to offset the $2 million of COVID-19 costs incurred during this period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a $13 million increase in our other operating expenses compared to prior year. Excluding our acquisitions, our other operating expenses were flat as the addition of resources to support growth, planned wage increases, higher travel and training spend, higher acquisition and integration costs, severance and lease termination costs related to hospice care center closures and consolidations and increased information technology fees were partially offset by higher gains on the sale of fleet vehicles and a favorable legal settlement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income includes the following items (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net increased $6 million year over year as a result of interest accrued in conjunction with the Infinity ZPIC audits discussed above and outstanding term loan borrowings under our Second Amended Credit Agreement (see Note 5 &#8211; Long-Term Obligations to our condensed consolidated financial statements for additional information regarding our Second Amended Credit Agreement). Gain on equity method investments for the prior year includes a $31 million gain related to our investment in Medalogix (see Note 1 &#8211; Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting clinician cost per visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manager cost per visit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost per visit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period January 1, 2021 through March 31, 2022 and the reinstatement of sequestration at 1% for the period April 1, 2022 through June 30, 2022. </span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $21 million on a $9 million decrease in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare, which contributed revenue of $14 million and an operating loss of $1 million to the quarter, as well as an $8 million accrual related to our Infinity ZPIC audits discussed above. Excluding our acquisitions and the Infinity ZPIC, our operating income decreased $12 million on a $15 million decrease in net service revenue primarily due to a year over year decline in volumes, the reinstatement of sequestration at 1%, a shift in our patient mix from episodic payors to lower margin per visit payors, the expiration of the CARES Act PRF funds and increases in our labor costs, integration costs and other operating expenses. These items were partially offset by the increase in reimbursement as well as improvement in our operating performance driven by improvements in clinician utilization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue decreased $9 million. Excluding our April 1, 2022 acquisitions of Evolution and AssistedCare and the Infinity ZPIC audits discussed above, our net service revenue decreased $15 million primarily due to a year over year decline in volumes and the reinstatement of sequestration at 1%. These items were partially offset by the 3.2% increase in reimbursement effective January 1, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $2 million during the three-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $2 million during the three-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, premiums paid to contract clinicians, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 1% primarily due to a 7% increase in our total cost per visit partially offset by a 6% decrease in total visits, resulting from improvements in clinician utilization, as evidenced by a decline of 1.0 visits per completed episode year over year. The 7% increase in our total cost per visit is primarily due to planned wage increases, higher new hire pay, an increase in salaried employees (partially due to our recent acquisitions), wage inflation, increased costs to hire and retain employees, visit mix and higher fuel prices partially offset by a decrease in COVID-19 costs. In addition, while we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which also resulted in an increase in our cost per visit due to the significant decline in visits year over year.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $7 million. Excluding our acquisitions, other operating expenses increased $3 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend and higher information technology fees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total includes acquisitions and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $7 million on a $1 million increase in net service revenue. Excluding a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information), operating income was flat on an $8 million increase in net service revenue. The quarter was impacted by the reinstatement of sequestration at 1%, an increase in our labor costs, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses which were partially offset by the increase in reimbursement effective October 1, 2021, lower revenue adjustments and a reduction in staffing levels.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the DOJ matters in prior year mentioned above, our net service revenue increased $8 million primarily due to the increase in reimbursement effective October 1, 2021 and lower revenue adjustments partially offset by the reinstatement of sequestration at 1%. Despite an increase in admissions, our same store average daily census, which is the main driver of hospice revenue, was flat year over year primarily due to a decline in our length of stay over the past year resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients. We have recently seen an increase in our length of stay, which has helped to drive a 2.5% sequential increase in our second quarter average daily census compared to the first quarter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $2 million during the three-month period ended June 30, 2021. We incurred COVID-19 related costs totaling less than $1 million during the three-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased 2% primarily due to a 2% increase in our cost of service per day. The increase in our cost of service per day is due to planned wage increases, wage inflation, increased costs to hire and retain employees and higher fuel prices partially offset by lower COVID-19 costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $3&#160;million primarily due to planned wage increases, higher travel and training spend, higher information technology fees and severance and lease termination costs associated with care center closures and consolidations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment increased $1 million on a $2 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases. These impacts have been mitigated by a reduction in our cost of service as most of our personal care employees are paid on an hourly basis as well as a reduction in our other operating expenses. </span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk revenue per episode</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk revenue per episode</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of admitting joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our high acuity care segment generated revenue totaling $4 million and an operating loss of $10 million. Although we expect our high acuity care segment to continue to generate operating losses throughout the remainder of the year, we also expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures and expansion into new lines of business such as palliative care at home.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on March 23, 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing joint ventures. As a result, our high acuity care segment includes revenue totaling approximately $2 million related to this joint venture's home health operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients&#8217; homes or via telehealth, as well as costs associated with our virtual care unit (&#8220;VCU&#8221;), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth. We continue to invest in the infrastructure of our VCU in anticipation of future growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses decreased approximately $5 million during the three-month period ended June 30, 2022 primarily due to higher gains on the sale of fleet vehicles, a favorable legal settlement and lower spend in various cost categories partially offset by higher acquisition and integration costs.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six-Month Period Ended June&#160;30, 2022 Compared to the Six-Month Period Ended June&#160;30, 2021 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income decreased $51 million on a $2 million increase in net service revenue. The year-over-year decrease in operating income is primarily due to the acquisitions of Contessa on August 1, 2021 and Evolution and AssistedCare on April 1, 2022 (which combined contributed $21 million in revenue and an operating loss of $19 million), an $8 million accrual related to our Infinity ZPIC audits and a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding both the ZPIC and DOJ matters). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our acquisitions, the Infinity ZPIC and the DOJ matters, our operating income decreased $17 million on a $4 million decrease in net service revenue primarily due to a decline in our home health volumes, a decline in our hospice average daily census, which is the main driver of hospice revenue, the reinstatement of sequestration at 1% effective April 1, 2022, a decrease in our other operating income due to the expiration of the CARES Act PRF funds, an increase in our cost of service resulting from labor cost increases and in increase in our other operating expenses. Partially offsetting these items, our results were positively impacted by rate increases, improvements in clinician utilization and reductions in hospice staffing levels. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we received CARES Act PRF funds in 2020 which were used to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. We recorded income related to these funds totaling $13 million in other operating income within our condensed consolidated statements of operations during the six-month period ended June 30, 2021. This income fully offset the COVID-19 costs incurred during this period, which totaled $13 million. Due to the expiration of the CARES Act PRF funds on June 30, 2021, we were not able to recognize any operating income during the six-month period ended June 30, 2022 to offset the $6 million of COVID-19 costs incurred during this period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a $25 million increase in our other operating expenses compared to prior year. Excluding our acquisitions, our other operating expenses increased $5 million (1%) due to the addition of resources to support growth, planned wage increases, higher travel and training spend, higher acquisition and integration costs, severance and lease termination costs related to hospice closures and consolidations and increased information technology fees partially offset by higher gains on the sale of fleet vehicles and a favorable legal settlement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income includes the following items (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in (loss) earnings from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net increased $8 million year over year as a result of interest accrued in conjunction with the Infinity ZPIC audits discussed above and outstanding term loan borrowings under our Second Amended Credit Agreement (see Note 5 &#8211; Long-Term Obligations to our condensed consolidated financial statements for additional information regarding our Second Amended Credit Agreement). Gain on equity method investments for the prior year includes a $31 million gain related to our investment in Medalogix (see Note 1 &#8211; Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting clinician cost per visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manager cost per visit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost per visit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,726,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period January 1, 2021 through March 31, 2022 and the reinstatement of sequestration at 1% for the period April 1, 2022 through June 30, 2022. </span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $24 million on a $2 million decrease in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare, which contributed revenue of $14 million and an operating loss of $1 million to the six-month period ended June 30, 2022, as well as an $8 million accrual related to our Infinity ZPIC audits discussed above. Excluding our acquisitions and the Infinity ZPIC, our operating income decreased $15 million on an $8 million decrease in net service revenue primarily due to a year over year decline in volumes and the impact of the COVID-19 Omicron variant in the first quarter which drove the highest number of clinician quarantines since the start of the pandemic, the reinstatement of sequestration at 1% effective April 1, 2022, the expiration of the CARES Act PRF funds, an increase in our labor costs and an increase in our other operating expenses. These items were partially offset by the increase in reimbursement as well as improvement in our operating performance driven by improvements in clinician utilization.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue decreased $2 million (less than 1%). Excluding our April 1, 2022 acquisitions of Evolution and AssistedCare and the Infinity ZPIC audits described above, our net service revenue decreased $8 million primarily due to a year over year decline in volumes and the impact of the Omicron variant in the first quarter, which drove the highest number of clinician quarantines since the start of the pandemic, as well as the reinstatement of sequestration at 1% effective April 1, 2022. These items were partially offset by the 3.2% increase in reimbursement effective January 1, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $7 million during the six-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $4 million during the six-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, premiums paid to contract clinicians, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our total cost of service increased 1% primarily due to an 8% increase in our total cost per visit partially offset by a 6% decrease in total visits, resulting from improvements in clinician utilization, as evidenced by a decline of 1.0 visits per completed episode year over year. The 8% increase in our total cost per visit is primarily due to planned wage increases, higher new hire pay, an increase in salaried employees (partially due to our recent acquisitions), wage inflation, increased costs to hire and retain employees, visit mix and higher fuel prices partially offset by a decrease in COVID-19 costs. In addition, while we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which also resulted in an increase in our cost per visit due to the significant decline in visits year over year.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $10 million. Excluding our acquisitions, other operating expenses increased $6 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend and higher information technology fees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total includes acquisitions and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $19 million on a $2 million increase in net service revenue. Excluding a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for additional information), operating income decreased $12 million on a $9 million increase in net service revenue primarily due to a decline in our average daily census, the reinstatement of sequestration at 1% effective April 1, 2022, an increase in our labor costs, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses. These items were partially offset by the increase in reimbursement effective October 1, 2021, lower revenue adjustments and reductions in staffing levels.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the DOJ matters in the prior year mentioned above, our net service revenue increased $9&#160;million primarily due to the increase in reimbursement effective October 1, 2021 as well as lower revenue adjustments partially offset by a decline in our average daily census, which is the main driver of hospice revenue and the reinstatement of sequestration at 1% effective April 1, 2022. Our same store average daily census was down 1% year over year primarily due to a decline in our length of stay resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $6 million during the six-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $2 million during the six-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased 3% primarily due to a 5% increase in our cost of service per day partially offset by a 1% decline in our average daily census. The increase in our cost of service per day is due to planned wage increases, wage inflation, higher costs associated with the utilization of contractors to supplement our staffing levels, increased costs to hire and retain employees and higher fuel prices partially offset by lower COVID-19 costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $8&#160;million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend, higher information technology fees and severance and lease termination costs associated with care center closures and consolidations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment remained flat on a $5 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases. These impacts have been mitigated by a reduction in our cost of service as most of our personal care employees are paid on an hourly basis as well as a reduction in our other operating expenses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk revenue per episode</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk revenue per episode</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of admitting joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our high acuity care segment generated revenue totaling $7 million and an operating loss of $17 million. Although we expect our high acuity care segment to continue to generate operating losses throughout the remainder of the year, we also expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures and expansion into new lines of business such as palliative care at home.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on March 23, 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing joint ventures. As a result, our high acuity care segment includes revenue totaling approximately $2 million related to this joint venture's home health operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients&#8217; homes or via telehealth, as well as costs associated with our virtual care unit (&#8220;VCU&#8221;), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth. We continue to invest in the infrastructure of our VCU in anticipation of future growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses decreased approximately $7 million during the six-month period ended June 30, 2022 primarily due to higher gains on the sale of fleet vehicles, a favorable legal settlement and lower spend in various cost categories partially offset by higher acquisition and integration costs.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased $16.0&#160;million during the six-month period ended June&#160;30, 2022 compared to the six-month period ended June&#160;30, 2021 primarily due to a decrease in operating income and an increase in income tax payments partially offset by the timing of the payment of accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities primarily consists of the purchase of property and equipment, investments and acquisitions. Cash used in investing activities increased $86.2&#160;million during the six-month period ended June&#160;30, 2022 compared to the six-month period ended June&#160;30, 2021 as a result of our investment and acquisition activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options, proceeds related to the purchase of stock under our employee stock purchase plan and our purchase of company stock under our stock repurchase program. Cash used in financing activities totaled $11.4 million during the six-month period ended June&#160;30, 2022 primarily due to the remittance of taxes associated with shares withheld on non-cash compensation and the repurchase of company stock partially offset by net borrowings under our Revolving Credit Facility. Cash used in financing activities totaled $107.3 million during the six-month period ended June&#160;30, 2021 due to the repurchase of company stock and net repayments of borrowings. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six-month period ended June&#160;30, 2022, we spent $2.8 million in capital expenditures as compared to $2.9 million during the six-month period ended June&#160;30, 2021. Our capital expenditures for 2022 are expected to be approximately $6.0 million to $8.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the six-month period ended June 30, 2022, pursuant to our authorized stock repurchase program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million. The repurchased shares are classified as treasury shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $26.6 million in cash and cash equivalents and $507.3 million in availability under our $550.0&#160;million Revolving Credit Facility. We used cash on hand and proceeds from borrowings under our Revolving Credit Facility to fund the acquisitions of Evolution and AssistedCare on April 1, 2022 (see Note 4 &#8211; Acquisitions to our condensed consolidated financial statements for additional information). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements for the next twelve months and beyond.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable increased $30.4&#160;million from December&#160;31, 2021 primarily due to our acquisition activity and the shift from submitting Requests for Anticipated Payment ("RAPs") to Notice of Admissions ("NOAs") for reimbursement from Medicare. The intermediaries were delayed in accepting the NOAs and remitting payments. Our cash collection as a percentage of revenue was 104% and 103% for the six-month periods ended June&#160;30, 2022 and 2021, respectively. Our days revenue outstanding at June&#160;30, 2022 was 46.8 days, which is an increase of 3.6 days from December&#160;31, 2021 and an increase of 4.1 days from June 30, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date of the last billable service in the 30-day billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:42.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At June 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.4&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over 365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021 by our average daily net service revenue for the three-month periods ended June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% for the three and six-month periods ended June 30, 2022, and 1.7% and 1.8% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 2.3% and 2.0% for the three and six-month periods ended June 30, 2022, respectively, and 1.4% and 1.5% for the three and six-month periods ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 15.4 and we are in compliance with our covenants under the Second Amended Credit Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2022, our availability under our $550.0 million Revolving Credit Facility was $507.3 million as we have $15.0&#160;million outstanding in borrowings and $27.7 million outstanding in letters of credit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 5 &#8211; Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2021 (the "2021 Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74&#160;million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2022. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe inflation has significantly impacted our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2021 Annual Report on Form 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. These critical accounting estimates include revenue recognition, business combinations and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2021 Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Eurodollar rate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LIBOR) and the Prime Rate, and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of June&#160;30, 2022, the total amount of outstanding debt subject to interest rate fluctuations was $456.6 million. A 1.0% interest rate change would cause interest expense to change by approximately $4.6 million annually, assuming the Company makes no principal repayments.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Quarterly Report on Form 10-Q, as of June&#160;30, 2022, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June&#160;30, 2022, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended June&#160;30, 2022, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of June&#160;30, 2022, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8211; Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended June&#160;30, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:33.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(a)&#160;Total&#160;Number<br/>of&#160;Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(b)&#160;Average&#160;Price<br/>Paid&#160;per&#160;Share&#160;(or<br/>Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number&#160;of<br/>Shares (or Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(d)&#160;Maximum&#160;Number&#160;(or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units) That May Yet Be<br/>Purchased Under the<br/>Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022&#160;to&#160;April 30,&#160;2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1,&#160;2022&#160;to May 31,&#160;2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022 to June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock and exercise of stock options previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report or Registration Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626221000110/amed-20213009xex32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 20, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20223006xexx311.htm">Certification of Christopher T. Gerard, President and Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20223006xexx312.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20223006xexx321.htm">Certification of Christopher T. Gerard, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20223006xexx322.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i3ab6a0ff70694f7e9af47b41f794c5b6_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.912%"><tr><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.062%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT G. GINN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Financial Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Duly Authorized Officer</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: July&#160;28, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>amed-20223006xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifeed45459e9e430baacfe428db7a11e2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher T.Gerard, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;28, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Christopher T. Gerard</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher T. Gerard</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>amed-20223006xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if3eca027cc96432781461229b50c6fa5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;28, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>amed-20223006xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i30ef9bd3fe994d20b0c45a368c3fa3d6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2022 (the &#8220;Report&#8221;), I, Christopher T. Gerard, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;28, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Christopher T. Gerard</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher T. Gerard<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>amed-20223006xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i993341abc2b14d0c802257b637203694_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2022 (the &#8220;Report&#8221;), I, Scott G. Ginn, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;28, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amed-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables">
        <link:definition>2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
        <link:definition>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
        <link:definition>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19">
        <link:definition>2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Tables" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables">
        <link:definition>2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Details" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details">
        <link:definition>2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>2116104 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>2317304 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails">
        <link:definition>2419410 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>2120105 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables">
        <link:definition>2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
        <link:definition>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1">
        <link:definition>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
        <link:definition>2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>2128107 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2329306 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASESHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE">
        <link:definition>2132108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>2433418 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS">
        <link:definition>2134109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2435419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_BusinessCombinationAcquiredNoncontrollingInterest" abstract="false" name="BusinessCombinationAcquiredNoncontrollingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ReversalOfLossContingencyAccrual" abstract="false" name="ReversalOfLossContingencyAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_EvolutionHealthMember" abstract="true" name="EvolutionHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CompanysinsurancecarriersMember" abstract="true" name="CompanysinsurancecarriersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonCashAccruedContingentConsideration" abstract="false" name="NonCashAccruedContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilized" abstract="false" name="CARESActProviderReliefFundsUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_ContributionsAttributableToNoncontrollingInterest" abstract="false" name="ContributionsAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Discountedclosingstockprice" abstract="false" name="Discountedclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LicensesMember" abstract="true" name="LicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" abstract="false" name="ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsContessaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AsanaHospiceAquisitionMember" abstract="true" name="AsanaHospiceAquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_CARESActInterestRepaidToGovernment" abstract="false" name="CARESActInterestRepaidToGovernment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TypeOfEquityMethodInvestmentDomain" abstract="true" name="TypeOfEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PriorCreditAgreementMember" abstract="true" name="PriorCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AcutePhaseForHighAcuityCareServices" abstract="false" name="AcutePhaseForHighAcuityCareServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_AccountsReceivablePortionDerivedFromMedicare" abstract="false" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_MajorSinglePayorCustomerMember" abstract="true" name="MajorSinglePayorCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_A2021ShareRepurchaseProgramMember" abstract="true" name="A2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" abstract="false" name="EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NewShareRepurchaseProgramMember" abstract="true" name="NewShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_A2022NewJointVentureMember" abstract="true" name="A2022NewJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AdditionalFundingDistributedToHealthcareProviders" abstract="false" name="AdditionalFundingDistributedToHealthcareProviders" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AssistedCareHomeHealthMember" abstract="true" name="AssistedCareHomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProviderReliefFundAdvance" abstract="false" name="ProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_FundsReceivedFromProviderReliefFundAdvance" abstract="false" name="FundsReceivedFromProviderReliefFundAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" abstract="false" name="IncreaseInEstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OneHundredMillionTermLoanMember" abstract="true" name="OneHundredMillionTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" abstract="false" name="ScheduleOfCaresActProviderReliefFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PotentialClosingPaymentAdjustmentMember" abstract="true" name="PotentialClosingPaymentAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonCashNoncontrollingInterestContribution" abstract="false" name="NonCashNoncontrollingInterestContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_Percentageofclosingstockprice" abstract="false" name="Percentageofclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_VariousAcquisitionsMember" abstract="true" name="VariousAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_COVID19PPEMember" abstract="true" name="COVID19PPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_COVID19DeferralOfSocialSecurityMember" abstract="true" name="COVID19DeferralOfSocialSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TotalCARESActProviderReliefFundsReceived" abstract="false" name="TotalCARESActProviderReliefFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_COVID19ExpensesIncurred" abstract="false" name="COVID19ExpensesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_BusinessCombinationAdjustmentsDomain" abstract="true" name="BusinessCombinationAdjustmentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_BusinessCombinationAdjustmentsAxis" abstract="true" name="BusinessCombinationAdjustmentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" abstract="false" name="PaymentOfDeferredSocialSecurityTaxUnderCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" abstract="false" name="BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ContessaHealthMember" abstract="true" name="ContessaHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CashPaidForFinanceLeaseLiabilities" abstract="false" name="CashPaidForFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19TextBlock" abstract="false" name="COVID19TextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_PayorsAxis" abstract="true" name="PayorsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_HighAcuityCareMember" abstract="true" name="HighAcuityCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentAxis" abstract="true" name="TypeofEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_NumberOfJointVentures" abstract="false" name="NumberOfJointVentures" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitsettlement" abstract="false" name="SecuritiesClassActionLawsuitsettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ExistingShareRepurchaseProgramMember" abstract="true" name="ExistingShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CertificateOfNeedAndLicensesMember" abstract="true" name="CertificateOfNeedAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashPaidForOperatingLeaseLiabilities" abstract="false" name="CashPaidForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_A2019ShareRepurchaseProgramMember" abstract="true" name="A2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SecondAmendmentToAmendedCreditAgreementMember" abstract="true" name="SecondAmendmentToAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" abstract="false" name="NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_EstimatedFutureCOVID19RelatedExpenses" abstract="false" name="EstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Businessacquisitionproformaoperatingincomeloss" abstract="false" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CARESActDeferralOfEmployerShareSocialSecurityTax" abstract="false" name="CARESActDeferralOfEmployerShareSocialSecurityTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsRepaid" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsRepaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_PayorsDomain" abstract="true" name="PayorsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" abstract="false" name="FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ReductionToNetServiceRevenue" abstract="false" name="ReductionToNetServiceRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FourHundredFiftyMillionTermLoanFacilityMember" abstract="true" name="FourHundredFiftyMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" abstract="false" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>amed-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_40a48876-b8bd-47bf-b587-134f4cb4d678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8f2a8d3d-84a4-412b-9021-4f65d6d956be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_40a48876-b8bd-47bf-b587-134f4cb4d678" xlink:to="loc_us-gaap_Liabilities_8f2a8d3d-84a4-412b-9021-4f65d6d956be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0fc0f7e-d10e-4545-9007-188eb58bf7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_40a48876-b8bd-47bf-b587-134f4cb4d678" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0fc0f7e-d10e-4545-9007-188eb58bf7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_083fdfbe-7be6-41db-9e92-b2ddca3ad8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b40da0a6-51bb-4077-8695-bfc8c10a5e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_083fdfbe-7be6-41db-9e92-b2ddca3ad8aa" xlink:to="loc_us-gaap_StockholdersEquity_b40da0a6-51bb-4077-8695-bfc8c10a5e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_acf6d308-7800-4293-b21f-3c71a77ce4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_083fdfbe-7be6-41db-9e92-b2ddca3ad8aa" xlink:to="loc_us-gaap_MinorityInterest_acf6d308-7800-4293-b21f-3c71a77ce4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a93aac57-524d-4171-af4c-53f9524da30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a93aac57-524d-4171-af4c-53f9524da30b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_93bafa03-3194-473b-bd81-60fdbe2eba03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:to="loc_us-gaap_RestrictedCash_93bafa03-3194-473b-bd81-60fdbe2eba03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c8b3fba1-925e-40ff-8f34-6e508fa229d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c8b3fba1-925e-40ff-8f34-6e508fa229d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_64d07df3-0caf-4e68-8f57-3f79172cac39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_64d07df3-0caf-4e68-8f57-3f79172cac39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_44f9e0b9-8e9b-40b1-91d6-c95340fefb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_de60e895-7e7e-4535-ac45-5ddea89c8b48" xlink:to="loc_us-gaap_OtherAssetsCurrent_44f9e0b9-8e9b-40b1-91d6-c95340fefb08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_646d04aa-9c8d-4e89-8249-16ebe1b78a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_AssetsCurrent_646d04aa-9c8d-4e89-8249-16ebe1b78a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9eeeab35-90bb-4d04-acc3-4b56ed6314f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9eeeab35-90bb-4d04-acc3-4b56ed6314f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d61b6a23-1f76-41e0-a23b-b807ca16df17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d61b6a23-1f76-41e0-a23b-b807ca16df17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_480787fe-9709-495e-a490-400b9b3005b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_Goodwill_480787fe-9709-495e-a490-400b9b3005b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e0315b89-feb7-45ef-a26d-2ca55a24707e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e0315b89-feb7-45ef-a26d-2ca55a24707e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_25f541ff-2ca8-43e3-a0f3-8dd71372c013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_25f541ff-2ca8-43e3-a0f3-8dd71372c013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2de8bb8b-4220-4525-bb25-d84e94cef20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05f881a6-8976-4550-a4e4-217f3a3bd1fc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2de8bb8b-4220-4525-bb25-d84e94cef20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_88bf25bd-9865-46f7-91fc-e0253351199e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:to="loc_us-gaap_AccountsPayableCurrent_88bf25bd-9865-46f7-91fc-e0253351199e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a93bad65-a470-4fc5-992d-7e5a642d24b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a93bad65-a470-4fc5-992d-7e5a642d24b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fbb87994-3f19-49a5-933b-05bde4aed114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fbb87994-3f19-49a5-933b-05bde4aed114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b670a4b8-cd0d-4804-bebd-6a3ca5c9eb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b670a4b8-cd0d-4804-bebd-6a3ca5c9eb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1b0cb2b5-dd98-4f46-ad2d-19055657a745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5638d837-2bf4-4237-abbf-6de103280a71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1b0cb2b5-dd98-4f46-ad2d-19055657a745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eba9ae1e-c2d3-42fc-8cb6-7a2c0c9dec27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:to="loc_us-gaap_LiabilitiesCurrent_eba9ae1e-c2d3-42fc-8cb6-7a2c0c9dec27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5b7c2e26-64e7-4653-b27b-e05b8ac5bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5b7c2e26-64e7-4653-b27b-e05b8ac5bc4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b76684eb-7ba4-4538-9308-73836eff4796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b76684eb-7ba4-4538-9308-73836eff4796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ade6ddaa-dd8f-4270-8eda-c4b4b034862f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ade6ddaa-dd8f-4270-8eda-c4b4b034862f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91f4ace8-695c-4088-b530-4c82f519aeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_36b3dd39-1b50-4315-b41c-447320ccd585" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91f4ace8-695c-4088-b530-4c82f519aeeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_9b76a085-2da7-4926-b8e3-5f3f6be44a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_9b76a085-2da7-4926-b8e3-5f3f6be44a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_33921b70-eb90-4317-bec9-413e93925783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:to="loc_us-gaap_CommonStockValueOutstanding_33921b70-eb90-4317-bec9-413e93925783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48ac118c-56e4-426b-bce7-8339e70c94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48ac118c-56e4-426b-bce7-8339e70c94f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_26480e32-84cf-4dd0-9a5a-a5c1ac500ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:to="loc_us-gaap_TreasuryStockValue_26480e32-84cf-4dd0-9a5a-a5c1ac500ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e04a0df1-4a0f-4cf1-a6a3-889d0554114a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21a4aa1c-04fb-4363-b513-927d47d4fcea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e04a0df1-4a0f-4cf1-a6a3-889d0554114a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_be74a79d-655c-460e-ae66-2586d14e410b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_be74a79d-655c-460e-ae66-2586d14e410b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_436eb24f-3f08-4596-aafd-90503d4af7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:to="loc_us-gaap_LaborAndRelatedExpense_436eb24f-3f08-4596-aafd-90503d4af7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d9626dc7-38b6-4a26-8b9c-6b2b83e0b1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:to="loc_us-gaap_ShareBasedCompensation_d9626dc7-38b6-4a26-8b9c-6b2b83e0b1ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bfbd9bd2-c0b7-41b2-950e-1a008afa119d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bfbd9bd2-c0b7-41b2-950e-1a008afa119d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_eb699410-2222-42da-92e0-5074dbfee766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9874240a-0292-45c5-ab4a-b6a5b5d1c186" xlink:to="loc_us-gaap_DepreciationAndAmortization_eb699410-2222-42da-92e0-5074dbfee766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_d68075d9-ddbe-4bef-b95d-81267ca730fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_d68075d9-ddbe-4bef-b95d-81267ca730fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_65c9dde3-d18f-4f48-9f18-4185a6a72d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:to="loc_us-gaap_InterestExpense_65c9dde3-d18f-4f48-9f18-4185a6a72d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b15d12b6-c2dd-4bb0-8c3b-a6ce503749e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b15d12b6-c2dd-4bb0-8c3b-a6ce503749e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d3f9255b-d1f4-486d-84a8-690e37829799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:to="loc_us-gaap_GainLossOnInvestments_d3f9255b-d1f4-486d-84a8-690e37829799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8f69c8e1-b172-4deb-9a2e-5361844dffe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_85a227fb-ed5e-42c9-b17b-26f7025a9725" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8f69c8e1-b172-4deb-9a2e-5361844dffe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90b3234f-ba32-4be9-9a29-1475db0f9f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ffec1162-7fd0-4272-b0cf-cf8a406664da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90b3234f-ba32-4be9-9a29-1475db0f9f42" xlink:to="loc_us-gaap_ProfitLoss_ffec1162-7fd0-4272-b0cf-cf8a406664da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_167b6fe1-ea1b-42bb-95cb-7aac40ea03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90b3234f-ba32-4be9-9a29-1475db0f9f42" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_167b6fe1-ea1b-42bb-95cb-7aac40ea03c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7c93c79b-c53f-4e07-8727-c6188b1b37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2915d5e2-13a1-45fe-9758-011050d694f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7c93c79b-c53f-4e07-8727-c6188b1b37a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2915d5e2-13a1-45fe-9758-011050d694f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e065a67f-6e3f-4ac0-a2ff-85f3235b18cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7c93c79b-c53f-4e07-8727-c6188b1b37a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e065a67f-6e3f-4ac0-a2ff-85f3235b18cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61f2dcce-afa2-43a7-812a-bb149c59cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_417194ef-7faf-4c27-acab-a2679a788ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61f2dcce-afa2-43a7-812a-bb149c59cf26" xlink:to="loc_us-gaap_OperatingIncomeLoss_417194ef-7faf-4c27-acab-a2679a788ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ff0edda4-5752-45af-b747-fcc6c77de09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61f2dcce-afa2-43a7-812a-bb149c59cf26" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ff0edda4-5752-45af-b747-fcc6c77de09d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ad001746-737e-4c4a-9afa-25ad0a63c4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a4bf5ec9-ab35-4264-91d5-4aef7062bc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ad001746-737e-4c4a-9afa-25ad0a63c4f3" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a4bf5ec9-ab35-4264-91d5-4aef7062bc96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a1d4158f-a166-414d-bdac-283605d8eeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ad001746-737e-4c4a-9afa-25ad0a63c4f3" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a1d4158f-a166-414d-bdac-283605d8eeba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_84351ea4-9f86-4d16-b554-6535a26beb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ad001746-737e-4c4a-9afa-25ad0a63c4f3" xlink:to="loc_us-gaap_CostsAndExpenses_84351ea4-9f86-4d16-b554-6535a26beb07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_c14dd19e-ea17-445c-bb14-1697a0a7aa15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_c14dd19e-ea17-445c-bb14-1697a0a7aa15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_024643db-bc8c-4aea-a0f1-b07cb83857b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_024643db-bc8c-4aea-a0f1-b07cb83857b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10f115b7-74a6-418b-b266-656670a0c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10f115b7-74a6-418b-b266-656670a0c5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_fe938892-ed8c-4e84-88dc-55a33ed1595a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_fe938892-ed8c-4e84-88dc-55a33ed1595a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_716b3c73-7b56-4acb-860f-93b900a3f528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_716b3c73-7b56-4acb-860f-93b900a3f528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_dce6457a-ffab-4745-a3d7-467f28dd9e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d4c1038-c8b1-453d-838a-fdfd6e90cfd5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_dce6457a-ffab-4745-a3d7-467f28dd9e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b4718bc5-572b-4bd1-a1b8-9659d1ed8dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c3db4cbe-f438-48a1-b243-69244658f455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b4718bc5-572b-4bd1-a1b8-9659d1ed8dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c3db4cbe-f438-48a1-b243-69244658f455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f3aabf3-07e7-4952-a48a-bb8aed5df733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b4718bc5-572b-4bd1-a1b8-9659d1ed8dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f3aabf3-07e7-4952-a48a-bb8aed5df733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4400ef98-819f-44b7-9847-9c179b89510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b4718bc5-572b-4bd1-a1b8-9659d1ed8dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4400ef98-819f-44b7-9847-9c179b89510f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bb5c346a-6ae6-444c-8493-fa45eba93f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_ProfitLoss_bb5c346a-6ae6-444c-8493-fa45eba93f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59bc1dfa-943b-40b1-a897-86511278557d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59bc1dfa-943b-40b1-a897-86511278557d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1a3669b1-cb3e-4c09-ab22-569e94440f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_ShareBasedCompensation_1a3669b1-cb3e-4c09-ab22-569e94440f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_3af7bc43-ba6e-4151-be1c-89238013a830" xlink:href="amed-20220630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_3af7bc43-ba6e-4151-be1c-89238013a830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7ea970c1-2bd0-4772-92ef-3bb42f5a158d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7ea970c1-2bd0-4772-92ef-3bb42f5a158d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_f30a6b25-3ca7-45fc-8ed2-ae135bdc27bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_f30a6b25-3ca7-45fc-8ed2-ae135bdc27bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8bf36c39-5885-435f-8847-8c6419587471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8bf36c39-5885-435f-8847-8c6419587471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_261d309c-295c-47ed-995c-22e347a6333a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_261d309c-295c-47ed-995c-22e347a6333a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_95389f2f-c480-4c6a-a677-ff39f306a475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_95389f2f-c480-4c6a-a677-ff39f306a475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c3f47e9f-91ed-462e-b2d9-96f4cc32a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c3f47e9f-91ed-462e-b2d9-96f4cc32a05f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d1e7e25e-8ffd-4d39-a5ae-6ebbef966ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d1e7e25e-8ffd-4d39-a5ae-6ebbef966ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dd5d7e2d-8d74-4e47-87fc-d608a89ee378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dd5d7e2d-8d74-4e47-87fc-d608a89ee378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_943cc3c6-e4dd-41e2-8d75-c1843989df65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_943cc3c6-e4dd-41e2-8d75-c1843989df65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_53bd9ca6-b522-4a61-9e26-1a0a2b5bdc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_53bd9ca6-b522-4a61-9e26-1a0a2b5bdc5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5e8e64e8-d24a-4dff-85e2-4eadfd5e0d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5e8e64e8-d24a-4dff-85e2-4eadfd5e0d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1558a007-fe33-4088-9285-c7acb619c87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1558a007-fe33-4088-9285-c7acb619c87b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_00f9a638-c5ae-4e0d-8f16-906c819fa0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_00f9a638-c5ae-4e0d-8f16-906c819fa0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_f5cd6340-42a4-447c-9190-476621087df2" xlink:href="amed-20220630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca0f30f-b100-4475-9b37-26944bec9565" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_f5cd6340-42a4-447c-9190-476621087df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b04e7c26-5732-4dab-9072-9191f80f824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b04e7c26-5732-4dab-9072-9191f80f824c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b6b01870-4f06-42f1-81cf-bcc9b9171ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b6b01870-4f06-42f1-81cf-bcc9b9171ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_134b0044-95d3-4982-9c26-8bea4fd83a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_134b0044-95d3-4982-9c26-8bea4fd83a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_5b2baa9e-709f-48d9-9ec6-e6fcb5e98fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_5b2baa9e-709f-48d9-9ec6-e6fcb5e98fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_43d2f6b5-cf86-4c88-a42e-2eedff266bb2" xlink:href="amed-20220630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_43d2f6b5-cf86-4c88-a42e-2eedff266bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_d4651ceb-832b-444d-8fb1-bab9a32615fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_d4651ceb-832b-444d-8fb1-bab9a32615fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b5f9afb4-f84e-4db4-8e88-a0f6993c85de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b5f9afb4-f84e-4db4-8e88-a0f6993c85de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_77a929ef-2e97-4bcd-8834-3ef7b59d0393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_77a929ef-2e97-4bcd-8834-3ef7b59d0393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ed0d460c-b8b3-4545-b3c8-527395d95ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ed0d460c-b8b3-4545-b3c8-527395d95ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_eb50dd63-bf15-4ea3-bf48-b1847887babd" xlink:href="amed-20220630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b68f5c5d-794f-42ac-bac2-2d584f6dff63" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_eb50dd63-bf15-4ea3-bf48-b1847887babd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_285e7f30-10d2-4731-87d3-afdb1df624b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_291025b7-e96f-4807-ac22-470a975c8661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_285e7f30-10d2-4731-87d3-afdb1df624b8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_291025b7-e96f-4807-ac22-470a975c8661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_19654b45-cc88-48cf-bef7-64eae636e545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_285e7f30-10d2-4731-87d3-afdb1df624b8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_19654b45-cc88-48cf-bef7-64eae636e545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_bbb1033e-bf47-4360-b2ac-00e35e254aec" xlink:href="amed-20220630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_285e7f30-10d2-4731-87d3-afdb1df624b8" xlink:to="loc_amed_NonVestedStockAndStockUnits_bbb1033e-bf47-4360-b2ac-00e35e254aec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_be5519cb-2f8f-41a3-a867-1f259c28aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_66ef6fd4-f2d9-4437-b68c-93dee0e472ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_be5519cb-2f8f-41a3-a867-1f259c28aa4a" xlink:to="loc_us-gaap_LongTermDebtCurrent_66ef6fd4-f2d9-4437-b68c-93dee0e472ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a2f8e65a-4aea-4410-be57-836a17e0b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_be5519cb-2f8f-41a3-a867-1f259c28aa4a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a2f8e65a-4aea-4410-be57-836a17e0b5ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bffb9fcf-25e8-4da4-95e6-abe9311d117e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6c25196d-3914-4601-9b65-d751f8c99bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bffb9fcf-25e8-4da4-95e6-abe9311d117e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6c25196d-3914-4601-9b65-d751f8c99bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a0b99bca-9a86-498e-8056-7c10d6af9594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bffb9fcf-25e8-4da4-95e6-abe9311d117e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a0b99bca-9a86-498e-8056-7c10d6af9594" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>amed-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended" id="ib371c0006bb147389736c99d7d7d4adc_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b0cee58-1074-443f-8bd8-2af5e16a3926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b0cee58-1074-443f-8bd8-2af5e16a3926" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a6b45ee1-3d4d-4405-b325-69aa8c97837a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_SharesOutstanding_a6b45ee1-3d4d-4405-b325-69aa8c97837a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e2f8525c-5c05-46ec-90fc-51238b66e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e2f8525c-5c05-46ec-90fc-51238b66e5da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83b1fd0a-2728-4e8a-b03e-3397e47e5540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83b1fd0a-2728-4e8a-b03e-3397e47e5540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_23fa3dce-16a5-4d54-bdc7-72c70bdb289b" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_23fa3dce-16a5-4d54-bdc7-72c70bdb289b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_6699c983-bd9d-4ca7-a266-d219ac10313f" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_6699c983-bd9d-4ca7-a266-d219ac10313f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_556b9053-dea7-4c0a-b10e-ba5e646665fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_556b9053-dea7-4c0a-b10e-ba5e646665fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_900e4396-4596-4fd9-9d72-c4dbb58b2b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_900e4396-4596-4fd9-9d72-c4dbb58b2b46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f949a36c-c837-41f1-b3c9-7363da8f005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f949a36c-c837-41f1-b3c9-7363da8f005c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93fd325b-ea9b-448e-a80d-c110cad94772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93fd325b-ea9b-448e-a80d-c110cad94772" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c91db251-735e-4bda-9fa2-1b3490650f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c91db251-735e-4bda-9fa2-1b3490650f63" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_ddb90372-f7cc-40cd-a804-1df9e93c0523" xlink:href="amed-20220630.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_SurrenderedShares_ddb90372-f7cc-40cd-a804-1df9e93c0523" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_81e5994f-658e-4460-8b1a-e1e41b4f34b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_81e5994f-658e-4460-8b1a-e1e41b4f34b9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_96794c00-7158-4003-bbf2-dca42ffc2b7c" xlink:href="amed-20220630.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_96794c00-7158-4003-bbf2-dca42ffc2b7c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e695a3bd-9987-4620-9991-6e0c9a395917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e695a3bd-9987-4620-9991-6e0c9a395917" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_a2fe32e4-48e9-46df-a6fd-8c1c8ee87a79" xlink:href="amed-20220630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_a2fe32e4-48e9-46df-a6fd-8c1c8ee87a79" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a49d5b63-a290-4934-b29d-d5fc79320677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_ProfitLoss_a49d5b63-a290-4934-b29d-d5fc79320677" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90e4b605-8fd0-4436-8a20-47a135cf8d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2e64b063-2083-4444-8a8a-2b43e4838b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57b81db1-2ac9-412a-9448-0e744bd5c1b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:to="loc_us-gaap_EquityComponentDomain_57b81db1-2ac9-412a-9448-0e744bd5c1b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:to="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f98a7015-1536-4758-9c6e-fc4678a32776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_CommonStockMember_f98a7015-1536-4758-9c6e-fc4678a32776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_17285999-30ee-4923-b453-a7760c5f8f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_17285999-30ee-4923-b453-a7760c5f8f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9714dfb8-6caa-4407-8055-4bfbf8979849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_TreasuryStockMember_9714dfb8-6caa-4407-8055-4bfbf8979849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96615b13-4afc-44d5-bd11-94e32eccb090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96615b13-4afc-44d5-bd11-94e32eccb090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_902e3be7-c8ff-4eff-a7f4-6ccf43c047f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_RetainedEarningsMember_902e3be7-c8ff-4eff-a7f4-6ccf43c047f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a486fbdd-7526-4687-8d77-b20471bff7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a486fbdd-7526-4687-8d77-b20471bff7a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_35a0dc67-7bbc-4ec2-9423-1b9033ff42d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_35a0dc67-7bbc-4ec2-9423-1b9033ff42d6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="ia6ab143cc7904e22adc6e96b68e3d361_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_72171ed5-c901-4d55-8d9b-39c36464d8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_72171ed5-c901-4d55-8d9b-39c36464d8b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_afce27ca-54f9-4d58-b8bb-65c72ac8a89f" xlink:href="amed-20220630.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_OperatingCareCenters_afce27ca-54f9-4d58-b8bb-65c72ac8a89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a95b26b-471e-45e6-80c5-4fbad785dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a95b26b-471e-45e6-80c5-4fbad785dbb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_fc8323d2-2d97-40b9-aab8-f1370b7b7bfe" xlink:href="amed-20220630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_fc8323d2-2d97-40b9-aab8-f1370b7b7bfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_68fe52ba-379e-4b48-b5ec-bef87ec34e88" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_68fe52ba-379e-4b48-b5ec-bef87ec34e88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_0c98cf73-e1fc-4f17-a469-40263f97bec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_0c98cf73-e1fc-4f17-a469-40263f97bec3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_127211d4-4649-4428-b175-2ec45e2e35e5" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_127211d4-4649-4428-b175-2ec45e2e35e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_096078ac-e10e-405f-b20f-c722d4def180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_096078ac-e10e-405f-b20f-c722d4def180" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_3b6317f7-b89a-4780-b01f-0532d1daf0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_3b6317f7-b89a-4780-b01f-0532d1daf0f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_98a52558-9121-47fc-859a-aa849acb4def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EquityMethodInvestments_98a52558-9121-47fc-859a-aa849acb4def" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_22c11896-66d6-4517-9ef4-f0e44030b273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_22c11896-66d6-4517-9ef4-f0e44030b273" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_b0ba9f00-3eba-406f-bcf1-d1f949bfa426" xlink:href="amed-20220630.xsd#amed_NumberOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_NumberOfJointVentures_b0ba9f00-3eba-406f-bcf1-d1f949bfa426" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_37dd0836-941a-4de4-b7bc-c6852c9bb0da" xlink:href="amed-20220630.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_37dd0836-941a-4de4-b7bc-c6852c9bb0da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdf9a8a3-eeff-4572-81fc-fd749eac2689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdf9a8a3-eeff-4572-81fc-fd749eac2689" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d519357-5db5-496a-97f6-74d4ace6a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d519357-5db5-496a-97f6-74d4ace6a08c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_203144a6-a8af-407e-b154-05bbc2c78841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_OtherAssetsCurrent_203144a6-a8af-407e-b154-05bbc2c78841" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e3f856c4-69fb-46c2-a890-43bcdb6ea2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AssetsCurrent_e3f856c4-69fb-46c2-a890-43bcdb6ea2cb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bdd1e66b-1668-48a2-af5e-7ff681b97aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bdd1e66b-1668-48a2-af5e-7ff681b97aaa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_21ed79a7-54de-4468-a9df-aa686f887df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Goodwill_21ed79a7-54de-4468-a9df-aa686f887df3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27423287-4a7a-449a-a17b-9fdb67748856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27423287-4a7a-449a-a17b-9fdb67748856" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efe558ca-1cc7-4d25-a80b-177448d0368e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Assets_efe558ca-1cc7-4d25-a80b-177448d0368e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c176897c-0aa4-4c57-b553-2c48361e53c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c176897c-0aa4-4c57-b553-2c48361e53c6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d7ab2238-f5a7-4421-8fbe-53627a13aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d7ab2238-f5a7-4421-8fbe-53627a13aef4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa5831b-c8cc-4965-87b9-fc7ca905c780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa5831b-c8cc-4965-87b9-fc7ca905c780" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_027578b1-f5bb-4bfe-909a-b1df7012ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_LiabilitiesCurrent_027578b1-f5bb-4bfe-909a-b1df7012ab31" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3587ea9a-0c76-454d-b36f-76c1cff78b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3587ea9a-0c76-454d-b36f-76c1cff78b14" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af44b35f-3400-4d66-87e5-e150615bd989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Liabilities_af44b35f-3400-4d66-87e5-e150615bd989" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_1ead2268-56e9-4819-9bf2-935a16c8d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_1ead2268-56e9-4819-9bf2-935a16c8d88d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_47286bd0-b67e-4a4b-a750-443dc45f7c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_47286bd0-b67e-4a4b-a750-443dc45f7c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_28a9cbaf-7969-4dc2-9c1f-311ca17d3344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_28a9cbaf-7969-4dc2-9c1f-311ca17d3344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dc6d8714-b345-4320-b80a-82b1558ab9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dc6d8714-b345-4320-b80a-82b1558ab9db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8a41289a-6a5b-49fd-a0ee-80cb39a11698_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8a41289a-6a5b-49fd-a0ee-80cb39a11698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_664eaa6a-d58f-4824-9f60-7ca6157959db" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:to="loc_amed_MedicareRevenueMember_664eaa6a-d58f-4824-9f60-7ca6157959db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d5abb959-1bbd-463a-9b92-89c5d9cf9c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d5abb959-1bbd-463a-9b92-89c5d9cf9c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3c5d391e-daa1-4717-bb29-6b242d3e314e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:to="loc_us-gaap_SegmentDomain_3c5d391e-daa1-4717-bb29-6b242d3e314e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:to="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_81a9d5d1-8cc5-4fb7-b22c-52ce086d7337" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HomeHealthMember_81a9d5d1-8cc5-4fb7-b22c-52ce086d7337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_16b4f008-1c71-4df2-81ee-cbc55c1e92f4" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HospiceMember_16b4f008-1c71-4df2-81ee-cbc55c1e92f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a16c1591-0d0b-4af7-84fe-f4b9b434087d" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_PersonalCareMember_a16c1591-0d0b-4af7-84fe-f4b9b434087d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_bbdd29e7-455f-49cf-8a48-a72ed7f917fc" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HighAcuityCareMember_bbdd29e7-455f-49cf-8a48-a72ed7f917fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3ac9411-cb46-4d06-a66b-0d79d67d8561_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:to="loc_srt_ProductsAndServicesDomain_f3ac9411-cb46-4d06-a66b-0d79d67d8561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:to="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_5478491a-20d6-4479-bfbf-c12a12de0608" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:to="loc_amed_MedicareRevenueMember_5478491a-20d6-4479-bfbf-c12a12de0608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_39717690-5d45-45a6-ad28-2953bccb576e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_39717690-5d45-45a6-ad28-2953bccb576e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:href="amed-20220630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_0dd92786-e03b-44ff-95ae-4b3ca8d0442c_default" xlink:href="amed-20220630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_0dd92786-e03b-44ff-95ae-4b3ca8d0442c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:href="amed-20220630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_8771e499-ed2e-4796-bc4f-36e3996a6437" xlink:href="amed-20220630.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:to="loc_amed_MedalogixMember_8771e499-ed2e-4796-bc4f-36e3996a6437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84200003-653a-4168-9829-5f97653b934d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84200003-653a-4168-9829-5f97653b934d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_bb5144f9-778e-42bf-b624-97cd22e61df3" xlink:href="amed-20220630.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:to="loc_amed_EvolutionHealthMember_bb5144f9-778e-42bf-b624-97cd22e61df3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i56e59a720d5c4ad194a9840759c75265_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85ec7f5d-d71c-4b9d-b1f4-6a4ea193067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85ec7f5d-d71c-4b9d-b1f4-6a4ea193067a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_ef2840de-29e9-4c61-a681-1d6a615d1806" xlink:href="amed-20220630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_ef2840de-29e9-4c61-a681-1d6a615d1806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_4ae03912-d5ab-456f-b7ac-88294d998258" xlink:href="amed-20220630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_4ae03912-d5ab-456f-b7ac-88294d998258" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_84c5c94a-f5d3-4b7d-9400-fa88e31e1123" xlink:href="amed-20220630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_84c5c94a-f5d3-4b7d-9400-fa88e31e1123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_31d0945c-dead-489a-b2f1-365394890984" xlink:href="amed-20220630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_31d0945c-dead-489a-b2f1-365394890984" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_34190eed-9abc-4549-99e3-f5c967374f1a" xlink:href="amed-20220630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_34190eed-9abc-4549-99e3-f5c967374f1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_44524335-bc42-4b99-9388-05f5b89a0308" xlink:href="amed-20220630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_44524335-bc42-4b99-9388-05f5b89a0308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_503ae44c-f22c-425d-a76d-75d5d7f54e05" xlink:href="amed-20220630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_SecondThresholdOfServicesRequired_503ae44c-f22c-425d-a76d-75d5d7f54e05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_7fed5ef7-f4fa-4de0-94f6-e29f5561cfbd" xlink:href="amed-20220630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_7fed5ef7-f4fa-4de0-94f6-e29f5561cfbd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_36059833-52cd-47c4-904f-a52bfe2c49a5" xlink:href="amed-20220630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_36059833-52cd-47c4-904f-a52bfe2c49a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_663676cc-a5a0-4a29-b881-5685d8fe8602" xlink:href="amed-20220630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NonMedicareRevenueTermRates_663676cc-a5a0-4a29-b881-5685d8fe8602" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_c6c09016-a57c-405c-874b-29515939baef" xlink:href="amed-20220630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_c6c09016-a57c-405c-874b-29515939baef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_00830a20-1db3-4876-9cf4-1c13de7c5571" xlink:href="amed-20220630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_00830a20-1db3-4876-9cf4-1c13de7c5571" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_ceb47965-1759-4422-9d62-c33f9b2426be" xlink:href="amed-20220630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_ceb47965-1759-4422-9d62-c33f9b2426be" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_c83c1e9a-70dc-44f8-8dc2-2e5ad0cf6d16" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_c83c1e9a-70dc-44f8-8dc2-2e5ad0cf6d16" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices_5e428d76-f758-42ac-ab45-08c841168dc6" xlink:href="amed-20220630.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_AcutePhaseForHighAcuityCareServices_5e428d76-f758-42ac-ab45-08c841168dc6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a700f41-3dee-4880-a358-e2e692e4ef93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a700f41-3dee-4880-a358-e2e692e4ef93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_d6cd4871-c5ae-4715-ad3a-929626b1b32c" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:to="loc_amed_CompassionateCareHospiceMember_d6cd4871-c5ae-4715-ad3a-929626b1b32c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_fba57afd-1c8d-497c-bde5-bde972b53a6a" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:to="loc_amed_AseraCareHospiceMember_fba57afd-1c8d-497c-bde5-bde972b53a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_6726d78a-1987-4ccc-af8c-9824e0dbca57" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:to="loc_amed_MedicareRevenueMember_6726d78a-1987-4ccc-af8c-9824e0dbca57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f905d1a3-8247-4b9f-b4ba-2134b96996a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f905d1a3-8247-4b9f-b4ba-2134b96996a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea94a86-4cb8-4562-a253-b5c510de15bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea94a86-4cb8-4562-a253-b5c510de15bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_5133af04-21da-4c7f-b975-b3418aabd37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_5133af04-21da-4c7f-b975-b3418aabd37e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:href="amed-20220630.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_8869f0d0-9775-499e-9940-a29da5ad00c1_default" xlink:href="amed-20220630.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:to="loc_amed_CapYearDomain_8869f0d0-9775-499e-9940-a29da5ad00c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:href="amed-20220630.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:to="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_429bf51f-a6b3-4d56-af49-ba2c127fead8" xlink:href="amed-20220630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_429bf51f-a6b3-4d56-af49-ba2c127fead8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1c483e69-a0fe-49c3-85e3-133700571b75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:to="loc_us-gaap_SegmentDomain_1c483e69-a0fe-49c3-85e3-133700571b75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:to="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_4e7374be-d764-45cc-9df9-be413d9bf39f" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HomeHealthMember_4e7374be-d764-45cc-9df9-be413d9bf39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ad55844b-70bc-4eed-8bdb-f2c0f8fcf72c" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HospiceMember_ad55844b-70bc-4eed-8bdb-f2c0f8fcf72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_4e4077dc-c55b-4ef7-b17b-908659ca2754" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HighAcuityCareMember_4e4077dc-c55b-4ef7-b17b-908659ca2754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31464e15-eba6-4b9a-b799-11b665e23241_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:to="loc_srt_RangeMember_31464e15-eba6-4b9a-b799-11b665e23241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:to="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4122c7e-b683-4a2c-9744-3f33798f69b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:to="loc_srt_MinimumMember_d4122c7e-b683-4a2c-9744-3f33798f69b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_329d6f14-962b-4817-a668-8231030c8a1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:to="loc_srt_MaximumMember_329d6f14-962b-4817-a668-8231030c8a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:to="loc_srt_ProductsAndServicesDomain_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:to="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_4f46fdd3-25e7-4960-8c58-b09335b4e8b6" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:to="loc_amed_MedicareRevenueMember_4f46fdd3-25e7-4960-8c58-b09335b4e8b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended" id="i25f1ee2a97f0423fbfde9ac1cbcda2ac_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_ff154cc8-a7eb-4ea0-81a3-5111097b4ca6" xlink:href="amed-20220630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_ff154cc8-a7eb-4ea0-81a3-5111097b4ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:href="amed-20220630.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:to="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_a64c1cc7-2737-4de9-a8ea-27cb523ede23_default" xlink:href="amed-20220630.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:to="loc_amed_PayorClassDomain_a64c1cc7-2737-4de9-a8ea-27cb523ede23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:href="amed-20220630.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:to="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_dc26fe49-d689-4cc6-a068-9b327b776056" xlink:href="amed-20220630.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthMedicareMember_dc26fe49-d689-4cc6-a068-9b327b776056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_3e217efe-8802-4622-81f2-31f85cde7dee" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_3e217efe-8802-4622-81f2-31f85cde7dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_5b702682-dbb3-4a51-b5e1-fb030141d0e0" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_5b702682-dbb3-4a51-b5e1-fb030141d0e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_5a479642-1952-4d5f-8cb1-1a83ab4986c6" xlink:href="amed-20220630.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HospiceMedicareMember_5a479642-1952-4d5f-8cb1-1a83ab4986c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_46361f05-b37a-43a7-a370-9bfc8e9f67ef" xlink:href="amed-20220630.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HospiceNonMedicareMember_46361f05-b37a-43a7-a370-9bfc8e9f67ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e95ab3cf-7e30-4a5e-816e-1775c5064ff4" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_PersonalCareMember_e95ab3cf-7e30-4a5e-816e-1775c5064ff4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_f2acad88-d5dc-493a-8177-ebba3012a602" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HighAcuityCareMember_f2acad88-d5dc-493a-8177-ebba3012a602" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="idd29db39cf124dcca5e89227b9fa1e4d_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8194c6bb-c0b0-4dbe-814e-e56bd568a780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8194c6bb-c0b0-4dbe-814e-e56bd568a780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_01bc942c-8e29-43e8-a08d-d75305b70414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_RestrictedCash_01bc942c-8e29-43e8-a08d-d75305b70414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06eaa6ea-5c86-4d90-ba7f-0b0d6ecdded3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06eaa6ea-5c86-4d90-ba7f-0b0d6ecdded3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d81e3fbe-f532-4a55-8c05-a2a781bb545f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d81e3fbe-f532-4a55-8c05-a2a781bb545f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_73aa8076-b1a1-447b-8bc3-8159d3bbdcc7" xlink:href="amed-20220630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_AsanaHospiceAquisitionMember_73aa8076-b1a1-447b-8bc3-8159d3bbdcc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_273f8c29-c7a7-49f3-840d-4a0d73682d47" xlink:href="amed-20220630.xsd#amed_COVID19PPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_COVID19PPEMember_273f8c29-c7a7-49f3-840d-4a0d73682d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5671b443-6f4b-4d8a-badc-17b7e0847126" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_AseraCareHospiceMember_5671b443-6f4b-4d8a-badc-17b7e0847126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_900a6f87-e952-47dc-bdd7-023ddb211645_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_900a6f87-e952-47dc-bdd7-023ddb211645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_9b47fec3-0f51-4078-81a1-4d144672b546" xlink:href="amed-20220630.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:to="loc_amed_AsanaHospiceMember_9b47fec3-0f51-4078-81a1-4d144672b546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_886981ac-0713-4fe0-960a-a7e948fc9756" xlink:href="amed-20220630.xsd#amed_VariousAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:to="loc_amed_VariousAcquisitionsMember_886981ac-0713-4fe0-960a-a7e948fc9756" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="i22a2a2f20cda4250bb9206effedc7546_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_a710c275-fd18-4b51-b764-ac1360131325" xlink:href="amed-20220630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_a710c275-fd18-4b51-b764-ac1360131325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fc31e347-65a2-4c6e-a10d-38f32f0d2e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fc31e347-65a2-4c6e-a10d-38f32f0d2e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_42e0df02-9c09-4f67-bbf9-d1351b9b4e82" xlink:href="amed-20220630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_42e0df02-9c09-4f67-bbf9-d1351b9b4e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0211934b-40d7-4997-844b-0d779f6c96c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0211934b-40d7-4997-844b-0d779f6c96c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7e93dcc1-9ca7-42e3-b038-93af640df9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7e93dcc1-9ca7-42e3-b038-93af640df9aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_abc3d271-7e37-4335-81e5-201a08d3f28d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_abc3d271-7e37-4335-81e5-201a08d3f28d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_6ed13c43-4c1d-4187-923e-6cf2da852d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:to="loc_us-gaap_AccountsReceivableMember_6ed13c43-4c1d-4187-923e-6cf2da852d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab048c83-d634-47d6-8f2d-7c16d90020d0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab048c83-d634-47d6-8f2d-7c16d90020d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:to="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_023dbc20-b091-43bf-a91a-7dbbd5dd3cc0" xlink:href="amed-20220630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:to="loc_amed_MajorSinglePayorCustomerMember_023dbc20-b091-43bf-a91a-7dbbd5dd3cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60b783a8-cf26-4b8f-870c-703041be043d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60b783a8-cf26-4b8f-870c-703041be043d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_7c48d914-c96e-4673-b2d5-5fb5e2d92e94" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:to="loc_amed_CompassionateCareHospiceMember_7c48d914-c96e-4673-b2d5-5fb5e2d92e94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i2c892f77f82d4ac389bc6cfa7af354a3_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96077062-c051-4785-9dac-edb813a80173" xlink:href="amed-20220630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96077062-c051-4785-9dac-edb813a80173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e86e2e27-9200-45ef-aa6c-412c0b65592e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:to="loc_us-gaap_LongTermDebtFairValue_e86e2e27-9200-45ef-aa6c-412c0b65592e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_985e5523-6e5a-4baf-8f28-1824fb66af88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_985e5523-6e5a-4baf-8f28-1824fb66af88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_24a439ad-ac51-4a94-98dd-c95ca7b9bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_24a439ad-ac51-4a94-98dd-c95ca7b9bf3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fc6d6d6b-ce1b-4d66-98fb-0a74c3ca0c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fc6d6d6b-ce1b-4d66-98fb-0a74c3ca0c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aaca399f-38f7-446a-bfdf-647828df4921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aaca399f-38f7-446a-bfdf-647828df4921" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20220630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended" id="i55f41b9b32d94d32928f67d80f93e927_NOVELCORONAVIRUSPANDEMICCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_b73a8d16-7032-4618-82e8-7bc8af46d582" xlink:href="amed-20220630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_b73a8d16-7032-4618-82e8-7bc8af46d582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_12b4b92d-6b1a-433b-bde7-02ba380645f9" xlink:href="amed-20220630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_12b4b92d-6b1a-433b-bde7-02ba380645f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_ec9a70a8-ea19-47a2-a74c-d5b01f1a7255" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingReceivedFromCARESAct_ec9a70a8-ea19-47a2-a74c-d5b01f1a7255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_a704a58c-a4a6-4160-8b2c-9e768a5d77e3" xlink:href="amed-20220630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_ProviderReliefFundAdvance_a704a58c-a4a6-4160-8b2c-9e768a5d77e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_3fdefd9b-376a-47fc-a0af-5ad1cad007cd" xlink:href="amed-20220630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_3fdefd9b-376a-47fc-a0af-5ad1cad007cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_45fa315b-4368-49a8-99d6-da1e0035c4b4" xlink:href="amed-20220630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_45fa315b-4368-49a8-99d6-da1e0035c4b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_6274cf7e-bfb4-4a36-bb39-866539e0ba86" xlink:href="amed-20220630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_6274cf7e-bfb4-4a36-bb39-866539e0ba86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_911f39d1-587a-4671-a8df-bc6009d9749f" xlink:href="amed-20220630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_COVID19ExpensesIncurred_911f39d1-587a-4671-a8df-bc6009d9749f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_9a64c136-bc2d-4bb5-ac96-d8d4b46f4121" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_9a64c136-bc2d-4bb5-ac96-d8d4b46f4121" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_301cf0f3-cb77-4a17-9449-daa5cf097770" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_301cf0f3-cb77-4a17-9449-daa5cf097770" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_55a088a5-954d-45ea-85de-5decf451b127" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_55a088a5-954d-45ea-85de-5decf451b127" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_76dafaf8-b6bc-4ab0-92b2-b1e90458b11d" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_76dafaf8-b6bc-4ab0-92b2-b1e90458b11d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_f93935d6-3b06-49b8-accc-b49d5dbc902e" xlink:href="amed-20220630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_f93935d6-3b06-49b8-accc-b49d5dbc902e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment_14153871-c747-438d-b153-cec5a3297a81" xlink:href="amed-20220630.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActInterestRepaidToGovernment_14153871-c747-438d-b153-cec5a3297a81" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_e4020751-253f-411b-bc61-71d0e81457db" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_e4020751-253f-411b-bc61-71d0e81457db" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a5b9c948-d82f-43f6-bcdd-0b38eea5329f" xlink:href="amed-20220630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a5b9c948-d82f-43f6-bcdd-0b38eea5329f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6c9c5cb4-42a4-44b0-b616-c1e175cc1cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6c9c5cb4-42a4-44b0-b616-c1e175cc1cb1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_abb8bacc-87df-4c47-8c73-127bd1e95a95" xlink:href="amed-20220630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_abb8bacc-87df-4c47-8c73-127bd1e95a95" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_1df4973b-96ec-476c-a9da-7b78b3600dda" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_1df4973b-96ec-476c-a9da-7b78b3600dda" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_c303b924-aad1-44fe-9f07-a4096859d882" xlink:href="amed-20220630.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_c303b924-aad1-44fe-9f07-a4096859d882" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5886be1f-3f1a-471e-a42d-652f90baeb2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5886be1f-3f1a-471e-a42d-652f90baeb2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_164487d5-e2e1-4155-b39b-b8e20fe32d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_164487d5-e2e1-4155-b39b-b8e20fe32d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd394221-c453-4cfd-a45a-112dc5d5f41b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd394221-c453-4cfd-a45a-112dc5d5f41b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_de4e25eb-a5f9-46f7-9131-2a14e8868239" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:to="loc_amed_AseraCareHospiceMember_de4e25eb-a5f9-46f7-9131-2a14e8868239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_41008152-2d73-4d33-888f-28d46e947f35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:to="loc_us-gaap_SegmentDomain_41008152-2d73-4d33-888f-28d46e947f35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:to="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_7ce6e463-1cf9-446a-9533-e65f2a4babb5" xlink:href="amed-20220630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_HomeHealthAndHospiceMember_7ce6e463-1cf9-446a-9533-e65f2a4babb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_7acf3d1a-3b5a-4695-ba9e-fc61bba83d77" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_PersonalCareMember_7acf3d1a-3b5a-4695-ba9e-fc61bba83d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1c12e611-8dad-4dc0-b314-70543c5850d9" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_HomeHealthMember_1c12e611-8dad-4dc0-b314-70543c5850d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_dd25453a-3634-4950-9f5d-f41a33a9afa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_dd25453a-3634-4950-9f5d-f41a33a9afa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_d81312d8-a1d7-4877-921b-555d6b4663d9" xlink:href="amed-20220630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_d81312d8-a1d7-4877-921b-555d6b4663d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cb0a8f61-ac30-4029-8a37-720c06fce785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cb0a8f61-ac30-4029-8a37-720c06fce785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d68c7a47-23c3-44e0-ab59-c4d4f81b094a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:to="loc_us-gaap_SubsequentEventMember_d68c7a47-23c3-44e0-ab59-c4d4f81b094a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="ie4d23fcdd3cd4e2a8314fc9488187663_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_4f63ef58-bf2b-4610-9133-0eb7ca82ea6d" xlink:href="amed-20220630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_PercentageofSharesOutstanding_4f63ef58-bf2b-4610-9133-0eb7ca82ea6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1aac9734-8c80-45d9-b0f7-1d938577762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1aac9734-8c80-45d9-b0f7-1d938577762a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_05f4eb77-62ea-40fe-afef-1e579f300ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_05f4eb77-62ea-40fe-afef-1e579f300ea5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_44b12acf-589e-4063-b510-c735871cb770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_44b12acf-589e-4063-b510-c735871cb770" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_10edbcea-681d-440a-8d80-3206aec695c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_10edbcea-681d-440a-8d80-3206aec695c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_b7df3e1d-b642-4594-bc99-1a6b56659bd4" xlink:href="amed-20220630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_b7df3e1d-b642-4594-bc99-1a6b56659bd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_89867aa1-3ce5-4a4e-b3af-4419ae4924b5" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_89867aa1-3ce5-4a4e-b3af-4419ae4924b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a6850051-bec4-4193-82a3-7dbd8a5a0707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a6850051-bec4-4193-82a3-7dbd8a5a0707" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_594e36fc-5726-4755-aba3-c509d418a8bc" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_594e36fc-5726-4755-aba3-c509d418a8bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1b408ab9-c1a1-4ffb-a2fc-e691b0a19c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1b408ab9-c1a1-4ffb-a2fc-e691b0a19c99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_bb257c4a-4494-4dda-b49b-f5933e85943d" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_bb257c4a-4494-4dda-b49b-f5933e85943d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9d8b3cdf-a5d9-48cc-a69a-de0c2e63adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9d8b3cdf-a5d9-48cc-a69a-de0c2e63adaa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_8e1eacf3-edfd-4800-9cd5-6b270b3c4358" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_8e1eacf3-edfd-4800-9cd5-6b270b3c4358" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9c34cf31-b4a7-4bbc-9ec2-a41f5aaade85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9c34cf31-b4a7-4bbc-9ec2-a41f5aaade85" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_941adf4e-2a8a-49aa-8904-8c4b234ef57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_941adf4e-2a8a-49aa-8904-8c4b234ef57b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_e5e9fd4f-40d4-43f0-a2a9-abc7979e946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_e5e9fd4f-40d4-43f0-a2a9-abc7979e946a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9311c084-4ea2-4a9e-aa2c-b0534c0ec8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9311c084-4ea2-4a9e-aa2c-b0534c0ec8cb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_56773342-6bb3-4918-be18-c0baf89dafb8" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_56773342-6bb3-4918-be18-c0baf89dafb8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_37d7bdaa-4aed-48be-80fe-2565189faf8e" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_37d7bdaa-4aed-48be-80fe-2565189faf8e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_49f251f0-4519-4295-bd36-21c095fbc2a7" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_49f251f0-4519-4295-bd36-21c095fbc2a7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0aa9a0cd-c2df-475c-b5ac-0302439d103b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0aa9a0cd-c2df-475c-b5ac-0302439d103b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_bb89d403-82e6-4822-b4af-92a2050e1d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_bb89d403-82e6-4822-b4af-92a2050e1d6d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0124f173-c71f-4752-bed3-60646578d0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0124f173-c71f-4752-bed3-60646578d0dd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e055a34a-2f0d-4d3e-a864-a0b52a552929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e055a34a-2f0d-4d3e-a864-a0b52a552929" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0782235d-484d-4ff9-a726-0eb3d13499d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0782235d-484d-4ff9-a726-0eb3d13499d3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_80fb98b6-17f7-426b-8fb8-dfe5bac56de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_80fb98b6-17f7-426b-8fb8-dfe5bac56de5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_aa258de9-7359-4b6b-97ea-96be3597bd01" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_aa258de9-7359-4b6b-97ea-96be3597bd01" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_5b633470-7927-4ada-9c08-d5ea8500579b" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_5b633470-7927-4ada-9c08-d5ea8500579b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_26f4ca97-7be2-401f-a3e5-1c58313c0920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_26f4ca97-7be2-401f-a3e5-1c58313c0920" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1f6b4fe9-24e4-480b-9070-d2ea008279bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1f6b4fe9-24e4-480b-9070-d2ea008279bb" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3d487774-db17-4eb9-8f34-9d507908a677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3d487774-db17-4eb9-8f34-9d507908a677" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_43f42a4d-c8a2-49a6-bcfc-3ac6dd3b97b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_43f42a4d-c8a2-49a6-bcfc-3ac6dd3b97b0" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_067bd89a-7f3a-4f10-ac6b-63c6fc8fd491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_067bd89a-7f3a-4f10-ac6b-63c6fc8fd491" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_5e0f1bfb-407b-45ff-b300-5ee5ef7e3dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_5e0f1bfb-407b-45ff-b300-5ee5ef7e3dc6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_475ec98e-d44a-45d0-a07d-2790abbfb98c" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_475ec98e-d44a-45d0-a07d-2790abbfb98c" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_10928db5-aa1b-4e97-b175-3adc52082c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_10928db5-aa1b-4e97-b175-3adc52082c24" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_9abd023f-d7ca-449f-9de1-c510b740bb39" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_9abd023f-d7ca-449f-9de1-c510b740bb39" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_b8b32303-b6f7-4349-8bd8-eda6122d9f0a" xlink:href="amed-20220630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_b8b32303-b6f7-4349-8bd8-eda6122d9f0a" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_fbf66aec-9972-4ca5-b107-a320422fb64c" xlink:href="amed-20220630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_fbf66aec-9972-4ca5-b107-a320422fb64c" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ea8e3323-f84a-428e-82f9-e2eec6fff101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ea8e3323-f84a-428e-82f9-e2eec6fff101" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_44168d90-1584-4691-b790-027f6d1483b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_RestrictedCash_44168d90-1584-4691-b790-027f6d1483b9" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_78f7d4d7-af94-4863-8ad4-8697b824add8" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_78f7d4d7-af94-4863-8ad4-8697b824add8" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_1bc3e4c1-c713-4bc1-8ed0-d7d3132c1e88" xlink:href="amed-20220630.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_NonCashAccruedContingentConsideration_1bc3e4c1-c713-4bc1-8ed0-d7d3132c1e88" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ef454b0a-5be5-41c1-ab9f-237d6c54243c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ef454b0a-5be5-41c1-ab9f-237d6c54243c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember_8c4d1929-4169-4c51-8dfa-a9656a3f277d" xlink:href="amed-20220630.xsd#amed_A2022NewJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_A2022NewJointVentureMember_8c4d1929-4169-4c51-8dfa-a9656a3f277d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_4a25f86f-03c2-4713-8bae-17bfe775086b" xlink:href="amed-20220630.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_EvolutionHealthMember_4a25f86f-03c2-4713-8bae-17bfe775086b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_6dd7685e-7c62-42a0-ad18-3e81984b5c4d" xlink:href="amed-20220630.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_AssistedCareHomeHealthMember_6dd7685e-7c62-42a0-ad18-3e81984b5c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_90b169e3-d672-45e3-92b3-456227562126" xlink:href="amed-20220630.xsd#amed_ContessaHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_ContessaHealthMember_90b169e3-d672-45e3-92b3-456227562126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_09b8e21e-3064-45e5-800b-8c4c91ce2f7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:to="loc_us-gaap_SegmentDomain_09b8e21e-3064-45e5-800b-8c4c91ce2f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:to="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_dc1b7b20-aadb-4fb2-9d77-52866e546273" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HospiceMember_dc1b7b20-aadb-4fb2-9d77-52866e546273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_d1cf3d5b-1187-4af9-9f64-e6bf4c5e81e9" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HomeHealthMember_d1cf3d5b-1187-4af9-9f64-e6bf4c5e81e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_6bf5ee8a-3b2b-47d6-b3af-62d73b218e72" xlink:href="amed-20220630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HomeHealthAndHospiceMember_6bf5ee8a-3b2b-47d6-b3af-62d73b218e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_e4a4d58a-cb77-45ec-a202-6f4b8768a432" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HighAcuityCareMember_e4a4d58a-cb77-45ec-a202-6f4b8768a432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66d4cf28-0270-4d54-85b8-742dea897bc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66d4cf28-0270-4d54-85b8-742dea897bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_489ffe4b-4c29-44b0-9dad-5657f3b8dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_TradeNamesMember_489ffe4b-4c29-44b0-9dad-5657f3b8dc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4c89f626-c424-4c50-a1f4-673472e482c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4c89f626-c424-4c50-a1f4-673472e482c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_8c89a2df-c47a-432e-895b-15151fe600f1" xlink:href="amed-20220630.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_AcquiredNamesMember_8c89a2df-c47a-432e-895b-15151fe600f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_c5fc9c4c-985e-4f18-9b9c-008c8d6262c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_c5fc9c4c-985e-4f18-9b9c-008c8d6262c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_0e22cc6b-6894-4f2c-8ac5-a5c1401d81be" xlink:href="amed-20220630.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_MedicareLicenseMember_0e22cc6b-6894-4f2c-8ac5-a5c1401d81be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_34b0f8fa-005a-43a1-9d9b-d52492d845ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_34b0f8fa-005a-43a1-9d9b-d52492d845ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_7e042148-f9a7-432d-a582-cb63cf5ba0a3" xlink:href="amed-20220630.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_CertificatesOfNeedMember_7e042148-f9a7-432d-a582-cb63cf5ba0a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_7abf1ae8-68ec-4e42-bf0f-dcb685cc72e0" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_CertificateOfNeedMember_7abf1ae8-68ec-4e42-bf0f-dcb685cc72e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb23995c-b776-4f28-af13-101a259d7119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb23995c-b776-4f28-af13-101a259d7119" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember_e6cb3ade-2c1f-4d78-8f51-f690b0509c5e" xlink:href="amed-20220630.xsd#amed_LicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_LicensesMember_e6cb3ade-2c1f-4d78-8f51-f690b0509c5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a9a571c9-a430-4996-85a6-15cfb7878b2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a9a571c9-a430-4996-85a6-15cfb7878b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_d9bf9d75-f817-41b6-81c5-6e511e1c546d" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_CertificateOfNeedMember_d9bf9d75-f817-41b6-81c5-6e511e1c546d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_3ac7eac6-c3ef-4ce0-a90c-61a4ead8591e" xlink:href="amed-20220630.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_MedicareLicenseMember_3ac7eac6-c3ef-4ce0-a90c-61a4ead8591e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember_837a4a72-69b0-4057-b53e-febc12cee692" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_CertificateOfNeedAndLicensesMember_837a4a72-69b0-4057-b53e-febc12cee692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_13142265-2ab3-4148-88e2-1341d7ca1d7b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:to="loc_srt_SegmentGeographicalDomain_13142265-2ab3-4148-88e2-1341d7ca1d7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:to="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_511d0749-196d-4514-ab6e-28274c4d7207" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_TN_511d0749-196d-4514-ab6e-28274c4d7207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_05dca25d-41f9-4807-b18d-9d0247ea2c23" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_WA_05dca25d-41f9-4807-b18d-9d0247ea2c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_ae8078b9-eb13-4b43-b637-8801663acecd" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_KY_ae8078b9-eb13-4b43-b637-8801663acecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_1fc7af36-1b3b-42b4-b17b-71d0a8c5591c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_NC_1fc7af36-1b3b-42b4-b17b-71d0a8c5591c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_417f97b2-9542-4cc6-b846-8c51bbdbea75" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_NY_417f97b2-9542-4cc6-b846-8c51bbdbea75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f10e0e73-31e6-48ba-9e40-31d91b6c1623_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:to="loc_srt_RangeMember_f10e0e73-31e6-48ba-9e40-31d91b6c1623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:to="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76afb06a-d0b1-4e75-a10a-bcf0921fc6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:to="loc_srt_MaximumMember_76afb06a-d0b1-4e75-a10a-bcf0921fc6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_f4e58eff-4daf-498e-b94d-afb7d0126ea6_default" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_f4e58eff-4daf-498e-b94d-afb7d0126ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember_8b856ffb-1264-41d6-80e7-0c818cb0b6f3" xlink:href="amed-20220630.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:to="loc_amed_PotentialClosingPaymentAdjustmentMember_8b856ffb-1264-41d6-80e7-0c818cb0b6f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONSProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended" id="i8824163d59e543e081e69dcb8396a6ca_ACQUISITIONSProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_374b28ee-ef55-4a70-b611-8ef4def277b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_374b28ee-ef55-4a70-b611-8ef4def277b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_cc79ceb1-7ae8-43b1-a1e5-3c6f27c1beac" xlink:href="amed-20220630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_cc79ceb1-7ae8-43b1-a1e5-3c6f27c1beac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4fc230b0-6f8c-4bfe-918b-0dae6a5ffff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4fc230b0-6f8c-4bfe-918b-0dae6a5ffff1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3fc21735-eb9d-4346-b644-e0f9905e4cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3fc21735-eb9d-4346-b644-e0f9905e4cdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_815ccf86-61da-4a58-a4ec-b0ed4c735a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_815ccf86-61da-4a58-a4ec-b0ed4c735a03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_86f5bb20-7a3a-4193-9221-4444ad3ed9f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:to="loc_us-gaap_SegmentDomain_86f5bb20-7a3a-4193-9221-4444ad3ed9f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:to="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6f3d452c-1a57-49bf-9960-d613a4e73db3" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:to="loc_amed_HospiceMember_6f3d452c-1a57-49bf-9960-d613a4e73db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98370534-db14-46e8-8b05-081adff10493_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98370534-db14-46e8-8b05-081adff10493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_a10f96db-83b7-4a42-91ee-d28d04ec53fb" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:to="loc_amed_CompassionateCareHospiceMember_a10f96db-83b7-4a42-91ee-d28d04ec53fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_988e3fa0-c1fd-4d72-abed-d75ca76f354f" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:to="loc_amed_AseraCareHospiceMember_988e3fa0-c1fd-4d72-abed-d75ca76f354f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_acae3b46-b463-4a29-abf7-57a7ee7e39b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_acae3b46-b463-4a29-abf7-57a7ee7e39b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4793052f-57f5-423e-a296-f41c796c7e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4793052f-57f5-423e-a296-f41c796c7e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6369a2e7-a916-438b-80be-ece5765032e9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:to="loc_srt_OwnershipDomain_6369a2e7-a916-438b-80be-ece5765032e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_da583019-2d2d-4fbc-9ecd-0c74a27bb378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:to="loc_srt_OwnershipDomain_da583019-2d2d-4fbc-9ecd-0c74a27bb378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_14c81301-b788-41de-8365-39f720e03ce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:to="loc_us-gaap_ClassOfStockDomain_14c81301-b788-41de-8365-39f720e03ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a04af40a-92c1-4030-b36d-64a6bf487d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:to="loc_us-gaap_ClassOfStockDomain_a04af40a-92c1-4030-b36d-64a6bf487d29" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended" id="i0dc12e7f289b4fca8bb3d5bca145b880_LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f4c09efa-444c-4cf0-92de-9aadfb309636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f4c09efa-444c-4cf0-92de-9aadfb309636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ffc4a35e-1088-47cf-a079-c581eb71f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ffc4a35e-1088-47cf-a079-c581eb71f43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_023801f3-7581-4cf6-90e3-7f73513c58da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebt_023801f3-7581-4cf6-90e3-7f73513c58da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_af3d6a4a-2ddf-4605-a9e8-21c8217acf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebtCurrent_af3d6a4a-2ddf-4605-a9e8-21c8217acf08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cf7c38b7-dab4-4081-9aa7-6b2ac4d5b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cf7c38b7-dab4-4081-9aa7-6b2ac4d5b7f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_70169b66-5c93-4002-ab68-a419cd40f762_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_70169b66-5c93-4002-ab68-a419cd40f762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_61722fc0-7ce4-4fad-8f94-fa61be7ea8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_LoansPayableMember_61722fc0-7ce4-4fad-8f94-fa61be7ea8a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_169f0d19-e508-44e3-afe0-5f9b79246df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_169f0d19-e508-44e3-afe0-5f9b79246df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_b8ff0165-4b2d-4e46-9836-ff4e6c6d87a4" xlink:href="amed-20220630.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_amed_PromissoryNotesMember_b8ff0165-4b2d-4e46-9836-ff4e6c6d87a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_628a7e7e-003c-44d9-a21b-384a58dc3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_628a7e7e-003c-44d9-a21b-384a58dc3d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2f9a70d4-92da-422b-acad-166a7cb64123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2f9a70d4-92da-422b-acad-166a7cb64123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_5934dbb5-b45a-4b61-a434-41b8035654e9" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_5934dbb5-b45a-4b61-a434-41b8035654e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_415fb63a-b65e-4bd3-b665-36f9239ac61d" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_415fb63a-b65e-4bd3-b665-36f9239ac61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_1a5dfc2a-b8a0-49a0-9d97-e4c7556b7240" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_1a5dfc2a-b8a0-49a0-9d97-e4c7556b7240" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_521b92d4-a5dd-471e-971f-264a42e90182_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:to="loc_us-gaap_VariableRateDomain_521b92d4-a5dd-471e-971f-264a42e90182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:to="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_01f64ac2-c6d8-482b-8fcd-7b823204561d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:to="loc_us-gaap_EurodollarMember_01f64ac2-c6d8-482b-8fcd-7b823204561d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i1f5345fd93554fe088c134ffaf3755aa_LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22a4dc91-90e1-487d-9904-a69a72f791a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22a4dc91-90e1-487d-9904-a69a72f791a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_9598cf28-031f-4811-b73a-367bdffd1496" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_9598cf28-031f-4811-b73a-367bdffd1496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_b1219b12-4253-445c-9042-1bebe3ea50a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_b1219b12-4253-445c-9042-1bebe3ea50a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b030be6-78eb-4ab9-9c41-3f67255eb42c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b030be6-78eb-4ab9-9c41-3f67255eb42c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_62d2cb06-c6ca-41c3-a389-57bfa8fe0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:to="loc_us-gaap_LoansPayableMember_62d2cb06-c6ca-41c3-a389-57bfa8fe0f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5ece1311-d2c6-4922-828c-7cae5fb6cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5ece1311-d2c6-4922-828c-7cae5fb6cecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8584d650-b31a-407a-82ad-95a79399f583_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8584d650-b31a-407a-82ad-95a79399f583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_720bfb57-59ff-4292-8465-e85051795143" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_720bfb57-59ff-4292-8465-e85051795143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_90a4676f-e6fe-4bf4-965c-fd864b491387" xlink:href="amed-20220630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_90a4676f-e6fe-4bf4-965c-fd864b491387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_49bdb15f-b6b5-475a-b684-bfb1682cbe5f" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_49bdb15f-b6b5-475a-b684-bfb1682cbe5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c0054cc2-9530-472a-a958-c804f86560b4" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c0054cc2-9530-472a-a958-c804f86560b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_72b41f36-f445-4874-8f7a-3f92ef69e655_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:to="loc_us-gaap_VariableRateDomain_72b41f36-f445-4874-8f7a-3f92ef69e655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:to="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_322be017-096f-4618-a53f-e1eb4ca34b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:to="loc_us-gaap_EurodollarMember_322be017-096f-4618-a53f-e1eb4ca34b78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="i6a85300c03dd43e5adac50612ca221f9_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_e6bcee05-2d85-44b0-bb5d-0777d005d87b" xlink:href="amed-20220630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_amed_ConsolidatedLeverageRatio_e6bcee05-2d85-44b0-bb5d-0777d005d87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3e8b675a-9f04-4c76-9b72-dece2bbcb13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3e8b675a-9f04-4c76-9b72-dece2bbcb13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_9827ceb2-c240-4e24-9c55-93bd96ed2135" xlink:href="amed-20220630.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_amed_LetterOfCreditFee_9827ceb2-c240-4e24-9c55-93bd96ed2135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6012ed7e-be28-4755-a3a0-caf7ef3c359e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6012ed7e-be28-4755-a3a0-caf7ef3c359e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a28f23ce-1c39-4204-aa2c-b81c7539dd61_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:to="loc_srt_RangeMember_a28f23ce-1c39-4204-aa2c-b81c7539dd61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:to="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b47a1e97-b41a-4d3d-a436-65fdbe2d7263" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:to="loc_srt_MinimumMember_b47a1e97-b41a-4d3d-a436-65fdbe2d7263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9833a78-8ca8-4ae6-bda6-cfed87c698c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:to="loc_srt_MaximumMember_f9833a78-8ca8-4ae6-bda6-cfed87c698c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51480994-e5e0-4382-851d-9bb78ec02550_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51480994-e5e0-4382-851d-9bb78ec02550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_bf7d5ae6-4da6-4013-9468-b4bc488d0f68" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_bf7d5ae6-4da6-4013-9468-b4bc488d0f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_df25f8ca-bdd5-4c47-ad6e-3fd72f061381" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_df25f8ca-bdd5-4c47-ad6e-3fd72f061381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_76deeb02-04d1-4e6c-8015-ee734a0b6175" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_76deeb02-04d1-4e6c-8015-ee734a0b6175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_a4c73543-c9c0-4246-b32a-fb3b9be54e29" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_a4c73543-c9c0-4246-b32a-fb3b9be54e29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5c488f79-0671-4421-b08c-69e4f393721f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:to="loc_us-gaap_VariableRateDomain_5c488f79-0671-4421-b08c-69e4f393721f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:to="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_e0848df1-b53a-40e5-af95-c0d742c7206b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:to="loc_us-gaap_EurodollarMember_e0848df1-b53a-40e5-af95-c0d742c7206b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_71aa3c20-4abc-4539-94d4-c5570acd7729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:to="loc_us-gaap_BaseRateMember_71aa3c20-4abc-4539-94d4-c5570acd7729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a8da227-c7a5-4b4c-9759-fd433b24d73e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a8da227-c7a5-4b4c-9759-fd433b24d73e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_890ae642-c03a-4975-8ac3-40d8c9e6c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_890ae642-c03a-4975-8ac3-40d8c9e6c6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6a92d09f-dd64-449d-9f93-5df828ea5da9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:to="loc_us-gaap_CreditFacilityDomain_6a92d09f-dd64-449d-9f93-5df828ea5da9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f14c27d4-6617-4a98-a577-e6cc07ee1925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:to="loc_us-gaap_CreditFacilityDomain_f14c27d4-6617-4a98-a577-e6cc07ee1925" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="idea9291f307048608f7c08642338d79c_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_21cae38f-56ff-41db-9133-e76881b7346c" xlink:href="amed-20220630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_21cae38f-56ff-41db-9133-e76881b7346c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_7460e256-4324-403d-aaf0-7d5d99602abe" xlink:href="amed-20220630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_7460e256-4324-403d-aaf0-7d5d99602abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0a1d4a46-35c8-4a64-b7f7-2c6667cb4a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0a1d4a46-35c8-4a64-b7f7-2c6667cb4a77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_09f917a8-9d9e-4525-a820-d64431d4f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_09f917a8-9d9e-4525-a820-d64431d4f10c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_9a9a6945-895d-40f3-9ba1-cba413e96635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_9a9a6945-895d-40f3-9ba1-cba413e96635" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_aed4564e-e0e0-4ae1-bb36-981792688744" xlink:href="amed-20220630.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_TotalLeverageRatio_aed4564e-e0e0-4ae1-bb36-981792688744" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_5e405e04-0731-4038-83de-6fe000cc12a9" xlink:href="amed-20220630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_5e405e04-0731-4038-83de-6fe000cc12a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f1172f11-c6ee-4c9d-b2e3-e1d1a02c784b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f1172f11-c6ee-4c9d-b2e3-e1d1a02c784b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_50383045-b6f5-4f49-86df-2afd3841dba9" xlink:href="amed-20220630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_RevolvingCreditFacilityTotal_50383045-b6f5-4f49-86df-2afd3841dba9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_bb32cba5-6558-44b7-b23b-dfcafa498931" xlink:href="amed-20220630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_bb32cba5-6558-44b7-b23b-dfcafa498931" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_e764e1e9-4fde-40cf-86bb-031aac463090" xlink:href="amed-20220630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_e764e1e9-4fde-40cf-86bb-031aac463090" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_30b8d00d-b8b1-4a56-96b5-d0c097c01cf8" xlink:href="amed-20220630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_30b8d00d-b8b1-4a56-96b5-d0c097c01cf8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_9dbc579b-f4f7-4cff-aa1a-f597038bee90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_9dbc579b-f4f7-4cff-aa1a-f597038bee90" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1e2649d0-cc84-43d7-8e10-4221584838c6" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1e2649d0-cc84-43d7-8e10-4221584838c6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_a33fefa0-e22e-4d5d-83d5-907f5b7d67bf" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_a33fefa0-e22e-4d5d-83d5-907f5b7d67bf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_050eaeb0-e195-4c88-8c15-20c23ca044da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_050eaeb0-e195-4c88-8c15-20c23ca044da" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_ae61cbd7-7be6-4652-bd43-c221f98ba4d9" xlink:href="amed-20220630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_ae61cbd7-7be6-4652-bd43-c221f98ba4d9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_69b4bb6c-42dc-4266-afe4-e23d39b28913" xlink:href="amed-20220630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_69b4bb6c-42dc-4266-afe4-e23d39b28913" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0eb59d74-b778-4ae4-a2ce-2da06a773aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0eb59d74-b778-4ae4-a2ce-2da06a773aca" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_326bddcf-98b1-4e6a-b55c-15d46baac2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_326bddcf-98b1-4e6a-b55c-15d46baac2df" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b6c86f3c-38c0-4a74-89eb-693d42e2c150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b6c86f3c-38c0-4a74-89eb-693d42e2c150" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_5eb164a2-308f-4688-b621-9b1ad9c122c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_5eb164a2-308f-4688-b621-9b1ad9c122c5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f28dfe89-56f5-47be-98bc-f9837772725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f28dfe89-56f5-47be-98bc-f9837772725f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_58798233-d1a9-485b-91b9-2230f0bb5839" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_58798233-d1a9-485b-91b9-2230f0bb5839" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2dabb69a-e23b-4e10-98c7-bc92e23114ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2dabb69a-e23b-4e10-98c7-bc92e23114ee" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_320c5839-ea08-4d06-9869-3c60ff1cb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:to="loc_us-gaap_SubsequentEventMember_320c5839-ea08-4d06-9869-3c60ff1cb64f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_096c659f-1388-4b29-a948-573f50365e19_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:to="loc_srt_RangeMember_096c659f-1388-4b29-a948-573f50365e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:to="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9af4039-a1ca-4393-80d7-00b1cf536e9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:to="loc_srt_MinimumMember_e9af4039-a1ca-4393-80d7-00b1cf536e9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6f5dbd42-8776-45a5-ac48-409143a9c29f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:to="loc_us-gaap_VariableRateDomain_6f5dbd42-8776-45a5-ac48-409143a9c29f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:to="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7732a456-7efd-4969-836a-f09a5bbf3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:to="loc_us-gaap_BaseRateMember_7732a456-7efd-4969-836a-f09a5bbf3ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9d4b7b26-8686-4d12-b2bd-5c549eb4971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:to="loc_us-gaap_EurodollarMember_9d4b7b26-8686-4d12-b2bd-5c549eb4971b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ec46379-065d-4234-8c74-0e673c3996e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ec46379-065d-4234-8c74-0e673c3996e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_26abd8c8-723f-4f8d-83c4-3cf5699f7d49" xlink:href="amed-20220630.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_SwingLineLoanMember_26abd8c8-723f-4f8d-83c4-3cf5699f7d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9005a826-6529-4943-836a-5e55e260d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LetterOfCreditMember_9005a826-6529-4943-836a-5e55e260d9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c34bfbc9-bc10-43cd-867e-a232be45d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LoansPayableMember_c34bfbc9-bc10-43cd-867e-a232be45d1e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bc76dec3-3f9b-47c5-8d01-4b1afed0e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bc76dec3-3f9b-47c5-8d01-4b1afed0e02a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_eed078d9-de36-4dc7-a849-f4219076fbff" xlink:href="amed-20220630.xsd#amed_PriorCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_PriorCreditAgreementMember_eed078d9-de36-4dc7-a849-f4219076fbff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_29af52e9-95ea-4d55-91c3-20fe1e70c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LineOfCreditMember_29af52e9-95ea-4d55-91c3-20fe1e70c2a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c3616bd5-df0a-4e7a-ab72-230a0c01f9a9" xlink:href="amed-20220630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_AmendedCreditAgreementMember_c3616bd5-df0a-4e7a-ab72-230a0c01f9a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_a5d0d513-81aa-4b5c-9fc1-abddbb263866" xlink:href="amed-20220630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_a5d0d513-81aa-4b5c-9fc1-abddbb263866" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_e9aeb71e-338c-4419-af03-2f8eb61e0dc4" xlink:href="amed-20220630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_AmendedCreditAgreementMember_e9aeb71e-338c-4419-af03-2f8eb61e0dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_301b518f-fe9f-4dfc-95a9-c0b8cae89203" xlink:href="amed-20220630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_OneHundredMillionTermLoanMember_301b518f-fe9f-4dfc-95a9-c0b8cae89203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_6a709682-e9d5-4994-bc4e-854e7e488c87" xlink:href="amed-20220630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_6a709682-e9d5-4994-bc4e-854e7e488c87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_d1e0627e-87ac-4f92-aabb-2f873c5a4f9c" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_d1e0627e-87ac-4f92-aabb-2f873c5a4f9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a00d4084-3a72-411f-9a2e-cfd6a87535fd" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a00d4084-3a72-411f-9a2e-cfd6a87535fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_6bed0cbc-73fb-4934-be7b-3e5998140fc7" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_6bed0cbc-73fb-4934-be7b-3e5998140fc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_f6c085d1-5214-44da-b11c-f60eced6a573" xlink:href="amed-20220630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_f6c085d1-5214-44da-b11c-f60eced6a573" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ie64921c759e94952bc231eb58bda2954_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_696a8f37-37c1-40d3-92fb-21443000891d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_696a8f37-37c1-40d3-92fb-21443000891d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_f5723948-3c26-4155-abd7-6418b9ce2832" xlink:href="amed-20220630.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_Numberofpatients_f5723948-3c26-4155-abd7-6418b9ce2832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_3a45fa37-7ce9-4f84-9b3f-0a9e83a4f56b" xlink:href="amed-20220630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_3a45fa37-7ce9-4f84-9b3f-0a9e83a4f56b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_907ce932-1e0e-446c-8725-6014effdf7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_907ce932-1e0e-446c-8725-6014effdf7f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_d467f370-44e9-4f08-b57e-1bc6900e2794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_d467f370-44e9-4f08-b57e-1bc6900e2794" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_0f91a545-d0f9-4d3a-bcc7-a4a8fb3011d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_0f91a545-d0f9-4d3a-bcc7-a4a8fb3011d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_c84371b9-a15c-4785-9bd8-e614f8962ccd" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_c84371b9-a15c-4785-9bd8-e614f8962ccd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_b39f55ec-3832-4b55-8cdf-111cb2f77da6" xlink:href="amed-20220630.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_NumberOfBeneficiaries_b39f55ec-3832-4b55-8cdf-111cb2f77da6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_44997fab-5c89-44bd-a975-59275af617cd" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_44997fab-5c89-44bd-a975-59275af617cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_5a172598-1e89-45c4-b65c-cadc440f71d0" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_5a172598-1e89-45c4-b65c-cadc440f71d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_47868fde-7e34-4f73-b104-731c4400083a" xlink:href="amed-20220630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_47868fde-7e34-4f73-b104-731c4400083a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_380cb1b0-51d4-4ba6-8db5-0494f1f3987e" xlink:href="amed-20220630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_380cb1b0-51d4-4ba6-8db5-0494f1f3987e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_298954e8-7ae5-4ce8-9b5e-ccaff23ceb33" xlink:href="amed-20220630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_298954e8-7ae5-4ce8-9b5e-ccaff23ceb33" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_0f40ada5-ad9f-42b3-9e96-a112142d472f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_0f40ada5-ad9f-42b3-9e96-a112142d472f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_07d8fab5-d9f5-479c-88cf-741cfb688e6a" xlink:href="amed-20220630.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ActualClaimsPayment_07d8fab5-d9f5-479c-88cf-741cfb688e6a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_aa02f900-2851-407d-952e-f60a15bb7070" xlink:href="amed-20220630.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ErrorRatePercentage_aa02f900-2851-407d-952e-f60a15bb7070" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_3d300e9d-a3c3-493e-8920-40b9a67bfcb5" xlink:href="amed-20220630.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_IndemnificationAmount_3d300e9d-a3c3-493e-8920-40b9a67bfcb5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_7a6586c3-8f4d-4da4-a51d-c3e5e3f35d84" xlink:href="amed-20220630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_FloridaZpicRevenueReduction_7a6586c3-8f4d-4da4-a51d-c3e5e3f35d84" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9de528e3-a32b-450e-b460-5cf2c7c43df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9de528e3-a32b-450e-b460-5cf2c7c43df7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_139ca174-a577-46de-a3c9-d62618b00e4f" xlink:href="amed-20220630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_HealthInsuranceRetentionLimit_139ca174-a577-46de-a3c9-d62618b00e4f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_f7972b02-6ff1-4b45-80ae-76387d539854" xlink:href="amed-20220630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_f7972b02-6ff1-4b45-80ae-76387d539854" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_2dbdbbaf-ed97-4145-8a7a-6b1562e1cb42" xlink:href="amed-20220630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_2dbdbbaf-ed97-4145-8a7a-6b1562e1cb42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_5890509e-5e92-43a8-95e3-47814c813ff6" xlink:href="amed-20220630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_5890509e-5e92-43a8-95e3-47814c813ff6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_b2b8115c-93ae-4756-9810-3a1bbc38e8f6" xlink:href="amed-20220630.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ReductionToNetServiceRevenue_b2b8115c-93ae-4756-9810-3a1bbc38e8f6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:href="amed-20220630.xsd#amed_PayorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_edf4264d-5df2-4770-865f-cf4bfc8fce89_default" xlink:href="amed-20220630.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:to="loc_amed_PayorsDomain_edf4264d-5df2-4770-865f-cf4bfc8fce89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:href="amed-20220630.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:to="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_460caa78-3d20-413b-a964-99d3e0aea5c0" xlink:href="amed-20220630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:to="loc_amed_CompanysinsurancecarriersMember_460caa78-3d20-413b-a964-99d3e0aea5c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3cc8374b-ba5e-42d7-a98f-c69d6997525e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:to="loc_srt_LitigationCaseTypeDomain_3cc8374b-ba5e-42d7-a98f-c69d6997525e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:to="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_8ff7d462-5cd0-4112-8eeb-62fb690cc26e" xlink:href="amed-20220630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_UsDepartmentOfJusticeMember_8ff7d462-5cd0-4112-8eeb-62fb690cc26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_e2beaf1d-904f-4422-8c41-1cd196748253" xlink:href="amed-20220630.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_AmedisysCIAMember_e2beaf1d-904f-4422-8c41-1cd196748253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_0dd4d6b3-3d4d-4bff-bac9-c5aadfd0eabc" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_0dd4d6b3-3d4d-4bff-bac9-c5aadfd0eabc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_0b984331-138f-4466-9385-d94c2a5defc9" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_0b984331-138f-4466-9385-d94c2a5defc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_029eb538-809e-4b56-8ee1-63e3f3cb2ebc" xlink:href="amed-20220630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_029eb538-809e-4b56-8ee1-63e3f3cb2ebc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_884615a8-2161-4b5d-a7c4-32a510cb6ad3" xlink:href="amed-20220630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_InternalAuditComplianceReviewMember_884615a8-2161-4b5d-a7c4-32a510cb6ad3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_97a77b49-6603-43cc-881c-0f3821d26302_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:to="loc_srt_SegmentGeographicalDomain_97a77b49-6603-43cc-881c-0f3821d26302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:to="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4e19492d-bdfb-4a4e-8d39-2f9f7052e8d1" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_MA_4e19492d-bdfb-4a4e-8d39-2f9f7052e8d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_273df6f1-478d-437b-9795-15dc2d6faa9d" xlink:href="amed-20220630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_amed_MorgantownWestVirginiaMember_273df6f1-478d-437b-9795-15dc2d6faa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_e935845d-b97c-41bd-ad24-3dfdf53ff938" xlink:href="amed-20220630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_amed_ParkersburgWestVirginiaMember_e935845d-b97c-41bd-ad24-3dfdf53ff938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_230d2165-ac90-4647-8cca-fb9ea804327a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_SC_230d2165-ac90-4647-8cca-fb9ea804327a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_20228234-8561-4761-98a5-2a1664f4c5c0" xlink:href="amed-20220630.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:to="loc_amed_LakelandFloridaMember_20228234-8561-4761-98a5-2a1664f4c5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_f3ca6084-785e-41c0-a953-ad26404a7157" xlink:href="amed-20220630.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:to="loc_amed_ClearwaterFloridaMember_f3ca6084-785e-41c0-a953-ad26404a7157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de42af6a-a7bc-44d3-8e74-b12c146a86fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:to="loc_us-gaap_SegmentDomain_de42af6a-a7bc-44d3-8e74-b12c146a86fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:to="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_37827368-a358-4a2e-be57-0c1f7e723cb7" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:to="loc_amed_HospiceMember_37827368-a358-4a2e-be57-0c1f7e723cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_16428748-3814-4190-8369-1651c5890d5a" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:to="loc_amed_HomeHealthMember_16428748-3814-4190-8369-1651c5890d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d947c4b5-2bbd-4dac-add0-6367dff05f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d947c4b5-2bbd-4dac-add0-6367dff05f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_dd9ab3e6-1dde-4a6e-bfc9-684af7390c78" xlink:href="amed-20220630.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:to="loc_amed_InfinityHomeCareMember_dd9ab3e6-1dde-4a6e-bfc9-684af7390c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_50694ff1-2570-4c10-99cd-a2134c772549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:to="loc_us-gaap_LossContingencyNatureDomain_50694ff1-2570-4c10-99cd-a2134c772549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:to="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_dec6e19a-e3a1-40fb-9f01-c91c30d5f0bf" xlink:href="amed-20220630.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:to="loc_amed_ExtrapolatedMember_dec6e19a-e3a1-40fb-9f01-c91c30d5f0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_b9638783-559a-4a0f-aec8-133090a435d5" xlink:href="amed-20220630.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:to="loc_amed_UnfavorableMember_b9638783-559a-4a0f-aec8-133090a435d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_815c94e4-67f8-4d47-a921-98cf431ed0be_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:to="loc_srt_RangeMember_815c94e4-67f8-4d47-a921-98cf431ed0be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:to="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46d5bb30-aa11-4d05-b566-7cbb9636a4aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:to="loc_srt_MinimumMember_46d5bb30-aa11-4d05-b566-7cbb9636a4aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db755d81-01ed-4f2e-baf4-70260a0e6348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:to="loc_srt_MaximumMember_db755d81-01ed-4f2e-baf4-70260a0e6348" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i853e5f1f5208493c8a8c35c856b8d33c_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_81fb1172-7560-4686-b869-24735b030966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_81fb1172-7560-4686-b869-24735b030966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_985ccdb9-37df-4e01-be84-24f78522af10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_985ccdb9-37df-4e01-be84-24f78522af10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_211926c3-8b79-440f-9762-397e15127dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_211926c3-8b79-440f-9762-397e15127dee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_42e56a38-879d-4c97-9faa-a892b2bb0ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_42e56a38-879d-4c97-9faa-a892b2bb0ae6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_76b60f43-3c81-45c5-a044-0d3d06bb43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_DepreciationAndAmortization_76b60f43-3c81-45c5-a044-0d3d06bb43e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b2542ce9-bfe0-41a7-bd7a-7ea45d600530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_CostsAndExpenses_b2542ce9-bfe0-41a7-bd7a-7ea45d600530" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1557617-99c3-4290-bcf1-1e06980f1d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1557617-99c3-4290-bcf1-1e06980f1d7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f6bc122f-28bf-4c92-807e-12d80526e114_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:to="loc_us-gaap_SegmentDomain_f6bc122f-28bf-4c92-807e-12d80526e114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:to="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_3863f6c9-22a0-4a91-8739-56532a425c5a" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HomeHealthMember_3863f6c9-22a0-4a91-8739-56532a425c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_80e4170a-c905-4aba-8785-3c6484a47012" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HospiceMember_80e4170a-c905-4aba-8785-3c6484a47012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_5a99d51f-900e-46c0-b510-2595a5eeae34" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_PersonalCareMember_5a99d51f-900e-46c0-b510-2595a5eeae34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_1a812e2c-6fa9-4e85-970e-d038c5d30e50" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HighAcuityCareMember_1a812e2c-6fa9-4e85-970e-d038c5d30e50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c9cf4c6a-397a-4812-922a-39e0ac356844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c9cf4c6a-397a-4812-922a-39e0ac356844" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="id83721be981f49ba8e7f6d3b8329f55a_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d01fd2fd-331f-451f-b807-c6d88d5042ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d01fd2fd-331f-451f-b807-c6d88d5042ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_262656c8-b04f-4480-acbc-c0109f4b971c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_262656c8-b04f-4480-acbc-c0109f4b971c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_52d04130-28bc-43a5-9a6e-30ac10d9cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_52d04130-28bc-43a5-9a6e-30ac10d9cd4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_6b3b4d9e-54f1-4e1b-96cb-2736a3d0ce55" xlink:href="amed-20220630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_PercentageofSharesOutstanding_6b3b4d9e-54f1-4e1b-96cb-2736a3d0ce55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bd4b293f-28de-487b-bf17-7c7c7a2a8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bd4b293f-28de-487b-bf17-7c7c7a2a8ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_b19d35e5-af24-4d00-95ed-b4c8d7f3cf33" xlink:href="amed-20220630.xsd#amed_Discountedclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_Discountedclosingstockprice_b19d35e5-af24-4d00-95ed-b4c8d7f3cf33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_9f52941f-4bcd-4df4-9261-ae44089e2cee" xlink:href="amed-20220630.xsd#amed_Percentageofclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_Percentageofclosingstockprice_9f52941f-4bcd-4df4-9261-ae44089e2cee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_abf83927-f477-449c-a301-5ad321738cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_abf83927-f477-449c-a301-5ad321738cf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_264f8bde-6944-4206-9ca7-b40e6cca6df8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_264f8bde-6944-4206-9ca7-b40e6cca6df8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_7febadc7-3723-4476-9a99-f8167c09213a" xlink:href="amed-20220630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_7febadc7-3723-4476-9a99-f8167c09213a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_4bba1de4-f606-439a-9418-4b02800bbc18" xlink:href="amed-20220630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_4bba1de4-f606-439a-9418-4b02800bbc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_1c6fc8ca-99ef-4e7c-aa98-6a9e4066f2f6" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_ShareRepurchaseProgramMember_1c6fc8ca-99ef-4e7c-aa98-6a9e4066f2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_712cdaae-862b-458f-b4a4-4829b5a3f1ce" xlink:href="amed-20220630.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_712cdaae-862b-458f-b4a4-4829b5a3f1ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_48d543b0-afb3-4adf-a1c3-eab44908c54a" xlink:href="amed-20220630.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_NewShareRepurchaseProgramMember_48d543b0-afb3-4adf-a1c3-eab44908c54a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87e5a079-877b-46d1-8649-57cf72d3479e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:to="loc_us-gaap_SubsequentEventMember_87e5a079-877b-46d1-8649-57cf72d3479e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="ifd7b70fbb5a54ced8034e2be320f8faa_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_190aeb71-b405-49b7-9d83-5ec4186de11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_190aeb71-b405-49b7-9d83-5ec4186de11d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_82c296c2-8e07-44b5-982d-749aecad1e84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:to="loc_us-gaap_RelatedPartyDomain_82c296c2-8e07-44b5-982d-749aecad1e84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:to="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_1b8f6ab6-96b5-4481-a605-526c33df2bff" xlink:href="amed-20220630.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:to="loc_amed_MedalogixMember_1b8f6ab6-96b5-4481-a605-526c33df2bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1790d929-6c75-46a2-96e0-808947152429_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1790d929-6c75-46a2-96e0-808947152429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0bb6d8f4-dd9b-4328-a0f5-e64d94ea5d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0bb6d8f4-dd9b-4328-a0f5-e64d94ea5d63" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>amed-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_85bb10e5-2bc3-4dad-b333-16f1aa184565_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue period of care payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Period of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20220630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_958cbc50-cbd8-4d94-9c49-bab5588ff505_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20220630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1fb69cca-43d7-492b-a5c3-536fcc7a0af3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_3b880be6-18ac-4b4f-9927-5b3ecf3ee6f8_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20220630.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9708b661-6cfb-4271-a2ea-385794ed81d2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9042f747-f27f-442d-b8d9-94700a1918cf_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_ff543402-4297-4633-a054-9467c777c598_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a055a4e6-8a08-4e74-807c-51d6e9f4c017_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5723068c-2828-4ebb-acdb-671f30486288_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_aee38884-6f4a-4e9d-b883-08374f854d7c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_853491a2-5ab4-4cb4-81a3-36043d457210_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5ab8582d-dac4-4ad1-9e04-e0bbec28f505_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_df40c739-3fff-47cb-a17b-234b2fdbcd7b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a0280f6e-7e07-452b-aac5-e1d6cc2903f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_afa87a92-2b57-48ac-844b-c83b2f935e53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_03ca3e1d-9bcf-4674-aa69-4ce7c541cd2e_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20220630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_0768b439-77a3-4b26-a4a7-198dfa4fb012_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_00ed14ea-abb1-4077-a17b-a48b8ff0ec31_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6ea07859-377b-4378-83aa-b9df42408e5a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_11578aec-40b0-44f7-a1da-7ef94a926361_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_10fb8753-87f8-49a2-bbc4-2b2a255005f1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0229bbae-cf84-4204-8336-6cca28645832_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_3435bb48-661d-43a9-b0fb-17fb02a4e14f_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20220630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_75394d93-d2f6-4332-af7c-556a11f5cfde_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2e5d6637-b7dd-45fa-8da7-2e790136aa07_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_dd5d7738-b403-4554-8dab-a958a67de3c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_88c16707-c860-4803-89d4-693caf87cad0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_4eb77458-4118-49be-b972-1731642adf59_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_label_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:to="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_05de0357-7cc7-4011-8111-0a400f03df5a_terseLabel_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember" xlink:href="amed-20220630.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExistingShareRepurchaseProgramMember" xlink:to="lab_amed_ExistingShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d62b9c33-0e7a-4cac-82e3-e6b0b9f0793f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_27c52f8d-dcce-429f-92e3-d6a8ce2550ff_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e2f7badb-cb4b-45ed-b9fe-ad209b77b146_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_05e7ed66-df61-47d4-844f-d6031ffa349f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_d577f53c-53f5-4b8a-9041-19f0e50a763e_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings</link:label>
    <link:label id="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_label_en-US" xlink:label="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings</link:label>
    <link:label id="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount paid to the seller as a result of a business combination using cash on hand and proceeds from borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:to="lab_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_002ce4ac-ff5a-45f2-94e0-c39ccdcabbd0_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20220630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_9a44952b-cf93-45fd-9180-be73b89dade9_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20220630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a22ebc30-fe18-4e2f-911f-34dc79091015_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2329320a-0cfc-46a5-9b88-0fee96599119_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_e42dc056-3f29-4112-94ad-970290785513_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember" xlink:href="amed-20220630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember" xlink:to="lab_amed_MajorSinglePayorCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_267ad204-987a-4746-9961-68038b6f8f0c_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20220630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1b0331c7-bc3d-4ae4-91f1-450de9dc6f69_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_d96dd0bc-9249-44bb-a1fe-328e57ca2e45_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20220630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_cf28f19b-c669-4739-bc3e-69a3dab8c8cc_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20220630.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_50aadf8d-d09d-40d7-b69a-1df46c9c5d47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5fef8c7-507a-4a73-a72f-243893c83e76_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_73cf81a9-3aa6-4ddd-9195-022cd47d8243_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acc6d3de-1509-487c-a1fd-55076e74aba7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7efad22d-feed-4041-b675-0e5996063f17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_34aa3027-6dd1-45d2-aa74-156979e2132b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0d366892-acb8-4c3a-820b-45b152261db1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_810be32f-1781-4fc3-9417-b7cc30c1fc5b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_1fbd2aff-073e-49f2-ad4d-c97dd75719d9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3d7328b-7714-462f-b8bc-8595d8815211_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_4ce56b8e-22cd-4e6c-877d-8fb9c2d28867_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20220630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_8bf17d50-4394-4782-b4b9-ac692ccd2a72_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20220630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_fd03c575-0e09-4835-94e5-293963a5a80c_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20220630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_4fe25190-7584-4dd6-8d1b-5ad8a8030e7a_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_93ea50da-718b-4a44-8a79-2b0803eee7e8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_177fb5ba-a1cd-47ec-9cab-0530f8622165_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_70049221-7455-4fd7-8ef7-e708e0cc3d16_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_fe8de24a-f7a7-4029-bf6c-948500de57ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_c4eb711c-ad0f-41a2-affe-109b29dd23ae_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20220630.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_2a3fcf59-086c-409b-b33b-9e3f89eb470e_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0e55a808-3c41-4118-90fa-f43357d3cf6a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_48f1e6dc-ffd6-4796-9d5d-075d39884e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_68604f50-c653-4a8a-8b77-973c693f7dac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bda5ff1a-0e8e-4883-b74d-8e29910528b6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_41e034d7-f500-486f-8d55-56aef4b14ca7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_c35e1543-dced-43fd-81c4-ed25d0d79d7f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_90bb97bb-deee-42c4-b9c7-b58ca02a197e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c317ff34-546b-488f-a4f2-cc5dc872ff6a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_be20dfcc-a132-45f9-9ebf-fb75735686ef_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_31451d97-2a57-4be3-906e-557cdc2f5a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_25ef0d76-11e1-4898-8cb5-3b7449d74d6f_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20220630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_b318480c-fe77-4f1b-868e-37ece05a3fa4_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to operating lease liabilities</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:href="amed-20220630.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c2acef32-f394-41c1-b1e0-6c181c244d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0a795eb9-89f5-49c9-b093-6b70b8f3a363_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_909e85e7-5ce4-45dc-a8b7-a9a42cfb1d80_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_772f2402-122e-4001-a242-4cc409624a13_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_b177b56c-eb60-410d-8087-153f264c64b3_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProviderReliefFundAdvance_4c7219d0-e9ed-4d28-9175-7cc201c822c3_terseLabel_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable related to funds received from the government related to COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance" xlink:href="amed-20220630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProviderReliefFundAdvance" xlink:to="lab_amed_ProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_65b03a2f-ec17-42f9-8e97-705e1cbca5b2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bcdd5bd9-433e-4e21-917c-248505f0d1b3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_53dd7eb8-9bb4-4f56-8f35-e8e3fa94540c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3fbe4808-504a-4405-8e39-b422108081a7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_2dcbef8c-ceca-4104-bd26-19f70fe01704_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_aa02ed9f-c0b4-4728-87c8-8f06c90b0b4a_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f7d2757-36ac-4d6f-a212-88bd94ea86c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_fcd95c9f-bba7-42e1-abd4-cc9d1da40efc_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20220630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_804a91da-937c-4e5d-a609-4e685d6f85c7_terseLabel_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions Attributable To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:href="amed-20220630.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:to="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_e498bd02-ded7-4697-90a4-2a1b433303b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3559b8f7-bc4b-4405-b970-e3b6bc7ed6f9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_ee98916d-6b9e-465a-85b8-a88876c245ef_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_948a8f30-e4bf-466a-aee3-c956e5d101bd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_e6bcdf9b-d138-48c0-8bf9-7016b521205e_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20220630.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b05d69c8-e2d5-4f32-bede-11427cc640df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ca93c2d7-ed2b-49da-86b4-204a7913dafa_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d92623d7-bd50-4373-9b98-86d92d84f428_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_727b2cdc-ca0f-4a99-8319-4a15b006a221_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_09b338f9-bb37-47e6-b71f-5be6ed3756c3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6fabc7e-2b18-4857-a417-ed630e83130f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_a66f2f0e-66a3-4983-aac1-ed1e93a61df4_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20220630.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_673e742f-ff67-4478-b946-3b78d7b0b05d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_fdc87d9d-9b3b-4164-b58b-297404449e41_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_9610c4c3-9148-485c-bc0b-ebc4f852b66f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_795a0a51-40c6-4feb-ad11-9bf74c71b844_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_74b267f9-95e4-48cf-99b4-f973334bf33d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a98885c-b73b-4ff2-aeca-02dde1b06a9d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_ab470a37-8e8f-4b18-9a48-9daacece2618_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_label_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:to="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_4546a668-a867-404d-9586-6498256ca350_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9c6dfcef-6647-4cc2-a085-8192f7d196e3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2c5310d8-3018-454e-b000-4ec560111d67_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_ebd25248-4ada-490f-905b-28fa1aa039a5_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20220630.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_7d70c675-e600-461b-974d-e704799aceeb_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20220630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_4ad6ecaa-65c9-4421-8af9-2621ef1663a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_ec2bb46d-5ed7-45d9-bcbe-b60077df8707_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_e85b5396-1294-4d61-bb1c-151f562096b6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VariousAcquisitionsMember_b7fce61b-42fb-43aa-9e75-5f4722d793fb_terseLabel_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_label_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions [Member]</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_documentation_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember" xlink:href="amed-20220630.xsd#amed_VariousAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VariousAcquisitionsMember" xlink:to="lab_amed_VariousAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_1d56fd0b-5c6d-43bc-aa1a-29a55ce50ddc_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_620f3c94-0e95-4968-94a9-def6f804cd1f_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20220630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_eb9400ae-8ef9-4f13-8693-db645761275d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_90399c23-0223-4fce-9bf0-d2e64d874224_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8127e261-87b6-4cae-90a2-d222511ddbff_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_97f14f4f-66db-47dc-a4cb-a523c7d4d572_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_fc3b6ff8-b3b1-4a98-b944-c7e1b234ce69_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_f54771c4-024e-403d-9df0-226c9f1e4327_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:href="amed-20220630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3939638c-7f1a-42f8-89bd-877178ddc479_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f97ed41-35c3-4ba9-b939-ff6b494b3f91_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_f1548c4c-54d8-45bf-b636-d820a0d12f07_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d0265ad8-6f27-411a-af22-59346a859a9b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_2c50ca68-46ba-4fc9-8134-63261d490fb9_terseLabel_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:href="amed-20220630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:to="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsDomain_9a918b0e-5b87-422b-a98a-d410e0da6d8f_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_label_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_documentation_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain" xlink:href="amed-20220630.xsd#amed_PayorsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain" xlink:to="lab_amed_PayorsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_c26cb902-0d93-4c33-b419-2fbc1b62ffb3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_9f4a0a69-1c54-4ffd-8c4c-b982324c9129_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c9224f3e-28b2-4828-baca-8f3aacbcb90d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_94a5a785-5235-4f79-873f-5a2936fb3412_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:href="amed-20220630.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:to="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_ce8f4766-dd67-4cc8-b45a-6c50c1321848_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_b093e974-ec73-4c08-897f-51062e3b1b41_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_38b846ef-a3c7-4085-ab9b-f3104b240787_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_36401c03-23c6-4016-9424-0ecca6445b7f_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20220630.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_188deaa1-f89a-4b1f-87ce-b74f0afc59bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2459887f-76ca-4978-b077-637b8346322f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8b21e79e-17f2-4fb1-b979-4f273e57e2f4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e047db21-5e14-48fd-bb04-a52935b6b08d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_5d7cc3a5-aa5a-4028-8187-2f721555891b_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20220630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_6e6bbfb4-1142-4587-b07c-07112cf687eb_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time that goodwill is deductible for income tax purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20220630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_cedddd85-44db-4dcf-aa16-1286eaaa6f55_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ab9df624-2206-460d-b90e-d46c35287b21_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ac88e6ee-03ba-4f71-a24c-ebb4e5fafa01_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_fcfd8eff-c7c8-4ec8-89a4-0e9f6481a04e_terseLabel_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_label_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_documentation_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual" xlink:href="amed-20220630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReversalOfLossContingencyAccrual" xlink:to="lab_amed_ReversalOfLossContingencyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_53e5f812-095a-40e3-b794-ea52cb709d7e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_7e54ddcf-f1ba-4917-8c14-3c071c8f78f8_terseLabel_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20220630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32b9216e-eac6-4ef1-b43e-2d29662781a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fc7218fe-24f2-41f8-98a2-94d1ceb42cc3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_89ce12f1-3c0a-4315-9c06-dcf26b27eab9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_2a989f7e-6b16-46de-8f44-761f3e8f9dff_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_2f6ffcc5-3b34-4cbe-8eeb-16e6557f2796_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8222568a-2c7d-483c-b844-af4e61245db7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_70ec812d-afdc-4834-b8ca-f9fb594f42ab_terseLabel_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember" xlink:href="amed-20220630.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NewShareRepurchaseProgramMember" xlink:to="lab_amed_NewShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d1716675-2e3f-4cb0-8c60-abc01abca9c0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70588fda-ba8e-4791-8d75-d118ce9e9a10_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_f8ef9a7c-f6ed-4f55-a6f1-da9161f5f7b6_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ca6a7c71-40af-4c00-a94e-e1ce07545ffa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_a4dbf694-2f9b-4ae6-841c-5a40eeeaf081_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity assumed at acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_57fafcdb-20c6-418f-b388-c6a23cd68eba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_2d0a0d21-e4ea-4eeb-95ee-08f534047695_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20220630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_2caf138c-40d8-4a08-84f8-dbf57cf95f15_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20220630.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_543aa396-548f-45ec-acb6-c0a8645c31dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_80625f93-36c3-4702-af74-7d222b0e32eb_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20220630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4e33f688-7089-4c3a-98f4-82c6b76b6e41_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_90f73654-6206-461b-a1fc-b0829effb82d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in technology assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_fb059a38-d128-4bf0-9087-bc33a4399d73_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember" xlink:href="amed-20220630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember" xlink:to="lab_amed_OneHundredMillionTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_5ccd70dc-38c7-4e49-936e-a5256412f8c5_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_229ab293-9a32-4e5f-9db8-27bd4d91bc62_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1c7c02a4-d692-4cf7-9480-426708d26eef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7daf70f8-e9b0-4f57-b113-ead5edafd800_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fd4e1028-4671-4e58-9287-12a337d958fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b652ae1d-3f38-4e7d-9bd5-488bf6906d0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_df6feb60-2990-48d0-af54-566230c44219_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:href="amed-20220630.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_3a467796-1406-4f06-b060-7e120b79251c_terseLabel_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_label_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_documentation_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment" xlink:href="amed-20220630.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActInterestRepaidToGovernment" xlink:to="lab_amed_CARESActInterestRepaidToGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_cedf1941-2c81-4b23-bed4-dbd116f153f4_terseLabel_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_label_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_documentation_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:href="amed-20220630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:to="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_b48ade94-5980-4f47-b809-196c9184b38c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_4639ca84-d44f-4905-9ab7-a913cf8e310e_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_42f41c02-1764-4fa8-bb6a-bf9bfe431233_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20220630.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c6755927-d580-4fdc-8d0b-de14c71ffe94_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_f3b5d558-50a1-426a-9425-4d134561d729_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20220630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f47f83c8-8bf5-4c68-8e21-a3680b3ced04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8a24463e-1341-4338-ba53-8bd0b7191db5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_f80e8389-2d99-4320-9388-3292eb50f2ec_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:href="amed-20220630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_173f1fbe-14a4-43af-82b6-c25a8a492e56_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_fa78e984-87fb-4dc0-b32e-8a1bd52dc45b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_840fb61e-b607-47d1-8eb8-11381b98d76a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_b95bb11c-2c63-451b-af69-5b213581c7fc_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20220630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_418855c7-5873-4efe-9939-e5345aa3b8ce_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c6aeb845-2376-4242-b637-af06e03f0c1e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b356ea9c-e6ea-439f-8f24-7db851fe753f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_908cf66e-8f1d-4492-9c7d-105b4b6d9ac2_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20220630.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ec03d13f-dbcd-4265-8450-d67c4d08b83c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_aeb2e4e8-f1bc-453a-bd64-e48d974d6ac3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_51ca0787-8c89-42db-b6d9-9794dd28125f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_92b1fc47-4776-4371-9086-522f6342d272_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c40f4f60-9920-484f-a2ce-2a92f23d237d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 6</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d105d4d5-a484-48c3-a848-476c2626af4f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_bb0fff0b-5ba3-4953-ba50-fb321823f2af_terseLabel_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_label_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health [Member]</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_documentation_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember" xlink:href="amed-20220630.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AssistedCareHomeHealthMember" xlink:to="lab_amed_AssistedCareHomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_718304e1-b9a1-431f-9443-50b11c5699d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_87a06fff-ed0f-4e01-8394-dd16716977d1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_4aaa76db-6fb2-4c3a-ae8c-95d250b7df62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_e9184361-f8df-48c9-bb5d-4ef526371312_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_a2faa7e2-74d2-4641-8cb4-6e4a1050fe31_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4d12a320-4dc4-48ec-a511-a76fbc78bf0f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2022NewJointVentureMember_67a427cf-aaef-49e9-9764-22aeaaee585a_terseLabel_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture</link:label>
    <link:label id="lab_amed_A2022NewJointVentureMember_label_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture [Member]</link:label>
    <link:label id="lab_amed_A2022NewJointVentureMember_documentation_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember" xlink:href="amed-20220630.xsd#amed_A2022NewJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2022NewJointVentureMember" xlink:to="lab_amed_A2022NewJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_13e8e38c-7cc0-4044-aa24-60cecb4c21e1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e09c0778-e48e-4fb4-a33e-523dba6c5837_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_df867e47-c59e-4bf8-812d-da8112a3e31a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_f477bc75-685d-46b6-8e28-a4fd27e8c439_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8fd6a43d-31b7-4972-b9c4-dd1c47c571b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_bea4d38a-92ac-476c-9017-8ab80a0e214b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_a045566b-3a78-4f14-94f1-247bde52adb7_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:href="amed-20220630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_7d126120-ae48-4fed-896f-83b2e12918b5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_463deb47-3733-461a-b96b-e7b435a414c0_terseLabel_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_label_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash, Noncontrolling interest contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_documentation_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributed in noncash investing and financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution" xlink:href="amed-20220630.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashNoncontrollingInterestContribution" xlink:to="lab_amed_NonCashNoncontrollingInterestContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_069f37b4-86c1-4115-93ea-21df1457edbe_terseLabel_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated expenses as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20220630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_68cae425-64ad-4026-9b3f-4194f3fd83a6_terseLabel_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:href="amed-20220630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_c2597ffe-e617-4c6d-a659-6bb13b38d5dd_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20220630.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_713bdb69-78d8-4853-b361-0d3a37fa8dda_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_b1717c1d-43e1-442f-81cb-bf0a94d90639_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20220630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_bf65f7d5-8910-4522-9925-c3d28b496f1a_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20220630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_bcabe036-4104-4379-905c-b459359f178f_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseProgramMember" xlink:to="lab_amed_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c305413f-bc14-419d-9f4b-07a782674633_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_0a20f0c3-ccea-4d42-8f75-1923e91df744_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_87fe69f2-c8fe-46ac-b601-c405bb87ec28_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20220630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_c803a87f-8f61-4a8b-b7aa-44d7cb3b6c5a_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a46abf39-8cf6-44fd-9f76-20f5eef67b7f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a47a189e-1e55-4377-b9b4-c840261bd3d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b71f8d6c-7344-41d4-ac65-653fc2e5c3a7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_1431b958-edba-4131-ae51-25a89d272269_terseLabel_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contingent consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_label_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash, Accrued contingent consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_documentation_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash accrued contingent consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration" xlink:href="amed-20220630.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashAccruedContingentConsideration" xlink:to="lab_amed_NonCashAccruedContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_0e3000b6-2cec-457e-a79d-337bc18036e0_terseLabel_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_label_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_documentation_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:href="amed-20220630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:to="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_ba9575c7-7264-47c4-89d1-511d1538d14d_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4b9efdce-7e3e-46d2-b43e-8cbae1e7dbfb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8391398c-b859-4dbc-a87e-e28f2a845f15_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_0f9ae8bb-9895-4c52-854a-bae334fb2334_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_2b0b2197-7f62-4c27-831d-d1a66d6fe6bd_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20220630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_317388d0-e7c8-450a-bd7a-0da98288bdf7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1b74ee04-f97f-48e8-a1ed-5c85df790ac0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3aac9770-83af-4f98-8bea-463ff41620c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_714bd2c7-3d20-4f90-8474-35c9a56954c8_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9282a51a-6373-4f23-9682-7e2658ac2606_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f459da1d-478f-4aae-8b18-1f21df846139_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_138c02b1-77a4-499b-b3c3-d8d3935b7ea8_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_7e58fdc8-8228-47a6-bd96-0363003e2374_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_82f918a1-7329-4098-90e9-43ad70d302c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2ca8e13d-459f-471a-94f3-471ef9949f8c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_b5746e5b-3549-4f6c-ab9b-767e4850ea01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_d224a6c2-d625-4fa7-8e1f-91d5c671f915_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_46b872e5-7b8e-4c83-b300-0762600ea337_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dff3fe2d-c4a5-4734-8e3d-3cc3f6ca402a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_9458a619-5d67-4efe-b065-e1d01f22c463_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_08737f15-d69f-4ddf-946f-5b1ad70eb7e4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_94aed2af-1e14-4123-bb71-6e92f2ff9c0b_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_65744144-2ae8-444a-ba62-a4ea60481fba_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20220630.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_eb866983-b8d7-4c54-8b60-14cdce2a88d1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_5a949e1b-6153-40ec-a652-94a7ed23e68f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HighAcuityCareMember_8730f0a4-877a-40a2-a8ed-3c5f653c16d1_terseLabel_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_label_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care [Member]</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_documentation_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HighAcuityCareMember" xlink:to="lab_amed_HighAcuityCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_e3b30b15-646f-4538-826a-5787bc4f269d_terseLabel_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:href="amed-20220630.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:to="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4bdd008b-441e-4bc1-bfb7-03097111f468_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_627a217b-c5ba-4ece-b311-a238fb722661_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b13fb26c-d6f7-4cec-964e-3853c9ccf762_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_17dea4b9-b353-4718-8deb-75463a454dfc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_3f27c0ee-4f6e-4de1-985d-d7dd81ab267d_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_def814ed-225f-4704-a225-f5f6d5d4c535_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f79e82c0-19a8-46a6-889f-1a3e0266cb21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_47c041db-bd50-461f-9000-54a6c1cbf26a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_31d9b63b-ce89-49e0-8faf-c82b0914588b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_3d8793e7-5fb2-4ede-b58b-80d6d0725040_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20220630.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_9d9dd2ca-3935-4dcc-87a8-14a050cd6cfe_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2bdd2ed6-6f9e-43bd-9fe0-7d7ceea94c9b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_da770826-6be4-43a8-8c33-3b2724f30af4_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c9e49753-429d-45ed-b4e3-7df8199eae1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_77bd5bf3-bef6-43ab-b59a-edfd9bdcee68_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContessaHealthMember_4c86c492-d77e-4845-95cd-4682d681b51e_terseLabel_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:label id="lab_amed_ContessaHealthMember_label_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health [Member]</link:label>
    <link:label id="lab_amed_ContessaHealthMember_documentation_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember" xlink:href="amed-20220630.xsd#amed_ContessaHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContessaHealthMember" xlink:to="lab_amed_ContessaHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_835ea328-800e-4456-a65c-e3f51cb037e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f6502ac4-dc68-4aa2-a8ea-1193be593335_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e6215b21-3c13-47ba-8fe7-edfbd6eee3f5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_d1972d25-d197-4d02-91c9-b5711cc6e74d_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20220630.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_692ecf04-1b50-442b-8f0e-50b0cce0e55e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_d645ea13-68ac-4fdb-94f8-12678b9da312_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20220630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fe7eb542-3886-4d5d-8c26-015d8f3d5e35_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_4431a841-d319-449b-ae9f-228608103f07_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_29c5499a-0df8-43da-9354-37dd117a80a5_terseLabel_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_label_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_documentation_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:href="amed-20220630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:to="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_18818a30-8d71-4329-9957-8626ba4a00d9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_748214a5-0c79-4d99-bf02-84204d84332a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_441a18e3-c9f9-47dc-a48f-dff84d297a09_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_eb43ed97-3a72-46c9-b108-c7f8f6cc4209_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20220630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_7131a475-c9f3-4373-a879-4142520749a3_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_8ec386b8-9ed9-4c80-8bb9-0c280a38097d_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2022</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:href="amed-20220630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_86133f9a-0260-4d87-9155-576af7d68a89_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c3177a5f-c305-43b6-98bc-8015ad67a00c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsAxis_212ea4a7-2d7b-4bdf-89ce-5ee2b626dcea_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_label_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_documentation_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis" xlink:href="amed-20220630.xsd#amed_PayorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis" xlink:to="lab_amed_PayorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_92b8d1ed-05cf-4d46-a075-5957c8fed823_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20220630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1a11bf94-be27-480d-80a5-7e43993cac6a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_a633116c-c589-4f1c-ab4d-2a54f655bd82_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2acd1d03-4075-4e4d-932b-8e0a37a1f3d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_975673c8-cbf9-47a7-8206-c1c4fd80dffd_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_8059c9bd-4db1-48dc-9f96-4ab4c6ff9d07_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20220630.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock_b0dfadf0-3dbe-4301-892f-2f385c565641_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of Evolution business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:href="amed-20220630.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_f789195f-c266-4330-9000-7e517c5c5ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_daf9cc42-8d12-4180-b461-d151449b4d41_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_a92f9fcb-eb44-4e9e-a238-986f3879a8fd_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20220630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3b230dac-b4af-400a-b4bb-ea3a89b91e4f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dc7816f2-5320-4ea9-a144-ac80d306cbcf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_a1a0e039-9ec3-42d6-b88f-fdd4f53449df_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20220630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d022bce1-142b-4e7c-943a-61529d201636_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7b370a13-15d5-472e-80fd-3cbe77fbe6cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_64732360-8215-4404-9337-3aebed5c9a5d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d54f4be6-2e50-4a27-bfb8-f1565416bb85_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_3ef53a57-f526-4422-aa29-80c23402902e_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20220630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7f4aa085-b810-42e1-b633-93b0f019d129_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_fe41309c-25e1-4e93-a3a7-2249fa9ccbb6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_8e188710-8b53-4760-8912-c3041456bfe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_1e21631d-99a1-46c8-89c6-8f151f935e22_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20220630.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_3df22e97-19b5-4482-999f-ecb2e922ec68_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20220630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_47e734d9-f49c-4d1b-bf66-625fdee81920_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5b1540c6-5787-4c15-9050-75491a93b74d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_9b5079a5-f2b0-4b29-a83d-38c0a6449eee_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20220630.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_90497c79-33ea-4774-8846-8cd99205248d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_2ae38ac2-9ab1-4752-8037-7b46794d72b9_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20220630.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3951374f-9612-4336-9a28-ac8cdd4e84ba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f855b5fd-3039-4055-92ef-6c7aec217f5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_de5619da-ea67-4b7e-b614-daf341f3e35e_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_246bc7d2-c771-427a-83c4-f397148816ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_eb0b85ef-69a7-4b17-8940-b99ac9e7c8a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EvolutionHealthMember_b3884169-8c3f-42bd-a6bf-df2dcbc60b42_terseLabel_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_label_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health [Member]</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_documentation_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember" xlink:href="amed-20220630.xsd#amed_EvolutionHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EvolutionHealthMember" xlink:to="lab_amed_EvolutionHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_76c73b77-b23b-4bfb-93a0-07e673135414_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_04900dbe-7a2e-4785-bc7b-759fbd586edc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bed24a59-cd91-45c2-aa19-3d2334d25a81_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ab00ad7e-2b7b-4645-9cdf-8185cc226cb8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58d09ab9-f198-490b-9c3b-5a48697d94de_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c63dff9-03e4-4edd-8a8b-781706d8cf93_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9432ec99-160a-49ca-ada1-0c3d799f1efd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_86668fce-6951-461d-b885-569df4024cc8_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5ab4cb3b-0f77-41c4-b52f-19ede9e2085e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_001162f0-12e1-4306-be5c-438f6729b437_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8b7230a3-c64f-4ff2-bf38-076e68d09329_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_123ca304-c890-448c-8671-1436197f95ae_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20220630.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_37a334ff-713c-4c9e-94b8-e768419014f6_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8cecc816-7ffb-4e7b-a30e-15d256a044fb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4bb1057d-a466-42db-b5dd-2d68098497a7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cce62841-6078-4576-85f7-f1dd9b148025_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_47bf1ffe-e763-45f2-84f8-ca9b7a7b656f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_fd74f95e-c8ee-4f8f-8e3d-49b0c80439bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_b10768b6-ea18-427c-918a-e2bd2f78c039_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20220630.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_23c6a764-f819-4917-bc09-0aa4edd754d5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareLicenseMember_fe5444d9-210e-43b0-b211-acad30420d68_terseLabel_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_label_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_documentation_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember" xlink:href="amed-20220630.xsd#amed_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareLicenseMember" xlink:to="lab_amed_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3eeae768-5b23-4324-ab3f-db314ec067b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18716154-5714-413f-8729-7243073939b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_74f4d289-91f3-41f0-9f8e-7612dd45626e_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20220630.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0973eb6d-da33-4bcc-849e-3b7970b36116_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_02ed70cc-3b21-496c-af06-934ef7da0001_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Axis]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_label_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Axis]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis" xlink:to="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_d5aa4c66-263b-4656-b810-2235667baeaa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_72f4b6e3-aeee-442c-984e-7766482ec5a9_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_a30f4875-7053-4cec-bf38-af89da78bbfa_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20220630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7a9b99a9-c11e-4470-a71e-26907b45f092_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cd5816a2-8b56-4e0d-9917-0c5884d1b863_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_3871763b-4d6d-4b1d-9a3c-30d44a6c2700_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3f07480d-c384-4887-bca5-5aabb7ddaee0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_6adfcdc8-6a8e-4604-bc3b-4dbe29c56bc5_terseLabel_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_label_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment [Member]</link:label>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_documentation_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember" xlink:href="amed-20220630.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PotentialClosingPaymentAdjustmentMember" xlink:to="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_ed62714a-f1d0-4631-8177-89dc8bd94a36_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Lease Contract [Member]</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_bfacdcef-904e-44b8-bbe2-2e744c3871d5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_7f7a637b-bbd1-46f6-bf27-2c81cde23f69_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20220630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_4833c316-fcfb-4c92-9bc0-1a92ebf74900_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20220630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e934137c-96dc-4208-ac6e-8c68dfddb8a8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_e2acfe3a-8563-45db-9d8c-460fdb478875_terseLabel_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:href="amed-20220630.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:to="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_5ccf6ee9-6fb8-496b-8d4b-ae8d896f2820_terseLabel_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_label_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_documentation_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue" xlink:href="amed-20220630.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReductionToNetServiceRevenue" xlink:to="lab_amed_ReductionToNetServiceRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_32d31e79-e660-4355-b9ec-e10579444ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_cfc4a269-b314-4560-a68b-63a9b4772748_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20220630.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_9896575e-b3fc-4d30-b497-d1567007de63_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20220630.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_584d90b0-361b-43e8-a4aa-e676a601efdb_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20220630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_405634c1-10ab-4a72-895d-4e61bcf05ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_beee2dc1-6993-4c33-a2fd-4f1f87899537_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_d5fb2f03-8e18-4070-be5d-2f63c195fd24_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_95129440-eb3c-47dd-974c-90b26bc50865_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_5bd7cfaa-3d38-4bee-b572-86df4af73686_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1269e7e3-d922-4f11-9490-e2240bf5b5a1_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20220630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b6da1e34-8873-4273-b1f8-cc9c8b8fecf8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PriorCreditAgreementMember_b63643cb-1689-49a5-8225-77696536bde0_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember" xlink:href="amed-20220630.xsd#amed_PriorCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember" xlink:to="lab_amed_PriorCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c1e0e017-969e-4d4c-80e2-fb61b2321047_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc642954-f014-4d3b-a6c7-c75c90e31946_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4e384dee-cef8-403a-8f7a-27cadbc9823e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_07570055-17b2-4942-9aeb-57d4eb68bd67_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19ExpensesIncurred_acbe1236-03f5-495c-826c-4499c3bcac13_terseLabel_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_label_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_documentation_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred" xlink:href="amed-20220630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19ExpensesIncurred" xlink:to="lab_amed_COVID19ExpensesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_d9925bdc-62c6-42c9-bf9e-933385de5434_terseLabel_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:to="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a8d98a7b-06de-4f2d-a2c4-c6a2accd0a7b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_c41466c2-f8f0-4819-9606-7a0ad705df01_terseLabel_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember" xlink:href="amed-20220630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019ShareRepurchaseProgramMember" xlink:to="lab_amed_A2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8f050137-3337-42c1-aded-8901d06a6ef5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_ecfcb528-0556-4a80-981e-3ba2bbb2a1ef_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20220630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_387679cb-9657-42fe-85f9-3cbeb9baa570_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abe66a0e-8b85-4452-b923-c052a65cf9e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_57e78826-5deb-4712-9dae-c3ae238b2cd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_64119c62-5b2d-41a3-a462-c03ce6cec8b4_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ed1d413d-1576-48fe-a36b-282b67824674_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5dabe4c5-8def-443d-90c7-816c108bf246_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_c0ae358a-62f4-4c87-a011-dd73021b4c4e_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_eabbb646-2222-4836-86c3-16119c6cb8a0_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember" xlink:href="amed-20220630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAquisitionMember" xlink:to="lab_amed_AsanaHospiceAquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c1c7248c-20c9-42b2-8cb1-84a9715c3dcd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4ae01ec8-6688-49c4-b762-80e3e3d45c68_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7f22bbec-3d5b-443a-907a-6693f576b05c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1145dc30-87d6-4f9b-99af-728ae9227a14_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19TextBlock_3fd2d437-9098-43b7-9f03-191164486c5a_terseLabel_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_amed_COVID19TextBlock_label_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Text Block]</link:label>
    <link:label id="lab_amed_COVID19TextBlock_documentation_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock" xlink:href="amed-20220630.xsd#amed_COVID19TextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19TextBlock" xlink:to="lab_amed_COVID19TextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_96755bfc-c171-4dca-8f31-ce0735fd97d6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_3e63675d-fd35-472c-abff-d589081bc524_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_44503bbb-4d2d-405a-8098-42f548a04bf2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_096e6227-8e0b-40df-a2b7-d80bff61934f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_e4675a3c-b964-4b59-982d-95bc796f6b77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3529613e-3de0-4e24-b3b6-af55ea962033_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_965a69ae-3758-4084-9864-958c71fe72ab_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb980c93-7c53-4297-ba56-eeef06f29e2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_c754a593-69dc-45ef-b41f-da935bc695a5_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_da7a7968-1c84-4dbc-81f2-7361c7bf7656_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20220630.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_68eb4acb-419a-4075-b5bc-c3016f0402fb_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20220630.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8602e87-31db-439d-a7a1-e31fd07b43c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f30c16d1-531a-47b4-8a22-5610b09f43f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LicensesMember_369714ee-fbcc-4c64-abd8-4ac238367ba2_terseLabel_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_amed_LicensesMember_label_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses [Member]</link:label>
    <link:label id="lab_amed_LicensesMember_documentation_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember" xlink:href="amed-20220630.xsd#amed_LicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LicensesMember" xlink:to="lab_amed_LicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_c50264f3-000b-494e-b131-a43c0b5840b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_636e99c4-9769-4c8a-8ec2-3cc8d67ca98f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a21ea787-6442-4d38-ac88-99a4ccb3e4de_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c5e61baf-14b9-4acb-ad5e-1c39a769deac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f25860dd-2c19-4903-81bd-b838fd61abc9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75db6117-4786-4df4-9022-873963f9fbd2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_28dd7f35-e25e-42cd-b423-22551c0394fe_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_49395f8d-5c57-452d-ab03-75d9f2815f99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_c096aa21-c175-44a7-b886-796a76896d0f_terseLabel_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_label_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_documentation_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:href="amed-20220630.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:to="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_8034542b-64e6-4c1c-aa6d-deb962b05da1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1bf2cde5-7c9a-4805-b2c9-ca22ef25272f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7b6c7a37-880d-4092-89be-cb26c749201a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_54d8dbb2-b936-4b4d-bfc0-de2d66aa7714_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_a4d31b2a-427c-436e-bf8a-d5f33d661e79_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20220630.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_83bd3a16-af7e-4ffe-b3fb-40302e019ee8_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses</link:label>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedAndLicensesMember" xlink:to="lab_amed_CertificateOfNeedAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_189a5cd8-ec48-45bf-8b24-3eb3fa70ee29_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember" xlink:href="amed-20220630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember" xlink:to="lab_amed_CompanysinsurancecarriersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_451a8eaa-4c99-41d0-b406-5071667511dd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $9,109 and $19,900</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dfb06bea-39f0-4837-87cb-234a2b12ec87_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_2df2c8c6-f189-470a-9dd4-ef1feec8fba6_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_label_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain" xlink:to="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_94ab13cf-cf13-4920-bd86-d32d878142ab_terseLabel_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember" xlink:href="amed-20220630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021ShareRepurchaseProgramMember" xlink:to="lab_amed_A2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_bab3738b-5780-4b09-831e-fe28091c32e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_c9e228d8-91f5-48f5-870b-6e2c58dced46_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20220630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e9cd5cc-1c04-42ae-8249-be03f084b2a0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_7f285ac4-7dc5-4fa7-b3bc-ab60451bac17_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost 5,347,715 and 5,164,899 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_eafb5550-3bae-4d73-af4b-0f008459a174_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_b7fa614e-c49a-493b-ad78-5a9d59ddb709_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_b4679b9a-2a38-4b67-b649-423ba2c22d19_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2b65b828-b1b0-4d60-9acf-c69b65b11b8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a6ab4a05-399a-4cfa-8fc8-06271ec716ed_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in loss (earnings) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c9b1c448-614b-4343-a36b-7ae19626687c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_528b63d4-5790-4437-861f-40441f32f170_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_fcfbb9ba-36d3-4f1e-8f80-1d6c42f229fe_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:href="amed-20220630.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1a23fadd-cdc4-4f49-9525-18c04b297bfd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_acce14a0-0836-4043-9e5d-f78137495a52_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_ae854545-1dc7-4a83-a848-16f1b682a3be_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_34f542d9-1f52-4fa9-8353-93f88430afa8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_5020b3a4-ff9e-4bb6-8773-270e5e58e776_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_6c81852b-8bcd-4a57-94f4-c43c02b06dfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_d778a37f-c35b-4c73-9edd-26f14dd470e3_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20220630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_ba1ed8d9-295a-40e4-9cfa-13db82a3fb0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2393eaeb-5d7b-4ec4-a7e0-46787a65c3df_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e869f6de-947b-4d71-9696-8e9a164c6b0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_27833bd7-cc8b-4a59-a7f1-8842a9dc88ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4da64519-888b-4632-b34d-9706a8abd06b_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_b15ccef4-1676-41fe-8f6a-40aad7f6d7a7_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20220630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_76af18e7-3fcf-4b2a-aa8c-08498535c201_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_218ca021-5ad2-493f-be72-1181c8b3a77a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bde8004a-0d8f-4db4-a44b-be30e4ba9f2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_6c4cf43e-ab6c-4376-b103-c38ccb45bc03_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_944574bf-da8b-4d10-ba45-5fd0d3ab116c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e61358a4-9327-4715-a289-d49f36d26f16_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_c0833f6e-9ec0-44c8-ae7b-6191f0860f69_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_5af4cbb5-7565-49c9-80f7-e7835df8bd26_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_a381fb2b-8f2a-45d1-9278-9321083f7e79_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20220630.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_5d10b39a-0ec9-42e4-bcf3-7fbda06f13ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8e106a03-1452-452f-9fcf-70d63db23c0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4b1ec531-f5a1-4902-9847-83d51dbd9ab8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_80c2d27c-e45f-4117-857b-aeb47f1a76d1_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20220630.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e6050b5f-1158-47bc-8d6c-f5f08c5d2ba7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_93a8f8fa-caea-4b7b-b767-f3f6bbcaa28d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $100,265 and $96,937</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7206b927-8449-4919-bd4f-cbf797546228_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_c1e6cbe9-7758-47c4-8a32-de6938b4c2f5_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20220630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a1e8df30-c545-4b74-97ec-e2cc6ba3d742_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d5ca2697-4593-4e1c-998d-22c63b2087b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_ba7f581e-2d1f-46f3-b0cf-e9401b0daa15_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_5a00cf5a-03a8-442b-94da-6e29916e89e0_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20220630.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8d8b4d6c-f0f5-4118-8c94-16cef590aed9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_31f29d8a-7f3b-4588-aa72-93e96b7bfd46_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0326aba7-5394-4231-89a2-13c7e2ad7c42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9172aaa1-2d87-45d7-8be3-bb93dd72dd8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b5b0668f-fbe7-49b4-b5ed-4984cb83b5c2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3f564c57-456f-414b-b8eb-2a5fe12a2def_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_1fd50306-7f70-4f96-9099-e378dc6d3b06_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20220630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_26fa5219-aabf-402e-989e-a8ac1f146f92_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_d3e1d9ee-2a84-4230-b004-ce642e0f9d73_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20220630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_7617d4e7-f6aa-49e8-9605-fb2c84510ab8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_a643a0f4-c096-42b9-97b0-ddf4dfceb0e6_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20220630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_966cc18b-6cc5-4cdb-87d8-31bcd745fe08_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_732d41a5-88c8-47d0-bd11-1b5fd06efa59_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_30264fca-5173-451d-a1a4-aa7e554d32c8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_80597f70-66bd-409e-9091-196019a0a4a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_912a6c69-65d8-44c2-b40b-6188505ad4ae_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_0f8bc01c-11ac-40b7-847e-918827b60ef6_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_ac2aff8d-6865-46fd-9af5-525241167de2_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_60f0afdd-e168-4a93-9bd5-79b16fe1dbee_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_6a9ef820-fd43-4a61-9468-1f4d692dd377_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20220630.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_679c48d0-8522-4014-a03f-8121ecb3973c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ceae9d8d-e74f-411d-8b56-4c064a72ebab_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Discountedclosingstockprice_fe89b836-98dd-4569-9e38-4c481b84225c_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice" xlink:href="amed-20220630.xsd#amed_Discountedclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice" xlink:to="lab_amed_Discountedclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_b269eaaf-49fd-4166-8c7e-b5c6b4b2b622_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20220630.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2fc2439d-0567-4fbc-a813-bc1f0c401a18_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1cbe1921-206b-450e-b909-c954f2126028_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3972ba5a-91dc-4fea-8362-ce28b22f01d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_d9eee07f-3fbd-4fa3-b0f2-8be34dc0c0f9_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_a73de9c7-e55b-449e-aa4f-2bbd615f4190_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20220630.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_3881b495-010e-4610-a73f-6e98a7702740_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_1a3eba27-ae36-43d1-a23d-b952151e5daa_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7f63aef7-f566-434e-be3f-9171afa36a65_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_20b4c4f1-9d22-417f-902b-f973b384f5e2_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_055b55c6-ad3c-4ec9-9ac7-31eeeee6e0f0_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_beecde48-bfc9-4ac8-964a-d8699ac93657_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4a482701-d973-4df6-bb1f-abf62c598d20_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_668c36ed-5c25-4550-a04f-9932c6062e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_86d47210-bdd2-46e2-affa-e89e753b6af1_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20220630.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_e6feaab2-57e2-4cd5-8d6c-0aa3ca3faea9_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20220630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_78894caf-901e-47ec-94a8-730c8b564c71_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_026f79e5-bac1-4666-b549-1b921ef563ce_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60e4eb8f-cd4f-4f44-b67c-68b62eabfb01_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64828e98-19f2-4492-a660-95ce4f8df3a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_460527be-8f49-4e6b-bed2-669192f759c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7d580727-f01e-47c9-9597-d07682c34653_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_e2d839db-573e-484b-affc-2520cec071f6_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:href="amed-20220630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_93cc7abe-e928-419d-a008-ee9084ad599f_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnSaleOfInvestments" xlink:to="lab_us-gaap_GainOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7a664b11-f1d4-42f8-804b-4d7c3c8f3a8d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_d459e894-b87d-42c4-ae8d-7a3a060e7876_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_ce545668-98a4-4175-b8ad-67aba47f6a43_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20220630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_350c4708-7550-4916-aac2-83d4408b6a2c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fd03da66-816e-4fce-a086-a8f6d79d019e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8dbc49cf-dd7c-403a-9c6a-8de6156925d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_b3bba5c6-33bf-4646-86ee-86c6284aa701_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_e5d33140-0d6b-4d57-8a78-5c609153a1b0_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20220630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6bd0977-65a4-4d53-b840-54e06d1a3dde_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bcfc48ab-2369-4143-b283-8c390755cd2e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_d807e779-a5c7-4ba8-804b-a23b9afbd7df_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_d296802b-2019-4e7c-bce0-72abdec77ace_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d3c0f2f0-8554-4996-9cf6-1b6867d3466f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_d4da89d7-8e39-4d1b-8745-45f03aff4662_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cfa8459a-05f9-4939-9531-6c399683404f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_5aa33380-40cd-41ff-98ee-c5ee8de88531_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_16d86baa-1d96-4c18-8594-886fea642f41_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7b9fd5e9-8043-4be7-b1f3-acbf65fdc0a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19PPEMember_dc5399c6-3961-49bb-aff5-824fb2dbf916_terseLabel_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_label_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_documentation_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember" xlink:href="amed-20220630.xsd#amed_COVID19PPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19PPEMember" xlink:to="lab_amed_COVID19PPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_9533faa1-4cba-4fd7-89c4-a29860cbf386_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20220630.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_05a3a170-bca8-49bf-80fc-b3cd03f58273_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2a049cbf-d4c5-4e58-b241-8cd499608b0f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_d34345cf-8398-4417-b62f-a2170576305e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26c3e7bb-07cd-4f13-a160-2ed0306a605a_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_67db8ea2-0e5f-40cd-9bec-615fba97e68e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0b3dfc36-7d4b-476d-b02a-d661ee6aee58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_112b31cf-f715-4202-8c5d-e79cc623921f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d57dda0-750b-4d44-9e77-638c61c53be2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_01372343-8a73-41ae-938f-a372cb3507da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b4630658-c6b3-4d1f-b144-5ed15591a6ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_04a784f8-7962-4deb-918d-ccc9148592fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba7f0692-7da6-49eb-9ae0-e9c2d1ebdbe8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_f35946b0-d25c-4db7-a5f8-288bd32ae380_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_17832299-8051-4557-bf3c-7d78d511b89e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f1c981-e37a-400c-aba8-dd09e9070829_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_5ef9b218-88ad-4ce6-8310-c2deaba61ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_227d14b0-1230-4cb6-bed7-80a9731abd95_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b0acb9f8-24d0-41bd-934f-49946fe63f0c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_704045f6-742f-4294-965b-965f18921967_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3eaea366-33e9-46ea-93b4-142763136585_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f98d4eb2-8428-4b97-886a-cc076647ce8c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9ab36119-95c5-4307-a46f-48123c945dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6be730fb-acd7-4bcd-a45c-acf2ce10c1bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_05407ca7-f5d2-4f36-a675-1368cc25ab76_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_0c11614e-674e-4c01-a6c8-7576a4db3a63_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfJointVentures_78e809b0-520a-4e94-a172-a572d52bfd9d_terseLabel_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_label_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_documentation_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of joint ventures owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures" xlink:href="amed-20220630.xsd#amed_NumberOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfJointVentures" xlink:to="lab_amed_NumberOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d152521b-5d57-41ae-82ab-af18c950cf6b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6f7fdd05-4670-4fda-866d-586259f3feae_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_d460aa2f-980e-4ebe-865b-3e04fcf02c46_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of equity assumed at the acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_bbdfaa04-6d2f-4517-8191-29e0b1d8f062_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_084685e5-8b74-4b04-8777-0a3b33e2875c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8b329fd9-97ba-4628-8d2a-fbf0de46bf60_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_4debadae-5f08-4a65-8b36-f3eaba8a7d55_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_9cfc1fdd-4706-4251-b49c-a42ab12deb9a_terseLabel_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Deferred Social Security Tax Under CARES Act</link:label>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_label_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Deferred Social Security Tax Under CARES Act</link:label>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_documentation_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Deferred Social Security Tax Under CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:href="amed-20220630.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:to="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_a4f96e14-baa0-4a2f-b6d9-3f1edf29b8cc_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20220630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_b57f94a9-5518-4131-80a7-299ab5ace76d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_fcc0468f-d902-4468-aa7b-71ecce8e2791_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e788aec3-1a92-411a-8163-8c8e66d1d4c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_c40bb06b-0fce-4eb0-9c9c-95e4f7dd447a_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20220630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_8fa93180-060f-4d73-afbb-606c25cefd36_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_395e2542-8e7a-49f8-89a2-184712d6b310_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ef07afc2-6a53-4115-a7b9-ca3596a2ace0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0f23599b-16d3-41f9-91d6-d5977a1e9997_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_84740b24-c24f-4588-86da-a35a5ccaa927_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_06a6eb40-d6bf-49e9-b38d-e188e9be8734_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20220630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_099336bb-48b7-4d30-b7a1-cb64ca068ac1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2a3ee17f-b631-46b6-94c5-db2dc57f672e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_bca6f641-6cea-4c17-ae66-b6e17b10c6c6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6f6e39a1-4975-4d96-8f70-81fca8e36df4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_dba72605-9ea0-4f8e-b2a2-3aec0c979199_terseLabel_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds received from Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:href="amed-20220630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:to="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_828c6f34-d5bb-4b5a-8ef9-65a7261d5198_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_52f0e263-bdd6-4a08-9fe2-951c8ecaf7ca_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_29761c1c-163a-4141-a827-c22763205e2b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_16efd392-7629-48a3-b70e-c016303538d2_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilized" xlink:to="lab_amed_CARESActProviderReliefFundsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_be9fee81-bf04-49f9-aada-1e133a806c1b_terseLabel_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_label_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_documentation_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:href="amed-20220630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:to="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_0c9968c3-ab63-4125-b9d7-94c7cd2e4e0f_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20220630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47776400-b6ad-4b77-88ae-e53c291ac634_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofclosingstockprice_d4060a99-777e-44db-a1cd-b999f4ab33e4_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice" xlink:href="amed-20220630.xsd#amed_Percentageofclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice" xlink:to="lab_amed_Percentageofclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_fcd5c9b6-905e-42d4-b2f2-d3a0edb5735a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5b60a479-5209-4935-9b74-faff338895da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,780,242 and 37,674,868 shares issued; and 32,432,527 and 32,509,969 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c3cea3e8-71a9-4344-8fd3-3feffc7f180b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_cdf15d36-1e01-423a-a90a-aa76ca46fee2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_4e1ec7fc-9b8d-44e8-90c3-72eb7c6b351e_terseLabel_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_label_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_documentation_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The deferral of the employer's share social security tax provided by the CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:href="amed-20220630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:to="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_17f2c8e1-d891-4dd1-93a1-61573e35b82f_terseLabel_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services</link:label>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_label_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services</link:label>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_documentation_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices" xlink:href="amed-20220630.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcutePhaseForHighAcuityCareServices" xlink:to="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_33025791-1bbf-4fe5-871f-b16088dadcc3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c1676d59-2d39-4d06-b0b4-e11c5034fc18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_0312cfd4-fcea-481a-aa4d-463123bfe6d4_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_label_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents that amount of noncontrolling interest acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:to="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>amed-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d65f1b45-dd37-4ff3-81f3-a4490be605e0,g:0356b5ef-bce2-4aad-8ae3-79e320bedd06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_426e9664-973b-4f2b-89df-c4a5fdf41140" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentType_426e9664-973b-4f2b-89df-c4a5fdf41140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a20146b6-911d-4bd5-8883-85321f5a332c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentQuarterlyReport_a20146b6-911d-4bd5-8883-85321f5a332c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b3f36ce-243f-4fc8-be9c-24b2bf1595c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentPeriodEndDate_2b3f36ce-243f-4fc8-be9c-24b2bf1595c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9c79517f-3c61-40cd-a48c-100c8284a0fd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentTransitionReport_9c79517f-3c61-40cd-a48c-100c8284a0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_54965d94-391a-459a-850e-423aeed5b63a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityFileNumber_54965d94-391a-459a-850e-423aeed5b63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5cfa00ac-111a-421c-b24b-464db5235e9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityRegistrantName_5cfa00ac-111a-421c-b24b-464db5235e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0225d8a6-b4f4-4f17-9188-b41d8d42cf1e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0225d8a6-b4f4-4f17-9188-b41d8d42cf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6bf428c2-d4e3-4d33-919f-94dd6e61e4d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityTaxIdentificationNumber_6bf428c2-d4e3-4d33-919f-94dd6e61e4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2650d306-3f44-4dd8-b88c-d80ad3f3ef81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityAddressAddressLine1_2650d306-3f44-4dd8-b88c-d80ad3f3ef81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8e701689-ad7e-41d1-88c1-fd1817318df3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityAddressAddressLine2_8e701689-ad7e-41d1-88c1-fd1817318df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b78d9890-4390-43c3-a262-e2cf6d7935c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityAddressCityOrTown_b78d9890-4390-43c3-a262-e2cf6d7935c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c8518e13-edea-4c09-bda9-c8e10cd1295b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityAddressStateOrProvince_c8518e13-edea-4c09-bda9-c8e10cd1295b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e73a6cc0-e60b-4f48-af6f-d37245c40a88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityAddressPostalZipCode_e73a6cc0-e60b-4f48-af6f-d37245c40a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_efba0f41-f885-4b46-b8ce-bdd2b03574da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_CityAreaCode_efba0f41-f885-4b46-b8ce-bdd2b03574da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9177ce85-584f-4eb5-bc3e-6455d595ac27" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_LocalPhoneNumber_9177ce85-584f-4eb5-bc3e-6455d595ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de7a268f-a4d7-421c-ab57-fd937cbab959" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_Security12bTitle_de7a268f-a4d7-421c-ab57-fd937cbab959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c7451de5-67b6-4767-9ed2-a6df1e706624" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_TradingSymbol_c7451de5-67b6-4767-9ed2-a6df1e706624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8da2ac4e-283b-4a37-9215-c2a244aba35e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_SecurityExchangeName_8da2ac4e-283b-4a37-9215-c2a244aba35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_dff38911-d180-4a70-8c37-977d1b0f584b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityCurrentReportingStatus_dff38911-d180-4a70-8c37-977d1b0f584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_565b9821-8a77-4e2a-b7cd-c8b964821a50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityInteractiveDataCurrent_565b9821-8a77-4e2a-b7cd-c8b964821a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_173547fc-6c2d-4608-8add-6bdf24c943b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityFilerCategory_173547fc-6c2d-4608-8add-6bdf24c943b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0c9c297a-81a7-4586-8a33-a6a810277d85" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityEmergingGrowthCompany_0c9c297a-81a7-4586-8a33-a6a810277d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_fdc741e6-0576-44fc-82c5-b38611a334fd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntitySmallBusiness_fdc741e6-0576-44fc-82c5-b38611a334fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_538a1078-23da-46be-bcea-d25778626e4e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityShellCompany_538a1078-23da-46be-bcea-d25778626e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e868e8d3-7594-4698-a1a5-1259b69758a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e868e8d3-7594-4698-a1a5-1259b69758a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ce3b16a0-bff2-49a0-b247-1c454020e3a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_AmendmentFlag_ce3b16a0-bff2-49a0-b247-1c454020e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_07955330-2e17-4693-a84a-d8e381fc13e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentFiscalYearFocus_07955330-2e17-4693-a84a-d8e381fc13e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b5d8f9bb-af69-4c3c-a08a-fe153df1c718" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b5d8f9bb-af69-4c3c-a08a-fe153df1c718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7f3c1c11-982f-49d2-b02a-74015033bf89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityCentralIndexKey_7f3c1c11-982f-49d2-b02a-74015033bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c837a7ce-b8a8-4fb6-a575-c631a0ded05b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_CurrentFiscalYearEndDate_c837a7ce-b8a8-4fb6-a575-c631a0ded05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_13f8780b-c3f2-42f7-a02c-801221855a63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityVoluntaryFilers_13f8780b-c3f2-42f7-a02c-801221855a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6855a4f0-f90f-4ba8-83ad-55162c04bfa6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c6cdfa7-7bed-4fea-abf8-f9a0886ac6b5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6855a4f0-f90f-4ba8-83ad-55162c04bfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e3a88f55-bf16-4ba0-8738-2abe3d1f5a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e3a88f55-bf16-4ba0-8738-2abe3d1f5a20" xlink:to="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1aae306d-f844-4bd8-8271-648981aeaae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1aae306d-f844-4bd8-8271-648981aeaae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9e758173-ead6-4626-b8e3-ad58a3273a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_RestrictedCash_9e758173-ead6-4626-b8e3-ad58a3273a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e321cd59-fce8-4dbd-87f4-05349b0ec533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e321cd59-fce8-4dbd-87f4-05349b0ec533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5e7dd74b-b820-40f4-8475-0bb67039397f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5e7dd74b-b820-40f4-8475-0bb67039397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_36b7b8da-bcd5-4e53-a9fb-296e0c9eeace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_OtherAssetsCurrent_36b7b8da-bcd5-4e53-a9fb-296e0c9eeace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_97991812-1672-47dc-8ca3-dda07b4426e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_132167c2-b1c9-4ec4-99ec-a413cf29a5c2" xlink:to="loc_us-gaap_AssetsCurrent_97991812-1672-47dc-8ca3-dda07b4426e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ebd79c85-fb8d-462b-94de-d6dd303d4695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ebd79c85-fb8d-462b-94de-d6dd303d4695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e23829c-a0b8-42dc-948b-d43468602e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e23829c-a0b8-42dc-948b-d43468602e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f4d31204-60e8-483e-98a3-b65c673b0392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_Goodwill_f4d31204-60e8-483e-98a3-b65c673b0392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8c11b26-1fc7-42a7-8170-2d8424ea02a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8c11b26-1fc7-42a7-8170-2d8424ea02a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cf03adda-e68a-4e09-97b9-7c66b44ab42f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cf03adda-e68a-4e09-97b9-7c66b44ab42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9495dca6-f691-43cc-9ebb-f5605c8f9ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9495dca6-f691-43cc-9ebb-f5605c8f9ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_808a36b4-b3a0-4c7e-bcb0-817629bfc938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cdb36f9-b550-43b5-83e7-029c384dbe9f" xlink:to="loc_us-gaap_Assets_808a36b4-b3a0-4c7e-bcb0-817629bfc938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e3a88f55-bf16-4ba0-8738-2abe3d1f5a20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6ee9e93a-529b-447b-9eac-485b67c09c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_AccountsPayableCurrent_6ee9e93a-529b-447b-9eac-485b67c09c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c00ee1e3-0227-4c47-89df-0f52d2f96b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c00ee1e3-0227-4c47-89df-0f52d2f96b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cf096c40-94b8-4ae8-9b4d-9d5523a8dd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cf096c40-94b8-4ae8-9b4d-9d5523a8dd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1b4791a9-2714-4f18-91dd-ce4bbce7be27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1b4791a9-2714-4f18-91dd-ce4bbce7be27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_437eeaf3-4c02-45ce-a9a4-eddd4377dbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_437eeaf3-4c02-45ce-a9a4-eddd4377dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c5fea84-c9ac-4810-b275-b14a647e0734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67906044-a90d-4c1e-abd5-e142a5f6cc1b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c5fea84-c9ac-4810-b275-b14a647e0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_af33e95d-c9a2-446b-94f3-7d45af9d3422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_af33e95d-c9a2-446b-94f3-7d45af9d3422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_898914f2-34b8-43e7-854a-e66ef5e4da45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_898914f2-34b8-43e7-854a-e66ef5e4da45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_85e4ead4-ad07-4c70-bc14-d088e8515f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_85e4ead4-ad07-4c70-bc14-d088e8515f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7bc5c7a7-33b3-4bf6-b6c2-44991191e5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7bc5c7a7-33b3-4bf6-b6c2-44991191e5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4926e61f-8eec-4178-97db-5e76dc112428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_Liabilities_4926e61f-8eec-4178-97db-5e76dc112428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b807a345-5fdf-4996-b884-5b39420ac81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b807a345-5fdf-4996-b884-5b39420ac81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_2096bd77-f7bd-496c-ac3d-2c0d1715886f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_2096bd77-f7bd-496c-ac3d-2c0d1715886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_97c4cf52-dc93-4b11-88bd-2ea91194b592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_CommonStockValueOutstanding_97c4cf52-dc93-4b11-88bd-2ea91194b592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_920d76ff-cc73-4beb-9a08-76c95ab89851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_920d76ff-cc73-4beb-9a08-76c95ab89851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6c43ea76-a61b-4394-aece-7c65f21a4a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_TreasuryStockValue_6c43ea76-a61b-4394-aece-7c65f21a4a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf99b76a-7344-4ae1-8a93-33a6fe6f7eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf99b76a-7344-4ae1-8a93-33a6fe6f7eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8607f634-cfa5-41c7-868c-b86fd9a52887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_StockholdersEquity_8607f634-cfa5-41c7-868c-b86fd9a52887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_db082950-71f6-4c41-a25f-c04e24d6128b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_MinorityInterest_db082950-71f6-4c41-a25f-c04e24d6128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_01eb2d87-2a2d-447a-9f88-74222511c9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_85918c20-82e7-432a-9200-558029412aba" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_01eb2d87-2a2d-447a-9f88-74222511c9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb79226c-1eee-41b8-8c1e-f825e54b9210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6417b44c-a35f-415c-9dca-9086e52151c3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb79226c-1eee-41b8-8c1e-f825e54b9210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5e3afcb-cc57-4e04-8f7f-98e13091607c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5e3afcb-cc57-4e04-8f7f-98e13091607c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6de6a3b6-d1f5-4d10-be42-48e1d67c490a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6de6a3b6-d1f5-4d10-be42-48e1d67c490a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_37e775da-e46c-4339-93dd-4444f234983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_37e775da-e46c-4339-93dd-4444f234983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_946fd3d7-217b-46c0-8bf3-76cedf433489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_946fd3d7-217b-46c0-8bf3-76cedf433489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_971030a7-ca70-4b14-853a-d7d6665ecf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_PreferredStockSharesIssued_971030a7-ca70-4b14-853a-d7d6665ecf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2308c5a8-00ea-4779-b356-7b7c13f7528c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2308c5a8-00ea-4779-b356-7b7c13f7528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3b042e9-0226-4d77-a2f2-1f3045830809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3b042e9-0226-4d77-a2f2-1f3045830809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_613fa91c-7638-48ab-9d60-8f7b545d90c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_613fa91c-7638-48ab-9d60-8f7b545d90c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d8110175-7f4a-469f-aecb-05cd6d954deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_CommonStockSharesIssued_d8110175-7f4a-469f-aecb-05cd6d954deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e7c7084-e371-4861-87a1-705d43e65ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e7c7084-e371-4861-87a1-705d43e65ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_8ee158eb-89b4-4d55-a6d5-c88a26996e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d4924f7-5b49-475a-8969-7dd6e40673df" xlink:to="loc_us-gaap_TreasuryStockShares_8ee158eb-89b4-4d55-a6d5-c88a26996e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_54364472-a917-423d-9c34-5ab6fa8ea334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_54364472-a917-423d-9c34-5ab6fa8ea334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac22bb86-2c4c-4210-8b21-b6def26fa14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac22bb86-2c4c-4210-8b21-b6def26fa14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_100e163e-7df6-44ce-b9e2-bf17c0f957c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_100e163e-7df6-44ce-b9e2-bf17c0f957c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4210685e-c167-464c-8327-c74065c4fa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4210685e-c167-464c-8327-c74065c4fa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_ed7fe878-09fb-4afd-8106-e0a4093be460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4210685e-c167-464c-8327-c74065c4fa3a" xlink:to="loc_us-gaap_LaborAndRelatedExpense_ed7fe878-09fb-4afd-8106-e0a4093be460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1dadd03a-01b0-4687-866e-bcd97c577bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4210685e-c167-464c-8327-c74065c4fa3a" xlink:to="loc_us-gaap_ShareBasedCompensation_1dadd03a-01b0-4687-866e-bcd97c577bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bcdd9304-6989-400d-a608-8ccb6cd82fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4210685e-c167-464c-8327-c74065c4fa3a" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bcdd9304-6989-400d-a608-8ccb6cd82fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_0ee70629-ea5c-4d0d-a1c4-4982e15c8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_DepreciationAndAmortization_0ee70629-ea5c-4d0d-a1c4-4982e15c8bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bd306648-7be6-4cad-a877-c4932a5936c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_CostsAndExpenses_bd306648-7be6-4cad-a877-c4932a5936c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85f348fe-131e-4bb1-b2d0-2e96c0ab6a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_OperatingIncomeLoss_85f348fe-131e-4bb1-b2d0-2e96c0ab6a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_398d05a5-5659-4e72-b206-c04a89b26cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_398d05a5-5659-4e72-b206-c04a89b26cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cf755898-c0b5-456f-9efd-2c8259e4e3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_InterestExpense_cf755898-c0b5-456f-9efd-2c8259e4e3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_786c2b6e-89fe-42ce-9707-48de1674292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_786c2b6e-89fe-42ce-9707-48de1674292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_a2e4f264-956a-4839-9956-fd1257d459a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_GainLossOnInvestments_a2e4f264-956a-4839-9956-fd1257d459a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb783b5-1708-4904-8a1c-adc86dbd06b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb783b5-1708-4904-8a1c-adc86dbd06b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_14713983-da62-4621-acc6-2c897f278ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5d691e73-bd45-4b23-afec-0ba6818dd086" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_14713983-da62-4621-acc6-2c897f278ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_76ec346f-2f7d-4eb8-8261-daa37805c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_76ec346f-2f7d-4eb8-8261-daa37805c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_630f3ee0-20e2-4cf7-a621-313dd59e8fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_630f3ee0-20e2-4cf7-a621-313dd59e8fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98339947-94dc-4082-a900-9aab095e69b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_ProfitLoss_98339947-94dc-4082-a900-9aab095e69b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea86205e-1793-4b44-8bf4-4f47ef7b2f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea86205e-1793-4b44-8bf4-4f47ef7b2f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20021a28-3410-4150-a618-bb2cce76b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_NetIncomeLoss_20021a28-3410-4150-a618-bb2cce76b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_bdf38f5d-535b-42bd-9bf1-89bdb1d25488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_bdf38f5d-535b-42bd-9bf1-89bdb1d25488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_04e30b91-ddb0-48bc-bd55-118b869a5d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bdf38f5d-535b-42bd-9bf1-89bdb1d25488" xlink:to="loc_us-gaap_EarningsPerShareBasic_04e30b91-ddb0-48bc-bd55-118b869a5d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4b2c249-7987-48e0-bfab-772b3b4a4ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bdf38f5d-535b-42bd-9bf1-89bdb1d25488" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4b2c249-7987-48e0-bfab-772b3b4a4ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_fc34db4e-e172-4332-b04c-7c2b055b3b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_629c0e85-ec1c-4d09-9131-6a1975a5443f" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_fc34db4e-e172-4332-b04c-7c2b055b3b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_adcc00ec-c2d8-4542-a8b8-ea183ea61d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fc34db4e-e172-4332-b04c-7c2b055b3b28" xlink:to="loc_us-gaap_EarningsPerShareDiluted_adcc00ec-c2d8-4542-a8b8-ea183ea61d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_979f7171-abb9-4be0-8412-ceabc5c1ee91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fc34db4e-e172-4332-b04c-7c2b055b3b28" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_979f7171-abb9-4be0-8412-ceabc5c1ee91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_29deb183-c0ee-4e92-a39f-69672a72057e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_29deb183-c0ee-4e92-a39f-69672a72057e" xlink:to="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57b81db1-2ac9-412a-9448-0e744bd5c1b2" xlink:to="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f98a7015-1536-4758-9c6e-fc4678a32776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_CommonStockMember_f98a7015-1536-4758-9c6e-fc4678a32776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_17285999-30ee-4923-b453-a7760c5f8f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_17285999-30ee-4923-b453-a7760c5f8f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9714dfb8-6caa-4407-8055-4bfbf8979849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_TreasuryStockMember_9714dfb8-6caa-4407-8055-4bfbf8979849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96615b13-4afc-44d5-bd11-94e32eccb090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96615b13-4afc-44d5-bd11-94e32eccb090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_902e3be7-c8ff-4eff-a7f4-6ccf43c047f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_RetainedEarningsMember_902e3be7-c8ff-4eff-a7f4-6ccf43c047f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a486fbdd-7526-4687-8d77-b20471bff7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a486fbdd-7526-4687-8d77-b20471bff7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_35a0dc67-7bbc-4ec2-9423-1b9033ff42d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07875743-db5c-412b-a513-ca41fcd5d6d9" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_35a0dc67-7bbc-4ec2-9423-1b9033ff42d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2101f469-637e-413c-bb58-291964234fab" xlink:to="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b0cee58-1074-443f-8bd8-2af5e16a3926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b0cee58-1074-443f-8bd8-2af5e16a3926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a6b45ee1-3d4d-4405-b325-69aa8c97837a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_SharesOutstanding_a6b45ee1-3d4d-4405-b325-69aa8c97837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e2f8525c-5c05-46ec-90fc-51238b66e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e2f8525c-5c05-46ec-90fc-51238b66e5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83b1fd0a-2728-4e8a-b03e-3397e47e5540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83b1fd0a-2728-4e8a-b03e-3397e47e5540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_23fa3dce-16a5-4d54-bdc7-72c70bdb289b" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_23fa3dce-16a5-4d54-bdc7-72c70bdb289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_6699c983-bd9d-4ca7-a266-d219ac10313f" xlink:href="amed-20220630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_6699c983-bd9d-4ca7-a266-d219ac10313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_556b9053-dea7-4c0a-b10e-ba5e646665fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_556b9053-dea7-4c0a-b10e-ba5e646665fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_900e4396-4596-4fd9-9d72-c4dbb58b2b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_900e4396-4596-4fd9-9d72-c4dbb58b2b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f949a36c-c837-41f1-b3c9-7363da8f005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f949a36c-c837-41f1-b3c9-7363da8f005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93fd325b-ea9b-448e-a80d-c110cad94772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93fd325b-ea9b-448e-a80d-c110cad94772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c91db251-735e-4bda-9fa2-1b3490650f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c91db251-735e-4bda-9fa2-1b3490650f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_ddb90372-f7cc-40cd-a804-1df9e93c0523" xlink:href="amed-20220630.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_SurrenderedShares_ddb90372-f7cc-40cd-a804-1df9e93c0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_81e5994f-658e-4460-8b1a-e1e41b4f34b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_81e5994f-658e-4460-8b1a-e1e41b4f34b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_96794c00-7158-4003-bbf2-dca42ffc2b7c" xlink:href="amed-20220630.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_96794c00-7158-4003-bbf2-dca42ffc2b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e695a3bd-9987-4620-9991-6e0c9a395917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e695a3bd-9987-4620-9991-6e0c9a395917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_a2fe32e4-48e9-46df-a6fd-8c1c8ee87a79" xlink:href="amed-20220630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_a2fe32e4-48e9-46df-a6fd-8c1c8ee87a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a49d5b63-a290-4934-b29d-d5fc79320677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_ProfitLoss_a49d5b63-a290-4934-b29d-d5fc79320677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90e4b605-8fd0-4436-8a20-47a135cf8d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90e4b605-8fd0-4436-8a20-47a135cf8d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2e64b063-2083-4444-8a8a-2b43e4838b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a98b944-1592-4114-a0f6-aa17bf3d51ef" xlink:to="loc_us-gaap_SharesOutstanding_2e64b063-2083-4444-8a8a-2b43e4838b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a6fc974-2a79-4a6a-aba7-29852308b24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a6fc974-2a79-4a6a-aba7-29852308b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_db1b1298-e98d-4b66-a976-cad1e3ea53ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a6fc974-2a79-4a6a-aba7-29852308b24a" xlink:to="loc_us-gaap_ProfitLoss_db1b1298-e98d-4b66-a976-cad1e3ea53ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a6fc974-2a79-4a6a-aba7-29852308b24a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_50a96119-b8be-420e-8814-74c0118938d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_50a96119-b8be-420e-8814-74c0118938d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_067d6099-e239-48f1-8c1b-c857b142dae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_ShareBasedCompensation_067d6099-e239-48f1-8c1b-c857b142dae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_b8086912-1829-4c14-9859-7e0f97f84535" xlink:href="amed-20220630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_b8086912-1829-4c14-9859-7e0f97f84535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8a14ebb6-a570-4379-b014-6e855da0f372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8a14ebb6-a570-4379-b014-6e855da0f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_95db35f5-c413-4ff6-b92c-c711608e0466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_95db35f5-c413-4ff6-b92c-c711608e0466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f8c3cd50-2244-4598-a7ab-13cec804548a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f8c3cd50-2244-4598-a7ab-13cec804548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_adf9e091-0b7a-4783-909a-614180068cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_adf9e091-0b7a-4783-909a-614180068cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_800f8b21-2125-450c-8a84-8556b8f3298f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_800f8b21-2125-450c-8a84-8556b8f3298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bc97b3ce-1977-413c-8501-486112990663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bc97b3ce-1977-413c-8501-486112990663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e7afc08-4dc8-4e18-b21c-807fb93036b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2c309146-9426-465d-8120-585df44891f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2c309146-9426-465d-8120-585df44891f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d7fce6e-8020-46b2-bb2b-f551446ddd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d7fce6e-8020-46b2-bb2b-f551446ddd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3d02a6e-83cc-42f7-884e-d92dbdb6999d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3d02a6e-83cc-42f7-884e-d92dbdb6999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0041675d-9820-44c6-8b73-b9df31337393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0041675d-9820-44c6-8b73-b9df31337393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_55a5b99f-727f-4b78-9169-dbd522dbccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_55a5b99f-727f-4b78-9169-dbd522dbccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267d46f6-aa55-459c-973c-7ac0d38fbc63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267d46f6-aa55-459c-973c-7ac0d38fbc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_498cddb1-dc43-450e-98e1-1d1a2534bbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_498cddb1-dc43-450e-98e1-1d1a2534bbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_3e41e30e-803e-41b9-b6e2-525c87b60b9b" xlink:href="amed-20220630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e60e76c3-0917-4e14-9a16-087104ac33da" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_3e41e30e-803e-41b9-b6e2-525c87b60b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bbaf270-33e1-4adc-84d3-8b471bf2443c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a6fc974-2a79-4a6a-aba7-29852308b24a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bbaf270-33e1-4adc-84d3-8b471bf2443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_d9012019-51f6-44dd-906e-062150f0a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_d9012019-51f6-44dd-906e-062150f0a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_488ff1d1-30f7-4bc3-89f9-d1487edcef05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_488ff1d1-30f7-4bc3-89f9-d1487edcef05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d795141d-e209-41bb-9c6e-850f63974f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d795141d-e209-41bb-9c6e-850f63974f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_af97be48-26db-467d-ae34-de584b6b9cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_af97be48-26db-467d-ae34-de584b6b9cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_223fcc59-62c1-4235-b5be-edb5b30094ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_223fcc59-62c1-4235-b5be-edb5b30094ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b1c12a6d-81c9-4c04-870e-356316e2b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b1c12a6d-81c9-4c04-870e-356316e2b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aabfb9de-5fca-46af-98c8-31bd3a27f138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e9a065b-21a7-4c53-a1d6-f02776f27788" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aabfb9de-5fca-46af-98c8-31bd3a27f138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f5ef404d-b512-477b-a0b4-fb5f9d073161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f5ef404d-b512-477b-a0b4-fb5f9d073161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_43772e21-8b48-40c0-bac9-1d773192d5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_ProceedsFromStockPlans_43772e21-8b48-40c0-bac9-1d773192d5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6f98cd99-cd1f-42bb-8868-73bced8fa7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6f98cd99-cd1f-42bb-8868-73bced8fa7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_9b593295-8fa3-44da-b205-5b09c9df1fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_9b593295-8fa3-44da-b205-5b09c9df1fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_a50b010e-2e7a-47a3-84c2-5054ae00e6cf" xlink:href="amed-20220630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_a50b010e-2e7a-47a3-84c2-5054ae00e6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_b9b754f2-1a56-4561-b89b-621e82b53f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_b9b754f2-1a56-4561-b89b-621e82b53f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e092bd1d-4626-467a-ad84-35ec4e5c021f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e092bd1d-4626-467a-ad84-35ec4e5c021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_eb0bb579-cd28-4eb3-baca-561807c3912b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_eb0bb579-cd28-4eb3-baca-561807c3912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7649f5d6-6215-4c26-a5e0-dfc2f9762e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7649f5d6-6215-4c26-a5e0-dfc2f9762e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_1809ad74-752b-4e9e-b13b-bb99230c02e6" xlink:href="amed-20220630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_1809ad74-752b-4e9e-b13b-bb99230c02e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34984e39-057b-4d00-b3cd-dc2a00a700e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e47e60a-08df-41a7-91f0-9da80e632659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34984e39-057b-4d00-b3cd-dc2a00a700e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5fd1ad01-6311-4189-8095-7fcf678754db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5fd1ad01-6311-4189-8095-7fcf678754db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d363bde4-0c0a-4f31-8a46-5b63992fa3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d363bde4-0c0a-4f31-8a46-5b63992fa3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_938e0b35-525d-4d8d-ae6d-cf013548964d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_938e0b35-525d-4d8d-ae6d-cf013548964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a8334c65-7a09-410e-b563-26861d96e007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:to="loc_us-gaap_InterestPaidNet_a8334c65-7a09-410e-b563-26861d96e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_e5469e5f-13c2-4678-97a9-5291215bfb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_e5469e5f-13c2-4678-97a9-5291215bfb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities_547461f0-c471-4605-89fc-98d825b3ce20" xlink:href="amed-20220630.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:to="loc_amed_CashPaidForOperatingLeaseLiabilities_547461f0-c471-4605-89fc-98d825b3ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities_90cc50d5-de42-4d7c-b29a-16358ffdd1a6" xlink:href="amed-20220630.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3e0d9c6f-e8b3-426b-95bb-a054d3396b50" xlink:to="loc_amed_CashPaidForFinanceLeaseLiabilities_90cc50d5-de42-4d7c-b29a-16358ffdd1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55d654d1-88a8-48f7-8a42-2420433045bb" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d2e325fd-bea3-46ec-9f56-95419e8cd250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d2e325fd-bea3-46ec-9f56-95419e8cd250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_db26e926-7359-4bc8-b7e8-ed56b7e3b26a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_db26e926-7359-4bc8-b7e8-ed56b7e3b26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_6b80940d-551c-4e35-a9f2-b81ad9ff3d2d" xlink:href="amed-20220630.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_6b80940d-551c-4e35-a9f2-b81ad9ff3d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_ff34488f-aa17-4a29-b300-d1aff1840468" xlink:href="amed-20220630.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:to="loc_amed_NonCashAccruedContingentConsideration_ff34488f-aa17-4a29-b300-d1aff1840468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution_99e90869-8c8b-4e57-8564-13fa8d4caf97" xlink:href="amed-20220630.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_303da37d-82f2-449e-95be-191d3558d6a4" xlink:to="loc_amed_NonCashNoncontrollingInterestContribution_99e90869-8c8b-4e57-8564-13fa8d4caf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20220630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8295dc80-ba92-4bda-aae2-5d11fed34927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dac50bd2-afe4-4a81-9b99-e5061f80adcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8295dc80-ba92-4bda-aae2-5d11fed34927" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dac50bd2-afe4-4a81-9b99-e5061f80adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="simple" xlink:href="amed-20220630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635bceb8-b1ba-4d27-9384-9b6388313488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_d67133bd-63a3-40ef-921c-ebfa717b4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635bceb8-b1ba-4d27-9384-9b6388313488" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_d67133bd-63a3-40ef-921c-ebfa717b4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90835ee2-8291-486a-ac03-8c49586cbeae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90835ee2-8291-486a-ac03-8c49586cbeae" xlink:to="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fa0a279-929e-4c1e-a18b-cf3ee70f32e3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_47286bd0-b67e-4a4b-a750-443dc45f7c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3550ad30-dbc6-46ec-b014-006e3a67d855" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_47286bd0-b67e-4a4b-a750-443dc45f7c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_28a9cbaf-7969-4dc2-9c1f-311ca17d3344" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dc6d8714-b345-4320-b80a-82b1558ab9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84a1a31d-0088-4991-982d-a09e44bb68d6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dc6d8714-b345-4320-b80a-82b1558ab9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a41289a-6a5b-49fd-a0ee-80cb39a11698" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_664eaa6a-d58f-4824-9f60-7ca6157959db" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:to="loc_amed_MedicareRevenueMember_664eaa6a-d58f-4824-9f60-7ca6157959db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d5abb959-1bbd-463a-9b92-89c5d9cf9c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_efa9e498-b517-4bf5-855b-98697040fb23" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d5abb959-1bbd-463a-9b92-89c5d9cf9c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c5d391e-daa1-4717-bb29-6b242d3e314e" xlink:to="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_81a9d5d1-8cc5-4fb7-b22c-52ce086d7337" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HomeHealthMember_81a9d5d1-8cc5-4fb7-b22c-52ce086d7337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_16b4f008-1c71-4df2-81ee-cbc55c1e92f4" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HospiceMember_16b4f008-1c71-4df2-81ee-cbc55c1e92f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a16c1591-0d0b-4af7-84fe-f4b9b434087d" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_PersonalCareMember_a16c1591-0d0b-4af7-84fe-f4b9b434087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_bbdd29e7-455f-49cf-8a48-a72ed7f917fc" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_607e1023-61b1-45c8-aed9-244af9430ee2" xlink:to="loc_amed_HighAcuityCareMember_bbdd29e7-455f-49cf-8a48-a72ed7f917fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f3ac9411-cb46-4d06-a66b-0d79d67d8561" xlink:to="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_5478491a-20d6-4479-bfbf-c12a12de0608" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b24b268-4a47-4e87-be4e-28a4e50f023c" xlink:to="loc_amed_MedicareRevenueMember_5478491a-20d6-4479-bfbf-c12a12de0608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7809aff7-0fb0-455e-bc7e-b4e4cf3e380a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_39717690-5d45-45a6-ad28-2953bccb576e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_972d600a-1307-4346-9abb-56128cdba639" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_39717690-5d45-45a6-ad28-2953bccb576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:href="amed-20220630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:href="amed-20220630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_0dd92786-e03b-44ff-95ae-4b3ca8d0442c" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_8771e499-ed2e-4796-bc4f-36e3996a6437" xlink:href="amed-20220630.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_4e60cb19-d852-4bef-8cbf-1a673758d862" xlink:to="loc_amed_MedalogixMember_8771e499-ed2e-4796-bc4f-36e3996a6437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84200003-653a-4168-9829-5f97653b934d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_bb5144f9-778e-42bf-b624-97cd22e61df3" xlink:href="amed-20220630.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c55e7a0-bcaf-4751-9a38-1c858322ede9" xlink:to="loc_amed_EvolutionHealthMember_bb5144f9-778e-42bf-b624-97cd22e61df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4356f0b3-e912-4ad3-bd58-173de41b0fb0" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_72171ed5-c901-4d55-8d9b-39c36464d8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_72171ed5-c901-4d55-8d9b-39c36464d8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_afce27ca-54f9-4d58-b8bb-65c72ac8a89f" xlink:href="amed-20220630.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_OperatingCareCenters_afce27ca-54f9-4d58-b8bb-65c72ac8a89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a95b26b-471e-45e6-80c5-4fbad785dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a95b26b-471e-45e6-80c5-4fbad785dbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_fc8323d2-2d97-40b9-aab8-f1370b7b7bfe" xlink:href="amed-20220630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_fc8323d2-2d97-40b9-aab8-f1370b7b7bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_68fe52ba-379e-4b48-b5ec-bef87ec34e88" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_68fe52ba-379e-4b48-b5ec-bef87ec34e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_0c98cf73-e1fc-4f17-a469-40263f97bec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_0c98cf73-e1fc-4f17-a469-40263f97bec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_127211d4-4649-4428-b175-2ec45e2e35e5" xlink:href="amed-20220630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_127211d4-4649-4428-b175-2ec45e2e35e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_096078ac-e10e-405f-b20f-c722d4def180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_096078ac-e10e-405f-b20f-c722d4def180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_3b6317f7-b89a-4780-b01f-0532d1daf0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_3b6317f7-b89a-4780-b01f-0532d1daf0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_98a52558-9121-47fc-859a-aa849acb4def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EquityMethodInvestments_98a52558-9121-47fc-859a-aa849acb4def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_22c11896-66d6-4517-9ef4-f0e44030b273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_22c11896-66d6-4517-9ef4-f0e44030b273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_b0ba9f00-3eba-406f-bcf1-d1f949bfa426" xlink:href="amed-20220630.xsd#amed_NumberOfJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_NumberOfJointVentures_b0ba9f00-3eba-406f-bcf1-d1f949bfa426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_37dd0836-941a-4de4-b7bc-c6852c9bb0da" xlink:href="amed-20220630.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_37dd0836-941a-4de4-b7bc-c6852c9bb0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdf9a8a3-eeff-4572-81fc-fd749eac2689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdf9a8a3-eeff-4572-81fc-fd749eac2689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d519357-5db5-496a-97f6-74d4ace6a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d519357-5db5-496a-97f6-74d4ace6a08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_203144a6-a8af-407e-b154-05bbc2c78841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_OtherAssetsCurrent_203144a6-a8af-407e-b154-05bbc2c78841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e3f856c4-69fb-46c2-a890-43bcdb6ea2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AssetsCurrent_e3f856c4-69fb-46c2-a890-43bcdb6ea2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bdd1e66b-1668-48a2-af5e-7ff681b97aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bdd1e66b-1668-48a2-af5e-7ff681b97aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_21ed79a7-54de-4468-a9df-aa686f887df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Goodwill_21ed79a7-54de-4468-a9df-aa686f887df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27423287-4a7a-449a-a17b-9fdb67748856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27423287-4a7a-449a-a17b-9fdb67748856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efe558ca-1cc7-4d25-a80b-177448d0368e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Assets_efe558ca-1cc7-4d25-a80b-177448d0368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c176897c-0aa4-4c57-b553-2c48361e53c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c176897c-0aa4-4c57-b553-2c48361e53c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d7ab2238-f5a7-4421-8fbe-53627a13aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d7ab2238-f5a7-4421-8fbe-53627a13aef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa5831b-c8cc-4965-87b9-fc7ca905c780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa5831b-c8cc-4965-87b9-fc7ca905c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_027578b1-f5bb-4bfe-909a-b1df7012ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_LiabilitiesCurrent_027578b1-f5bb-4bfe-909a-b1df7012ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3587ea9a-0c76-454d-b36f-76c1cff78b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3587ea9a-0c76-454d-b36f-76c1cff78b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af44b35f-3400-4d66-87e5-e150615bd989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_Liabilities_af44b35f-3400-4d66-87e5-e150615bd989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_1ead2268-56e9-4819-9bf2-935a16c8d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_789c890e-c5b3-4610-ae0c-ef69014618e0" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_1ead2268-56e9-4819-9bf2-935a16c8d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_32610601-6d4e-4814-a141-447e4845bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3cdff0c6-0798-4513-bd75-471e75198dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32610601-6d4e-4814-a141-447e4845bcc2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3cdff0c6-0798-4513-bd75-471e75198dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_47ac10bc-6126-4860-9c7b-a362b7515a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_47ac10bc-6126-4860-9c7b-a362b7515a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97ade3e7-3baf-42f2-a569-d59b6d124cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97ade3e7-3baf-42f2-a569-d59b6d124cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8e96f5df-d0dd-472a-9662-797e73ced5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_UseOfEstimates_8e96f5df-d0dd-472a-9662-797e73ced5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d115c883-555a-4427-af30-b4142ed6fa58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d115c883-555a-4427-af30-b4142ed6fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_fb002646-852a-43ba-8afd-1afde4165768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_fb002646-852a-43ba-8afd-1afde4165768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_14ac879e-2543-4d3f-b774-c326ca735851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_14ac879e-2543-4d3f-b774-c326ca735851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_ade7bde7-b158-477f-b1f1-35246d173a99" xlink:href="amed-20220630.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_ade7bde7-b158-477f-b1f1-35246d173a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9dfa621a-92e5-4dd4-8c56-600de52bba7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9dfa621a-92e5-4dd4-8c56-600de52bba7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9e72a203-baba-4c75-9e25-ea86f1647ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9e72a203-baba-4c75-9e25-ea86f1647ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_109862b1-2623-450c-bf5b-9b84756a7da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_109862b1-2623-450c-bf5b-9b84756a7da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_246dc3ca-a72a-4bbc-a5ee-f2843c24f12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_246dc3ca-a72a-4bbc-a5ee-f2843c24f12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_25823f8b-3157-464f-9729-5aa51310b423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f042d900-c677-4da1-bdd0-7181ae46c8d6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_25823f8b-3157-464f-9729-5aa51310b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0560a006-4f76-4e04-be36-740148c62609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_068a8965-1ec7-4caf-b5b2-01cefdd348b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0560a006-4f76-4e04-be36-740148c62609" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_068a8965-1ec7-4caf-b5b2-01cefdd348b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_b5dbdf2d-030c-4469-a892-a4000d50abfe" xlink:href="amed-20220630.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0560a006-4f76-4e04-be36-740148c62609" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_b5dbdf2d-030c-4469-a892-a4000d50abfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_c461e2b5-62cc-4b95-a999-c85de7e86dca" xlink:href="amed-20220630.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0560a006-4f76-4e04-be36-740148c62609" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_c461e2b5-62cc-4b95-a999-c85de7e86dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0e8d47a2-9453-4b91-b16f-8debf2d20473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0560a006-4f76-4e04-be36-740148c62609" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0e8d47a2-9453-4b91-b16f-8debf2d20473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bed0c9ec-310c-4dad-ac7c-23e0c1f8dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bed0c9ec-310c-4dad-ac7c-23e0c1f8dc51" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a700f41-3dee-4880-a358-e2e692e4ef93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_d6cd4871-c5ae-4715-ad3a-929626b1b32c" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:to="loc_amed_CompassionateCareHospiceMember_d6cd4871-c5ae-4715-ad3a-929626b1b32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_fba57afd-1c8d-497c-bde5-bde972b53a6a" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4190e35-9865-4cd2-9bec-cabeb5de1f6e" xlink:to="loc_amed_AseraCareHospiceMember_fba57afd-1c8d-497c-bde5-bde972b53a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3c9b3d14-337c-4e9f-9ac0-61fb73e72f25" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_6726d78a-1987-4ccc-af8c-9824e0dbca57" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:to="loc_amed_MedicareRevenueMember_6726d78a-1987-4ccc-af8c-9824e0dbca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f905d1a3-8247-4b9f-b4ba-2134b96996a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8179d99-a34c-4619-adac-188f51f7e51b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f905d1a3-8247-4b9f-b4ba-2134b96996a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aea94a86-4cb8-4562-a253-b5c510de15bb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_5133af04-21da-4c7f-b975-b3418aabd37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36538c17-746c-4b35-aa4a-34a311dcd80c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_5133af04-21da-4c7f-b975-b3418aabd37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:href="amed-20220630.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:href="amed-20220630.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_8869f0d0-9775-499e-9940-a29da5ad00c1" xlink:to="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_429bf51f-a6b3-4d56-af49-ba2c127fead8" xlink:href="amed-20220630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_7c80fe92-dfe8-40a4-af8a-70e740332fdb" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_429bf51f-a6b3-4d56-af49-ba2c127fead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c483e69-a0fe-49c3-85e3-133700571b75" xlink:to="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_4e7374be-d764-45cc-9df9-be413d9bf39f" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HomeHealthMember_4e7374be-d764-45cc-9df9-be413d9bf39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ad55844b-70bc-4eed-8bdb-f2c0f8fcf72c" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HospiceMember_ad55844b-70bc-4eed-8bdb-f2c0f8fcf72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_4e4077dc-c55b-4ef7-b17b-908659ca2754" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_51e41eb2-8b95-4a92-bf75-5d21cea85a9b" xlink:to="loc_amed_HighAcuityCareMember_4e4077dc-c55b-4ef7-b17b-908659ca2754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31464e15-eba6-4b9a-b799-11b665e23241" xlink:to="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4122c7e-b683-4a2c-9744-3f33798f69b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:to="loc_srt_MinimumMember_d4122c7e-b683-4a2c-9744-3f33798f69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_329d6f14-962b-4817-a668-8231030c8a1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ecdfeefb-1b67-4faf-b02f-8cea57bdaee0" xlink:to="loc_srt_MaximumMember_329d6f14-962b-4817-a668-8231030c8a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c5ce4c3d-55fe-4629-93e7-2f6b2f81912c" xlink:to="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_4f46fdd3-25e7-4960-8c58-b09335b4e8b6" xlink:href="amed-20220630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a626d44-9778-4512-a21b-7bbdf6b43701" xlink:to="loc_amed_MedicareRevenueMember_4f46fdd3-25e7-4960-8c58-b09335b4e8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c0046d55-ee74-4924-81ac-ae85ddaaf694" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85ec7f5d-d71c-4b9d-b1f4-6a4ea193067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85ec7f5d-d71c-4b9d-b1f4-6a4ea193067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_ef2840de-29e9-4c61-a681-1d6a615d1806" xlink:href="amed-20220630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_ef2840de-29e9-4c61-a681-1d6a615d1806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_4ae03912-d5ab-456f-b7ac-88294d998258" xlink:href="amed-20220630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_4ae03912-d5ab-456f-b7ac-88294d998258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_84c5c94a-f5d3-4b7d-9400-fa88e31e1123" xlink:href="amed-20220630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_84c5c94a-f5d3-4b7d-9400-fa88e31e1123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_31d0945c-dead-489a-b2f1-365394890984" xlink:href="amed-20220630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_31d0945c-dead-489a-b2f1-365394890984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_34190eed-9abc-4549-99e3-f5c967374f1a" xlink:href="amed-20220630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_34190eed-9abc-4549-99e3-f5c967374f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_44524335-bc42-4b99-9388-05f5b89a0308" xlink:href="amed-20220630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_44524335-bc42-4b99-9388-05f5b89a0308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_503ae44c-f22c-425d-a76d-75d5d7f54e05" xlink:href="amed-20220630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_SecondThresholdOfServicesRequired_503ae44c-f22c-425d-a76d-75d5d7f54e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_7fed5ef7-f4fa-4de0-94f6-e29f5561cfbd" xlink:href="amed-20220630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_7fed5ef7-f4fa-4de0-94f6-e29f5561cfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_36059833-52cd-47c4-904f-a52bfe2c49a5" xlink:href="amed-20220630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_36059833-52cd-47c4-904f-a52bfe2c49a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_663676cc-a5a0-4a29-b881-5685d8fe8602" xlink:href="amed-20220630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NonMedicareRevenueTermRates_663676cc-a5a0-4a29-b881-5685d8fe8602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_c6c09016-a57c-405c-874b-29515939baef" xlink:href="amed-20220630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_c6c09016-a57c-405c-874b-29515939baef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_00830a20-1db3-4876-9cf4-1c13de7c5571" xlink:href="amed-20220630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_00830a20-1db3-4876-9cf4-1c13de7c5571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_ceb47965-1759-4422-9d62-c33f9b2426be" xlink:href="amed-20220630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_ceb47965-1759-4422-9d62-c33f9b2426be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_c83c1e9a-70dc-44f8-8dc2-2e5ad0cf6d16" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_c83c1e9a-70dc-44f8-8dc2-2e5ad0cf6d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices_5e428d76-f758-42ac-ab45-08c841168dc6" xlink:href="amed-20220630.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b5f0126e-a0fc-4919-b533-f7ecc366d5dc" xlink:to="loc_amed_AcutePhaseForHighAcuityCareServices_5e428d76-f758-42ac-ab45-08c841168dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_30ad1af6-9a21-438b-9202-4529cc8a78c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_30ad1af6-9a21-438b-9202-4529cc8a78c1" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:href="amed-20220630.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:to="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:href="amed-20220630.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_a64c1cc7-2737-4de9-a8ea-27cb523ede23" xlink:to="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_dc26fe49-d689-4cc6-a068-9b327b776056" xlink:href="amed-20220630.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthMedicareMember_dc26fe49-d689-4cc6-a068-9b327b776056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_3e217efe-8802-4622-81f2-31f85cde7dee" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_3e217efe-8802-4622-81f2-31f85cde7dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_5b702682-dbb3-4a51-b5e1-fb030141d0e0" xlink:href="amed-20220630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_5b702682-dbb3-4a51-b5e1-fb030141d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_5a479642-1952-4d5f-8cb1-1a83ab4986c6" xlink:href="amed-20220630.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HospiceMedicareMember_5a479642-1952-4d5f-8cb1-1a83ab4986c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_46361f05-b37a-43a7-a370-9bfc8e9f67ef" xlink:href="amed-20220630.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HospiceNonMedicareMember_46361f05-b37a-43a7-a370-9bfc8e9f67ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e95ab3cf-7e30-4a5e-816e-1775c5064ff4" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_PersonalCareMember_e95ab3cf-7e30-4a5e-816e-1775c5064ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_f2acad88-d5dc-493a-8177-ebba3012a602" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_3d5bb676-341c-4c64-ac03-4b4497e83d16" xlink:to="loc_amed_HighAcuityCareMember_f2acad88-d5dc-493a-8177-ebba3012a602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_615f0b23-c332-4bbf-9e6e-54198964526f" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_ff154cc8-a7eb-4ea0-81a3-5111097b4ca6" xlink:href="amed-20220630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_cc42a0a9-321b-4921-962d-c9251d917e59" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_ff154cc8-a7eb-4ea0-81a3-5111097b4ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15be73af-74f5-416c-b0e7-631000d871c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15be73af-74f5-416c-b0e7-631000d871c3" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d81e3fbe-f532-4a55-8c05-a2a781bb545f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_73aa8076-b1a1-447b-8bc3-8159d3bbdcc7" xlink:href="amed-20220630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_AsanaHospiceAquisitionMember_73aa8076-b1a1-447b-8bc3-8159d3bbdcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_273f8c29-c7a7-49f3-840d-4a0d73682d47" xlink:href="amed-20220630.xsd#amed_COVID19PPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_COVID19PPEMember_273f8c29-c7a7-49f3-840d-4a0d73682d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5671b443-6f4b-4d8a-badc-17b7e0847126" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b4ec0942-7c47-4b4b-a93b-780d3f76ce02" xlink:to="loc_amed_AseraCareHospiceMember_5671b443-6f4b-4d8a-badc-17b7e0847126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_900a6f87-e952-47dc-bdd7-023ddb211645" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_9b47fec3-0f51-4078-81a1-4d144672b546" xlink:href="amed-20220630.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:to="loc_amed_AsanaHospiceMember_9b47fec3-0f51-4078-81a1-4d144672b546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_886981ac-0713-4fe0-960a-a7e948fc9756" xlink:href="amed-20220630.xsd#amed_VariousAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8efc9ec-8436-4d68-8830-e1b9be47b391" xlink:to="loc_amed_VariousAcquisitionsMember_886981ac-0713-4fe0-960a-a7e948fc9756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_2c94b672-7eca-438c-b95d-6ad46636d540" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8194c6bb-c0b0-4dbe-814e-e56bd568a780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8194c6bb-c0b0-4dbe-814e-e56bd568a780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_01bc942c-8e29-43e8-a08d-d75305b70414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_RestrictedCash_01bc942c-8e29-43e8-a08d-d75305b70414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06eaa6ea-5c86-4d90-ba7f-0b0d6ecdded3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5fa81e54-ff64-4998-be0a-bc409653954c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06eaa6ea-5c86-4d90-ba7f-0b0d6ecdded3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0211934b-40d7-4997-844b-0d779f6c96c9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7e93dcc1-9ca7-42e3-b038-93af640df9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_55d45747-ccd8-4f15-b627-df88f713f0c7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7e93dcc1-9ca7-42e3-b038-93af640df9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abc3d271-7e37-4335-81e5-201a08d3f28d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_6ed13c43-4c1d-4187-923e-6cf2da852d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec9e74fe-5c32-407c-8b26-fb4231414aa3" xlink:to="loc_us-gaap_AccountsReceivableMember_6ed13c43-4c1d-4187-923e-6cf2da852d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ab048c83-d634-47d6-8f2d-7c16d90020d0" xlink:to="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_023dbc20-b091-43bf-a91a-7dbbd5dd3cc0" xlink:href="amed-20220630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e49f90e6-cdc2-4ca7-acd3-6f715f70c9d7" xlink:to="loc_amed_MajorSinglePayorCustomerMember_023dbc20-b091-43bf-a91a-7dbbd5dd3cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60b783a8-cf26-4b8f-870c-703041be043d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_7c48d914-c96e-4673-b2d5-5fb5e2d92e94" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0c34634-f87c-44d2-880c-393c24f54e6a" xlink:to="loc_amed_CompassionateCareHospiceMember_7c48d914-c96e-4673-b2d5-5fb5e2d92e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c949ca02-49e6-42ff-a9e3-a7bebea9a789" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_a710c275-fd18-4b51-b764-ac1360131325" xlink:href="amed-20220630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_a710c275-fd18-4b51-b764-ac1360131325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fc31e347-65a2-4c6e-a10d-38f32f0d2e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fc31e347-65a2-4c6e-a10d-38f32f0d2e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_42e0df02-9c09-4f67-bbf9-d1351b9b4e82" xlink:href="amed-20220630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_24fe67f8-ac16-430f-b3c8-ecf5f837a1af" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_42e0df02-9c09-4f67-bbf9-d1351b9b4e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_9028adfb-a2d4-45e1-b755-44b75fea896a" xlink:href="amed-20220630.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_9028adfb-a2d4-45e1-b755-44b75fea896a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_0c408918-cfca-455f-a188-4bd27b8ef2aa" xlink:href="amed-20220630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_0c408918-cfca-455f-a188-4bd27b8ef2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_52193f29-4dc2-477d-a47c-87666c2e42e6" xlink:href="amed-20220630.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_52193f29-4dc2-477d-a47c-87666c2e42e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_636892bf-b419-4ea8-bcc2-bfb2b96817ac" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_636892bf-b419-4ea8-bcc2-bfb2b96817ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_8a9e9608-8460-430a-8c1a-3b11eae45326" xlink:href="amed-20220630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_8a9e9608-8460-430a-8c1a-3b11eae45326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_ac8cea6e-d33a-4d19-92eb-fb768b13c59b" xlink:href="amed-20220630.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_ac8cea6e-d33a-4d19-92eb-fb768b13c59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_0af1280b-8aa7-4039-a45a-9208128790fb" xlink:href="amed-20220630.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38dcfe31-5230-4339-a35a-0eaf92c309ca" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_0af1280b-8aa7-4039-a45a-9208128790fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae740adb-ce1b-4a0e-a0cd-5e835876f846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae740adb-ce1b-4a0e-a0cd-5e835876f846" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_985e5523-6e5a-4baf-8f28-1824fb66af88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_24a439ad-ac51-4a94-98dd-c95ca7b9bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_24a439ad-ac51-4a94-98dd-c95ca7b9bf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fc6d6d6b-ce1b-4d66-98fb-0a74c3ca0c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fc6d6d6b-ce1b-4d66-98fb-0a74c3ca0c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aaca399f-38f7-446a-bfdf-647828df4921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b47e2712-7f53-4c95-9e2a-cfcc0963229e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aaca399f-38f7-446a-bfdf-647828df4921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7dd65b9c-89b2-45d3-b301-c241d042e95a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96077062-c051-4785-9dac-edb813a80173" xlink:href="amed-20220630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96077062-c051-4785-9dac-edb813a80173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e86e2e27-9200-45ef-aa6c-412c0b65592e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59a68859-df0a-42f0-9f55-8a77f6317452" xlink:to="loc_us-gaap_LongTermDebtFairValue_e86e2e27-9200-45ef-aa6c-412c0b65592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8cbcd2fa-a5eb-48b6-908c-a29d4ae46705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67d43605-3bc7-49f9-a5a9-1fa976af9aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cbcd2fa-a5eb-48b6-908c-a29d4ae46705" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67d43605-3bc7-49f9-a5a9-1fa976af9aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f00233f2-2986-408b-9cf0-c4cdb783086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cbcd2fa-a5eb-48b6-908c-a29d4ae46705" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f00233f2-2986-408b-9cf0-c4cdb783086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c7a8b4ad-31ca-48b0-8db1-845e392dfefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f00233f2-2986-408b-9cf0-c4cdb783086e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c7a8b4ad-31ca-48b0-8db1-845e392dfefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_1a3ba911-92e5-4f90-8987-d79cc34ee0ee" xlink:href="amed-20220630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f00233f2-2986-408b-9cf0-c4cdb783086e" xlink:to="loc_amed_NonVestedStockAndStockUnits_1a3ba911-92e5-4f90-8987-d79cc34ee0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dc98f8a0-d245-4bae-b81e-67ec77eb04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cbcd2fa-a5eb-48b6-908c-a29d4ae46705" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dc98f8a0-d245-4bae-b81e-67ec77eb04b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cf7795c-50f3-47ec-966c-3a8a4bcc2f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cbcd2fa-a5eb-48b6-908c-a29d4ae46705" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cf7795c-50f3-47ec-966c-3a8a4bcc2f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20220630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_786f808d-cafd-45d9-a291-59d6f1a582d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock_e52a6b5c-f5f3-42bd-af51-3e50d3e7a2b7" xlink:href="amed-20220630.xsd#amed_COVID19TextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_786f808d-cafd-45d9-a291-59d6f1a582d0" xlink:to="loc_amed_COVID19TextBlock_e52a6b5c-f5f3-42bd-af51-3e50d3e7a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20220630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6998b06c-e696-4afb-b49d-c2d00237cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_82d45586-56b2-47f7-a94a-77753ff9a806" xlink:href="amed-20220630.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6998b06c-e696-4afb-b49d-c2d00237cd47" xlink:to="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_82d45586-56b2-47f7-a94a-77753ff9a806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20220630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_289873ae-ed52-4ceb-8359-781c75168c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_289873ae-ed52-4ceb-8359-781c75168c23" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5886be1f-3f1a-471e-a42d-652f90baeb2f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_164487d5-e2e1-4155-b39b-b8e20fe32d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c174ab8c-7b6e-4740-ab81-3ce7e023cc8f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_164487d5-e2e1-4155-b39b-b8e20fe32d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd394221-c453-4cfd-a45a-112dc5d5f41b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_de4e25eb-a5f9-46f7-9131-2a14e8868239" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c9f4e9f-4e70-49d9-a25e-5516ed928ecd" xlink:to="loc_amed_AseraCareHospiceMember_de4e25eb-a5f9-46f7-9131-2a14e8868239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41008152-2d73-4d33-888f-28d46e947f35" xlink:to="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_7ce6e463-1cf9-446a-9533-e65f2a4babb5" xlink:href="amed-20220630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_HomeHealthAndHospiceMember_7ce6e463-1cf9-446a-9533-e65f2a4babb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_7acf3d1a-3b5a-4695-ba9e-fc61bba83d77" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_PersonalCareMember_7acf3d1a-3b5a-4695-ba9e-fc61bba83d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1c12e611-8dad-4dc0-b314-70543c5850d9" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a7eb5ab-a7f8-4512-9195-df095bd71917" xlink:to="loc_amed_HomeHealthMember_1c12e611-8dad-4dc0-b314-70543c5850d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_dd25453a-3634-4950-9f5d-f41a33a9afa9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_d81312d8-a1d7-4877-921b-555d6b4663d9" xlink:href="amed-20220630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_5a979c51-3a22-4aee-b8b9-d659e3b8861d" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_d81312d8-a1d7-4877-921b-555d6b4663d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cb0a8f61-ac30-4029-8a37-720c06fce785" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d68c7a47-23c3-44e0-ab59-c4d4f81b094a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1d39db76-5435-4f81-bd59-239efd1ab665" xlink:to="loc_us-gaap_SubsequentEventMember_d68c7a47-23c3-44e0-ab59-c4d4f81b094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_582becc9-e2f2-4d54-bd60-7ab6f21a4b33" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_b73a8d16-7032-4618-82e8-7bc8af46d582" xlink:href="amed-20220630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_b73a8d16-7032-4618-82e8-7bc8af46d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_12b4b92d-6b1a-433b-bde7-02ba380645f9" xlink:href="amed-20220630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_12b4b92d-6b1a-433b-bde7-02ba380645f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_ec9a70a8-ea19-47a2-a74c-d5b01f1a7255" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingReceivedFromCARESAct_ec9a70a8-ea19-47a2-a74c-d5b01f1a7255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_a704a58c-a4a6-4160-8b2c-9e768a5d77e3" xlink:href="amed-20220630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_ProviderReliefFundAdvance_a704a58c-a4a6-4160-8b2c-9e768a5d77e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_3fdefd9b-376a-47fc-a0af-5ad1cad007cd" xlink:href="amed-20220630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_3fdefd9b-376a-47fc-a0af-5ad1cad007cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_45fa315b-4368-49a8-99d6-da1e0035c4b4" xlink:href="amed-20220630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_45fa315b-4368-49a8-99d6-da1e0035c4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_6274cf7e-bfb4-4a36-bb39-866539e0ba86" xlink:href="amed-20220630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_6274cf7e-bfb4-4a36-bb39-866539e0ba86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_911f39d1-587a-4671-a8df-bc6009d9749f" xlink:href="amed-20220630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_COVID19ExpensesIncurred_911f39d1-587a-4671-a8df-bc6009d9749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_9a64c136-bc2d-4bb5-ac96-d8d4b46f4121" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_9a64c136-bc2d-4bb5-ac96-d8d4b46f4121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_301cf0f3-cb77-4a17-9449-daa5cf097770" xlink:href="amed-20220630.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_301cf0f3-cb77-4a17-9449-daa5cf097770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_55a088a5-954d-45ea-85de-5decf451b127" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaid_55a088a5-954d-45ea-85de-5decf451b127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_76dafaf8-b6bc-4ab0-92b2-b1e90458b11d" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures_76dafaf8-b6bc-4ab0-92b2-b1e90458b11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_f93935d6-3b06-49b8-accc-b49d5dbc902e" xlink:href="amed-20220630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_f93935d6-3b06-49b8-accc-b49d5dbc902e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment_14153871-c747-438d-b153-cec5a3297a81" xlink:href="amed-20220630.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_CARESActInterestRepaidToGovernment_14153871-c747-438d-b153-cec5a3297a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_e4020751-253f-411b-bc61-71d0e81457db" xlink:href="amed-20220630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_e4020751-253f-411b-bc61-71d0e81457db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a5b9c948-d82f-43f6-bcdd-0b38eea5329f" xlink:href="amed-20220630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a5b9c948-d82f-43f6-bcdd-0b38eea5329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6c9c5cb4-42a4-44b0-b616-c1e175cc1cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6c9c5cb4-42a4-44b0-b616-c1e175cc1cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_abb8bacc-87df-4c47-8c73-127bd1e95a95" xlink:href="amed-20220630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_abb8bacc-87df-4c47-8c73-127bd1e95a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_1df4973b-96ec-476c-a9da-7b78b3600dda" xlink:href="amed-20220630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_1df4973b-96ec-476c-a9da-7b78b3600dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_c303b924-aad1-44fe-9f07-a4096859d882" xlink:href="amed-20220630.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1e44d3b4-62b7-4b14-8da5-987c26f8eb48" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_c303b924-aad1-44fe-9f07-a4096859d882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_23b54f68-68c7-43f2-bf44-0cf0fcf5cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e5e1af83-d713-42e3-a49c-0c741d0f854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_23b54f68-68c7-43f2-bf44-0cf0fcf5cc18" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e5e1af83-d713-42e3-a49c-0c741d0f854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e77f214a-b87a-4338-b104-88f0bb8cd7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_943f915b-37c3-47fa-a58b-8c9e5c986fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e77f214a-b87a-4338-b104-88f0bb8cd7f9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_943f915b-37c3-47fa-a58b-8c9e5c986fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_789de001-e67e-46f9-86b7-1e3fd359b775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e77f214a-b87a-4338-b104-88f0bb8cd7f9" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_789de001-e67e-46f9-86b7-1e3fd359b775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock_533bb924-3958-4d0d-9038-4811d31fda2a" xlink:href="amed-20220630.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e77f214a-b87a-4338-b104-88f0bb8cd7f9" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock_533bb924-3958-4d0d-9038-4811d31fda2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_cf70e587-6628-4068-a296-6c89be52750c" xlink:href="amed-20220630.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e77f214a-b87a-4338-b104-88f0bb8cd7f9" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_cf70e587-6628-4068-a296-6c89be52750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7b2b7d55-ddba-41c9-8fca-9fd19167abb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7b2b7d55-ddba-41c9-8fca-9fd19167abb8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef454b0a-5be5-41c1-ab9f-237d6c54243c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember_8c4d1929-4169-4c51-8dfa-a9656a3f277d" xlink:href="amed-20220630.xsd#amed_A2022NewJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_A2022NewJointVentureMember_8c4d1929-4169-4c51-8dfa-a9656a3f277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_4a25f86f-03c2-4713-8bae-17bfe775086b" xlink:href="amed-20220630.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_EvolutionHealthMember_4a25f86f-03c2-4713-8bae-17bfe775086b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_6dd7685e-7c62-42a0-ad18-3e81984b5c4d" xlink:href="amed-20220630.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_AssistedCareHomeHealthMember_6dd7685e-7c62-42a0-ad18-3e81984b5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_90b169e3-d672-45e3-92b3-456227562126" xlink:href="amed-20220630.xsd#amed_ContessaHealthMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b012058-0da0-4aa0-b620-d555758f221a" xlink:to="loc_amed_ContessaHealthMember_90b169e3-d672-45e3-92b3-456227562126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09b8e21e-3064-45e5-800b-8c4c91ce2f7b" xlink:to="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_dc1b7b20-aadb-4fb2-9d77-52866e546273" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HospiceMember_dc1b7b20-aadb-4fb2-9d77-52866e546273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_d1cf3d5b-1187-4af9-9f64-e6bf4c5e81e9" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HomeHealthMember_d1cf3d5b-1187-4af9-9f64-e6bf4c5e81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_6bf5ee8a-3b2b-47d6-b3af-62d73b218e72" xlink:href="amed-20220630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HomeHealthAndHospiceMember_6bf5ee8a-3b2b-47d6-b3af-62d73b218e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_e4a4d58a-cb77-45ec-a202-6f4b8768a432" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5b467d40-6d5d-4744-8012-3027f68fd4e4" xlink:to="loc_amed_HighAcuityCareMember_e4a4d58a-cb77-45ec-a202-6f4b8768a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66d4cf28-0270-4d54-85b8-742dea897bc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_489ffe4b-4c29-44b0-9dad-5657f3b8dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_TradeNamesMember_489ffe4b-4c29-44b0-9dad-5657f3b8dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4c89f626-c424-4c50-a1f4-673472e482c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4c89f626-c424-4c50-a1f4-673472e482c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_8c89a2df-c47a-432e-895b-15151fe600f1" xlink:href="amed-20220630.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_AcquiredNamesMember_8c89a2df-c47a-432e-895b-15151fe600f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_c5fc9c4c-985e-4f18-9b9c-008c8d6262c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_c5fc9c4c-985e-4f18-9b9c-008c8d6262c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_0e22cc6b-6894-4f2c-8ac5-a5c1401d81be" xlink:href="amed-20220630.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_MedicareLicenseMember_0e22cc6b-6894-4f2c-8ac5-a5c1401d81be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_34b0f8fa-005a-43a1-9d9b-d52492d845ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_34b0f8fa-005a-43a1-9d9b-d52492d845ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_7e042148-f9a7-432d-a582-cb63cf5ba0a3" xlink:href="amed-20220630.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_CertificatesOfNeedMember_7e042148-f9a7-432d-a582-cb63cf5ba0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_7abf1ae8-68ec-4e42-bf0f-dcb685cc72e0" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_CertificateOfNeedMember_7abf1ae8-68ec-4e42-bf0f-dcb685cc72e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb23995c-b776-4f28-af13-101a259d7119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb23995c-b776-4f28-af13-101a259d7119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember_e6cb3ade-2c1f-4d78-8f51-f690b0509c5e" xlink:href="amed-20220630.xsd#amed_LicensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_909954be-df15-433b-b6bc-988745f0a117" xlink:to="loc_amed_LicensesMember_e6cb3ade-2c1f-4d78-8f51-f690b0509c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a9a571c9-a430-4996-85a6-15cfb7878b2d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_d9bf9d75-f817-41b6-81c5-6e511e1c546d" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_CertificateOfNeedMember_d9bf9d75-f817-41b6-81c5-6e511e1c546d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_3ac7eac6-c3ef-4ce0-a90c-61a4ead8591e" xlink:href="amed-20220630.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_MedicareLicenseMember_3ac7eac6-c3ef-4ce0-a90c-61a4ead8591e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember_837a4a72-69b0-4057-b53e-febc12cee692" xlink:href="amed-20220630.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7aa50ea-7244-4acc-9fae-3815a9ff31e4" xlink:to="loc_amed_CertificateOfNeedAndLicensesMember_837a4a72-69b0-4057-b53e-febc12cee692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_13142265-2ab3-4148-88e2-1341d7ca1d7b" xlink:to="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_511d0749-196d-4514-ab6e-28274c4d7207" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_TN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_TN_511d0749-196d-4514-ab6e-28274c4d7207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_05dca25d-41f9-4807-b18d-9d0247ea2c23" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_WA_05dca25d-41f9-4807-b18d-9d0247ea2c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_ae8078b9-eb13-4b43-b637-8801663acecd" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_KY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_KY_ae8078b9-eb13-4b43-b637-8801663acecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_1fc7af36-1b3b-42b4-b17b-71d0a8c5591c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_NC_1fc7af36-1b3b-42b4-b17b-71d0a8c5591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_417f97b2-9542-4cc6-b846-8c51bbdbea75" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1e3d82bf-0797-4290-b8c9-e5018c32754e" xlink:to="loc_stpr_NY_417f97b2-9542-4cc6-b846-8c51bbdbea75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f10e0e73-31e6-48ba-9e40-31d91b6c1623" xlink:to="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76afb06a-d0b1-4e75-a10a-bcf0921fc6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92b31031-6156-41d5-b7ee-67142aaf440e" xlink:to="loc_srt_MaximumMember_76afb06a-d0b1-4e75-a10a-bcf0921fc6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_f4e58eff-4daf-498e-b94d-afb7d0126ea6" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember_8b856ffb-1264-41d6-80e7-0c818cb0b6f3" xlink:href="amed-20220630.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain_e11e2ab3-c695-427e-b900-87fc885ad389" xlink:to="loc_amed_PotentialClosingPaymentAdjustmentMember_8b856ffb-1264-41d6-80e7-0c818cb0b6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_904d6ae4-5d75-489e-b1c0-4d37db515196" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_4f63ef58-bf2b-4610-9133-0eb7ca82ea6d" xlink:href="amed-20220630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_PercentageofSharesOutstanding_4f63ef58-bf2b-4610-9133-0eb7ca82ea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1aac9734-8c80-45d9-b0f7-1d938577762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1aac9734-8c80-45d9-b0f7-1d938577762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_05f4eb77-62ea-40fe-afef-1e579f300ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_05f4eb77-62ea-40fe-afef-1e579f300ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_44b12acf-589e-4063-b510-c735871cb770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_44b12acf-589e-4063-b510-c735871cb770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_10edbcea-681d-440a-8d80-3206aec695c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_10edbcea-681d-440a-8d80-3206aec695c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_b7df3e1d-b642-4594-bc99-1a6b56659bd4" xlink:href="amed-20220630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_b7df3e1d-b642-4594-bc99-1a6b56659bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_89867aa1-3ce5-4a4e-b3af-4419ae4924b5" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_89867aa1-3ce5-4a4e-b3af-4419ae4924b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a6850051-bec4-4193-82a3-7dbd8a5a0707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a6850051-bec4-4193-82a3-7dbd8a5a0707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_594e36fc-5726-4755-aba3-c509d418a8bc" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_594e36fc-5726-4755-aba3-c509d418a8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1b408ab9-c1a1-4ffb-a2fc-e691b0a19c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1b408ab9-c1a1-4ffb-a2fc-e691b0a19c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_bb257c4a-4494-4dda-b49b-f5933e85943d" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_bb257c4a-4494-4dda-b49b-f5933e85943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9d8b3cdf-a5d9-48cc-a69a-de0c2e63adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9d8b3cdf-a5d9-48cc-a69a-de0c2e63adaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_8e1eacf3-edfd-4800-9cd5-6b270b3c4358" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_8e1eacf3-edfd-4800-9cd5-6b270b3c4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9c34cf31-b4a7-4bbc-9ec2-a41f5aaade85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9c34cf31-b4a7-4bbc-9ec2-a41f5aaade85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_941adf4e-2a8a-49aa-8904-8c4b234ef57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_941adf4e-2a8a-49aa-8904-8c4b234ef57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_e5e9fd4f-40d4-43f0-a2a9-abc7979e946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_e5e9fd4f-40d4-43f0-a2a9-abc7979e946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9311c084-4ea2-4a9e-aa2c-b0534c0ec8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9311c084-4ea2-4a9e-aa2c-b0534c0ec8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_56773342-6bb3-4918-be18-c0baf89dafb8" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_56773342-6bb3-4918-be18-c0baf89dafb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_37d7bdaa-4aed-48be-80fe-2565189faf8e" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_37d7bdaa-4aed-48be-80fe-2565189faf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_49f251f0-4519-4295-bd36-21c095fbc2a7" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_49f251f0-4519-4295-bd36-21c095fbc2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0aa9a0cd-c2df-475c-b5ac-0302439d103b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0aa9a0cd-c2df-475c-b5ac-0302439d103b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_bb89d403-82e6-4822-b4af-92a2050e1d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_bb89d403-82e6-4822-b4af-92a2050e1d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0124f173-c71f-4752-bed3-60646578d0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0124f173-c71f-4752-bed3-60646578d0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e055a34a-2f0d-4d3e-a864-a0b52a552929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e055a34a-2f0d-4d3e-a864-a0b52a552929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0782235d-484d-4ff9-a726-0eb3d13499d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0782235d-484d-4ff9-a726-0eb3d13499d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_80fb98b6-17f7-426b-8fb8-dfe5bac56de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_80fb98b6-17f7-426b-8fb8-dfe5bac56de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_aa258de9-7359-4b6b-97ea-96be3597bd01" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_aa258de9-7359-4b6b-97ea-96be3597bd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_5b633470-7927-4ada-9c08-d5ea8500579b" xlink:href="amed-20220630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_5b633470-7927-4ada-9c08-d5ea8500579b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_26f4ca97-7be2-401f-a3e5-1c58313c0920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_26f4ca97-7be2-401f-a3e5-1c58313c0920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1f6b4fe9-24e4-480b-9070-d2ea008279bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1f6b4fe9-24e4-480b-9070-d2ea008279bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3d487774-db17-4eb9-8f34-9d507908a677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3d487774-db17-4eb9-8f34-9d507908a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_43f42a4d-c8a2-49a6-bcfc-3ac6dd3b97b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_43f42a4d-c8a2-49a6-bcfc-3ac6dd3b97b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_067bd89a-7f3a-4f10-ac6b-63c6fc8fd491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_067bd89a-7f3a-4f10-ac6b-63c6fc8fd491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_5e0f1bfb-407b-45ff-b300-5ee5ef7e3dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_5e0f1bfb-407b-45ff-b300-5ee5ef7e3dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_475ec98e-d44a-45d0-a07d-2790abbfb98c" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_475ec98e-d44a-45d0-a07d-2790abbfb98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_10928db5-aa1b-4e97-b175-3adc52082c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_10928db5-aa1b-4e97-b175-3adc52082c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_9abd023f-d7ca-449f-9de1-c510b740bb39" xlink:href="amed-20220630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_9abd023f-d7ca-449f-9de1-c510b740bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_b8b32303-b6f7-4349-8bd8-eda6122d9f0a" xlink:href="amed-20220630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_b8b32303-b6f7-4349-8bd8-eda6122d9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_fbf66aec-9972-4ca5-b107-a320422fb64c" xlink:href="amed-20220630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_fbf66aec-9972-4ca5-b107-a320422fb64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ea8e3323-f84a-428e-82f9-e2eec6fff101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ea8e3323-f84a-428e-82f9-e2eec6fff101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_44168d90-1584-4691-b790-027f6d1483b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_us-gaap_RestrictedCash_44168d90-1584-4691-b790-027f6d1483b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_78f7d4d7-af94-4863-8ad4-8697b824add8" xlink:href="amed-20220630.xsd#amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings_78f7d4d7-af94-4863-8ad4-8697b824add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_1bc3e4c1-c713-4bc1-8ed0-d7d3132c1e88" xlink:href="amed-20220630.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_09c971e4-ebb8-4551-b6ce-fde6c1d1cf8e" xlink:to="loc_amed_NonCashAccruedContingentConsideration_1bc3e4c1-c713-4bc1-8ed0-d7d3132c1e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#ACQUISITIONSProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_550d620c-67bd-4f50-bf31-18261fda98f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_550d620c-67bd-4f50-bf31-18261fda98f4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86f5bb20-7a3a-4193-9221-4444ad3ed9f6" xlink:to="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6f3d452c-1a57-49bf-9960-d613a4e73db3" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e8d66e38-dbaf-4318-95f6-5c4eb10dcdd4" xlink:to="loc_amed_HospiceMember_6f3d452c-1a57-49bf-9960-d613a4e73db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98370534-db14-46e8-8b05-081adff10493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_a10f96db-83b7-4a42-91ee-d28d04ec53fb" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:to="loc_amed_CompassionateCareHospiceMember_a10f96db-83b7-4a42-91ee-d28d04ec53fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_988e3fa0-c1fd-4d72-abed-d75ca76f354f" xlink:href="amed-20220630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa945669-f2e4-4684-98bc-90a22e86da52" xlink:to="loc_amed_AseraCareHospiceMember_988e3fa0-c1fd-4d72-abed-d75ca76f354f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4793052f-57f5-423e-a296-f41c796c7e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_acae3b46-b463-4a29-abf7-57a7ee7e39b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4793052f-57f5-423e-a296-f41c796c7e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_da583019-2d2d-4fbc-9ecd-0c74a27bb378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6369a2e7-a916-438b-80be-ece5765032e9" xlink:to="loc_srt_OwnershipDomain_da583019-2d2d-4fbc-9ecd-0c74a27bb378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a04af40a-92c1-4030-b36d-64a6bf487d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14c81301-b788-41de-8365-39f720e03ce5" xlink:to="loc_us-gaap_ClassOfStockDomain_a04af40a-92c1-4030-b36d-64a6bf487d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e610c9a2-61d2-4bf4-882a-364f190349fd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_374b28ee-ef55-4a70-b611-8ef4def277b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_374b28ee-ef55-4a70-b611-8ef4def277b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_cc79ceb1-7ae8-43b1-a1e5-3c6f27c1beac" xlink:href="amed-20220630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_cc79ceb1-7ae8-43b1-a1e5-3c6f27c1beac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4fc230b0-6f8c-4bfe-918b-0dae6a5ffff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4fc230b0-6f8c-4bfe-918b-0dae6a5ffff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3fc21735-eb9d-4346-b644-e0f9905e4cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3fc21735-eb9d-4346-b644-e0f9905e4cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_815ccf86-61da-4a58-a4ec-b0ed4c735a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f811b010-3f37-4b6b-ad6a-9934cd393add" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_815ccf86-61da-4a58-a4ec-b0ed4c735a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_324d00f6-a57d-4035-b775-d8d9b77da5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_76b16d55-302f-491f-864b-db87b9f77d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_324d00f6-a57d-4035-b775-d8d9b77da5b6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_76b16d55-302f-491f-864b-db87b9f77d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4ef7b033-d32c-4431-a62b-f7183c37add6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_55753dc2-b74e-4989-95b2-9691b9274795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ef7b033-d32c-4431-a62b-f7183c37add6" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_55753dc2-b74e-4989-95b2-9691b9274795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_6039d631-cbc5-4874-a75b-a7a2d788636e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ef7b033-d32c-4431-a62b-f7183c37add6" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_6039d631-cbc5-4874-a75b-a7a2d788636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_177f98a0-4101-4755-8d12-32d6badd3a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_177f98a0-4101-4755-8d12-32d6badd3a57" xlink:to="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_70169b66-5c93-4002-ab68-a419cd40f762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_61722fc0-7ce4-4fad-8f94-fa61be7ea8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_LoansPayableMember_61722fc0-7ce4-4fad-8f94-fa61be7ea8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_169f0d19-e508-44e3-afe0-5f9b79246df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_169f0d19-e508-44e3-afe0-5f9b79246df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_b8ff0165-4b2d-4e46-9836-ff4e6c6d87a4" xlink:href="amed-20220630.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_amed_PromissoryNotesMember_b8ff0165-4b2d-4e46-9836-ff4e6c6d87a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_628a7e7e-003c-44d9-a21b-384a58dc3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1013ac2-f4bc-45c0-b2bf-b9000fde4f02" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_628a7e7e-003c-44d9-a21b-384a58dc3d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f9a70d4-92da-422b-acad-166a7cb64123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_5934dbb5-b45a-4b61-a434-41b8035654e9" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_5934dbb5-b45a-4b61-a434-41b8035654e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_415fb63a-b65e-4bd3-b665-36f9239ac61d" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_415fb63a-b65e-4bd3-b665-36f9239ac61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_1a5dfc2a-b8a0-49a0-9d97-e4c7556b7240" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8aa575b8-4065-4e40-884e-c3064347647e" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_1a5dfc2a-b8a0-49a0-9d97-e4c7556b7240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_521b92d4-a5dd-471e-971f-264a42e90182" xlink:to="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_01f64ac2-c6d8-482b-8fcd-7b823204561d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_82797904-8a4f-4974-bcca-0e4f7d88073c" xlink:to="loc_us-gaap_EurodollarMember_01f64ac2-c6d8-482b-8fcd-7b823204561d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4d7dab-b3dc-4aa7-a2cc-e411921ca3a4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f4c09efa-444c-4cf0-92de-9aadfb309636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f4c09efa-444c-4cf0-92de-9aadfb309636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ffc4a35e-1088-47cf-a079-c581eb71f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ffc4a35e-1088-47cf-a079-c581eb71f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_023801f3-7581-4cf6-90e3-7f73513c58da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebt_023801f3-7581-4cf6-90e3-7f73513c58da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_af3d6a4a-2ddf-4605-a9e8-21c8217acf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebtCurrent_af3d6a4a-2ddf-4605-a9e8-21c8217acf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cf7c38b7-dab4-4081-9aa7-6b2ac4d5b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3a3c53dd-72bd-4959-a7c4-f0e26ae581e9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cf7c38b7-dab4-4081-9aa7-6b2ac4d5b7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4acdf166-0c0c-44e3-b7b1-ad4d68547ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4acdf166-0c0c-44e3-b7b1-ad4d68547ac5" xlink:to="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b030be6-78eb-4ab9-9c41-3f67255eb42c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_62d2cb06-c6ca-41c3-a389-57bfa8fe0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:to="loc_us-gaap_LoansPayableMember_62d2cb06-c6ca-41c3-a389-57bfa8fe0f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5ece1311-d2c6-4922-828c-7cae5fb6cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d3ed573-c16b-4c3f-aaf4-0fac1e19fdd8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5ece1311-d2c6-4922-828c-7cae5fb6cecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8584d650-b31a-407a-82ad-95a79399f583" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_720bfb57-59ff-4292-8465-e85051795143" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_720bfb57-59ff-4292-8465-e85051795143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_90a4676f-e6fe-4bf4-965c-fd864b491387" xlink:href="amed-20220630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_90a4676f-e6fe-4bf4-965c-fd864b491387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_49bdb15f-b6b5-475a-b684-bfb1682cbe5f" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_49bdb15f-b6b5-475a-b684-bfb1682cbe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c0054cc2-9530-472a-a958-c804f86560b4" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_334f6b89-a44d-4538-99a5-e24f1c3cb0d2" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c0054cc2-9530-472a-a958-c804f86560b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_72b41f36-f445-4874-8f7a-3f92ef69e655" xlink:to="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_322be017-096f-4618-a53f-e1eb4ca34b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6462feca-bb20-4bda-a058-efce06249d92" xlink:to="loc_us-gaap_EurodollarMember_322be017-096f-4618-a53f-e1eb4ca34b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c0d70a2-8d9f-40b0-8438-6bab6413197e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22a4dc91-90e1-487d-9904-a69a72f791a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22a4dc91-90e1-487d-9904-a69a72f791a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_9598cf28-031f-4811-b73a-367bdffd1496" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_9598cf28-031f-4811-b73a-367bdffd1496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_b1219b12-4253-445c-9042-1bebe3ea50a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d47c360d-d4cc-425a-8ac7-fe30ab5e8eb1" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_b1219b12-4253-445c-9042-1bebe3ea50a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_82c9a041-4615-4d99-a2c3-0e2a1be08697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_82c9a041-4615-4d99-a2c3-0e2a1be08697" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a28f23ce-1c39-4204-aa2c-b81c7539dd61" xlink:to="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b47a1e97-b41a-4d3d-a436-65fdbe2d7263" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:to="loc_srt_MinimumMember_b47a1e97-b41a-4d3d-a436-65fdbe2d7263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9833a78-8ca8-4ae6-bda6-cfed87c698c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_205300b3-20c8-4026-a1af-97307a8b3c78" xlink:to="loc_srt_MaximumMember_f9833a78-8ca8-4ae6-bda6-cfed87c698c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_51480994-e5e0-4382-851d-9bb78ec02550" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_bf7d5ae6-4da6-4013-9468-b4bc488d0f68" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_bf7d5ae6-4da6-4013-9468-b4bc488d0f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_df25f8ca-bdd5-4c47-ad6e-3fd72f061381" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_df25f8ca-bdd5-4c47-ad6e-3fd72f061381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_76deeb02-04d1-4e6c-8015-ee734a0b6175" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_76deeb02-04d1-4e6c-8015-ee734a0b6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_a4c73543-c9c0-4246-b32a-fb3b9be54e29" xlink:href="amed-20220630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_564b2975-1da5-434b-84bc-ddaa06ef515f" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_a4c73543-c9c0-4246-b32a-fb3b9be54e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_5c488f79-0671-4421-b08c-69e4f393721f" xlink:to="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_e0848df1-b53a-40e5-af95-c0d742c7206b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:to="loc_us-gaap_EurodollarMember_e0848df1-b53a-40e5-af95-c0d742c7206b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_71aa3c20-4abc-4539-94d4-c5570acd7729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8400727c-6a91-489f-8841-c39f7e223ae6" xlink:to="loc_us-gaap_BaseRateMember_71aa3c20-4abc-4539-94d4-c5570acd7729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_890ae642-c03a-4975-8ac3-40d8c9e6c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8a8da227-c7a5-4b4c-9759-fd433b24d73e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_890ae642-c03a-4975-8ac3-40d8c9e6c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f14c27d4-6617-4a98-a577-e6cc07ee1925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6a92d09f-dd64-449d-9f93-5df828ea5da9" xlink:to="loc_us-gaap_CreditFacilityDomain_f14c27d4-6617-4a98-a577-e6cc07ee1925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5c2ebc56-bb1f-4127-9be1-f33458b83201" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_e6bcee05-2d85-44b0-bb5d-0777d005d87b" xlink:href="amed-20220630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_amed_ConsolidatedLeverageRatio_e6bcee05-2d85-44b0-bb5d-0777d005d87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3e8b675a-9f04-4c76-9b72-dece2bbcb13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3e8b675a-9f04-4c76-9b72-dece2bbcb13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_9827ceb2-c240-4e24-9c55-93bd96ed2135" xlink:href="amed-20220630.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_amed_LetterOfCreditFee_9827ceb2-c240-4e24-9c55-93bd96ed2135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6012ed7e-be28-4755-a3a0-caf7ef3c359e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_014020ca-8b3f-44a0-95a3-65c096a3294b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6012ed7e-be28-4755-a3a0-caf7ef3c359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a1428e98-2d03-44ae-b04b-8ac7008c5649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a1428e98-2d03-44ae-b04b-8ac7008c5649" xlink:to="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2c79b19-7a6a-4a37-af9f-a3fc4c602ee4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_320c5839-ea08-4d06-9869-3c60ff1cb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_16bc9aeb-e04a-4a16-ad9a-8a4ae36ec6b8" xlink:to="loc_us-gaap_SubsequentEventMember_320c5839-ea08-4d06-9869-3c60ff1cb64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_096c659f-1388-4b29-a948-573f50365e19" xlink:to="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9af4039-a1ca-4393-80d7-00b1cf536e9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e685f524-a89f-4165-83d6-13642d302fdf" xlink:to="loc_srt_MinimumMember_e9af4039-a1ca-4393-80d7-00b1cf536e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6f5dbd42-8776-45a5-ac48-409143a9c29f" xlink:to="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7732a456-7efd-4969-836a-f09a5bbf3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:to="loc_us-gaap_BaseRateMember_7732a456-7efd-4969-836a-f09a5bbf3ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9d4b7b26-8686-4d12-b2bd-5c549eb4971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1160c21f-6ad1-4fda-bb9d-3f76673dbc2c" xlink:to="loc_us-gaap_EurodollarMember_9d4b7b26-8686-4d12-b2bd-5c549eb4971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ec46379-065d-4234-8c74-0e673c3996e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_26abd8c8-723f-4f8d-83c4-3cf5699f7d49" xlink:href="amed-20220630.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_SwingLineLoanMember_26abd8c8-723f-4f8d-83c4-3cf5699f7d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9005a826-6529-4943-836a-5e55e260d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LetterOfCreditMember_9005a826-6529-4943-836a-5e55e260d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c34bfbc9-bc10-43cd-867e-a232be45d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LoansPayableMember_c34bfbc9-bc10-43cd-867e-a232be45d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bc76dec3-3f9b-47c5-8d01-4b1afed0e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bc76dec3-3f9b-47c5-8d01-4b1afed0e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_eed078d9-de36-4dc7-a849-f4219076fbff" xlink:href="amed-20220630.xsd#amed_PriorCreditAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_PriorCreditAgreementMember_eed078d9-de36-4dc7-a849-f4219076fbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_29af52e9-95ea-4d55-91c3-20fe1e70c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_us-gaap_LineOfCreditMember_29af52e9-95ea-4d55-91c3-20fe1e70c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c3616bd5-df0a-4e7a-ab72-230a0c01f9a9" xlink:href="amed-20220630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_AmendedCreditAgreementMember_c3616bd5-df0a-4e7a-ab72-230a0c01f9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_a5d0d513-81aa-4b5c-9fc1-abddbb263866" xlink:href="amed-20220630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d783fd0c-fcb4-420d-875a-6d9e0744616d" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_a5d0d513-81aa-4b5c-9fc1-abddbb263866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5fd1b858-d66b-4a2e-9bd2-6f84e5b1d82c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_e9aeb71e-338c-4419-af03-2f8eb61e0dc4" xlink:href="amed-20220630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_AmendedCreditAgreementMember_e9aeb71e-338c-4419-af03-2f8eb61e0dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_301b518f-fe9f-4dfc-95a9-c0b8cae89203" xlink:href="amed-20220630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_OneHundredMillionTermLoanMember_301b518f-fe9f-4dfc-95a9-c0b8cae89203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_6a709682-e9d5-4994-bc4e-854e7e488c87" xlink:href="amed-20220630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_6a709682-e9d5-4994-bc4e-854e7e488c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_d1e0627e-87ac-4f92-aabb-2f873c5a4f9c" xlink:href="amed-20220630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_d1e0627e-87ac-4f92-aabb-2f873c5a4f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a00d4084-3a72-411f-9a2e-cfd6a87535fd" xlink:href="amed-20220630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a00d4084-3a72-411f-9a2e-cfd6a87535fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_6bed0cbc-73fb-4934-be7b-3e5998140fc7" xlink:href="amed-20220630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_6bed0cbc-73fb-4934-be7b-3e5998140fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_f6c085d1-5214-44da-b11c-f60eced6a573" xlink:href="amed-20220630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_701ffa8b-420a-4f34-8045-f16582ebea88" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_f6c085d1-5214-44da-b11c-f60eced6a573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1a4794-4ab8-4713-b6db-664216317c16" xlink:to="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_21cae38f-56ff-41db-9133-e76881b7346c" xlink:href="amed-20220630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_21cae38f-56ff-41db-9133-e76881b7346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_7460e256-4324-403d-aaf0-7d5d99602abe" xlink:href="amed-20220630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_7460e256-4324-403d-aaf0-7d5d99602abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0a1d4a46-35c8-4a64-b7f7-2c6667cb4a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0a1d4a46-35c8-4a64-b7f7-2c6667cb4a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_09f917a8-9d9e-4525-a820-d64431d4f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_09f917a8-9d9e-4525-a820-d64431d4f10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_9a9a6945-895d-40f3-9ba1-cba413e96635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_9a9a6945-895d-40f3-9ba1-cba413e96635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_aed4564e-e0e0-4ae1-bb36-981792688744" xlink:href="amed-20220630.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_TotalLeverageRatio_aed4564e-e0e0-4ae1-bb36-981792688744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_5e405e04-0731-4038-83de-6fe000cc12a9" xlink:href="amed-20220630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_5e405e04-0731-4038-83de-6fe000cc12a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f1172f11-c6ee-4c9d-b2e3-e1d1a02c784b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f1172f11-c6ee-4c9d-b2e3-e1d1a02c784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_50383045-b6f5-4f49-86df-2afd3841dba9" xlink:href="amed-20220630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_RevolvingCreditFacilityTotal_50383045-b6f5-4f49-86df-2afd3841dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_bb32cba5-6558-44b7-b23b-dfcafa498931" xlink:href="amed-20220630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_bb32cba5-6558-44b7-b23b-dfcafa498931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_e764e1e9-4fde-40cf-86bb-031aac463090" xlink:href="amed-20220630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_e764e1e9-4fde-40cf-86bb-031aac463090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_30b8d00d-b8b1-4a56-96b5-d0c097c01cf8" xlink:href="amed-20220630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_30b8d00d-b8b1-4a56-96b5-d0c097c01cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_9dbc579b-f4f7-4cff-aa1a-f597038bee90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_9dbc579b-f4f7-4cff-aa1a-f597038bee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1e2649d0-cc84-43d7-8e10-4221584838c6" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1e2649d0-cc84-43d7-8e10-4221584838c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_a33fefa0-e22e-4d5d-83d5-907f5b7d67bf" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_a33fefa0-e22e-4d5d-83d5-907f5b7d67bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_050eaeb0-e195-4c88-8c15-20c23ca044da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_050eaeb0-e195-4c88-8c15-20c23ca044da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_ae61cbd7-7be6-4652-bd43-c221f98ba4d9" xlink:href="amed-20220630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_ae61cbd7-7be6-4652-bd43-c221f98ba4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_69b4bb6c-42dc-4266-afe4-e23d39b28913" xlink:href="amed-20220630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_69b4bb6c-42dc-4266-afe4-e23d39b28913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0eb59d74-b778-4ae4-a2ce-2da06a773aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0eb59d74-b778-4ae4-a2ce-2da06a773aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_326bddcf-98b1-4e6a-b55c-15d46baac2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_326bddcf-98b1-4e6a-b55c-15d46baac2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b6c86f3c-38c0-4a74-89eb-693d42e2c150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b6c86f3c-38c0-4a74-89eb-693d42e2c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_5eb164a2-308f-4688-b621-9b1ad9c122c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_5eb164a2-308f-4688-b621-9b1ad9c122c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f28dfe89-56f5-47be-98bc-f9837772725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f28dfe89-56f5-47be-98bc-f9837772725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_58798233-d1a9-485b-91b9-2230f0bb5839" xlink:href="amed-20220630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_58798233-d1a9-485b-91b9-2230f0bb5839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2dabb69a-e23b-4e10-98c7-bc92e23114ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_96a8b54a-f2e9-4a0f-b1c1-500687a31d78" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2dabb69a-e23b-4e10-98c7-bc92e23114ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20220630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_95017dae-16cd-4017-a6c4-b0d6bfa171ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8b24e822-09ac-447b-ae43-24fd7e24d978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_95017dae-16cd-4017-a6c4-b0d6bfa171ec" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8b24e822-09ac-447b-ae43-24fd7e24d978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b3150d7-32bd-4baa-a20d-c6db9a305a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b3150d7-32bd-4baa-a20d-c6db9a305a06" xlink:to="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:href="amed-20220630.xsd#amed_PayorsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:href="amed-20220630.xsd#amed_PayorsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_edf4264d-5df2-4770-865f-cf4bfc8fce89" xlink:to="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_460caa78-3d20-413b-a964-99d3e0aea5c0" xlink:href="amed-20220630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_b031359b-bb80-4f1f-8b07-48b1eb209646" xlink:to="loc_amed_CompanysinsurancecarriersMember_460caa78-3d20-413b-a964-99d3e0aea5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3cc8374b-ba5e-42d7-a98f-c69d6997525e" xlink:to="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_8ff7d462-5cd0-4112-8eeb-62fb690cc26e" xlink:href="amed-20220630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_UsDepartmentOfJusticeMember_8ff7d462-5cd0-4112-8eeb-62fb690cc26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_e2beaf1d-904f-4422-8c41-1cd196748253" xlink:href="amed-20220630.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_AmedisysCIAMember_e2beaf1d-904f-4422-8c41-1cd196748253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_0dd4d6b3-3d4d-4bff-bac9-c5aadfd0eabc" xlink:href="amed-20220630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_0dd4d6b3-3d4d-4bff-bac9-c5aadfd0eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_0b984331-138f-4466-9385-d94c2a5defc9" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_0b984331-138f-4466-9385-d94c2a5defc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_029eb538-809e-4b56-8ee1-63e3f3cb2ebc" xlink:href="amed-20220630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_029eb538-809e-4b56-8ee1-63e3f3cb2ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_884615a8-2161-4b5d-a7c4-32a510cb6ad3" xlink:href="amed-20220630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_932f5799-542d-4c6f-b735-a680d3093f84" xlink:to="loc_amed_InternalAuditComplianceReviewMember_884615a8-2161-4b5d-a7c4-32a510cb6ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_97a77b49-6603-43cc-881c-0f3821d26302" xlink:to="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4e19492d-bdfb-4a4e-8d39-2f9f7052e8d1" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_MA_4e19492d-bdfb-4a4e-8d39-2f9f7052e8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_273df6f1-478d-437b-9795-15dc2d6faa9d" xlink:href="amed-20220630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_amed_MorgantownWestVirginiaMember_273df6f1-478d-437b-9795-15dc2d6faa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_e935845d-b97c-41bd-ad24-3dfdf53ff938" xlink:href="amed-20220630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_amed_ParkersburgWestVirginiaMember_e935845d-b97c-41bd-ad24-3dfdf53ff938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_230d2165-ac90-4647-8cca-fb9ea804327a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_SC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_SC_230d2165-ac90-4647-8cca-fb9ea804327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_941b29af-df98-435d-aefd-03f35193e17c" xlink:to="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_20228234-8561-4761-98a5-2a1664f4c5c0" xlink:href="amed-20220630.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:to="loc_amed_LakelandFloridaMember_20228234-8561-4761-98a5-2a1664f4c5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_f3ca6084-785e-41c0-a953-ad26404a7157" xlink:href="amed-20220630.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_1fc65d1b-42e1-433c-bab8-63acb822b49b" xlink:to="loc_amed_ClearwaterFloridaMember_f3ca6084-785e-41c0-a953-ad26404a7157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de42af6a-a7bc-44d3-8e74-b12c146a86fc" xlink:to="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_37827368-a358-4a2e-be57-0c1f7e723cb7" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:to="loc_amed_HospiceMember_37827368-a358-4a2e-be57-0c1f7e723cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_16428748-3814-4190-8369-1651c5890d5a" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8ee1cba5-ac56-4381-9156-322911feb09b" xlink:to="loc_amed_HomeHealthMember_16428748-3814-4190-8369-1651c5890d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d947c4b5-2bbd-4dac-add0-6367dff05f5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_dd9ab3e6-1dde-4a6e-bfc9-684af7390c78" xlink:href="amed-20220630.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e392085b-166f-4178-a10c-8e92cfe4f597" xlink:to="loc_amed_InfinityHomeCareMember_dd9ab3e6-1dde-4a6e-bfc9-684af7390c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50694ff1-2570-4c10-99cd-a2134c772549" xlink:to="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_dec6e19a-e3a1-40fb-9f01-c91c30d5f0bf" xlink:href="amed-20220630.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:to="loc_amed_ExtrapolatedMember_dec6e19a-e3a1-40fb-9f01-c91c30d5f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_b9638783-559a-4a0f-aec8-133090a435d5" xlink:href="amed-20220630.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_99509a46-c12e-4d2f-8551-722afb05be67" xlink:to="loc_amed_UnfavorableMember_b9638783-559a-4a0f-aec8-133090a435d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_815c94e4-67f8-4d47-a921-98cf431ed0be" xlink:to="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46d5bb30-aa11-4d05-b566-7cbb9636a4aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:to="loc_srt_MinimumMember_46d5bb30-aa11-4d05-b566-7cbb9636a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db755d81-01ed-4f2e-baf4-70260a0e6348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3815cbec-ea2a-440f-8d8f-b9412aa37e1c" xlink:to="loc_srt_MaximumMember_db755d81-01ed-4f2e-baf4-70260a0e6348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_14f4b77d-0d34-445c-b961-48733c594c87" xlink:to="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_696a8f37-37c1-40d3-92fb-21443000891d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_696a8f37-37c1-40d3-92fb-21443000891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_f5723948-3c26-4155-abd7-6418b9ce2832" xlink:href="amed-20220630.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_Numberofpatients_f5723948-3c26-4155-abd7-6418b9ce2832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_3a45fa37-7ce9-4f84-9b3f-0a9e83a4f56b" xlink:href="amed-20220630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_3a45fa37-7ce9-4f84-9b3f-0a9e83a4f56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_907ce932-1e0e-446c-8725-6014effdf7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_907ce932-1e0e-446c-8725-6014effdf7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_d467f370-44e9-4f08-b57e-1bc6900e2794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_d467f370-44e9-4f08-b57e-1bc6900e2794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_0f91a545-d0f9-4d3a-bcc7-a4a8fb3011d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_0f91a545-d0f9-4d3a-bcc7-a4a8fb3011d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_c84371b9-a15c-4785-9bd8-e614f8962ccd" xlink:href="amed-20220630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_c84371b9-a15c-4785-9bd8-e614f8962ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_b39f55ec-3832-4b55-8cdf-111cb2f77da6" xlink:href="amed-20220630.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_NumberOfBeneficiaries_b39f55ec-3832-4b55-8cdf-111cb2f77da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_44997fab-5c89-44bd-a975-59275af617cd" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_44997fab-5c89-44bd-a975-59275af617cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_5a172598-1e89-45c4-b65c-cadc440f71d0" xlink:href="amed-20220630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_5a172598-1e89-45c4-b65c-cadc440f71d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_47868fde-7e34-4f73-b104-731c4400083a" xlink:href="amed-20220630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_47868fde-7e34-4f73-b104-731c4400083a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_380cb1b0-51d4-4ba6-8db5-0494f1f3987e" xlink:href="amed-20220630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_380cb1b0-51d4-4ba6-8db5-0494f1f3987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_298954e8-7ae5-4ce8-9b5e-ccaff23ceb33" xlink:href="amed-20220630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_298954e8-7ae5-4ce8-9b5e-ccaff23ceb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_0f40ada5-ad9f-42b3-9e96-a112142d472f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_0f40ada5-ad9f-42b3-9e96-a112142d472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_07d8fab5-d9f5-479c-88cf-741cfb688e6a" xlink:href="amed-20220630.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ActualClaimsPayment_07d8fab5-d9f5-479c-88cf-741cfb688e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_aa02f900-2851-407d-952e-f60a15bb7070" xlink:href="amed-20220630.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ErrorRatePercentage_aa02f900-2851-407d-952e-f60a15bb7070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_3d300e9d-a3c3-493e-8920-40b9a67bfcb5" xlink:href="amed-20220630.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_IndemnificationAmount_3d300e9d-a3c3-493e-8920-40b9a67bfcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_7a6586c3-8f4d-4da4-a51d-c3e5e3f35d84" xlink:href="amed-20220630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_FloridaZpicRevenueReduction_7a6586c3-8f4d-4da4-a51d-c3e5e3f35d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9de528e3-a32b-450e-b460-5cf2c7c43df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9de528e3-a32b-450e-b460-5cf2c7c43df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_139ca174-a577-46de-a3c9-d62618b00e4f" xlink:href="amed-20220630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_HealthInsuranceRetentionLimit_139ca174-a577-46de-a3c9-d62618b00e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_f7972b02-6ff1-4b45-80ae-76387d539854" xlink:href="amed-20220630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_f7972b02-6ff1-4b45-80ae-76387d539854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_2dbdbbaf-ed97-4145-8a7a-6b1562e1cb42" xlink:href="amed-20220630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_2dbdbbaf-ed97-4145-8a7a-6b1562e1cb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_5890509e-5e92-43a8-95e3-47814c813ff6" xlink:href="amed-20220630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_5890509e-5e92-43a8-95e3-47814c813ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_b2b8115c-93ae-4756-9810-3a1bbc38e8f6" xlink:href="amed-20220630.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7567df24-03a0-46a1-a74e-06e22a781910" xlink:to="loc_amed_ReductionToNetServiceRevenue_b2b8115c-93ae-4756-9810-3a1bbc38e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20220630.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2bb78e63-4370-401b-aef0-ee6f69b721a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b1ab9b4c-483d-499d-8980-79d6cfe56f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bb78e63-4370-401b-aef0-ee6f69b721a9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b1ab9b4c-483d-499d-8980-79d6cfe56f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20220630.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f811671-a0b4-4d9e-8dba-6d38579a7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_11c948be-8425-4438-b506-53575de9a87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f811671-a0b4-4d9e-8dba-6d38579a7ff3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_11c948be-8425-4438-b506-53575de9a87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3f174332-776e-4f53-8335-28c5abaf1cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3c5095e2-f5a7-4d2f-b9be-d06294abd20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3f174332-776e-4f53-8335-28c5abaf1cc5" xlink:to="loc_us-gaap_NumberOfReportableSegments_3c5095e2-f5a7-4d2f-b9be-d06294abd20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e5ac3aa-af3d-498f-bdf8-db552398c6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e5ac3aa-af3d-498f-bdf8-db552398c6aa" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6bc122f-28bf-4c92-807e-12d80526e114" xlink:to="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_3863f6c9-22a0-4a91-8739-56532a425c5a" xlink:href="amed-20220630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HomeHealthMember_3863f6c9-22a0-4a91-8739-56532a425c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_80e4170a-c905-4aba-8785-3c6484a47012" xlink:href="amed-20220630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HospiceMember_80e4170a-c905-4aba-8785-3c6484a47012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_5a99d51f-900e-46c0-b510-2595a5eeae34" xlink:href="amed-20220630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_PersonalCareMember_5a99d51f-900e-46c0-b510-2595a5eeae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_1a812e2c-6fa9-4e85-970e-d038c5d30e50" xlink:href="amed-20220630.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_amed_HighAcuityCareMember_1a812e2c-6fa9-4e85-970e-d038c5d30e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c9cf4c6a-397a-4812-922a-39e0ac356844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1be9c33-866a-40b4-8a5e-34d0295ad30f" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c9cf4c6a-397a-4812-922a-39e0ac356844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cbf21269-01e8-479e-950b-50289b9871e9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_81fb1172-7560-4686-b869-24735b030966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_81fb1172-7560-4686-b869-24735b030966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_985ccdb9-37df-4e01-be84-24f78522af10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_985ccdb9-37df-4e01-be84-24f78522af10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_211926c3-8b79-440f-9762-397e15127dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_211926c3-8b79-440f-9762-397e15127dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_42e56a38-879d-4c97-9faa-a892b2bb0ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_42e56a38-879d-4c97-9faa-a892b2bb0ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_76b60f43-3c81-45c5-a044-0d3d06bb43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_DepreciationAndAmortization_76b60f43-3c81-45c5-a044-0d3d06bb43e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b2542ce9-bfe0-41a7-bd7a-7ea45d600530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_CostsAndExpenses_b2542ce9-bfe0-41a7-bd7a-7ea45d600530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1557617-99c3-4290-bcf1-1e06980f1d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2dffaacd-f35b-4484-82e7-48d96e9233ee" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1557617-99c3-4290-bcf1-1e06980f1d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20220630.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_69668d79-0450-41f6-87b2-1c54937d1348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_9dcf0bbe-a157-4e11-b72e-0a9136573dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69668d79-0450-41f6-87b2-1c54937d1348" xlink:to="loc_us-gaap_TreasuryStockTextBlock_9dcf0bbe-a157-4e11-b72e-0a9136573dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fabc6d3c-fa50-4ed7-845f-beab7bed1879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fabc6d3c-fa50-4ed7-845f-beab7bed1879" xlink:to="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_264f8bde-6944-4206-9ca7-b40e6cca6df8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_7febadc7-3723-4476-9a99-f8167c09213a" xlink:href="amed-20220630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_7febadc7-3723-4476-9a99-f8167c09213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_4bba1de4-f606-439a-9418-4b02800bbc18" xlink:href="amed-20220630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_4bba1de4-f606-439a-9418-4b02800bbc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_1c6fc8ca-99ef-4e7c-aa98-6a9e4066f2f6" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_ShareRepurchaseProgramMember_1c6fc8ca-99ef-4e7c-aa98-6a9e4066f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_712cdaae-862b-458f-b4a4-4829b5a3f1ce" xlink:href="amed-20220630.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_712cdaae-862b-458f-b4a4-4829b5a3f1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_48d543b0-afb3-4adf-a1c3-eab44908c54a" xlink:href="amed-20220630.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_73ccbb06-7b70-4393-82ff-0ca4a7516b79" xlink:to="loc_amed_NewShareRepurchaseProgramMember_48d543b0-afb3-4adf-a1c3-eab44908c54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_04ddd5fc-e7c3-4365-8176-8d1146c6a0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87e5a079-877b-46d1-8649-57cf72d3479e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f02d7d96-fa2d-4c95-8d2d-57f16485b643" xlink:to="loc_us-gaap_SubsequentEventMember_87e5a079-877b-46d1-8649-57cf72d3479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:href="amed-20220630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_0d0291a1-a88f-4747-8bfa-67ebc6a22474" xlink:to="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d01fd2fd-331f-451f-b807-c6d88d5042ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d01fd2fd-331f-451f-b807-c6d88d5042ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_262656c8-b04f-4480-acbc-c0109f4b971c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_262656c8-b04f-4480-acbc-c0109f4b971c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_52d04130-28bc-43a5-9a6e-30ac10d9cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_52d04130-28bc-43a5-9a6e-30ac10d9cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_6b3b4d9e-54f1-4e1b-96cb-2736a3d0ce55" xlink:href="amed-20220630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_PercentageofSharesOutstanding_6b3b4d9e-54f1-4e1b-96cb-2736a3d0ce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bd4b293f-28de-487b-bf17-7c7c7a2a8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bd4b293f-28de-487b-bf17-7c7c7a2a8ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_b19d35e5-af24-4d00-95ed-b4c8d7f3cf33" xlink:href="amed-20220630.xsd#amed_Discountedclosingstockprice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_Discountedclosingstockprice_b19d35e5-af24-4d00-95ed-b4c8d7f3cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_9f52941f-4bcd-4df4-9261-ae44089e2cee" xlink:href="amed-20220630.xsd#amed_Percentageofclosingstockprice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_amed_Percentageofclosingstockprice_9f52941f-4bcd-4df4-9261-ae44089e2cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_abf83927-f477-449c-a301-5ad321738cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_4e9f7992-3de1-4ff3-879a-932cbf774637" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_abf83927-f477-449c-a301-5ad321738cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20220630.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4cc2f812-b45f-4968-b7f8-eda56a1d37ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7430a9cf-1f80-46df-8fbc-cf0e67b9c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4cc2f812-b45f-4968-b7f8-eda56a1d37ed" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7430a9cf-1f80-46df-8fbc-cf0e67b9c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20220630.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_52bb39dc-a837-4eec-b5fd-74396bd995cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_52bb39dc-a837-4eec-b5fd-74396bd995cd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82c296c2-8e07-44b5-982d-749aecad1e84" xlink:to="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_1b8f6ab6-96b5-4481-a605-526c33df2bff" xlink:href="amed-20220630.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_88df4b3a-7ae4-4f27-a78d-de0421f85b0c" xlink:to="loc_amed_MedalogixMember_1b8f6ab6-96b5-4481-a605-526c33df2bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0bb6d8f4-dd9b-4328-a0f5-e64d94ea5d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1790d929-6c75-46a2-96e0-808947152429" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0bb6d8f4-dd9b-4328-a0f5-e64d94ea5d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45fe805d-d066-4090-b31f-db4be061deaa" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_190aeb71-b405-49b7-9d83-5ec4186de11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2025cc82-64e4-4160-9d66-59993db4d1bf" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_190aeb71-b405-49b7-9d83-5ec4186de11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>amed-20220630_g1.jpg
<TEXT>
begin 644 amed-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
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M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N#^)D7_ "#I1_TT4_\ CI']:[RN2^(MOYGA^&8#F&<9^A!'\\5C
M65Z;,JJO!GF=%%%>6><%%%% !7H/@_P?Y/EZEJT?[S[T,##[O^TP]?0=OKT/
M!_@_R?+U+5H_WGWH8&'W?]IAZ^@[?R[BNVC1^U([*5+[4@IDTT=O"\T[K'&@
MW,S'  HFFCMX7FG=8XT&YF8X %>6^*O%4FMS&WMBT=BA^5>AD/\ >/\ 05T5
M*BIHVJ5%!!XJ\52:W.;>V+1V*'Y5Z&0_WC_05S=%%>9*3D[L\^4G)W84445)
M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
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MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
M]<15X7XF5A_B9JT445WG:%%%% '*>.?$$NEVD=G9N4N+@$LXZHGM[FO,223D
M\FNH^()<^)_G^Z(5V_3G^N:Y>O+KR<INYY]:3<V%=5X(U^2PU..PG<FUN6VJ
M"?N.>A'U/%<K4EN76ZB,7WPX*X]<\5G"3C*Z,XR<7='NM%(N=HSUQS2U[!Z@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
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M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
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MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
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MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
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MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
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MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
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M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
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M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
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M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368859196512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,443,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368858163872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,566<span></span>
</td>
<td class="nump">$ 42,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">22,198<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">305,413<span></span>
</td>
<td class="nump">274,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">15,199<span></span>
</td>
<td class="nump">10,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">25,493<span></span>
</td>
<td class="nump">25,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">394,869<span></span>
</td>
<td class="nump">356,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $100,265 and $96,937</a></td>
<td class="nump">17,847<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">107,723<span></span>
</td>
<td class="nump">101,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,289,672<span></span>
</td>
<td class="nump">1,196,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $9,109 and $19,900</a></td>
<td class="nump">106,189<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">84,686<span></span>
</td>
<td class="nump">73,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,000,986<span></span>
</td>
<td class="nump">1,856,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">43,509<span></span>
</td>
<td class="nump">38,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">161,068<span></span>
</td>
<td class="nump">141,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">176,239<span></span>
</td>
<td class="nump">150,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="nump">12,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">34,035<span></span>
</td>
<td class="nump">31,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">427,372<span></span>
</td>
<td class="nump">374,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">442,413<span></span>
</td>
<td class="nump">432,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">72,619<span></span>
</td>
<td class="nump">69,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">13,408<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">961,991<span></span>
</td>
<td class="nump">880,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,780,242 and 37,674,868 shares issued; and 32,432,527 and 32,509,969 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">743,276<span></span>
</td>
<td class="nump">728,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost 5,347,715 and 5,164,899 shares of common stock</a></td>
<td class="num">(457,981)<span></span>
</td>
<td class="num">(435,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">700,313<span></span>
</td>
<td class="nump">639,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">985,646<span></span>
</td>
<td class="nump">931,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">53,349<span></span>
</td>
<td class="nump">44,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">1,038,995<span></span>
</td>
<td class="nump">976,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 2,000,986<span></span>
</td>
<td class="nump">$ 1,856,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368859063632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 100,265<span></span>
</td>
<td class="nump">$ 96,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 9,109<span></span>
</td>
<td class="nump">$ 19,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,780,242<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,432,527<span></span>
</td>
<td class="nump">32,509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">5,347,715<span></span>
</td>
<td class="nump">5,164,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368858080288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 557,890<span></span>
</td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 1,103,147<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">316,211<span></span>
</td>
<td class="nump">308,691<span></span>
</td>
<td class="nump">621,031<span></span>
</td>
<td class="nump">605,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">127,758<span></span>
</td>
<td class="nump">114,335<span></span>
</td>
<td class="nump">251,238<span></span>
</td>
<td class="nump">230,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">5,148<span></span>
</td>
<td class="nump">6,156<span></span>
</td>
<td class="nump">12,495<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">54,912<span></span>
</td>
<td class="nump">54,731<span></span>
</td>
<td class="nump">108,552<span></span>
</td>
<td class="nump">103,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,220<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">14,228<span></span>
</td>
<td class="nump">14,276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">510,249<span></span>
</td>
<td class="nump">490,634<span></span>
</td>
<td class="nump">1,007,544<span></span>
</td>
<td class="nump">967,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">47,641<span></span>
</td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,311)<span></span>
</td>
<td class="num">(1,932)<span></span>
</td>
<td class="num">(11,484)<span></span>
</td>
<td class="num">(4,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings (loss) from equity method investments</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
<td class="num">(744)<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(7,285)<span></span>
</td>
<td class="nump">31,030<span></span>
</td>
<td class="num">(11,515)<span></span>
</td>
<td class="nump">30,388<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">40,356<span></span>
</td>
<td class="nump">109,165<span></span>
</td>
<td class="nump">84,088<span></span>
</td>
<td class="nump">177,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(11,319)<span></span>
</td>
<td class="num">(28,546)<span></span>
</td>
<td class="num">(23,338)<span></span>
</td>
<td class="num">(46,461)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">29,037<span></span>
</td>
<td class="nump">80,619<span></span>
</td>
<td class="nump">60,750<span></span>
</td>
<td class="nump">130,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">542<span></span>
</td>
<td class="num">(470)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">(892)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 29,579<span></span>
</td>
<td class="nump">$ 80,149<span></span>
</td>
<td class="nump">$ 61,250<span></span>
</td>
<td class="nump">$ 130,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,522<span></span>
</td>
<td class="nump">32,588<span></span>
</td>
<td class="nump">32,538<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">32,681<span></span>
</td>
<td class="nump">32,981<span></span>
</td>
<td class="nump">32,722<span></span>
</td>
<td class="nump">33,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368854645520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2020</a></td>
<td class="nump">$ 810,741<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 698,287<span></span>
</td>
<td class="num">$ (319,092)<span></span>
</td>
<td class="nump">$ 429,991<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">13,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(6,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(74,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">130,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,019<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2021</a></td>
<td class="nump">875,887<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">714,334<span></span>
</td>
<td class="num">(400,110)<span></span>
</td>
<td class="nump">560,010<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,553,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2021</a></td>
<td class="nump">789,574<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">707,006<span></span>
</td>
<td class="num">(398,752)<span></span>
</td>
<td class="nump">479,861<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,538,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">6,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">80,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,149<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2021</a></td>
<td class="nump">875,887<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">714,334<span></span>
</td>
<td class="num">(400,110)<span></span>
</td>
<td class="nump">560,010<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,553,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2021</a></td>
<td class="nump">976,323<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">728,118<span></span>
</td>
<td class="num">(435,868)<span></span>
</td>
<td class="nump">639,063<span></span>
</td>
<td class="nump">44,972<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">12,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(4,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ContributionsAttributableToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">9,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">60,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,250<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2022</a></td>
<td class="nump">1,038,995<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">743,276<span></span>
</td>
<td class="num">(457,981)<span></span>
</td>
<td class="nump">700,313<span></span>
</td>
<td class="nump">53,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,780,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2022</a></td>
<td class="nump">1,020,652<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">736,536<span></span>
</td>
<td class="num">(440,550)<span></span>
</td>
<td class="nump">670,734<span></span>
</td>
<td class="nump">53,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,763,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">5,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ContributionsAttributableToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">29,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,579<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2022</a></td>
<td class="nump">$ 1,038,995<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 743,276<span></span>
</td>
<td class="num">$ (457,981)<span></span>
</td>
<td class="nump">$ 700,313<span></span>
</td>
<td class="nump">$ 53,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,780,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ContributionsAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ContributionsAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368855878432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 60,750<span></span>
</td>
<td class="nump">$ 130,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,228<span></span>
</td>
<td class="nump">14,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">12,495<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">22,463<span></span>
</td>
<td class="nump">19,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">6,003<span></span>
</td>
<td class="nump">22,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss (earnings) from equity method investments</a></td>
<td class="nump">744<span></span>
</td>
<td class="num">(2,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity method investments</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(21,344)<span></span>
</td>
<td class="num">(22,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(4,468)<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">220<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,498<span></span>
</td>
<td class="num">(6,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">29,529<span></span>
</td>
<td class="num">(1,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(20,657)<span></span>
</td>
<td class="num">(17,955)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(1,662)<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">106,030<span></span>
</td>
<td class="nump">121,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from the sale of deferred compensation plan assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,782)<span></span>
</td>
<td class="num">(2,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Investments in technology assets</a></td>
<td class="num">(559)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Other investments</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(73,311)<span></span>
</td>
<td class="num">(2,503)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(91,587)<span></span>
</td>
<td class="num">(5,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(4,762)<span></span>
</td>
<td class="num">(6,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Noncontrolling interest contributions</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distributions</a></td>
<td class="num">(975)<span></span>
</td>
<td class="num">(794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">298,500<span></span>
</td>
<td class="nump">389,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(283,500)<span></span>
</td>
<td class="num">(410,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(6,975)<span></span>
</td>
<td class="num">(5,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(17,351)<span></span>
</td>
<td class="num">(74,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundsReceivedFromProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(11,448)<span></span>
</td>
<td class="num">(107,292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">83,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">48,764<span></span>
</td>
<td class="nump">92,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,489<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">22,977<span></span>
</td>
<td class="nump">8,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">22,319<span></span>
</td>
<td class="nump">19,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForFinanceLeaseLiabilities', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">26,590<span></span>
</td>
<td class="nump">20,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Reductions to right of use assets resulting from reductions to operating lease liabilities</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">19,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashNoncontrollingInterestContribution', window );">Noncontrolling interest contribution</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for finance lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundsReceivedFromProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundsReceivedFromProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashAccruedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash accrued contingent consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashAccruedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashNoncontrollingInterestContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashNoncontrollingInterestContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856642416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 74% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021. As of June&#160;30, 2022, we owned and operated 353 Medicare-certified home health care centers, 174 Medicare-certified hospice care centers, 14 personal-care care centers and 9 admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 24, 2022 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.0 million and $48.1 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:61.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368855737872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 74% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day periods of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June&#160;30, 2022, we have recorded $4.2 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $22.2&#160;million and $3.1&#160;million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 68% of our patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856778384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19"<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19TextBlock', window );">COVID-19</a></td>
<td class="text">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the PRF funds received; all unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $0.2&#160;million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and has been reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The suspension of sequestration increased net service revenue by $4&#160;million and $13&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $10&#160;million and $18&#160;million during the three and six-month periods ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55&#160;million of social security taxes. Approximately $27&#160;million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856778384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $8.5&#160;million, other intangibles of $0.4&#160;million (certificate of need and licenses) and noncontrolling interest of $8.9&#160;million within our condensed consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $16.7&#160;million placed into escrow, $1.0&#160;million has been set aside for any potential closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price is subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. We expect to finalize any changes to the purchase price resulting from the closing payment adjustment during the three-month period ending September 30, 2022. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $15&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolution contributed $11.3&#160;million in net service revenue and an operating loss of $1.8 million during the three and six-month periods ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $67.8&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's preliminary valuation, we recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names ($0.1&#160;million). The acquired names will be amortized over a weighted average period of one year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AssistedCare contributed $2.6&#160;million in net service revenue and operating income of $0.7&#160;million during the three and six-month periods ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $0.6&#160;million from $240.7&#160;million to $241.3&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired, liabilities assumed and noncontrolling interests. Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($28.3&#160;million), technology ($19.8&#160;million) and non-compete agreements ($6.2&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years, and the technology will be amortized over a weighted-average period of 7.0 years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $4.4&#160;million in net service revenue and an operating loss of $9.7&#160;million (inclusive of technology intangibles amortization totaling $0.7&#160;million) during the three-month period ended June 30, 2022 and $7.2&#160;million in net service revenue and an operating loss of $17.3&#160;million (inclusive of technology intangibles amortization totaling $1.5&#160;million) during the six-month period ended June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details regarding the Company's 2021 acquisitions, see Note 4 to the audited consolidated financial statements in our 2021 Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368860485792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.2% at June 30, 2022); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.7% at June 30, 2022); due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2022, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:9.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% for the three and six-month periods ended June 30, 2022, and 1.7% and 1.8% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 2.3% and 2.0% for the three and six-month periods ended June 30, 2022, respectively, and 1.4% and 1.5% for the three and six-month periods ended June 30, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 15.4 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our availability under our $550.0 million Revolving Credit Facility was $507.3 million as we have $15.0&#160;million outstanding in borrowings and $27.7 million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div>Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368859161456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $6.5 million recorded to accrued expenses in our condensed consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2022, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an extrapolated overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an extrapolated overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearing for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As of the date of this filing, we do not have a demand for repayment from Palmetto for the Clearwater Care Center or the Lakeland Care Centers. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing of the demand for repayment; however, the Company has updated its estimates of potential loss based on the ALJ's decisions. We have increased our total accrual related to these matters from $17.4 million to $25.8&#160;million. The net of these two amounts, $8.4&#160;million, was recorded as a reduction to net service revenue in our condensed consolidated statements of operations during the three-month period ended June 30, 2022. We expect to be indemnified by the prior owners for approximately $10.9 million and have recorded this amount within other assets in our condensed consolidated balance sheets. As of June&#160;30, 2022, $1.5 million of receivables have been impacted by these matters.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $2.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368857820192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATIONOur operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856632032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74&#160;million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856788112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs totaling $2.3 million and $4.7&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $1.3&#160;million and $2.6&#160;million during the three and six-month periods ended June 30, 2021, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368855974256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div>This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 24, 2022 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.0 million and $48.1 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:61.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 74% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day periods of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June&#160;30, 2022, we have recorded $4.2 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div>In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $22.2&#160;million and $3.1&#160;million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 68% of our patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy disclosure text block for government grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856557136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:61.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368860314880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856639392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock', window );">Schedule of Cares Act Provider Relief Funds</a></td>
<td class="text">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $0.2&#160;million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cares Act Provider Relief Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856634128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock', window );">Schedule of Business Acquisitions, Evolution</a></td>
<td class="text">Based on the Company's preliminary valuation, the total estimated consideration of $67.8&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock', window );">Schedule of Business Acquisitions, Contessa</a></td>
<td class="text">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Evolution business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856559856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.2% at June 30, 2022); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.7% at June 30, 2022); due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:9.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856572256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text">Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368853617280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>numberOfJointVentures </div>
<div>state</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>numberOfJointVentures </div>
<div>state</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum ownership percentage for cost method investment (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment Owned, at Cost</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">26,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">305,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">25,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">394,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">17,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,289,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,196,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">106,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,000,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">161,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">176,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">427,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">13,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">961,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfJointVentures', window );">Number of Joint Ventures | numberOfJointVentures</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer [Member] | Product Concentration Risk | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of joint ventures owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368850342000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AcutePhaseForHighAcuityCareServices', window );">Acute Phase for High Acuity Care Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AcutePhaseForHighAcuityCareServices', window );">Acute Phase for High Acuity Care Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember', window );">Cap Year 2016 Through 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenue from Contract with Customer [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AcutePhaseForHighAcuityCareServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AcutePhaseForHighAcuityCareServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368854616112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368952890144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,566<span></span>
</td>
<td class="nump">$ 42,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">22,198<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">48,764<span></span>
</td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">$ 92,646<span></span>
</td>
<td class="nump">$ 83,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember', window );">Various acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368855879472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368858116688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 456,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">476,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368859177312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,522<span></span>
</td>
<td class="nump">32,588<span></span>
</td>
<td class="nump">32,538<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">32,681<span></span>
</td>
<td class="nump">32,981<span></span>
</td>
<td class="nump">32,722<span></span>
</td>
<td class="nump">33,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368853617200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding for Healthcare Providers, Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsRepaid', window );">Estimated CARES Act Provider Relief Fund Amounts Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures', window );">Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalCARESActProviderReliefFundsReceived', window );">Total CARES Act Provider Relief Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActInterestRepaidToGovernment', window );">CARES Act Interest Repaid to Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact', window );">Extension of Temporary Suspension of Sequestration, Revenue Impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember', window );">COVID-19 Deferral of Social Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct', window );">Payment Of Deferred Social Security Tax Under CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActInterestRepaidToGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Interest Repaid to Government</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActInterestRepaidToGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts Repaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Deferred Social Security Tax Under CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalCARESActProviderReliefFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total CARES Act Provider Relief Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalCARESActProviderReliefFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368847268944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 1,103,147<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,198<span></span>
</td>
<td class="nump">$ 3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,900<span></span>
</td>
<td class="nump">391,400<span></span>
</td>
<td class="nump">389,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900<span></span>
</td>
<td class="nump">73,400<span></span>
</td>
<td class="nump">92,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,300<span></span>
</td>
<td class="nump">675,600<span></span>
</td>
<td class="nump">677,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,700<span></span>
</td>
<td class="nump">124,100<span></span>
</td>
<td class="nump">148,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(17,300)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember', window );">2022 New Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationAcquiredNoncontrollingInterest', window );">Business Combination, Acquired Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember', window );">2022 New Joint Venture | Certificate of Need and Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 67,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Business Acquisition, Goodwill, Expected Tax Deductible Amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings', window );">Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings</a></td>
<td class="nump">51,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Potential Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Business Acquisition, Goodwill, Expected Tax Deductible Amount</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings', window );">Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings</a></td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Certificates Of Need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationAcquiredNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents that amount of noncontrolling interest acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationAcquiredNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount paid to the seller as a result of a business combination using cash on hand and proceeds from borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity assumed at the acquisition date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total liabilities and equity assumed at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time that goodwill is deductible for income tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashAccruedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash accrued contingent consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashAccruedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationAdjustmentsAxis=amed_PotentialClosingPaymentAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationAdjustmentsAxis=amed_PotentialClosingPaymentAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368858103696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 459.0<span></span>
</td>
<td class="nump">$ 449.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">454.9<span></span>
</td>
<td class="nump">445.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(12.5)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">442.4<span></span>
</td>
<td class="nump">432.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">441.6<span></span>
</td>
<td class="nump">447.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368859080208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">2.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368854502592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368854352800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_SecondAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_SecondAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368850043136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReversalOfLossContingencyAccrual', window );">Reversal of Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Massachusetts | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Morgantown, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Parkersburg, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReductionToNetServiceRevenue', window );">Reduction to Net Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReductionToNetServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction to Net Service Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReductionToNetServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReversalOfLossContingencyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of Loss Contingency Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReversalOfLossContingencyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368856766144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368857832688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 557,890<span></span>
</td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 1,103,147<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">316,211<span></span>
</td>
<td class="nump">308,691<span></span>
</td>
<td class="nump">621,031<span></span>
</td>
<td class="nump">605,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">187,900<span></span>
</td>
<td class="nump">175,300<span></span>
</td>
<td class="nump">372,300<span></span>
</td>
<td class="nump">347,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,220<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">14,228<span></span>
</td>
<td class="nump">14,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">510,249<span></span>
</td>
<td class="nump">490,634<span></span>
</td>
<td class="nump">1,007,544<span></span>
</td>
<td class="nump">967,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">47,641<span></span>
</td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">340,200<span></span>
</td>
<td class="nump">349,300<span></span>
</td>
<td class="nump">675,600<span></span>
</td>
<td class="nump">677,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">190,400<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="nump">373,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">87,900<span></span>
</td>
<td class="nump">81,300<span></span>
</td>
<td class="nump">171,100<span></span>
</td>
<td class="nump">161,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">282,400<span></span>
</td>
<td class="nump">272,900<span></span>
</td>
<td class="nump">551,500<span></span>
</td>
<td class="nump">537,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">57,800<span></span>
</td>
<td class="nump">78,700<span></span>
</td>
<td class="nump">124,100<span></span>
</td>
<td class="nump">148,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">198,400<span></span>
</td>
<td class="nump">197,900<span></span>
</td>
<td class="nump">391,400<span></span>
</td>
<td class="nump">389,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">107,400<span></span>
</td>
<td class="nump">105,200<span></span>
</td>
<td class="nump">213,800<span></span>
</td>
<td class="nump">206,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">51,600<span></span>
</td>
<td class="nump">48,400<span></span>
</td>
<td class="nump">102,900<span></span>
</td>
<td class="nump">94,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">159,600<span></span>
</td>
<td class="nump">154,300<span></span>
</td>
<td class="nump">318,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">45,900<span></span>
</td>
<td class="nump">73,400<span></span>
</td>
<td class="nump">92,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">22,200<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="nump">26,800<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(9,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">37,200<span></span>
</td>
<td class="nump">42,400<span></span>
</td>
<td class="nump">77,900<span></span>
</td>
<td class="nump">84,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">47,200<span></span>
</td>
<td class="nump">86,700<span></span>
</td>
<td class="nump">95,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (40,500)<span></span>
</td>
<td class="num">$ (47,200)<span></span>
</td>
<td class="num">$ (86,700)<span></span>
</td>
<td class="num">$ (95,600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368854918208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,351<span></span>
</td>
<td class="nump">$ 74,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember', window );">2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury Stock Acquired, Average Cost Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember', window );">New Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury Stock Acquired, Average Cost Per Share</a></td>
<td class="nump">$ 115.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember', window );">New Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140368952881328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>amed-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20220630.xsd" xlink:type="simple"/>
    <context id="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib7a29abe30dd410abda89d13c08ad47a_I20220722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="if19ffbe3490c49479b91f735381591d3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ddf9fbb9d354501832c0641468f679d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i884839468e984a559b74bef4467c132b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i71f5d916ca034210bdab3c3695b2b7d5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i51eae5477dbe4bb3813cfeef5b1df172_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2230db8bb5304021a778e00e8cbc9e95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i32561722ebd4483cb2b211fd8482b221_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab48083f8c03445890bc710f5ef75ea7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9747ba22c25643a981e544cb176796d5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4391a27b2ec040e3b60979194de2e669_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6c4aeb15060148eba081e4dfc943a331_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib2ba1440544d42adba0dee3d24db10cd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icc52bda628494beea698958f49b62ec5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib9621fe17f1f49e2abf92921c9bbd090_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3db8313abf4642c7a45dab30e9b2b38e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c0b9d2e84db40329330261a2e77cf52_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae38203cf58b41608713238c84238a48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i32c45951e3954adf99132111ec0188e3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9333e57ab0fb4dc2aed54d98767627d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d48e25a4ab747bea24391142246d356_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e12a01376444b3e9c94160b47756002_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7645017f9994d879ea8bd6a157e52a6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe75fdc74ac74e3095b40024bdf5e396_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibf858571fd5b4c4796c9d0b50d88e266_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if2e9c6f9bcae458e87824df14a960f90_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i97712cb7eec54f298eacfb74dd9aa06e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f7e2f3718a14010b98f596f57fe8413_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1e1ebf15a9194fddad714c86f2a2011f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9951a73c939a4d0aaf3f9c73a0930342_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac753950cce74a30b0bff2362d5e2d03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0f83eb525d94a3eb4a2470165f6dff2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib37433eb056c4c17b9f3d15134197084_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4d5a9872b4a463fa7cbc23245d2f3f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbc77839e04f4069814115134fefaae4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8b210127b1934564bef8ed600a885868_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id5ec7ab4116e4010b85638d99e1435a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafa2140950ab4b4ca199f88ab42de2aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9be67241b82145fa8bc84a4faa53dbcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f13336bd8884514937d120c30ec2a30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9218609305b4e9cbeae0653ba8615ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7704d89a5ea49bda984ff3bb25a28ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64f18cac2d0249a097657acce73eae01_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6eae4c7f67f4524a74a58848d23caef_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i12d3114d05584bdc834ec068c834314b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i952b1caa605842b8b2c6cc1f6ed49167_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f689c40db574abeba5ad517246536ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idacfe2999ae746bea86d800a07b26023_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica0fc66197bf4246a3cb7df9b28e8f04_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id11e4c1c56094d87b2ab9c56771f2868_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia755b346de2741dfa14730fe4f9e2fb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i361addb20cb8421d8de1392e96b0844f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iea0b040e8e1d408f99b5efc4817437de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied4fd711d218438abe660d1442afcde4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ec1a19c1ba94e878ec8fda9cd5339f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8da76d47f10d4c0c8c8c8b0fd249aa26_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfd2cc70011c4d8ca45f2cd8312980c3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa76b1acfeaf486da02b9af11cc816a6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i751a2debd3674a8cb7cef6a38ae12130_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82c50b0e545d4a1785eeb7d1a9c185cc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic1b3730a17e64e0f992cd153fd840cf2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6061248324244eebe4d0db40312edac_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib24ed3919fc848288bb8ac2ced90d84b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07a28a2b65f4472ab0c894d89400b474_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53cca52064ef477ab34029b221d6d69d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6190b80120f43e2a1575644159feb4e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i63963cb819344481af520c8bff0b5d1d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64fbb473e60d4729802929c3f20aeafe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89df7c974a654e3a941400b05e8929a4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5749f12c34ef4e4a81639e239b7a472e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica66251978d1405bb862d424880702f5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1eb4c6bf9b7f441aba17bfa2e6583e74_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i356d5eeddab246eca55259b8d751e968_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i88871dd43ddc4081830db6b06e82af59_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic5e997d4464b4ea4bfa067035b64249a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35822c2e8f8846808fd72e3482edc1a8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1dddcac370504787ba0022ab6dfadefd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id920f2f6a7f04db3b0281051fbbc33cf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5f1e1d42e8bb4d88b2aed4812e852cbb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i926108a7b35d4c89a57993c4c6997466_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4b91dd04f2634b899d9d8c66e3339361_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac48d82a63114da69e22201712a8c0c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie3a945b2920249189593bc4dfb36414a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic21dc870eef3444a90c0b71790318d59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icc3a77e521b04aeebf04452b84789764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6279924dc89846fe9e81f87aed338b84_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibcff0785ecd9434fb01d7a18ff154dc6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i76cd0bb8003d49c6a5231bf472e9ed5b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibec5f07fc2aa4973b444a7171d9a0911_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="i559e5275bf6a413d992d5f29b2508130_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i09472bba331640d7b8fce12ca5f6d194_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i39ddd6046a8c4277a4a08449e4ec5af5_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf597362dfa64e339e5ded664c4686cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61fa6d510c13404db32529ba1a32617b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1d84b1e5c3f433e9b75ae592fa0fd06_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id339d8bb1ad54c308f39f7c547fbc108_D20220323-20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="i78865dd720d74892af146d51ab673d72_I20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="ib7f617d6993d44d1bad636bee8dc70e0_I20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i6b948e672fa043169982437976dfddd2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id86fb111888b450497127e23c0316217_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:BusinessCombinationAdjustmentsAxis">amed:PotentialClosingPaymentAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3846fa0b86854a5bb6a4eea857e8c9c5_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib4fb833a0ee942bf86af673e369faa07_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3b561742ec7246caa23ec4b10eecde20_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9100b6fd13145b3a354118b53a94340_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="idc1b8914368b467da2e1219eea19c95b_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="icd47e369277544c6aac2253ba6754c51_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ic36a53a0d50446a995344011bef59e29_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i13b7e4cb24c04e1eae0d3bc51631a3c0_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="ifd89d4de539544fdb048cd299395703f_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2e82315a0db4ef2930ad63880f79a3f_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="iaa48e07aa67b4e89a0601d5f3eee5d03_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i1ac7ec89f6e9427cb5d656763a3bddc5_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i4eb3273c875947fb92f75066e32951a9_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="id39d0ab5b15a45f6b8ac1c1e71d6931a_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i9ac3f76ab9614d4688b0b8101d455be8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3e721858874346608ff8de6222b8c390_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i043295b1e6fd4805ad86f88638f693aa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7bd5c5b90ca64ac5b24203d891eb6fa6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id0111dd48d164a73bdbda6add2995d5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35487ebf2851440e915cf218928141e1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic12425e6cf2b4507ae0eb717031bd48e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib714a01635724ae086d93a794a849aa8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3e1f02a946da41c68f1054d698474350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fdd1926c3d342b398329f841ae4f949_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id68e48e4accd47829e3f2c108a5e0128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i395b376b36064fa0b151bf87dcfde162_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i5e933e2b55f0441d8ade42bb9a6422c9_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i368407cb268545c8a429573f1fdb24fd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i98096f04576b4100a1338db93629914d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f7d430c8d0f426aacb10538dea5c466_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3dfdd0581d7248b8b729caa375e55f7d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i914232c463aa4978b4a531ac7e62be33_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26d1ddcfb1a14175839570fdd3546981_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ef3b974ffc54477b347ad7aba261ff0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3471a8de624944a9847b252690bec01b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i61200e8a017c49809e956ccc90265bd5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ea37ed79d51491fa4d4fe86aabbcd2b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i651fdb8c74b14b81967263e6ff2e0db9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i289a8de993e54ffabcd97d4bed94c9ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6c330947191b484cabb14457b2008fec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d6b509d3e8d4a32b2dc334213e3e90e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7de7001e37e54eaea710b0dd411e567a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f8f5ae337584aee9a115925a8e2d3ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2c044924a75b44968b0831ab81455994_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i342d3f4c7f564db587a6511cf32380e8_D20210730-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="ia7465164416942ac8228a0f9daf738ff_D20210730-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i17a72248de9c483b86fc97e68ef07f13_D20231001-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="i325318cf209c4cb4a2a43b717a15c820_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i03d87584c975497d9c6f614b6f3f8e5e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icff1249baba74d4bb0802f6d4bcf1199_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2dd2a0aeede64a10a02cea3509dc8376_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5fdfe5f5157c462fa0c08492c5359787_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i27ef4862c0c741ad8c38872eb9eb8d3c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i908c39c20d774cf49e9e8591ddd0e31a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6ac967f423744c484ee9385ced160bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i64b5c595294245a18e553707a117c3d6_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i647490c601a147899ef03e7f74558833_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i0ea90e266fd540c1b73334141496eeda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie02b1044c0fa4fadb08f8e9354318b47_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5a818c66a5b04529bf0bde65307825f1_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="i093a633cdc1f40ff80f2e4fe49d565e7_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="ic33cb6496cb44a3fa5ff85100d4ce238_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="ie73580cf813f4bacb80a34a16b93b064_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="i694cb74b423248c896a972c561852442_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="ie5b0119f2b2547fa916994d37a51982e_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="i361b5e96bbca4bd8a455e792020b20e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57695b07d1464993ae80368c4d54fbe4_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="i71f2e16b6e58440aa8210596de7977c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b93980fcec94641a3ac5597a6cf39a7_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ib07ad9b0c2284a67950bf5935cd96810_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="if7a5f95eb6a3431691a8916273d87b3a_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i7510142fa85d4f9d92232c8c96e894e5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i509592a5ae784f308e714e6df14f611e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3aaeb76718a141288630010cd2fca7f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i832d375adc9a4e25b37e1d449314a0b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a583ddc36234cbbac97618ef468484a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic98dab006fb24cf1a5c08315e4408d0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia015b8b24487424e96577269736c5919_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie5c1cff898334365963d7bbf377923db_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id8fa5b9a73964a099d44236118212346_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i072195f45aa04718bf17aab9a9987275_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i00db5755e15345ea91550fbfc954caac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d43362c8b95458aac1aefacb3f78f19_I20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="i915c545146e94aa887017c72ca239d02_D20201223-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8e2ca64538594598a876edcc7a6780f5_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="iec884be61eb14776a28fa489974af68b_D20210802-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i23c6ff4104d347999b50900a9055f693_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41519bdb02894e4c88aa2695cb5691b9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice6cf5eaf69a43afa1bd9eefc44f8038_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8db1257495a248b09b389531c6e0153f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="numberofjointventures">
        <measure>amed:numberOfJointVentures</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segments">
        <measure>amed:Segments</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY180LTEtMS0xLTM1NzQ3_c188aa8e-3291-4f85-9294-0529c63e4638">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY182LTEtMS0xLTM1NzQ3_8bbb8022-3a9c-440d-8037-79dccef21ae8">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY183LTEtMS0xLTM1NzQ3_84f4ac99-0023-4f9f-b368-c870b5a55344">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY185LTEtMS0xLTM1NzQ3_d08381d7-2660-48a0-9ef5-03e1388711d8">AMEDISYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY18xMC0xLTEtMS0zNTc0Nw_9f7a05b7-8420-4dfe-8435-6bd810dbeda8">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80L2ZyYWc6YTg0MzkzMThmMzlkNDY5Mjk0MTc2YjM1ODg4ZTJhYTAvdGFibGU6NDU2ZDNlYTk4ZDJmNGMzZmE4NTcyNDg0Yjg1MWU1ZWMvdGFibGVyYW5nZTo0NTZkM2VhOThkMmY0YzNmYTg1NzI0ODRiODUxZTVlY18xMS0xLTEtMS0zNTc0Nw_9636a18e-5805-45e8-9335-c623044cbf40">--12-31</dei:CurrentFiscalYearEndDate>
    <amed:AcutePhaseForHighAcuityCareServices
      contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa">P5D</amed:AcutePhaseForHighAcuityCareServices>
    <amed:AcutePhaseForHighAcuityCareServices
      contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f">P7D</amed:AcutePhaseForHighAcuityCareServices>
    <us-gaap:OperatingIncomeLoss
      contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMS0xLTEtMS0zNTc0Nw_b14f540b-061a-42ab-b186-b8d38fd74bf0"
      unitRef="usd">-9700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMS0yLTEtMS0zODgzMQ_6f1c4e78-56e2-4b4e-83b0-49fb33499aff"
      unitRef="usd">-17300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMi0xLTEtMS00Mjk2Nw_92db16db-464f-4eb5-8665-71a4d312fac1"
      unitRef="usd">-1800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81NS9mcmFnOmEzYmEyNjVlM2FiZTRkNTRhM2Q0ZjJiNzg3OTQwYTljL3RhYmxlOjM3MGZmNGZkN2IwMDRhMzU5MjYwYWRhNGJlM2VkNjY5L3RhYmxlcmFuZ2U6MzcwZmY0ZmQ3YjAwNGEzNTkyNjBhZGE0YmUzZWQ2NjlfMi0yLTEtMS00Mjk2Nw_a5bf5e3a-7eae-491c-ad2d-e4254e5b0df7"
      unitRef="usd">-1800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i64b5c595294245a18e553707a117c3d6_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82MS9mcmFnOjE1NWUxNmI2NGFiZjQ4OTk4MjM3YjI3MzAwMTBiM2I3L3RleHRyZWdpb246MTU1ZTE2YjY0YWJmNDg5OTgyMzdiMjczMDAxMGIzYjdfODA5_e99ac26b-23f1-49fd-b5c5-57f40a59fba3">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i647490c601a147899ef03e7f74558833_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82MS9mcmFnOjE1NWUxNmI2NGFiZjQ4OTk4MjM3YjI3MzAwMTBiM2I3L3RleHRyZWdpb246MTU1ZTE2YjY0YWJmNDg5OTgyMzdiMjczMDAxMGIzYjdfODEw_823b03b5-9a76-4afc-b50b-4057a1696ff5">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:CostsAndExpenses
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83My9mcmFnOmMxZDZkOTQ5ODVlYjRkMWM4YzVhYzA5MzIzNzIyNDMzL3RhYmxlOjdlMDY5MGEwMmRjYjRjNjRiYjZhMjhiZTRmM2E0NGFkL3RhYmxlcmFuZ2U6N2UwNjkwYTAyZGNiNGM2NGJiNmEyOGJlNGYzYTQ0YWRfNS0xLTEtMS00MjA5Ng_721e0f53-2b28-45db-b636-c8e627a86189"
      unitRef="usd">510249000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83My9mcmFnOmMxZDZkOTQ5ODVlYjRkMWM4YzVhYzA5MzIzNzIyNDMzL3RhYmxlOjdlMDY5MGEwMmRjYjRjNjRiYjZhMjhiZTRmM2E0NGFkL3RhYmxlcmFuZ2U6N2UwNjkwYTAyZGNiNGM2NGJiNmEyOGJlNGYzYTQ0YWRfNC0yLTEtMS00MTA3NQ_b805dbf5-9036-4235-b098-660ec9bb6623"
      unitRef="usd">490634000</us-gaap:CostsAndExpenses>
    <dei:DocumentType
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM4_2d9ae044-6227-446a-ab36-b42aa2a7413c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6YzUxZmJlMDk2Yjg4NGU2OGExMzEzYmU2MmJlODY2MzAvdGFibGVyYW5nZTpjNTFmYmUwOTZiODg0ZTY4YTEzMTNiZTYyYmU4NjYzMF8wLTAtMS0xLTM1NzQ3_4549e0c1-44be-478b-bbef-7622a6e7d9ca">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8xMzg_030db3c3-facc-446e-becd-6153bf986996">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6Njg1ZjgwYzI3MWEyNGMyNGFjZDZjNzk2NWM2YzhkY2IvdGFibGVyYW5nZTo2ODVmODBjMjcxYTI0YzI0YWNkNmM3OTY1YzZjOGRjYl8wLTAtMS0xLTM1NzQ3_6e7644be-1ef2-4b75-a165-6a4d14f7ea7e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQy_f8174a68-f199-4060-a807-827b92fa938d">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6ZDZhZTBmMGI1OWQzNDc4ZTliOTczZWNhOWMzNWZiYTQvdGFibGVyYW5nZTpkNmFlMGYwYjU5ZDM0NzhlOWI5NzNlY2E5YzM1ZmJhNF8xLTAtMS0xLTM1NzQ3_babb8ce9-7521-4b2b-8485-d471dc189414">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6ZDZhZTBmMGI1OWQzNDc4ZTliOTczZWNhOWMzNWZiYTQvdGFibGVyYW5nZTpkNmFlMGYwYjU5ZDM0NzhlOWI5NzNlY2E5YzM1ZmJhNF8xLTItMS0xLTM1NzQ3_765fc8ff-3aee-4283-854d-3e2eccc3f74e">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM5_890f908e-d521-4621-94cb-55d879920f41">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQz_1fcaa8a8-dae1-43bd-bb70-ce1712240785">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjMy_5edbedbd-cfce-428e-92c3-55a4d2480490">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjMz_ece58989-ba45-47f2-8873-e5b6638c096e">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM0_1f5a5763-3ec9-4f68-812d-4ff24a9bc2c0">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQw_3c9ce76f-f75e-4454-8eea-b781da20815e">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM1_2c43934a-7b1e-4570-af10-5a29655c32c5">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTAtMS0xLTM1NzQ3_18e9a63a-bf8b-4b06-8a45-eb2a8a544c05">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTItMS0xLTM1NzQ3_7959c87c-2f6e-4a38-9e95-095e6852c183">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6M2E4NjU0NGVhZDJlNGYxMzk3OWViNTk2YWI5MDU2NzEvdGFibGVyYW5nZTozYTg2NTQ0ZWFkMmU0ZjEzOTc5ZWI1OTZhYjkwNTY3MV8xLTQtMS0xLTM1NzQ3_e451f382-e90c-454d-bee5-45ea90fab3c9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM2_1aff40c3-6712-4ff3-9c08-56b88ce72f56">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjM3_47e52576-9d67-433d-94cd-6d1403ae98a6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF8xLTAtMS0xLTM1NzQ3_7d9198b8-75f1-4f6d-aea9-7ebf17192268">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF8zLTYtMS0xLTM1NzQ3_c9cf0ce2-e459-4e27-ad0e-fed21a1ebcf6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGFibGU6NTZhODdjYTU4ZjNlNDgzYmJjOTM5ZjQ0YjNmZGNkZjAvdGFibGVyYW5nZTo1NmE4N2NhNThmM2U0ODNiYmM5MzlmNDRiM2ZkY2RmMF81LTItMS0xLTM1NzQ3_dd7c18ab-ebfe-4ca3-bce4-9cedddabba79">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMjQx_105a0d34-afcc-41a8-9393-3057f3728bfa">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib7a29abe30dd410abda89d13c08ad47a_I20220722"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xL2ZyYWc6MTQ4NDk3ZmZmZWQ3NDg1NDhjNWYxMjY5MzI2MWY2M2UvdGV4dHJlZ2lvbjoxNDg0OTdmZmZlZDc0ODU0OGM1ZjEyNjkzMjYxZjYzZV8yMTk5_660dc719-92f4-4db4-8f0f-c149930a67c2"
      unitRef="shares">32443341</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMy0xLTEtMS0zNTc0Nw_9653ab6b-112e-446a-bf2c-bcfc769ff868"
      unitRef="usd">26566000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMy0zLTEtMS0zNTc0Nw_2a75a866-dac0-4719-86d2-9df275e3dae4"
      unitRef="usd">42694000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNC0xLTEtMS0zNTc0Nw_b2b50f87-bf9e-47ce-9e8e-c6f6f05ee95a"
      unitRef="usd">22198000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNC0zLTEtMS0zNTc0Nw_697c3790-d8e4-4f58-8050-e3310dff25d6"
      unitRef="usd">3075000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNS0xLTEtMS0zNTc0Nw_def2d44a-4b52-4041-befa-f9199fc71421"
      unitRef="usd">305413000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNS0zLTEtMS0zNTc0Nw_970bac61-d8e0-43ee-9bc2-a4d4afa0acfd"
      unitRef="usd">274961000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNi0xLTEtMS0zNTc0Nw_8e816394-026e-43f9-b0d4-3527c03b9aad"
      unitRef="usd">15199000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNi0zLTEtMS0zNTc0Nw_161f8a00-8d1b-484e-98e7-cb83961f6ffa"
      unitRef="usd">10356000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNy0xLTEtMS0zNTc0Nw_4391beaf-931e-479f-8af4-110f1e6c7a5f"
      unitRef="usd">25493000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNy0zLTEtMS0zNTc0Nw_f2927236-023c-4742-8eb9-22012f88f132"
      unitRef="usd">25598000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOC0xLTEtMS0zNTc0Nw_6c27fff5-7175-4761-9791-63b0db1d0cfb"
      unitRef="usd">394869000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOC0zLTEtMS0zNTc0Nw_d169b3b4-4da1-46da-9a72-aa7932f84656"
      unitRef="usd">356684000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjE2MDkwYWIyYzNlODRhYjViYzBjMzdkNjIxMDc4ZDU1XzYz_3629e6ef-4a41-4cf3-ab63-3fd7f8a4135e"
      unitRef="usd">100265000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjE2MDkwYWIyYzNlODRhYjViYzBjMzdkNjIxMDc4ZDU1Xzcw_33bf26fa-eacc-4d40-9932-240daa2e7cda"
      unitRef="usd">96937000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0xLTEtMS0zNTc0Nw_d5dbd9cc-5787-4370-aaca-639369557ab0"
      unitRef="usd">17847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfOS0zLTEtMS0zNTc0Nw_9021878f-9902-41a8-b2ba-b7cacc24f1cf"
      unitRef="usd">18435000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTAtMS0xLTEtMzU3NDc_978f4696-61d3-4bc7-873a-5c117fb077b9"
      unitRef="usd">107723000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTAtMy0xLTEtMzU3NDc_82553caf-2933-4f09-8088-2de5da8f8b97"
      unitRef="usd">101257000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTEtMS0xLTEtMzU3NDc_2f048f88-02b5-4823-8566-e1c7087e8ab1"
      unitRef="usd">1289672000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTEtMy0xLTEtMzU3NDc_04515a5c-f42e-49ec-ba91-01645131d77e"
      unitRef="usd">1196090000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpmN2FjNzkzMWQyZTE0M2FhOGJlNTYzNDAyOGQwMGRhOF81OA_520210d9-137c-4c8c-85fe-d6a66d9e9bef"
      unitRef="usd">9109000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpmN2FjNzkzMWQyZTE0M2FhOGJlNTYzNDAyOGQwMGRhOF82NQ_258123da-8f15-4926-badd-b2517ff4a1d8"
      unitRef="usd">19900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMS0xLTEtMzU3NDc_56d721e8-0bd1-4c2f-9bf4-2aa4ec263b02"
      unitRef="usd">106189000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTItMy0xLTEtMzU3NDc_abffa7bc-002c-46a7-8e66-740162a4dd00"
      unitRef="usd">111190000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTMtMS0xLTEtMzU3NDc_d411550b-db21-4f3a-b995-23af16d08a34"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTMtMy0xLTEtMzU3NDc_0f61db1b-0105-4c99-a3f2-aaca4fa54a5e"
      unitRef="usd">289000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTQtMS0xLTEtMzU3NDc_3df489e4-6f88-4ba0-b4b1-d88a9857300f"
      unitRef="usd">84686000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTQtMy0xLTEtMzU3NDc_8fa33ebf-2f3a-4e04-b4de-4d1de54b8462"
      unitRef="usd">73023000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTUtMS0xLTEtMzU3NDc_1e715a86-7cdc-49d3-ae5d-ee91ea2d90a0"
      unitRef="usd">2000986000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTUtMy0xLTEtMzU3NDc_3e42870f-2217-40fb-979c-0002d5d676e6"
      unitRef="usd">1856968000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTgtMS0xLTEtMzU3NDc_d5f87da0-1189-4222-85c7-565a6993b254"
      unitRef="usd">43509000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTgtMy0xLTEtMzU3NDc_90d22c14-d1f5-4872-9f39-4e72fde2cc16"
      unitRef="usd">38217000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTktMS0xLTEtMzU3NDc_6a47560f-f899-47fb-a4cc-6b3965dcf8cc"
      unitRef="usd">161068000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMTktMy0xLTEtMzU3NDc_95eef06e-5661-4746-b4e7-787f313f042a"
      unitRef="usd">141001000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjAtMS0xLTEtMzU3NDc_3ac89db5-ff5c-4746-9bbb-8ba19ce863ee"
      unitRef="usd">176239000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjAtMy0xLTEtMzU3NDc_5f2bcf3a-889d-479b-9712-2d3a98760096"
      unitRef="usd">150836000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjEtMS0xLTEtMzU3NDc_a4197291-aa0f-4f12-9e89-690b296c23d3"
      unitRef="usd">12521000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjEtMy0xLTEtMzU3NDc_9b7af371-db11-4e57-81db-fdd5ab12b465"
      unitRef="usd">12995000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjItMS0xLTEtMzU3NDc_706bde4d-ae85-4d8d-b516-a73545f04304"
      unitRef="usd">34035000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjItMy0xLTEtMzU3NDc_c8feea01-ae18-4dd4-809f-d6975e6346a9"
      unitRef="usd">31233000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjMtMS0xLTEtMzU3NDc_a211b362-0bb0-4889-b3d5-029f5b19d614"
      unitRef="usd">427372000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjMtMy0xLTEtMzU3NDc_5c22d425-e4d7-4d14-ac2e-1706c9ca396d"
      unitRef="usd">374282000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjQtMS0xLTEtMzU3NDc_6c8a64f0-fa59-4124-b2fc-dc4d9a85000d"
      unitRef="usd">442413000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjQtMy0xLTEtMzU3NDc_8bb59ea6-ebb1-40fb-a4fc-0e217d6479f1"
      unitRef="usd">432075000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjUtMS0xLTEtMzU3NDc_d1970fad-befe-4b53-9fc9-5b61fcdafc01"
      unitRef="usd">72619000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjUtMy0xLTEtMzU3NDc_1cee193d-bb10-4f01-ae89-75ddec0b1940"
      unitRef="usd">69309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjYtMS0xLTEtMzU3NDc_5405ccad-5790-42c3-9fb2-4347dd1d1831"
      unitRef="usd">6179000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjYtMy0xLTEtMzU3NDc_983e93ca-0137-4245-adc1-66fc79c3d31b"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjctMS0xLTEtMzU3NDc_229d5886-dee7-4e27-956f-bb98eceba7b7"
      unitRef="usd">13408000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjctMy0xLTEtMzU3NDc_c84d41f9-21ae-4823-9185-000a74ffb750"
      unitRef="usd">4979000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjgtMS0xLTEtMzU3NDc_f089c6f3-7e95-46eb-a353-2070413c3728"
      unitRef="usd">961991000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjgtMy0xLTEtMzU3NDc_67ace592-cc42-4634-b719-5212822bee2a"
      unitRef="usd">880645000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMjktMS0xLTEtMzU3NDc_9ebbf8d7-a81c-4dcc-bc5a-ed4bd0db5827"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8yMQ_155018ef-27ba-41bc-93b2-d779358753df"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8yMQ_3b6b63de-27cb-427a-950e-9b6a54723821"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8zNQ_1084daff-aee0-402e-a9a7-99aaab60acac"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV8zNQ_6561b659-b195-4a1d-b56b-134a9c4e68e8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_07e97639-1a14-4987-ad35-61419eff52f1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_5ea9a778-b01c-4091-b839-36391c2bf5da"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_9d5bd820-3f7d-43f9-9adb-0687b6883a66"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjpkMjczNmU1MzM5Y2I0ZDY5OTQ5OWNlMTE4NTU2MjhhMV81Nw_aedc33f9-ce97-45d4-80d2-7db560253126"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMS0xLTEtMzU3NDc_573ab912-8c3f-4a5d-bbac-021a1006b193"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzEtMy0xLTEtMzU3NDc_28ce2e12-89de-4d79-96d2-c5c06a4dcae1"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8xOA_a84b11e2-623e-47ec-aa7d-11fd1cafcda2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8xOA_f6b46d95-2d6c-4530-be6a-231d4f2023d2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8zMg_72c6ac0d-4c58-40de-82c4-94f21730655f"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl8zMg_965ec9ce-227a-4e7d-8191-cf78c242be21"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl81NA_8bb15419-3389-49bf-83d7-93cdb67c2f61"
      unitRef="shares">37780242</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl82MQ_0df9233d-495c-4ff1-bb3a-b26de8c9c4d9"
      unitRef="shares">37674868</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl84Mw_655f33a9-8674-49bf-bb00-6c06ddc65459"
      unitRef="shares">32432527</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplZjQ2ZTJmM2JjMWE0YmJjOGVjYjkxMTc5OTEyNmVhZl85MA_baec4329-5dbc-4b6b-8e59-dc0cc8f72b07"
      unitRef="shares">32509969</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMS0xLTEtMzU3NDc_e541e48f-1f3f-4e24-a226-d73a5ccdf5c9"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzItMy0xLTEtMzU3NDc_f978fb98-60a2-46c2-b490-e5623d9d17c5"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzMtMS0xLTEtMzU3NDc_c293f7de-975f-4861-bde8-76ddd13681ed"
      unitRef="usd">743276000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzMtMy0xLTEtMzU3NDc_bbbf5adf-c14e-476c-82ac-6f426652c0d8"
      unitRef="usd">728118000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplNzhjYTAwZTU3ZTg0YzJhOGYzNjM2OTUyOTRkZDQyNV8yOA_dcf89d31-20e7-456c-8e91-d63e51ff86ae"
      unitRef="shares">5347715</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMC0xLTEtMzU3NDcvdGV4dHJlZ2lvbjplNzhjYTAwZTU3ZTg0YzJhOGYzNjM2OTUyOTRkZDQyNV8zNQ_1811b1bb-3f4e-4d5b-8d56-36479feaa29a"
      unitRef="shares">5164899</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMS0xLTEtMzU3NDc_73faf4d8-8269-4c58-8cf6-021fa9addd90"
      unitRef="usd">457981000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzQtMy0xLTEtMzU3NDc_89d16991-9030-4c2f-8e2c-104968988779"
      unitRef="usd">435868000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzYtMS0xLTEtMzU3NDc_e78565a2-70f2-414e-bd23-ac82fab9f898"
      unitRef="usd">700313000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzYtMy0xLTEtMzU3NDc_a8bb99df-d7d8-4492-9e1b-78c7e342f657"
      unitRef="usd">639063000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzctMS0xLTEtMzU3NDc_e25d26f1-a5ea-4299-b526-be96c0dd24d1"
      unitRef="usd">985646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzctMy0xLTEtMzU3NDc_0793e8c8-6ade-42a9-b664-e0c5ca40c51c"
      unitRef="usd">931351000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzgtMS0xLTEtMzU3NDc_611f506c-3381-4d33-a076-6ff9d1cad345"
      unitRef="usd">53349000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzgtMy0xLTEtMzU3NDc_b482383d-f8a5-48e4-99da-754a045c3b81"
      unitRef="usd">44972000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzktMS0xLTEtMzU3NDc_47e2b318-cb9b-4ad7-aaba-255407ec1eef"
      unitRef="usd">1038995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfMzktMy0xLTEtMzU3NDc_c1c41e8c-f993-41d2-b8ea-309f52549e0c"
      unitRef="usd">976323000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNDAtMS0xLTEtMzU3NDc_dbfa2ed8-ebfa-42fa-8b80-c181262e4fc6"
      unitRef="usd">2000986000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8xOS9mcmFnOjgyNTNlMDAwMGY2ZjQwZTNiZDA3M2RmNjlkMmY1YWI2L3RhYmxlOmJjN2RhMDRmY2NkMDRhNThiMzE3NGM5OTU2NDI0Y2U2L3RhYmxlcmFuZ2U6YmM3ZGEwNGZjY2QwNGE1OGIzMTc0Yzk5NTY0MjRjZTZfNDAtMy0xLTEtMzU3NDc_9bf5c9ac-88ad-411d-8513-ea0b70669b7b"
      unitRef="usd">1856968000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi0xLTEtMS0zNTc0Nw_da58fbb7-0fb7-4d27-b7d7-659b300fc147"
      unitRef="usd">557890000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi0zLTEtMS0zNTc0Nw_5a1e9b08-4cb3-4c23-baff-dc4ea3e87c9d"
      unitRef="usd">564166000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi01LTEtMS0zNTg3NA_e7048ecd-ee39-4107-add6-4dcadcd46bd2"
      unitRef="usd">1103147000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMi03LTEtMS0zNTg3NA_72811195-21a4-4431-b19c-d54f79135ad2"
      unitRef="usd">1101310000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy0xLTEtMS0zNTc0Nw_d7939c85-13e8-4e89-aeae-290ab8110630"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy0zLTEtMS0zNTc0Nw_799d746a-d4ca-42d2-99c2-37a89b60e2aa"
      unitRef="usd">4603000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy01LTEtMS0zNTg3NA_315da929-8cf2-426a-bdf4-d1398a68d1ca"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMy03LTEtMS0zNTg3NA_d7b11aae-e024-4034-8ffb-73cd45caa2b3"
      unitRef="usd">13304000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC0xLTEtMS0zNTc0Nw_40623407-7425-4afd-9b91-d95629142d33"
      unitRef="usd">316211000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC0zLTEtMS0zNTc0Nw_6fad0a6e-e670-45c8-8f35-f71542a08340"
      unitRef="usd">308691000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC01LTEtMS0zNTg3NA_709924b0-5ce7-49b6-a8e3-8048d3127bc4"
      unitRef="usd">621031000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNC03LTEtMS0zNTg3NA_e12c6b8d-c0b2-42cb-8815-d4a3858c073c"
      unitRef="usd">605894000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi0xLTEtMS0zNTc0Nw_e17f95e9-d41a-42c8-99ed-445d86e0c4ed"
      unitRef="usd">127758000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi0zLTEtMS0zNTc0Nw_d0630321-e9f0-48a2-828d-364f9e09b94e"
      unitRef="usd">114335000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi01LTEtMS0zNTg3NA_29b88be8-6999-4303-8735-d49751cc9ef9"
      unitRef="usd">251238000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNi03LTEtMS0zNTg3NA_d9168c1d-dbfb-4db1-b023-1c8d19caab8e"
      unitRef="usd">230160000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy0xLTEtMS0zNTc0Nw_418566da-8412-427b-8b4f-443161a6f85e"
      unitRef="usd">5148000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy0zLTEtMS0zNTc0Nw_9d24da02-2810-499d-b1c3-168d0bcf3cca"
      unitRef="usd">6156000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy01LTEtMS0zNTg3NA_6296f59b-f249-4180-b056-3441195e2d7b"
      unitRef="usd">12495000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfNy03LTEtMS0zNTg3NA_1a4c401d-cdfd-43a7-a224-8391ec0622b0"
      unitRef="usd">13463000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC0xLTEtMS0zNTc0Nw_2743e81b-46a0-4762-b334-f8ad64ebecb0"
      unitRef="usd">54912000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC0zLTEtMS0zNTc0Nw_e142b514-8ddc-401a-9bcb-d52f0a7fd230"
      unitRef="usd">54731000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC01LTEtMS0zNTg3NA_e09d567b-a5d9-4387-b4f0-97ac5c1728bf"
      unitRef="usd">108552000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOC03LTEtMS0zNTg3NA_0e5c001b-c9c4-4ae6-a132-9863dec3d70f"
      unitRef="usd">103837000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS0xLTEtMS0zNTc0Nw_a2765de2-ccba-4832-b691-2cd2ea322909"
      unitRef="usd">6220000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS0zLTEtMS0zNTc0Nw_5d3d2e61-c223-4283-9a99-a50490ea5fff"
      unitRef="usd">6721000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS01LTEtMS0zNTg3NA_dbc20050-90fd-4465-b7b1-41ef5aa322ec"
      unitRef="usd">14228000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfOS03LTEtMS0zNTg3NA_52d7598a-57a8-4d55-8aa8-cb8e95c2263e"
      unitRef="usd">14276000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtMS0xLTEtMzU3NDc_6a79a4ba-95ed-4d70-98d3-bac6212b64d7"
      unitRef="usd">510249000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtMy0xLTEtMzU3NDc_edc9a59b-06fe-4500-b328-cb86c222f9a2"
      unitRef="usd">490634000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtNS0xLTEtMzU4NzQ_2581b4b7-a055-4a92-81d0-0db13e25146d"
      unitRef="usd">1007544000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTAtNy0xLTEtMzU4NzQ_91783ce7-9c14-4de2-9f3c-6cb062b8d568"
      unitRef="usd">967630000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtMS0xLTEtMzU3NDc_325058c3-5760-4fc0-8b68-1cd35fc939be"
      unitRef="usd">47641000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtMy0xLTEtMzU3NDc_dd6d942c-aeaa-44b1-90e4-351f77dae909"
      unitRef="usd">78135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtNS0xLTEtMzU4NzQ_fd0fd453-fad0-44eb-ba41-735205caa498"
      unitRef="usd">95603000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTEtNy0xLTEtMzU4NzQ_2da13426-72b2-47c8-acac-02501a08d6bd"
      unitRef="usd">146984000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtMS0xLTEtMzU3NDc_7b37da7a-6034-4991-8dd6-b5e47d458822"
      unitRef="usd">36000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtMy0xLTEtMzU3NDc_b4f80158-6895-44b1-b10b-8ab1bd69ee60"
      unitRef="usd">25000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtNS0xLTEtMzU4NzQ_9d7107c3-ecef-42fa-9747-3a788da7cada"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTMtNy0xLTEtMzU4NzQ_f13b51d5-4299-4e1e-8bc2-ec8fe5be6fb0"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtMS0xLTEtMzU3NDc_1ab5223d-0a73-4f73-ab9c-7d6b4bc5b8f4"
      unitRef="usd">8311000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtMy0xLTEtMzU3NDc_b9bc6fc8-b6dc-4764-acba-7eb2969e448c"
      unitRef="usd">1932000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtNS0xLTEtMzU4NzQ_407cce90-1412-4c6e-81c7-d93d80d7c592"
      unitRef="usd">11484000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTQtNy0xLTEtMzU4NzQ_8f012391-0ed7-4290-8af4-dcc390a1327d"
      unitRef="usd">4004000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtMS0xLTEtMzU3NDc_c1cfaa6c-cdec-46cb-a94f-34d0aed641d0"
      unitRef="usd">659000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtMy0xLTEtMzU3NDc_1b824a55-c762-4e70-a30d-4b22b591e4c1"
      unitRef="usd">1370000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtNS0xLTEtMzU4NzQ_f3c01cbc-a020-45a9-a291-6048681935ad"
      unitRef="usd">-744000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTUtNy0xLTEtMzU4NzQ_5d536b40-0a3e-4f3e-abd0-9d8baf4b2c8e"
      unitRef="usd">2488000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMS0xLTEtMzU4OTI_e37166d8-c064-40ef-b7b0-37d8168dbbf2"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMy0xLTEtMzU4OTI_f18077cf-ded9-49ee-8a82-6de0f83884db"
      unitRef="usd">31092000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNS0xLTEtMzU4ODc_052246d4-5401-48c3-88f6-dd9302509138"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNy0xLTEtMzU4ODc_e3241bce-3d2c-462c-a023-5be97d0c7d13"
      unitRef="usd">31092000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMS0xLTEtMzU3NDc_22adee1a-a160-4cc0-8e14-51ec64d1ab3a"
      unitRef="usd">331000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtMy0xLTEtMzU3NDc_0484e0c9-388c-434c-ba55-4bb20f67109e"
      unitRef="usd">475000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNS0xLTEtMzU4NzQ_3dc5cf99-03ef-412a-ac76-401b38821d89"
      unitRef="usd">664000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTYtNy0xLTEtMzU4NzQ_a255a46f-86bc-4801-9fcf-da48acb5d819"
      unitRef="usd">763000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctMS0xLTEtMzU3NDc_b05109e7-ee14-4276-b64f-0815583c0204"
      unitRef="usd">-7285000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctMy0xLTEtMzU3NDc_836a72df-d2a3-49bf-a145-23fab82da285"
      unitRef="usd">31030000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctNS0xLTEtMzU4NzQ_1ae0e058-cca9-4b8a-9205-3eca50f8cd1f"
      unitRef="usd">-11515000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTctNy0xLTEtMzU4NzQ_0aaebcb7-b064-4880-884c-c8bb670d0096"
      unitRef="usd">30388000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtMS0xLTEtMzU3NDc_108ed650-1fe0-4359-a5e8-999de6f65c92"
      unitRef="usd">40356000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtMy0xLTEtMzU3NDc_7a33a751-34a9-4117-9ce3-a1f4a44d7fe2"
      unitRef="usd">109165000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtNS0xLTEtMzU4NzQ_7fc97e76-45e4-45ae-8d7a-7afe59185a4b"
      unitRef="usd">84088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTgtNy0xLTEtMzU4NzQ_df78fdbe-dee7-4311-be6b-c1e447122536"
      unitRef="usd">177372000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktMS0xLTEtMzU3NDc_d9576197-c313-49f1-afef-da5efa1c83b4"
      unitRef="usd">11319000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktMy0xLTEtMzU3NDc_7c841f6a-0134-4c78-aa58-4f3d895985b2"
      unitRef="usd">28546000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktNS0xLTEtMzU4NzQ_deb3e8ac-4cf0-4f62-ad15-48fcd3046fbb"
      unitRef="usd">23338000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMTktNy0xLTEtMzU4NzQ_f994af65-a4b6-488f-be91-aaa145f76a0b"
      unitRef="usd">46461000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtMS0xLTEtMzU3NDc_3b904a2c-c233-4fac-b19c-74e6bde62cfc"
      unitRef="usd">29037000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtMy0xLTEtMzU3NDc_880281e1-9e04-42ac-98dd-eb64c33b592a"
      unitRef="usd">80619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtNS0xLTEtMzU4NzQ_3e5822ab-3b45-4f57-b47e-f3b337810993"
      unitRef="usd">60750000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjAtNy0xLTEtMzU4NzQ_df465871-5e33-4d59-b5e1-9a27d6ee455b"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtMS0xLTEtMzU3NDc_bb9093e3-f676-41f7-88dd-18b3bdf8e158"
      unitRef="usd">-542000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtMy0xLTEtMzU3NDc_f6a7b550-11f2-4efa-ae41-9eadb3566374"
      unitRef="usd">470000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtNS0xLTEtMzU4NzQ_3fb425b3-1530-4f56-a905-9860159b5285"
      unitRef="usd">-500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjEtNy0xLTEtMzU4NzQ_239a30b8-8262-47b0-bc8f-12bba7baeaae"
      unitRef="usd">892000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItMS0xLTEtMzU3NDc_975104c0-9f70-42bf-a41c-739447988d8f"
      unitRef="usd">29579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItMy0xLTEtMzU3NDc_90eedf2a-a297-4395-9f9d-950700e3a824"
      unitRef="usd">80149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItNS0xLTEtMzU4NzQ_77ffc5b2-8117-4766-b70b-9a4decb06b67"
      unitRef="usd">61250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjItNy0xLTEtMzU4NzQ_ff9836f3-7ae1-4272-bb16-99755e00e0c0"
      unitRef="usd">130019000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjQtMS0xLTEtMzU3NDc_3aec8512-d584-43b7-9502-59f70681c02a"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjQtMy0xLTEtMzU3NDc_d60cb35f-a465-4691-ad49-9701191f331c"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNS0xLTEtMzU4ODc_150552d8-6446-485f-a1f3-7d4f23f33eb5"
      unitRef="usdPerShare">1.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNy0xLTEtMzU4ODc_f703bfc7-49d9-464d-84ca-18a3dcbb3fab"
      unitRef="usdPerShare">3.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtMS0xLTEtMzU3NDc_3d26fd30-f575-41db-be39-95f8df12a4c8"
      unitRef="shares">32522000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtMy0xLTEtMzU3NDc_5063da07-4530-4cb7-b045-95918f35eba9"
      unitRef="shares">32588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNS0xLTEtMzU4NzQ_7c95f3ef-3b68-4ca0-bd0b-edc59ce4d798"
      unitRef="shares">32538000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjUtNy0xLTEtMzU4NzQ_041b94d3-fe44-4e00-8fe1-09eab9bd7132"
      unitRef="shares">32684000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjctMS0xLTEtMzU3NDc_7752012c-0aba-4b5a-8fab-17f48faa1903"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjctMy0xLTEtMzU3NDc_37cf39f4-f344-4118-bd20-1f45ab73582b"
      unitRef="usdPerShare">2.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNS0xLTEtMzU4ODc_df1ca802-43b9-4d6c-bad2-8b0d8b5e6cd0"
      unitRef="usdPerShare">1.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNy0xLTEtMzU4ODc_883c2c4d-422f-45fb-9094-c7b94ce34255"
      unitRef="usdPerShare">3.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtMS0xLTEtMzU3NDc_e3207499-b61f-47c3-900c-5d9d5da0d7ca"
      unitRef="shares">32681000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtMy0xLTEtMzU3NDc_53a0925b-5d2b-4ce7-9935-19061e44a65e"
      unitRef="shares">32981000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNS0xLTEtMzU4NzQ_a9f91595-2dd8-4d55-a948-74f9952f4165"
      unitRef="shares">32722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yNS9mcmFnOjc2NjkxNTQ4NjEyZTQ5MDlhYzQ2OTZjZTIzNDlhOWFiL3RhYmxlOjI2MzJlMDg1ZTBjOTRlN2M4YmZkNDhhNDMxYzc5M2Y5L3RhYmxlcmFuZ2U6MjYzMmUwODVlMGM5NGU3YzhiZmQ0OGE0MzFjNzkzZjlfMjgtNy0xLTEtMzU4NzQ_3c048e98-cc96-4396-a007-63920c18d177"
      unitRef="shares">33085000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i884839468e984a559b74bef4467c132b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xLTEtMS0zNTc0Nw_87eaa2e5-848d-4777-8d1b-5404bcae5e57"
      unitRef="usd">1020652000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i71f5d916ca034210bdab3c3695b2b7d5_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0zLTEtMS0zNTc0Nw_1862fd7e-f6df-4107-b195-8d166badefcf"
      unitRef="shares">37763705</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71f5d916ca034210bdab3c3695b2b7d5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy01LTEtMS0zNTc0Nw_d140bfe4-d666-4754-903d-a9c763e40b08"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51eae5477dbe4bb3813cfeef5b1df172_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy03LTEtMS0zNTc0Nw_bf30a1c1-7af2-4a33-a3fc-7ba53697fbe3"
      unitRef="usd">736536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2230db8bb5304021a778e00e8cbc9e95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy05LTEtMS0zNTc0Nw_b5becda2-8399-4517-b2e7-fc9021b24b84"
      unitRef="usd">-440550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32561722ebd4483cb2b211fd8482b221_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xMS0xLTEtMzU3NDc_e8c7519a-b634-4bb9-b8cd-a433eedef9b4"
      unitRef="usd">670734000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab48083f8c03445890bc710f5ef75ea7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMy0xMy0xLTEtMzU3NDc_e980fa6a-22c0-453d-a516-e30e850dd4d5"
      unitRef="usd">53894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC0xLTEtMS0zNTc0Nw_678c08b3-0bfc-4a8c-95a4-94857b639833"
      unitRef="usd">906000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC0zLTEtMS0zNTc0Nw_951907ab-64cf-4810-8a76-034b04bbc8a4"
      unitRef="shares">6184</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNC03LTEtMS0zNTc0Nw_ebde7948-6e4c-43b6-be0e-f219104f15ef"
      unitRef="usd">906000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS0xLTEtMS0zNTc0Nw_10375f7b-e9e7-492f-89fa-d734c46c954d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS0zLTEtMS0zNTc0Nw_be04eae2-9bd6-4614-9cda-0102db89b11b"
      unitRef="shares">3812</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS01LTEtMS0zNTc0Nw_ec8e994a-85e5-4840-8231-f2ddfd96cb6b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNS03LTEtMS0zNTc0Nw_6ec629ef-fae2-4342-bd77-c502efe3e50a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi0xLTEtMS0zNTc0Nw_c8ee1787-48b3-4ba9-b75a-c8962803b9bf"
      unitRef="usd">686000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9747ba22c25643a981e544cb176796d5_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi0zLTEtMS0zNTc0Nw_ab0b4c9e-039e-4d19-b472-b51de100c9f5"
      unitRef="shares">6541</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNi03LTEtMS0zNTc0Nw_8911a46e-ac6f-4629-a429-c3c5fcf5f638"
      unitRef="usd">686000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNy0xLTEtMS0zNTc0Nw_c2b00f08-d5f4-4fb8-952c-866970189609"
      unitRef="usd">5148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i04c3134e96224eb4b9730f1d0d308e53_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNy03LTEtMS0zNTc0Nw_ab456a92-5b87-444a-86cc-b0de1d9b35bd"
      unitRef="usd">5148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOC0xLTEtMS0zNTc0Nw_ab8a6a87-ebaf-4dfb-b6ea-fd4545ebd61e"
      unitRef="usd">80000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOC05LTEtMS0zNTc0Nw_ca5976d3-2ce3-4bd9-8cbe-c811a3fb500c"
      unitRef="usd">80000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xLTEtMS0zODUzNQ_624998eb-79df-4244-a6da-a73fa02b74c6"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ida01d662674e4c9cad246670fadbaaec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS05LTEtMS0zODUzNQ_16d2b9d6-d1c3-48ec-bc52-5458fa79b17e"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xLTEtMS0zNTc0Nw_47b24c5d-1a3d-432d-a9a1-39aaf304ac68"
      unitRef="usd">300000</amed:ContributionsAttributableToNoncontrollingInterest>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfOS0xMy0xLTEtMzU3NDc_48b4b3bf-e4b8-4fc1-b52f-b670b2a7c582"
      unitRef="usd">300000</amed:ContributionsAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTAtMS0xLTEtMzU3NDc_631ff6f3-9a5a-444a-930f-81784ccd18fe"
      unitRef="usd">303000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTAtMTMtMS0xLTM1NzQ3_2e86e3c3-2360-4a3a-86a7-79636f9df26b"
      unitRef="usd">303000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMS0xLTEtMzU3NDc_8df57704-2ec7-4787-b6bb-495b30d206bd"
      unitRef="usd">29037000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4391a27b2ec040e3b60979194de2e669_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMTEtMS0xLTM1NzQ3_4656a466-93d8-490d-870e-bcc20f1d5b20"
      unitRef="usd">29579000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id819fc0b602a48dcb4da66d6fe844810_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTEtMTMtMS0xLTM1NzQ3_f712b06e-12c5-4a8e-9ef6-c45f39e08f47"
      unitRef="usd">-542000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMS0xLTEtMzU3NDc_c9c041b2-0fab-4153-a767-c3006a8063ef"
      unitRef="usd">1038995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMy0xLTEtMzU3NDc_5a9c65f9-06fe-4bdd-9524-50e8b77402a5"
      unitRef="shares">37780242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItNS0xLTEtMzU3NDc_e4370d3b-052a-4699-b4fc-6a44d74b829e"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2ba1440544d42adba0dee3d24db10cd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItNy0xLTEtMzU3NDc_a47a0ac0-33d7-41d7-aa12-9fa97beea0e1"
      unitRef="usd">743276000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc52bda628494beea698958f49b62ec5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItOS0xLTEtMzU3NDc_815d46d2-c24d-42ac-a8b3-8e01f2d53294"
      unitRef="usd">-457981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9621fe17f1f49e2abf92921c9bbd090_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMTEtMS0xLTM1NzQ3_3cede677-8c62-416a-8335-8747e2802d14"
      unitRef="usd">700313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTItMTMtMS0xLTM1NzQ3_506440ee-10a2-4417-a29c-67b00ee72605"
      unitRef="usd">53349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3db8313abf4642c7a45dab30e9b2b38e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMS0xLTEtMzU3NDc_60c68ba0-8d84-4000-bd7c-ab06814d5ceb"
      unitRef="usd">789574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMy0xLTEtMzU3NDc_c963a8d9-1612-42d5-b78f-ef12e43ac2e2"
      unitRef="shares">37538837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a9c084ce2754cbfbd6f699cf9e01e12_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctNS0xLTEtMzU3NDc_c61df3a3-c04a-4c95-af16-3c479c32968d"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c0b9d2e84db40329330261a2e77cf52_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctNy0xLTEtMzU3NDc_d912c650-e03f-47ff-9cd7-8b2a9dcd2a26"
      unitRef="usd">707006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae38203cf58b41608713238c84238a48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctOS0xLTEtMzU3NDc_6121b704-95be-48de-b512-3040da236858"
      unitRef="usd">-398752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32c45951e3954adf99132111ec0188e3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMTEtMS0xLTM1NzQ3_99007f67-9006-43ad-9e9b-5ea02587fdaf"
      unitRef="usd">479861000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9333e57ab0fb4dc2aed54d98767627d6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTctMTMtMS0xLTM1NzQ3_d9646f83-4dc1-48b4-bbb4-44d12b5cc4bf"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtMS0xLTEtMzU3NDc_f3798d00-24cc-4909-9656-43309b1e5c8f"
      unitRef="usd">913000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtMy0xLTEtMzU3NDc_e072bad0-b3e7-4315-8bdd-da5728def4c6"
      unitRef="shares">4060</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTgtNy0xLTEtMzU3NDc_dab6c3b6-368f-4c86-ae7c-2979ef6d1f3d"
      unitRef="usd">913000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktMS0xLTEtMzU3NDc_1d879c12-9b69-4422-a462-34844ba7b213"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktMy0xLTEtMzU3NDc_542a6082-d339-43bb-983d-4f8219b57fcb"
      unitRef="shares">4068</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktNS0xLTEtMzU3NDc_737a00e6-2edd-4aa4-beb6-1b687cbd35f5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMTktNy0xLTEtMzU3NDc_3cbdb883-dfb3-41a3-8eac-cdc6f86e3ca1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtMS0xLTEtMzU3NDc_3e383fbc-e4d0-4391-ba1b-8b1f31d63232"
      unitRef="usd">259000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i86ddbd8b9acb476a8ff6e1cf70fb6f80_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtMy0xLTEtMzU3NDc_c76a6787-0e07-4bdd-a725-4db260c1dbc5"
      unitRef="shares">6390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjAtNy0xLTEtMzU3NDc_c604b08e-b3ab-444f-a100-f8a02020df96"
      unitRef="usd">259000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjEtMS0xLTEtMzU3NDc_363b7ca3-33ea-46a0-87db-8bc1051644ee"
      unitRef="usd">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d48e25a4ab747bea24391142246d356_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjEtNy0xLTEtMzU3NDc_3e8e2f75-5089-4245-8e3a-50e796552aa0"
      unitRef="usd">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjItMS0xLTEtMzU3NDc_165dbdfa-7d20-4134-84aa-395a10d4221d"
      unitRef="usd">170000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjItOS0xLTEtMzU3NDc_f24b5d68-4fe0-43de-910d-a5747cbcf528"
      unitRef="usd">170000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjMtMS0xLTEtMzU3NDc_4b5ff3d9-263c-4969-b007-cf37131a4586"
      unitRef="usd">1188000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i14c495664b294fa0a1ab27069c7ab08e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjMtOS0xLTEtMzU3NDc_be44f33f-bbe8-4942-9abd-50e4c61f1d3d"
      unitRef="usd">1188000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjQtMS0xLTEtMzU3NDc_788295c6-a08c-4e47-81e0-0a44b6ef646d"
      unitRef="usd">276000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3e12a01376444b3e9c94160b47756002_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjQtMTMtMS0xLTM1NzQ3_5fa0f2f4-80d9-4799-a54c-d8c31bb26903"
      unitRef="usd">276000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMS0xLTEtMzU3NDc_79d6faee-81dc-452c-af8e-524e87bd4e93"
      unitRef="usd">80619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic7645017f9994d879ea8bd6a157e52a6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMTEtMS0xLTM1NzQ3_7605bc3e-79ee-49b9-bede-16b195503890"
      unitRef="usd">80149000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e12a01376444b3e9c94160b47756002_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjUtMTMtMS0xLTM1NzQ3_4520ee48-61cf-4fe7-9313-e4c2b91d188e"
      unitRef="usd">470000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMS0xLTEtMzU3NDc_6fc005cf-d7ba-417b-a3fd-f06bc729c539"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMy0xLTEtMzU3NDc_308431b1-4c7a-45b8-9fb4-070e6cb50ee2"
      unitRef="shares">37553355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtNS0xLTEtMzU3NDc_aa31f256-96a4-4778-a360-37f063670b8f"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e9c6f9bcae458e87824df14a960f90_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtNy0xLTEtMzU3NDc_381094a8-cbc1-4cb9-9df1-211cb2eb7616"
      unitRef="usd">714334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97712cb7eec54f298eacfb74dd9aa06e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtOS0xLTEtMzU3NDc_197d55f0-b2dc-4007-be30-ec40b74313f0"
      unitRef="usd">-400110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f7e2f3718a14010b98f596f57fe8413_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMTEtMS0xLTM1NzQ3_61b9202b-e418-4cc4-b40f-67e0f08c5878"
      unitRef="usd">560010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e1ebf15a9194fddad714c86f2a2011f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMjYtMTMtMS0xLTM1NzQ3_ee0177b2-df39-4435-8210-ac43f52f9843"
      unitRef="usd">1615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMS0xLTEtMzYxMTE_2d7ffb68-ced9-4fa5-9779-834b1b04d26d"
      unitRef="usd">976323000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i9951a73c939a4d0aaf3f9c73a0930342_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMy0xLTEtMzYxMTE_ddf475dd-160a-45f3-87da-594e621e25e6"
      unitRef="shares">37674868</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9951a73c939a4d0aaf3f9c73a0930342_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtNS0xLTEtMzYxMTE_52cf6ddf-c0fa-4043-901b-67e1e04b5546"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac753950cce74a30b0bff2362d5e2d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtNy0xLTEtMzYxMTE_ccbbb17e-ece8-406e-988e-6cdd200905b5"
      unitRef="usd">728118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0f83eb525d94a3eb4a2470165f6dff2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtOS0xLTEtMzYxMTE_55847c5f-33c2-44bf-a477-7d01c74874f2"
      unitRef="usd">-435868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib37433eb056c4c17b9f3d15134197084_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMTEtMS0xLTM2MTMy_f1c72806-7c6e-4376-8be6-938dbf8a7959"
      unitRef="usd">639063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4d5a9872b4a463fa7cbc23245d2f3f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzEtMTMtMS0xLTM2MTMy_4efdf866-5792-44bf-a981-b8e1a4cc0cc0"
      unitRef="usd">44972000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItMS0xLTEtMzYxMTE_3aebaa07-7ddf-4c33-b830-f4bc2fa9eb10"
      unitRef="usd">1891000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItMy0xLTEtMzYxMTE_4d6fd480-5b13-42d6-812c-724dd6cc3946"
      unitRef="shares">13345</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzItNy0xLTEtMzYxMTE_95a684e2-3853-4339-b61c-56e6000dc13a"
      unitRef="usd">1891000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtMS0xLTEtMzYxMTE_3b08a3e2-5424-4c93-aeae-19f807c4973a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtMy0xLTEtMzYxMTE_b869cf1a-732c-44fd-8a22-eb08fcc474fe"
      unitRef="shares">84306</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtNS0xLTEtMzYxMTE_cdae35ce-9e70-4451-9d6f-b987f2f84f41"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzMtNy0xLTEtMzYxMTE_7578cbaa-a778-4ce2-83d9-35bc902daf3c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtMS0xLTEtMzYxMTE_63740a1f-b851-4527-b216-5569520efbda"
      unitRef="usd">772000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icbc77839e04f4069814115134fefaae4_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtMy0xLTEtMzYxMTE_7a7256fb-00cb-4c02-97d9-064210a2a442"
      unitRef="shares">7723</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzQtNy0xLTEtMzYxMTE_50a7d43e-3c92-43da-b88c-8fca5e19022c"
      unitRef="usd">772000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzUtMS0xLTEtMzYxMTE_a8856928-6344-45e7-8fc2-ce31cf8c014d"
      unitRef="usd">12495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ccbed30720945e9be8d6edeb7e5c001_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzUtNy0xLTEtMzYxMTE_58233c1f-a360-41ae-b032-64bf4e6f458e"
      unitRef="usd">12495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzYtMS0xLTEtMzYxMTE_b631af8b-6dcc-49b5-b31a-b4a6fa5e6a19"
      unitRef="usd">4762000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzYtOS0xLTEtMzYxMTE_acf401fe-15d0-4cee-826b-451313848bac"
      unitRef="usd">4762000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMS0xLTEtMzYxNDU_3e73db0f-db0a-4e87-accd-fb917aedb956"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8aea8bdbb0b24508b6cdf1d55c7299b3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctOS0xLTEtMzYxNDU_2f35f8e9-464a-4421-9b78-3837f92b310e"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMS0xLTEtMzYxMTE_eabfc283-74ff-46e0-8e6b-afaa07d1bc2d"
      unitRef="usd">9852000</amed:ContributionsAttributableToNoncontrollingInterest>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzctMTMtMS0xLTM2MTMy_67944bc5-0224-40f8-a5d1-8425adf40f3b"
      unitRef="usd">9852000</amed:ContributionsAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzgtMS0xLTEtMzYxMTE_96da3402-b6cb-44cd-9a6c-6f5b8827edb0"
      unitRef="usd">975000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzgtMTMtMS0xLTM2MTMy_e75c5142-3863-402b-8838-725f8fada1d8"
      unitRef="usd">975000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMS0xLTEtMzYxMTE_0aa8d2a7-cbb1-4238-ab48-86ca93c0b043"
      unitRef="usd">60750000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8b210127b1934564bef8ed600a885868_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMTEtMS0xLTM2MTMy_a6704051-643c-4821-bb92-8f72c4c241ea"
      unitRef="usd">61250000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0957520864eb4c48897b80a5a22857b4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfMzktMTMtMS0xLTM2MTMy_6736e143-f578-4783-a153-95ad65108952"
      unitRef="usd">-500000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMS0xLTEtMzYxMTE_124cd356-06c5-4b54-8ecf-23a09a506c3c"
      unitRef="usd">1038995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMy0xLTEtMzYxMTE_ad675a32-c20c-422c-be5e-2d099900b22b"
      unitRef="shares">37780242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c4aeb15060148eba081e4dfc943a331_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtNS0xLTEtMzYxMTE_1ce512f1-2fe7-4255-a911-f866273ab152"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2ba1440544d42adba0dee3d24db10cd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtNy0xLTEtMzYxMTE_22fda383-3cd7-4667-92cc-2f1096bcb491"
      unitRef="usd">743276000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc52bda628494beea698958f49b62ec5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtOS0xLTEtMzYxMTE_6a7e593d-55f5-4088-aba8-8ed969270dcb"
      unitRef="usd">-457981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9621fe17f1f49e2abf92921c9bbd090_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMTEtMS0xLTM2MTMy_27475af6-ca27-46cb-b957-b5512cd4529a"
      unitRef="usd">700313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f6eb883b3cb4981a2a32d5a73a9430d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDAtMTMtMS0xLTM2MTMy_f71ac87c-765c-4c3e-a1c4-a58b2fdff8fd"
      unitRef="usd">53349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5ec7ab4116e4010b85638d99e1435a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMS0xLTEtMzYwODY_050e8e2f-7814-4350-9e89-ce08f8858ce0"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iafa2140950ab4b4ca199f88ab42de2aa_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMy0xLTEtMzYwODY_0946dc7a-e848-47b8-9b8c-d7c7ba5237b8"
      unitRef="shares">37470212</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafa2140950ab4b4ca199f88ab42de2aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtNS0xLTEtMzYwODY_68af1289-79e9-422a-9267-a984fede5b4b"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9be67241b82145fa8bc84a4faa53dbcf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtNy0xLTEtMzYwODY_8828b8d2-3776-4bee-9936-1a5145032444"
      unitRef="usd">698287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f13336bd8884514937d120c30ec2a30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtOS0xLTEtMzYwODY_aa71648a-6568-413b-9b3e-f093c76492bd"
      unitRef="usd">-319092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9218609305b4e9cbeae0653ba8615ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMTEtMS0xLTM2MDg2_afb69fa3-b3a4-4947-a7d7-12ec9d55526e"
      unitRef="usd">429991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7704d89a5ea49bda984ff3bb25a28ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDUtMTMtMS0xLTM2MDg2_999cb2f6-ba83-4565-a05c-f8e7d88f38ba"
      unitRef="usd">1517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtMS0xLTEtMzYwODY_3629293c-b258-475d-a3eb-13073cf3d9dd"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtMy0xLTEtMzYwODY_24576aa7-f982-403a-a509-24a6c0533f35"
      unitRef="shares">8262</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDYtNy0xLTEtMzYwODY_52253ecb-d96f-482f-b2f1-a81635ef35e8"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctMS0xLTEtMzYwODY_a3c364e4-defd-428a-a88c-119066845917"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctMy0xLTEtMzYwODY_30e066de-1d45-4eb4-86e0-a7e8a4e6bccd"
      unitRef="shares">61069</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctNS0xLTEtMzYwODY_8903a3ae-fc9f-4883-ad1f-ae8d45b0cf14"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDctNy0xLTEtMzYwODY_1d9b88c9-641d-423b-baf6-b9caeb16234d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtMS0xLTEtMzYwODY_4cd757f4-fb37-4548-b523-b27dfeada94c"
      unitRef="usd">623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8105a457c04f4416aa8ca51a3f04a03f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtMy0xLTEtMzYwODY_15b9cc6f-3d39-459c-9225-4dadc5033ebc"
      unitRef="shares">13812</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDgtNy0xLTEtMzYwODY_d18e6790-d8bf-46ec-806e-d5b646e4ae10"
      unitRef="usd">623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDktMS0xLTEtMzYwODY_3530c730-045d-40f9-aab2-8c76bcd1838e"
      unitRef="usd">13463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1c876e1fe33d436a9f36ca6a8f1e295f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNDktNy0xLTEtMzYwODY_96dbdacc-0499-48f4-aa39-d1e07a61442e"
      unitRef="usd">13463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTAtMS0xLTEtMzYwODY_fe90d4e1-768d-4b5c-a152-d76bec97da6f"
      unitRef="usd">6944000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i64f18cac2d0249a097657acce73eae01_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTAtOS0xLTEtMzYwODY_40121735-7010-4892-9491-8bbc36020c39"
      unitRef="usd">6944000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTEtMS0xLTEtMzYwODY_3b13fcd1-97af-470a-af83-f5401f830ee0"
      unitRef="usd">74074000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i64f18cac2d0249a097657acce73eae01_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTEtOS0xLTEtMzYwODY_d564fb18-74c2-401f-ae9b-c4208a0b75e5"
      unitRef="usd">74074000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTItMS0xLTEtMzYwODY_fb8d676c-cfcb-43a5-99f2-3044d4045f90"
      unitRef="usd">794000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTItMTMtMS0xLTM2MDg2_a7413441-7ce7-4cfb-8522-e265aef95837"
      unitRef="usd">794000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMS0xLTEtMzYwODY_aa8cd8d0-2e9f-44d1-9ac0-bade06b76c12"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie6eae4c7f67f4524a74a58848d23caef_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMTEtMS0xLTM2MDg2_1e63f801-fcbc-4e0c-a815-7b9a57bcab14"
      unitRef="usd">130019000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2ff6ab9eb09f4356a5f3069aad87d97d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTMtMTMtMS0xLTM2MDg2_8c43633b-bd4c-48ff-8b50-d67ac0cf0c1b"
      unitRef="usd">892000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMS0xLTEtMzYwODY_766f7898-0bc9-4cab-a653-2db314958bae"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMy0xLTEtMzYwODY_576d1772-a5fc-4a54-8db9-d77b2507543f"
      unitRef="shares">37553355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf858571fd5b4c4796c9d0b50d88e266_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtNS0xLTEtMzYwODY_68b81735-0079-40fa-a211-b15cfc4629ea"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e9c6f9bcae458e87824df14a960f90_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtNy0xLTEtMzYwODY_f87e69fd-5791-48a0-8f11-54c8f2d81ded"
      unitRef="usd">714334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97712cb7eec54f298eacfb74dd9aa06e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtOS0xLTEtMzYwODY_5e38ce66-6e24-431f-b08d-f568fcf73d89"
      unitRef="usd">-400110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f7e2f3718a14010b98f596f57fe8413_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMTEtMS0xLTM2MDg2_8763ab42-1f15-4e36-8083-c420e585cbb5"
      unitRef="usd">560010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e1ebf15a9194fddad714c86f2a2011f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8yOC9mcmFnOjA1MGEwYmE2MDBlNjQ3ODY5NWVmYmQ5ZDFmNGE5ODMzL3RhYmxlOjdjODI0OTA5ZDA3ZjQ1OGY4NDM4NTJkZDJlOGE4YmRkL3RhYmxlcmFuZ2U6N2M4MjQ5MDlkMDdmNDU4Zjg0Mzg1MmRkMmU4YThiZGRfNTQtMTMtMS0xLTM2MDg2_e2ab0635-1b27-44a1-9d16-e9aa03227bd1"
      unitRef="usd">1615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMy0xLTEtMS0zNTc0Nw_8919c176-9fbc-4f41-a273-184a10a18e8d"
      unitRef="usd">60750000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMy0zLTEtMS0zNTc0Nw_4297a351-dd22-4755-a938-67263df90567"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNS0xLTEtMS0zNTc0Nw_4e752b23-3f1e-48d1-b486-419af23beffe"
      unitRef="usd">14228000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNS0zLTEtMS0zNTc0Nw_1dd21d50-3ca2-4f74-9d7f-5dd353ff8153"
      unitRef="usd">14276000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNi0xLTEtMS0zNTc0Nw_1864f1e8-9b37-4be4-b137-64db42e72149"
      unitRef="usd">12495000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNi0zLTEtMS0zNTc0Nw_5dd053c4-762e-4315-bd07-74f16304250b"
      unitRef="usd">13463000</us-gaap:ShareBasedCompensation>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNy0xLTEtMS0zNTc0Nw_837774ca-6df5-4efc-bed8-f6b69d999f6e"
      unitRef="usd">22463000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNy0zLTEtMS0zNTc0Nw_c0876304-6bf6-486b-b25f-21e7e2172dbd"
      unitRef="usd">19702000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOC0xLTEtMS0zNTc0Nw_cfd86b3d-e276-4471-bcd0-7315b41b9d4d"
      unitRef="usd">-531000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOC0zLTEtMS0zNTc0Nw_e0473c08-1a60-491e-987c-064cde8b8861"
      unitRef="usd">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0xLTEtMS0zNjM1NQ_d8d3d43d-8065-4e42-8cff-1bceb5a7d327"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0zLTEtMS0zNjM1NQ_300edbb5-0808-40f6-ba7f-13fc867d8a61"
      unitRef="usd">31092000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0xLTEtMS0zNTc0Nw_b1a59435-c457-4c6a-9ad3-f0b75fbce138"
      unitRef="usd">6003000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfOS0zLTEtMS0zNTc0Nw_a3710e95-f3d8-4ce9-bf9d-e4d7113db152"
      unitRef="usd">22716000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTAtMS0xLTEtMzU3NDc_3c3a0502-6ba4-4af1-9400-278bbb2bbf2e"
      unitRef="usd">-744000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTAtMy0xLTEtMzU3NDc_cc6746fb-66cd-4477-b21f-0e4ee0f3701c"
      unitRef="usd">2488000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTEtMS0xLTEtMzU3NDc_6ad35214-8d86-4256-b466-63b01c0c67cb"
      unitRef="usd">495000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTEtMy0xLTEtMzU3NDc_07ed9f3c-d18f-465a-84a1-314966147363"
      unitRef="usd">432000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTItMS0xLTEtMzU3NDc_0d84f8b5-a26c-4b08-a23b-fe1d15d123da"
      unitRef="usd">2428000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTItMy0xLTEtMzU3NDc_461edb8a-0be2-48b1-a6f1-1d83672045dd"
      unitRef="usd">2683000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTQtMS0xLTEtMzU3NDc_b720cdaa-fc85-45d2-a9cc-aafbb6b1afc9"
      unitRef="usd">21344000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTQtMy0xLTEtMzU3NDc_4bf003bd-dc2c-4a2d-81e4-94df27412880"
      unitRef="usd">22787000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTUtMS0xLTEtMzU3NDc_a31acdc6-a90b-4357-96cc-144d8c6a2493"
      unitRef="usd">4468000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTUtMy0xLTEtMzU3NDc_cc8d76e5-617d-4a17-ba63-9c18c9c59271"
      unitRef="usd">-3560000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTYtMS0xLTEtMzU3NDc_ba2779c1-fce6-4768-bcd9-9a2a56369d8e"
      unitRef="usd">-220000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTYtMy0xLTEtMzU3NDc_5b2b601a-3d1c-46fa-b0cc-a6beba6c6449"
      unitRef="usd">52000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTctMS0xLTEtMzU3NDc_e8e53106-8f23-4ed9-a0e4-1f04ca861122"
      unitRef="usd">4498000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTctMy0xLTEtMzU3NDc_7fde7649-8a47-4368-9f96-7506534ecfb1"
      unitRef="usd">-6530000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTgtMS0xLTEtMzU3NDc_81bb68ca-3b79-4c65-a151-3b654b980b00"
      unitRef="usd">29529000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTgtMy0xLTEtMzU3NDc_2424ec6f-f001-4304-8770-80d87a3c9cad"
      unitRef="usd">-1627000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTktMS0xLTEtMzU3NDc_24d18948-bc21-4823-8134-7206f73ed3c2"
      unitRef="usd">-223000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMTktMy0xLTEtMzU3NDc_df24fbd2-0c1c-4fca-8605-298f47ca97f2"
      unitRef="usd">-1736000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjAtMS0xLTEtMzU3NDc_7123c4bb-32e8-4d08-9130-eb1971ec7e9c"
      unitRef="usd">-20657000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjAtMy0xLTEtMzU3NDc_9f84cec3-ef8b-4ecd-832d-a99710cefa1d"
      unitRef="usd">-17955000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjEtMS0xLTEtMzU3NDc_8a223cc7-e356-48c2-a50d-777adccf4801"
      unitRef="usd">-1662000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjEtMy0xLTEtMzU3NDc_27ae7f07-c173-4633-948f-02f6270d0f98"
      unitRef="usd">-1524000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjItMS0xLTEtMzU3NDc_242b930b-9e73-4db6-8f92-40c9f49e4941"
      unitRef="usd">106030000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjItMy0xLTEtMzU3NDc_6224ea17-4442-445c-8f6e-d2d23cddad29"
      unitRef="usd">121960000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjQtMS0xLTEtMzU3NDc_fc60a92f-0aa3-47ae-b583-df5a36f501ca"
      unitRef="usd">28000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjQtMy0xLTEtMzU3NDc_030d2d0c-3b2e-4ea3-949e-79d6e99edc8e"
      unitRef="usd">25000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjUtMS0xLTEtMzU3NDc_a2cbc18c-e657-4bca-886c-6eb3d8d78ad9"
      unitRef="usd">37000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjUtMy0xLTEtMzU3NDc_f03d1d03-bd83-44e9-9f7f-a3fd47b0ce7b"
      unitRef="usd">42000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjYtMS0xLTEtMzU3NDc_1a91aabf-835b-4243-8dbd-789b0428a62f"
      unitRef="usd">2782000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjYtMy0xLTEtMzU3NDc_a905caec-41e4-4e4c-8374-cad1bb658cea"
      unitRef="usd">2943000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjctMS0xLTEtMzU3NDc_e6382fd5-b19a-4b50-a40c-be6ec6fcbabc"
      unitRef="usd">559000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjctMy0xLTEtMzU3NDc_ece005a3-6da4-47dc-a440-68973beefe37"
      unitRef="usd">0</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjgtMS0xLTEtMzU3NDc_87a42831-5d3d-4427-8897-f88be8b3037c"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjgtMy0xLTEtMzU3NDc_3a3ef4e7-4c35-48ed-8bdd-93b5ab66c9d6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjktMS0xLTEtMzU3NDc_e547cb48-dd35-463b-8238-bff201f5ed8f"
      unitRef="usd">73311000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMjktMy0xLTEtMzU3NDc_a4978aae-fa94-4c85-a4b7-d3eb169e1a1c"
      unitRef="usd">2503000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzAtMS0xLTEtMzU3NDc_28dee853-65b5-4035-a794-01279384d957"
      unitRef="usd">-91587000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzAtMy0xLTEtMzU3NDc_16b1dacf-0f90-4c1b-94c7-b3c6a7fa3844"
      unitRef="usd">-5379000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzItMS0xLTEtMzU3NDc_b5b519df-aa74-4753-afb6-7a7740d68920"
      unitRef="usd">772000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzItMy0xLTEtMzU3NDc_65ecf07e-9c59-477f-99a2-749268540b1c"
      unitRef="usd">623000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzMtMS0xLTEtMzU3NDc_e2641664-54f9-4bd2-9eaa-c48fe5ec35aa"
      unitRef="usd">1891000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzMtMy0xLTEtMzU3NDc_ab9c3069-6b82-45db-ae71-818d5f9f7765"
      unitRef="usd">1961000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzQtMS0xLTEtMzU3NDc_ea37a411-37bb-46ce-a248-57dd78844e1e"
      unitRef="usd">4762000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzQtMy0xLTEtMzU3NDc_932cd504-ee8e-4585-b272-5a666e9d22f4"
      unitRef="usd">6944000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzUtMS0xLTEtMzU3NDc_6ec9f869-3b95-47e3-85a2-1b95ca038f61"
      unitRef="usd">952000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzUtMy0xLTEtMzU3NDc_6dd25c24-b187-439f-a640-0165148a32b2"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzYtMS0xLTEtMzU3NDc_87283b9a-8131-40da-980a-6f5772373a2a"
      unitRef="usd">975000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzYtMy0xLTEtMzU3NDc_82cd77d4-8e93-43e3-9e96-9f61e4ae908f"
      unitRef="usd">794000</amed:CashDistributionToNoncontrollingInterest>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzctMS0xLTEtMzU3NDc_d7fc5aec-1df0-4b37-88be-d582ce2cc5f9"
      unitRef="usd">298500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzctMy0xLTEtMzU3NDc_1684d4d0-427d-44db-9656-91d7bdf0dd6e"
      unitRef="usd">389200000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzgtMS0xLTEtMzU3NDc_744ec7f5-a232-40d2-88a6-3cdfbcc40118"
      unitRef="usd">283500000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzgtMy0xLTEtMzU3NDc_b60b0118-2156-48d6-92e1-3eca42b910ad"
      unitRef="usd">410200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzktMS0xLTEtMzU3NDc_111e6f70-2dc8-4923-89be-a1b7918d196e"
      unitRef="usd">6975000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfMzktMy0xLTEtMzU3NDc_a225e629-5bc4-4a1d-ae63-14b1d1ccf5a6"
      unitRef="usd">5392000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDAtMS0xLTEtMzU3NDc_a4067d10-0be7-4c31-ab24-df48f1e25917"
      unitRef="usd">17351000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDAtMy0xLTEtMzU3NDc_0dc169f2-043f-4344-bc03-a6dd6bed7f0f"
      unitRef="usd">74074000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDEtMS0xLTEtMzU3NDc_90468678-f2bd-47fe-ac7f-f994fa9c209c"
      unitRef="usd">0</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDEtMy0xLTEtMzU3NDc_d01d0af8-74ac-4d32-a178-c357f3693759"
      unitRef="usd">-1672000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDItMS0xLTEtMzU3NDc_8d2b335a-62f7-430f-854d-f45256f78456"
      unitRef="usd">-11448000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDItMy0xLTEtMzU3NDc_1adc16df-c7e0-4f9c-aa08-1407b8b226a2"
      unitRef="usd">-107292000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDMtMS0xLTEtMzU3NDc_fe5f55ae-a236-4fd2-83e4-18c02cedc93b"
      unitRef="usd">2995000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDMtMy0xLTEtMzU3NDc_acdd876c-dd0d-42d1-aecf-08cb7936a06c"
      unitRef="usd">9289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDQtMS0xLTEtMzU3NDc_ba622055-0716-4acc-ae9e-6de500cfe71d"
      unitRef="usd">45769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5ec7ab4116e4010b85638d99e1435a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDQtMy0xLTEtMzU3NDc_bfc8d4e2-d14c-4510-bca9-f6a74cabfb05"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDUtMS0xLTEtMzU3NDc_dd3c8ed5-e38a-47cf-a2c6-d7e257762e5d"
      unitRef="usd">48764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibe75fdc74ac74e3095b40024bdf5e396_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNDUtMy0xLTEtMzU3NDc_4c461e5f-4f4d-43f1-94c6-b519cee7bad3"
      unitRef="usd">92646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTMtMS0xLTEtMzU3NDc_97ba49ca-d7f7-4868-96f9-35a9d4904b62"
      unitRef="usd">4489000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTMtMy0xLTEtMzU3NDc_a30d1901-f97c-4286-b441-157e01a51704"
      unitRef="usd">1914000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTQtMS0xLTEtMzU3NDc_48f86985-5e07-4436-97e0-bd855eab1df7"
      unitRef="usd">22977000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTQtMy0xLTEtMzU3NDc_6ecfcfb1-aaf1-49f3-8e23-f24c8f6157dc"
      unitRef="usd">8667000</us-gaap:IncomeTaxesPaidNet>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTUtMS0xLTEtMzU3NDc_c00b895a-ff3d-40b5-bab6-a12670a2e561"
      unitRef="usd">22319000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTUtMy0xLTEtMzU3NDc_67349c5a-1449-45bd-92bf-073ff91e1ace"
      unitRef="usd">19479000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTYtMS0xLTEtMzU3NDc_763bf131-e5f5-487b-b725-f18b0c1b3260"
      unitRef="usd">735000</amed:CashPaidForFinanceLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTYtMy0xLTEtMzU3NDc_841bda49-bde1-438d-a28a-b2a78d05fdac"
      unitRef="usd">1017000</amed:CashPaidForFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTgtMS0xLTEtMzU3NDc_41a2b62c-5ecf-490d-88aa-30ce80cc238d"
      unitRef="usd">26590000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTgtMy0xLTEtMzU3NDc_6e75aa30-c245-4924-aa6e-8ecd7143c569"
      unitRef="usd">20689000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTktMS0xLTEtMzU3NDc_3219ea18-80d4-4cd2-a247-44ade552588e"
      unitRef="usd">1316000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNTktMy0xLTEtMzU3NDc_267ca97d-7605-4558-88f5-cbcff1d93a4f"
      unitRef="usd">527000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMS0xLTEtMzU3NDc_2295cfe9-e80c-4af0-b597-7d9b16788552"
      unitRef="usd">2763000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMy0xLTEtMzU3NDc_c8361e88-c0e1-44c6-97df-63c58625e79b"
      unitRef="usd">904000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:NonCashAccruedContingentConsideration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMS0xLTEtNDI4MDA_b7071ebe-2eec-4642-a4e4-b0e8fdfae972"
      unitRef="usd">19195000</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashAccruedContingentConsideration
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjAtMy0xLTEtNDI4NDE_06dcb23d-88b1-4d24-914e-36404a56e88a"
      unitRef="usd">0</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjEtMS0xLTEtMzU3NDc_d7ca1fd8-7670-4a97-bdc2-3bd7e4df46af"
      unitRef="usd">8900000</amed:NonCashNoncontrollingInterestContribution>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zMS9mcmFnOjkwNDcwY2VmNTk2MTRhZDk5YTBhZDAwZjNmYzEyMWZmL3RhYmxlOmQ2YzIyMGM3ZjQzZDQ0MGJhZjYwYjQ1MGIyY2YzYjVhL3RhYmxlcmFuZ2U6ZDZjMjIwYzdmNDNkNDQwYmFmNjBiNDUwYjJjZjNiNWFfNjEtMy0xLTEtMzU3NDc_544c62bd-e475-4cae-af11-1d6832097a2a"
      unitRef="usd">0</amed:NonCashNoncontrollingInterestContribution>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Mw_7b872b71-7efd-49ce-9737-c53034f5e1d7">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 74% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021. As of June&#160;30, 2022, we owned and operated 353 Medicare-certified home health care centers, 174 Medicare-certified hospice care centers, 14 personal-care care centers and 9 admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 24, 2022 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.0 million and $48.1 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzQx_43389de9-dc1f-430a-962a-e21f76afc337"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12d3114d05584bdc834ec068c834314b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzQx_4bcc37b8-769b-406a-8880-ccd543730d34"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDM4NQ_2e2553cb-a0e7-4a8b-bb4e-4b07b34845d7"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDM4NQ_a9ca6c13-31a2-4dff-98b6-8c0863f8d928"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i952b1caa605842b8b2c6cc1f6ed49167_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDg0_c9d50f7b-ddde-439f-9210-cdf7eea89be4"
      unitRef="care_center">353</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i6f689c40db574abeba5ad517246536ed_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNTMy_413f654f-6b2c-4605-afe6-0b59e7b86a81"
      unitRef="care_center">174</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="idacfe2999ae746bea86d800a07b26023_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNTc2_736a9e9e-e2ed-49ce-b452-8b768656f4c1"
      unitRef="care_center">14</amed:OperatingCareCenters>
    <amed:NumberOfJointVentures
      contextRef="ica0fc66197bf4246a3cb7df9b28e8f04_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjEw_550154a7-4356-4c22-8e4a-17d80532d510"
      unitRef="numberofjointventures">9</amed:NumberOfJointVentures>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjQ4_84d58fe7-3aa7-42c7-8996-c24196a5012c"
      unitRef="state">38</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2NA_5362b1a1-1ec8-42b1-8d17-d112a6bf05c5">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 24, 2022 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Ng_6df0a7f9-5f9d-44a2-822b-7a2993d47f02">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2Nw_1e39a1bc-10c7-48e5-b823-8c5dc159332f">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM1Nw_109d4007-6091-42c8-9fd7-e5627e2636cb">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.0 million and $48.1 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzA4NA_1e09ad75-f3ac-4cfe-a180-0a514bd3418a"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzM4NA_cf5fe446-945a-47c1-8241-75fe9fd18087"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzU3Ng_0c56c056-4786-40d5-8e7b-b487bf4f5e32"
      unitRef="usd">45000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMzU4Mw_aa6d238f-e202-457e-ba7a-96b49848ec97"
      unitRef="usd">48100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="id11e4c1c56094d87b2ab9c56771f2868_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfMTA5OTUxMTYzNDcxMQ_a33fc84f-2ee0-4cc8-ab78-0364f896360b"
      unitRef="usd">31100000</us-gaap:GainLossOnSaleOfInvestments>
    <amed:MaximumPercentOwnershipForCostMethodPercent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDIyMw_b02dcd50-e821-49a9-991c-663694bf1df8"
      unitRef="number">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ia755b346de2741dfa14730fe4f9e2fb7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDQyNg_521eea87-49ac-4715-9dc5-c7335fb20ab1"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDU4MA_adcafc95-a9b2-4ec8-b6b7-ca88152b0586"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNDU4Nw_cf7a5622-0050-4c06-b457-4a6637c3f654"
      unitRef="usd">5000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RleHRyZWdpb246ZjM4NDFhMjIwMGExNGRmZTg3ODAzM2M4YTQ1ZmI4ZjJfNjM2OQ_b0021b94-fd82-4fdc-b814-396cc2ae6130">The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMy0xLTEtMS0zNTc0Nw_1d593092-db0c-40ca-8c63-fc78fa50c469"
      unitRef="usd">10400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMy0zLTEtMS0zNTc0Nw_eea23de3-4849-4b59-be03-3c216c61f38b"
      unitRef="usd">3100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNC0xLTEtMS0zNTc0Nw_8093620c-3bfe-410b-b6e3-be4270449876"
      unitRef="usd">4100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNC0zLTEtMS0zNTc0Nw_ae4d18ea-60ac-4bbb-9191-00fa4d3c2bf0"
      unitRef="usd">2400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNS0xLTEtMS0zNTc0Nw_7a3caac5-fcf0-434d-a118-0fb9b2612185"
      unitRef="usd">400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNS0zLTEtMS0zNTc0Nw_1415baf0-6757-4003-8520-107a6d1a0e7d"
      unitRef="usd">100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNi0xLTEtMS0zNTc0Nw_34a27fa5-c2a5-458c-bab9-fab62c68073e"
      unitRef="usd">14900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNi0zLTEtMS0zNTc0Nw_4d62ac9a-bcb9-49ad-a381-810b9216a789"
      unitRef="usd">5600000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNy0xLTEtMS0zNTc0Nw_f8d18914-78a3-4e25-8b18-a0963f908789"
      unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfNy0zLTEtMS0zNTc0Nw_9372fb8f-6c47-4287-9dbd-e947398e9d04"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOC0xLTEtMS0zNTc0Nw_4377c7c1-581a-4432-a6e4-b0bdfcb3c4ba"
      unitRef="usd">8500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOC0zLTEtMS0zNTc0Nw_879652b8-be0d-4e96-ae2e-b5c17fd3f21e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOS0xLTEtMS0zNTc0Nw_c81e27d2-83ce-4332-b10f-01052d8c5c62"
      unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfOS0zLTEtMS0zNTc0Nw_aa647b97-4cdd-4c51-ad43-fd0fa071a6bd"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTAtMS0xLTEtMzU3NDc_dabb0d05-cca8-47b6-bc5d-2237b9946859"
      unitRef="usd">24000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTAtMy0xLTEtMzU3NDc_56419427-357e-4e34-8c92-fcca173d56ff"
      unitRef="usd">5700000</us-gaap:Assets>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTMtMS0xLTEtMzU3NDc_c5922ac7-81a7-4615-8759-7c5ac9d903a7"
      unitRef="usd">700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTMtMy0xLTEtMzU3NDc_ec499166-0c1c-49cc-bac6-88f1b0bc4c8d"
      unitRef="usd">300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTQtMS0xLTEtMzU3NDc_7b6f35d5-fadc-487e-b786-24f493035969"
      unitRef="usd">4800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTQtMy0xLTEtMzU3NDc_ce29157f-c412-44c5-bef5-9a1a6d00eebe"
      unitRef="usd">3400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTUtMS0xLTEtMzU3NDc_831da9e8-fd25-4aea-9c4e-9fd29dcfcde0"
      unitRef="usd">200000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTUtMy0xLTEtMzU3NDc_8f319189-710a-4c68-937b-8b9333df5b83"
      unitRef="usd">800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTYtMS0xLTEtMzU3NDc_a3a58391-1781-4fab-9a70-4403d82c7b88"
      unitRef="usd">5700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTYtMy0xLTEtMzU3NDc_40da0b40-806e-47e9-9f14-5514d2acc0d0"
      unitRef="usd">4500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTctMS0xLTEtMzU3NDc_c52e6455-334f-4ad5-99fe-70c1f71ad689"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTctMy0xLTEtMzU3NDc_2ae470cf-a110-428f-bb84-a1b5d6946589"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i361addb20cb8421d8de1392e96b0844f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTgtMS0xLTEtMzU3NDc_349c9b49-fa07-4e67-838e-863ccb630549"
      unitRef="usd">5700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iea0b040e8e1d408f99b5efc4817437de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl8zNy9mcmFnOmYzODQxYTIyMDBhMTRkZmU4NzgwMzNjOGE0NWZiOGYyL3RhYmxlOjJhOWY4NjQyNzc3ODQ1NTA4OTQ2MmE0NmQ1OTk2MzQyL3RhYmxlcmFuZ2U6MmE5Zjg2NDI3Nzc4NDU1MDg5NDYyYTQ2ZDU5OTYzNDJfMTgtMy0xLTEtMzU3NDc_f7656798-6697-494f-a437-bee040aa5b64"
      unitRef="usd">4500000</us-gaap:Liabilities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTE_eea1145a-84dd-4331-bebe-abae406ca85c">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 74% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day periods of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June&#160;30, 2022, we have recorded $4.2 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa"&gt;five&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f"&gt;seven&lt;/span&gt; days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by applying the grant model in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $22.2&#160;million and $3.1&#160;million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 &#x2013; Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 68% of our patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTQ_8db2824e-2464-4a52-96b9-6eacdea2892a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 74% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day periods of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June&#160;30, 2022, we have recorded $4.2 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NjU_bae0a8b3-ac99-42b5-a9de-dda3407024aa"&gt;five&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTU0NzE_cb27ed1c-e66c-4a77-8e1c-895c7614ae3f"&gt;seven&lt;/span&gt; days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i55e43d13bcce4e119e4d67bcdeb4abe8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjMyMw_43389de9-dc1f-430a-962a-e21f76afc337"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12d3114d05584bdc834ec068c834314b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjMyMw_4bcc37b8-769b-406a-8880-ccd543730d34"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i07475fb18b794060b4b9ad767d221a6f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjcwMQ_4a864edd-74e7-4179-bf83-f66d17a1c798"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie4c913bea1014480946a8c968df1dc43_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MjcwMQ_d727dcb2-42e6-4add-8c0a-207c0f9c39cb"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMzg2Mw_972f2e82-44e1-4a8d-8df2-7d34e4bfedb1"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDY_6f6a46b9-a30e-44fe-912d-45168a13467c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ied4fd711d218438abe660d1442afcde4_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy0xLTEtMS0zNTc0Nw_95689e72-ec96-4697-893d-87dfef87eeae"
      unitRef="number">0.40</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6ec1a19c1ba94e878ec8fda9cd5339f1_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy0zLTEtMS0zNTc0Nw_2258c018-a946-4142-841a-9d1f758b1d37"
      unitRef="number">0.42</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i8da76d47f10d4c0c8c8c8b0fd249aa26_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy01LTEtMS0zNjQ0OQ_59e7e3fd-2413-4115-a061-dd74580f7014"
      unitRef="number">0.40</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ibfd2cc70011c4d8ca45f2cd8312980c3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMy03LTEtMS0zNjQ0OQ_2b1b2ae5-3eb6-4946-b5a8-033b3bf72f0b"
      unitRef="number">0.42</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iaa76b1acfeaf486da02b9af11cc816a6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC0xLTEtMS0zNTc0Nw_d941cbb1-928c-402b-87fc-596418c0600e"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i751a2debd3674a8cb7cef6a38ae12130_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC0zLTEtMS0zNTc0Nw_e5ff7eda-7738-4694-bfee-51a1546e092a"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i82c50b0e545d4a1785eeb7d1a9c185cc_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC01LTEtMS0zNjQ0OQ_2403145c-cd60-43e9-bcc5-ae24df31d605"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic1b3730a17e64e0f992cd153fd840cf2_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNC03LTEtMS0zNjQ0OQ_839ab64e-eb3b-4aea-8326-a40a5c9b1830"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia6061248324244eebe4d0db40312edac_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS0xLTEtMS0zNTc0Nw_87579fe2-b960-404e-af7f-eb8684c069f7"
      unitRef="number">0.13</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib24ed3919fc848288bb8ac2ced90d84b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS0zLTEtMS0zNTc0Nw_a15bb436-fe3e-40e3-8b44-ead2fc375dc4"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i07a28a2b65f4472ab0c894d89400b474_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS01LTEtMS0zNjQ0OQ_17b62680-beb2-49bd-a6b8-cd8fe463e936"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i53cca52064ef477ab34029b221d6d69d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNS03LTEtMS0zNjQ0OQ_c58aef29-e98d-40c4-bca3-4e059ebfd217"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id6190b80120f43e2a1575644159feb4e_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy0xLTEtMS0zNTc0Nw_04f69329-8de4-4ecc-a4d7-b192754bad31"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i63963cb819344481af520c8bff0b5d1d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy0zLTEtMS0zNTc0Nw_8a05e671-1035-4f7a-a0e8-6043a3c4dcbb"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i64fbb473e60d4729802929c3f20aeafe_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy01LTEtMS0zNjQ0OQ_25e9bdb0-e5cb-4396-8d74-a464c78b3dcb"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i89df7c974a654e3a941400b05e8929a4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfNy03LTEtMS0zNjQ0OQ_a3d665d9-5be0-4a9d-8387-adfc6aeef9bc"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i5749f12c34ef4e4a81639e239b7a472e_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC0xLTEtMS0zNTc0Nw_f1deeebc-df27-4e73-b368-e97dfa089aee"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ica66251978d1405bb862d424880702f5_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC0zLTEtMS0zNTc0Nw_29b049d1-dc48-4b8c-8acc-4442ffaa08d2"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i1eb4c6bf9b7f441aba17bfa2e6583e74_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC01LTEtMS0zNjQ0OQ_5ae88ac0-dc57-4775-93b3-f711b91137c4"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i356d5eeddab246eca55259b8d751e968_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOC03LTEtMS0zNjQ0OQ_0fba5a68-2280-4172-a3f8-4729b8186fba"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i88871dd43ddc4081830db6b06e82af59_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS0xLTEtMS0zNTc0Nw_d533eabb-0e95-4c32-912b-d0eec2e75710"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic5e997d4464b4ea4bfa067035b64249a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS0zLTEtMS0zNTc0Nw_74f03d0d-3594-4e78-953f-2073b20accdc"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i35822c2e8f8846808fd72e3482edc1a8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS01LTEtMS0zNjQ0OQ_018a0809-2ea3-4aac-a098-32dda34ac537"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i1dddcac370504787ba0022ab6dfadefd_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfOS03LTEtMS0zNjQ0OQ_4d6f1959-ba13-4747-bc00-98f75f05bc59"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id920f2f6a7f04db3b0281051fbbc33cf_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtMS0xLTEtNDA3NTY_e55d59bb-628e-4773-88c2-8b78de3d4cba"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i5f1e1d42e8bb4d88b2aed4812e852cbb_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtMy0xLTEtMzU3NDc_16ae3d34-ae2f-4bb5-b364-1445588f09a3"
      unitRef="number">0</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i926108a7b35d4c89a57993c4c6997466_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtNS0xLTEtMzY0NDk_bb609b69-bcf6-4bf6-8952-b077e494d70a"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i4b91dd04f2634b899d9d8c66e3339361_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTAtNy0xLTEtMzY0NDk_e74f6986-edaf-4275-9301-96ba7bbe0f82"
      unitRef="number">0</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtMS0xLTEtMzU3NDc_3d216b0d-c533-4618-ac65-7950318d1f83"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtMy0xLTEtMzU3NDc_c6b4d485-26b0-418e-9975-7ad8d41e5817"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtNS0xLTEtMzY0NjM_a92b5f17-ec57-463e-9c28-da0190a82a6f"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjc0ZGVlMzI2YTM2ZjQ5YWVhMzhhOGMzNjcxZGFkZDY1L3RhYmxlcmFuZ2U6NzRkZWUzMjZhMzZmNDlhZWEzOGE4YzM2NzFkYWRkNjVfMTEtNy0xLTEtMzY0NjM_3ea261ca-6145-4ade-84fa-c975b82984e1"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNDQ5MQ_6a27d38b-0595-4a69-ab8e-9254cd54488d">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNDUyNg_1d04be51-73a0-4ce5-9f6c-8ea8d4ca5e29">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTM4Nw_1d04be51-73a0-4ce5-9f6c-8ea8d4ca5e29">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTQxNQ_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNTU0NA_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjAwMQ_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjA4Mg_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjM1Mw_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjU0Nw_904fd5e5-7ecc-4a38-9f70-2e953c053f72"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjczNw_96fcd39d-5bbd-4d8a-a6ee-aa8fbc9c1072"
      unitRef="visit">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjc0Mw_b7ca17ed-97ff-46da-83a6-ae20a30b3965"
      unitRef="visit">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNjkwNw_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNzA0Mg_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfNzM2MA_29522484-c571-4fd0-b71e-1b6a87b6c205"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NonMedicareRevenueTermRates
      contextRef="i91be1f1d8d8b4b9fa0e14a01cd10a1f3_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfOTE3Mw_347cf8ad-a6d3-47a5-977c-6dc7385b07bb"
      unitRef="number">0.95</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="ie1adf8f80cc54434b720221f09820d2b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfOTE3OQ_06fc1d13-edbb-4dc0-bc6a-d2518c6d285a"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_4853c769-3e90-4b1c-8c8e-bf9766b74abd"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_6abe8cdd-8cb8-4bfd-849a-83cfef992c0e"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_b86821b3-6885-47bb-ac43-3350993c6455"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTAzNTc_ed0f8263-9030-440f-b19e-8e34db82869c"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTEzNjY_519d0fb6-a806-4cf3-bca8-ecc0481aef2d"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="iac48d82a63114da69e22201712a8c0c4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTIxMTM_d840192f-a181-4b3a-a179-8e4475d01dea"
      unitRef="usd">4200000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="ie3a945b2920249189593bc4dfb36414a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTIyODI_8141cb9b-c414-4f47-b0fe-f083b3a78609"
      unitRef="usd">4500000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTQ4ODc_facf2de3-ec62-416d-b063-0cd1010267e6">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTQ5MDM_d9a01fa1-e5b8-49f9-b978-541d4659f138">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUwODE_facf2de3-ec62-416d-b063-0cd1010267e6">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUxNjk_d9a01fa1-e5b8-49f9-b978-541d4659f138">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i87135d7bdcf84aea864211c41b58b7af_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUzMzU_facf2de3-ec62-416d-b063-0cd1010267e6">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i6f99919d31ee4db7bd28b5eb4881560f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTUzNDU_d9a01fa1-e5b8-49f9-b978-541d4659f138">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:GovernmentGrantsPolicyTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTk_559acf22-cb51-4220-a320-5a35d6de1270">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by applying the grant model in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").&lt;/span&gt;&lt;/div&gt;</amed:GovernmentGrantsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDM_86a4344b-8a12-4370-bcd6-129a517e17b0">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $22.2&#160;million and $3.1&#160;million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 &#x2013; Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="ic21dc870eef3444a90c0b71790318d59_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MzU5Mg_74b568e1-13a0-4b73-b404-a5c615bfdac1"
      unitRef="usd">22200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="icc3a77e521b04aeebf04452b84789764_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTgzNjI_e30b6c56-626a-456a-99ec-798a880ad417"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzODk_4c501004-18c7-46ea-baed-1082ee9ac5e4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMS0xLTEtMS0zNTc0Nw_a78386a4-f282-4c89-b620-e4c04b91930b"
      unitRef="usd">26600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMS0zLTEtMS0zNTc0Nw_e8098997-df44-408b-a2ff-15bcb900a29a"
      unitRef="usd">42700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMi0xLTEtMS0zNTc0Nw_9784e1fb-aacd-4d57-94bc-6dbcaf36a5f4"
      unitRef="usd">22200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMi0zLTEtMS0zNTc0Nw_444eed69-ce0b-412b-91a7-15929fc0d53f"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMy0xLTEtMS0zNTc0Nw_2125a20d-fa16-4898-a1eb-052577d03d78"
      unitRef="usd">48800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmUxYzE1YzU5NjlhNzQ3YzBhYzk2ZDUwNTIyZGQzOTZkL3RhYmxlcmFuZ2U6ZTFjMTVjNTk2OWE3NDdjMGFjOTZkNTA1MjJkZDM5NmRfMy0zLTEtMS0zNTc0Nw_573c198d-a893-4170-8ce3-b8fdff9c66fa"
      unitRef="usd">45800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzODU_f969a1b2-4a6b-447d-bf1f-b25da88e3655">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 68% of our patient accounts receivable at June&#160;30, 2022 and December&#160;31, 2021, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTkyNzY_977d75ed-2d6e-4b9d-a825-06ea67a95f22"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk3MzU_2c5a56d2-4df4-4ac3-ae52-e318bc563327"
      unitRef="number">0.68</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk3MzU_64b1f648-bedd-42d8-a100-5703ef95198d"
      unitRef="number">0.68</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTk4NTg_faf59125-3564-43d8-93cf-2a4c69d53bcc"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMTA5OTUxMTY1MzYxMA_038d3628-be99-44fa-882a-e7db0f0bfa4a">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MDE_e144f12f-511a-4fe1-bc35-516920d3f476">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTM_accd323b-fb24-4376-b414-f07c5597d3b7">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQ0MTU_64fe5ab8-f1cb-4cf4-ba4a-9b0d3a5a000f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi0xLTEtMS0zNTc0Nw_898bca59-e6b8-4523-a45b-41ee5a5cc337"
      unitRef="usd">456800000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6279924dc89846fe9e81f87aed338b84_I20220630"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi0zLTEtMS0zNTc0Nw_40dc2241-2850-453c-91d1-e9c815637db7"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ibcff0785ecd9434fb01d7a18ff154dc6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi01LTEtMS0zNTc0Nw_eee6f716-4cba-463c-9933-dd6e463bf316"
      unitRef="usd">476900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i76cd0bb8003d49c6a5231bf472e9ed5b_I20220630"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOmIzNDJkNWQxZjQzNDQ4N2I4NzhmZTQ5YTI1ZGM3N2JhL3RhYmxlcmFuZ2U6YjM0MmQ1ZDFmNDM0NDg3Yjg3OGZlNDlhMjVkYzc3YmFfMi03LTEtMS0zNTc0Nw_4406bfc0-8220-434a-b04e-2bd8da68b2d7"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTI_3a61968a-52d3-4f26-8be2-811877b60031">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RleHRyZWdpb246MmU0NDVkNGU0ODA3NDVhN2IzOTUxZDEwMmVhYTA5YjdfMjQzOTU_37c61de2-438a-4b33-82ad-05838b168f02">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi0xLTEtMS0zNTc0Nw_9c71983c-207c-4541-b5dc-03a4f7ef7a5d"
      unitRef="shares">32522000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi0zLTEtMS0zNTc0Nw_d3a1ee6f-d767-49ef-b628-818a49b61cd4"
      unitRef="shares">32588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi01LTEtMS0zNjUzNA_bff20cc0-2718-4e8e-842a-9022006f388c"
      unitRef="shares">32538000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfMi03LTEtMS0zNjUzNA_ce7560ab-c14c-4b07-b28f-1226c8ce3cbf"
      unitRef="shares">32684000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC0xLTEtMS0zNTc0Nw_28668252-b840-4c1a-994d-92134fe284f0"
      unitRef="shares">46000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC0zLTEtMS0zNTc0Nw_d28e78fd-6966-4460-b99a-4a3bb713faa4"
      unitRef="shares">139000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC01LTEtMS0zNjUzNA_f070cc12-2c2a-4566-afad-9f513d1c05b1"
      unitRef="shares">56000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNC03LTEtMS0zNjUzNA_b90fd759-a692-49a7-b4d6-6844b2ca58e6"
      unitRef="shares">145000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS0xLTEtMS0zNTc0Nw_6b75cbbc-aeee-46e5-8ac2-aff901f790b4"
      unitRef="shares">113000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS0zLTEtMS0zNTc0Nw_277e68b6-d63f-437a-b134-b68591340200"
      unitRef="shares">254000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS01LTEtMS0zNjUzNA_d2d94783-63d0-4f01-9548-c18081380f02"
      unitRef="shares">128000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNS03LTEtMS0zNjUzNA_91f78155-4ca5-49a0-8500-cb8792daa17a"
      unitRef="shares">256000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi0xLTEtMS0zNTc0Nw_80075471-0034-4f0c-b4b9-7680082c8353"
      unitRef="shares">32681000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi0zLTEtMS0zNTc0Nw_2c75c986-cc82-4eab-8f2a-a6a7e698ecb6"
      unitRef="shares">32981000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi01LTEtMS0zNjUzNA_633a71e0-2537-4a6e-be9d-51468c9c91dd"
      unitRef="shares">32722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNi03LTEtMS0zNjUzNA_676b7caf-afdb-43ad-90a0-4256bb36c347"
      unitRef="shares">33085000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy0xLTEtMS0zNTc0Nw_c71fe7c7-1e94-4069-93b8-45186243a320"
      unitRef="shares">283000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy0zLTEtMS0zNTc0Nw_5231586c-ff11-4a6f-bbe3-2166500a0b92"
      unitRef="shares">71000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy01LTEtMS0zNjUzNA_632b6b91-7c85-4fea-8ab3-ef234dc87576"
      unitRef="shares">250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80My9mcmFnOjJlNDQ1ZDRlNDgwNzQ1YTdiMzk1MWQxMDJlYWEwOWI3L3RhYmxlOjk3NTk5YTgyMDcyYzRlMGRiZDJhNTllNGYyYmFiYWJmL3RhYmxlcmFuZ2U6OTc1OTlhODIwNzJjNGUwZGJkMmE1OWU0ZjJiYWJhYmZfNy03LTEtMS0zNjUzNA_f8b08c1e-142c-419b-893c-c0a41b64976d"
      unitRef="shares">58000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <amed:COVID19TextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNDA0Mg_5850ce9b-e57e-4bad-941c-f50c1566ad4e">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not fully utilize the PRF funds received; all unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by consolidated entities (excludes $0.2&#160;million of interest repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and has been reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The suspension of sequestration increased net service revenue by $4&#160;million and $13&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $10&#160;million and $18&#160;million during the three and six-month periods ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55&#160;million of social security taxes. Approximately $27&#160;million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</amed:COVID19TextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNzI5_55dd53fe-1c52-4e33-80d8-8e7580345ffd"
      unitRef="usd">175000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfODU0_665cd09f-c0bb-44e4-b5cf-a0cf2c81243a"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i559e5275bf6a413d992d5f29b2508130_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTIxNA_a021af0b-7218-485f-bcb1-ebd44443ff2f"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="ibec5f07fc2aa4973b444a7171d9a0911_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTIzMg_51bf78d2-47a5-4bc4-82d8-76ed0c575bb4"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i09472bba331640d7b8fce12ca5f6d194_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTMxNw_c03e0c40-cecd-4c4e-ba60-b328e3a68eee"
      unitRef="usd">2000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingReceivedFromCARESAct
      contextRef="i39ddd6046a8c4277a4a08449e4ec5af5_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTQyMg_d905ba9d-2213-4196-9d68-74105fcb9b8d"
      unitRef="usd">6000000</amed:FundingReceivedFromCARESAct>
    <amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfNDA0MA_fca9aab6-ca7f-43df-ae0c-9603a16a4987">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by consolidated entities (excludes $0.2&#160;million of interest repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMS0xLTEtMS0zNTc0Nw_55affef6-d72a-4d36-9eb6-f87208da74da"
      unitRef="usd">46600000</amed:CARESActProviderReliefFundsUtilized>
    <amed:CARESActInterestRepaidToGovernment
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjMzMmRkZmExNTVjMzRlNjM5ODkyOTY0MmZjYmQzOWQ4Xzcw_b17b2ed2-8689-40fa-837b-5edc5d432b15"
      unitRef="usd">200000</amed:CARESActInterestRepaidToGovernment>
    <amed:EstimatedCARESActProviderReliefFundAmountsRepaid
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMi0xLTEtMS0zNTc0Nw_9d9d6e4d-2ebb-4690-8235-3d827541bf3e"
      unitRef="usd">58300000</amed:EstimatedCARESActProviderReliefFundAmountsRepaid>
    <amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures
      contextRef="ib4983345eb0940ae9eb287f27ba6eb04_D20200327-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfMy0xLTEtMS0zNTc0Nw_6a02594c-5ca9-4716-88c9-5f2fbc45b55e"
      unitRef="usd">1300000</amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures>
    <amed:EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfNC0xLTEtMS0zNTc0Nw_d697a39a-271b-4668-9126-b46100a8d195"
      unitRef="usd">600000</amed:EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures>
    <amed:TotalCARESActProviderReliefFundsReceived
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RhYmxlOjU4OGE1NzVlMTMwMjRhZjNhY2M3MmU1OGJkM2FjZDNlL3RhYmxlcmFuZ2U6NTg4YTU3NWUxMzAyNGFmM2FjYzcyZTU4YmQzYWNkM2VfNS0xLTEtMS0zNTc0Nw_ca78e1d0-2d77-4d62-9271-d8df372fea5c"
      unitRef="usd">106800000</amed:TotalCARESActProviderReliefFundsReceived>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzUwMw_85516709-5d4a-4936-b6c4-015e9befc7e7"
      unitRef="usd">4000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTA5OTUxMTYzMjIwNw_7ca0c453-70d3-4490-b8d8-a06475c57b90"
      unitRef="usd">13000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMTA5OTUxMTYzMjAwNg_e06bdd30-7f57-44e0-921d-65e48e07aed7"
      unitRef="usd">10000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzUxMA_e7f53ac3-f9ae-4e98-b373-b887521719d6"
      unitRef="usd">18000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="icf597362dfa64e339e5ded664c4686cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzgxNA_05b81eb7-3423-414c-9de1-99af1e98ec69"
      unitRef="usd">55000000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct
      contextRef="i61fa6d510c13404db32529ba1a32617b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzg1Nw_c2a8cfad-fbbf-4d47-9b9d-35c988d53d3b"
      unitRef="usd">27000000</amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id1d84b1e5c3f433e9b75ae592fa0fd06_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl80OS9mcmFnOmU4ODI0MmFhZDc4YTQwM2M4YTQxZjNhNmNmZmRjZGQ5L3RleHRyZWdpb246ZTg4MjQyYWFkNzhhNDAzYzhhNDFmM2E2Y2ZmZGNkZDlfMzg1Nw_efc04b74-1c7e-4fd6-8128-ed46cbd06855"
      unitRef="usd">27000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0Ng_0bbcd6f2-dbba-4615-9e20-30521d95833d">ACQUISITIONS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $8.5&#160;million, other intangibles of $0.4&#160;million (certificate of need and licenses) and noncontrolling interest of $8.9&#160;million within our condensed consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total $16.7&#160;million placed into escrow, $1.0&#160;million has been set aside for any potential closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price is subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. We expect to finalize any changes to the purchase price resulting from the closing payment adjustment during the three-month period ending September 30, 2022. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect $15&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolution contributed $11.3&#160;million in net service revenue and an operating loss of $1.8 million during the three and six-month periods ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $67.8&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's preliminary valuation, we recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names ($0.1&#160;million). The acquired names will be amortized over a weighted average period of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AssistedCare contributed $2.6&#160;million in net service revenue and operating income of $0.7&#160;million during the three and six-month periods ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $0.6&#160;million from $240.7&#160;million to $241.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired, liabilities assumed and noncontrolling interests. Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include acquired names ($28.3&#160;million), technology ($19.8&#160;million) and non-compete agreements ($6.2&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years, and the technology will be amortized over a weighted-average period of 7.0 years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contessa contributed $4.4&#160;million in net service revenue and an operating loss of $9.7&#160;million (inclusive of technology intangibles amortization totaling $0.7&#160;million) during the three-month period ended June 30, 2022 and $7.2&#160;million in net service revenue and an operating loss of $17.3&#160;million (inclusive of technology intangibles amortization totaling $1.5&#160;million) during the six-month period ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For details regarding the Company's 2021 acquisitions, see Note 4 to the audited consolidated financial statements in our 2021 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id339d8bb1ad54c308f39f7c547fbc108_D20220323-20220323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTU3MQ_76b02b6c-5dee-4819-b040-141dda341203"
      unitRef="usd">8500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i78865dd720d74892af146d51ab673d72_I20220323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTU5Ng_1cd5f8b8-ace7-47ce-956c-468151c1bfe7"
      unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <amed:BusinessCombinationAcquiredNoncontrollingInterest
      contextRef="ib7f617d6993d44d1bad636bee8dc70e0_I20220323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY2NQ_9e036146-aa0d-41fa-8842-eebf1be7947d"
      unitRef="usd">8900000</amed:BusinessCombinationAcquiredNoncontrollingInterest>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjU4NQ_99f01391-2bc5-40b1-84b6-2812cd921251"
      unitRef="care_center">15</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjU4OQ_52bd2f85-303c-4128-9db7-a32b4e59cd55"
      unitRef="usd">67800000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings
      contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY0OTI2NzQ1NTY4MQ_4d559175-c88b-4a89-856f-32f27cbac09a"
      unitRef="usd">51100000</amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings>
    <us-gaap:RestrictedCash
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA3OTM2MA_f2c940d8-00eb-4edc-83f2-5bd7204f84d9"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTY0OTI2NzQ1NTY2Ng_db43943d-c51d-42ef-8c6d-efece35d459f"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <amed:NonCashAccruedContingentConsideration
      contextRef="id86fb111888b450497127e23c0316217_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgzNw_38712355-d37e-4385-b266-24f575612ce2"
      unitRef="usd">1000000</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTg1MQ_0a0d0770-095e-4b21-819f-9c7a78a5bbb4"
      unitRef="usd">15700000</amed:NonCashAccruedContingentConsideration>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i3846fa0b86854a5bb6a4eea857e8c9c5_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDM2Nw_6a9d6648-06bb-4ae1-a222-77f30f3c4261"
      unitRef="usd">15000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i8427b9905afb44afa9f5cf0e37399d3d_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDQ3Mw_ee0eb62b-86be-4553-88aa-d54f848c6f61">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i65f9736c393f4089a098fe07c6aa1845_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDUwMA_89b6eaa9-3d99-4829-b4ef-f0adbd5c346d"
      unitRef="usd">11300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4NDUwMA_ac0732de-f093-4b43-8423-61afdade436d"
      unitRef="usd">11300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNjMzOA_89e86df5-3467-4c63-b2a9-c948ab0f7024">Based on the Company's preliminary valuation, the total estimated consideration of $67.8&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTUyNg_f7283e39-6e2b-407e-bf02-c83b3a81ea8d"
      unitRef="usd">67800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMi0xLTEtMS00MDk5Nw_de75dfb6-4ea4-49c6-b7c9-afd0a306a519"
      unitRef="usd">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMy0xLTEtMS00MDk5Nw_fc98027b-ed94-4511-8bad-da3bd1f29721"
      unitRef="usd">200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNC0xLTEtMS00MDk5Nw_bb846b9e-e793-40be-81cf-cb2479e7942b"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNS0xLTEtMS00MDk5Nw_0d2aa237-c77b-4f78-9919-d47eda211f5a"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNi0xLTEtMS00MDk5Nw_082921e7-3eea-402f-8e78-de2a3dc3c6e0"
      unitRef="usd">3200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib4fb833a0ee942bf86af673e369faa07_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfNy0xLTEtMS00MDk5Nw_af7e0ec6-6e11-43f6-8940-207127df8477"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfOC0xLTEtMS00MDk5Nw_b8c46430-6da4-427a-ae55-7f32f76c4642"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfOS0xLTEtMS00MDk5Nw_62bc8188-82e1-457c-8426-bae2c64bfb25"
      unitRef="usd">16500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTEtMS0xLTEtNDEwMDA_b04a9c4b-1a8a-4bc0-ace3-e9f1d7a035af"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTItMS0xLTEtNDEwMDA_fc08a3ab-1399-4b8c-bd3a-75eb3c77f835"
      unitRef="usd">2700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTMtMS0xLTEtNDEwMDA_99ecd5b9-40e9-4647-bda0-a38fc084b5b7"
      unitRef="usd">2400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTQtMS0xLTEtNDEwMDA_9316bc60-d52d-47c6-accf-2e483d923a7d"
      unitRef="usd">2800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTUtMS0xLTEtNDEwMDA_d3f638ba-e7ad-418d-a809-babb846c04de"
      unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTYtMS0xLTEtNDEwMDA_f960fc74-f3dc-4ce4-ac0d-713b3bb70bbe"
      unitRef="usd">-600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTctMS0xLTEtNDEwMDQ_997fe9cb-4d0d-47f4-adf0-ee45a4be3414"
      unitRef="usd">9700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTgtMS0xLTEtNDEwMDI_4b227fd8-334f-43c9-8250-601c756b8687"
      unitRef="usd">6800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idfa7bffede02427a89db5d1d9fd6ad96_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMTktMS0xLTEtNDEwMDI_c42dc15c-28ff-4383-af8d-776f750447f5"
      unitRef="usd">61000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6b948e672fa043169982437976dfddd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjlkNzE5ZjUzMjZmNDRiYjc5N2Y1YjA3MDk2MWE2ODU2L3RhYmxlcmFuZ2U6OWQ3MTlmNTMyNmY0NGJiNzk3ZjViMDcwOTYxYTY4NTZfMjAtMS0xLTEtNDEwMDI_481f5ad7-25b2-4da8-937f-7794d88b4ffd"
      unitRef="usd">67800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYyMA_7a6a7277-d25f-4127-a353-84ef5f9f197d"
      unitRef="care_center">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYwNA_4fdecdbd-d8f9-4462-98d8-4227177ee1e9"
      unitRef="usd">24700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgyMg_e3b2ef9f-8c64-4101-b4d3-1ffa56311f02"
      unitRef="usd">22200000</amed:BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings>
    <us-gaap:RestrictedCash
      contextRef="i3b561742ec7246caa23ec4b10eecde20_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc0ODc3OTA4MDAxMw_62061785-1ce9-4de2-b83f-aa09467e211f"
      unitRef="usd">2500000</us-gaap:RestrictedCash>
    <amed:NonCashAccruedContingentConsideration
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MTgwOA_c963930f-4af0-4b67-a127-c0e05f444ef6"
      unitRef="usd">2500000</amed:NonCashAccruedContingentConsideration>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU1NQ_80d7dab1-6cc6-4ab1-a921-9827092a31ba"
      unitRef="usd">24000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="id9100b6fd13145b3a354118b53a94340_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU1NQ_fc148cf2-7baa-4c93-9318-5d85b086f5d2"
      unitRef="usd">24000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id9100b6fd13145b3a354118b53a94340_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNzMxNg_4e699044-0dd0-4d24-95fb-140528c0995e"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="idc1b8914368b467da2e1219eea19c95b_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU3MA_dfe3dc46-c20e-402b-9698-4c272df94ce8"
      unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="icd47e369277544c6aac2253ba6754c51_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU4NA_559f0d98-b391-4376-bca8-83c9346411fa"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic36a53a0d50446a995344011bef59e29_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTU5OA_24af93fc-60fe-4965-b559-2e0e06854d99"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i13b7e4cb24c04e1eae0d3bc51631a3c0_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNTYxOA_1ce8cce9-dcee-4426-a073-9bb9c6e59a5b">P1Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="ib3fab92b1d89499ea0092820568f5338_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzNjM4NA_67f86a80-da03-4a94-b96d-983d28511644">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjM5MA_3923ca7b-689e-40ac-a02c-869c487e7f12"
      unitRef="usd">2600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjM5MA_bbc49720-c876-4c05-97bd-a4ac66ef2a55"
      unitRef="usd">2600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="i229a4ac83a574e319c2197742c5cdcc8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjQwNA_2b2191d2-e4a1-4926-9e3a-3863cb93093c"
      unitRef="usd">700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c1a47c2af0c46c5969ed2e055eac70a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTY0MjQwNA_a043fc91-0f99-4eb2-ae05-f422ac204195"
      unitRef="usd">700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTk5MQ_e7336e9b-25b5-4c3b-a344-1fd8ce7c6dfa"
      unitRef="usd">240700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="ifd89d4de539544fdb048cd299395703f_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ0Ng_823fc43b-567d-41ad-b83b-2368b76cd69b"
      unitRef="usd">600000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8087521da4e24bdd8bae8e7364409c3d_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ1NA_7ed7f028-3790-480c-b1e8-d5b272813713"
      unitRef="usd">240700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjQ2MA_e511200c-27bf-465a-ad92-260bb2446d8e"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0OQ_b3dad2fe-2355-4075-bb3e-41dc19b2564e">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjc3Ng_a294a910-55e3-4e89-8f0a-0d4dadbe72fa"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMi0xLTEtMS0zNTc0Nw_9eb07a11-de8b-4eca-add6-74e471d766ff"
      unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMy0xLTEtMS0zNTc0Nw_a8c59744-7dcd-4819-b28b-dd5e800539ce"
      unitRef="usd">300000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNC0xLTEtMS0zNTc0Nw_cc3e6581-2bb6-419c-a273-ebf31d3f990c"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNS0xLTEtMS0zNTc0Nw_974c32e5-0e92-4121-9456-5120a8010458"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNi0xLTEtMS0zNTc0Nw_a2c0262e-7f13-4c22-98f4-658a47f4a8ee"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfNy0xLTEtMS0zNTc0Nw_99ef5fc3-ad8c-4ed2-815d-e27b05376df7"
      unitRef="usd">54300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfOC0xLTEtMS0zNTc0Nw_1287870a-3651-4d16-9503-43295cd86450"
      unitRef="usd">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfOS0xLTEtMS0zNTc0Nw_7aef234c-d601-4308-9ed2-3fc55d321e24"
      unitRef="usd">60400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTEtMS0xLTEtMzU3NDc_953c612b-64f4-45de-97ff-9df4bf5b8e3b"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTItMS0xLTEtMzU3NDc_03e0aa7b-180d-4364-8646-54cb8355a6f5"
      unitRef="usd">600000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTMtMS0xLTEtMzU3NDc_6f38f2b1-4966-4489-82ee-b940b13b8796"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTQtMS0xLTEtMzU3NDc_35bb11bd-c2dd-4e60-9eb9-c2036e8a14db"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTUtMS0xLTEtMzU3NDc_19f31ddc-159a-4487-8196-03ca0122dc3b"
      unitRef="usd">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTYtMS0xLTEtMzU3NDc_41198824-7245-4f00-8284-ff2f10fe8b11"
      unitRef="usd">-900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTctMS0xLTEtMzU3NDc_35f0370c-7c12-4279-80c9-0494bf620bdf"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTgtMS0xLTEtMzU3NDc_58f857b4-4d3a-473b-b8b3-aaa63be3182d"
      unitRef="usd">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMTktMS0xLTEtMzU3NDc_2f1da03e-eb5d-41c5-ad02-df8f26bac17f"
      unitRef="usd">43900000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjAtMS0xLTEtMzU3NDc_3ed616af-53bc-472a-b794-86254c060e28"
      unitRef="usd">-43900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjEtMS0xLTEtMzU3NDc_5cf7c9e1-4b01-494a-a51c-90a9bbe35943"
      unitRef="usd">-53000000.0</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjItMS0xLTEtMzU3NDc_68dab358-4407-4f50-b3f2-c8f69e0bc97c"
      unitRef="usd">7400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjMtMS0xLTEtMzU3NDc_9a33a00d-a337-4dea-999b-44f822764e9d"
      unitRef="usd">233900000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i95fd0b6c754e4afaaa045b94ec9b3b15_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RhYmxlOjQ2NjkxNDZmZWJiZjQ2ZTY5YmMxNmU5YTE0YjJkNzQzL3RhYmxlcmFuZ2U6NDY2OTE0NmZlYmJmNDZlNjliYzE2ZTlhMTRiMmQ3NDNfMjQtMS0xLTEtMzU3NDc_1eef9b70-d61f-468c-b6f2-117e539d3458"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic2e82315a0db4ef2930ad63880f79a3f_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjk4MQ_2166f6e8-4456-4c09-a116-3340451d01a3"
      unitRef="usd">28300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iaa48e07aa67b4e89a0601d5f3eee5d03_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMjk5OA_438ef73c-09ce-49b1-9098-f57fea319d35"
      unitRef="usd">19800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1ac7ec89f6e9427cb5d656763a3bddc5_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzAzMA_2636ab8d-a29b-4184-9d4e-4bc66f310117"
      unitRef="usd">6200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4eb3273c875947fb92f75066e32951a9_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzExNA_716748bc-12bd-43dc-ae41-0210d4e442f6">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id39d0ab5b15a45f6b8ac1c1e71d6931a_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzE4OQ_3dbc69fa-495b-4311-b160-8ca8ce20b989">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="if1b5f67982a043f9a5db90d0388aa2bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzQxMQ_204f3636-cdc2-42ef-829c-e978ac86586f"
      unitRef="usd">4400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i9ac3f76ab9614d4688b0b8101d455be8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMzc0NA_4921a180-d725-450f-a1a8-995b30b3b768"
      unitRef="usd">700000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia5af77f74fe5494b8dc53db8bf9087ea_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjYzMQ_28b7aa2a-0196-4bc1-b2a6-d79df8619475"
      unitRef="usd">7200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i3e721858874346608ff8de6222b8c390_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81Mi9mcmFnOjlhNzhiZjlhMzBmNDRkMGViYzg1MjM4MjU3MDE1M2RkL3RleHRyZWdpb246OWE3OGJmOWEzMGY0NGQwZWJjODUyMzgyNTcwMTUzZGRfMTA5OTUxMTYzMjY1OQ_c2e3856f-b533-4226-9e70-585250b61331"
      unitRef="usd">1500000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2Ng_2d93126d-0dbe-4d0a-98b0-85cb8fe13646">LONG-TERM OBLIGATIONS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.2% at June 30, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.7% at June 30, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Second Amendment to the Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2022, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% for the three and six-month periods ended June 30, 2022, and 1.7% and 1.8% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 2.3% and 2.0% for the three and six-month periods ended June 30, 2022, respectively, and 1.4% and 1.5% for the three and six-month periods ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 15.4 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our availability under our $550.0 million Revolving Credit Facility was $507.3 million as we have $15.0&#160;million outstanding in borrowings and $27.7 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;Contessa and Asana Joinder,&#x201d; and together with the CCH Joinder and the AseraCare Joinder, the &#x201c;Joinders&#x201d;). &lt;/span&gt;&lt;/div&gt;Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2Nw_5a9b1dcd-62aa-4387-b11b-24a404b86591">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.2% at June 30, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.7% at June 30, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i043295b1e6fd4805ad86f88638f693aa_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzQ_1348e0db-17da-4322-bb9d-69e600b3983a"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i7bd5c5b90ca64ac5b24203d891eb6fa6_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzEwNw_be90d15b-b8a6-4d7d-9683-f5d4cd183e97"
      unitRef="number">0.032</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjRmMTY1OGQwZWRjNTQ4NWM4ZDAxNTQ2Yzk2YzFmMTU2XzEzNA_d69a42da-6c3e-41b5-aff5-1745340db782">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i043295b1e6fd4805ad86f88638f693aa_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0xLTEtMS0zNTc0Nw_ce47fab0-0e78-441c-84e9-907f86bbee05"
      unitRef="usd">441600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id0111dd48d164a73bdbda6add2995d5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMS0zLTEtMS0zNTc0Nw_87cbc60c-faad-4232-a050-6bff8d192a46"
      unitRef="usd">447200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzQ_09399347-acb0-4e40-8fe6-7e94684f5c2b"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i35487ebf2851440e915cf218928141e1_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzEwOTk1MTE2Mjc5NTg_c5f014ce-ce2c-455a-86a3-232ebfe4289d"
      unitRef="number">0.027</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0wLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjZiYzczNTdjZmU5ZDQzNDZhM2UzMDliM2M1ZTc1YjZhXzE1MQ_4b04893e-d462-4ff1-999a-ebbb99453792">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0xLTEtMS0zNTc0Nw_09396a21-2c54-40b9-91f4-a8c06d16d283"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic12425e6cf2b4507ae0eb717031bd48e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMi0zLTEtMS0zNTc0Nw_33eaf906-5a5e-4a82-ad21-6568bb7334a7"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib714a01635724ae086d93a794a849aa8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMy0xLTEtMS0zNTc0Nw_bcad530a-be20-41d8-bac2-4d168568ae3d"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3e1f02a946da41c68f1054d698474350_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfMy0zLTEtMS0zNTc0Nw_4a089904-504c-45b8-904e-117f453f5786"
      unitRef="usd">800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3fdd1926c3d342b398329f841ae4f949_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNC0xLTEtMS0zNTc0Nw_0e3e4a08-ba14-4e33-8254-a16f45160c0c"
      unitRef="usd">2200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id68e48e4accd47829e3f2c108a5e0128_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNC0zLTEtMS0zNTc0Nw_31efe446-3950-4790-ae7e-03ed9223f132"
      unitRef="usd">1600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNS0xLTEtMS0zNTc0Nw_1aa91f5c-a13c-4b82-ba8f-8e3094eca14f"
      unitRef="usd">459000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNS0zLTEtMS0zNTc0Nw_58dcfaaa-c8dd-4757-8832-ce7f17029240"
      unitRef="usd">449600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNi0xLTEtMS0zNTc0Nw_5a1e0c2e-8ef3-4dbf-8496-d3438e5a8d61"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNi0zLTEtMS0zNTc0Nw_66a0ddb3-db8d-4e63-aa34-c8c0325c7383"
      unitRef="usd">4500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNy0xLTEtMS0zNTc0Nw_f3583c98-3f0b-441b-9e9e-04feab7f49b1"
      unitRef="usd">454900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfNy0zLTEtMS0zNTc0Nw_fb872b90-6e7c-4087-a606-0c55a6d6674e"
      unitRef="usd">445100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOC0xLTEtMS0zNTc0Nw_609162aa-6955-45e4-a473-a5292721eabb"
      unitRef="usd">12500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOC0zLTEtMS0zNTc0Nw_97bd43a8-9b29-4084-82d3-4f68cdbd49b2"
      unitRef="usd">13000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOS0xLTEtMS0zNTc0Nw_b836efb7-2850-4664-9061-f20c00cf1917"
      unitRef="usd">442400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1ddf9fbb9d354501832c0641468f679d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOmQ1N2U1NWVkMzlhYjQ4MWQ5NWZkNWNlNGI1ZTcyYjU2L3RhYmxlcmFuZ2U6ZDU3ZTU1ZWQzOWFiNDgxZDk1ZmQ1Y2U0YjVlNzJiNTZfOS0zLTEtMS0zNTc0Nw_14b9a0d6-25a9-4113-a722-8739fe0d74dd"
      unitRef="usd">432100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i395b376b36064fa0b151bf87dcfde162_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDUx_67ad79c5-2e9d-4e21-85ef-02fd08df2159"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5e933e2b55f0441d8ade42bb9a6422c9_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDcy_540ec138-94da-491b-bf91-3c978886b6c4"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTU5_908f2000-433b-4211-915a-a70bac691680"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf8bddefd1ce421f9de88f4f9d3b5012_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzAz_68318572-68a7-4db8-b389-79ee21ebc66e"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5Nw_b2a5fb5c-9bda-4c90-8444-130bd2377569"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTIxNg_862f73b2-aa0c-4e77-b170-762d6a950a38"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i368407cb268545c8a429573f1fdb24fd_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTYxMw_324d2796-d482-4c20-b7fd-4014af603510"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i98096f04576b4100a1338db93629914d_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTY1MA_c14fbbbc-7fbe-4cc9-b986-ee846d913d55"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNzg2NQ_80c9ec5e-f5c1-49dd-ae26-e0dbf1a937d7">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="i0f7d430c8d0f426aacb10538dea5c466_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmI0MmI2NzgwYWI0YjQzM2VhYzgyNjgyNDA5YmMzZDgwXzY_6f093086-c1f5-4ef7-b048-2ef62d7effa2"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3dfdd0581d7248b8b729caa375e55f7d_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0yLTEtMS0zNTc0Nw_900e1332-3312-4132-a349-dbe6ce70f147"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i914232c463aa4978b4a531ac7e62be33_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS0zLTEtMS0zNTc0Nw_5cde740e-14e6-4e1f-8a4c-9ae130803c1c"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS00LTEtMS0zNTc0Nw_923660db-dd72-45a8-80c1-c7e7e7ce0587"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMS01LTEtMS0zNTc0Nw_b6b92155-9032-48a0-b80e-67beebcfc7f7"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i26d1ddcfb1a14175839570fdd3546981_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjBhYzNiNWVlYzJmZjQ2YzFiOTc0ODE3MGExOTllMzMyXzc_3befe24d-fadb-4e3b-b8b8-b1e8a70351a5"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i5ef3b974ffc54477b347ad7aba261ff0_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOjBhYzNiNWVlYzJmZjQ2YzFiOTc0ODE3MGExOTllMzMyXzIz_5a27fa69-e7f4-49e5-aa47-cea2c2942f23"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3471a8de624944a9847b252690bec01b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0yLTEtMS0zNTc0Nw_4372fae5-4441-4cd8-8ef5-d66c6f58ae00"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i61200e8a017c49809e956ccc90265bd5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi0zLTEtMS0zNTc0Nw_8339b509-837b-479b-8cea-74d4f8daed3a"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi00LTEtMS0zNTc0Nw_df858993-d942-40ad-bbf4-21ac5469a3cc"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ic69e65fac7bb42cc8c86c6b1d81b4f67_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMi01LTEtMS0zNTc0Nw_85849ff5-8b11-47ee-8f46-d573a9208958"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i6ea37ed79d51491fa4d4fe86aabbcd2b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmZjZGZhNGE3YTgwODQ3NGNiM2NiNGVkNzM0MzIzYjVjXzY_5ee40b16-c035-4e31-9b13-3e1eda05a1b1"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i651fdb8c74b14b81967263e6ff2e0db9_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmZjZGZhNGE3YTgwODQ3NGNiM2NiNGVkNzM0MzIzYjVjXzIy_7b602401-6a7e-4896-8e78-11de8e4415d5"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i289a8de993e54ffabcd97d4bed94c9ec_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0yLTEtMS0zNTc0Nw_8b244faf-5abd-4d9b-adde-22e394cb18b4"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6c330947191b484cabb14457b2008fec_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy0zLTEtMS0zNTc0Nw_ae1b60d5-8791-492c-90ce-52df5fb4021d"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy00LTEtMS0zNTc0Nw_6bd102ca-eb59-4e54-a330-51d08ee08b5b"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i5b2006f725ed49d2b8950429be0b6bd5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfMy01LTEtMS0zNTc0Nw_7e67013d-e503-452f-a42f-151e3c9973bc"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i3d6b509d3e8d4a32b2dc334213e3e90e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0xLTEtMS0zNTc0Ny90ZXh0cmVnaW9uOmU2NWZiZGI5MmNkODRhZDk5NmJiODkwZGQ0NmJhM2JlXzY_b087651e-8b4d-4a3a-a6fb-3dc82254d122"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7de7001e37e54eaea710b0dd411e567a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0yLTEtMS0zNTc0Nw_81045cb7-4ecf-448d-8e1d-b3161d7aba96"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7f8f5ae337584aee9a115925a8e2d3ce_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC0zLTEtMS0zNTc0Nw_bd49e054-56cb-4c4a-8ef8-758b8a946185"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i2c044924a75b44968b0831ab81455994_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC00LTEtMS0zNTc0Nw_f4a92a51-8703-402c-96a3-0df69d0129a6"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i2c044924a75b44968b0831ab81455994_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RhYmxlOjAwY2M4YmI3ZGExZTRkODc5YTk3OTkyZGFiODVjZTJiL3RhYmxlcmFuZ2U6MDBjYzhiYjdkYTFlNGQ4NzlhOTc5OTJkYWI4NWNlMmJfNC01LTEtMS0zNTc0Nw_ee7ba182-6545-4462-95f9-7c5a9c5a1170"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i342d3f4c7f564db587a6511cf32380e8_D20210730-20260730"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTkwNQ_9601aa35-9f6d-4c65-a9ab-f769757d3d96">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="ia7465164416942ac8228a0f9daf738ff_D20210730-20230930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjEyMA_0b3e7d13-3831-4ae5-bf00-77026c7b2000"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i17a72248de9c483b86fc97e68ef07f13_D20231001-20260730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjIwOQ_84d59e5d-4d85-4c0a-af68-764bc8292004"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="i325318cf209c4cb4a2a43b717a15c820_D20210730-20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMjgzMA_724391db-052b-4b7e-aa87-944bf7d78b9a"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDEyNA_1ffb12f6-5aa4-4558-b85b-9bc7930e6604"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="ic06a840380f3401e8def8eb8be1cac42_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDMwNw_e5748ee5-3dca-4624-9e86-abdd587143d2"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDU3Mg_417771d5-fac9-4e86-bb2f-bd4ddde01d23"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i03d87584c975497d9c6f614b6f3f8e5e_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDYwNQ_50c82b4f-a41f-463c-9636-1d8eaa3741da"
      unitRef="number">0.029</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i1dd885163504491c94c4e3eebdb99108_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDYwNQ_da2724f6-06ca-46d6-83fc-25935a15e3be"
      unitRef="number">0.029</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="icff1249baba74d4bb0802f6d4bcf1199_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjEyOQ_916ce642-f617-4724-976c-997b35025f0b"
      unitRef="number">0.017</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i2dd2a0aeede64a10a02cea3509dc8376_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjEzNQ_17e8742c-0e63-4fc4-964c-75f5af22790e"
      unitRef="number">0.018</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i5fdfe5f5157c462fa0c08492c5359787_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDc0OA_f40edf77-0368-4362-b4fe-7206ba8bf059"
      unitRef="number">0.023</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i35a01e50a9ca418f8048677caf1d859f_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDc1NQ_9dde5797-cefb-4f7e-8eaa-eade7e531ca5"
      unitRef="number">0.020</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i27ef4862c0c741ad8c38872eb9eb8d3c_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjE0MQ_a2def64c-ab7c-46f3-a9b0-a8d876c19151"
      unitRef="number">0.014</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i908c39c20d774cf49e9e8591ddd0e31a_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfMTA5OTUxMTYzNjE0Nw_1d02fb30-212f-483e-a8be-0add6e2ae4ee"
      unitRef="number">0.015</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDg3Nw_7a74808f-2ca6-43bc-bad2-e1b1fa7dfaac"
      unitRef="number">1.7</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="if19ffbe3490c49479b91f735381591d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNDkyNg_0493790e-b5b1-4179-af89-374bb9425eb9"
      unitRef="number">15.4</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTMxMQ_37a04269-4e67-4d4b-abf8-f506dfb5e3ce"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM0NA_cd8c4f8c-ec8b-4358-b075-2262016f7f8f"
      unitRef="usd">507300000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a2c05fc0e0b4b2dac2360a7c711f149_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM1OA_09396a21-2c54-40b9-91f4-a8c06d16d283"
      unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ie6ac967f423744c484ee9385ced160bb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl81OC9mcmFnOjM1ODMxMjM5ZjgyMDRhMDFhMWEwMzI3MWQ0MDkxNzZkL3RleHRyZWdpb246MzU4MzEyMzlmODIwNGEwMWExYTAzMjcxZDQwOTE3NmRfNTM4OA_84e72066-cb4c-480b-98dc-3874cc292b19"
      unitRef="usd">27700000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAyNDE_89acf6cb-df30-44c0-9d84-c43b78e1026b">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $6.5 million recorded to accrued expenses in our condensed consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;), Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;) and the Office of the Inspector General (&#x201c;OIG&#x201d;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2022, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an extrapolated overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an extrapolated overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the results of the ALJ hearing for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As of the date of this filing, we do not have a demand for repayment from Palmetto for the Clearwater Care Center or the Lakeland Care Centers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing of the demand for repayment; however, the Company has updated its estimates of potential loss based on the ALJ's decisions. We have increased our total accrual related to these matters from $17.4 million to $25.8&#160;million. The net of these two amounts, $8.4&#160;million, was recorded as a reduction to net service revenue in our condensed consolidated statements of operations during the three-month period ended June 30, 2022. We expect to be indemnified by the prior owners for approximately $10.9 million and have recorded this amount within other assets in our condensed consolidated balance sheets. As of June&#160;30, 2022, $1.5 million of receivables have been impacted by these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of $2.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0ea90e266fd540c1b73334141496eeda_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODk3_8bcd4f1f-3cb2-4d4a-83da-ed4e5ef3419b"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReversalOfLossContingencyAccrual
      contextRef="ie02b1044c0fa4fadb08f8e9354318b47_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODk3_8d247b22-fdc4-4379-8d35-c2a11c749c76"
      unitRef="usd">6500000</amed:ReversalOfLossContingencyAccrual>
    <amed:Numberofpatients
      contextRef="i5a818c66a5b04529bf0bde65307825f1_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTIxOQ_ffce2d09-133f-4452-bb97-828b6eff9c50"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i093a633cdc1f40ff80f2e4fe49d565e7_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTk2Mg_5ac26a20-8bf3-4357-8091-6a7400436d6a"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="ic33cb6496cb44a3fa5ff85100d4ce238_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMjU5Mg_fd93329e-389a-4335-8a48-b8d089db038a"
      unitRef="patient">68</amed:Numberofpatients>
    <amed:NumberOfBeneficiaries
      contextRef="ie73580cf813f4bacb80a34a16b93b064_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMzY2OA_8cda4e3b-b1a2-402c-ac8c-b931d3cf378e"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="i694cb74b423248c896a972c561852442_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDExMg_155a1e08-fc2d-4210-80d1-f19d4f8c7681"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ie5b0119f2b2547fa916994d37a51982e_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDkxNQ_c3e7ee94-1f6d-4f57-852f-a6adef80fbac"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="ie5b0119f2b2547fa916994d37a51982e_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDk0MQ_9f2a93b5-81a5-42d7-bc32-3dd573860ec6"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNDk3NA_98ca610d-2b8e-452a-8d7f-46794b96f7fc"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="i694cb74b423248c896a972c561852442_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTAwNQ_aa214ae9-75de-4fbe-b3b0-5d29a1233856"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i74ac2bf066d449fca098c27a8191bdff_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTA3OA_76e6df1f-bb84-4783-8cbc-273bf6bebfd3"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="i361b5e96bbca4bd8a455e792020b20e7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTMyMw_e158d13d-dc5c-4a4d-997c-1c8860b8178a"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <amed:IndemnificationAmount
      contextRef="i57695b07d1464993ae80368c4d54fbe4_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTgyOA_9f8c173d-2a3d-4df6-8992-42a36bc7d6f8"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i71f2e16b6e58440aa8210596de7977c5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNTgyOA_e832aa7c-6ea3-438f-aecf-c464d9c49339"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjY3Mw_4c5b8487-aa79-45bd-ac74-5035a5a1ed06"
      unitRef="usd">34000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ib07ad9b0c2284a67950bf5935cd96810_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjcyMw_97925fcd-6060-4fa9-af66-d9d78f6e6609"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjc1MQ_d8b24e71-66b2-42ff-b12e-14a1c933713b"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i1b93980fcec94641a3ac5597a6cf39a7_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjc4OA_a68819a6-fce4-4d69-b11f-cbba79ce81ee"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjgyNA_cb01ab9a-5a88-4392-81f1-293afe4b354d"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="if7a5f95eb6a3431691a8916273d87b3a_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjg3NQ_a1313ad2-6383-4c1d-9f42-2a48e0ff89f6"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjkwMw_a6e66330-6589-49b7-9aaf-cbee0eaac431"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i5896b8d5a4ed4201b4ae7106218c9ee6_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNjk0MA_f4862944-a595-4d3f-8bdd-d5988d32e3c7"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i7510142fa85d4f9d92232c8c96e894e5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNzMwNA_cfd42072-330a-4f37-a482-1ebf87426037"
      unitRef="usd">26000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i509592a5ae784f308e714e6df14f611e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfNzM4Ng_eb284e9c-4f59-4312-b901-e29f13bef88f"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i3aaeb76718a141288630010cd2fca7f8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODgwNQ_60190571-457e-48d1-a8ef-581a934f04e9"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i832d375adc9a4e25b37e1d449314a0b7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTA5OTUxMTY0MTIxMw_e8a78ff1-6a06-4f59-90d4-b66ac73dc105"
      unitRef="usd">25800000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReductionToNetServiceRevenue
      contextRef="i5a583ddc36234cbbac97618ef468484a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTA5OTUxMTY0MTIyOA_bc310bb1-00e1-455a-9040-6d505da9aca6"
      unitRef="usd">8400000</amed:ReductionToNetServiceRevenue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i832d375adc9a4e25b37e1d449314a0b7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfODg5OA_0b8f88ff-252b-4c19-a540-d1019836f029"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic98dab006fb24cf1a5c08315e4408d0f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfOTIyNQ_3d9e215b-2a35-4594-a710-3962bce9ddc9"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAwNDc_20418646-f2e1-4993-8ee5-de11f02808b4"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAxNDQ_06613b99-9f3c-410c-9fa7-8046adfeaa8d"
      unitRef="usd">2000000</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl82NC9mcmFnOjYxNzg2Zjg3YTUwZTQwNjRhNDQxY2JiZWZkMmViOTFhL3RleHRyZWdpb246NjE3ODZmODdhNTBlNDA2NGE0NDFjYmJlZmQyZWI5MWFfMTAyMjY_4dff07b6-2987-498d-9931-0e31b0ed7d53"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfMTU5Mw_300c40a3-e7e7-41a3-a9e0-17f2b0fd4276">SEGMENT INFORMATIONOur operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfODI_4329c70e-6529-4fd7-ac85-b30dd69c8f31"
      unitRef="segments">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RleHRyZWdpb246ZmJiOGMwODgwOGJmNGI4NWJmZjZlNDFjYmE0OWRlYzlfMTU4OA_057103b8-38f2-4e99-8f53-e7575b57d16c">Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0xLTEtMS0zNTc0Nw_7e03ff0a-b692-4a70-87c2-c167476d8e44"
      unitRef="usd">340200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0zLTEtMS0zNTc0Nw_89c4aa2f-dfdf-4943-9236-24cb88ea4112"
      unitRef="usd">198400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi01LTEtMS0zNTc0Nw_c88718a2-8321-44be-9205-6355a5cd4551"
      unitRef="usd">14900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi03LTEtMS0zNTc0Nw_02e3c6a4-30b4-4e1c-9aff-24d4e3573d89"
      unitRef="usd">4400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi05LTEtMS0zNTc0Nw_ae78381a-f76f-45a5-bbbf-72f71e7ddaa4"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMi0xMS0xLTEtMzU3NDc_9c9c5b21-0d09-451a-a493-08788f1a80a0"
      unitRef="usd">557900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0xLTEtMS0zNTc0Nw_cf8d9889-578c-4556-a987-ce068f93741f"
      unitRef="usd">193000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0zLTEtMS0zNTc0Nw_aadd6b70-fcf3-4fe6-89ff-1beff749ac39"
      unitRef="usd">107400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy01LTEtMS0zNTc0Nw_2becf7e4-6694-4492-a2d1-99b8ef890444"
      unitRef="usd">11400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy03LTEtMS0zNTc0Nw_1c3b0fc5-b161-4fc1-840c-9b520222ce37"
      unitRef="usd">4400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy05LTEtMS0zNTc0Nw_fd068273-7e23-43bf-aa5e-bb731cc32b56"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMy0xMS0xLTEtMzU3NDc_81607c31-94d2-4c8a-a0fa-0f63401e21e8"
      unitRef="usd">316200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0xLTEtMS0zNTc0Nw_afa7c7f4-723b-499c-a874-0a40e0ded1c9"
      unitRef="usd">87900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0zLTEtMS0zNTc0Nw_0a5ff394-3afa-4054-882d-6ad56d9a4c91"
      unitRef="usd">51600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC01LTEtMS0zNTc0Nw_d4637064-0f02-4e58-8a6c-99e8d5a6b9dd"
      unitRef="usd">2300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC03LTEtMS0zNTc0Nw_a59a9383-bd58-4c00-8ef9-94c69ac133a4"
      unitRef="usd">8900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC05LTEtMS0zNTc0Nw_5036f463-2d3f-46e6-9dc4-a0730a5b9529"
      unitRef="usd">37200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNC0xMS0xLTEtMzU3NDc_fba22b29-bd97-4be8-b1f4-7ef4d7b901fd"
      unitRef="usd">187900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0xLTEtMS0zNTc0Nw_fa09ae80-13c4-4cca-8158-c3a724efc77b"
      unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0zLTEtMS0zNTc0Nw_488e8f74-2a56-4f25-a6f4-402d04e6266b"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS01LTEtMS0zNTc0Nw_a1cc49b5-5d45-4e0f-939a-84c569df4442"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS03LTEtMS0zNTc0Nw_36cd66e6-b92d-4cba-a0c9-f39ba978eecd"
      unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS05LTEtMS0zNTc0Nw_448f11c6-6fde-472c-b646-5aca4ebcc291"
      unitRef="usd">3300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNS0xMS0xLTEtMzU3NDc_d2c15a5d-1c29-48a5-850b-05d1083cc904"
      unitRef="usd">6200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi0xLTEtMS0zNTc0Nw_7ba0d3b5-7d3d-4e99-868b-8ea21ef92fc3"
      unitRef="usd">282400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi0zLTEtMS0zNTc0Nw_0d8a51fb-06be-40f5-a47c-7d6ddb71ec88"
      unitRef="usd">159600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi01LTEtMS0zNTc0Nw_c7db19c3-b809-44f0-888f-ae19462109ba"
      unitRef="usd">13700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi03LTEtMS0zNTc0Nw_70bcc25d-c665-4088-b6de-1cfe0e115ed7"
      unitRef="usd">14100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNi05LTEtMS0zNTc0Nw_afeb8f81-1ccd-4f0f-924e-dbccf2f6574a"
      unitRef="usd">40500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i68b4cd10a0354cb4996ea94d3de04d47_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0xLTEtMS0zNTc0Nw_729d38b6-f02a-457d-8c2e-888773a4c40c"
      unitRef="usd">57800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i99336a150f6c4f2b8de8ab50cd6cb378_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0zLTEtMS0zNTc0Nw_22dd5fe2-db46-44fd-8349-1d8a740e7ab5"
      unitRef="usd">38800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i23aac7cc3e004ff7a8004adce50707a3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy01LTEtMS0zNTc0Nw_b461feba-0994-4731-874e-a047ceb50021"
      unitRef="usd">1200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i90df2dbcd4a648249d3a763359be7885_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy03LTEtMS0zNTc0Nw_3102372c-fd88-4ddd-966f-33774fe86a7f"
      unitRef="usd">-9700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib738180a6831463f8f7c2d9adb5010a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy05LTEtMS0zNTc0Nw_df09cb23-e7bc-4d28-87eb-c115d82aa7ac"
      unitRef="usd">-40500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfNy0xMS0xLTEtMzU3NDc_e99a6272-d787-4a8a-b762-44547b023c0b"
      unitRef="usd">47600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMS0xLTEtMzU3NDc_87d6eaa4-2a6d-44fa-a1e3-28f6952629d3"
      unitRef="usd">349300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMy0xLTEtMzU3NDc_386c1a97-6417-4fbb-8d2b-a84f6ee1edf2"
      unitRef="usd">197900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtNS0xLTEtMzU3NDc_f956b474-9a53-43af-aee9-ed123f35b7c0"
      unitRef="usd">17000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtNy0xLTEtMzU3NDc_83d9245b-9619-4e00-8d70-66f0b93b49ae"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtOS0xLTEtMzU3NDc_9b1adae8-3368-4d79-9477-c002ce8c940a"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTEtMTEtMS0xLTM1NzQ3_307736b9-6ea6-42ec-8d86-c4d3aeade6b7"
      unitRef="usd">564200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMS0xLTEtMzU3NDc_e8a9264e-8985-4154-909f-d6051382b2c3"
      unitRef="usd">2300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMy0xLTEtMzU3NDc_968575e2-8aed-4330-be46-f8e42f98deef"
      unitRef="usd">2300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItNS0xLTEtMzU3NDc_bee28046-8814-4424-8186-f10c2d900d3f"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItNy0xLTEtMzU3NDc_b70dad2d-1d1e-4429-8bea-318881d723a3"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItOS0xLTEtMzU3NDc_11784033-2a24-4643-93a0-6779a8cefd29"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTItMTEtMS0xLTM1NzQ3_54a9e6e9-04ba-4d05-8229-8d755f9d3b95"
      unitRef="usd">4600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMS0xLTEtMzU3NDc_ec6a05d6-19e3-4f6b-a787-c85752942cf3"
      unitRef="usd">190400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMy0xLTEtMzU3NDc_476e2acc-d39d-40c2-8cdd-24e25b7532fa"
      unitRef="usd">105200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtNS0xLTEtMzU3NDc_478d4dc2-1797-4b13-960c-cb7816e4b773"
      unitRef="usd">13100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtNy0xLTEtMzU3NDc_f3625954-c065-4381-868e-3ccd893be716"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtOS0xLTEtMzU3NDc_c6fbbd86-a6c0-47cd-b85c-3962c87ec3df"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTMtMTEtMS0xLTM1NzQ3_78936338-09f3-4ac9-9075-189a340a22d1"
      unitRef="usd">308700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMS0xLTEtMzU3NDc_07af11ac-d410-4d84-a64e-840bec446198"
      unitRef="usd">81300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMy0xLTEtMzU3NDc_01aad823-40a7-47c4-9458-b1ffd3f4f14a"
      unitRef="usd">48400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtNS0xLTEtMzU3NDc_13002a2a-0c1a-4bc0-9f77-76981469bb01"
      unitRef="usd">3200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtNy0xLTEtMzU3NDc_b4099be0-ebaa-48fe-be2d-31219f5fbead"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtOS0xLTEtMzU3NDc_eded922b-18cc-490b-b48e-8367e85751f5"
      unitRef="usd">42400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTQtMTEtMS0xLTM1NzQ3_cc7a2f94-2ff7-46e5-9599-7156979ed05a"
      unitRef="usd">175300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMS0xLTEtMzU3NDc_6e87c3b6-2727-400c-96f4-34c2ca9f5e1f"
      unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMy0xLTEtMzU3NDc_7d8f83ee-826c-4c87-8854-ede72c59013f"
      unitRef="usd">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtNS0xLTEtMzU3NDc_ee45c6f9-9028-42a0-8e15-45c676b00e81"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtNy0xLTEtMzU3NDc_bbd452ed-5a67-4032-9e6e-828c197178d0"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtOS0xLTEtMzU3NDc_4952fdf8-4ede-4295-97a6-a9f397156af7"
      unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTUtMTEtMS0xLTM1NzQ3_a9825107-ea94-4b43-89e5-fa1abedf6f1b"
      unitRef="usd">6700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtMS0xLTEtMzU3NDc_371038dd-2885-401d-9854-d0867425c8ec"
      unitRef="usd">272900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtMy0xLTEtMzU3NDc_1e160dd9-7579-42fe-a203-122cfbfd02aa"
      unitRef="usd">154300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtNS0xLTEtMzU3NDc_1f432a4d-0512-4cb2-8a63-748e07f8060b"
      unitRef="usd">16300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtNy0xLTEtMzU3NDc_b868015a-4a68-416a-8c5b-73c55b9e51b0"
      unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTYtOS0xLTEtMzU3NDc_d9d0efda-aaaf-4a79-8841-81acab24dee5"
      unitRef="usd">47200000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc981aa9b6ed4850a8a12c5014afc348_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMS0xLTEtMzU3NDc_3c693861-2fd4-4423-b856-d29712d9b563"
      unitRef="usd">78700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i42cdb46726754c8f8208bb41fc3a8bf0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMy0xLTEtMzU3NDc_b3075e0e-435f-4f80-9909-c83bda810005"
      unitRef="usd">45900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3acb9fa669f64e6ca048ce06ade75e58_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctNS0xLTEtMzU3NDc_252f7b3c-54cb-4a30-8618-0f4a3c973ca3"
      unitRef="usd">700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia015b8b24487424e96577269736c5919_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctNy0xLTEtMzU3NDc_741cf825-b1a7-42f7-8af1-7628da5d3905"
      unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4af18205663849b1855b2aaaff8945f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctOS0xLTEtMzU3NDc_ba0d40c4-aefa-45ab-a22a-75ce7cd8967c"
      unitRef="usd">-47200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b8ce88bbc3f4c52ac5ca613def27ed2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMTctMTEtMS0xLTM1NzQ3_9a617909-2f63-43e8-9986-bf43a3fd689f"
      unitRef="usd">78100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMS0xLTEtMzY3NDQ_bd6472d1-7c54-47f3-9354-3398421a662a"
      unitRef="usd">675600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMy0xLTEtMzY3NDQ_cf2ff98c-21de-4621-86e5-a93e50be21d1"
      unitRef="usd">391400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtNS0xLTEtMzY3NDQ_be9f84bf-4957-49ce-9ebf-cf123770844f"
      unitRef="usd">28900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtNy0xLTEtMzY3NDQ_43022bc1-d124-4e40-94d6-7453ce95f895"
      unitRef="usd">7200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtOS0xLTEtMzY3NDQ_2d7ad864-b3b0-47a5-aff0-ed1eb9a5f15c"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjEtMTEtMS0xLTM2NzQ0_2e9fe6a2-0355-4f6a-a7ae-8914f9d224d7"
      unitRef="usd">1103100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMS0xLTEtMzY3NDQ_1488516f-1f1c-4e97-8507-54fcd030ab22"
      unitRef="usd">378000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMy0xLTEtMzY3NDQ_4518f1f6-dc54-4d79-93a8-c3cf82292c77"
      unitRef="usd">213800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItNS0xLTEtMzY3NDQ_12567481-1cd6-4043-91cb-efeff5c7240c"
      unitRef="usd">22200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItNy0xLTEtMzY3NDQ_08d49ce8-5c09-44b6-8588-3312fd0b689d"
      unitRef="usd">7000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItOS0xLTEtMzY3NDQ_a098c280-b382-43f6-8f52-7ac4e3fcfe2a"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjItMTEtMS0xLTM2NzQ0_81257ea6-6b1e-4cf5-bf04-e20c95467bc7"
      unitRef="usd">621000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMS0xLTEtMzY3NDQ_edee54a8-6b21-4dea-b4de-9928bb325789"
      unitRef="usd">171100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMy0xLTEtMzY3NDQ_3ac995ec-5bc2-48c9-b924-d84229dcd859"
      unitRef="usd">102900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtNS0xLTEtMzY3NDQ_28902541-3495-4b19-b983-f0d98d43fd28"
      unitRef="usd">4500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtNy0xLTEtMzY3NDQ_7e95b3fc-b4ab-4339-8b25-4e92c3a35bbf"
      unitRef="usd">15900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtOS0xLTEtMzY3NDQ_a6e82684-0e58-41ac-8cee-085c161285a0"
      unitRef="usd">77900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjMtMTEtMS0xLTM2NzQ0_2649dba7-98a2-4244-b966-0f743b9be215"
      unitRef="usd">372300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMS0xLTEtMzY3NDQ_5035ee75-1412-4ef0-8b02-562ec80e6678"
      unitRef="usd">2400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMy0xLTEtMzY3NDQ_c26ad4c4-5cf6-4fe5-869c-47955a52b414"
      unitRef="usd">1300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtNS0xLTEtMzY3NDQ_c9f22da0-f267-4d72-b321-6a1ae91e68b7"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtNy0xLTEtMzY3NDQ_2d0b3561-b289-48c0-98e8-c6a029a4cdcb"
      unitRef="usd">1600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtOS0xLTEtMzY3NDQ_56983de5-d9ac-478c-bc69-917b6d31d306"
      unitRef="usd">8800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjQtMTEtMS0xLTM2NzQ0_da738f64-1a31-4f52-bf73-a17f34646b02"
      unitRef="usd">14200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMS0xLTEtMzY3NDQ_08f88899-b7b1-4e9f-b125-0f4be982c74c"
      unitRef="usd">551500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMy0xLTEtMzY3NDQ_cc3500e2-211d-491f-baed-c9e42b1e5b8c"
      unitRef="usd">318000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtNS0xLTEtMzY3NDQ_edbf116f-f370-49dc-9012-3b2fbc30feaa"
      unitRef="usd">26800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtNy0xLTEtMzY3NDQ_75b0d8ea-2bc1-4ad2-bb49-85d8028b664e"
      unitRef="usd">24500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtOS0xLTEtMzY3NDQ_dd43a571-992b-460c-b20f-6e20df95edc2"
      unitRef="usd">86700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjUtMTEtMS0xLTM2NzQ0_8564cca7-470c-47af-b7e4-a4a95b731ccf"
      unitRef="usd">1007500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i071b62e5dda84505bd97cfa1dc66bfce_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMS0xLTEtMzY3NDQ_f754d515-72d2-4f88-b982-dd66ed30b7a4"
      unitRef="usd">124100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id99e227336f04f0b81c5ae6189fc71db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMy0xLTEtMzY3NDQ_970d5888-69ef-476d-911b-a381632a1fad"
      unitRef="usd">73400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1c7d08361f984b53b83b4110010c1eb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtNS0xLTEtMzY3NDQ_ce629814-c834-4bf1-b32c-a62dcaa6b5cc"
      unitRef="usd">2100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie5c1cff898334365963d7bbf377923db_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtNy0xLTEtMzY3NDQ_9e7f8624-490e-408c-90c2-48c4c716a300"
      unitRef="usd">-17300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d03bc7d51b74a52851381b5b3d19005_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtOS0xLTEtMzY3NDQ_323398df-059c-4d1e-a087-f117effc2fd7"
      unitRef="usd">-86700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMjYtMTEtMS0xLTM2NzQ0_f8a6ba29-2b29-4351-a300-68384fb70dd3"
      unitRef="usd">95600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMS0xLTEtMzY3NjA_54390473-cd3b-4f68-b6be-8362e91fda6d"
      unitRef="usd">677900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMy0xLTEtMzY3NjA_7f4e7e07-5ddc-4f0a-a52c-b50bcb05c528"
      unitRef="usd">389400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtNS0xLTEtMzY3NjA_86526c7c-18ad-4401-b931-39865f9611ff"
      unitRef="usd">34000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtNy0xLTEtMzY3NjA_905e05b1-e8eb-4cc9-9682-00486cab83cb"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtOS0xLTEtMzY3NjA_0517d2ec-f61f-47fe-81a6-1247263876f7"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzAtMTEtMS0xLTM2NzYw_616fab8c-8342-42ea-b2ca-58bc3702b9f6"
      unitRef="usd">1101300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMS0xLTEtMzY3NjA_051aaf35-85de-4cfd-8080-bdfc9a3a1eb6"
      unitRef="usd">7300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMy0xLTEtMzY3NjA_0aa952ec-c38b-40c8-a270-fae5170b2c08"
      unitRef="usd">6000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtNS0xLTEtMzY3NjA_c10d59ef-ba93-44db-993d-3c6300593c22"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtNy0xLTEtMzY3NjA_6ab98f6d-ea33-4a97-9f59-95f75a63a599"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtOS0xLTEtMzY3NjA_33e11ab7-a336-42d3-b8f2-5e7ebc2b5de9"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzEtMTEtMS0xLTM2NzYw_74a3e2fa-0f37-4aed-ab47-5c8c768c236f"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMS0xLTEtMzY3NjA_d465630b-e90c-431e-8d3c-8c0c5a5bbfcc"
      unitRef="usd">373400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMy0xLTEtMzY3NjA_6b0c1556-aca1-4ccb-828e-c30807c27954"
      unitRef="usd">206800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItNS0xLTEtMzY3NjA_653a7be7-960e-4e8f-b7a0-98f4a1e92766"
      unitRef="usd">25700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItNy0xLTEtMzY3NjA_5ff2099a-2c64-4af6-af60-bee655374bb6"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItOS0xLTEtMzY3NjA_5a71d9e3-2a0f-4573-ad77-533f83a03c94"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzItMTEtMS0xLTM2NzYw_59729320-a6e4-497f-bf3b-05c453f2c0cd"
      unitRef="usd">605900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMS0xLTEtMzY3NjA_00a2ffa8-f98e-43b5-936e-0834b01cbd0d"
      unitRef="usd">161400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMy0xLTEtMzY3NjA_ee6d83f8-9efa-4b5d-b89a-bac62ddb9b14"
      unitRef="usd">94900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtNS0xLTEtMzY3NjA_ea3040a4-3a1d-49cb-b330-66e17ba46d18"
      unitRef="usd">6200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtNy0xLTEtMzY3NjA_5b2a17e8-c48b-4fc9-b864-0d61ece05b6d"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtOS0xLTEtMzY3NjA_f6603d40-99e8-4d51-ad18-718060578d78"
      unitRef="usd">84900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzMtMTEtMS0xLTM2NzYw_9b57d007-9040-4104-9afc-fde118d471a5"
      unitRef="usd">347400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMS0xLTEtMzY3NjA_eeeeef77-52a6-4715-ad65-c99228ee9a62"
      unitRef="usd">2200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMy0xLTEtMzY3NjA_4830990e-fe31-4444-b874-39fc5670a2ae"
      unitRef="usd">1300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtNS0xLTEtMzY3NjA_081f1bdc-5323-4d15-9651-f59418793e0f"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtNy0xLTEtMzY3NjA_4f39e56c-3827-44be-b247-3c75f3fe3388"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtOS0xLTEtMzY3NjA_c780e109-2fb8-4773-9f7e-ca01b77603a3"
      unitRef="usd">10700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzQtMTEtMS0xLTM2NzYw_abac6d44-8e28-4b0d-88ca-47b9a46e25ff"
      unitRef="usd">14300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMS0xLTEtMzY3NjA_be733967-ebb8-4f0f-8529-7cf736c5510d"
      unitRef="usd">537000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMy0xLTEtMzY3NjA_3358c24a-7126-4f78-9ea0-17962b181019"
      unitRef="usd">303000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtNS0xLTEtMzY3NjA_8f65d0fd-6dcf-467c-bd9c-e44d1bf1d7a2"
      unitRef="usd">32000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtNy0xLTEtMzY3NjA_d824deae-8e61-4237-bb3e-8dfac38f8f4c"
      unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtOS0xLTEtMzY3NjA_02c1d668-9156-4294-9f64-a0b8a4899572"
      unitRef="usd">95600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzUtMTEtMS0xLTM2NzYw_fd0e18b2-d97e-4556-befa-42d5b0800baf"
      unitRef="usd">967600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id8fa5b9a73964a099d44236118212346_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMS0xLTEtMzY3NjA_bd4efc8e-21f1-4e8c-b58f-37f968e9585f"
      unitRef="usd">148200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c439dda87c545e8a5e1d77239e68424_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMy0xLTEtMzY3NjA_0e541e77-cd8c-4655-9d7d-cdb0cabf478a"
      unitRef="usd">92400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i072195f45aa04718bf17aab9a9987275_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtNS0xLTEtMzY3NjA_bfea90f8-d656-429c-bdb3-e511d6f042d2"
      unitRef="usd">2000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00db5755e15345ea91550fbfc954caac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtNy0xLTEtMzY3NjA_0e63b5ac-949d-4260-b9cf-d6039f434dfd"
      unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f7881a87c5b465c84135807b3ad6077_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtOS0xLTEtMzY3NjA_e3b699b8-33de-43b4-af20-5014e231a652"
      unitRef="usd">-95600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaba0d7d38b304e11a9e0713fe0f6717b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83MC9mcmFnOmZiYjhjMDg4MDhiZjRiODViZmY2ZTQxY2JhNDlkZWM5L3RhYmxlOmExMmI0ZDY0OWNjYTQ3ZWZhNDRmOTAxYzZkYTI2YWI5L3RhYmxlcmFuZ2U6YTEyYjRkNjQ5Y2NhNDdlZmE0NGY5MDFjNmRhMjZhYjlfMzYtMTEtMS0xLTM2NzYw_61168e94-25f2-42ea-97e0-c547f9638deb"
      unitRef="usd">147000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:TreasuryStockTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMjE0Mg_c90d1c16-3120-4e78-9faa-7411dbce09a9">SHARE REPURCHASES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74&#160;million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3d43362c8b95458aac1aefacb3f78f19_I20201223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTY3_0947e4b5-cbf4-4ebb-bb1e-c3c0d7c8ba90"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i915c545146e94aa887017c72ca239d02_D20201223-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMjEw_d5f2466f-a2b7-470d-b569-7a6f2ffe1736">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE3Mg_d481cf72-eca5-41f5-9342-6531b647a21e"
      unitRef="shares">4757</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE2Mw_e1607321-e517-4452-90e8-410c21c7a902"
      unitRef="usdPerShare">249.72</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ad98e02be044a7aa54db88e680bf11f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE3OQ_ea678b15-3805-440f-bbf7-35a26ae5c989"
      unitRef="usd">1000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfODg2_8c1f6e3f-2945-47de-94c9-0afa883aa5f3"
      unitRef="shares">297105</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfOTQ3_0c477c48-a1e5-46f5-a4ac-a45412741d73"
      unitRef="usdPerShare">249.29</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4286842c46d3491dbb646d4eda44d4f0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfOTk0_c9a247c8-b69f-4d1c-85b6-9d270b1a8881"
      unitRef="usd">74000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i8e2ca64538594598a876edcc7a6780f5_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTI4OQ_a5978489-2066-4256-820f-501bd993f767"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="iec884be61eb14776a28fa489974af68b_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTMzMg_a5d3831e-4f46-4abd-a89e-a1d0b32605ae">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTEzMg_ce9d60a0-ccae-4279-ae71-60f44aabcb4f"
      unitRef="shares">150000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTEzMg_ed6f4a40-bc5c-4543-aee6-94fae0df0d9e"
      unitRef="shares">150000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE1NA_aa0ddfd8-21f7-4f4e-8fe6-7c6e15dee2f7"
      unitRef="usdPerShare">115.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE1NA_c74b1674-cd04-4c53-8fbd-47c092878454"
      unitRef="usdPerShare">115.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i23c6ff4104d347999b50900a9055f693_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE0MQ_0b0c10e5-d825-4428-ad55-10dcc58a83b2"
      unitRef="usd">17000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib4262d2c7ee34b74bedf47de00087189_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl83OS9mcmFnOmMyYmYwYWVjMmRlODQ3ZWNiNzUxOWQ3YmUwYzc3MDNiL3RleHRyZWdpb246YzJiZjBhZWMyZGU4NDdlY2I3NTE5ZDdiZTBjNzcwM2JfMTA5OTUxMTYzMTE0MQ_b0bc47f4-49e3-4d37-b72e-5dd103eb7b90"
      unitRef="usd">17000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfNDQ2_284c541f-7a13-4d56-b56d-fe5cf370cda1">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs totaling $2.3 million and $4.7&#160;million during the three and six-month periods ended June 30, 2022, respectively, and $1.3&#160;million and $2.6&#160;million during the three and six-month periods ended June 30, 2021, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMjU2_a3acfb26-6164-4789-9d88-8412b731c198"
      unitRef="usd">2300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i41519bdb02894e4c88aa2695cb5691b9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMjYz_d5c3ba15-7131-470e-a11c-b0557133cdd9"
      unitRef="usd">4700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ice6cf5eaf69a43afa1bd9eefc44f8038_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMTA5OTUxMTYyODUzMA_312bef3b-e738-40ac-acd9-7c0688b67a98"
      unitRef="usd">1300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i8db1257495a248b09b389531c6e0153f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhYjZhMGZmNzA2OTRmN2U5YWY0N2I0MWY3OTRjNWI2L3NlYzozYWI2YTBmZjcwNjk0ZjdlOWFmNDdiNDFmNzk0YzViNl84Mi9mcmFnOmU5MzY0NmZhOTVjYTQ3NTViYjM1OWFmMzg2ZDYzYzVmL3RleHRyZWdpb246ZTkzNjQ2ZmE5NWNhNDc1NWJiMzU5YWYzODZkNjNjNWZfMTA5OTUxMTYyODU0NA_c29c900b-91cd-4244-8105-231e21f12f8c"
      unitRef="usd">2600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !=0/Q4\=1)+\P%  "7'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6977.C-AB%_XK&[?1J'9!PG(\FGG%(TG6;W2;QMCO;3B\4D VS@*@0<?SO
M^PIL<+)"4&;)16P^SK$>)*$CZ6+#Q=<L8$RBESA*LLM1(&5Z;EF9%["89D<\
M90E<67$14PF'8FUEJ6#4+T1Q9!';GEHQ#9/1[*(X=R]F%SR749BP>X&R/(ZI
MV%ZQB&\N1WBT/_$8K@.I3EBSBY2NV9+)/])[ 4=6Y>*',4NRD"=(L-7E:([/
M7<=1@N*./T.VR0Z^(X7RQ/E7=;#P+T>V*A&+F">5!86/9^:R*%).4(Y_=Z:C
MZC>5\/#[WOVV@ >8)YHQET>?0U\&EZ/3$?+9BN:1?.2;]VP'=*S\/!YEQ7^T
M*>^=3$;(RS/)XYT82A"'2?E)7W8/XE" &P1D)R!O!+CI%YR=H'AR5EFR NN:
M2CJ[$'R#A+H;W-27XMD4:J )$U6-2RG@:@@Z.7/Y,Q-HC+* "I9=6!(\U17+
MV^FO2CUIT$_1!Y[(($,WB<_\UWH+RE(5B.P+=$6,AK_FR1%R['>(V(1HRN.V
MR:,C1(A._JHX3O5\G,+/,3Z?O^=/F130Y/[1/:'28:)W4/WP/$NIQRY'T-$R
M)I[9:/;3#WAJ_ZS#^TYFKV G%>S$Y#Z[YEX.752B3]N4Z4C-<FR/'W1(1E5/
MI.,*Z;@;TD-.A60BVJ)'EG(A=7AF*RERW4-QC:J>>-,*;]H-[YZ)D/NJ%R)X
M#V@KS^Q4];O&CF?4]^0\J3A/.K9,06$(*4: YGHT>ZUHE&DKTBCK"7A: 9X:
M"W63R%!NT6T8,?0QCY^8T(&9/>PQF9"IK4,S"GNBG55H9UW0'MDZ5"]1J,2/
M--:V4+//_,/-]6+Y98D6'UT=HU'=DQ';]3AJ=Z%<)!X7T"ZI:J+OT%)"9T1<
M()?GB11;^/2UZ"WNUS<Z8K.H+_)!=,!=D#_1%[3PH7.&J] KN TMN,42X[&#
M'7QB:UNQ6=R7E]2\I OOW/?!/5.5*U30;FK-+6[.Z?$$S6-X;WLT09_I5DML
M].A+7(<?;(P;WQ+GH7YL:?$I=&BN)1PB\. Z\6!S9GE+Z,*1%M!L<T6E&I%X
MOM:.+&9U7\@Z V%S<OFVX39$A!:?.WT-#A& <)V L#FXO(6[YYFD$?HK3)M?
MMF;'$_L43[6D0T0@7&<@; XN;L$)D_5F,+,!(<=:K"&"#ZZ3#S;'ECON07W=
M!SPQ19\6$W)&QL1VL)9OB/2#Z_B#S;GE4R@AU/$58M0+D!?13#_/-KNX/([A
M%;.4W/OZ#J54H&<:Y0S]:!_9-D8IS%*+.;SV 0P1C4@=C8@YO$!F]\-DC9;;
M^(E'.O86 Y7\M$L!0^0?4N<?8@XK:N"OZI6]> %-UG B09L@A#.B"+Q,O%T6
MV2&W>,^7UW/M;-HL[ M=AR#2*02YN1!J/E9.PHK:A4$EU[;L%L<OVG4GUZSJ
MRUE''](I^BP2J,%RK5%-K.D>7,MI=FSB'"( D3H D4X!2$T\898"N6#-A38!
MM?C<40&-?^YY#(S QB\MM<1#I"%2IR'2*0W=0/1>JX;["SC( ,;4.*6)'MUL
MV+B@8-;U!:V3$>F4C)8QC2)TE6=P63_TM/@T\PV1ATB=AX@YSNSY @9\INKK
MN1YDUO7%JW,1Z;0D]'K@7Q;K].CW7$+*3=2PJB7^3HEG]QQ*M^/"3>T+/<\<
M,IDXS@3BUK..L<Y&I&5-)V:)7RSLW494CV(V:*Z\(3*/4V<>IV7!9K]@>1MF
M*MY^89#8;N&DM@.VF#6MR)IE?1GK_..8,\I;QMT:=#.EV>Y!SSA$W''JN.-T
MBSN *0!QD?CL!?W&M.^9%BL;_D[/IF2JYQPB[C@'VUSF<++/<X?-U;29T&(W
M'F,RUL_&S,K_"VH=;'VJ ;W8$<Z0IY9;RUW0ZFRUZSPO]EJM^O9RR_H#57D@
M0Q%;@=0^.H$7GBAW@<L#R=-B(_6)2\GCXFO J,^$N@&NKSB7^P/U ]5>_.P_
M4$L#!!0    ( %U _%38W\O0;0<  *L>   8    >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULK5GM;MLV%'T5P@N&#5!C?DB4U"0&4B?;.G1MT&3;;T:F8Z&2
MZ$E44N_I=R79EBU2=#HT0!++.J3.)2_O.:0N7U3YI5I)J='7/"NJJ\E*Z_7;
MZ;1*5C(7U;E:RP+N+%69"PV7Y=.T6I=2+-I&>3:E&/-I+M)B,KMLO[LK9Y>J
MUEE:R+L2576>BW+S3F;JY6I")KLO/J=/*]U\,9U=KL63O)?ZS_5="5?3?2^+
M-)=%E:H"E7)Y-;DF;^<L:AJTB+]2^5(=?$9-*(]*?6DNWB^N)KAA)#.9Z*8+
M ?^>Y5QF6=,3\/AGV^ED_\RFX>'G7>^_M,%#,(^BDG.5_9TN].IJ$DW00BY%
MG>G/ZN4WN0TH:/I+5%:U?]'+%HLG**DKK?)M8V"0IT7W7WS=#L1! ^*/-*#;
M!O2U#=BV 6L#[9BU8=T(+6:7I7I!98.&WIH/[=BTK2&:M&BF\5Z7<#>%=GHV
M__3Q_M.']S?7#[<WZ-WUA^N/\UMT_]OM[<,]>H/^O+]!/YW]C,Y06J"'E:HK
M42RJRZF&)S?MI\GV*>^ZI]"1I_Q>%^>(80]13*FE^=S=_$8FT)RTS<EQ\RG$
MNP^:[H.F;7]L+.BZ+&6AD:@JJ:NWMGBZ#GQ[!\W:>ENM12*O)K!X*ED^R\GL
MQQ\(QQ>VZ+Y39T>QLGVLS-7[;"ZJ%8)90TGS0?Y3I\\B@^"ML]AUQ=NNF@+P
M/*,\X/QR^GP8CHGR*8_]/>J(I[_GZ3MY?I:5+M-$RXZIC5W707#(CI(X&K S
M40R'@9U<L"<7.,G="9VV"9,DJH:Q@P*62!C(QTS:B 86"H%/V("I":.A'W-B
MY\KW7+F;:RG7(ET@^15*?26M\\R-)Y. Q/& GP6%6<#M],(]O=!)[Y->R1(J
MV^$*M%$,S<$)_'@XA#94<) 21Q2C/<7(2?%!:9&]@F)D3G/L1WPXC!88K*EH
M9+W$>Y+QB6D&*2_UIEW;S;)>@[AJ#Q4@_6K99&J=UYEHUM-"0EU)4M'J)MP[
M(QA[L+#;IF<Q]V(6VN*+S?D/(S\<A&=!13X;67 $][J$W7D"T0'CX@EE$F0:
ME8T>-^QKN!B?DVVOQTD;AG28.%8<H4$XPOM 3XF3]Z]*+5[2++.2(^9#:13S
MD [968 DYCC&(_1ZY2-.L9F]+[0HGE(H7-M!M&:,R%6ITW_[C(D]@N,N7TCL
MQ1A;PZ.6,>4D&BX(&PY^1H/KI8ZXM>Y&+B4LV@6XE43E$FGQU94JS*"!ATQ-
M"#T(YYAFKW3$+75="700,R4L\GDTE&$++&3X(-./Z?5:1]QBUY4_!SV+;F&,
M8Y.@"211P&,^4I])+W&$O\K 9:EX3+,4Q-GNXHA3*K_5QGVOWHZ#[H63N)7S
M>F<^UF(SYCR(*8A0B[&Q DT8BR@9*WZ]<!*W<MZ)3:FRK-.D?)VIC93H419R
MF8[DDBF.A$/1&)HZ&\X'&1OQ2J174>*641C4LI9NMT1L0L@I,T;5@@MPQ$8<
M$^VUD+JU<)?NZZ8J=Q4Y4\73&RW+'*G'+'UJ*[65/+4('0TH&7"WPN)X1,9I
M+X?4+8<6ZFJ@[ >+V!J J87,QP<&8QN !48H&ZF&]&"KZ!;,8S-XBJNI;#X-
MF:'O%AP+?1K1$;:] E*W GZPI84' UU5^QBV4V'E;^J=[U-SYV+#,3JZS:*]
M--(3TCB>&]\0A448*2?#Y6J!\9CA$7FGO7Y2MW[:7,BIO#&5DI/0(&RB1BP3
M[964NG>+G1=Y?36Q[ EA-0[+M07FQ^'8R/8*2-T*V*W%4V-I:AOLJ>/8J'@F
M+HHP]\=RN!=!ZA;!N<KS5#>[L:H5PKDJFHR610*,?_P!=)9>?%1:(FZE[^S<
M;C*0]=#I?W1TTJW07EAI[+1HM[ EU1O[V9I3DK_Y<.T[]79\NM9K,W-K\UVY
M6^Z55LD7#YWA<_ E8-)*]"RR6GHH\, >-[^H6@G@@$2M5ZI,_Y6+"U2H0J*T
MJAH3HDJD:EW!#FT!"6,]H#-E>KAG<4*.@^Q5G)U0<4AI$._1"#EVA<A"+XRP
M1WW:K@>XY*'O13S:@;OP+[J[U ,I\0(:[B[!OGHQCW?@4R-D\0'#\N3&'(]1
M;Q28VRA<+Q9I4S>A0C7G;V_2 B5BG4+%LM(T'4 (<8?&6:L%1R-"QN@>' N[
MG<)#"0);EYO=I J-$E5I2%;FPWR1[G0H\ B'J8K[T5\"K$\&:VBF.7CC!V$<
M#2NP%<B":&Q_R'H;P4X=)FL!7X&M%V4!B6(_[+;8!(R9878L.,YBS$>L)>N-
M GO-1OLZEXNTVH"_>5\DY]VPKE2VD&4G%N%%>[RG-]883$L0PQ;;-]+(@H-(
M@Y']$^O] W/[AX\*3$ZAFUU?X]K2 ER$K$;>+IBN(&#,']H<"\P']S#BC5GO
M'MAKW(-C+$U#0#"+#C=!6X(6AQ%R-G;RPGKGP%YS\'S@;_:'NR.,(_-]C?4D
MQ@*TG\1,#]XD-J]Q_Q#E4UI48+V7T!*?AQ!TV;T9[2ZT6K<O%Q^5UBIO/ZZD
M@.1M '!_J<#I;"^:]Y7[]].S_P!02P,$%     @ 74#\5"\-_[FK P  3 P
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MU!PL]XB#73K8YSHXI4.>.;,@R\.:$D5& \%W2&AK4-,7>6YR;XB&I?HUSI6
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M?Y*URZ+!&E2L02?KA"<)[)3_I7Z#L^KWE%6#VL)O[0]?P'UF^9::]?1YN+6
MS[%LDM<:MW4!^1D57.K561S?[V/;M?>IVRP]W^U[_2/4;YW6ZNQ@>]3G%G0I
MV@"R7<?NV?X^>IME#P?07HZ@OW5'J[L]/L$Q66;BI8!'1*&02]7-[1QN8([K
M^]9^/VPSM#RW'^Q3F[6CGCYG_T'$FJ42Q70%GOC6!PE1'%V+@>*;_/2WX K.
MDOEE!,=]*K0!/%]QKEX'^D!9_8$8_0M02P,$%     @ 74#\5%:#U'B]!P
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M8S+*6VS7M]>59,JNM"6A*3BIKV>@B2%&^@'Z-])SSXK9YSA*6VS7M@/'/N5
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M#B1_;#]667$I>=G^W+!4)60#4-?O.9<O!\T-AB^J%O\'4$L#!!0    ( %U
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M-_GPF]@9Q$U_N2Q5^Q<][&2C"<HWJI&K76.MP:JHNO_9XVX@!@UT/W #LFM
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M965T-RYX;6S-6MMR&S<2_144HZ3L*HHB*<I6?%$5+<E9[=J6RI23AZU] &=
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M<,'83+\YF5"G4P@ /?\6_N4SNC3.^8/ZF)05$U#@A(0S-=4+]$5UK*SO*#M
MM6AHCLM)MX^^7B%LWUDA(@R;@L,FXX3-QJ^AZ_7* KS[H8YWNSK8A!KC]=*@
M'"?2E %JT?16-!=')XV727![BUR5:<QGLFQYY2^H@'3>O/)HG#WY&378U!4H
MJ$0;D2G >U$YD(Q779VVF>Y;CJZ33G-I*12/SR)E\,'#,@$T0Z%DV,LTY2\$
MU=;5XKZK [@S;X.>2:0?0GI)O'*CZC+/D.8^=MM6CQX0'Y%[<[I6( 7:;;^I
MKG4;$M<K99IB1:=1AWT#M>0\B^R"M?7;)[U?+\Y[3SD(,2%I+THVW5_@:*,
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M<5=TVG1/++[N3/9 6JEE OH.,F24A*:8U%:JR<='W?Y>(FPU281KC5RB@T+
M1UWF:9T16OPZ!S9K\4Y#_QQ!/NPQIL?Q<)L>-_CR_X@=:9+8<?NVC#YMYK5.
MW?7JAEJ![=K-&1MOD]#4 LV"6-;4ET"2;@87BN=*NOOK7&VRKU5>9/8.7 .6
MHQI&V#^7@$%@9*]:K.>D>X@#.!O D01%3.%)!D>$NRJB.2J8#U^4A0O6ILFG
M.0KT.*_*+INW%U??8FY+M:$\/V WKVNZL=@%-\![K).K70(# T6PD!R,O606
M$7*)U&I8HLAD/<^JW2Y=TZ2-*71=2VD;D/I^P%6!4U-YMU_:??S9X"FXV5?)
MBEU;6.#11^LQX#J*3XI26\]]!.D@F<W-*9TZ#$*S>SLE@O -INR$.((':9,T
M5S[! 93*70+JR(\8[G-@ZVLDFH)*GEC[*$A+]%XR7G3%NVNRMY!WUH4V&?)0
MOI$ :,$U6)268@<Y.E3/>N3F?<ZBB[,9=F <IK4!VB$N)N5JBM0,&$@5Z),\
MV,='I#E=3P9VC,Z-\WTB"UU*PF>Z5*1-= ;W"])]46%E:WA4!?:$%PU#^:J@
M:3M4EF;$X1-AW5+6 Y*<>^OF@D9+=5L$PLDXL$V#ZNB?$VDM(JLT#W0$4B*6
M:1RU:&;HQSE-YXK; /R-G'X7[L[:"X08@<UL$XN*VZ][Q?#/)NK7=;PA36OL
M\+4NM@5]Y_\A24'73$*$4#!5WC3\G01M\Y(:?'A@I><:]3F.MS19!T1$EF^A
M3QH0COSB;BN H8W@VE G<5 ">'4\ZX>[EVX>T77=Z/G+^A@*<J9#K=<[;B2_
MJL*$T9@N8#.^@'Y27_E 2*R'_NF+71P=G]TKBF(ZFYU?S\1IY1QG%&O[0IS2
M+7?(%'R@>**NLW_WT*<.)OASB%[Q*N9M<UL2H,NS]03OQUAYR7Y+-@X0)&*(
M!=>6TG#KY6@R^%D<#9Z)*T=I2RT(-"$E"D[[X6#,FW^Q-EW#;'$\..+KTM'X
MI;@P&"^6FC3HG%6_#>?%%WMB/$$GL8>SGHMW%],W%^\NKB_.6V]T O8"MMY1
MMQYT80Y2;8I"R!!"Z/^'8IHDCN8=2G1#&3X9',-=DT8N7RZ&?S[.K%GN$Y8W
MX!8L/-YR3Q<_I/($9@?O[I92&[UI?%=*,'V/)>WZQ^6#SL\,<N66_&,*OOXS
M9?C%0?.T^;W&-/Q,H5T>?NR!+G2IH52F%M@*9QWU N/57TI;\(\6YK8L;<X?
M033@!EJ ]W0[77^A YI?L9S\&U!+ P04    " !=0/Q477E-T<@@   ,:P
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MN$VGI<'D,BV6)<W0 *,$:T7N2 96S]F-LZ+#'B&"4!GP':MVEV@Y)P9\ *C
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MD0LI#ES7!;@*Q_ NKBW2QC>F*@@!S,3O5^*O[>_=7+[G7Z\E[09]>%&6AU<
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M/B3[L +I'9L=."T;#K]J)YL>@95TA#H6GHJ!?AMTD[Q67)#AN%1R A%\P9]
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MXJ9A0R"D"MZTIYXT7^Y*=D30$7-_\#?RO@3+?F1&'@(9-DW6U6<'<B;_W=5
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MIZ:<$5*,EK,:M?9^5H?['(]8(89141@5(,]?#M=5C/^FBE^:HBV1<>A3[T&
MCF+(C^H5.;&8OGW_8\[8VN\XC,W=&NUUS^L-/]S@U/-*X[>Q\R\3VMA?K.I@
M</&R&R4/US0=_?^:1JN:,,ET25^\K%_37C%<2AD9PY]20E7$6ZM9W%]\SR^
M&]HZC\!./HOMP_[XIYW=I9"PO#A78E8'KC)S<2RE"M=4S\]IN,.^26D7 8,X
MO;?&O1ZH#PZ6F\X& PE3P&3US/AC=V;N&4]UX]Q*%1][F\/7!UZ<R@)W9N*Y
MA=W2U2O#0Y*OSS4 PVC^>("U]E, JJ"B3 &A/Q]O6KW^XV!_TT>GP=)W0S#(
MS'\=Y6D5 T+XA-B][3[ 3L)WQ\7V\/46[#!#:8)E,AP=]C\>](0)7T3#@].U
M_PHYU0Y=S__$!0 7#]Z ]4R#Y>(#*^@^2Y_]%U!+ P04    " !=0/Q4A0+<
M%@D-  !^*0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S-6OMSVS82
M_E<PJJ=GS\BR'GXE33PC*VGC-DW2.+G.S<W] )&0A(8D5("TK?OK[]L%^))D
M6VYZO9NY:V026.SCV]UO2;ZX-?:+6RB5B[LTR=S+SB+/E\^/CERT4*ET/;-4
M&>[,C$UECC_M_,@MK9(Q;TJ3HV&_?WJ42IUU+E[PM0_VXH4I\D1GZH,5KDA3
M:5>7*C&W+SN#3GGAHYXO<KIP=/%B*>?J6N6?EQ\L_CJJI,0Z59G3)A-6S5YV
MQH/GE\>TGA?\7:M;U_@MR)*I,5_HCZOX9:=/"JE$13E)D/CG1DU4DI @J/%[
MD-FICJ2-S=^E]._9=M@RE4Y-3/*KCO/%R\YY1\1J)HLD_VANWZA@SPG)BTSB
M^+_BUJ\=C3HB*EQNTK 9&J0Z\__*N^"'QH;S_CT;AF'#D/7V![&6KV0N+UY8
M<RLLK88T^L&F\FXHIS,*RG5N<5=C7WXQGOSR^>KZZM/5^W?7+XYR2*3K1U'8
M?>EW#^_9?2I^-EF^<.)U%JNXO?\(FE3J#$MU+H</"ORQR'IBU.^*87\X?$#>
MJ#)OQ/)&]\B[+!RN."<F)IWJ3!(2G/CG>.IR"T#\:YO)7N+Q=HF4),_=4D;J
M90=9X)2]49V+;[\9G/:_>T#?XTK?XX>D/QJ.W7>+7Y6(3+I,5*Z _=\+[;2W
M?F9-*G)DELB-_U=GPMA86;JP+*PKE# %,A<^RM5\)<P,2R+D/)PYYUM(X"^H
M&.R!+%)BNA+J;BFSN%Q CM%T QDC<%VH;"&SJ+R]-%X;.CI2-D?U$'-EYE8N
M%SH2DLX2]#^1H-+0KJ4U-YITA#(+ Z472B;YHHL_W!(G=<5266<RF8@(V_G,
M!5(2MA<Z7_F+02O7$Y\6BDR-%J3?TI*J2ZEC@3+7]I9V(E-SDVNX(A;YPIJ"
MA-KTVV_.AX.S[QPTS.;Y0L!9F9-<:UP768Q+$7Z2S@P[=D4L\(,<(*'HRD&X
MF76%3 WY)5]0"!:P%@(H=M+*:;(6/?;EW1)%#<(BZ19BAL(*B\:M5>2!*#)%
M1LO8*%?9ZX70$D0U*9"YC !H!85C%%R2#"DFT3%;/4/F('9PK<MQ 34Y+V&T
M4-JB.#M2".6UJ:N@S5#L!V/B6YTD"'!&OB"!M'?=S59%9I[I?P>%(1J&1I2\
M"'F^&2]S0^Z2V5RSDV 2?)WE>J;9:SJK[SFGH/%41;+ ]B"N]B)JF-73PFL2
M[K:T0UZ0>^A$"4,B8Y>&+*E2I$?IEJ\ 1-Q'+F1S=#3LR2G^0BZ75FH'_\VT
M35D<5-(N)[_383,)+][(!(D7(U]M&DH59][#1I&KG(;?9C@[RUMZ!YA;E6B2
M:%?K+H2R)O(G(0 R_@T-1\5= DNFR/78TQ7%DAV0*;%2$DB:Y<JN^TA$B>'J
M0$$7>H8*D<$%!!5AII3?3J2&(>>9A&_J<VDYN]D8]H"L89[ 9IU /"'6@3:H
MN,>-H8WU]YGX6<(L,1SYOH'L0W2!?,O()F\WL]/G)ID#[U)8-\J$+RW"K>"-
M%'7!Y@"NHV#=HCHM2'R%F3(+26$6MFUO:[E&U!H53(!@65GCK-9+W0$BY)T-
M!7\S,$O<P,;"4HJ-J5+B%ZB(QR^BV;"8'4+I92G7YV4^8N7>>>\$M"))>)6O
M0#7&.!GV^KWC<HG8IV+-4,M9S4Q!H(]51(7#'?!?F<G88H-=T%]S+%P>3GQ6
MB:-(/%QZIC*1U&"8X7@\-Y*%-+CGJ%M@N,PER"D8G)(:3D2^IY0T,O)QDV4_
M*Z_V"%1CY$@B!@U,,=X)5(.35@0Y)A$C+M3%US<FX7HBWH0V]?;M!'DE8GVC
M7<CLUUGX[=>0E*Z(#2DZ+7D+K/BAH"21[64_ %P3X*'+!DQ(@8G)LL!U(7RB
MJ=M2&1'[G4J=SD'7=X-,P$DZ91^OUU4$Z?2L=UY&"?!"O[:EX"V5>'_O9- ;
ME.L/V/?<38E@+*CM)@F Y7LB)0LD+=CQ^#\\'@%%P7%38T&9J 6*(N-V#VQ\
M5-#_AOPR@?=U+KZ7$16&E0>$531]T.+]O<%I[VQ-D01DK:P#9'9$G"PT1\II
M^FEC1AEK2!J7U6PI5U3"NH+DIQDE("<Z)PI3$L>)&X#<\HV<6^4+(/<F:G"S
MQ'<<3;4/O4/77?S)J3"!I]!WC>=<S5IYJZC[)\[4.4^V1Y$ME"</64D"O"$)
MZ,<AI0I*=:+GH1@]42,<EGB.Q$%WOD9"-_) FPE)B]KDFP.*UWN/J=SD:)"M
M +9BYP/7Q8I>OUH 1Z.MJTQ0^Y#<;#V\T>I,3HV3^& [F*'/T4^/G_7[Z.%1
MX6TQV4:C\PVN)$YE%OE&3)'L\AQ*\B*YU&03.?I&6FT*5Y98] 98_IE!NQTT
MW6V)!A"Y8OH;0"0\FFM3*KMC/9L! (@+N2:_)>_4N0ZJ61![:S*_+8#W93'*
M"U(_;)$YKU+,=3QY(BV('"9@;7PXE$5@79GX:^K[#D7'E.3Q@=B(N+!TA[&Q
M@%<.4YHUB>9K0_,$X_Y:+>'+*=Q83HW-FD K]@8G#R(JX)9U+D<1(FYYF&;@
M-Z[K53>6VSBBAX6DY$-GI;)3P0\64KK1A@F1>K@IE2N* #*+HN9)1:-0$JH1
MW#H92;=0@6:KIB0REI@;ATAP5U>:(395C1*L;<Q4Q#.IK>91!T%\4&<)]G:M
M=%/L@V^XPZ+]NHJ\%L1"FJB RRN'PU45X:C*D>?WI'C#@SAQ2OPW+M#$B.'2
MJM"N<WE'8,+82*2$B#^WZCM&-0@W#B1NBIRJ.V^3<^T-!KU1I1,4SU ORAG5
M*C"IPH\0Y';/QZBH&C]\H.14W7 #EKS-Z;L6/!WA$^?^6(#.M9%98D!7#N0.
MZ$^"*EK=EO+;3(<1YTE_143NI<F7Y;#9 ,O?7&L6J-AVMU%_ZTK1+MGKI*"N
MO&&&"$UF-_T>R:$9R!QF6K%?5ZOR7'?P7(P]VL?7UZ\_78L/4) KA^_H/$<J
M?</CTIYX!E[RP2I.A:KS]7M#\9ZS!"EH>;/7N\^K"0"AT2LHM^1J- 11?E\C
M0U%5L_3(CPRAJ3*(&$'VU<:4ME_S8P*B/[QQZ"=V_KKW]@2ZX8EX>S6^O'I[
M]>GJ];48OWLE7O_R^>K3/S $!8-1.X.U^_W>V0$\LB(Z[ U(EXE9 :53#-\S
M&CWVA[1FO,X&</GX8,/"9NRPXOQ O%+H+GZPJC*S7+4B!4X.Q"1XM<$:MU,,
M+#\]",9O@\G^,]+U'7*U-05O^ND4R*R>,YP20_!"VR#&.H+PP]P^OS4M<E].
MR(&@CGEP5S%3[C>TKF3X5UG48Y]_?,,W>"JX#D^<P@"PR>[OD\>26C=#PN W
M"%B&K?N=YGVB]O6#F&05B/XV=C\\KCOB+NP>I6OX?\'NA_6T^A7DON;R_UL&
M/Z8'25LX_(I-VR#P_S6N#L-VH>H^',T8[$8X_A"9>%K_NO?Q!I!>#POUP+/Y
MB..L20ZB>I*N0-/H4[TM!;XJ'X%85P]$@-I^ [5=T7B"XJI'*+2HD6*>?0>)
MF4R#F'K$]K%86\)6(PSHFCB"GJ-ZI@3W4*.BMDL/,.>JY-#TG"D\U6N1^@4_
M/M-6E<3RKR9QK;K7XG'#WNDN-*[F<.'L]2A_#8O#?P<;CR#'Q1R#2V@I@W9+
MF4 F/4SMAO<9C$#_X@)-ZE#FA]QP6(4O4) B6EB>BV:A%HIR4?D*8Z?'.,/C
MALU=]A8N^^>50;F2E'H--P;.I\ZY7S??4MUK#K@/C8=_X;R[[2%!K4FW?"I,
MS#4,P_'CTRO6O )3];-K!9OPGHU?-6VX9[HB$-<)P#VU'61R&ZXTIIT_?^KH
M;J?T]S_W=4^NY^Q0FI*GG-?:^9E!QC%G'*+4?(\P593CN'TC=<(,L>']%.Y$
M2^&@>>_O.N^TW+C;P/-TU_QUH]  ;6C+*#1Z\BC$>W88A?K@VIN=\N1X?0 :
M/3  G=+;AR<-0(-'!R >.C8'H-&C U!_AP%H1 H\90!Z=A"\<>^*X2,C$@Y\
M=Q^Z]H]'=(+?3R&D:)9;F_=:LD.X&VOAVI-1K[_3,':&D%7#V'"$0^Z9QGR"
M[4"F-KC0\+S.3'"J7$6+S"1FOJ)7 ,_JQQ35ZZA#>I_.GT*4#8C$G#9(EZ^3
M]RQ]E%H=;E*K(:@G\QG_CH9K3JWG'Y%X5DI\RHNP_3T*<WMLVN'%&!/"V$!L
M7O)"ZA^A5/W);+!7$Y 6VSMNO'I\\D.[9XVNN,](<O2% EE0AZ$Y"810E$]<
M@5A^?MQOOE':I:VWZ"(KN'=6 ^T//'T\:[2AK[%DT!R?&Y:L\][MM/=[Q [
M08MUC3?W[7[.U+CY"4(7=BJ4)Z33<3D&R@)=?*=O3,)(ZPEWEA$[^ZBHJ!*3
MH*_RQ*!_^%-OVX=71XUOXE)EY_SE'PVZZ!C^\[CJ:O5QX=A_4U<O]U\F_BSM
MG+Y?2-0,6P&'DX[O=^4?N5GR%W93D^<FY9\+IOFT /=G!O:'/^B ZI/+B_\
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M11$V]9;!'KA3"%!28)R4$NI419@2?0LO=5U+A4J9>;/,:12<JG7N^X( O07
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M(YMR8V+AW1=[)\WF?D"15DGJ,27>,A"94+WQO7)>J7LJ4<KTJNZ&6M7_'[V
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M_"PMI*4%F%\:X[L!;=!_3#OY$U!+ P04    " !=0/Q4I5\D&LX$  "F#@
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M8M->_/HX MONW58@4X==MS3$FS,<N3&YH;P"OZ^,H9W@'71_?I/?4$L#!!0
M   ( %U _%1U9;:*=28  ,."   9    >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;.U]:W/;QI+V7T%IG5VIBJ(E6KXGKF(4V]%6'&LM.ZFMM]X/(#$D$8,
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M#=ATLR;/<B(=1C')P"9?EOF".).XAAE:=\(/C8%(_Y1-.A<J8"YD#C1%3L9
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M<@UY$/><EB+P_FQ6=XW8__^1T$A$ >%V9 8R@^\E<DK]W7ZUJ07N/XB^B0C
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M UM;\BG/1@$1D*Q?([1,V":()2:5B;GA1R2 EW6ZIG7;P?PV8!G@OEOF"M(
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M2&BJI8%SOJ$5$WZ6AL_XW(Z1]=6"??C>1 _P*VT@V7Y'$0@;41)0\9G]$(Q
M#001ECF$-.I&^#P,$ FEU@LF6H:Q"MS6/TN&@<&7:@\$P;_LG *1<IJ+'XT]
M599;WN=#M:$4#T%*=4@<#3'83K=U]+?XK2.U7*&8I2[$01P4HO:SK<Z4$6.T
M='4G5AUH@LHK2HS$J06;$77!N^THZ$#@R$']?W&=/QO7@:88-*_4<K7.A=I-
MOG2(<[?RR(RVAWB?%&@I)**1V;#.*&\"CBH,; ]:T4,N\,:L()$*Q6]^"YF'
M8&.DMUR?ML#9F:.1A4CJ/5%/!9PUGR5@79(*8.4C.5?"EG7=$%39&"/V$?]B
MZ=91/5>'M;5)10M(!#B-O:A0I/.F,3-@)G8$L'-;:5\^:L1IXK!Z;(F)<!2N
M,+>YAL("+BN)3[D2D]3O=5Z3]-K0? :1?W*]W_]V\=/QZ?,#P@>YX4Q0MR93
M)VV1J^U%0/L-0O5VAWTD\;H4*S%,&4LE.BUM;DF V('\A7)^%]5#6RAP3J&W
MPT'5F9]6U.9==+ZK:>MNWFZGQV$M./IH^1074\?,S%/URYE %CF[/-C2KM&J
M/XL2:R/EC9XE"B+]:@^[S(D6=I**8!MO+=XZC0DAGBNU6F8& NPDS#C6\F5]
MVT.%7[\*& >>T)HRE25;3XI1X0-78<TT*4&W^5+ ?3P[CD-9+O03A];T9SDN
M,>1:>-><#-R2Z[?C(IP@G>%3 U$5#)>=(FJ$ [YL6P2)EK0F(5*')J,?<9I=
MIQ+.M,']E[32&UA!(ZT*MA-!TU]S62,OBYU=YA\MF057H*914!L>H0G,,-$K
MSQ]_AZVR!T;\^OATZE"TT2'Q+6?3A[S;2AQ&U*ZA,I9/RO= S50S6R<Y"!03
MH4"&55;1.-E3>;W#0NA80@(*ZK]HIEU,5?/E)+NK+LG82K##+2,LPU%VBG@@
MVNV+A]D(O(]B1H8YW&5[SSU4,=L[ONC+;\Y6CMNR'*N;%,TX<K0H\!4RF&0P
M]1:B%&=5Q7?.F;,X;VT3UF#$VOFDNL=I&>4YC]7>&-OX^& $V5[;$B=_.\7'
M6 SM?+5;=EQ,[%$Q7X65I1Q]A3;IT-JA=M9:<-* OG>U=<!=T-0%/67.H7N8
MF=1ED5RQ5O00NN.*O2"^QG+;A==A%Y./K!&.#\%@O6-"SY^Z3*WXO8$BD(WZ
M*[/$O0PNZSPI.+R!R4S<C'V,L1\Z= #LA7>S+"@2TK1Q2H?&4E/G,W-'"MI>
MWSJGS8NA^>TD/*TKU6=^]\QEL0%CD8P3U#QGV3$*4M7%O[IP'K[L,/T0Q:S4
M'^>C76I<%RE.@@"_;@5%OC!BS=1F2?*!U36,4<.5 ;Q)1=)4G,]&?R$8?E7M
MN9D5KET2$YB/>'U<[0Q7#U0]]@C!U=[H5!S-WEFA.!*.@&<=VDTPIDHWLHO#
ML5SMR<]!J^ >LM<=7%2?[IMSQ'O=\""61IJJD2K@P!V;XX@ID7+>?-[GL8L)
M<A^-\B_ARM.*MOWW0;>]?R:&H=XA6>)8H8T%<K3/UHF5 ?-'GKLOE@V<AF$W
M7M2XI))<8+*,9.M&9M4#P8R6-,R760F%.YW4[\4'A:"K$EUG='_I]D:+=?7>
MX]G=L0^/L6;CO(NEDC0(5<S2^>>((22XY.]E<."12">.V[DQG ?ZW=IFUM(-
M#3>.YX>A$T=TLG:B'1"VT3+G^,#$UQ^]O-3%;F<:V=Z0$E0;O5"7S>MEV1G+
MPR1IWIA9S5GGR;.D#10O<DP@3U0JCX,DM4NC3$Y.GW#'!.*RKM#D"(;GSD*(
MO$K1G\142#R6_MF%II$6>0,^DB>8_F8DJX5,W\_;"F'=TZ;UF33Z_0J]F>1H
MSTF[VGU.D[U;9P$].!M/W$G:162J[Z>0@3VS2M,FP^RBK=:VD,O1(\*2=?!#
MT 72\:[C2KJ$+%K!XW_)%5A[=-#%_:=[86+R]'TQ5I]JEH!A733\G^J8\11_
M3PWTU[MG.UR:+[AH Z[9EGGQ%[MF<:'/D$<T?,?O]@Q .^B+<J6P/\C#VV>Q
MZI+&/A >V W6?N&@6H=XB5JD?-8?'V)C3G*L9$'R&6..WXV8EL5JD/1W8[W&
M$-O( ^6W,DH!*[90_;LG@6\/_P2UN,/I@#WG#J*0U]]U]B!PN<,\J-\23L(X
M,&QU?14'J+@#AAPZK4!DO@H5L #9W"LJJ@2NZF5:^H+%H*XU*F@E^KO&X%H_
M@CKI2^'&L%V85Y6FR$SMA97._2*9+OD8GEW(5)(#ESAOW/ QO.EE@[#QE2ES
M0@ 3\7OM#G=X<'7^GJ]>2MB-NY(5Q?$%0&B /+[?[MIKP("D[,'E]-PV>,*%
MWT"2Q%MD32*\@>Z7>@SPMRD*NK8*Y@9##[MN>N]+#?1,C:DY?3=T<!$E=6$!
ML=1D%VG0I'!><5&1]CNP1]*;((+.M*XIV#IVK6Q!5W%W3$Z8G)#=CM&4VI%&
MN^:()UDUI@_3*#F<'.TZ"?[/@]<?4N)2H3M;!A,#MDCG0>F^U*^H#>BM<R[!
M(/G 8'&2^-%17%L8':BP:]Q>DIW;'5W\Y(YO#NYOV!7AQKBTRQ[T]%U0=GR(
MLX_]06VBX)^3GY72>TDGCP_BHU_?T$W!<T$]&EW#$-)?::NOB3\'!,=CT9$?
M V]4;9:@!0:W=52IX-M_XM;==**2#WD4&M>N#Y(?0)$UCQX<6JRI(0L+=]0J
ME9-D6C:3J7=J<RJ8W1<B63* B6ZK5S*)=F G-!F!]"MC,"Q-.21,'P$V+3H[
M9,0=N>(S5[/2.R^;JAH+(M2SKLP*M=?&7,M,8[O<PDB1>*MW;-4LH6$+%U3Z
MW)*-&7 E!FWJ3Q_>!O+/%B=437OL>,D]TZ#)J8#!2[H_($_N,^Z7#\GN%R#1
ML=F!T[+^\*MMQB!'8"4<H8:%VT6_?[U]D[A6F)"1WKEU#SYO3R";)OU98A#C
M@EP?85Q 84F<[M/ 4>\]33?N*S&V6#CF7EOY]$4&=FQKHRA#)Y^"$(ZT8<ND
M#BD*AA <K1&AJP\ZZTQO<>6'O*YMY@G8AGV9G/ B?//E..1^PG+A@[YP&8A)
MLCD)*<-UU3X\Z<(W_1"E*\)UN C%MB@;T4)!&Z#(BH@/LT=F;*IF#)NRVI9@
M7V>!-#SQKB$DBTNF@SWF[1[S51.O/;?(/K"G1"<XANDG ^E8P6:QZ L,@6=E
M6-D77=J,P""Z^5Q6-^5HUV'ZH  LLH4=\XGTBZE]VQ:*G V'+NN55UIIH<:5
M+"]J%VAC5Y(W%V<5!@^L<#\9NQ0(7SEB9=P,&Q6VB]((=>3P+=F*LR#IX3ZD
MO#7JOL/T)+ [CN9!XDA= U<JN9:UV.T2YD1<L+.GF\ASUTWD^=Y&(&_]R;FW
M!-)PY]BO'*+?220XG;>4&^[;->33AN,P<%0^D4)%=.KX]&24!%-.&[1YYW$.
M/U:;?)X\>S0A<PJD@2)FRP0\<[+FLR0#TU^@?DBHFD31 # $Q,7TBH$8A=>Q
MP&T,<',\Z7V@9<3#(.]K:R(0$UV!PUAJB%XB(.>J/SC"7IJP(Z?WF&A2%W53
M&Q#-L$3VJJ2+S3/=G53KJ4H]H.ZZ?_7K0_3^BF-1U5 (UQ]+YE'7IGW!/IC6
M5::NJF:]">OD7<@B>-X>FF"LL.LP.0I^L=4QMGIS3#XM H,M#FBQECM]25^1
M2CL/RJ@NA\JH1/?Y<N?@[(V-+:4Q!00DCLY?01&IK]()IYWBZ/ '' I:\%I>
MVW/<5W@U 6R'Z1SNQ?GTP^LK?"8_>0^WGY[X%W.<[&76<^[@RIVG7@<-IP##
M!U(&=2[E4W1]\'4<>P<?[B%]_QGW-,2R3AATA)S<UK-&AE_%(%P$)X:L+R*D
M(J=GR3XTLU8+S(*^96OT=I'63$Q3R(2OY3TBML4Q-^NPG5CYM*4#E$%S.3G^
M9J-HW/+X.LT+=W!3[!^4(]D&Z%UC!O,&N]II:BC^P602)!&X/^<CWT:VWW63
M.3R&6'HT0L7 J<ND':]IYB"@H,[6I3XYPPG6*+G=+019_TR;K:,.ZL1%76IB
M26H(M9MMT#S.MK_SW=>UA"/,5O7AYY##=F<U@C1&8[YUM#B<!W._OJZ*3D)*
MK(U'R2^_G!.KN=_5<Q,I;3(.-@5'*X-^_!]^Y@ML7UPYZU6&"Q^G$7%<<U/G
MA9ZPG 3BZ<R)IVD(ZFX99(M/K)"5U+:\ 8G$LAXVD]S=%CJDA?,6@VG=283S
MOZ#SW;X6=Y,GXR=HBS89/]UB,"9W4/CY_<&EH9Z-G^'/8_JS3UH&KS$ZW?_.
M!S6$IY9#/KA*]$'Q^,VCB5Z5].E [P^F?N>#N#"ZN')1DG4KB=$+8S7?$C#O
MQ3]L'LRVV)2,4N9KTJ2QQWM_B&=P47*P H4,J'S6=)0]-)E+$[)T5[5_V()#
M!-".S)7UP06>*&FT]02O4VJ7@[.N*?E!I-T;H^$=.2Z,\5U9JS_7PI7?64[2
MN,;CZ9P3'.(-TTK0YGXP:]QR-14K$7<F%9/XU:5EL'B9V2(5HH*+E?DN/0GE
MJ\+"=O"Q@\S'M"!..@ERS&"12+5U;?N'*@!ALUHX(Z9L[>M]6-VXX535\/M=
M;)%&UTB=QET\C"^O<2<5?%E+%1T#&SX,0EQS@W[*=//"W\&V,FOTXDX-9391
M7:.SVU4JA^!Z?6KD5('&EDA=:9;8'JB<67HUXCCR_ '*[%"VQ($71DXUZKRX
M!1BL#TSI ]X*\JA_'ION?O+LNWO@ #+@7H8$(<$&H+0(?7<_HJV*HKA<Q\8U
M%]+NF"#P&7]4I,@[K8*6+"!D.2I3Z>N>^F2V11H#%&9=%CF=9EGVKZ6V02IS
MJPL;+"!B(?50X2EDC?<=J@DD3E'O+C[NOJ.!>7,TTB:3YMC6LZFW[R4X=R^Z
M<Z=K[*E9F[^12D+-:D8;MY5?M<_;X*9212PSW>,6("V4T8-<%CS8DYS"E%$Q
MCC[0V#?@=)IT]F=.PJ.7$KSD0\CD*)$O%!>QZ7D:8;H\+.@*+*&5ZXFWYXSO
M%T[![\Q"]VHG(\*0.A1/%/+=UU7\WZ9^Y:8."/'[;TQ4#Q39[KI3HU[A!GAR
M*\-L=S,R&KZ\I;YT,\2IW]]T*_8NNRQ*(RJQ&0JAJC1]+_'&^#03UP[Z(U$<
M'O=CLXKG.(DEC1U5P8P.WHX=<TO*'6]'Y?(XM#5PVQUA:TAC!06MF6G)749.
M1$9C*>R-%>?#<'X5C5$EMQ@WT-UOC:A)6K?YO/-MYR #V)IK G,N:D_7[\CR
M+7IF;\AFXIV0R?[W:=K8P7GP\K1!]^,;QNG':B-O.>CC[G_>\=J5@8CNU7GR
M[.3Q*!F>>!R[N]NG&Z(7PMD:L[_^=7#ATC(Y3S+5=O+:>VD4M?.61%UF?:?!
MEWW),< 2M5:U:R;!_AI>)VK;@)1;J.5H=X#UH+K=\YA]&XSKS&Y+S;3D)=K"
MN#++O8C3O00M"M+H*X>XU8WK[XY3FW@))]&W?9U;W/N=SV2$C8_$-O3K7'QA
M@"^@\D;:,-EPDT=$:^:K,O]'YSK]V\DU9L[H2Q%7%V,/U;SZD[-AY444[O>Q
MOLJQC^W&'306IO_"BS5IN^NJ4X^KKOX0/]GG%]G)Y<61$+II5T'1INT1JV>;
M]DD0_Q;BT[VO#7[U!IOQF]V,-XXW+GQH=%">_.E1>X$J$?=-[V6Z48"6/0(I
MY]:W/@@1>9_#T96^/'1'E"J CMCN@^N._!.8Z1.SV!#(T/PRKSX[$.SZKZ["
M=E[6MH/X5"3)5: %Y)4!X2^_#+X^ -&J)QRULOW@Z)>G3\;/@U\^QNM>D96*
MMTW=]0I"$,?VA]'R<M.QE;(($CQ2"8'S4KW#%M4,IH _96_/-76EOZ)1!WT%
M2M>(W64[Y7@ ]=4A@_#T7J[Q@M<X>?(R^84/.9VZ4*CB>.-PK%T;A%_%%A2I
M,O?OFNB]_V/<&WWB1K\08(+0BIW?A73"=6L5BRO-K?CMQ/IMI!T[FN0?$<QL
MR-D.9_H:E#H$;]1[ /2KJW-0<$I!5NXZ02LF!R#EY#4:RQMNKU'-*E$+.'#M
M;U*1QR_-8R"CIFQ,)J@S$U)=V)*G;?C[Z/5IMD\!U6R!JR_ST<KB')TV$CX4
MYF2QO!'HSNG\T+I20S56+[M!W"<^_6O13_>_T/QW@Q98)CN>:DNI*[(-#5[[
M[$S50?'YIT=%J;7J,A2,-"NI6VGK?-:U-G?:>T\P*HI1)X77<J+!$-<O$8_
M^FU]$!?5-,2W=_K^3M%RHZT2LQL%TG73\@V/&@$WM->W:DX&\?^0CQ.1'$Y?
M?<]-)<Y-4302'Z5M.0A^1:4^]N?%='+PD)[TM[_Z?D/@O"/O'1Y681;TZ,GX
MZ>,#Z6]FO[35!D,B$--6:_ZX,BDA!3?0]45%'*A?, $.8S)XK_X74$L#!!0
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M0T'K#?B\,(:."^^@_46-_P502P,$%     @ 74#\5)^7J#NB!   L P  !D
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MPDX?^%2"K74;#J')H)%4,,,2)CH TV$?M'(+RVY4"NE3_P92VO**-KR&T5'
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M=!WQPP7=_]"P OV?:=HNEA-VT-XH!_\"4$L#!!0    ( %U _%29+"^2"@4
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M%&]>JJ4)^'ZLM5UV:('^+C?Z!U!+ P04    " !=0/Q4!@!4CB\,  ")=
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M,_2!T4A.T=<QB^^8J+T)M5*::@@)PY P'Q)&@&"&KDZG>C;N[.-II,@5J">
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MZI1!T4QM*Z_,L9ME/S,[@QIGH#1<T%9GY_7?=T S)% T<QU$Y8BY5H^E_'W
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M/#90WR\9D[N3.$"^LV[X'U!+ P04    " !=0/Q4OYQ^>D(#   2#@  &0
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MGE;UR(1@2?%R18,%Y?D.\O,E8^+U39Z@>I+<Y/]02P,$%     @ 74#\5/-
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M?57Y:'1'OL_6MZ>ESE=5Y#\XE8W_8'O'&U61*$V,;)-W:LUQ%Z,U$Y0F.[5
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M3<SLY=VLIUQBM&2"TF27!BBJI!'G>6, YQU'^K%QOLRS>YV7GZNOENFZW"U
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MA<GA#J,UYCI 7=\P-4.S$[V%D6]9C?X#4$L#!!0    ( %U _%2;V) =A@,
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MID"8E<VC=3:/G-E\F\?I.)Y'"8EFV2(MVS+7*73-W!4VVLBB87"VE;?(@/2
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M JI)J*90FETT37<]"+"S*6B''*J%4(U"-0;5.%034$U"-872[/)H.N2!^Y8
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MRW:5E/9V;LV6R]MW=CM7<[UC!;TV+*I9K2:=-GUU\Q8;G=%!-1?5/%3S42U
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MY\NI\;<.WPET\F2/3"8IY\_&6.6Q%QA!0"%3A@'KY0"W0*DATC)^]YS>$-(
M3_=']@>;N\XEQ1)N.?U!<E7%WD</Y5#@EJH=[[Y G\^-X<LXE?:+.N<[#3V4
MM5+QN@=K!35A;L4O?1U. .'D B#L :'5[0)9E7=8X202O$/">&LVL[&I6K06
M1YCY*7LE]"W1.)7L[S^O[S=/:+5Y>-RM%T^KQPUZCS98"&S*A=[<@<*$RK>1
MKW0X _*SGGKIJ,,+U#.TYDQ5$MVS'/+_\;Z6.6@-CUJ7X57"KRT;H4GP#H5!
M&*(]E+HYE+Q"/!F*,+'$DTM%<%1H!PT7BK 2_5RD4@G=,K_.Y>W8IN?9S!C-
M98,SB#T])Q+$ ;SD]:OQ+/AT1>MTT#J]QIYLVCH%@7BA1\*HQ2D%E+92NTF)
MY-FB.-6.]\;RFED])-/(/YQ*\4_ZJ 91VFF1*.,M4ZZEAM-A(!>N#_^YNVE>
M8U$2)A&%0D.#T0<=5[@)<8;BC>W*E"O=XW9;Z4<%A''0]P7GZFB8 ,,SE?P%
M4$L#!!0    ( %U _%2,8O1\* D  *M!   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;+6<77/;N!6&_PI'W>DD,YN(^."7:VLF$;%K=^HD$V?;BYU>
MT!)L<58B59*RL_WU)2E%$'@.0<J%;Q))?O&"YP $'D"@+I_SXH]R)67E?-^L
ML_)JLJJJ[<5T6BY6<I.4[_.MS.J_/.3%)JGJM\7CM-P6,EFVA3;K*75=?[I)
MTFPRNVP_^U+,+O-=M4XS^:5PRMUFDQ1_?I3K_/EJ0B8_/OB:/JZJYH/I['*;
M/,H[6?VV_5+4[Z9'EV6ZD5F9YIE3R(>KR0=R(3RO*= J_IG*Y_+DM=.$<I_G
M?S1O;I97$[>Y(KF6BZJQ2.K_GN1<KM>-4WT=_SF83HYU-@5/7_]P_Z4-O@[F
M/BGE/%__*UU6JZM).'&6\B'9K:NO^?.U/ 347N B7Y?MO\[S0>M.G,6NK/+-
MH7!]!9LTV_^??#\DXJ1 [8,7H(<"M%N ]Q1@AP)L; W\4("/K<$[%&A#G^YC
M;Q,7)U4RNRSR9Z=HU+5;\Z+-?ENZSE>:-1WEKBKJOZ9UN6IV)WZ]%9^^.3>?
M?OG\]?;#MYO/GYQWSN>M+)(JS1Z=FVR1;Z23/SA?Y38OJN1^+9T[^5CWE:IT
MWL2R2M)U^;8N\]M=[+SYZ:WSDY-FSK=5OBN3;%E>3JOZ*INZIHO#%7W<7Q'M
MN2+FW.99M2H=D2WE$BD?F\O[AO+3.CO'%-$?*?I(C89_WV7O'>;^[%"74N1Z
MYN.+$RR<_Z]V\>+:M62P8W]AK1_KZR_[IC_TAGT/V0]7S6W_^S]JN7-3R4WY
M;ZSE]]X<]V[&Q(MRFRSDU:0>]$I9/,G)[*]_(;[[-RSM-LUBFV;"DIG60/S8
M0-SD/OM43RZ-9[J0]4#^)+.=Q%IB;^*W)LUD\C3SO"",W,OITVF.$9G/B>_K
MLAC*"'$9X8&N$ZB.,**JU6+VCC%[QI@_5RM9./EQT$K;00L+>^_CG5Q -V*H
MX+[+.O$.V@BH((RY'(_3/\;I&^.<YV75#,6']OW9D=\7Z]VR"7DIZ[ZT2/>W
M83WP.LFFN3__VWZ 9<('%\B(3PGII .1N:$?=60QE-5>=0_H9 61N5X8]:0E
M.*8E,*;E5YG5+;_>A[VL)\FTK)J>\"3K!-5$54IT&@I@$X5!Y'8[!"(+/-:5
MQ5#& @ID I'Q@+L]-T!XS$!HS$!\;NN'2'O1;N2(**#=EH<BPBD-.V&CJL#'
MHXZ.44?FV_YXPYN:.0)5>\2E/.H$"V4\<GW&.^%"&7'=P.,=G8"ZR ]\UM/.
MQ%6XYHZ,>3_(.6_6>5F^13'+A2$%]>C="1R1!2%A7B=P1!9Y8&04B(QP/PI[
M;G%RPJG$&/AU$^RU3-;5ROG]5F[N98$BAMGF7,:PZA9;=1.VW/0&H:I!Z"N2
MX,'<5C/9=(NMN@E;;GHS*5XG1MH<RX,'%WUB<BF8#5%=!*=#1.<']7C1G0]1
MG38+ZW$K#"9F#A[/A&:CL[LB!P%!#(BMUBF0.@/6FT)%U<2,U39QDR! W'0;
MT+\PG<MA J&.!2'P$ZB.]0(742A.S"S^0N@D$($QZ,1D!.E&4$:">DD%LH#H
M?-*?!47>Q(S>9X,G07#:@^$C*C 6Q8B*@IXB,!7MC5P1-S$C]SCX)!!\:0@O
M<H[I @KZ18SH/ \F4& Z%KB]82OD)F.9>Y@_$?)N;M%NZ% 6A &,'"%ORI&N
MCNAXV-O@5)$W-9/W=5YNFTG4!)]FBW.G$JMNL54W8<M-;PRU&J#D%>&36ETC
M6'6+K;H)6VYZ,ZDU C7"[5CX/+CHDWX(1TE4!V?/&-&QB,"I =.%4>^T2!5T
M4S-TCX=/L]'971'2- *?5NL42)U^[T1#%;]3,[_;A$\*^9BX =*_,)T'P0/1
M4<+ U"8PG>N'O<E19$[-9/Y"^*00ACT"UF1S1,;AW1@C,N)"9A&(+N*]*SRJ
M")R:"?QL]J38]C,('HH@C" B2.=B2*7'K9B;FIE[''E2#+0C)%Y,QY%! ]FY
M)LB""].YK'] 4,!-QP+W('E22+\LA.2)R+B'S"90IJ\@#X%#643[YQ)%W-1,
MW%]D4>99?;//DV* /HU&9\\E-MUBJV["EIO^%;A:"C#W%>F365TD6'6+K;H)
M6VYZ,ZE% C-_93"2/@\N^HH1;LE@L@",?S$BHR&<%!%9,Z;TC!9,$3<S$_=X
M\C0;G=T-(4J#S%C=5C=6J"?OY&R+&=MM,B>#6$S@$F2.R1C8U8@1&:4 3 4F
M\X+>7J5@G)EA_(6\R<;LA<\1%8/,C:@XW/="5'[OW@]3O,W,O'TV:K+A@R;#
MDAB1P VO 9$>L8)K9H;K<9#),,(%N#S'9#Y$3$1&?;BJ0F1-?^D+67$U&\O5
M@X#)QNQ/SQ$57$H@(HHT,J+J#UDQ-3,S]77ZN'(^+'9I]6>+EVBL1HNSYPF;
M;K%5-V'+36\,!?HL>DVJM K_5MUBJV["EIM^O%+!/S=_#S#V@"5R^@9._XBJ
M.T @D@#._$8C/5+%S]S,S^-9TFQT;N?CD(U!4JSNDALKU).G0)R;0=PF2W+(
MNEA?&D9P1 *7,,)HI*=#H34WH_4+"9)#H(6+J3FB I$CG WW>H3120_]Y$"V
M&9[/AD<.(19N7B$B$#.RG0U/X!B-]) 5+W,S+X^C1XZ0*_Q&=X[(0*100I'5
M@=%)#U6!,A\+RH/4R"&XOHL@+2,R$"_B1 *X VVTT@-6F,P',+F9%=#PC.7.
MG@1LNL56W80M-[T%%+7S\!5!D5OE>:MNL54W8<M-;R;%\]R\<3\6%.&!%3 B
M#$KB88DP2O3G;A0,>P/'T<<_>6-UU]L;YF:K%0ICA7KR%%][9KZVB8C>(#//
MAR7QL$08)7HB%"M[9E9^(1QZR/$-N#2:(S(.C^#%B"R 9TL$(@O[O\WV%"![
M9D ^FQ(]Y"0VW%Q%5!S 9(RHX/>E E$1MW=WV5. [ T<U1Y%BQZR >S"HZ.8
M#':*&)&%/F Q@<@B[12['O+) XMC 7F0&@].IP]-OD,#QW18Y(@.#1W18;%/
M3QX^W\CBL7WJOW06^2ZK]L\5'S\]_K+ A_9Y^L[G'\G%G""?Q^1"['\W0-GO
M?\;@-BD>TZQTUO*AKLI]']277.Q_&6#_ILJW[:/O]WE5Y9OVY4HF2UDT@OKO
M#WE>_7C35'#\?8;9_P!02P,$%     @ 74#\5.U:)^KS!0  \#<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&ULM9M;<^(V&(;_BH;N='9GML$V!X<T
M88;@8Z>[PX2FO>CTP@$%/(LM5I;#;J<_OO(A!A.CX.9M+H)M]#Z?C%[+EC[K
M>L?XEV1-J2#?HDV<W'360FRONMUDL:91D%RP+8WE-X^,1X&0NWS53;:<!LM<
M%&VZAJ8-NU$0QIWQ=7YLQL?7+!6;,*8S3I(TB@+^_99NV.ZFHW>>#]R%J[7(
M#G3'U]M@1>=4W&]G7.YU*\HRC&B<A"PFG#[>=";ZE6]HF2 O\7M(=\G!-LE.
MY8&Q+]F.O[SI:%F-Z(8N1(8(Y,<3G=+-)B/)>GPMH9TJ9B8\W'ZF._G)RY-Y
M"!(Z99L_PJ58WW0N.V1)'X-T(^[8SJ/E"0TRWH)MDOP_V95EM0Y9I(E@42F6
M-8C"N/@,OI4_Q(% <IH%1BDPC@7]$X)>*>B=&Z%?"OKG1AB4@L&Q8'A","P%
MPW,%9BDPSZW292FX/%<P*@6CW Y%^^6-;P4B&%]SMB,\*RUIV4;NH%PMVSR,
M,[//!9??AE(GQG-O<F>3.WMV?S?U)G.;? XX#S(#DO<6%4&X23Z0G\C]W"+O
MWWT@[TB7).N TX2$,;F/0Y%\E ?E]F]KEB9!O$RNNT+6*Z-W%V4=;HLZ&"?J
MT".?6"S6";'C)5TVZ"VU?OB:WE'K=>,U@/L*P%0 NK)%JF8QGIOEUE 2?TGC
M"]+3/A)#,XR&"DW/E^M-/^C;HMMOB^ZHY19=2+E^4NZ>+V^JO*>63]+5!=&,
MD]'],Z(;O5RN*8S0JZ[/7L[KG;H^LXN-W-%MRA=KV:F3/W^5)8@O:)3\U72I
M%;A^,RZ[=5XEVV!!;SKRWIA0_D0[XQ]_T(?:STTN0\(L),Q&PAPDS$7"/"3,
M!\%J/NY7/NZKZ./9LW_9(UFP:!O$WXF\N2V^-'E8B6KK823,*F##')8]1S[)
MOK\WD/W$TZ$Y7Y8R^YK9KY=RD!5SD3 /"?-!L)KK!I7K!DK797TX>=&%SCA;
M\2!J<IX2U]9Y2)B%A-E(F(.$N4B8AX3Y(%C-Q\/*QT/L4\ 0Z6,DS$+";"3,
M0<)<),Q#PGP0K.9CL_*QJ>R/Y]D=OZ$K_D@FJ5@S'OY-EV02L3063:Y6PMNZ
M&@FSD# ;"7.0,!<)\Y PWWSY8*9E?]4S5\VOEY5?+_^37XG];1MFTR0L)E8@
M:)-9E>2V9D7"+"3,1L(<=6M4(_N3,P/(RGA(F ^"U5P\JEP\4KNXF+#CE8V7
MY'TQB?>AR;A*6%OC%K#!P779-P=F?21D(2/:+R,:(U/7!D>C+V1,%PGSD# ?
M!*OY3M?VD\L:;M2O9K4U7DD[OB,<.0\:TVZ(*0?^QT$=:% 72O.@-!]%J]OO
M(+>A*^WW&Z=!DO+OI+B/3Q9?TY#3I7S:?*(\6%$R98D@,\J+.8)&4RHCM#9E
M0;L\[)SZHPO3.+8E,JI](JHQ.O8E,JH+I7E0FH^BU7UI['UI*'WYF>Y:S4JI
M<:U-B*194)H-I3E0F@NE>5":CZ+5#;U/4NG@+)4.35-!:1:49D-I#I3F0FD>
ME.:C:'5'[]-5NCI?]<:9*C6]M;^A.2PHS8;2'"C-A=(\O2'Y5Y]C*IW[?V2\
M]'W*2U?GO%J.]DO:X7A9'[P\JZDZ:FL/GA?5AD9UH#072O.@-!]%JWMPGZ[2
ME5F$EN/^84-2O<& T#34>4%M:% '2G.A- ]*\U&TNO_V:29=G6="#/S-%X-F
M71]<#/O'MH3FD<Z,:D.C.E":"Z5Y4)J/HM5]N4\GZ>H,AFK@3_XA\_0AH5]3
M&@MB/]$33Y;0O!*49D%I-I3F0&DNE.9!:3Z*5O?X/MFDC\!S ="$$Y1F06DV
ME.9 :2Z4YD%I/HI6?Q5_G\4RU%FLM[P%H$:W-3>49D%I-I3F0&GN*PU<>[&@
M><T -"V&HA5^[AZL_HDH7^5+QQ(Y[DIC42PTJ(Y6R],F^:*LH^.W^M54;SAN
MZ5=VL?ALCR_6PGT*^"J,$[*ACS*4=F'*82<OEI<5.X)M\[5'#TP(%N6;:QHL
M*<\*R.\?&1//.UF :I'?^%]02P,$%     @ 74#\5':+]Q#- @  ?0D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULK59M;]HP$/XK5E9-K=215^C$
M0B0@F=:I= CHIJG:!T,.B.K8S#;0_OO93LB@"JC:^)+8YWN>QW>7^!QN&7\2
M2P")GG-"1<=:2KEJV[:8+2''HL%60-7*G/$<2S7E"UNL..#4@')B>X[3LG.<
M42L*C6W(HY"M)<DH##D2ZSS'_*4'A&T[EFOM#*-LL93:8$?A"B]@#/)A->1J
M9E<L:98#%1FCB,.\8W7==M+4_L;A>P9;L3=&.I(I8T]Z<IMV+$=O" C,I&;
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MDZHWFN%2W8^ :P>U/F=,[B9:H+IQ17\ 4$L#!!0    ( %U _%0=S.H.4 ,
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M>0_NO8^"]7LJV/R'=O0;4$L#!!0    ( %U _%27BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 74#\5'U=-L:Q P
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MNZDW?IM#402F+BFGDJU/GX5.G[3>_0M02P,$%     @ 74#\5#QA]1J- 0
M3Q@  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W938Z"0!"&X:L0
M#F!;5?@W45>S<3OQ D1;,8(0NB>CMQ^C"_W,+&9C^EN1;D+QKAX(S+]\7<9#
M>PK5H0O9N:E/89%7,78?SH5-Y9LR#-K.GZYG=FW?E/&Z[/>N*S?'<N^=#H=C
MUS_/R)?SYYG9^M+Y_TQL=[O#QG^VF^_&G^(?@]U/VQ]#Y7W,LW79[WU<Y.Y<
M/[:#NQUD<)V<9ZOM(N]76\E=ZB"%($T?9!!DZ8,*""K2!XT@:)0^: Q!X_1!
M$PB:I ^:0M T?= ,@F;I@V2(,@X)DEZP)M!:D&LA\%H0;"$06Y!L(3!;$&TA
M4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%M?7K8)]%;46PGT5M1;
M"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT-M3;"/0VU-L(]#;4VPCTMI>/
M)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z%ZAW\4Z]0[S4/CQZ
M[FN\_SNICM=K_>/VM^5]$Y\7Q0UG!_\/EK]02P,$%     @ 74#\5)C$(26B
M 0  IA@  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;H,P$(1?!7&-@F,[
M37^4Y-+VVN;0%W!A"2B +=M)D[>O(3]2JQ0U2J7.!0N\.S-XI>\ T[>=(1=M
MZZIQL[CPWCPPYM*":N42;:@).[FVM?+AUBZ94>E*+8F)T6C"4MUX:OS0MQKQ
M?/I$N5I7/GK>AL>NU,TLME2Y.'K<%[9>LU@94Y6I\F&?;9KLF\OPX)"$SJ[&
M%:5Q@U 0L[,.[<[/!H>^UPU96V84+93U+ZH.56Q;,>=W%;FD7^),1IWG94J9
M3M=U:$F<L:0R5Q#YNDKVHH-^9Q].F/97?K5_)]-G&"H75AL7)F;I<KOC2-KN
MH0E"9'W9_XHGQR!]]?M1.^V,LE]ZA^/]T';5S<.Q;KG^C+_.^*1_80X!DD."
MY!B#Y+@!R3$!R7$+DN,.),<]2 X^0@F"0E2.@E2.PE2. E6.0E6.@E6.PE6.
M E:.0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:)0E:)0E:)0E:)
M0E:)0E:)0E:)0E:)0E:)0E:)0M;Q?Y+U7>O57W\Y;]>D5F5S]&?=[XGY)U!+
M 0(4 Q0    ( %U _%0'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 74#\5/X@S,OO    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M74#\5)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !=0/Q4\=1)+\P%  "7'P  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M74#\5-C?R]!M!P  JQX  !@              ("!$ X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %U _%0O#?^YJP,  $P,   8
M          " @;,5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !=0/Q45H/4>+T'  !=)0  &               @(&4&0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 74#\5%_/X)!(#   E7D
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M965T.2YX;6Q02P$"% ,4    " !=0/Q4A0+<%@D-  !^*0  &0
M    @($T;P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M %U _%0\JY*3( P  %\E   9              " @71\  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 74#\5-I/8D- #P  6BP  !D
M             ("!RX@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !=0/Q4 @&JE&,'  !8$P  &0              @(%"F   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %U _%2E7R0:S@0
M *8.   9              " @=R?  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 74#\5(MTCK<; P  " <  !D              ("!
MX:0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !=0/Q4
M=66VBG4F  ##@@  &0              @($SJ   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( %U _%12$)L4R@,  /\'   9
M      " @=_.  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 74#\5&5[K]>=!0  X T  !D              ("!X-(  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !=0/Q46N^TQPT#  "N!@
M&0              @(&TV   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( %U _%2?EZ@[H@0  + ,   9              " @?C;  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 74#\5(#*M!1U
M!   70H  !D              ("!T>   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !=0/Q4F2POD@H%  #7#0  &0
M@(%]Y0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %U
M_%0& %2.+PP  (ET   9              " @;[J  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 74#\5!HNBR*W!P  N$4  !D
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M=#(X+GAM;%!+ 0(4 Q0    ( %U _%2M7%-5L ,  +,-   9
M  " @68. 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M74#\5'YX?+'G!P  54X  !D              ("!31(! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !=0/Q4\T#GY0T8  ##4@$ &0
M            @(%K&@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( %U _%1539C7)P0  +X2   9              " @:\R 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 74#\5)O8D!V& P
M? T  !D              ("!#3<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !=0/Q4(VS-ZY$%  "'+   &0              @('*
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %U _%2M
M91];EPX  .7    9              " @9)  0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 74#\5#B3[Q3%#@  =>@  !D
M     ("!8$\! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %U _%0=S.H.4 ,  *X5   -              "
M 5AS 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 74#\5)>*NQS     $P(
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9>&UL4$L%!@     P #  !PT  #)_ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>254</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19"</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amed-20220630.htm">amed-20220630.htm</File>
    <File>amed-20220630.xsd</File>
    <File>amed-20220630_cal.xml</File>
    <File>amed-20220630_def.xml</File>
    <File>amed-20220630_lab.xml</File>
    <File>amed-20220630_pre.xml</File>
    <File>amed-20223006xexx311.htm</File>
    <File>amed-20223006xexx312.htm</File>
    <File>amed-20223006xexx321.htm</File>
    <File>amed-20223006xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="798">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20220630.htm": {
   "axisCustom": 4,
   "axisStandard": 22,
   "contextCount": 254,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 598,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://www.amedisys.com/20220630": 2,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 16
   },
   "keyCustom": 86,
   "keyStandard": 218,
   "memberCustom": 43,
   "memberStandard": 27,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i1ddf9fbb9d354501832c0641468f679d_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenuePeriodOfCarePaymentRateDuration",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ic21dc870eef3444a90c0b71790318d59_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ibec5f07fc2aa4973b444a7171d9a0911_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ibec5f07fc2aa4973b444a7171d9a0911_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ib7f617d6993d44d1bad636bee8dc70e0_I20220323",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:BusinessCombinationAcquiredNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i043295b1e6fd4805ad86f88638f693aa_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i6ab8d9bd0ef44aedab7b10f53379d788_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i5fdfe5f5157c462fa0c08492c5359787_D20220401-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "if19ffbe3490c49479b91f735381591d3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i3d43362c8b95458aac1aefacb3f78f19_I20201223",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "i05495d7733ba4558a18322e3d988ebb9_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ie529522693b04e3fb2af9623aa043d2e_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "id5ec7ab4116e4010b85638d99e1435a4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "id5ec7ab4116e4010b85638d99e1435a4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20220630.htm",
      "contextRef": "ieec61a56fbd146abbd9e67af13fa5873_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 74,
   "tag": {
    "amed_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Repurchase Program",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Repurchase Program",
        "label": "2021 Share Repurchase Program [Member]",
        "terseLabel": "2021 Share Repurchase Program"
       }
      }
     },
     "localname": "A2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2022NewJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 New Joint Venture",
        "label": "2022 New Joint Venture [Member]",
        "terseLabel": "2022 New Joint Venture"
       }
      }
     },
     "localname": "A2022NewJointVentureMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AcutePhaseForHighAcuityCareServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place",
        "label": "Acute Phase for High Acuity Care Services",
        "terseLabel": "Acute Phase for High Acuity Care Services"
       }
      }
     },
     "localname": "AcutePhaseForHighAcuityCareServices",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_AdditionalFundingDistributedToHealthcareProviders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Additional Funding Distributed to Healthcare Providers",
        "terseLabel": "Additional Funding Distributed to Healthcare Providers"
       }
      }
     },
     "localname": "AdditionalFundingDistributedToHealthcareProviders",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Four",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche One",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than 3.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Three",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Two",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice Aquisition",
        "label": "Asana Hospice Aquisition [Member]",
        "terseLabel": "Asana Hospice Aquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAquisitionMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AssistedCareHomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssistedCare Home Health",
        "label": "AssistedCare Home Health [Member]",
        "terseLabel": "AssistedCare Home Health"
       }
      }
     },
     "localname": "AssistedCareHomeHealthMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationAcquiredNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that amount of noncontrolling interest acquired at the acquisition date.",
        "label": "Business Combination, Acquired Noncontrolling Interest",
        "terseLabel": "Business Combination, Acquired Noncontrolling Interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationAdjustmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Adjustments",
        "label": "Business Combination Adjustments [Axis]",
        "terseLabel": "Business Combination Adjustments [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationAdjustmentsAxis",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_BusinessCombinationAdjustmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Adjustments [Domain]",
        "label": "Business Combination Adjustments [Domain]",
        "terseLabel": "Business Combination Adjustments [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationAdjustmentsDomain",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount paid to the seller as a result of a business combination using cash on hand and proceeds from borrowings.",
        "label": "Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings",
        "terseLabel": "Business Combination, Amount Paid to Seller With Cash or Proceeds From Borrowings"
       }
      }
     },
     "localname": "BusinessCombinationAmountPaidToSellerWithCashOrProceedsFromBorrowings",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity assumed at the acquisition date",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities and equity assumed at acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActDeferralOfEmployerShareSocialSecurityTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferral of the employer's share social security tax provided by the CARES Act",
        "label": "CARES Act Deferral of Employer Share Social Security Tax",
        "terseLabel": "CARES Act Deferral of Employer Share Social Security Tax"
       }
      }
     },
     "localname": "CARESActDeferralOfEmployerShareSocialSecurityTax",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActInterestRepaidToGovernment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Interest Repaid to Government",
        "label": "CARES Act Interest Repaid to Government",
        "terseLabel": "CARES Act Interest Repaid to Government"
       }
      }
     },
     "localname": "CARESActInterestRepaidToGovernment",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized",
        "label": "CARES Act Provider Relief Funds Utilized",
        "terseLabel": "CARES Act Provider Relief Funds Utilized"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilized",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19DeferralOfSocialSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Deferral of Social Security",
        "label": "COVID-19 Deferral of Social Security [Member]",
        "terseLabel": "COVID-19 Deferral of Social Security"
       }
      }
     },
     "localname": "COVID19DeferralOfSocialSecurityMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19ExpensesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses incurred as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 Expenses Incurred",
        "terseLabel": "COVID-19 Expenses Incurred"
       }
      }
     },
     "localname": "COVID19ExpensesIncurred",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19PPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 PPE",
        "label": "COVID-19 PPE [Member]",
        "terseLabel": "COVID-19 PPE [Member]"
       }
      }
     },
     "localname": "COVID19PPEMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19TextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19TextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]",
        "terseLabel": "Cap Year 2016 Through 2022"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for finance lease liabilities",
        "label": "Cash paid for finance lease liabilities",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "CashPaidForFinanceLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need and Licenses",
        "label": "Certificate of Need and Licenses [Member]",
        "terseLabel": "Certificate of Need and Licenses"
       }
      }
     },
     "localname": "CertificateOfNeedAndLicensesMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ContessaHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contessa Health",
        "label": "Contessa Health [Member]",
        "terseLabel": "Contessa Health"
       }
      }
     },
     "localname": "ContessaHealthMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ContributionsAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest",
        "label": "Contributions Attributable To Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "ContributionsAttributableToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsRepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts Repaid",
        "label": "Estimated CARES Act Provider Relief Fund Amounts Repaid",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts Repaid"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsRepaid",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures",
        "label": "Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "label": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "terseLabel": "Estimated CARES Act Provider Relief Funds Expected to be Utilized"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundsExpectedToBeUtilized",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated expenses as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Estimated Future COVID-19 related expenses",
        "terseLabel": "Estimated Future COVID-19 related expenses"
       }
      }
     },
     "localname": "EstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EvolutionHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolution Health",
        "label": "Evolution Health [Member]",
        "terseLabel": "Evolution Health"
       }
      }
     },
     "localname": "EvolutionHealthMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExistingShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Share Repurchase Program",
        "label": "Existing Share Repurchase Program [Member]",
        "terseLabel": "Existing Share Repurchase Program"
       }
      }
     },
     "localname": "ExistingShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic (\"COVID-19\").",
        "label": "Extension of Temporary Suspension of Sequestration, Revenue Impact",
        "terseLabel": "Extension of Temporary Suspension of Sequestration, Revenue Impact"
       }
      }
     },
     "localname": "ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FourHundredFiftyMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Hundred Fifty Million Term Loan Facility",
        "label": "Four Hundred Fifty Million Term Loan Facility [Member]",
        "terseLabel": "Four Hundred Fifty Million Term Loan Facility"
       }
      }
     },
     "localname": "FourHundredFiftyMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding for Healthcare Providers, Including Hospitals",
        "terseLabel": "Funding for Healthcare Providers, Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "label": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "terseLabel": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program"
       }
      }
     },
     "localname": "FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundsReceivedFromProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Funds received from Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "FundsReceivedFromProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time that goodwill is deductible for income tax purposes",
        "label": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
        "terseLabel": "GoodwillDeductibleForIncomeTaxPurposesPeriod"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HighAcuityCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High Acuity Care",
        "label": "High Acuity Care [Member]",
        "terseLabel": "High Acuity Care"
       }
      }
     },
     "localname": "HighAcuityCareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice",
        "label": "Home Health and Hospice [Member]",
        "terseLabel": "Home Health and Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in Estimated Future COVID-19 Related Expenses",
        "label": "Increase in Estimated Future COVID-19 Related Expenses",
        "terseLabel": "Increase in Estimated Future COVID-19 Related Expenses"
       }
      }
     },
     "localname": "IncreaseInEstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses",
        "label": "Licenses [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare license",
        "label": "Medicare license [Member]",
        "terseLabel": "Medicare licenses [Member]"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Period of Care Payment Rate Duration",
        "terseLabel": "Net service revenue period of care payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NewShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Share Repurchase Program",
        "label": "New Share Repurchase Program [Member]",
        "terseLabel": "New Share Repurchase Program"
       }
      }
     },
     "localname": "NewShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonCashAccruedContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash accrued contingent consideration",
        "label": "Non-Cash, Accrued contingent consideration",
        "terseLabel": "Accrued contingent consideration"
       }
      }
     },
     "localname": "NonCashAccruedContingentConsideration",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonCashNoncontrollingInterestContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest contributed in noncash investing and financing activities.",
        "label": "Non-Cash, Noncontrolling interest contribution",
        "terseLabel": "Noncontrolling interest contribution"
       }
      }
     },
     "localname": "NonCashNoncontrollingInterestContribution",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "label": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "terseLabel": "Number of Consolidated Entities Classified as Variable Interest Entities"
       }
      }
     },
     "localname": "NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of joint ventures owned by the entity as of the balance sheet date.",
        "label": "Number of Joint Ventures",
        "terseLabel": "Number of Joint Ventures"
       }
      }
     },
     "localname": "NumberOfJointVentures",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Deferred Social Security Tax Under CARES Act",
        "label": "Payment Of Deferred Social Security Tax Under CARES Act",
        "terseLabel": "Payment Of Deferred Social Security Tax Under CARES Act"
       }
      }
     },
     "localname": "PaymentOfDeferredSocialSecurityTaxUnderCARESAct",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PotentialClosingPaymentAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Closing Payment Adjustment",
        "label": "Potential Closing Payment Adjustment [Member]",
        "terseLabel": "Potential Closing Payment Adjustment"
       }
      }
     },
     "localname": "PotentialClosingPaymentAdjustmentMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProviderReliefFundAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable related to funds received from the government related to COVID-19",
        "label": "Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "ProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ReductionToNetServiceRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to Net Service Revenue",
        "label": "Reduction to Net Service Revenue",
        "terseLabel": "Reduction to Net Service Revenue"
       }
      }
     },
     "localname": "ReductionToNetServiceRevenue",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReversalOfLossContingencyAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Loss Contingency Accrual",
        "label": "Reversal of Loss Contingency Accrual",
        "terseLabel": "Reversal of Loss Contingency Accrual"
       }
      }
     },
     "localname": "ReversalOfLossContingencyAccrual",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, Contessa [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Contessa"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsContessaTableTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Evolution business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, Evolution [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Evolution"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsEvolutionTableTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cares Act Provider Relief Funds",
        "label": "Schedule of Cares Act Provider Relief Funds [Table Text Block]",
        "terseLabel": "Schedule of Cares Act Provider Relief Funds"
       }
      }
     },
     "localname": "ScheduleOfCaresActProviderReliefFundsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block",
        "label": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondAmendmentToAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment to Amended Credit Agreement",
        "label": "Second Amendment to Amended Credit Agreement [Member]",
        "terseLabel": "Second Amended Credit Agreement"
       }
      }
     },
     "localname": "SecondAmendmentToAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program",
        "label": "Share Repurchase Program [Member]",
        "terseLabel": "Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalCARESActProviderReliefFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total CARES Act Provider Relief Funds Received",
        "label": "Total CARES Act Provider Relief Funds Received",
        "terseLabel": "Total CARES Act Provider Relief Funds Received"
       }
      }
     },
     "localname": "TotalCARESActProviderReliefFundsReceived",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeOfEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Domain]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeOfEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VariousAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various acquisitions",
        "label": "Various acquisitions [Member]",
        "terseLabel": "Various acquisitions"
       }
      }
     },
     "localname": "VariousAcquisitionsMember",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20220630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r109",
      "r259",
      "r263",
      "r268",
      "r382",
      "r383",
      "r389",
      "r390",
      "r462",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r109",
      "r259",
      "r263",
      "r268",
      "r382",
      "r383",
      "r389",
      "r390",
      "r462",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r196",
      "r319",
      "r322",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r273",
      "r307",
      "r334",
      "r336",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r529",
      "r533",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r273",
      "r307",
      "r334",
      "r336",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r529",
      "r533",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r196",
      "r319",
      "r322",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r192",
      "r319",
      "r320",
      "r477",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r192",
      "r319",
      "r320",
      "r477",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r273",
      "r307",
      "r323",
      "r334",
      "r336",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r529",
      "r533",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r273",
      "r307",
      "r323",
      "r334",
      "r336",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r529",
      "r533",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r193",
      "r194",
      "r319",
      "r321",
      "r531",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r319",
      "r321",
      "r531",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NORTH CAROLINA",
        "terseLabel": "NORTH CAROLINA"
       }
      }
     },
     "localname": "NC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r465"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r23",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r50",
      "r53",
      "r54",
      "r55",
      "r111",
      "r112",
      "r113",
      "r388",
      "r536",
      "r537",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activity:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r345",
      "r346",
      "r347",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r114",
      "r115",
      "r116",
      "r117",
      "r126",
      "r207",
      "r208",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r258",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r358",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r453",
      "r479",
      "r480",
      "r481",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r337",
      "r338",
      "r349",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r161",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r93",
      "r293",
      "r302",
      "r303",
      "r442"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r49",
      "r50",
      "r53",
      "r54",
      "r55",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r174",
      "r181",
      "r188",
      "r213",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r382",
      "r389",
      "r422",
      "r463",
      "r465",
      "r498",
      "r514"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r48",
      "r106",
      "r213",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r382",
      "r389",
      "r422",
      "r463",
      "r465"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r333",
      "r335",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquired entity.",
        "label": "Business Acquisition, Name of Acquired Entity",
        "terseLabel": "Business Acquisition, Name of Acquired Entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Business Acquisition, Goodwill, Expected Tax Deductible Amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r29",
      "r95"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r96",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r431"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r104",
      "r106",
      "r129",
      "r133",
      "r134",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r213",
      "r259",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r305",
      "r306",
      "r308",
      "r309",
      "r422",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r247",
      "r503",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r254",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,780,242 and 37,674,868 shares issued; and 32,432,527 and 32,509,969 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r196",
      "r419",
      "r420",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r196",
      "r419",
      "r420",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r196",
      "r419",
      "r420",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r155",
      "r156",
      "r196",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue",
        "verboseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r152",
      "r155",
      "r156",
      "r157",
      "r419",
      "r421",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r196",
      "r419",
      "r420",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65",
      "r477"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r153",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r287",
      "r294",
      "r295",
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r105",
      "r109",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r300",
      "r301",
      "r302",
      "r303",
      "r443",
      "r499",
      "r500",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r298",
      "r500",
      "r513"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r270",
      "r300",
      "r301",
      "r441",
      "r443",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r40",
      "r273",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41",
      "r105",
      "r109",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r300",
      "r301",
      "r302",
      "r303",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r41",
      "r105",
      "r109",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r300",
      "r301",
      "r302",
      "r303",
      "r311",
      "r312",
      "r313",
      "r314",
      "r440",
      "r441",
      "r443",
      "r444",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r33",
      "r283",
      "r442"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r107",
      "r354",
      "r360",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r93",
      "r236"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r169"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r129",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r409",
      "r410",
      "r508",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r409",
      "r410",
      "r508",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r53",
      "r54",
      "r55",
      "r111",
      "r112",
      "r113",
      "r115",
      "r123",
      "r125",
      "r144",
      "r217",
      "r310",
      "r315",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r408",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r536",
      "r537",
      "r538",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r58",
      "r87",
      "r93",
      "r522"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r30",
      "r175",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments [Member]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r30",
      "r87",
      "r212",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r285",
      "r300",
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r412",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r285",
      "r324",
      "r325",
      "r330",
      "r332",
      "r412",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r285",
      "r300",
      "r301",
      "r324",
      "r325",
      "r330",
      "r332",
      "r412",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r285",
      "r300",
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r412",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r285",
      "r300",
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r227",
      "r230",
      "r233",
      "r235",
      "r478",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r227",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r68",
      "r93",
      "r209"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain on equity method investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Gain on equity method investments",
        "terseLabel": "Gain on equity method investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r62",
      "r63",
      "r93",
      "r505",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "terseLabel": "Gain on Sale of Investments"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r222",
      "r223",
      "r465",
      "r497"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r174",
      "r180",
      "r184",
      "r187",
      "r190",
      "r495",
      "r506",
      "r510",
      "r526"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r58",
      "r93",
      "r171",
      "r211",
      "r504",
      "r522"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss (earnings) from equity method investments",
        "terseLabel": "Equity in earnings (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r124",
      "r125",
      "r172",
      "r353",
      "r359",
      "r363",
      "r527"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r92",
      "r450"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r138"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r229",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r229",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r226",
      "r231"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $9,109 and $19,900",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r168",
      "r439",
      "r442",
      "r509"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Investment Owned, at Cost"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r106",
      "r182",
      "r213",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r383",
      "r389",
      "r390",
      "r422",
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r106",
      "r213",
      "r422",
      "r465",
      "r502",
      "r519"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r106",
      "r213",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r383",
      "r389",
      "r390",
      "r422",
      "r463",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r35",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r35",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r35",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r284",
      "r299",
      "r300",
      "r301",
      "r500",
      "r515"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r106",
      "r213",
      "r259",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r422",
      "r501",
      "r518"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r55",
      "r59",
      "r94",
      "r106",
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r135",
      "r174",
      "r180",
      "r184",
      "r187",
      "r190",
      "r213",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r410",
      "r422",
      "r507",
      "r523"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r52",
      "r55",
      "r124",
      "r125",
      "r386",
      "r397"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r315",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable Lease Contract [Member]"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffMarketLeaseUnfavorable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.",
        "label": "Off-market Lease, Unfavorable",
        "terseLabel": "Off-market Lease, Unfavorable"
       }
      }
     },
     "localname": "OffMarketLeaseUnfavorable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r174",
      "r180",
      "r184",
      "r187",
      "r190"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating Income (Loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r7",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r47",
      "r465"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r75",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Other investments",
        "verboseLabel": "Payments to Acquire Other Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedTerseLabel": "Investments in technology assets"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from the sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r78",
      "r340"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r55",
      "r86",
      "r106",
      "r114",
      "r124",
      "r125",
      "r174",
      "r180",
      "r184",
      "r187",
      "r190",
      "r213",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r381",
      "r385",
      "r387",
      "r397",
      "r398",
      "r410",
      "r422",
      "r510"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r238",
      "r465",
      "r511",
      "r520"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $100,265 and $96,937",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r331",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r456",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r331",
      "r456",
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r331",
      "r456",
      "r459",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r454",
      "r455",
      "r457",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r98",
      "r496",
      "r516"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r315",
      "r348",
      "r465",
      "r517",
      "r540",
      "r545"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r111",
      "r112",
      "r113",
      "r115",
      "r123",
      "r125",
      "r217",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r408",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r155",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r41",
      "r109",
      "r300",
      "r302",
      "r311",
      "r312",
      "r313",
      "r314",
      "r440",
      "r441",
      "r444",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r14",
      "r98",
      "r496",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r174",
      "r177",
      "r183",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r174",
      "r177",
      "r183",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r161",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r196",
      "r242",
      "r243",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r163",
      "r164",
      "r174",
      "r178",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r161",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r196",
      "r225",
      "r240",
      "r242",
      "r243",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r104",
      "r106",
      "r129",
      "r133",
      "r134",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r213",
      "r259",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r422",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r53",
      "r54",
      "r55",
      "r111",
      "r112",
      "r113",
      "r115",
      "r123",
      "r125",
      "r144",
      "r217",
      "r310",
      "r315",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r408",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r536",
      "r537",
      "r538",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r144",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r21",
      "r22",
      "r310",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r21",
      "r22",
      "r310",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r310",
      "r315",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r21",
      "r22",
      "r310",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r310",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r310",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r106",
      "r205",
      "r213",
      "r422",
      "r465"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r54",
      "r106",
      "r111",
      "r112",
      "r113",
      "r115",
      "r123",
      "r213",
      "r217",
      "r315",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r379",
      "r380",
      "r396",
      "r408",
      "r422",
      "r432",
      "r433",
      "r437",
      "r537",
      "r538",
      "r575"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r438",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r438",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r438",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury Stock Acquired, Average Cost Per Share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r44",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r44",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r22",
      "r310",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r44",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost 5,347,715 and 5,164,899 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r310",
      "r315",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r114",
      "r115",
      "r116",
      "r117",
      "r126",
      "r207",
      "r208",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r258",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r358",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r453",
      "r479",
      "r480",
      "r481",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r128",
      "r138"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r127",
      "r138"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r565": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r566": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r569": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000896262-22-000055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-22-000055-xbrl.zip
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M<P3A3)8T'(+EO2:$4H^FN@<A$_/!<,JL(7X1EC3F",+96.C(A([F  LD850
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M9?IYG%""I80XE0+E5$C'@4M!J7$R[V[B@LR_Y[4BB0D[8,%39RP57!DGE [
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M!$X@5#KCF!!&"R:B55(CEUK-E9>6+E)MWKDSAF8C:2%1E*Y2*6Z$==1(Z1@
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M=BXKS;]K^&>O5BM9?'_[?ZOUW4;S[PJVVM[=VJ_4L,NM.X(AM\RL?U-"K,3
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MCNF$_:[<IH85K.A9]/&KCZ>5,*<$5IG! +>I^/[,HZGD-IXX2+E#RU2_U7,
M%P%S7GP"OFY=/UNZ ,_<."EKZ=NB/OTT3)$8*Q%M]'K9M)WW[/Y/U58KW^$L
M9BN_,NDWHX^Y3<SU6H;MRLL+5]R\K9?5I:(;@.]XUJ)\4O2DG5NY #F!A0/N
M9+OU&O[5VFZWMD$R%WGF+=1Z"_.Z]>?TN:8F=/L*%P!]] >G_4E3\<G;66;5
M AQ!%^UJ_DPN/KUZBVR\N'[=2GP_\FY?M#:^R2[#[5+<68FV.^QG37ZS]SN9
M]/)59AS@B7, 5%)18?Y]559W8S+]R$SVW4C*QF<PCJOF"=O?%JF[/(9L-A_O
MC0>7K<:^1 >K96439_;*K8J^?/GRPF8K&Y;C%_"Y%RU@M\S?&4J7G\^\F,D#
MS+(\S4)N9]8!URZC-X,*G)OL=O1&E[>ZLM*_:&U?OGWEY6N.3#6<*1=FXQUF
MYUG570E,\=X%WV4,?/.\KMH2X&, ,U5]G;X];M6*:="'4?8R^X.?5:T3$T]M
M8I%ULK[[$_M\NS(?X&'>Q@MW!5:F''FLW+EOXK@ ;F[T].TJN?T;:*1BQND5
MP:8&VG,Q,\DTZ'!QD^%%W&'J6EY(^BCS8+[GB]8_V;*I^*)_[2.P^$UP.FDK
MEWO,Y;]][&2.'(_Z62:^%1$8^-TKKA2L.[ V^@M9=N-@-%TY3G*WNEYE^E\5
M:F<:E;*7R+BOI$#SO4NN;F?N. %+^0$7;/U2K:F3!ER=WJ<+L69Z!EJ"Y[D0
M[*] X8-8?1\F[N C:*TR,">+PP6E75T=VME^F!+G#>^_:5\Z[K/OZOSE_I<>
M&'I'G=/9MX<MUF[Q2A%B,O4 '@"Y7IC&%?O3(,O%]P!MPWZ>IAD1%IPA$-79
MM49C50P\B[/J+#GH][+3ER,VF9E!C&D,5@$X<\.Q/[J\[#5^;OTY'N19D0V
MT\ZDTUF6S\L\*]*DH2&\M'VY+EU$./XXRW;S1)@O<S\Y^-06+#O9Z[QHEPYO
M@!/L1Q>?FJYLK5>5<Y5MB]:K,3@7F:PFJ*[\XZ-*^L/+57H#N &ND6WLV!M.
M.>/-U+&$V[Z$E7/R=K=37;0*P.:Q3"ZZVS\!LAA=6%\WCJ,*TX*)_DT"?_2!
M2:I%N0)9_7/UV]TOINJ+' &<+/2S8 ]]&%FV&+.K/>J,QJ.KQD)6RE4SX;*;
MW1443QW7"?/E-R])/3N]WRQD%R?N?*B\Y&S57!H4%S'P%ZV\F-PPY\+E)+LD
M)[A<WUV_\33^7378RP;PH <.[V0HH];1:'3ZV[__G9<C< A?@!]^NPW1U VO
MQ7WM$;-N*J.!U+*3Q\I.WMWMSXO.(;>TI)B=,'=4@5QK\"-/VTNT;NI=\--/
M;&YZXN_$3YY4 AL[6YO;^X?[X-+MPJ)<%=I]]\?^]N;VQMOJD$AC>.+F\=^I
MIT#CG^*7C9,<+9]&ZOMCN%887L8QJG:=N;>K_?6)FNSI%U+SGVFRI]@+(>MO
MAT?P"XG93UWV^^\)7G]+0$)>*'.W 3U*I>/)3'^<MEWZ1]._6DW_&O?BU68?
M/9L-[QA^O4>^[:K)Y"(LV/K6W>2*+'XP49SUGSX.@%("F@[7^QA3^OW>(GB,
MO.N;!;"QOW^5NF]7ZZT/>_]NO#\IS8=<XR=;!M]']ZGZ[WNZ;U;&_<N+](3A
M,(Z&O_W4%)AYYI_2T**O41.(6]5OTVB-VN'19/<S_Y'W9#[;;HX]S>KV/H^.
M6T_;D?)NC_ZO!SWB[[.ISHUZMO^YWEB^->YU1F]S,O)X&-:JN ^,OGJADXA)
MR47&#?;<<&6< 9>)"::),"2P#]MY[<>2X;56B+YS8KO#_V\- 1IZ]B3F*Z*/
MUI[^EF?21B_D7UO?IM'&Z*4=#,Y ;/_8[CBNM2;1)[COU]%OO?$)"OTJ<3I?
M%O %XHL5TBJ/+K!_SMQF__/?].WG0[8S#L=;G]^_,L=[Q[M'A\?OCW9>O3_9
M/=^@>P=O3W;I.W'XGT.\2[?QSG\.&;QVO/N?;?HWV^T>GO?/#^'OPX,_3MX?
M^R^[QY_P^^/0W?O/GR>[FZ&SNPF_SS_AP_-_.KM=_75OWYSXDS][>\<?SW8/
M=KL[FQM?=EX=TO?';[Z\/]CMO-_<8#L4[GG<_;1S<D@.J_N\/3H\^=K=._GK
M>)>^/=K9?'MR2'<_P>^CW8.CSL[Y%MM]M2/V#M[1W<UM?$C?77X'[C5^3]_)
MPY,=]O[5UI?=5^^/#^D;^+U%]EYMG^\<>!C;)[%[<(AWCM\>OS]XGW;.\->_
M#[9&._OX?!?>W_WRP4B1?6"'"*$1<2XM<HEZY'SR2H*6M=1KZU2VP?#_GW]?
MGR'KDQW)AT#B@O#N 8TZE_9"4"M*4"2$9))S)C#!!2::48\E)USJ))4)%4'!
ME&>D$%2S".I\AJ"H5<)J*5&P'B.NB$%:!HI,2%2)R(*-N>@V;4O#&T10-9GU
M2V -OHUY\[[*F<KVX*WV/;W?P]](MTO-27493=\$GFFID$]=Y+/[<LXZ<M0)
MG+0"F\B =:1\1";JB+Q,,F$1HQ$6K"/:)D8_E'R^0P"+LH[NZA(_>^C694X4
MZ"X,NK-V@S3*,V4P"CIRQ)/02&.!462,X) 2%4&NK;,V5J)!R'T^0:37TT,A
MTZ,EPVG*6=[4^BD3XJX>VU+S4%TFQ,94Z&\O9;X;1]- ;6&EVEAI?\Z@"#'1
MP+E%W F*..8$N9@L2H88D[PB/)?08%BT.6$-<F?JWDIY]DBNRZ(H2'XD),_:
M%T9AF+J29/L"(\XBN ;.4V1YX#99;'T*N?,@;QM)&H3DYQ.8>#V(I[83JC-.
MO6&<VYTJ[DW=9L54XEL3@1<6JIN%.G/VA(Z:2&8XPE1&8*%DD,.!(R:H\I@Y
M8RVP$!%M,"\:Y.:4 $5#S8F"X$4C>-:.()(D;3%&.A"'N.9@1^BHD'>:@>60
M9$H6$(S;3#QX [8$*GX"A7O5:3=_+8NI1"@6;4I44M^HA%U8J&X6FD\#X<P0
M%VU"AI&\T6$2TC9Q1 A.)$JOK$C@S8@V-R4LL<+PK<N.*/!=*'QGC8A$#564
M27 #F ?X<HIT= 8!TQ*:M$Z$T0J^XN'[E V-13#59"/BH)]KPM5@1$PE<*<\
M\]6DJ-KV0 H[+8*=]N:S**2G"B:M0(HH >PD"3+*$"29P\&1@'UR:^O,\+:6
M=44I[@R0)0IA/&/0U[9=4D"_(-#/FB2!2..8XX@'2Q"7P2)C%476*L/ )N%2
MY/P+(=M2/SAQ\[% OX"#>C_7VV#!&R>Y=.GH;%(/\[_C3E7,L-W*]36J*HE^
M?))+L,8 6#L=Q%PR=%IW[5]/D\QP,9[-*\.!O[LQ_['1"QLG?1#P>?7ZQ=.]
M[MK>"-[;NGC 0@>UT<$^_G*-#LX,?O]_C[ _^:=G_V/&>\=;=&?STQ<8V]GA
M^6YW#\9Q>/Q/Y_#\C^.=\_!I]WC[Z\ZFY^\WWY'_>WYX_H%):J*,"7'+@4Q\
M8L@ZR1!+024-KS$1<Y 4MZF<3^>JYO%]9F:-F_-E9J[PS/1?/C#F$I7)H@BT
M"&L=Q\C ^H8HQ\%:&I4/=FW=R+9A:FYB_J#%RK./1M6W+WT+L'9CP5:=V)I+
M=Q/!!0/ $$HKQ)G"8/]Y"YZ?8=((H:S#P-NJK?D\.DI8>66 7-_V= 'RHP!Y
M+ML-U*.53K"X88HXL1HYZBQRRL.Z1WDB/@&0=9NS!Z?3-R_ W-RX\MZD*TCO
M8VM2]KN227;$JJ8L#PXSKS8KU;97?:&$O[,.WN;![*5WPU@%FPHMU78X^& C
M4]+$QCA_QW8W_0<#G,2ED4B"OA!W7B&MF$7"$Z*2PTHYDQU#U5;TP1O7)0&N
MN5BN;>.Z8/G1L'QV'<N:"L&\38@:!EA.V""-M48T1!&L3MH9E;%,VE0\V%MH
M7BI<<XV,5_U^R+WQ2M;;HBV)"TD7HJF/:+;FC ::, <ZT0A3)Q#7E"$MI$21
M>(6UBMHZ D33IMJTI:(-\F=*8**A9D,![D* .V,A8"Z(L,*CQ'.Q,A,]<M80
MA(F$=Q@)2N5MH#8QLHT-;A!P'S40\60;Q]N]D>U]K-K73&(/-^X9VRM;7D^U
M9_QG[KD8_^Y\CN';H"?)(5<V[:YNSA5DUX?L[='.RVO(_AQ>_</#__[5?4^[
MG]WQ*<CDSV-XKO.=_[PY>W^PA7?HGT=[K_[JPG7.=S<WSO9>O8'G>GNT]Z<F
M>QL?1&9I' PB3'G$O?:PHJ>(@K12!A.-BVEMW;0)GL\O>[+=X3('5V8.TMTW
M'ZC0H/-@D4X$K$I#)2Q.(2!'!5$I<4N"AL7)M V>7YD>L!/\+,([=?'^+-!V
MXVCKZ[1K7+'A%H*R&>=+R* HB>!\N9!3>6A"QB6.J+4\>IIS@FF.\L@VT>7(
M\@I#NJYEM$#ZT2$]XY99EY)5SB.,*5A?TBJDHY1(<7#,J.4AX)SE0;)C]F"G
MK 1N[X[&S=S(;U!UW?6Y$>C(?BT'F!_)TKB0_78E^@/[]9*=KI-1ZGR- 9W'
M0;_PT+UX:&?.M B<$"&P0\%1,"T2L\@9(Q!E-A$9L+:,KZU7/2/I[PT*#I6H
M;D--B^]AN&#U?EB=#>4F28(C#F&"P5OVQB#+$JW20WFR@MN<T4\?[@(L:Q#W
MZ4J=E+2Q1R]QLMOO^7(FL6[6>3-G(;"0N#:1(YFW?[FS&#GN<@U';8T6BF&<
MUM8U;TO=I&)+)?;04 .A0'CQ$)[-$DN6L>@2HMF^YQ%S@'"(B <2HN!.<TG7
MUA5KXT8E?-99+VT92IW<;$34TCYSA9MQW?WY5X:*ZRWG4KBW/NY]-V<^D:A(
M;L:%E \><5@]D8TBH!@-B98&@RT&IZT-DZMM'FY!W1<4#6\F6,CMV9%;O65K
M"KG52FXSAB6+G&J%P;"D1"&.D\M5JO*F%J9!!*EDE#FY4 O9-K*N,GK-*UGS
MXZ!5TWK+_[V]\<?VW]L'VUO[K8W=S=;6FW?;!X</:31^12L,Y![ZXYS36$NS
M^;OZZ(L9Y<IO>5YTF^]VK.MT.Z-._,F6\W?=;'G*:SR?7AX7;6Y:I_;LIA9A
M#PYG+;%Y==,CKHP%57?'L]>3^5,J -9N47V<WX\72:M@,2)$&\0II4@+KY"0
MPDICF*,BMVYF;7%#6O;21]L+):TH)=7=NJU0T@(I:<;),SA0Z@E'@:1\]%-1
M9!(#<HJ*IA"I]R17)=5M\ $;1$G/I]L*@&'0[W8GI4=/3KO]LQA;+O9BZI2L
MQ<6;25M3D;^-U>&CO[]Y486>:J>G3W,6D[1<"8D32MH *:GDD.7>(^F8D2+X
MI+U?6R>2M'%M$:@&1= +GNNV,0J>'Q?/L^:&@+F*90271Y+<ET4B!Z8&4EHE
M1EC"G.;F;ASPC$N3V"<*+ W&L32)?=1(3)9XH:(%4M'Q?*4\9KTVP0F4DO 3
M*C+..:2=)<9'+5G,M3.4;%.V@M&8@N,%A"\*CA\!QS,FA4C4^9SZJ '.N5-C
MWJ8F%-' K-%*8FSR-K7 ;<V:E,/\?$(8%UN0I[EPQZ3$3;??^XA&<7#2ZCL8
M757,HT0S%FYJ_ UB/P"I;T:7JX6_M*>=D>U6E3WWONFAT%;MM#5?<\]R8A0U
M!%F+$^()&,M$;9 TV%$C/66! 6W1MJ!-<H1*8*.AUD>!]M-!>S;(X91-3!$4
M'"&(1Z&0)L&A%(*PCE#'I:B@;<P*]@983H.D/],WX$JZ5(F /&Z_@ L'ZJR0
M5>UD-5]^2F'I0N0!V:@%XD$'Y 21R*J\'B7,&>9KZXRW\<,;F90H2'.QO)A^
M 07+"\7RC.'A=8K18O I(M& Y<"1QB:A((T243(NK0$LDS9EY2CHTQT%]?,I
MV0\)?3SC+MBUQ45*S':!1#5?F,K"2N*8I @[AQ'7VB#'@D"8FB0<,4&2G A+
M59O5UFY@64Y-%N@_;MRD0'^QT)_=KO&4!DX% I]#Y2(5'%E/(R+@B'CC+3,R
M@(VB>)OJI8'^RA?"^ONF_9IVJQN'PTMS9AI-*>&29NSB%!JKC\;F"V=)KZWD
M"<.D$@9Q0CER-'D4/ _&:@&3#FB,<]KFI$F^5HF;--4.*:!^?%#/EM)R3IAH
M)8K.D4G% \L!U#A2HH($QDXDG\^C;:R:% Q=^4/LLUV=KT1.:C1"GL5^\X+W
M;$K5OT50U7SEJ4",PLD&Y&**B#O!D$G>(.$D23[8Y#%0E:)M29I4,;BDCS34
M_"AP?EPXSU@>!.8J,0S@[ C.K9[S'HXV2(D (L:.&([7UJ5ILX=7!FA>RDAS
M#8^;&H:4U)"G[!IR)5X[USJDL-)#6.EPOC49Q\)[,#*$,L!*U&<CPU'$&5<A
MD "K#1@9LDU4.2"SPEA>6/>0[V&YM 'Z>1C/YJ-J%@WS%F'"%,"8"V2#)TC*
MY)7Q+##B:FL#5,(:]VTO4L["/%VWD:L,5%R=!;"1GS,J*#5!:"U!H!'8*%*%
MC) )/!^CHX_.*J?6U@EK<UPJ>JPPCFMM.5)PO'@<SR6;\L!),H@2&Q'7%)P#
MHD4N#VT5!XI6 J^M\[9YN'/0O(C%TN2:UA2L>,:)9@O(,2W$5!\QS5=935@;
M+Q-#*AJ!N(P.65 7HEAA3IAGBNJU=2-)VY@''ZV]+SZ6**CQC#&_@.32@OE:
M,3]CC$AE?12&(N\Y!<PSCIPB!@E*J*;4Q9CKBFF-VY+7E;G1O*S298M_O.R?
MG'1&)S'7L<_U35_"-V#@L><!,--XU&Y_%%OR(1T+[J2G"Z)<C%WP==CYK=?I
M_G]KH\$XSI+$%2GDQ*^K,BAL< <VF*\::J)S20>%K"8>\> ]<EY8% -W 0<G
M-%499#,T\&2]+.XU0Y_'QNO6?\>=T=G/=2JYJPWTE-=X5&X/G<\7%YY^'^4/
M_T9T-: G*6L]N-A9'X[Z_E.[]:_O4>_K.-@_LH-8BVNVO?OG+ 5?CF8_#^:U
M'>P-]D>Y/NP_MCN.W^X^M=)PX>4?\_(Y\/'+:[S\.;SZAX?__:O[GG8_N^/3
M3SO'_GSWY!W9.=\1AR"7]YN'</\W8N\_\$P'6WP7QK)S?'2T\X\^VWGS@8AL
MBL>$J'(6<>(\RCTS4%#*,*&58"%]?PF_91[]G+E?YM&2SB/FI),L1)A'WB%.
ME45&X(B,DU9P11D8GFOK^,5-)8CG7FB=VD'K<U9ONW7KU!MFM0\?A[VJ*3;<
M&(^.^@,@Y' WQ[-,Q4>?BN>[0&E8\V!30C9&C#BF$5EC%3+&6NLDMM[Z[U#:
MC?-J06Q6YM42S2LI)'%2&.1(CH%:DJOZ2(<(X]9X'J6.>FU=5(V)X?\[T-QD
MJK7LI?Y_;Q+=[8U'PY'M9=/VAVE$94H^^I0DNU\^8!6-DLP@8@E'W&APSX&A
MD"2<&'!M!,V'JQHTI[:'P_$LS97IU)3I)&)>*)5&#N<8#S8$.0VSB\$4(YZZ
M)()MU,I9IE.3IY,)P@5-,6))!<19,LC8X!"66CFI-;-2-FHZE16O\7/*QN!9
MGDD>5C[$156.+5"D MABF I&*,RI7O_'UM>/7^C%5J<BF%9_T.I_FQN7 =30
M^5RRT!:7W7$=HE6XYSX(+?N^=T3H[ D5Q2QHC"+M60(_1^03=-8CX%4+<T&"
M^\-J2VTOV:3-Q7%=&1L%QX^#XYG\#:I]I#'CV(2(>%!@?DE8*KT +5H>O(VD
MB3A^U'W8!F[CY=R%?J\1>WB3H92-E_I@NOTC@[@+XZ7O#_XZV:%_'>_\9PL?
MPMCV7OUS?'C\Z2M<$\:R=;9[\L_1^_S,&Q^LYHZ02)&D#%"NHD?6@KM%2 K$
MVURW@C[M!EZ91(V?1$DZ+H,1B ;IP:MB&+DH+0+E!IY SRS09=J]NS+ERA;+
MDLS#\YV/'Q3UTGH<$/="(X[!;M'4<V1@$A+%L!3B>]D(BXT8E4FUG)/*2!&]
M\1'1G)7 (RR.FAB"?%+:4TY=S*D)$B_EQMW<I+PI)%XF9&,F)-G=R"41B>#$
M(,:T0=RXA#0+"AGF@Y/*TR1)+M?<5AJW88+.S[^<V-T4%BP3KM$3CNZ\^8!!
M]Y0Q6%9-;LN<$D'.,8L<E2%JX$8>3#7AI.)M+>>/B%\0WB0<_OM/S+_%$=ZM
MH:0R"1LS"?G.EP_9=F/,&J1AEDU8SSF,D00>"L%+H*4\"6D[UX(55#6;]<JL
M:_ZL$SL;'YR-'B:402(XH#XG'=)1&!0\]EXG11U6U:P3V+2-G#]6?T%]]>S_
M/8O:5G7M_UT!W?RF0=D<N!^L9C;Y(AB@D>N$2,J;?)%R9"F5*"AFA?<A"9_9
M^,'58DH-NN;BM*[]O8+3&G$ZLXF7C-+)&8TDMOD0MJ?( :^B*"1EP02BO&@8
M3NML/=CLGL<;,. L;-MMG=I.0)U>RT]Z3)12<XLV#K[)_C6(?KLW;>YQA8M*
M=8CZB&F^W:"G)J=U1F24  -"2X)<B!HI<.8"85*3&-;6%6=MJF2#L@M*EE!#
MK8@"Z$<&](REX9Q+PH:$/.$YD4!ZI*GU2"9.I12@U*!S]PO=)J1)122?>[K0
MP2#:X7AP=I$P9$<@AN'HJ>*S%\.Y$BLK ;+Z</OFAP&RW?.CX\.##1CS._;^
MX"-<XZ^CO5>'Y[O'.R"S=V<@HT_O-]^<[?ZCS_8V/@2?-% W013GTK$BPSX:
M@H)D49"4M+0QGVID7+45F:_S])11V3+7EF>N52>S-2&..(=8RDM,$ [I("1B
M51NX:"TU-L\U(GE;F^_$8A-,J&])DL\R'OO+$_A<U_!6A7J*258KW&9\+,62
M33QH,,2DF>1$:9]D/HF1K($Y&TPN!RQ4V^CYQ+Q?2Y!V%<!;EW]5P+M@\,XV
M/C6!2 .6E,$, WAI L.*>D0P-U(;K94RN?&IN#'CXDG ^P-7*G2&IUU[EL<9
MOX_WQ_KD\PDUOXTC"R^&5K2#'@R]-#-9N+5S(?*MJ<0WO!^?C+OY\,)F3!W?
M*<T0:B30^4YI46DAA:5(X401SU$I%RA#UFN:K#/@M^: %,9M]O!V\"7"W%Q
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M'M8N::F9:B%E,W/UGFG,LG0!JJ^\[\%&IJ9)3.#\'=O=]!^D5<9R9Y$1N5I
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MA' FDEET6N>%0C8F^M@=G[@XV$L5(PWWOFEERDYEXZP^ZIJ+(04J4V 8):'
M@2/!(1<9.' BZ9 (M=QKH"[:%K2<=UUMF->>TUA@_G0PGXG3"-!6L!@LE.KX
MW*1;+!< <T-T8B(Z:R8PKZU';(%Y,V%>>T)?@7DC8B%5PI^'=9O%A)B3&F!N
M,7(!.Q2#%\9''I29KN8W%/8N,%\EF->>S59@WHAX0]7QG1-G>& H1<X1CQ@C
MG2)!V$3KC N@9UK!7&K>()BO_%G:S4YWG.,,-6>T_2 (7*[1P&L\G^C:XV26
MW7797N(-C9L><4DMDJ?++)M2<-G2N)>)X>?B@DH)\ &I1Q@,2<2=L&!B6(>(
M2AS^L,1@5D]N6?/\B$)"*TY"B\XM*R3TDR0T$[5DRB=F$D>)93^'$(U<H!B1
MQ(5UB@E-795=Q@H)%1):,A):='99(:&?(:&/<_EE(1%O-:8YP=X@'J1'S@:*
MM,-!.Q&E#[C*+WMP3Z-"0H6$5BR_K)#03Y+03(:9ULQ3SP/BE";$17+(8,.1
M5\YP'QFG0E099DVRA)[/Z<I%99C=-8UWB;CH23/,IG0TMV=5MJOJ)*_96%)D
M%"MN#'*2 'DISX"\L$<BF"!"7H"\G6Y7K>!)Q0+T)\@Q*T!_%*#/9IDQBPT5
M#I!-'0*[1"%CF$#$8$DBYU:*6 '=%*"O.- ?*\NL /VQ8R(Y <6:9(@P M$0
M=&[\)I U7"/%DS&")DZDJ("N'IXU7H#>:* _5IY9 ?ICQQVJMBL><QV-1MX;
MF6OE2F0Q5D@R0[$G.A"E .BLC;5H$-"KR,._JSP4^!TZG]?_!WY<W/K$#CYV
M>I/";?0Z&GW,?3X>'W@T ^_@*+:L]_T3N/=9;KS8ZX_@ZC#A6S"8W(7QX\!V
M6Z=V,&KU4VMT%(<Q@S'$WC!F6NI5->AL#D2D3L_V? <^#D 9Q1-XKN&W%@ZS
M$ID.@],72L!03_O#3M;@;X/8M:/.Y_C[ETX8'5WPPY4O3L3^&_[V%>M@$(#4
M6[_2%&FSZ]*X^C./MJ(+9IVT..5R.H8G%8U-7+G<$M" ]^+D!ZK7+KYT-+AX
M@E.@+>0&T7Y"-L$#_F:[7^S9<.W?UV<A3,$+N;_(4I\5V$0LZ__C!O#%6<W=
M_N:<<A]?X.I&@;<V=K8VM_</]]NM[=V7+UH;NYNM_7=_[&]O;F^\W=[:OW5V
M-N4!7N[M;F[M[F]MMN"O_;V_MS<W#N ?^P?P:V=K]V"_M?<G_&OOY?_YW[V_
M-[?>[O^__X^F1/W>VGKS;OO@L/'/]\O&"?#Q: A4 ^32'\.UPK#=BE]]!!Z^
MFKTWC6_^VOQ'>M>SX] !1KS?6"<IC)<D5Q46A#%W[>DP_G;QQ^^A,SSMVK/?
M.KWJSM67?I^N+E-FS,">#5/G^TW>GF+>B!? +QGVTVCY],931GA1,<+,^CEY
MCZD73));W\8O;G_O>Y=5+XBB/W75[[\GJ*A]K/*%ULLR5O&"LY\=SV./=;GF
M .=J:<;*\++(E> 76+,[7?8'FWT_3K0W<Y^]P5N>$/3CN,OZ1RM,9:G]V1]D
M2[QU<#2($>W YX^&K2VPR4/KKW$OMAANMW*$ZYH;-!76C/E-)J*9$>"@_V4V
MVG"74PLW?.T^!:N;+?2#_LAVOW>6YF>?_E:)FA64XLN)1;>?+;J['$QZD !7
M?4INP%BS PSS,OMDKVTGH$ZO^ONE/>T\]GQ==7$?@'L]' _.*@'_< 87\=Y3
MO&_CR,*+H1+O15)7JXBX1A%?[R]<"?JBR?#P#L8"O=%86#DI3>+]C[$ZK9SH
M)M&<.XAND0=8GR!G;U8ZM_4>Z=J>C^W6CAWXHQ8C-YCI=\B37)8^47<3RKVS
MHQO?)NINSWV/+E%:<\T,EWE7C%LAC%/<Q<2Y5)XPZCYL5_D,C)'O;W/N7SD%
MO?7?<6=TMMWSW7$6V.O^((_B;NWHEV'W<^_EQ>[G!MEYM?7E\&2+[FS^T=T]
M?L/V-@_%[G_^.3D\>2/>Y^^]VA)[FSOGWW8_P_'>YC;>.]B ]S?8^^,W9._5
M(=_=W.&[!W]]>K_Y5W?OU18_/'G[:7;W,^^2[AQ7.ZR?=C8#C.T=?W_\$>^<
M?R0[\/F=DW?\\."H\_[5VW29R[2/SW<//-[]\D&K:"V- H'* ^)**:0#<4AP
MS)VW442AUM9)&U/<EJ*N\GB-Z:!78[6=A['D\M#%S3F/)(E@B/06,TX)=L$Z
MYIDTPE&G@KB9,? <8?Q<YL-3G[A8$NR?SV"?:$E34!$E&1+B!"ODB!&9 *1T
M-L3DT]HZ4VTE65OA!R<_+!GXBUE4S*(:2&YQ9E&Q?.[#?F2&_0+AV*7(49!2
M@N4C.#*8!62-![Z+\";.=03KJB%86*^P7G.>^QZL)T@$-P \@^ B=XYIPGP"
M60A'0B**%F=P:2F1S5"B2PQ;X@E2-E'$+6/(LN21<E; ,J>2BVQM73'9AG\6
M7BR\N'*\^,L]B)%2AH/3S@F&.:;$*J5S&V[MG3?1?,<<',)CPE^%(1O/D&*6
M(86+/EB*-#,&<4' 9:91H>0-S !'N=-\;9USW!8"SS'DKX4<"SDN+SG>@QL9
M%1)L0QI=X%PS#PXR)20%S37\14DQ&I>6$K_.E3[07@EB+'*2<00N@D%.>W"D
M.6,QAIB, TZ4"K<5JZM4=R'&0HS->>Y[$*-U7&/-DO:8<2ZTP<XK@I.(28EH
M52'&)2;&F5(1T6B<K+2(4H]S5R+@1$$DB@R<!(%#X$&LK0O6UF9I>'%Y^QO<
M#<K;P^$XY\SDPZ>38V#5 3?R>RN>G';[9S%.7SX=#_R1'<;6:=?V5J7P5>UT
M5WO1JXKWLI)BV!P/,MO!(_3#/[8[CEM3#56?>3W5SVM03V&R>S#9[LNY)!&I
M8+G2CB'LDD?<:H^,L!P9KH4"J\]HQM;6#7YP3+#4P6@(DF],\C"**V=A,0/G
MCC-K-(F"<^^(DLK(('X YOELCYNQ/$D"N17,PY(34B/49W-"#'AR6%F')/<)
M<4TPTE9)!-:JP^#;>6VS,]<F#^^Z5,#^N&"O#!GZ>]%2H[5T'^.*>T88CT92
MRJ/CSBB&$PDX,*RC8,6X:B+CSFZZ1A>BRH7%9.0^%V"7R$4<4:+$$,P3$3$5
MXVH)D5SXMFBI:&E%M+3J1\4NXE[__L7G7]U<$ZW?^S6'P6#)09_C,%=<&W[W
M$/*2M21>[F#76]#(H.-SN<C\J8TO=A!VXV@O_=D?I-@9C2O__:JGG#I?8T#G
M<= O)MM]3+;]N7@8P4R)I!R*)BK$#4U(FV114(Q[+KT1/%QR5H.:53S!J:@5
M OS3Q\3NC_D2'7L0\&>C8^"8\6@C1<8%B;@D'!D?+,($T^"T<82XM776UJ2N
MDY(%]D\-^_EU_H&8+^M\4^$^>T0H>AV-X19I$07BFF.D*2,HT1!2,-([Z<HZ
MO_J ?]1 :P'\XP%^-A8KHY?4Q 03+N9FF)PB!PX=\@+3F"*+ ML"^"4%_,_%
MD(J6BI:*EAJGI57/0]SZ&@>^,[R2A]@_S8O,[67B5C+NW]3H:_7>WD0C%ZH*
MQ?JZC_75F0NK@K<5B=(*/"W'$'?6(*>$15Z#X:TQ<\:EM76IRT[XJJ#XZ4.J
MMP"YQ%!K0_EL#-4Z[+@W$6$&/W@@@'*NP-$2)$28+]XDD3,,!2_],Y<,YT^^
M2U^TM,2!KV)3U<"VLQ$M;0BQ7$9DO4R(2VJ0Y?##,R^23R))IHM-M80H+EQ;
MM%2TM"):6O7LPMU^#WD[/,H-%D]C;U@E%Y8\PL>*9&V$X_%P5/7'/>A_:^*3
M^_=L]Z:=>RIWV%DPN5Y>T=';^-]Q9]@9Q?TX^-SQ<6*NO8V^_[%77:6RW$H9
M@=HLN/D*[9XZC!/6*(C$$4].(R.H1UI*HS#11F*SMB[:A-=5JK3LHC1ZW2E:
M*EHJ6FI25*.LKTNTOLY&2*SC0EI#D7!YZXGG=#_I/7(X1!*,8\*%LKXN)2<4
MYBY:*EI:$2VM>L;/_G@PB+T0!_F<Y?<[0JYD$.X^I;=KBY# C_#;%<GO3Q,2
MBDEU9Y-J;[Y>F'7:2@O6%!B\"?&0''(R6I0"%UQ$%R2):^OZ(06R2XA\&>B_
M:*EHJ6BI:&D9M70?>R183(*45"H>N3?>!LJE5#C9X*R-OM@CCVJ/S';M\%88
M)0-#U,><6!P,TMY%Y#4AEB4G,/;%'EDJ=!8.+5HJB17KD_6A-8@7Y<C#\\JJ
M>)*@P<6VS\$@VN%X<%8EKE8;-1O^O^/.(&_Q#$<[<734O^-1@K*NWV%=OU*'
M:6_SW?GNFP^2<F- =TB9W,":<HZL#!99Q9+%U"GNY=HZ46TFYL\2W+L95PDU
M-WK5*%HJ6BI:*EI:1BT]2:RAF#%/9,:(&3.&R$"="1(%XAGB.GKDO*!(<*&3
M5<81%8L9LW2@+M1;M%3R&M:O=QYL=::M!ZM%K6I06*J:/%JFP\NK,K];@\BR
MM/]4A&*Z\\"5H]R+@(AE 7%& [+&$L2,M8EA;KW4:^L,SV\]E,AVHR'\Y)'M
MHJ6BI:*EHJ6BI:*EHJ4ET])]PGV:F.2QDYA:KH-W/%@I@TQ1\]R>LS@ S7(
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M?CV5S.NN[XWV+B13@6L!X#IZ.<=18DX(5B(1X :!2QI&0DR4&+30@F3!)8G
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MLIK5B?)H3I2K0CK*KR:5CWOO7Q:A[/32[E0BE98L!EY[<[1$^R049Z7O:DD
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M(H;].D=-O& ^IJB1D-! I%"&.(W4A$F9;-2>2U<."-I2WR<XH1[N;;0_[?;
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M!N.$]E3'K6W7YG:^OU/-/7I4E7]Y9[[4\J-6@/>=7J\XG?JY==8HW3,+RUD
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MUR\,YND,E,'@3MKKCRXG"%<'?KH0ZA)',0W;N';U\>"F.^#5.GBI<_"#R6F
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MP()^]YM'Y0^CO/[3+<I[E054K?U\4+0V9I5!2DV<5)Y($QFQ7#)B\&7D ZC
MUMRLM07VNU.0+HO@0W]R7#)"V_;RV/3+5E.<H[Z%>\JU9?>5;:6@ E+D?O]/
MW*1PR97[S#'/C]=7^FU+LN'"EWZ5CP@0_[- HOCWK4NB[L9"=]Z_'\![1)N7
M_>'H;D4X]+-;J[^*P_?O:%0ZTA+=82S^H$D1"Z7E>&D\GDMND^!;VU*]F%^M
M+439[H6C?1'9LY2RRR&X))14E%G!(S)@-$1LUL9-@O$8XX)5V3^4[.7!QW?>
MZ\2%S01POHE4!DCPIF2.H EBI87H$*>D?<&^(OM;PG6;17';X=,7N[J+O+5\
MLCE)N^ :A4\TV5;3Q@+30)*O<(S@N\V)S/ $8"W9Q>ZX\3!/S^80;;]PM\;A
M4'S&OG7J_^@/"@1/MX?.<#B^B(<>CY!>]4KE P3H,NE3VG]!TLH9< \NCH)G
MV,67+:!=XC)]M_^^\ZG=P'\Y+&]_.24<P*E')G_;72[(8?\#-*???1QU#SZB
M*5+T$,<ZW;PFWNV+ \#+6Y;E]!%*X$!Q 4T6P20$N(D=.QN4F-$+?XR?^+-[
MOGL^ZL3&352<3B]:2-7*.,KQ6QE&R76_/ *_8A!-;3-<65_NCP,N3WG#D*?K
MM#G<Z\&5<]U1.0:^XAMK_#P#B'WD=Y\;L2V"C8DQD)$A*E,G$V(P]\'A7\:P
MS*VV"S>^^2>*Z^?^<'C4>XM8=Y2O&.(5'+^=5A$_'?SRS@N1HY6Y%&2E:(9%
M2WPPEE"A9;9."TW#UK9@-P#E!/HNT/)]\?@%WYP,3XSW"^]E86NQ4<\OBS&-
M+X^=FC2*:^D3-V5/7/$!7$/3YK;]WNU:?P>(O>(AO1:L\@T?Y-Q1_0WU0.2S
M*09B;B\&4NMZU+H>&U37X\:8JCL4#;CQ>]_TD:\%Q_M>#U+C$$#"])5(^26Z
M?L0='3_%NJINGVGR&U[_X[M >8I)40*6,R*==\0Y%HE&?N!DR"QE6UH\W^3V
MF:>E7]PN$6?Z9J?+Q"N8^HTCZ#N\C0T]GH2DE;4(\**U>P?.<>"1L[2FYMPD
M,?/4)UB0Z7JC5!!2)^!&XMSX_Y^]-V^*(U?Z1K]*!7'?>.T(Q)&J5%62_5S'
MY1C&P\0 ML$S8?_CT IM-]T\7=W&\.EOIE35.YL!NS$U)XZ![EJT9/Z4>S)>
M9M0[[J5+O2[G79#9G#F@F)=TWZKSP$V'_<VH,NVC_M#*N]=2[[OSO://><HP
M1[-$PC6$ERPGTIJ<F#++<J]3JC2F=BTS!,W*N!-<BV&5C<HWZ\Q>2MYW,T]>
MSB>_RC@YH3U$3KLY;$U2EU/A![Z[^5E9H[R1.5%2IX1CYHDN=$F,$K#VJ::Y
M*!!#KZ7"7V63;+?\5EN^=_;9^%+E19H22G-4KFF!.:58B@(.SM*$_.*U5]?C
M3FN)O+=XV24UH8YJ0!^'[$\Y?ROW#>,-YAW(P3I6)_!7YR!>G(2:HKTFYU=A
MO2KO0FH!5J2:*K@5@-Z=G';[YU5B8)#HOL)(]VT%DL>X*.E89C[!Q8Z'P*"#
MT?4*I1\-?W9AYV)R.9H4T5<V76(BF:DN$<M^C4,*,5JXVTWT:#AM.9VDMMYF
MNA.S9O3,73+O<-TXY*..81N?>E>%BS1+ A.L@@4T/ 2H01T%JTVBCD":&VL;
MIUW5)#"XY4MZALD6^CP*=_B4B>^Q21$9C*(-RZISH&,"/Z;M0KC,U<@<AZ4]
M[0,#5?7L^V=X8O<3"S):$]V,/!B?'*9[@F?YE-"*R1J36&@'B],_Z1@42P.R
M]LPXYRDN ,H1TS+OU/-K&EX/&]OD46$,XS#$9:\G/7?4'W94G>E55U3#^9ZJ
M\_X@QN+ \ZIU#(A6NML!P1TOA3M" [=@J6X"R\-]@_ZPCT7;US'H&Z^-I!WW
MI6>#Y1JP)-( '@M(&G"U!<;J8GY>%,@G/93#3>H4HZ]@&O;(X6CJQ0BV>37X
MZN*5DXG70X'YQ"_&XE$U.L68\D VDP#%\,9QRT;<+S2S#72"@:'N^VE$R&[8
MV+%O.O:%Q@;1 +B=$(Z)1(I(N%D'2F)@TGH=90G %4SN\+-6(\YC#M4D3+[>
M@5EN2_PHN#KBD*>DP;LRZLV<W9%-&]II.O;%\>IKF!3.EP!"C^Y@0)8":#T9
M!R=,(<H$2# 8 ;;LN*,[H,/6T;08R!M)N#Y')[R*2X:$7_GS.8J+=N9P^C:H
M\^#E4@_,L;,C=)/\4\?P-1%IV_40GG*JP?Z[SYJ"V*0E)]X*D,^]-40+QDDF
M"V-2Y0J&BSH7X2ILSIP"[:DL>9DZ4*:$<WFA=9G3TBY$N"*A 8@.0OAX3'N9
M!O=0;+Y\V9 2(L]4,_F;AG[/RFDQVAK38KLA+?A9DVT##ZGER^KYBZO+JMZ(
MA<<FV^5VSNM6ZM7_A)KT$T](*(0/"-!5IY5[T?SRTG8J..'/7W1Z@8_#32_K
M4=7N$_2YS'>*PG'&KVMW@N0;()6C1R'TKQK7[J^=#1O!V3!7US]^5["-O.27
M?DTWV*7?7?585FRP(OVAQU[]75Z6]S]8L<'$S1Y;]P>[K+W+95U<KKAT2<^5
M2'P_I[6(N,Z)$/O?+DKB\]TBGMQJ-*IJ8V!E,RMR#:'\2$ODG[D0USN7XDH<
M'&Q/^<!^H'_H5(\0; (2@#^T"+FT(])]="=]P!'>>N-_K%O@+VTT]'HT& 2=
M*!SM+WYH_Z_I>[42SW@ )EZYO8R6MLO^Q;9.M18+OZ"N]4UU9Y*#;MBZ\W=N
M-+9LBK]-I[ ,=#5K=4J-%CQE5EC',IDZ66@J./<W];&$5KT]BS^V)V2T.7Q=
M:Q#_H"/IL=O88Q^P+W\=[__[D>]]>7>^=V% 37O']@XW^?[ANW3W!*X_><?V
ML:?8Q;OS^3Y@\'W^Z<M1NK>UD\&]H/9]8+M;1_G>UL=S4//23UL?\OT0\/:7
M'_< .Z 7>X>&8F*CS65&94JLIH9P:A01ILB(-Z4 Y9H:7LBU5XQN+%9^_+&.
MO(^HXWB+0*LTM]OTA%544TZ=<,QR*KR4.G?><,%*GI76W=3EUR+0 R#0Q1P"
M.:?2S+J,<,$EX3J71#N:D<RDK# %\YG $-Q+(W!_!0 ]!9']:C'O;>T3&=>1
MB&X!-$==*MRGMUN@I9#[J''IOB2CNJII]7Z\YGMN6*M8+1S= H[V7B\(1(+*
MK( =(IGVCG!&-=$%H)-V/"TIYU*4Q=HK?G<X6@X)O[)S=,NH]RU M(QZ?XPZ
M+S<HQRT33I&"8EBCUII()AFAU"MN07K0GJZ]2N^NN-PCH[;FH1"YFY@9<^ /
M"0PWU=$>-0[=E\ 05GTS+':+/C^ /@<+8D*I,J.4R8DWGA*><4L48X)0KZ5.
M"Y8RD:^]^BW-)BU[WK>8T++G7=ES7CA@G.5: 6<6)08<4YH1D:>4,%JJPC+L
MB&>1/5NCPBH)!U?_>]C'H,A[$!WJ=;O>3?M[HM:]62%:P/I1P.HLR!,95VGI
M54Y,"O_P7!BBE99 ++I(32%HF3GLO[6QV)/IQ]29FU'_([)(/%5VOC=;1<O.
M/\[.\_('MT6JC%1$&V!B+A6H!YE@1#"J9<H*50J)J4_%H^#FIV"V>#O ) S,
M9NW9$+9RB@'PK6GBH:6(9MW?=E5ON-FSV\W2[[D6A6Z%0HO!'5Y8)B3CI!0J
M(]RE.1&:":*H+#(OJ0@H1#?2%=*"6B/%BLH'+:/>'Z/.BPLR*U.OA2>%X=B1
M4Y1$6FV)D[S,I'!81J<U5_Q\-GO3[]NS3K?;AC0\M!C0K'2+)+= DOW%\ 6
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MH]Z8 1+$(#48 OO#!*:_ !:J7^=@K/6O Q?2M1"N BQO)(?'-WS>5?QXY'H
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M"!)P!%F?DA*$5<>U=U:SM5=2+CMQ>A---/ U\&WCT.Q44^:BX8SNW]B:IDV
M 227V_7F8I;FPT&N"G6\%!RN":E[<B&2\O(0R3;:L8UV_(VB'9=&C%T; 387
M9 2:5BYUH5/!!$]E*:TLN"^T*='FDKJU2]YS?7#2['N,%EY9[CRH85QY+0J9
MP:'G"[A6,NT?/#+MP!P[.^JZ?5_C^@&("8#.?P8!^34 __[@2/5J8>,04?Q)
M!ZUM??Q<^$)QC%)3&75PJ'I')$LMX3ELOF(9+TJS+ CMEX9E3#P$T?& #AY4
M!FNE/=BY0Q+J4C]/N-Z#B-4_FW0%"DD+DZ,Q9$F@C*A.*_>B^>6E[52G777^
MHM,+8PLWO:Q%_/H\Q4-X+DDB8$W\>G*^;-!XQM2)Q/6;ZZ\WPE=S*1_Q.RXW
M9)I=^C7=8)=^=]5C&=W(9?Y#C[WZNSR[_*7M8%=PL 5-;_38:]+@KRU=(1<N
M_<6=Y<2-&LO]4=NC#M$>17:#'>IM;8?:GK%#W:#AV.^^2 >=[W-+%,3E*];I
MKE0UE89[6:K;DFRWU5Y-%'=NTKWN)A-^:@O'[H,+?].U:8GJ7HCJ]Z\O%X=F
MT4 6-*<7(4@$KUI[]6?_Q"51P?JQ%IN+;4SO1F@_J==J.\B?/,BV[%)CO6Y;
M7UWEDK'<VY(QFS+!,Z&T*PIJ&>>IPA8(_*:Q8<$E4]L;]'FP-@1C@ZK4Q-+0
M]\'.T'/#VLI0&QD>O9NF+IMAZ*<W_W1W+_!]N^FG+^]@7/\<[UX<'^^_P6(;
MYONG-W]\_;3UD<V7S=B[>/_UT[\?+G9Q;A<PMZWN\:=_MR_VWVSSCQ>[Z=[%
M'U\__OO^Z]Z7?_RX9,8!O=@[-'3O[+/,"R%=F1)G9$$XELX0,K-$E-8[+TKG
M%)P]G/ZLSCLKAQ3_YT';6;= LM8IG&&*2<.TDMR)4C@CO%72V#S+I&<W#1EK
M@>1G LG%')"D:2X,98+ )@*0,)X2P9DBTC)?YD(SBQ&K_,Y-<5H@:8'D$B 1
M5I6%Y:5GU')#C<#_:>IMRJ52:7&K()$62'X2D+ QD'QY1_???<Y!''&9MR3E
M+ ,@83E1M&#$VI+G@OJ2,MY*)"V0/""0:( ,8TI*&3/<"J-X[E-C1<92*:BY
M<=QS"R0_$TBR.2!)-=.I<CG)G"ZP(&!!=*X$H5FF,^W+U%/=2B1/R+IZG=D'
MTSG'@8LDV3[M5'WXBX18V+:[QQ6 J4#PTDP9[Y3GHK"*IEHJ#_!I!"M4T=J"
M5@XP]UXOV(*LY,QHS8A,A2$<]I"(TAN2RX(S4.X*2ETHF_ES.@2L''K\F.#5
M=ABY.8Z4.5.I==IF1<F5,+HTSA<J$\JQE&6T-06M(H[,FX)<[GWIK")EF0FT
M*7.BO7,$-I?EO' 4Z_.U.-+BR,-9@E*34TU=SG/+%2M%[IPN+5/2,)$;TUJ"
M5A%'YBU!*:<9X[DAQA:4\,Q)HHW)B7(IMSYC\&G>XDB+(P^'(X9IK,\ ".(*
M[JB7,C66Y9FW@E/CT]80M(HX,F\($IE4&O:/.)UIPI531&1I012G*C=2,P';
MUN)(&_ZSW Z$?[K:%I3\N"WHJ1C/54$+EG+@,)YR#G*7XY9:C6=Y"DJ!:6U!
MJX>9!PNV(%'FI?0N)5JB[$4!/94O/4"H* 0WM)"^7'O%LM9XWGKA'LH+EW)G
M,\FD-X*+5 BMA3*I<592D+]T:PQ:12"9-P8IEFO-LX)XESD $I<1H3DG3MG4
MFZS,K>$ )*T7K@62AP(26JI4J%07N>>\3)6F1DANX?^4:E[RUAJTBD R;PUB
MI2[20E#L.I02+K4EJM""&"N\XT7F9%:T0-("R0,"29X9HW( ".X\+TNE,TY3
MJ=.4V<(6TK;FH%4$DGESD,F%<CZ5Q$EA02(QG&BC,L(=S:7#V"]6MD#RA.*"
MKLZZK$Z!]^Z4<;DJJ8#M,V[PC-;\V68_WD 4L 635 O*4NIYYE)0<\N\X)SE
MTCO-76OE7#U18#'[D7*/I=,D$=9Q$ ",(8K;DF@FTS+G6MF,K;W*6BMGJU,\
M6/9C)HO,:,%DQCD73'E0,(S0WE.=6V9;*^<J LF\E5,HFKNB9(31+"?<EXHH
MZ@0I*,]49K@U6K= T@+)0P()]UKS,G,%M;S$1*54IM)D/J7**>]:*^<J LE"
MS%ONI+::$I<;33@<#B";E!S$DH*;4NC,8N>';+%73 LD+9#<4_"LM+XTLN2J
MR+G+E.0,'25PP D %,5;*^<J LF\E5-EMBAR*TFN'25<24M$)DJBK#>%<LY+
M;5J)Y E9.6\3]=8F.U[E!2JY]"PU&7J!'%>"@0[GTDSJ4H'@U9I^5@\?]Q>3
M'3VSSCEMB/5I2;@K,Z*S0A G2^L5%1(P<NW5G9U OTE0<)M<\ #)!:HHTIS)
M4E@0L'*M19%:GG(A:$E3G[>6GU7$D86Z5U)3+BTCUG!!N!:&"&4,X9RGWBM
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M:<&H4*7.<CC4A%1Y*65FN"FD+'G1=L%;33@9U^"\@'EO??VL=4&E+K#DN2\
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MOV6*$DT(:/Y%A(AFE9GUFOKW>-",YA2D/:('3GTERL-@7ZCNF3JOUOXSRVS
M:?7#!?H";COWFV<7_*0E*Y?S[N[VUL[!QX/U9&?O]4:RN;>5''SX[\'.UL[F
M^YWM@Y4?_][^X?9!<KB?'/ZYG;S>W]O:WCO8WL+?#O;_WMG:/(0__MC9V]Q[
MO;/Y=W)P"!_L;N\=KO[$GGWH!>AQ]ODRHI[C^R@*%);E4A<Z%4SP5);2RH+[
M0IN2YKE(W5H3)>CL)JH$A:+*ED)FQG@NE54JLSQ37BI7QMJJR]]CM/#*<N<]
MLUQY+0J9@7#CBS*GDFD__QZ9,:.*3&6EHMRX4MO<@1!4T!2&235?>Q3''#J/
MEL8@U9&B33!O'8P2/S6=:/_0\1:-J6G)LQ.G>E&Z4,.I8%.\^!P-'1,9N^LP
MH ,.E_^@02.\%:4+T$.#@%&?ID&JQL -]1T?"QO3'PR?KS<C@D,GG(?#(1Y?
MU5>0T>'@ZHT&5?!?G!Z?5^'@:D*[X92L3D%5/1Y_TH@\8X$)M8)D"" :#<PA
M90>--=-1R]/6XG!^!CD*WQ0";_$0Q;@OC(Z-0^BHWD:R@^J"C1'$M0$G.<(7
MP4>^Z[YW0,7 ()@I :T'DCM*](-^3WWK#$"? ?*P[@2T[V=KK_?_V=DB3*[!
M>KS>/0AG^_=@OT8YP7?J@!88]&2#8.##$>XC*/Q',?3&UAIU$_1S.H*IF88$
M0#(9',&)?[Z1;$T)CO4HUC'^=W:'FZV#@4Q>&RWRYS&(1SL'[-:KAH-1".:9
M7:?@<!K3!]S5J:E#.Z/JN/U (+X30HQQ2T>PJ>%1S9(T;E,8#WQ?^P,:T30&
M&1F47J/4BK2*2F-PS)_$:'YX)JIUG9I:&[D*%Z!Y2?"Z-N%$P:(WMQ23^=>R
MWGAXD=9JIFK(=D**==1XE,7/X%OD,H-:'%P6*7)X#<]N/#8?^E7)<GL@V?Y(
MPMS/GMXMLQUC*'G'D"AOUQ.[;;C'_49>_.N6!^Y-<B+@'3V$Q KM)I-KQ_O3
MW!2"#FH%:IQY<8J9?\#PT8P-( #@$\()U0!.D\&T^WGRQ$W[305';8RD42?5
M2R#Y,[2Z!UZIW/A%: 3ZANP7ES1D&00@=4?]82>J/G!@U#QVHKZ 9C,,J2-3
MKKYK/'W+"]W>S=4W[YP&BF^F7Y/%(0P;;2;5TS64@$2<[9Y]SGAIO%"6J,)B
M@Q&5$UF6AA36E)G(-2VU7GLE\R6&DJO\=\MC#N[FP&NW]8;;BOVG"F^891EQ
M5FO"K:%$FT(1F^9,F,*F(E?+"R>$"(,)_N!JWLC6Q-+5/A_PV'/U&9&LT!GQ
M9M!'J\^25(=^C#8W9H &*!CR.)IZC,2VMDDW&1-X,-3@#0(1RNK]QK8UEK'[
M$U-7$+9)3#6+.QU**EQE\XJ'4CW")BG/=KP'<0K/'NV&9RB2XELQ+="J@:UM
M6G7,^%C\<\T7,$B-3U48!VSC@5'+E^%LZ0QL=/JZJ:3/:*9;2+*+1K(!"NTV
M2L3A<4<SJXQ1]F/;7V\QXR18!R?NCYO8 N&1O6D*:ZZY@?4OF(1]-P29';NI
MS0F.[!I93P=-['ZC5JD$<VA/,!@MY@#4<:]+YC.[I' Z]V/@?2<(#I7K>A*D
MAT@=^%4=,%OOL>I-2Q=]4ILX;X8+8K5QX<]^=8I+]7M7R&AF^1@$_RNWZ\'A
M<I8%I]VY=63P)5]&B1Q8J $64%152&%'E7LT0&/&V+L0,AAJ$X%'IJT#E\>9
MW.-,[/C.9=<$)*XC#?"#]>0(M%5,@>OT&NT\?CZ5]!N4VW'Y$/0[=8:NSL5X
M/_6PQN54 \ O++Y54^Z<I(=2WF8SQ#_Z@WKLKY^T[W/W<!/[&'_F(L],64B2
M.4D)U\P0880CVLNR*'3)E;:_M)YMNZ>WWM-":2>,M;"36F#3$/B-2XRU,]YY
M*5-#W2\MK][NZ:WW5(M"I$QGI! B!]T;-#5E>$:R+*?8V*> 3?FEE5O;/;WU
MGCJ+W36*C$B: ?9RZHEFTA'A,FZU2$4AS=HK62[HW3_PP?]I1/Z8$#!EP8["
MWH(64*MK&)-?!QUTOI,3()_C<>$ C%.QR5^CGHOAMAD-A<C2<#E^G-2?L-IB
M'^00K"A1.=#14,":%8NF R1Q="\F86/->&(!E*:JR5B^P5(K^(MVYWWXO?X^
MN'Z:3)Q&8,/W-R\)KPVU8S!Q.FAQ$Y6I61)T=?4JM%;"HP@\J,E].-@9ISY$
MT0L^F$ECKH.63Y0=YV!W584J%Q9+:V;0[7@7?3$#=P1:7W VH"O-H3QX$G:J
MFU1]@X',9_W!5W1;]0<3'2U8B9LI!<GO\=9T.#R^M!A/IUHH.S1'O56SQ_72
MA%H]4T+VK,-K/8K6&(DY[:5"UU5O_.0;KZ)<I57\UT5KQ)S58:FKX 86BR8"
ML@F^0ASI]%3M-D6[D0[);'<+VYQ*OAPX5>$GH]Y4W)0!OD#C4Z?Z>E6$9_1+
MW,0.LVJAGU9*EZ8@8A6><D^U8"97KF!">E,R>YW-NPW]O,T1O'VQ]^7CYYQ)
M.(1U092@!>'&9T0;)8@SAG+!%&@L]L=B/X%2%P,^E\9Y/CZ0WAPGMV+EM< ]
MEX@1LTFQ3=)K2&NMF7Z27EC-A7I&UJLKW#6A#<OC/J,1-A:8&V?@]F:,&Z?Q
MK='FVPOLJ::KZ#62"%XY-KO,94F&UX ,U!E&::3"\^$TS$&-KR7ZG$S2A()I
M*51C:]!*3<6V8G'I&6".0?&3:\-P,&XBQ&ZX[\8YK X7Y:U_&_-ZXXN=MKV'
M>B[3 <)C!(P+ $"&*!M]S&@(@\5%X.M5(?1A>-R)N(CA&OAAK&6'-:P#'FO5
M#>=S=>P<YL&_K6>\6(0PF(P'[K0_&#8QKW5TR<0Z%K>G.5#@F/[#Z4&H;9N*
M!_&XR!O1^?#XE[I[QD8_++J'2'+N%-#@I #PN'@0' H%B,:8;3X8=>N20+BH
M>$?(NC7'Z&"/\<>(()-[?5T,RW?P,*CO"*RG01R-'+IOAGU,Z675<%):$#X_
M@)/<A63?C Z/-Y+-(- N:@1!Q XQ2&,3[/]SZ=DXJNR\D=!P8;$#1<88MZK
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MC+\BL'.@6WG%05JFX/!DO!;3<' T7HXQOV@:@& TLIP.QR39$Y2YA-J=5,%
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M07I'QR#IYV6FN4SA50AP9$_++8TJ<3 )&"^3S%G<2B/F?4[V5>EFFRU?-FL
M\646L# 5E2$>/O_C^AVN6RGA9!MYZ7[8C1/Q\K^+PI$Y'FO0X:X]&<8_QC_\
M"3'-2=>>_]'I%9I8?.C/:E15(4BN'ID_8Y3'65ZN2ART6E?$Y"J'ZH13]<55
M <1Z40 Q5WQ37E-RG3)VY66\3JZ\=MUC0<^%5+=Z[ T'LU9@SWE2I.!E7=J/
MH 4OJPK9(^_26R#QI9^QW$*[\UE#"ZNX]$S;=Y\NO+D>\]%-W'_\H)=_HD6H
M2_*'8+L8XR(Z;#BVT41'M4I4.2OA;^.<#:-J>06JF*U?J4+H)7[$QTIXGWH
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M_% >L'P+/D:G6]1"OLHGUW[QHL.[+BN$H)@[Q1'QN:M>"A)I0C6*@0,VPS)
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MDR!L4BHIGJ+(!RPU1'9@LK5+!FL5;25'I,:Y!Y:L]H;8:7_\UFSO730_PS^
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M_?L%##&,\SV'^T3KT_Z7UJ=6M_5FF^RW_?G>YX]TOO9V?_,CVV]_)/N?WE_
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MQIF=_XSZQ2BZLH$G&_E6MUJ >]</RF1[^3G8RG:2RXESQN5Y-N7_/9J<]\&
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M=4-OWM! P?&D%*7@.>),&:0#$\A32XA7W'@ELWMWO4#]YOSZ.$^V"ZVJSCL
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MK1#H"H.X< %9KS@2F F;\XT!RZT=QF\;7C#+RJR5\4;Z0!S*&==;:T+6!4'
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M.(%$X +QB!,RS(#ZY5Y($Q+GG-;*M>\ S)T'QJOV[0RTJT%Q)L$FRE$U9V@
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ML$P3I*6.B'D?M&$N*B*[KANN8-Y ,'<>3:]@?G PKT;2O4S.Y9)7*SU&7/F
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M45*C"4=>,XZX2R2?(/'(2AJ\M=()GV<-5'.LTMA3HK$?OFX:;P(O##]50GL
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MZ( <(FWP'94Z__X!\./.^E+V94*<-DX998R&E#&:!XD(\$922)@["O69L&9
M07@W*6;*<IYA@ZV&ZYD?I&#F^>#=,K(W8K:FW2BLL$>UK]J80^M!@EI=F&W(
M;#%Q$(T#^I80ZE3?&&?,(\2H(>@O>3]30:[#]Z[@(>&=,9<^W D7GB)T-0F9
M2 CV"&!/S4AD1[S;R5,4=<[";!RYGK=$U:Z 8)FGZO3-\1!+!<$DEW%S89C^
MK1_6"S'G>."F!\L0QNG?>62EM6C3&;X.S[<SX;= 4DS=YC820<%I*,P]A9$F
ME[-"J"Z .;^__(F!\J(%?!(*P3[[D6!]UF3G_FSF1!) C&#^?(3]NQ&>Y4B
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M"*74\R#@W@U]#EML77H,%7+/_8DCNYLZ%BUA'H;Q3- "FZ2U&*D!?(QC:ZK
M_E1P6/K%2=IQ@(N(LTZ[:?,%SJ(O/\DH@6-AR,#Q;5Q.XILUQ:'*EJ&[;\(F
MW1!PBXK7@PRY.'_HKL4V'/!O.YET"A98-% D]P^?ZO C1ZP85--\B@7^U<!/
MQ-^Q<\M=I<LX+G/%2^!_.,=2CB"=?'&Z9HZYV6'HQ';$# 1A@<S:KA9^J1;%
M&;@0N-@1IJ"!<OR)!T!XL]-@6/KU 2-$55>%+;4D9T 7+^0I;(#DH>^)!)5
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MVF(/!B.HLZ4L]C1MAK/7G2P3'Q.,EC/<LY:0/9^$S5W_QOF6HX^1TN<SC^*
MLI(NT]3&!N:\9ZE0Q*8KX#HTF.83_I#2Z#JCT9.2]71SWM-17O(95N"2CS$\
MC-9;.50'DLEQV)@V3/+TEA0)/O7J^P^8B/9!YB%?R]SC;7+,#C6]#5EVA?PY
ME><6S_!>PS_0RW*^M<JQ3M-."]G,FU/LGE_^S:UF6W05=%:?SNJK<O*7SNJK
M*6-KFIRFL_JJE-67SCEUY%[0]9**(O7U/V8>?4**0T0;V#-W3BVN*T*XGCXG
M^?L-+T.7]0-9<OR>-#"XZ[K?^_#W6099_]-/8<,X@NW/.;8]1*MP^'7=%,L=
M1NUV^_OBAI?H$%?+7*5DKG>H$L+'<2K]V?>:F[1SS3.>3'/T;!B'.BWMR9AD
M/!MB_,OEI94#4_?!BIE+I6N>!8!IJU/U\LEA?[ []MNNI*A0=EO]V#O8N9[W
M2[&W]C[(Y=J".4?FC>@T^4JP:;!O > 2>2/EU03GQ4)O1Y8BWQD,=RZA6[[X
M2NV9U-D7N5$[ ]M<GPNPJ*O,G'@6&*&*>JCF:/#DX-,OO0%Y"32ABK*W8QA/
MCA1UL U(U=R.Y0U(4I_PR/P/8[#['5#M?[PTD_J&]C^>D;[OQ3P0EI.EH_.9
M#T/[IY!6<B2;77/?:S,5=2HJR:)=3T=U/&('Q^"!F.3>L>%CR#*HQ=5!P^SN
MZQ.5XTKM([-AM 177H*[PWTS:$H&55M>5W)]PNLUGPEV'?F!8#]2B7IV8N0J
MC#\NM73Y+G()LU^W&F+M?8@DN^HILBHJZ*">/-=FM73FY<U*20X=SGC8.CU7
M*<+RB<=Q%=W.)Y8^2O55=V_^O"D=)1=P';[9#C7W.*6C]EZ?K/;&[9D3AGCS
M[LB\ON<Z1BJY6&N?;[N8VG%*1^U]/JGT)(0M.S$W[X?J:<Q/GJN <OGD>K^M
M[G'[>KO>+ZBN=.RB]9+"29Z/U;+NDZ>7>K)N ZZ2,[T^D/X?L:#:?TY(XV'O
M><19DTES<]+9,Z:^K1-VR#9J[S*</6Z'5%UK8 Q[#7.@\VO*SJ;!J&&V-3+&
M\U'XB[!P*!,83'2$D9+AL-$;Z%L_9>?2J#$T-6K6RX0.]+6?7'[GH-,8=A]7
MO5Y?_"DS@_NC1MLLZ\TNI7>2@:B1]XE[9=DCE:6-EZZX>=!D)LN?S5V!M?;%
MW E]>\_+4A7>&/3,ACG<<]U65/=6DDW=1L_<U;_6^[<=(C@P$GXCV'*R#YN+
M8%5-L)/NHY"!:YII7J%\\DZCW:G^+5$M<U62.;,QZNU9GDOOOG=QZVZ=$-&S
M-JCN5=#!NGL/G4."(FL/;[O[324 KM8;Y/)LD ^G1G]%[8FWA2WXS;$<CHB%
M843JE#3K8R2T;E[(NBF66].,!JV=/=_RF0,M<Y62N79K\%R)8SIZ\>K[<]+4
MW&70$K\AM_<^A5WS8TZCW>KO6FV]?'O[FC-IU.H>,%^@]DZ</(E^G-_VN$/*
MZAO8[>=?[J5FM >M45G+,KZ0/ZAEN2ZRW&X9>[J2NL3HDX0&CBVWL=/HM=N-
M45N[E*5GU,#L-T;&KJ;NJ?W*[P@W_?M5:'C50Q,7]=MNKTC//^,P<B8+^97C
MV<*+WC:-(3'PA:EIRGN IXQJ/X54^\G)8&E9@-5%0QA@2.#6X& BE#"SIMR[
MP2>9'P?I27J#%8IH8#%2Z9RJ$_9&[GXY\X/DXN5$(6?/"2^;\9#QM"-_0C\]
ML@?5RAS:#U0WK<*,0V:+"="%>I?Y0H28C+/F$;L3;,IOA:JX#$_AD.%[5W#P
MNK%IES[<"1>>F@'!IR$-+HQX$,5SU8P<,E9K!F8A=6%<G(79.'(]MXK@LY45
M+?.4%6[9.I[EQC9TP-U\N0&B5K"46;\M#4:M;:A@FOC8H>C02>B0$<#Z.Z;X
M.\RT(26EB:*"E( 1^[?^U@1H9P1(>=XYY&R[IVS'-!M'*AB^Z2W! T\M/,&M
M*=N<V(>K"G]I[3J$0$Q<82E-%\8AUE17JS04?\<BC *I%)<4UD_<BWFP8$:#
M(:HY_ 0VYP:&R ,8:$=^;1)?\:U .!YP.Q(SI>"*C8.>,-XL=W$&JLME24M)
M!S_%GF"=MORVQ:HJ++U3MMUY/CZ 1)GZH$BF@KO1=.5-WUN3ZLF &(X-7XP7
MFQM('\[>M^, 3\<R1CS5@OS^_XV#[[[?V)BB3]=L#;"=N2_5Q-M N" DM^+=
MG6-'4^4+Y5^4+LK;=O8*'\/F)XXVOY)3F]+R'$@,.J,EN/7<O],@(_.-:(X#
MP?]J\@D,]BUW[_@B?/5=84XSQVLNT7!Y^IOYL,(-B>TB-Y/=M8;F("23X["%
MY4O-\1;\7!'@4_DZT%]$&+NYC=P]D^N79VXP ]3=KML@!W,9:@_LHP4R$,(2
M?6UV&73ODJ(&[0E?I'\G3Z&?ZJW"A;;8);2] ,O"?.A-?@HDO<#E0[]P-N=6
ME.F-HAK.&W#4XQ?HXJ1E^,_ L0GAW7-R6^^F#M@""Z8=..,8FTQL$;SXVLCF
M0!7\O=R,7807HH?29R)?FBCG6Y-\S<1*" ]U7,$J--"A!;?4);?:8Z^'64^6
M%<3D.KODTT*K2.N/'CC"3K1@OU]]/&<\ME&KVDYHQ2'2FX^!5BUV\0V]&!P?
MOE.@1&+G"@T]S$>C5^!C8:@/,!(=>Y!C$$+0V (GPI?9"BV@C&$#TA'-QBF9
MG.P1SB]__?B^:8S8Y<RQ NC[%AKF8*CA3?Q]X@3@Z?\-!A^TCV*K'4!'TK"
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M44ODGF2)WW+'Q1 M;:CC4*S=.QLM]@/\C*OY;NJ#Y#7].PPVA/$X=&P'%ID
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M]T65&AO##?FV^ILW6YL4 QTZJ56"L@S2"GWC@H.7PG@^!WN3G%W>$"A2JDS
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M-,QWVATI-YOZ-?!&RJL)SHOI;T=6;L0T.JT#5K#0I4:V8E*[?T@FU=X9^#'
M"XXR>4$#J65T,0:#5EE1MC2,VA/ Z0Y+R][:NQV;\E*/S/\PVF;K@"@EVO_8
MJGIN]Y \JKW[L7+#B*^[870<>UVCU='A",VB(_8+'@A)[AT:/H84@RTG7^[U
M->@\^;% F7PE+<!U%^"164X!KI$CN3[QE<K)7E,9UQ_IGB [,7()L(_+*NT
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M)L[ @\"UCL@"#13C3SP NIN=!L.ZKP_8("JY*FRI)#D#LG@A3RO]2Q;ZGDB
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MJJE7"#1UZUM?9^T11_MT[Y2IR,PVO:I*?&-2EM39;GM7\SPW2>#[R^NK*+G
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M!('Q%9@1[([8TM4(5D@&L(AT:21&[J)VL4#\8QOHUD1U%> 3$&4J91>,:QP
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M.[3NZ0_BP$*$TYE\&_9NN^CX!1T5E $_8#: 09D$H$G$VTI!* &&N@N/XV-
M9_;N75IQ+2U IR/84K+<>\^S2%-(Y"G,"NJ'3>$[0O! +L!7/F;)'3B"8:Y)
M125VGZ;X0R8:Y76,[:.@@:\D8X&5H>;# =:.8B8OD,EJMO(A+W:[JR]V<;FV
M]=^?["8;=5A]/.[6._W6N,O[;-SJCEK&N-MOF>U1Y__ZK4^YNPU^EZ"]%3+\
M[N(/9>#I\M]__!Q<W@WO!G?#?UYH@\MS#;[X$7T^']Z>_;BZ_7ES<:L-OEW]
MO-/^&-S\_>).NQG>_KUP4N-/R4_Y$QP&J>\K/=ZWQ2]I78V=T Q"Q4=L=_%:
M6,B[X^3N%WG+ZCLMD_F@[C$8TV.!O'M*WS&K4!]@,K9<#/+YB]#W+,]QF"\?
M.GKC$,LM0]5LG>N'"_K\])OV8_CMZN8XMA*O?;2";P!2M>@[GX.PY;5U(C$E
MY)_+N8W?,YF8(&X?Q3)51=(C@WY6WZ*2]4%62V+ZIGTV&/.HB7#T;VZ28;44
ML)"F6[I,;;4[>B>Z H6)-0-#$A;?4O;X(]W7F"P4J3@(V ^"(-D/6ME+AE0K
MF0$OE$"L4;P"RO[(H%*^(#AIOP BKI<*00.SB<T)G!F";T/NWOU4 %;;4JSV
M[.KR[N;JQRVQV>N;J[.+<^2L&_+1 VWCXH$Y81Q.?6X+T_' CI6Q:;[GR%-S
MC?%O8$<7T);X4RF 0/1LY-AB H?82K9IIK<YB[>IV#>CFR34#^715R&C&AK[
MGLN4KAGZY 5#3X0Y ;U>'0Y0&#TZSZ#!R?%A!#AT(2G]+$ K%71#"7RE>=,S
MZ/V2*Z0(%F6HHCXIE+:Y$(D2HH(-,RPXX& Q1K_9(L=5%%5+#EFTHQKUK^F'
MZ2OCZW$-Q14JX#X\79/0 $T:_H03#_A%#W8MM31I4>"ZX /Z &WI,B;?9>16
MP8@DZ251OZ96C /$"P%6,K6% &#\%ZPB=-3O""*AW-1I@,%'Y@@/%?9P&DH;
M2\:K3J>ABUJZ!"8"+V7&X",9+GIXD'RSM';@?18L6A"WQ3!?GUATC**$?(KG
MO!NBX]9U.?F!DWC>&7)KGR5N?@#O/T*PAKD/T'ANS/R#"&N%K$NH4X0SS'\0
MD?V9S,<P*<F>Q3,NHBGMQ\5?$JG"GX!\\$3!2V"RP3SRX$:_)Y:O^KTF0Q9<
M*S0EB6A\@>7A:OAX+(\I&9MJ-2\S"8*!"(%/4)0,I9R,R6,M(7!#1&PTV8G1
M/N)2K3':EOH$XP#=WA.=)A!+G\OB4=>WR#=/!)0 NO9:+"(*R%&0"FC9A(NC
M_1]C5WJ;,WDW!A0Z:TB:J,2U(H)1=Z@45!BE*V2<F(WC  _E-4PTV2$JAA@0
M%LG]PM%>RME#CAYW05-'@K&C/2IRT1!]*5J3LHR2I%EREN'EC*LM>:C'Q\>2
M'FE:#T213P(BN7'XCR2)E;E=M=3[J'?[-FK9L9.ZALXG>6&LJ':N.?8O%%%D
MWRZ]4-MNGQL[NG,3N3=T$<L@QW_@K9XRB(#?7"QS\,*2\=7;"4++(QM-&G]H
M9J[CI)Z?24MB]:$A?^R,'+D!OHXWN# +D*?&?9\"(=!U#!_'/@LM-%HC A5S
M :9W#<\LT#2>EPGH8G3A&JO?9+W/Y'UU#<Q9-];&/=>9I]AZC?88.4)K*2Y/
M&Y9!#>EYZ6JA^U6DU?7H&GK* WD+*-=!2O[2Z]H4@T!\/G8D4#E=[<:3^5P=
M8 'P-&EN$?CH)!>Q5P-F<H'=*,]#!&D:=R3?@'TB9XD\PLJA9/MT"0KZ\??0
MQ[EJ\+RT])6DLJ,#XZ0.#.:R.<[2-@2!?U$YBI>2!G<$V67 HO:>N%"LD!9)
MF$=J()Q+L")ZB%=*SSH+%E8#HX1*][==](^8\NZ8!H#S,$87?BW%Z"6=<2NZ
M<%BQ97G/(,,-X*"3 4*31S<;!)=(\3^9,G7#[R(*QBQT5 (>O4/>9<M[="5H
MY&Y2H!<V7J DNP?8!.P7UQ.S&E\C P81;/M@Q."Y27(?;9>2ED.Z.)&$(3QI
M5PF*2(#G,#<O%)$B^^C13!Z&.'!OA@<!\UP6@B?P\/IT9L;I@R">T;@[CZ@[
M30:@X\CP"X 4JO#(>M65S\*=$!MYH3P*)*SLB>>1[C0. V0RQ")$RJ<7@1D(
M<(FH<"%J640[H&YC)AZ1<&QLX\$ATL.+(0"JTJ>1JF9> ',AHU)S)[$8.KHU
M_BTM(1%M.IO^%8=8,A0HE8\&C8Q=/.@I)QXZGM&KC!P3#<M:ZFRS.=(+8A18
MJ06F)7KL4A24TEU2X2.*K<)LREA31K7%,?=$+GDQ+&?A,C)1C:6O>P,5>K\N
MD%HJ?&?9$E.NV6Q+:Q/AM_C,.ANB1.9#XCK,NJ?ZZ)>,O7U<,L+^#GS+>!CS
M\'IP<Z<-A\ J[OYV<:,-+[]?W?PQN!M>7>[JT#?JS1<\^H?SA"<.?4/7?ES\
M/O@AG?@7Y\/+WW/CQ5\=,$,)8YTD3@;=J4$2ZX**!W!E[I(P4/>1VR:.I1VP
MR$W!-(@L$X??8X5*F2B/F7H[W_H8]4X1KGV,@4[WY-KWP=G=U<VF%)(?2S/#
M81(Y%-+:!VG,=(,N U91&S!]>Y3<3;P0&84#S#F+?"#/8_]W)Y1^$0BEH6L_
M+V\N?A_>WEW<7)QKMX,?%[?:U7?MXA\_AW?_TFXOSG[>#.^&%_+F\.?M!?ZH
M>$_.&0]:#6,/;TY(XR.U**ZK(LV8A&.0/JIRU$F5C(.^IZ !HQH42CMG=;RP
M\JQQT#(C98JB>,7&B3J+JMF79^#-0X$S"<=8_:(B<&CKL9G@7Z(_OH(".W/8
M_(OMTGCTTE=%%4IG0W5CN20ELA_YL])$^EV]V>FA,J(*8JJ)E9ZBDYZR5--.
M_M9LZKU>:^7/==U8^=NZ80T#%M38:=AUOS7T3GNW4=<NMJ7W.YV]+[:NM]NK
M)_TPB^UN-NP+Y5RWK-KZ-N4D>R^)#=EZD_C5!A5:U^Q)FESOLZOEPHC9NSIB
MQY+#41US^><E)>^0U>.-Y5>4/R7DWT>>2E7[Z=J!.*;GKJ,\C-?!Y_UP_F+9
MR'I&V<BRX'RD<#Z063WRPS6F]DAD,MN2W\VBK$3"?XQ^>@JQOTG!XBWJWQ8+
MBN:JDR/_]L8$)GER-(":EG5>Y+-,'2W,<EAX^SH<.;;IS%&3EV4CY-<.DRY'
ME<8H/C(>+(6'/]B3/0VGSS$14>P@":+4SBG6E[[^)W-"?HQ*:X*KF,+%L7:'
MWNX_V%S[%P^T;WP1?UJ<=+H!8DI?VWPP\VU'4QG,$OB!IW@-_03:O3*]X(&=
MNECOI75-_FI5&[UM*_+GO!=1$5I O#'$R]8'HV1=DXQF6^^URW7J]M @H#0L
MM6KQ5C&K\C"K.E5LP/]R2M"E[_2&)H"14E\C_99L@Z;Q6L4V QRE9K39Z']3
M7KH;Q>501:T(*I<$M9/V55PTJ2I"%9KRC:9>H]9I]6K]0V*J])XOJDZE'%]X
M@[Y0K>HUCJX"$ERKT]E-1ZW<56^E"Q27F(Q&73=VM'ER9*>7'$NO\K54:,J]
M*K!'3+W63_ :[6V;OIZE\(%V6MN*XKU#ZB,9]<N11-E(R6CT?&#"S9VJLVMS
M]GT *-\GVFBT]%;_@QWJBN>_EUNF-"12<=2*H[Z/?^SP1R:[5WP>\B5>Z+1N
MZ.WHV%2-U;,:JP^CAL1)YLU"UHW LC:NK$"!Q:D%%1]0>?]\.G.\.9=)A8(%
MMAC/M8 ]4;K/Q',LU?<!NTB(P+=_Q?7]4XWL[.RR9 ]8*!H3#,>:Z[DG^#%N
M5H%)C?R)^Z:M2B[0MYZJ0(!U2&PO%,Y<8X_,MU0#""S6E2PXZ638J-=[LG-/
MW>AI5U/7'L$N 2Y8/.!!UKGDKI!Y3!1^N7O6FM$H0M9:4]?.+[X/?OZXN]5^
M7E]=:K<7E\.KFU2V6KXSTRX]-ZL\WZ8X:A<!1RU=^V-X>:'=#KY?W/TK7<XY
M[[@)HEKJ($Q>@:5>$;#4WBB!/E_XR3P[:A4?LI!$?R^%)!I&3LK5 QS,$X"M
MS\S@BZSN.E_*'6WFX.AT=.WB?_\V_#:\>Y&CO>.J5Z="\Z>)/<)J1%1Y/E7O
MU/0] >K5?#KR'.V("NZVOAY3<1U9T3<J!)8Y HMT?3E,]/[B,*'ORNK&:E);
M)-5:=6V M8U6K8X)3/L7O^(%_C\Y9JIP%)7(D86H*"5;:D.>/Z=^8$*6*?2Q
M:("J%D&[FJ5:15%+E4[=.!H='QGUXR/;MBD=YH;?AZI9S^W)WY.&<.^;! VG
M2*_+D[1M%G1?;[3Z;Y!3V^PU]YY3VVKJS<YNJ;HO)  W>GM?;*,)D-TMO?S]
M%]O3F]UV0=;:U=OUS=9:GL3J"\G\2#BJU.,R9C-N!HQSSPR)K9]3+9?90MNW
MCP>.J'*-C\+(QNJ<4AQ%Q8\^,&C W->^@RS75+9J&D#565IF+$!!5UC04H%J
MC'5(39Z5G;MD3$FU=<6EQ"K'[LL75SM!?R-'<C7E>TRYN_C-/B>'BUQMZL:[
M\8C5,;OK[BO&XS?;OER<A9U5B'%^(<<S/@5K8IDVN;+5OAY\@=K$YV/@4T$P
M^W)Z^OCXJ,,R]7OOX73@FQ.LZWK*K7OFGUHL8*>]?J?1:9S":@VCWS0:[7K7
MZ'2Z]>:IQ9^:ACX)@$NC,QT]0.2V/T,\C:E?"WX<NK"&F><O].>(NDQ1$6<A
MR[Y2=5_J;",-SJA7=E+CRVAA7'2]^]=3MNP..00%'O3V\2Z!8ESM?&U_E[AR
MW_H&!O7NNYWJS!O*PS&T^DFCU>C4][']1N;V-X\#.2A77WN;O=NUL]S/CMK2
MVXCNZM'2ZR>K\V<J_:2$^DE=_MDP2%>IGX(J89U@.=IFO=Y_ F6ED:&L?)N?
M_&"/8A>]Y,H,/*QZVY#96D:EE>Q/*[GELX GE;B:,8@KU>0#JR:-2C7YP(^6
M1S51U[Q@/5<NE"*K*)&&T0 -HP,:QE/3B!PBL0]$.3W.)KXM -X3$'%WNO8[
M]YEOU;1KGV,C,-7&]FQB\[%V$;?"N5)M;H[6],DYKBW<R=_*@,M(;#8BQ>:6
M^2/F<G%R]>3P>=10&,S]QENK+85]M!('N7ZTC.*@LEA+)@X:*\3!K0E6FO8[
M" +;=6LIEO]/C*//D@K?XPX^&5+A66>T2BI44N%#/EHZJ1 )AT9E*Y1,.#0.
M;2L8/>VG?JN?Z8ORP6BVZ]AC66.6-PN68GX7GNS7.Y4DJ21).1\ML22IS(R2
M29*<F!E&3S5XJJ3*H=G6DE3I5%(E'X^63JH8=4,?7M[F0*(< @A#2E+3_O?;
MS0]MZ(J >L>?:'?4)U5]M*+4#,N#B5V9*8W=<U4KWB'BE<F&].<L8#(Z?\1-
M%@H8)A!R^(#="\KAPWMQRU+9?O$8R3JB^?2WP4EA'ZWT[5P_6DK.>'OVMXHS
M:G?LR7.]Z1P4T("[@C*QS F?,BU*6ZM85<6JBO-H*5G5V>!'Q:JR6-49<\RH
MGL$/V_TU8H)7C*MB7 5\M)2,Z_SB>\6XLAC7.1_;KKW MRIV5;&KXCQ:2G;U
M8_"M8E=9[.H'&W%'5"I6Q;.*_&@I>=;US47%L[)X%EZA MHJX[#B7(5_M#R<
MRZBW/BB[.O-@*=HUNU]UK7@T]OPI"S  @XF%:T., <&:H R^L?!N4I7!TD
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M+-(O1[%-SY/=( ]MXCA@?K#P )3&ZAVUF8C&$WQ%GL3FS$-FB,F953 )]>S
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MZ>3/V9HBHC8L9^68+D4Q+^@#:!UX1,L-\O_W],]<&1L-%A832J8!,O. BKF
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M/G_6-%?2;6;)1LQ:O %WHIX.O(JB9 Y,.NF91@\L<H5,J>!0.S1&\WURZR'
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MCK01!JE8U(:<( +%DRF^W(P;]';<=@^L0R!"?W)OL I<"]<O(04G="[1,YL
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MSWRM!R[10.:IV"RZG27N#.7[H-9^-;:&<+M%=H_2Q0S??X(I$KKKY4I6GM_
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M!QB]=TZ\ F#_K1*W5,%-)>X@OQZ7W9MP,)&[CR4R&MXQ7:"PR&7M]H)@7,R
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MA6[-__WEU7<Q*$D)5-HQ:T#6/%1D('AFRA<E"\\219L.2_>A>O8<Z5WT?9O
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MCM80;;?(*GGXDWHM[,VH6X ':@9\T)Z\/TE@5:EN8<Z,1^41P="+T2V8LN'
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M%IQ[8223V1&ALU+,>U^8]%E;#-H599J\]_?".CASHC\E]'AE\A+< LN2_EW
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M7>Y]M7TNJYR<C$_@]SG>072Y*"1 T>K:@S=H%E,(3("-AER_$'.WNNYW#G$
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M!09:<:9#L,P;L.3OIA*==S[*-H;CAD"_BZ.XELIKX)P\ '?M:]8%<M,CN2U
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ML+=4**WD>K+$%GMP_[6?^NW@4*&-C\=X[0+)@FZ)]]4P(Z0%TMU.C&0J>RV
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MBP^.'#_8YN%;N[<?[;ST7@>\^V/Y16L".4D\W444SG/K6+>QD?6QG9E>/H'
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MY- WD0[M'!]D(E:ABY*DM<&:3F+?;]UST(*&3%>,W\ZAOAI^6VGLJV%&2%T
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M:U_6?Y_^GK["9%:\GLO\_VZF,W2[EW>-S66$B>9$A5CN&L:)3<D3S;/7CH;
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M+O_B9O9E/!G^.Y57AIO1C TB93GR'(D0>#7)<C]YM/9)T-':J*CDT*CC3#>
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M-#V,=) "1)9LFRJR[AB?OGU&,WWI=NKUE5L#"_\NGM4TV0Z(FL8!'F)ZF@!
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M_)2?\E/^TT4!,"']F0$&@"W 2SIS RP QQ]GW\D#<9+"S-S9V5Z,C\_6B=?
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MLCW+SNY*BAQRUZ6I'QV3=JVYNF&;E+O@,*ZGZ!@I<)-9^)&(R%IZ"1&8U+4
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MN !Q=C2\37HT^/66'VG-?EKDF1A-/9*[J_](?I\(DJ+1[VT%;T1:07>H*XA
M;7H11_9<K&-YVFB91[:^Y>D<+S?NI0RN&]93V3"=1*IN9$F5%$7%W&FH%]\'
M!O(I!UQGU-O<,Z)W&,,G0P4.(?7]_2NW('QOV ^_MD,O) 58P:0]%V_DABM"
M($PI*,Z0OYH\_X\2]59OIQ0B8+I\:@G46#W$>^N([^@>CB#9MZ2>E+=XRTK[
M8:GC!,W5T,T]6F?H?(F)1I*XM9D*_6;!5*]:F7#WT)B<G7T :S"J,+%!37V6
MT?Y?S<-B[?X!-^?%R4G9U5LHMHL([' M+/>G;;#T9&RPM(C_(W*F; X<A0Y
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MKE<3*!*0O-,,[&-<E?:03)BV,?V8Z4'HHUV*"DDZ7,YS\[SR@EOH/8O&H<2
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ME-[-&G,7N%>AZQ-R%UE]%D0$EA_]S?JC6V*0BE[?:Q4YDK'N]+LH@_ C=V2
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M*-@H(]XM)D;J^WN=%-]?BKV=.JHUF#6IUE;?&_7T*'P>\10!GY[CF2H_ME#
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M>GM##+J)#)_6K?;<>U&,6=6G?!A4'D<UU]3DT.O+PESUO*IE8S8I:[X_G#N
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MH$0U8?H6Q+GD]IJ<&F+GK=C(1B-AB:*_8PH"_V(*)0=,(0^"<Z'2ZSFN^H/
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ME+NQ%X99Y#[=)Q5L(\Z1X-K]0-UKFTMC?1LKG\&FVL8IF2%(9#6TP>O7%E$
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M4B=7.;4NQC\OI*3%,VY>D"HH Z+6ZC^E_*"H%0!YK0%XKE0 F0!4*@&>:RV
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MKJ0%]3963MNE_ =6$A<&?&DZ$AHKU(#X#KQ M9*#'UK9?P17"[!&O)(?5 J
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M#6G/0"-OCX%"NM#T&RITM-=Q@X5T07@3+J3]HAW=U&X:=Z5L7!TOM"4:*H\
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M*D_9UTI@"FAWV3K=QD:L8F>HWW91.].7;4YSY&I?EQ^5;;=[#OGCUFK3E)-
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MH-M[?0KHZ%+K(]^.M[T?@1"4Q"!; "YW5O)[?^+E8\9 NI;;C!FZ,*=^P-T
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M:L%B.5%+U2HBZ;RL?U8NI(>BDV:Q@W BUPZ8^)&TFGG ( Z=1/X4QH&TH>.
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M?K6Q$4J\T/,E^Q(6.!#YD0\3HLK8A_(O+$8">4;N3(;]3XUQ6_'!AOQGZ@X
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M])"]_"S;J CQ'TC]".L?*Q8\WOHHQ*6M9,LU^B\,F/;FG!1ECFDYXZ' *E8
M>L15O@!!!#%RU=%OZ#M<VLZ^H^6;:]7[U&A$/S=+JX%AE('9V.C9FX,A/C !
M]0GV,&EP=D$;/PO.2H+I)<'9!<<J!\Z;1BR\G:X6(EU(-E6Y/E76L";Q*PY#
MX0F'PS#$/D1)[$.,J2N)S>6)CT.7"?T<POO[F!I]M5*"5DP#]YP#*'934$_8
M#'Y1O@.+36+A _@8>"V=CM-(SDH6>)EY(G4CT>F =.#5\?R.NF7?<C<Z\JB=
M=7=''SE;SOFUN.,/ZF.XY<]97E;1]ZM#VP^OS1^K8_I9&/D\0IZ 0H1R6XBB
M&)($A= G4<PBXBBG)!,;ST*&J5%EJX*ZRF_D!"LM-J\ZS@!Y73U17WL8VGPV
M(Z9G^0T\#@/3\C!#8&P)G@!BK_:@C1RC6H4G +5K&Y[2E&U4?9/)K)!]/LJ^
MVH#^F6 TCEC"8$)\ I$;(DB"F$ OB9"#$$HX<LT\,@_V-3TWS+6H:A:2+,^S
M;U5AN>6B+K?;5O*6_5<3E585H4U#ZP]AKT=SI^$Y5N#\)I"5E.OL('U&T!^!
MHN> ^4.]C1P??T3IM^'PQUZP3$PD)\&UV"Z*?LN?ZJ2*']K)<X'E-Z(\[Y+0
M=2BB/DQ<5!VM44BH0R G%(DX\(C<H1KE)3+J?FH6UTI2@%]P.F]\J]X034TP
M0#3Z&28I,AL@/?H9#O:!.>ESP]FUZ*"575W-MD.Q$A^T\O>8GL@*MWZS$YF)
M,&YR(BMXWN0FLFO%XICM>L%_E9-5]G3'7R2WOGY*7_B7=#ZOG(3RI\\97K02
M-(<C41)@!P<N1 X-(1*<0,Q<5UI:(D(T<DF,](_@S/N?&@-*#4"C FAT $H)
MT&@!E!I Z;&:JS8G518#I7'*-RS\ S/A=)$W.#\<=@1&.EL<9"3,3A_M<>P\
MF;1H=KQ32WN=MTXT3VC&,F5'4VC[AN=WCSCG'W"1TEF$B!=&(H%)P)&*7Q<P
M20B"(HE\WT=$^+Y99HY]O4QM]?C*2Y5R5Q4 Q)MIC\L,G,NQ28O7X@Q<+>A/
M0#[S)&=246;T3Y7:70IW!HC2"?RP+)BJX@0*I:=A"M#]@Z%G1)\,\< K1"L?
MD *"2L(S4,G88Y*-+@CZS:6QMZ=Q4V9T*?LF,T;GP[;1V(Q7UR_\L\HO?257
MML5#NO+<^X+_GN47<UP47^57\3%3%O,LQ$D<5]OT2!T%"N%!K K0.AYCW"6.
M_+L1KUC(,#766:L YU6>[K42C2?O&:CT )4B0&D"_JAU,;PGL1DQ/?(9>!P&
MO[X>8@@L0K^M0>PY$MQ<CI$#PZV!>ALG;M^4Q19?)5Z3/'S;Y.3_)%7[(AMO
M[Z_/[\YO+JY_O_KH)FW"MKMEH>(HF\,\^=N''#_-,$&1@_T(QCP6$"G'P@0C
M^1^&Y2=.N1>Z6A&,?0HU-6)MU *M7D I!I1FE=M%5?\4*.5 I1UTDW7>PVT%
M0:.AP4:UKX'6.#=XA^$;F(__/S%R!N<.[S""(QU&C#B29D<4/4/>>6[15U_C
M'6;TC,[6"4??;5NZ\./BL8TM4B)LA.C.4(!"'(8J>[9RYG(0@TD0AS!$2>P%
M(<5^X!@Y[!_N:VIKIA)U'3A89<K<D-;0$[\#8KU=14_ #;Q:66)F[E!_'(U^
MW><[^AO76?ZXXF]<XS5>F4"4/2]G"0V9H%S ,$22;"CU(';B ,9NXHF(N4G(
MC6IB]RS?U AJJ$AH;NAQU?=GH$>([SBX Y/H.XSK^\:Q\V$<ROJ6\5\W,IT?
M=%X;JAN[!>4FY\\X92H;_Z+@%W4\^\RC@>\Z+(:^HX)& \0A<1P'(DZ#T'%=
MEX5:15\[>YD:N3=" EY+:9C";S^0>L1Z,CP#TV.+3"/@&6A$[(_<.A'HE:+V
M]S0JT70JNTL7W0];' +7Q:0S\5QGZ"UFG# O\)0'*V88HL01,'$" KU88!=C
MQT]PH'V:N]OZU"9Y4X0^$Z"5T.!P[@UT&N>CIP R\+3N%PN#$\=3,!GIZ-
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M3W^Z^GK^]>+J_#.XD[^\_"+_=F=F]?0^]'I&T7L.Z,#DUDL:C;6* U52'VH
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MH-F*09(1)$2$PRAQJLIKU^W<>*66VAQD?-6M=D:]8UB7'=YVO#(\BB,SS!;
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M?7$L(FV!LQT)#(S>R+S02@NVXH*=O.!7(S&H11ZRV+0]0,.6G;;H=]H"U/9
MO"I%[?"J3U0_+7_3LY9MRH?_T%N2O^7E@]YITM:^C5C HI!D,%-II/DFRB".
M0P%%2--4I$JFS-[!UMO5W&AF3]@;8,0%G;PNL>V]X%IXN :#;&1N.8^6UY6
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MK=IJ9)Q#C4KZIT8GEWC::P;18A<YU=",3%';4;G=CLJ>)L"H8C(.[I0!6VW
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MX@QF#*4902*+F%4\8F\O<Z,!(V>7W+>3U.=4["RJ%L;2$%B-S .CP^22H7H
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M 2)!()B$&8TD1)G)'L@S!K.$*"82G$K!W<K GNUK;AS4B@IJ6<&>L%Z)?OI
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MM89U&HD8RQAF:6P,54/(D+ D@1F.(QY1C5+ME>IS9(RQ,>U.G-)B_@V:09^
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M3G5XS' DZZ[3#NMZW-:%AA=/SVS^:FS8\J6P>]B"%<74L%OS/L>$LDQ( I5
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M&W2@L*8JF\Y71NY\_;9MOUK-J[?39<+:ODUN(V>SRG\L'Y5: EO7(E0+BC9
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M60D-WJW$_LE.Q::;8R-Z+P&+_H@%-7(\AA_4R/&'9=_(Z?"$KID8I^L"-K4
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M9;4+A!D;5ZYTL:=WC39V$=^SUU4*A.=YW243Y7AL-Q#\?9_>'4&^T>0*U+H
MJPS8U@;\5NG33ZWO$,"&/<V[1*!A#_4"0'=PMA?BF1T3=Q?S<C&;RGI[N:I,
MOEFE29++&/$(QDD:V9J]&')E:_9&C.9IS+BDF5<*;\M@8Z/+^V(Z%]/GF3%D
M;+W%;<D],WK;$';CP5"X]<QS.V(.T[3 !9FP*<!M PZ;#.R@^D%:L,L]78/)
MOSZJV>RF/@B9\(@)3NT)$9*&.F(N(4V1AHA2A+7"J8Z< JB./WYL9-'$1U<B
M@D9&W^CQ'?C:>>%R4'IF B\\.L2('U/[PN#PG4<.'!5^3)W#</"C5W4HF7;]
MI.;2GC?O]!Q]_61,CX)]LXU&IXL'>X3YJ!Y^7S15U/,(12C3&.8H,:LXH0A2
MG''['QT3FL04Y\Z5^[M(,+8EOZ%2)<%*<E")_E_FWV4)'A[9W(9YL!EX6(#T
M3U%D#XWC/T6 ORS!GZN^9$5]5;+YI4>AJ4X3V<XL@TQ/WT$ZM?C@L#_RZ]Y$
M78%&#9O#TJ7I0*<9\*C8U?=,#%1XJ^.,!*J9=0F(K:6O.CUXN I6E^B]4XCJ
MH@=U#$C:',"LXEY2Q11+,89IJBA$6#%C47($8Y3D.(U3G)',)Y_Z< BO3\P
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M;6I.*X)->O\>Q5C#"^H,N9ZU['"@F;1'[@J\H9HAMP;1L.VQ#B['FQP?'6'
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M%54+8 X55YLAVAI?B?+VZE2&./]^]GS&$_JP)-GWTH.@3""780\B+F7@V)A
M$EI$->[V*'$\P;E6VK3NA&-367OT D4PV-#;RE5[%W%=NZ@[''LWCMI#V,(^
MTL.E8R/IG4D'MI3T('AI+FD^=\()C0LN>):1Q8VXK)H59O?*Q;A/:4P6]YRN
MU9&0&7F:.QQQ:1Q1Z>\%##J.M)]"BV+HVSSRJ1=A%VG5R&PU^^B4T"8WON%
MQ3\;'D#)!*BX  T;0/+1X@R"MH T8O-]PMZWSAHAXBV.@/2!_( 9NVP'^S))
MMV;B[WD5F0!Y)8&\D4!!GO82#]1#&U%V?'+$%%NM8R3:@PY_IL24WU</F!@/
MTF*MF=)UP6]5Y]M_I]E_XV\/\H(<]5S-4Q>JGR-?V#3@"+(@E&8M8PB&F"#H
M(=?''+M18.LGRVI,.+85I209E#0#D69 40TJLL%YJ=MJP@T4F@[N&JM&QVCV
MO%!\%) &BT''@ ZD_[6!G8"+=>U;Q GX\1#3![ D?Y2'B\MM8G4S3:7ZB)/J
MMDWC$!7M9G'&Y3*_JNL?EW<7Y'O9-;NS#64#$1Q=)G3&&6YE,.!J;S$P>:Y=
M6$/E"DEW1N4$20_F>4IIMB8+.4'V+"^5P>!;GL4INTIHQB4A%[SZ=XZQ9;N^
M7!-0I/I-">["P$<"1LBS@H 11BDVB7>TIF1L*X9BI&S>4W,"2,7*!*Q*^E4.
M:$DX^,1J%C1[4)TN-+V0R2"BZ'FY*:6PPP28-E*H2 =7&RE<O"L%X^#*R0AV
M&G5I3\V@X9B303N,TYP^8-NV3,IV5PF7*AU3&NF73^I('#_C"1=Q,:?(\SWF
MAM!F.)0VM>7!R(H<R!&BKH4=09%1[<IWYAN;@FS(W23#DR==JT\783T]UR%N
M/6NS#61UFKFD%=3$@D\UN1VJ+TU@.FZ=='S.@;LE:0'PLD&2WF,M?/6S=1XG
M7.FS952;YU-:-9';+\:TJ41E8613P1PHRFXM 5)[40Z#CB>_P)'@'M//NS:>
M?FQ*IV$ [' P 0T/Q@6MNA"0AHO?*^P]ZZP1(FX0"^@5^<$BPW$.^(+7!=17
M<NSJ\-(#*0 I*PTJOS]YO1*>]%MJ49&BC ^7G_.XC RH8XQ=%69H#?71"(#Y
MJ,/% UISO!<=:#_*6^O/KD"_R/_]\E-S1?X52</XEY_^!%!+ P04    " !=
M0/Q4O.Q!==*K  "590< %0   &%M960M,C R,C V,S!?<')E+GAM;-R]:7=;
M.9(F_+U_14[.UT$E]J5/=\]1>JGRVTY+8RNKIN<+#Y: =+LHTDU23KM__1O@
M8FO7%7FA"]6I4TY9DHE8'@0B H&(?_G?7R^F/WV!Q;*;S_[U9_8G^O-/,(OS
MU,W._O7GWT_?$OOS__ZW?_JG?_D?A/S?7S^^_^GU/%Y>P&SUTZL%^!6DG_[H
M5N<__2W!\N\_Y<7\XJ>_S1=_[[YX0OYM_8]>S3]_6W1GYZN?..7\YD\7_YRT
MRBQ(15(2ALB<!;$,__!2.AI 4P7T?YW],Q5*!P69A B<2.\3L1X$,0X$Q]]+
MB>KUATZ[V=__N?P1_!)^0N9FR_5?__7G\]7J\S__\LL??_SQIZ]A,?W3?''V
M"Z=4_++[[9^WO_[UUN__(=:_S9QSOZQ_^OU7E]U=OX@?RW[YO[^]_Q3/X<*3
M;K9<^5DL"RR[?UZNO_E^'OUJ+?-'Z?KIWM\H?R.[7R/E6X1Q(MB?OB[3S__V
M3S_]M!''8CZ%CY!_*O_]_>.[:TOZ"TC=\MOR3W%^\4OYA5]>S1$.2.KZGZZ^
M?89__7G977R>PNY[YPO(__IS^8>DZ)1J0<N"_W/S#W_YL>[G!2P1*FL^W^,W
MMO^^K/)T&N#K"F8)-GSM5IC.X[5?FA:ISK__RZD/,%U_=Y*@FZP_]2@L5PL?
M5Q,:=4S9&V(0/H@\\,2';$EVGEJK?43 76>YD+Q$FM=*6$+\T]G\RR_XP:@,
MSOY+EB_)YLNU/&XMN9'-?K3O]MTI_NY$<@U.:TF<$0%)YX%8ES*)TJN<LF1,
MTH-)O[KB=<JOZO5H$7^:+Q(LT'CLEO2+>$O'UX&[_8U?/OL%?A")Y]TT[?YU
ML2)#Z&PU'T!Z&]4@N3__A%QG6"P@O=]HYE[FUIRMT*3"^C>'T/K_N?0+_,3I
MMX_P>;Y833RG3.J@B6,,Y1"2(M9:-)U*<):5%X+'P0!P8_%>6.#M8^$0F38"
MBQ-8=//T9I9>XU$\X4%DH2,>!%)D%$BT)("+^-? 0V;*J<@' \6UI7M!0K0/
MB?WEV0@@3A=^MNR*X+>@=M$XQ4PF(FI&)(T)/2L;":,T6FZEISD-=U+<6+T7
M+&3[L#A(JB,CX\ULU:V^O>VF\.'R(L!BHJ33*CE)A&.>2.4\6C@*1'+A 9(*
M6OB#$7%SU5Y(4.TBX2 I-H& CW#6%2',5A_0W9ZHF#VE'B'+"OV<11+0KA&I
M90J*"P4N#X2"ZROW0H)N'0D'2+,)-+S#$'^!IFPM^$\H?W@UOYRM%M]>S1-,
M,*A3R7I-@LP29<,,^D063S_)DDV2Q\Q@(' \2$@OK)C6L3*<K)N SJG_^BZA
M^+K<;3(86XNH0Y;<1DZ2!$%D$@(9<9DXF9(&S4 F-A!H[B&A%UQLZW 90KY-
M .4H)53!<ON?]]T,V(1K19.@FH@L$>TI(= M.D[)4I_0VX9LAP+)'<OW HAK
M'2"'RK51</")!4.9MH[X9-"38HEA !X9R8E99@2S*8MJX.#]4ESTY:'C:8)M
M"1VO\,OCQ>G\C]DD&)N<=91(L?XC"N*YY@3P@-3).#%$;N.>Q?LAH^'LYQ!"
M;0D7:R?J>'&RF'_I9A$FT2IF@0D""44B(W4D).](Q&]B;,ZX4V%8<-R@H!]"
M&LZ)#B;>EF!R,E^N_/3_=9_7CC88X76,E("F)>LO+?%99Y*$X5)%2;VUPX+D
MVOK](-)PCG0@T8X,D&+]CA;@-W3GX&F6>!!:JX@,$J,P&P'1G7B@0AF9#D^%
M75VQ'P@:SHCN+;Z1U5YNVZ<GY_/9+G_GF#$1D&QE9282@B(A"B!:*I644SYR
M<[#J;Z[:3_T-IT$/$N/($/@$\7*!\&4\G':K*> W#7H[-A,OD]DD[7Q0!KUB
M)TP,/CCE#H; S57[0:#A_.=!8AP9 J<+7^J:/GV["//I)!JI6 )%M F:2*,-
M<9 X\3IEAA&3UEP>K/]K2_93?L,)S?T%V,CF?_,UGOO9&:RS]C9Y[J,$PFVI
M _$"Z>=,D<@]E]('+]3A:>Z[5NZ'@X8SE0>+LXDPX=7EHHAK<Z=;8(TZN%Q.
M4L[".L9(8A:C8F\HL;$P8TQB@68\ZH:*)N^FH!\\FL]3#B#>)F#R;H:?AN+H
MOL!KO_);MB9*J^ L9\1Z@^<><$^"B0FCXN"TQ!]X=7@-WD,4]*O#:CYA.8!X
MFX!)*0Y8O/(K.)LOODV8$4J:'(F.'&6BJ45&4B(ZI,QE=%*$P^.+.Q;N!XKF
M<Y7["[,)++RY@,49FKP_+^9_K,Y?S2\^^]DW%(F+W!E/+$.Y2&4ULB$$^DO>
M,LK1_MG#"XX?(* ?-IK/4AXNW"8P\NG"3Z>_7BZ[&2R7DYS0FV:@"54&?6F)
M8+<\8C0MK&8,&9$#U.G=L7 _3#2?EMQ?F&U@X1RFTQV2E;">46,)%\FCM0M0
M'KUXDK@RQFJN00Y5?7-UW7Y(:#@W>: HFP "$GY1BH3F\>^?SE%NR^/+57D[
M5*+N"5AMP29!C'(2N7&6>'2#"./*!>V,LO[PA-7C=/0#2L-9S(%%/3)PCBY@
MEDJ5\MNI/YM$$(%I3TG(F1/IRE=<&L*B5))R"L(?[G=>6[(?'!K.:.XOP$:*
M_M]VR^BG_P%^\1:_LYQ0XY02@A(.S!3PHA=D)5H]"\*R')F PV\Z[UF\'QH:
M3G$.(=2F<+%YT[)A(JADLPNA7,\Z(J.(!*7A20:F1,HL&C8T,JXLWP\;#:<]
MAQ%L&XX&LK'PTW>S!%__';Y-3!:11<:(LSRCV4N<!,H],9(R185 \0SF6UQ?
MNA\JVL]V'B#0L6LB-BFW'Q9O]P N6F&\*3?ZUEN42-#$*Z-(U()YFB#1 >JJ
M[EN]WYO"AM.;@XBU"6/QU_GT$F6_V*3EEA,FLC66!A)%\9%X-FCM. ;9E''.
MK%)>#U6H>V/I?J!H/KUYB$";0,3?,,C^]]G\C]DG\,OY#-*[Y?*R/%(HM,I,
M40X4K5Y ?%OA$U&*:1ZI#-GK@9!Q#PG]$-)\DG,( 0^&E'_YY98PW^,W]FXP
M<OSAT_'[=Z^/3M^\_O7H_=&'5V\^_>7-F]-/UPGOV73DW@\;IA%)/UH/;$YR
MN21GWG^>K"MOBX=YG-]V,S^+';J9\\W3X^_ P@C4VJP41JA,%PA08HVPA./G
MB50Z%?"'+AZS7X:UOK>+KC?:+S!=+7??6>\W0MFVD<S_? IU^YJ6W1I'RR6L
MEM]Y%3$%H;,C0:E2H1X4PAT,H=Q%864*#S]3W9_7ZW2,T_ZD&BIVYF8 H8]X
M&EVG?NMM?6>""<ZTB>AULX@1&41)G ,,RR03,7/G'WXP<BAR;I S+H .T>^=
M4#E$V T@YI5?GA_-4OG/F_^Z[+[X*3*S/%J]\HO%MVYV]E<_O80)\QX$U8ED
M6][4A81'+3>,:&F=91[PQW7L;"_R6D#403"8U]9) T#[""B9+JY@S=?$@5'E
MP1T!G]!&:UX*YD$0GY3U@AOQ\!.4_1%UG8YQ&CC5@\X!4FX (T<QEG8 RX\0
M 6$?IO !5KLJ*$"QQ*0<R1$L0=.<\%3/DE EI L4HA(/1=H'G&(/4#5.MZ=Z
M^!E, PV@Z60!GWV7WGS]#+,E?"^F Y.2D0$W L<3GR+]5AI%: C:4.&$,W7<
MZ#O)&:<M5#W\'"[S!H!SO#J'Q3793(0.)MCD2< -@#)1:$-=#H0[#30Z !\?
M*D39'S6W:1FG?U0]R!PH[0;P<IUX9YQCEG&"$N%$FA2)C5Z0E#PU09:.FP_E
M_0:*ML;I+57Q8-I;QOL#9+[RTX%.HOEG6*R^G4P]BF.6BE?_N60Q\'"=0$C&
M1:M(1L@7'RV4/C9 DDY)4)&D=@^5PAYR(-U/50M^\2!!^F"B;\#.'",GOCP?
M>0]^"1]+)_'C_/L2UN*:4.#"HD2(IP&],XY[PDD;2))":JLI!_I0/Z$#CJB'
MR&K!01X$2,,)OP$D_7D^3W]TT^DDRR08IY)H6EQZE 9Q&!F2H%741@1TSNJD
M!G<4M.  #X*/O43: !3>H;AG9QU&>AMAH%U\\S5.+TOMYW>>@HV,!:X)R[$\
M;/:&6&8HX<E*+L%3[NO I ]U+3C$@T!H<%4T *_7VV5+Y\<+./5?O[,VB9D*
MCQX; 6T]NH/4$6>"(R9J'<HK6<GK1.+WT]2"USP(E 82>P, NA(>?IC/XBX
MD$ZEZ#7)VK'2K@O/6PB!9*6IBC9CC%@G?7PG.>,T9ZWAY!PL[ 80LZ%_8BF>
MNHAH$H1'.413'KP$6JREYB[DZ$0=B&S6'Z<#:[5KSB>)LX&0^WWG0S?M5ATL
M,>I;/VTYGT]1Z,L2 :Z^?1>-EJQD#-!S%RH3R12"&\%.'+4:%&>*Q3K7"GTI
M'#<4KUYP4451#5BA*WS=S(-IXZBF4A+O:,*MQ(#X,F(%&+IS*NL8V4.UQ(-
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ML6];*J-M:/6TA;A;)[_&'>(=BWC4B]*&V ?BDJ8E]@Y*JN1HK#2RZWZBQKX
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MN_%RLK7$2HF,@]-)):A)\@>#F!Q#E\]A(;:+7D8*,;5F!2"!"J'4;!O'M+;
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M%/2M%+YG"OHVTA\:7.=_-&OV6J4^!P[:.EL8VH+7$P*"-8F57#OEZ2"4=ZV
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MBU0)F4@JD.FM_A[)@D4ODC,JY&Q;(8:^>@LM]--]I-Q9=N \LVY4V.PKSS&
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MR)]D^H$T Q</44]GL20WS#!KC*\3)!RA7D662X(".OB@VDVJWW+A=G>+_&@
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M3)90'#<2?1;/0&.!Z3^^-C_^5C]W#8WZNQ4LK@%QO<R JN]&4<WN4AO:Y_A
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M*$^E8J5ZE6B7@[W/K.VP=%)GS-6$WC>:BA\WF[OK\[PYW6Y<BH_)TB]))LM
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M557_&';U0?G+NWGZ]]_^ E!+ P04    " !=0/Q4W^<]1ML'  "!'P  &
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M^8R8IIFD.9+:IM*PWRJN$1W9@MU0J;1EJF _*9VS?J_S&TN4!AFQOP,5HT*
M\9>JH)<O^C_T3O9[;9_\;:82=IZ3D&9AVNRZB"/8Z?@9VFD0L1^YP2)AAWS!
M;@LUSTA,J1W,I8.1A,*,A0) 0B"7!>/%@E6%U15!84"F1T_8A+,<;UKRC"6
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M(F2!";C1#XL\M-8\N+_NOJMMNMSKS_\&4$L#!!0    ( %U _%1>&0%$U00
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MQ,T/W0QNHA7A2UJBYK5J=<2KU=8K_S_$S"\P8QP;94U,'V)+*H*:,7XUY9>
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M=O=?W+#-7?_L'U!+ 0(4 Q0    ( %U _%3PEQ5D1&P" "(6'0 1
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M &%M960M,C R,C V,S!?9S$N:G!G4$L! A0#%     @ 74#\5&(+9Z(Q(@$
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M,2YH=&U02P$"% ,4    " !=0/Q47AD!1-4$  !&$   &
M@ %B904 86UE9"TR,#(R,S P-GAE>'@S,C(N:'1M4$L%!@     +  L Y (
' &UJ!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
